0001376339-24-000033.txt : 20240430 0001376339-24-000033.hdr.sgml : 20240430 20240430160403 ACCESSION NUMBER: 0001376339-24-000033 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 79 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240430 DATE AS OF CHANGE: 20240430 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MIMEDX GROUP, INC. CENTRAL INDEX KEY: 0001376339 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 262792552 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35887 FILM NUMBER: 24897057 BUSINESS ADDRESS: STREET 1: 1775 W OAK COMMONS COURT, NE CITY: MARIETTA STATE: GA ZIP: 30062 BUSINESS PHONE: (770) 651-9100 MAIL ADDRESS: STREET 1: 1775 W OAK COMMONS COURT, NE CITY: MARIETTA STATE: GA ZIP: 30062 FORMER COMPANY: FORMER CONFORMED NAME: Alynx, Co. DATE OF NAME CHANGE: 20060922 10-Q 1 mdxg-20240331.htm 10-Q mdxg-20240331
000137633912/312024Q1false00013763392024-01-012024-03-3100013763392024-04-24xbrli:shares00013763392024-03-31iso4217:USD00013763392023-12-31iso4217:USDxbrli:shares00013763392023-01-012023-03-310001376339us-gaap:CommonStockMember2023-12-310001376339us-gaap:AdditionalPaidInCapitalMember2023-12-310001376339us-gaap:TreasuryStockCommonMember2023-12-310001376339us-gaap:RetainedEarningsMember2023-12-310001376339us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001376339us-gaap:CommonStockMember2024-01-012024-03-310001376339us-gaap:RetainedEarningsMember2024-01-012024-03-310001376339us-gaap:CommonStockMember2024-03-310001376339us-gaap:AdditionalPaidInCapitalMember2024-03-310001376339us-gaap:TreasuryStockCommonMember2024-03-310001376339us-gaap:RetainedEarningsMember2024-03-310001376339us-gaap:CommonStockMember2022-12-310001376339us-gaap:AdditionalPaidInCapitalMember2022-12-310001376339us-gaap:TreasuryStockCommonMember2022-12-310001376339us-gaap:RetainedEarningsMember2022-12-3100013763392022-12-310001376339us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001376339us-gaap:CommonStockMember2023-01-012023-03-310001376339us-gaap:TreasuryStockCommonMember2023-01-012023-03-310001376339us-gaap:RetainedEarningsMember2023-01-012023-03-310001376339us-gaap:CommonStockMember2023-03-310001376339us-gaap:AdditionalPaidInCapitalMember2023-03-310001376339us-gaap:TreasuryStockCommonMember2023-03-310001376339us-gaap:RetainedEarningsMember2023-03-3100013763392023-03-310001376339srt:RevisionOfPriorPeriodReclassificationAdjustmentMember2024-03-310001376339us-gaap:EquipmentMember2024-03-310001376339us-gaap:EquipmentMember2023-12-310001376339us-gaap:FurnitureAndFixturesMember2024-03-310001376339us-gaap:FurnitureAndFixturesMember2023-12-310001376339us-gaap:LeaseholdImprovementsMember2024-03-310001376339us-gaap:LeaseholdImprovementsMember2023-12-310001376339us-gaap:ConstructionInProgressMember2024-03-310001376339us-gaap:ConstructionInProgressMember2023-12-310001376339mdxg:AssetRetirementCostMember2024-03-310001376339mdxg:AssetRetirementCostMember2023-12-310001376339us-gaap:PatentsMember2024-03-310001376339us-gaap:PatentsMember2023-12-310001376339us-gaap:LicensingAgreementsMember2024-03-310001376339us-gaap:LicensingAgreementsMember2023-12-310001376339us-gaap:DistributionRightsMember2024-03-310001376339us-gaap:DistributionRightsMember2023-12-310001376339us-gaap:TrademarksAndTradeNamesMember2024-03-310001376339us-gaap:TrademarksAndTradeNamesMember2023-12-310001376339mdxg:PatentsinProcessMember2024-03-310001376339mdxg:PatentsinProcessMember2023-12-310001376339mdxg:CitizensCreditAgreementMemberus-gaap:LineOfCreditMember2024-01-190001376339mdxg:CitizensCreditAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2024-01-190001376339us-gaap:LetterOfCreditMembermdxg:CitizensCreditAgreementMemberus-gaap:LineOfCreditMember2024-01-190001376339mdxg:CitizensCreditAgreementMemberus-gaap:LineOfCreditMemberus-gaap:BridgeLoanMember2024-01-190001376339mdxg:CitizensCreditAgreementMemberus-gaap:SecuredDebtMemberus-gaap:LineOfCreditMember2024-01-19xbrli:pure0001376339mdxg:CitizensCreditAgreementMembersrt:MinimumMemberus-gaap:BaseRateMemberus-gaap:LineOfCreditMember2024-01-192024-01-190001376339srt:MaximumMembermdxg:CitizensCreditAgreementMemberus-gaap:BaseRateMemberus-gaap:LineOfCreditMember2024-01-192024-01-190001376339mdxg:CitizensCreditAgreementMembersrt:MinimumMembermdxg:SecuredOvernightFinancingRateSOFRMemberus-gaap:LineOfCreditMember2024-01-192024-01-190001376339srt:MaximumMembermdxg:CitizensCreditAgreementMembermdxg:SecuredOvernightFinancingRateSOFRMemberus-gaap:LineOfCreditMember2024-01-192024-01-190001376339mdxg:CitizensCreditAgreementMembermdxg:SecuredOvernightFinancingRateSOFRMemberus-gaap:LineOfCreditMemberus-gaap:BridgeLoanMember2024-01-192024-01-190001376339mdxg:CitizensCreditAgreementMembermdxg:DebtAmortizationYearOneMemberus-gaap:SecuredDebtMemberus-gaap:LineOfCreditMember2024-01-190001376339mdxg:CitizensCreditAgreementMemberus-gaap:SecuredDebtMemberus-gaap:LineOfCreditMembermdxg:DebtAmortizationYearTwoMember2024-01-190001376339mdxg:CitizensCreditAgreementMemberus-gaap:SecuredDebtMemberus-gaap:LineOfCreditMembermdxg:DebtAmortizationYearThreeMember2024-01-190001376339mdxg:CitizensCreditAgreementMembermdxg:DebtAmortizationYearFourMemberus-gaap:SecuredDebtMemberus-gaap:LineOfCreditMember2024-01-190001376339mdxg:CitizensCreditAgreementMemberus-gaap:SecuredDebtMemberus-gaap:LineOfCreditMembermdxg:DebtAmortizationYearFiveMember2024-01-190001376339mdxg:CitizensCreditAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2024-01-192024-01-190001376339mdxg:CitizensCreditAgreementMemberus-gaap:SecuredDebtMemberus-gaap:LineOfCreditMember2024-01-192024-01-190001376339mdxg:HayfinLoanAgreementTermLoanMemberus-gaap:NotesPayableOtherPayablesMember2024-01-192024-01-1900013763392024-01-192024-01-190001376339mdxg:CitizensCreditAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2024-02-272024-02-270001376339mdxg:CitizensCreditAgreementMemberus-gaap:SecuredDebtMemberus-gaap:LineOfCreditMember2024-03-310001376339mdxg:HayfinLoanAgreementTermLoanMemberus-gaap:NotesPayableOtherPayablesMember2023-12-310001376339mdxg:CitizensCreditAgreementMembersrt:MinimumMemberus-gaap:BaseRateMemberus-gaap:LineOfCreditMemberus-gaap:SecuredDebtMember2024-01-192024-01-190001376339srt:MaximumMembermdxg:CitizensCreditAgreementMemberus-gaap:BaseRateMemberus-gaap:LineOfCreditMemberus-gaap:SecuredDebtMember2024-01-192024-01-190001376339mdxg:CitizensCreditAgreementMembersrt:MinimumMemberus-gaap:LineOfCreditMemberus-gaap:SecuredDebtMembermdxg:SecuredOvernightFinancingRateSOFRMember2024-01-192024-01-190001376339srt:MaximumMembermdxg:CitizensCreditAgreementMemberus-gaap:LineOfCreditMemberus-gaap:SecuredDebtMembermdxg:SecuredOvernightFinancingRateSOFRMember2024-01-192024-01-190001376339mdxg:CitizensCreditAgreementMembersrt:MinimumMemberus-gaap:LineOfCreditMemberus-gaap:SecuredDebtMembermdxg:SecuredOvernightFinancingRateSOFRMember2024-03-310001376339mdxg:TermLoanFacilityAndHayfinLoanAgreementMember2024-01-012024-03-310001376339mdxg:TermLoanFacilityAndHayfinLoanAgreementMember2023-01-012023-03-310001376339mdxg:CitizensCreditAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2024-01-012024-03-310001376339us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-03-310001376339us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-03-310001376339us-gaap:EmployeeStockOptionMember2024-01-012024-03-310001376339us-gaap:EmployeeStockOptionMember2023-01-012023-03-310001376339us-gaap:PerformanceSharesMember2024-01-012024-03-310001376339us-gaap:PerformanceSharesMember2023-01-012023-03-310001376339us-gaap:EmployeeStockMember2024-01-012024-03-310001376339us-gaap:EmployeeStockMember2023-01-012023-03-310001376339us-gaap:SeriesBPreferredStockMember2024-01-012024-03-310001376339us-gaap:SeriesBPreferredStockMember2023-01-012023-03-310001376339us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-03-310001376339us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-03-310001376339us-gaap:RestrictedStockMember2024-01-012024-03-310001376339us-gaap:RestrictedStockMember2023-01-012023-03-310001376339us-gaap:EmployeeStockMember2024-01-012024-03-310001376339us-gaap:EmployeeStockMember2023-01-012023-03-310001376339us-gaap:PerformanceSharesMember2024-01-012024-03-310001376339us-gaap:PerformanceSharesMember2023-01-012023-03-310001376339us-gaap:EmployeeStockOptionMember2024-01-012024-03-310001376339us-gaap:EmployeeStockOptionMember2023-01-012023-03-310001376339mdxg:TELAAPAMember2024-03-152024-03-150001376339mdxg:TELAAPAMembersrt:MinimumMember2024-03-152024-03-150001376339srt:MaximumMembermdxg:TELAAPAMember2024-03-152024-03-150001376339mdxg:TELAAPAMemberus-gaap:DistributionRightsMember2024-03-152024-03-150001376339mdxg:TELAAPAMember2024-03-31mdxg:service_site0001376339mdxg:HospitalSiteOfServiceMember2024-01-012024-03-310001376339mdxg:HospitalSiteOfServiceMember2023-01-012023-03-310001376339mdxg:PrivateOfficeSiteOfServiceMember2024-01-012024-03-310001376339mdxg:PrivateOfficeSiteOfServiceMember2023-01-012023-03-310001376339mdxg:OtherSiteOfServiceMember2024-01-012024-03-310001376339mdxg:OtherSiteOfServiceMember2023-01-012023-03-31mdxg:product_line0001376339mdxg:WoundMember2024-01-012024-03-310001376339mdxg:WoundMember2023-01-012023-03-310001376339mdxg:SurgicalMember2024-01-012024-03-310001376339mdxg:SurgicalMember2023-01-012023-03-310001376339us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMembermdxg:RegenerativeMedicineBusinessUnitMember2024-01-012024-03-310001376339us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMembermdxg:RegenerativeMedicineBusinessUnitMember2023-01-012023-03-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the
Quarterly Period Ended
March 31, 2024

OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _____________________to______________________

Commission File Number 001-35887
MIMEDX GROUP, INC.
(Exact name of registrant as specified in its charter)
Florida 26-2792552
(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)
1775 West Oak Commons Ct NE
Marietta, GA
 30062
(Address of principal executive offices) (Zip Code)
(770) 651-9100
(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
 
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per shareMDXGThe Nasdaq Stock Market

Securities registered pursuant to Section 12(g) of the Act: None.

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes x No ¨
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.



Large accelerated filer x
Accelerated filer ¨
Non-accelerated filer ¨
Smaller reporting company
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ☐ No x
 
There were 147,603,955 shares of the registrant’s common stock, par value $0.001 per share, outstanding as of April 24, 2024.




Table of Contents
Part I     FINANCIAL INFORMATION 
Item 1Financial Statements (Unaudited) 
 Condensed Consolidated Balance Sheets
 Condensed Consolidated Statements of Operations
Condensed Consolidated Statements of Stockholders’ Equity (Deficit)
 Condensed Consolidated Statements of Cash Flows
Notes to the Condensed Consolidated Financial Statements
Item 2Management’s Discussion and Analysis of Financial Condition and Results of Operations
Item 3Quantitative and Qualitative Disclosures About Market Risk
Item 4Controls and Procedures
Part II   OTHER INFORMATION
Item 1Legal Proceedings
Item 1ARisk Factors
Item 2Unregistered Sales of Equity Securities and Use of Proceeds
Item 3Defaults upon Senior Securities
Item 4Mine Safety Disclosures
Item 5Other Information
Item 6Exhibits
Signatures 

3


Explanatory Note and Important Cautionary Statement Regarding Forward-Looking Statements
As used herein, the terms “MIMEDX,” the “Company,” “we,” “our” and “us” refer to MiMedx Group, Inc., a Florida corporation, and its consolidated subsidiaries as a combined entity, except where it is clear that the terms mean only MiMedx Group, Inc.
Certain statements made in this Quarterly Report on Form 10-Q (this “Quarterly Report”) are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and section 21E of the Securities Exchange Act of 1934, as amended. All statements relating to events or results that may occur in the future are forward-looking statements, including, without limitation, statements regarding the following:
our strategic focus and current business priorities, and our ability to implement these priorities, including as a result of our no longer being able to market our micronized products and certain other products;
the advantages of our products and development of new products;
our expectations regarding the size of potential markets for our products and any growth in such markets;
our expectations regarding ongoing regulatory obligations and oversight and the changing nature thereof impacting our products, research and clinical programs, and business, including those relating to patient privacy;
our expectations regarding our ability to procure sufficient supplies of human tissue to manufacture and process our products;
our expectations regarding costs relating to compliance with regulatory requirements;
our expectations regarding government and other third-party coverage and reimbursement for our existing and new products;
our expectations regarding capital allocation;
our expectations regarding future revenue growth;
our expectations regarding the outcome of pending litigation and investigations;
our belief in the sufficiency of our intellectual property rights in our technology;
our expectations regarding future income tax liability;
demographic and market trends; and

our ability to compete effectively.
Forward-looking statements generally can be identified by words such as “expect,” “will,” “change,” “intend,” “seek,” “target,” “future,” “plan,” “continue,” “potential,” “possible,” “could,” “estimate,” “may,” “anticipate,” “to be” and similar expressions. These statements are based on numerous assumptions and involve known and unknown risks, uncertainties and other factors that could significantly affect the Company’s operations and may cause the Company’s actual actions, results, financial condition, performance or achievements to differ materially from any future actions, results, financial condition, performance or achievements expressed or implied by any such forward-looking statements. Factors that may cause such a difference include, without limitation, those discussed under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023 (our “2023 Form 10-K”), filed with the Securities and Exchange Commission (“SEC”) on February 28, 2024 and those discussed in Part II, Item 1A, Risk Factors, if any.
Unless required by law, the Company does not intend, and undertakes no obligation, to update or publicly release any revision to any forward-looking statements, whether as a result of the receipt of new information, the occurrence of subsequent events, a change in circumstances or otherwise. Each forward-looking statement contained in this Quarterly Report is specifically qualified in its entirety by the aforementioned factors. Readers are advised to carefully read this Quarterly Report in conjunction with the important disclaimers set forth above prior to reaching any conclusions or making any investment decisions and not to place undue reliance on forward-looking statements, which speak only as of the date of the filing of this Quarterly Report with the SEC.
Estimates and Projections
4


This Quarterly Report includes certain estimates, projections and other statistical data. These estimates and projections reflect management’s best estimates based upon currently available information and certain assumptions we believe to be reasonable as of the date of this Quarterly Report. These estimates are inherently uncertain, subject to risks and uncertainties, many of which are not within our control, have not been reviewed by our independent auditors and may be revised as a result of management’s further review. In addition, these estimates and projections are not a comprehensive statement of our financial results, and our actual results may differ materially from these estimates and projections due to developments that may arise between now and the time the results are final. There can be no assurance that the estimates will be realized, and our results may vary significantly from the estimates, including as a result of unexpected issues in our business and operations. Accordingly, you should not place undue reliance on such information. Projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.
5


PART I - FINANCIAL INFORMATION
Item 1. Financial Statements
MIMEDX GROUP, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)
(unaudited)
 March 31,
2024
December 31,
2023
ASSETS 
Current assets:  
Cash and cash equivalents$48,487 $82,000 
Accounts receivable, net57,016 53,871 
Inventory24,454 21,021 
Prepaid expenses 6,095 5,624 
Other current assets2,801 1,745 
Total current assets138,853 164,261 
Property and equipment, net7,340 6,974 
Right of use asset3,499 2,132 
Deferred tax asset, net38,747 40,777 
Goodwill19,441 19,441 
Intangible assets, net12,550 5,257 
Other assets1,251 205 
Total assets$221,681 $239,047 
LIABILITIES AND STOCKHOLDERS’ EQUITY
  
Current liabilities:  
Current portion of long term debt$1,000 $1,000 
Accounts payable9,697 9,048 
Accrued compensation17,913 22,353 
Accrued expenses9,196 9,361 
Current liabilities of discontinued operations344 1,352 
Other current liabilities4,071 2,894 
Total current liabilities42,221 46,008 
Long term debt, net18,453 48,099 
Other liabilities5,276 2,223 
Total liabilities$65,950 $96,330 
Commitments and contingencies (Note 12)
Stockholders' equity
Common stock; $0.001 par value; 250,000,000 shares authorized; 147,528,596 issued and outstanding at March 31, 2024 and 146,227,639 issued and outstanding at December 31, 2023
148 146 
Additional paid-in capital280,000 276,249 
Accumulated deficit(124,417)(133,678)
Total stockholders' equity
155,731 142,717 
Total liabilities and stockholders’ equity
$221,681 $239,047 
See notes to unaudited condensed consolidated financial statements
6


MIMEDX GROUP, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except share and per share data)
(unaudited)
 Three Months Ended March 31,
 20242023
Net sales$84,709 $71,676 
Cost of sales12,987 12,419 
Gross profit71,722 59,257 
Operating expenses:
Selling, general and administrative55,129 52,250 
Research and development2,841 3,484 
Investigation, restatement and related311 3,673 
Amortization of intangible assets189 190 
Impairment of intangible assets54  
Operating income (loss)13,198 (340)
Other expense, net
Interest expense, net(1,690)(1,553)
Other (expense) income, net
(99)2 
Income (loss) from continuing operations before income tax11,409 (1,891)
Income tax expense from continuing operations(2,348)(51)
Net income (loss) from continuing operations9,061 (1,942)
Income (loss) from discontinued operations, net of tax200 (3,041)
Net income (loss)$9,261 $(4,983)
Net income (loss) from continuing operations available to common stockholders$9,061 $(3,626)
Basic net income (loss) per common share:
Continuing operations$0.06 $(0.03)
Discontinued operations (0.03)
Basic net income (loss) per common share$0.06 $(0.06)
Diluted net income (loss) per common share:
Continuing operations$0.06 $(0.03)
Discontinued operations (0.03)
Diluted net income (loss) per common share$0.06 $(0.06)
Weighted average common shares outstanding - basic146,404,587 114,398,813 
Weighted average common shares outstanding - diluted150,028,107 114,398,813 

See notes to unaudited condensed consolidated financial statements

7


MIMEDX GROUP, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)
(in thousands, except share data)
(unaudited)
Common Stock IssuedAdditional Paid - inTreasury StockAccumulated
SharesAmountCapitalSharesAmount DeficitTotal
Balance at December 31, 2023146,227,639 $146 $276,249  $ $(133,678)$142,717 
Share-based compensation expense— — 4,340 — — — 4,340 
Exercise of stock options109,920 — 766 — — 766 
Employee stock purchase plan121,783 — 797 — — — 797 
Issuance of restricted stock, net1,069,254 2 (2,152)— — — (2,150)
Net income— — — — — 9,261 9,261 
Balance at March 31, 2024147,528,596 $148 $280,000  $ $(124,417)$155,731 
Common Stock IssuedAdditional Paid - inTreasury StockAccumulated
SharesAmountCapitalSharesAmount DeficitTotal
Balance at December 31, 2022113,705,447 $114 $173,804  $ $(191,906)$(17,988)
Share-based compensation expense— — 4,345 — — — 4,345 
Issuance of restricted stock1,439,676 1 (179)(57,770)178 —  
Restricted stock shares canceled/forfeited— — 179 58,104 (179)—  
Employee stock purchase plan 235,419 — 680 — — — 680 
Net loss— — — — — (4,983)(4,983)
Balance at March 31, 2023115,380,542 $115 $178,829 334 $(1)$(196,889)$(17,946)
8


MIMEDX GROUP, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands)
(unaudited)
 Three Months Ended March 31,
 20242023
Cash flows from operating activities:  
Net income (loss) from continuing operations$9,061 $(1,942)
Adjustments to reconcile net income (loss) from continuing operations to net cash flows provided by (used in) operating activities from continuing operations:  
Share-based compensation4,340 3,904 
Change in deferred income taxes2,031  
Loss on extinguishment of debt1,401  
Depreciation558 714 
Non-cash lease expenses317 334 
Bad debt expense199 (60)
Amortization of intangible assets189 190 
Loss on fixed asset disposal185  
Accretion of asset retirement obligation22 22 
Amortization of deferred financing costs69 121 
Increase (decrease) in cash resulting from changes in:  
Accounts receivable(3,344)(1,551)
Inventory(2,941)(1,474)
Prepaid expenses(471)934 
Other assets(1,001)1,030 
Accounts payable283 (686)
Accrued compensation(4,440)(2,494)
Accrued expenses522 1,956 
Other liabilities(195)(398)
Net cash flows provided by operating activities from continuing operations6,785 600 
Net cash flows used in operating activities of discontinued operations
(807)(4,648)
Net cash flows provided by (used in) operating activities5,978 (4,048)
Cash flows from investing activities:  
Consideration paid pursuant to TELA APA (Note 12)
(5,000) 
Purchases of equipment(1,144)(633)
Patent application costs120 (44)
Net cash flows used in investing activities(6,024)(677)
Cash flows from financing activities:  
Proceeds from Citizens Revolving Credit Facility30,000  
Proceeds from Citizens Term Loan Facility19,783  
Proceeds from exercise of stock options766  
Principal payments on finance lease(13)(4)
Prepayment premium on Hayfin term loan(500) 
Deferred financing cost(1,101) 
Repayment of Hayfin term loan(50,000) 
Repayment of Citizens Revolving Credit Facility(30,000) 
Principal payments on Citizens Term Loan Facility(250) 
Stock repurchased for tax withholdings on vesting of restricted stock units(2,152) 
Net cash flows used in financing activities(33,467)(4)
Net change in cash(33,513)(4,729)
Cash and cash equivalents, beginning of period82,000 65,950 
Cash and cash equivalents, end of period$48,487 $61,221 
See notes to unaudited condensed consolidated financial statements
9


MIMEDX GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE MONTHS ENDED MARCH 31, 2024 AND 2023

1.Nature of Business
MiMedx Group, Inc. (together with its subsidiaries, except where the context otherwise requires, “MIMEDX,” or the “Company”) is a pioneer and leader in placental biologics focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. All of our products sold in the United States are regulated by the United States Food and Drug Administration (“FDA”).
The Company’s product portfolio and product development focuses on Wound and Surgical markets.
The Company’s business is focused primarily on the United States of America but the Company also has a small commercial presence in several international locations, including Japan.
2.Significant Accounting Policies
Please see Note 2, Significant Accounting Policies, to the Company’s Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Form 10-K”), filed with the Securities and Exchange Commission (“SEC”) on February 28, 2024 for a description of all significant accounting policies.
Basis of Presentation
The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations for the periods presented have been included. The operating results for the three months ended March 31, 2024 and 2023 are not necessarily indicative of the results that may be expected for the full fiscal year. The balance sheet as of December 31, 2023 was derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.
These unaudited condensed consolidated financial statements should be read in conjunction with the historical consolidated financial statements of the Company included in the 2023 Form 10-K.
Reclassifications
Current portion of long term debt of $1.0 million as of December 31, 2023, which was presented in other current liabilities in previously-issued financial statements, has been reclassified to be presented in a separate line item still within current liabilities in the March 31, 2024 balance sheet presentation.
Principles of Consolidation
The consolidated financial statements include the accounts of MiMedx Group, Inc. and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation.
Use of Estimates
GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported consolidated statements of operations during the reporting period. Actual results could differ from those estimates. Significant estimates include estimated useful lives and potential impairment of property and equipment, estimates of impairment for goodwill and intangible assets, estimates of useful lives for intangible assets, estimates of loss for contingent liabilities, estimate of allowance for doubtful accounts, estimate of fair value and the probable achievement of share-based payments, estimates of returns and allowances, and valuation of deferred tax assets.
10


Recently Issued Accounting Standards Not Yet Adopted
In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, “Segment Reporting: Improvements to Reportable Segment Disclosures (Topic 280)”. The standard improves disclosures about a public entity’s reportable segments and addresses requests from investors for additional, more detailed information about a reportable segment’s expenses. Additionally, ASU 2023-07 extends the disclosure requirements under Accounting Standards Codification (“ASC”) Topic 280 to entities with a single reportable segment. ASU 2023-07 is effective for annual reporting periods beginning after December 15, 2023, and interim periods in fiscal years beginning after December 15, 2024. As of March 31, 2024, the Company is evaluating the impact of this standard on its consolidated financial statements.
In December 2023, the FASB issued ASU 2023-09, “Improvement to Income Tax Disclosures (Topic 740)”, which requires additional disclosures for income tax rate reconciliations, income taxes paid, and certain other tax disclosures. ASU 2023-09 is intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to the rate reconciliation and income taxes paid information. Adoption is required for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures.
All other ASUs issued and not yet effective as of March 31, 2024, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company’s current and future financial position and results of operations.
3. Accounts Receivable, Net
Accounts receivable, net, consisted of the following (in thousands):
 March 31, 2024December 31, 2023
Accounts receivable, gross$60,282 $57,015 
Less: allowance for doubtful accounts(3,266)(3,144)
Accounts receivable, net$57,016 $53,871 
Activity related to the Company’s allowance for doubtful accounts for the three months ended March 31, 2024 was as follows (in thousands):
Allowance for Doubtful Accounts
Balance at December 31, 2023
$3,144 
Bad debt expense199 
Write-offs(77)
Balance at March 31, 2024
$3,266 
Allowance for Doubtful Accounts
Balance at December 31, 2022
$3,783 
Bad debt expense reversal
(60)
Write-offs(122)
Balance at March 31, 2023
$3,601 
4.     Inventory
Inventory consisted of the following (in thousands):
 March 31, 2024December 31, 2023
Raw materials$1,136 $825 
Work in process8,609 8,521 
Finished goods14,709 11,675 
Inventory$24,454 $21,021 
11


5.    Property and Equipment, Net
Property and equipment, net, consisted of the following (in thousands):
 March 31, 2024December 31, 2023
Laboratory and clean room equipment$14,504 $13,954 
Furniture and equipment2,205 1,989 
Leasehold improvements8,141 8,141 
Construction in progress1,870 1,791 
Asset retirement cost889 938 
Finance lease right-of-use asset189 189 
Property and equipment, gross27,798 27,002 
Less: accumulated depreciation and amortization(20,458)(20,028)
Property and equipment, net$7,340 $6,974 
6.     Intangible Assets, Net
Intangible assets, net, are summarized as follows (in thousands):
March 31, 2024December 31, 2023
Gross Carrying AmountAccumulated AmortizationNet Carrying AmountGross Carrying AmountAccumulated AmortizationNet Carrying Amount
Amortized intangible assets
Patents and know-how$9,968 $(7,949)$2,019 $10,039 $(7,818)$2,221 
Licenses1,000 (67)933 1,000 (54)$946 
Distribution rights7,602  7,602    
Total amortized intangible assets$18,570 $(8,016)$10,554 $11,039 $(7,872)$3,167 
Unamortized intangible assets:
Tradenames and trademarks$1,008 $1,008 $1,008 $1,008 
Patents in Process988 988 1,082 1,082 
Total intangible assets$20,566 $12,550 $13,129 $5,257 
The Company recognized $0.1 million of impairment of intangible assets during the three months ended March 31, 2024 related to patents which were abandoned.
Expected future amortization of intangible assets as of March 31, 2024, is as follows (in thousands):
Year ending December 31,Estimated
Amortization
Expense
2024 (excluding the three months ended March 31, 2024)
$1,708 
20251,883 
20261,729 
20271,728 
20281,726 
Thereafter1,780 
Total amortized intangible assets$10,554 
12


7. Accrued Expenses
Accrued expenses consisted of the following (in thousands):
March 31, 2024December 31, 2023
Commissions to sales agents$2,954 $4,136 
Accrued rebates1,380 745 
Legal and settlement costs1,235 834 
Accrued Group Purchasing Organization fees
1,235 1,338 
Estimated sales returns1,085 1,096 
Accrued travel142 433 
Other1,165 779 
Accrued expenses$9,196 $9,361 
8.    Long Term Debt, Net
Citizens Credit Agreement
On January 19, 2024, the Company entered into a Credit Agreement (the “Citizens Credit Agreement”) with certain lenders party thereto, and Citizens Bank, N.A., as administrative agent (the “Agent”). The Citizens Credit Agreement provides for senior secured credit facilities in an aggregate principal amount of up to $95.0 million consisting of: (i) a $75.0 million senior secured revolving credit facility (the “Revolving Credit Facility”) with a $10.0 million letter of credit sublimit and a $10.0 million swingline loan sublimit, and (ii) a $20.0 million senior secured term loan facility (the “Term Loan Facility” and, together with the Revolving Credit Facility, the “Credit Facilities”). All obligations are required to be paid in full on January 19, 2029 (the “Maturity Date”). The Company has the option to obtain one or more incremental Term Loan Facilities and/or increase the commitments under the Revolving Credit Facility in an aggregate principal amount equal to the greater of (i) $50.0 million and (ii) 1.00 times the Company’s Consolidated EBITDA (as defined therein), each subject to the existing or any new lenders’ election to extend additional term loans or revolving commitments.
At the Company’s option, borrowings under the Citizens Credit Agreement (other than any swingline loan) will bear interest at a rate per annum equal to (i) the Alternate Base Rate, as defined therein, or (ii) a Term SOFR as defined therein, in each case plus an applicable margin ranging from 1.25% and 2.50% with respect to Alternate Base Rate borrowings and 2.25% and 3.50% for Term SOFR borrowings, plus a fallback provision of 0.1%. Swingline loans will bear interest at a rate per annum equal to one-month Term SOFR plus the applicable margin. The applicable margin will be determined based on the Company’s consolidated total net leverage ratio.
The Company is required to pay a quarterly commitment fee on any unused portion of the Revolving Credit Facility, letter of credit fees, and other customary fees to the Agent and the Lenders. The Term Loan Facility will amortize on a quarterly basis at 1.25% (for year one and two), 1.88% (for year three and four), and 2.5% (for year five) based on the aggregate principal amount outstanding under the Term Loan Facility, with the remainder due on the Maturity Date. The Company must make mandatory prepayments in connection with certain asset dispositions and casualty events, subject in each case to customary reinvestment rights. The Company may prepay borrowings under the Credit Facilities at any time, without premium or penalty, and may, at its option, reduce the aggregate unused commitments under the Revolving Credit Facility in whole or in part, in each case subject to the terms of the Credit Agreement. The Company must also comply with certain financial covenants, including a maximum total net leverage ratio and a minimum consolidated fixed charge coverage ratio, as well as other customary restrictive covenants.
On January 19, 2024, the Company borrowed $30.0 million under the Revolving Credit Facility and $20.0 million under the Term Loan Facility. Proceeds from the initial drawings under the Credit Facilities together with cash on hand were used to repay in full the $50.0 million principal amount and other outstanding obligations under the Company’s prior senior secured term loan with Hayfin (the “Hayfin Loan Agreement”) and to pay related fees, premiums, costs and expenses (collectively with the entry into the Citizens Credit Agreement and the initial borrowings thereunder, the “Debt Refinancing Transactions”). The Company recorded a loss on extinguishment of debt of $1.4 million. This amount is reflected as a part of interest expense, net on the unaudited condensed consolidated statement of operations for the three months ended March 31, 2024. The composition of the loss on extinguishment of debt was as follows (amounts in thousands):
13


January 19, 2024
Unamortized deferred financing costs
$781 
Unamortized original issue discount
120 
Prepayment premium
500 
Loss on extinguishment of debt
$1,401 
In addition, on February 27, 2024, the Company repaid the initial $30.0 million drawing under the Revolving Credit Facility and had no outstanding borrowings under this facility as of March 31, 2024. Deferred financing costs and original issue discount allocated to the Revolving Credit Facility are amortized straight-line through the expiration of the commitment term. The Revolving Credit Facility is currently subject to a commitment fee of 0.25% per annum of the amount undrawn, which is recognized as interest expense.
Original issue discount and deferred financing costs incurred as part of the Credit Facilities were allocated between the Term Loan Facility and the Revolving Credit Facility on the basis of the maximum potential principal outstanding permitted under the Citizens Credit Agreement. The allocation of the deferred financing costs and original issue discount between the Term Loan Facility and the Revolving Credit Facility were as follows (in thousands):
January 19, 2024
Term Loan Facility
Revolving Credit Facility
Total
Long term debt
Other assets
Original issue discount
$224 $839 $1,063 
Deferred financing
54 202 256 
The balances of the Term Loan Facility as of March 31, 2024 and the Hayfin Loan Agreement as of December 31, 2023 were as follows (in thousands):
March 31, 2024December 31, 2023
Current portion of long term debt
Long term debt, netCurrent portion of long term debtLong term debt, net
Outstanding principal$1,000 $18,750 $1,000 $49,000 
Deferred financing costs (82) (781)
Original issue discount (215) (120)
Long term debt, net$1,000 $18,453 $1,000 $48,099 
The Citizens Term Loan Facility bears interest at a rate per annum equal to (i) the Alternate Base Rate, as defined therein, or (ii) a Term SOFR as defined therein, in each case plus an applicable margin ranging from 1.25% and 2.50% with respect to Alternate Base Rate borrowings and 2.25% and 3.50% for Term SOFR borrowings, plus a fallback provision of 0.1%. The applicable margin is determined based on the Company’s consolidated total net leverage ratio. The Term Loan Facility carried an interest rate of 7.9% as of March 31, 2024. Interest expense related to the Term Loan Facility and the Hayfin Loan Agreement included in interest expense, net in the unaudited condensed consolidated statements of operations, was as follows (amounts in thousands):
Three Months Ended March 31,
20242023
Stated interest$661 $1,436 
Amortization of deferred financing costs29 105 
Accretion of original issue discount13 16 
Interest expense$703 $1,557 
Interest expense related to the Revolving Credit Facility included in interest expense, net in the unaudited condensed consolidated statements of operations, was as follows (amounts in thousands):
14


Three Months Ended March 31,
2024
Commitment fee
$30 
Amortization of deferred financing costs16 
Accretion of original issue discount42 
Interest expense$88 
A summary of principal payments due on the Term Loan Facility, by year, from March 31, 2024 through maturity are as follows (in thousands):
Year ending December 31,Principal
2024 (excluding the three months ended March 31, 2024)
$750 
2025
1,000 
2026
1,500 
2027
1,500 
2028
2,000 
Thereafter13,000 
Outstanding principal$19,750 
                                                                                
As of March 31, 2024, the fair value of the Term Loan Facility was $19.3 million. This valuation was calculated based on a series of Level 2 and Level 3 inputs, including a discount rate based on the credit risk spread of debt instruments of similar risk character in reference to U.S. Treasury instruments with similar maturities, with an incremental risk premium for risk factors specific to the Company. Fair value was calculated by discounting the remaining cash flows associated with the Term Loan Facility to March 31, 2024 using this discount rate.
9. Net Income (Loss) Per Common Share
Net income (loss) per common share is calculated using two methods: basic and diluted.
Basic Net Income (Loss) Per Common Share
The following table provides a reconciliation of net income (loss) to net income (loss) available to common stockholders and calculation of basic net income (loss) per common share for each of the three months ended March 31, 2024 and 2023 (in thousands, except share and per share amounts):
 Three Months Ended March 31,
 20242023
Net income (loss) from continuing operations$9,061 $(1,942)
Income (loss) from discontinued operations, net of tax$200 $(3,041)
Net income (loss)9,261 (4,983)
Adjustments to reconcile to income (loss) available to common stockholders:
Accumulated dividend on previously converted Series B Preferred Stock 1,684 
Net income (loss) available to common stockholders from continuing operations$9,061 $(3,626)
Weighted average common shares outstanding146,404,587 114,398,813 
Basic net income (loss) per common share:
Continuing operations$0.06 $(0.03)
Discontinued operations (0.03)
Basic net income (loss) per common share$0.06 $(0.06)
15


Diluted Net Income (Loss) Per Common Share
The following table sets forth the computation of diluted net income (loss) per common share (in thousands, except share and per share amounts):
 Three Months Ended March 31,
 20242023
Net income (loss) available to common stockholders from continuing operations$9,061 $(3,626)
Adjustments:
Dividends on Series B Preferred Stock 1,684 
Less: antidilutive adjustments (1,684)
Total adjustments  
Numerator
Net income (loss) available to common shareholders from continuing operations9,061 (3,626)
Income (loss) from discontinued operations, net of tax200 (3,041)
Weighted average shares outstanding146,404,587 114,398,813 
Adjustments:
Potential common shares (a)
Restricted stock unit awards2,016,109  
Outstanding stock options1,499,970  
Performance stock unit awards106,802  
Employee stock purchase plan639  
Total adjustments3,623,520  
Weighted average shares outstanding adjusted for potential common shares150,028,107 114,398,813 
Diluted net income (loss) per common share:
Continuing operations$0.06 $(0.03)
Discontinued operations (0.03)
Diluted net income (loss) per common share$0.06 $(0.06)
(a) Weighted average common shares outstanding for the calculation of diluted net income (loss) per common share does not include the following adjustments for potential common shares below because their effects were determined to be antidilutive for the periods presented.
Three Months Ended March 31,
20242023
Series B Preferred Stock 29,559,946 
Restricted stock unit awards 567,167 
Restricted stock awards 5,152 
Employee stock purchase plan 5,740 
Performance stock unit awards 13,133 
Outstanding stock options  
Potential common shares 30,151,138 
10. Income Taxes
On a continuing operations basis, the effective tax rates for the Company were 20.6% and (2.7)% for the three months ended March 31, 2024 and 2023, respectively. Restricted stock vestings impacted the effective tax rate for the three months ended March 31, 2024. Net operating losses generated for the three months ended March 31, 2023 were offset by a valuation allowance.
16


11.    Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities
Selected cash payments, receipts, and non-cash activities are as follows (in thousands):
Three Months Ended March 31,
 20242023
Cash paid for interest$1,403 $1,452 
Cash paid for income taxes8  
Non-cash activities:
Present value of minimum earn out
2,731  
Right of use assets arising from operating lease liabilities1,820  
Issuance of shares pursuant to employee stock purchase plan797 680 
Purchases of equipment in accounts payable626 223 
Consideration payable to TELA
366  
Unpaid deferred financing costs149  
12. Commitments and Contingencies
TELA and Regenity Agreements
On March 15, 2024, the Company entered into an Asset Purchase Agreement (the “TELA APA”) with TELA Bio, Inc. (“TELA”) to obtain exclusive rights to sell and market a 510(k)-cleared collagen particulate xenograft product in the United States pursuant to a preexisting Manufacturing and Supply Agreement (the “TELA-Regenity Supply Agreement”) between TELA and Regenity Biosciences, Inc. (“Regenity”), which retains all intellectual property rights and regulatory clearances related to the product. Pursuant to the TELA APA, the Company paid $5.0 million of initial consideration to TELA and will be required to make future payments of $0.4 million to acquire TELA’s remaining product inventory, as well as future profit share payments (the “Profit Share Payments”) of between a minimum of $3.0 million and a maximum of $7.0 million based on MIMEDX’s net sales of the product over the two-years following its commercialization of the product.
Simultaneously with entry into the TELA APA, the Company executed a new Manufacturing and Supply Agreement (the “Supply Agreement”) with Regenity, replacing the previous TELA-Regenity Supply Agreement. The Supply Agreement maintains MIMEDX’s exclusive right to sell and market the product in the United States and requires MIMEDX to purchase a minimum amount of the xenograft product from Regenity annually through December 31, 2033. Should MIMEDX fail to meet a purchasing minimum in any one period, it has the option (among others) to amend its distribution rights under the Supply Agreement to be non-exclusive.
The transaction was accounted for as an acquisition of assets. The cost to acquire the assets on the transaction date was assessed to be $8.1 million, reflecting the $5.0 million of initial consideration, $0.4 million to acquire inventory, and $2.7 million, reflecting the fair value of the minimum amount of the Profit Share Payments, were allocated amongst the assets acquired. The Company assigned $7.6 million to the distribution rights acquired and $0.5 million to inventory. These amounts are reflected in the consolidated balance sheets as part of intangible assets, net and inventory, respectively, on the unaudited condensed consolidated balance sheet as of March 31, 2024.
The $2.7 million fair value for the minimum amount of Profit Share Payments reflects the anticipated timing of such Profit Share Payments, discounted to present value at a discount rate approximating the Company’s borrowing rate plus a risk premium.
Of the minimum Profit Share Payment, $1.1 million is reflected as part of other current liabilities in the unaudited condensed consolidated balance sheet as of March 31, 2024, reflecting the extent of the obligation that is anticipated to be repaid within twelve months of that date. The remaining balance is reflected in other liabilities.
Litigation and Regulatory Matters
In the ordinary course of business, the Company and its subsidiaries may be a party to pending and threatened legal, regulatory, and governmental actions and proceedings (including those described below). In view of the inherent difficulty of predicting the outcome of such matters, particularly where the plaintiffs or claimants seek very large or indeterminate damages or where the matters present novel legal theories or involve a large number of parties, the Company generally cannot predict what the eventual outcome of the pending matters will be, what the timing of the ultimate resolution of these matters will be, or what the
17


eventual recovery, loss, fines or penalties related to each pending matter may be. The Company's unaudited condensed consolidated balance sheet as of March 31, 2024 reflects the Company's current best estimate of probable losses associated with these matters, including costs to comply with various settlement agreements, where applicable. For more information regarding the Company’s legal proceedings, refer to Note 16, “Commitments and Contingencies” in the 2023 Form 10-K.
The Company has not accrued for any potential losses related to legal matters as of March 31, 2024. The Company made no payments toward the resolution of legal matters involving the Company during the three months ended March 31, 2024. The Company paid $0.2 million during the three months ended March 31, 2023.
The following is a description of certain litigation and regulatory matters to which the Company is a party:
Welker v. MiMedx, et. al.
On November 4, 2022, Troy Welker and Min Turner, former optionholders of the Company, brought a lawsuit in Fulton County State Court against the Company, former directors Terry Dewberry and Charles Evans, and former officers Parker H. “Pete” Petit, William C. Taylor, and Michael Senken alleging violations of the Georgia Racketeer Influenced and Corrupt Organizations (“RICO”) Act against all defendants, and conspiracy to violate the Georgia RICO Act and breach of fiduciary duty against the individual defendants. On motion by the Company, the case has been moved to the Fulton County Business Court. The Company and the individual defendants filed answers and motions to dismiss, which were denied on the RICO claims, but granted with respect to the breach of fiduciary duty claims against the individual defendants. The Company is defending against the allegations and is obligated to indemnify certain of its current and former officers and directors who are party to this proceeding.
Former Employee Litigation and Related Matters
On January 12, 2021, the Company filed suit in the Circuit Court of the Eleventh Judicial District in and for Miami-Dade County, Florida (MiMedx Group, Inc. v. Petit, et. al.) against its former CEO, Parker H. “Pete” Petit, and its former COO, William C. Taylor, seeking a determination of its rights and obligations under indemnification agreements with Petit and Taylor following a federal jury’s guilty verdict against Petit for securities fraud and Taylor for conspiracy to commit securities fraud. On March 26, 2024, the Company filed an amended complaint against only Petit as the Company previously reached as settlement with Taylor. The Company is seeking a declaratory judgment that Petit is not entitled to indemnification in connection with certain cases and the Company is also seeking to recoup amounts previously paid on behalf of Petit in connection with such cases.
As noted above, the Company and Mr. Taylor reached an agreement to settle the matter between them. Negotiations with Mr. Petit are ongoing.
13.     Revenue
Net Sales by Site of Service
MIMEDX has three main sites of service for its products (1) Hospital settings and wound care clinics, which are stable reimbursement settings in which products are used for surgical applications, (2) Private offices, which generally represents doctors and practitioners with independent operations, and (3) Other, which includes federal facilities, international sales, and other sites of service.
Below is a summary of net sales by site of service (in thousands):
Three Months Ended March 31,
20242023
Hospital$43,757 $42,171 
Private Office30,332 21,487 
Other10,620 8,018 
Total$84,709 $71,676 
Net Sales by Product Line
MIMEDX has two product lines (1) Wound, which reflects products typically used in Advanced Wound Care settings, including the treatment of chronic, non-healing wounds, and (2) Surgical, which reflects products principally used in surgical
18


settings, including the closure of acute wounds or to protect and reinforce tissues and/or regions of interest. The Company manages its product portfolio and pipeline, based upon opportunities in each of these settings.
Below is a summary of net sales by product line (in thousands):
Three Months Ended March 31,
20242023
Wound
$57,049 $45,206 
Surgical
27,660 26,470 
Total$84,709 $71,676 
The Company did not have significant foreign operations or a single external customer from which 10% or more of revenues were derived during the three months ended March 31, 2024 or 2023.
AXIOFILL
The Company received a determination letter on March 25, 2024 reaffirming the FDA’s position that AXIOFILL does not meet the regulatory classification requirements of a Human Cell, Tissue or Cellular or Tissue-based Product under Section 361 of the Public Health Service Act. The Company strongly disagrees with this determination and has filed suit in the U.S. District Court for the Northern District of Georgia against the FDA on this matter.
14. Discontinued Operations
Disbanding of Regenerative Medicine Business Unit
On June 20, 2023, the Company announced the disbanding of its Regenerative Medicine business unit and the suspension of its Knee Osteoarthritis clinical trial program. During the fourth quarter of 2023, the Company materially completed the regulatory obligations associated with the clinical trial.
Financial Statement Impact of Discontinued Operations
The income and expenses of the discontinued operation have been classified as income (loss) from discontinued operations in the consolidated statements of operations for the three months ended March 31, 2024 and 2023 as follows (in thousands):
Three Months Ended March 31,
20242023
Selling, general and administrative expense
 29 
Research and development expense
$(200)3,012 
Income (loss) from discontinued operations
$200 $(3,041)

19


Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Overview
Executive Summary
During the first quarter of 2024, the Company continued its trend of strong commercial performance, delivering 18.2% growth in net sales year-over-year. This growth was driven by execution across all care settings.
Operating and financial highlights during the quarter included:
Net sales of $84.7 million, reflecting 18.2% growth over the prior year period.
GAAP net income from continuing operations and net margin for the first quarter of 2024 of $9.1 million and 10.7%, respectively.
Improved capital structure with new senior secured credit facilities and debt refinancing.
Announced surgical portfolio expansion through a distribution agreement with Regenity Biosciences for a 510(k)-cleared collagen particulate xenograft product.
Appointed two new independent directors to the Company’s Board of Directors.
Introduced an online product ordering and account management platform for our customers.
Overview
MIMEDX is a pioneer and leader in placental biologics focused on delivering innovative solutions to patients and the healthcare professionals who treat them. With more than a decade of experience helping clinicians manage acute and chronic wounds, MIMEDX has been dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. All of our products sold in the United States are regulated by the U.S. Food & Drug Administration (“FDA”). We apply Current Good Tissue Practices (“CGTP”) and other applicable quality standards in addition to terminal sterilization to produce our allografts.
This discussion, which presents our results for the three months ended March 31, 2024 and 2023, should be read in conjunction with the financial statements and accompanying notes included in this Form 10-Q and the financial statements and accompanying notes and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023.
20


Results of Operations
Three Months Ended March 31, 2024 Compared to the Three Months Ended March 31, 2023
Three Months Ended March 31,
(in thousands)
20242023$ Change% Change
Net sales$84,709 $71,676 $13,033 18.2 %
Cost of sales12,987 12,419 568 4.6 %
Gross profit71,722 59,257 12,465 21.0 %
Selling, general and administrative55,129 52,250 2,879 5.5 %
Research and development2,841 3,484 (643)(18.5)%
Investigation, restatement and related311 3,673 (3,362)(91.5)%
Amortization of intangible assets189 190 (1)(0.5)%
Impairment of intangible assets54 — 54 — %
Interest expense, net(1,690)(1,553)(137)8.8 %
Other (expense) income, net(99)(101)nm
Income tax provision expense(2,348)(51)(2,297)nm
Net income (loss) from continuing operations9,061 (1,942)11,003 nm
Changes noted as “nm” in the table above indicate that the percentage change is not meaningful.
Net Sales
We recorded net sales for the three months ended March 31, 2024 of $84.7 million, a $13.0 million, or 18.2%, increase compared to the three months ended March 31, 2023, in which we recognized net sales of $71.7 million.
Our sales by product line were as follows (amounts in thousands):
Three Months Ended March 31,Change
20242023$%
Wound
$57,049 $45,206 $11,843 26.2 %
Surgical
27,660 26,470 1,190 4.5 %
Total$84,709 $71,676 $13,033 18.2 %
Net sales of our Wound product portfolio were $57.0 million for the three months ended March 31, 2024, a $11.8 million or 26.2% increase compared to $45.2 million for the three months ended March 31, 2023. The increase was driven by strong sales, particularly in the private office subsegment of the market.
Net sales of our Surgical products totaled $27.7 million, reflecting growth of $1.2 million, or 4.5% compared to the three months ended March 31, 2023. The increase was primarily driven by, growing contributions from AMNIOEFFECT® and, to a lesser degree, AXIOFILL®. In addition, Surgical sales for the three months ended March 31, 2023 reflects approximately $1 million of sales of our dental product which we have since discontinued.
Cost of Sales and Gross Profit Margin
Cost of sales for the three months ended March 31, 2024 and 2023 was $13.0 million and $12.4 million, respectively, an increase of $0.6 million, or 4.6%, year-over-year. Gross profit margin for the three months ended March 31, 2024 was 84.7% compared to 82.7% for the three months ended March 31, 2023. The year-over-year improvement in gross margin was driven by favorable product mix and our continued execution on yield improvement projects. Increases in cost of sales were driven by increases in sales volume noted above.
21


Selling, General and Administrative Expense
Selling, general and administrative (“SG&A”) expense for the three months ended March 31, 2024 was $55.1 million, compared to $52.3 million for the three months ended March 31, 2023, an increase of $2.9 million, or 5.5%, year-over-year. The increase in SG&A was driven by year-over-year increases in commissions due to greater sales volume, as well as a larger proportion of sales through sales agents during the three months ended March 31, 2024.
Research and Development Expense
Our research and development (“R&D”) expense decreased $0.6 million, or 18.5%, to $2.8 million for the three months ended March 31, 2024, compared to $3.5 million for the three months ended March 31, 2023. The decrease was driven primarily by lower headcount and the timing of R&D activities compared to the prior year.

Investigation, Restatement and Related Expense
Investigation, restatement and related expense for the three months ended March 31, 2024 was $0.3 million compared to $3.7 million for the three months ended March 31, 2023. The decrease was related to expenses under our last proceeding entailing material obligations under an indemnification agreement, which substantially ceased in 2023.
Amortization of Intangible Assets
Amortization expense related to intangible assets was $0.2 million for each of the three months ended March 31, 2024 and 2023.
Interest Expense, Net
Interest expense, net was $1.7 million for the three months ended March 31, 2024 compared to $1.6 million for the three months ended March 31, 2023, an increase of $0.1 million, or 8.8%, year-over-year. The increase was the result of the loss on extinguishment of debt due to repaying and terminating our Hayfin Loan Agreement during the first quarter of 2024 ($1.4 million), offset by decreases in outstanding debt and lower interest rates under the Citizens Credit Facilities as well as improvement in our treasury management.
Income Tax Provision Expense
The effective tax rates for the Company were 20.6% and (2.7)% for the three months ended March 31, 2024 and March 31, 2023, respectively. The effective tax rate for the three months ended March 31, 2024 was favorably impacted by vestings of restricted stock units. Net operating losses generated for the three months ended March 31, 2023 were offset by a valuation allowance.
Discussion of Cash Flows
Operating Activities
Net cash provided by operating activities from continuing operations during the three months ended March 31, 2024 was $6.8 million, compared to cash provided by operating activities from continuing operations of $0.6 million for the three months ended March 31, 2023. The change was primarily the result of year-over-year increases in net sales, which drove increases in collections from customers. These increases were partially offset by year-over-year increases in operating expenses.
Investing Activities
Net cash used for investing activities during the three months ended March 31, 2024 was $6.0 million, compared to $0.7 million for the three months ended March 31, 2023. This increase was largely the result of our investment to expand our product portfolio through the TELA and Regenity agreements as described below in “Liquidity and Capital Resources”.
Financing Activities
Net cash used for financing activities during the three months ended March 31, 2024 was $33.5 million. Cash used in financing activities was immaterial during the three months ended March 31, 2023. The increase during the three months ended March 31, 2024 was due to the Company repaying the initial $30.0 million drawing under the Revolving Credit Facility, as described below in “Liquidity and Capital Resources,” deferred financing costs incurred under the Citizens Credit Agreement, and stock repurchases for tax witholdings upon vesting of employee restricted share units.
22


Liquidity and Capital Resources
We require capital for our operating activities, including costs associated with the sale of product through direct and indirect sales channels, research and development activities, compliance costs, costs to sell and market our products, regulatory fees, and legal and consulting fees in connection with ongoing litigation and other matters. We generally fund our operating capital requirements through our operating activities and cash reserves. We expect to use capital to invest in the broadening of our product portfolio, including through potential acquisitions, licensing agreements or other arrangements, the international expansion of our business and certain capital projects.
As of March 31, 2024, we had $48.5 million of cash and cash equivalents, total current assets of $138.9 million and total current liabilities of $42.2 million, reflecting a current ratio of 3.3, and we had no borrowings outstanding and $75 million of availability under our Revolving Credit Facility (as defined below).
The Company is currently paying its obligations in the ordinary course of business. We believe that our cash from operating activities, existing cash and cash equivalents, and available credit under the Citizens Credit Agreement, as defined below, will enable us to meet our operational liquidity needs for the twelve months following the filing date of this Quarterly Report.
Citizens Credit Facilities
On January 19, 2024, we entered into a Credit Agreement (the “Citizens Credit Agreement”) with a syndicate of banks comprised of Citizens Bank, N.A. as administrative agent (the “Agent”), and Bank of America, N.A. The Citizens Credit Agreement was designed to simultaneously improve our capital structure, providing the ability to refinance our prior $50 million senior secured term loan under the Hayfin Loan Agreement (as defined below) at lower interest rates and have access to additional borrowing capacity that could be deployed in the future in support of our organic and potential inorganic growth objectives.
The Citizens Credit Agreement provides for senior secured credit facilities in an aggregate principal amount of up to $95.0 million consisting of: (i) a $75.0 million senior secured revolving credit facility (the “Revolving Credit Facility”) with a $10.0 million letter of credit sublimit and a $10.0 million swingline loan sublimit, and (ii) a $20.0 million senior secured term loan facility (the “Term Loan Facility” and, together with the Revolving Credit Facility, the “Credit Facilities”). All obligations are required to be paid in full on January 19, 2029 (the “Maturity Date”), and are guaranteed by certain of the our subsidiaries, and secured by substantially all of the assets of the Company and the guarantors pursuant to a customary security agreement. Subject to the terms of the Citizens Credit Agreement, we have the option to obtain one or more incremental term loan facilities and/or increase the commitments under the Revolving Credit Facility in an aggregate principal amount equal to the greater of (i) $50.0 million and (ii) 1.00 times our Consolidated EBITDA as defined therein, each subject to the existing or any new lenders’ election to extend additional term loans or revolving commitments.
At our option, borrowings under the Citizens Credit Agreement (other than any swingline loan) will bear interest at a rate per annum equal to (i) the Alternate Base Rate, as defined therein, or (ii) a Term SOFR as defined therein, in each case plus an applicable margin ranging from 1.25% and 2.50% with respect to Alternate Base Rate borrowings and 2.25% and 3.50% for Term SOFR borrowings. Swingline loans will bear interest at a rate per annum equal to one-month Term SOFR plus the applicable margin. The applicable margin will be determined based on the Company’s consolidated total net leverage ratio.
We are required to pay a quarterly commitment fee on any unused portion of the Revolving Credit Facility, letter of credit fees, and other customary fees to the Agent and the Lenders. The Term Loan Facility will amortize on a quarterly basis at 1.25% (for year one and two), 1.875% (for year three and four), and 2.5% (for year five) based on the aggregate principal amount outstanding under the Term Loan Facility, with the remainder due on the Maturity Date. We must make mandatory prepayments in connection with certain asset dispositions and casualty events, subject in each case to customary reinvestment rights. We may prepay borrowings under the Credit Facilities at any time, without premium or penalty, and may, at its option, reduce the aggregate unused commitments under the Revolving Credit Facility in whole or in part, in each case subject to the terms of the Credit Agreement. We must also comply with certain financial covenants, including a maximum total net leverage ratio and a minimum consolidated fixed charge coverage ratio, as well as other customary restrictive covenants.
On January 19, 2024, we borrowed $30.0 million under the Revolving Credit Facility and $20.0 million under the Term Loan Facility. Proceeds from the initial drawings under the Credit Facilities, together with cash on hand, were used to repay in full the $50.0 million principal amount and other obligations under that certain Loan Agreement, dated as of June 30, 2020 (as amended from time to time), by and among the Company, the guarantors party thereto, the lenders party thereto and Hayfin Services LLP, as administrative and collateral agent (as amended from time to time, the “Hayfin Loan Agreement”) and to pay related fees, premiums, costs and expenses (collectively with the entry into the Citizens Credit Agreement and the initial borrowings thereunder, the “Debt Refinancing Transactions”).
23


On February 27, 2024, we repaid the initial $30.0 million drawing under the Revolving Credit Facility.
Hayfin Term Loan
In June 2020, we entered into the Hayfin Loan Agreement, pursuant to which Hayfin provided us with a senior secured term loan of $50 million (the “Hayfin Term Loan”). The Hayfin Term Loan was to mature on June 30, 2025. Interest on any borrowings was based on SOFR, plus a fallback provision of 0.15%, subject to a floor of 1.5%, plus a margin of 6.75%.
As noted above, in January 2024, we repaid the Hayfin Term Loan in full and terminated the Hayfin Loan Agreement.
Contractual Obligations
Except as described below, there were no significant changes to our contractual obligations during the three months ended March 31, 2024 from those disclosed in the section Item 7, “Management’s Discussion and Analysis of Financial Condition and Results from Operations”, in our 2023 Form 10-K.
TELA and Regenity Agreements
On March 15, 2024, the Company entered into an Asset Purchase Agreement (the “TELA APA”) with TELA Bio, Inc. (“TELA”) and a manufacturing and supply agreement (the “Supply Agreement”) with Regenity Biosciences, Inc. (“Regenity”), adding to the Company’s product portfolio a 510(k)-cleared collagen particulate xenograft product (the “Xenograft Product”) indicated for the management of moderately to heavily exudating wounds and to control minor bleeding. Under the terms of the TELA APA, the Company made an initial $5.0 million payment to TELA and will be required to make additional future payments aggregating between a minimum of $3.0 million and a maximum of $7.0 million based on net sales of the Xenograft Product over the next two years.
The Supply Agreement maintains MIMEDX’s exclusive right to sell and market the Xenograft Product in the United States and requires MIMEDX to purchase a minimum amount of the Xenograft Product from Regenity annually through December 31, 2033. Should MIMEDX fail to meet a purchasing minimum in any one period, it has the option (among others) to amend its distribution rights under the Supply Agreement to be non-exclusive.
Critical Accounting Estimates
In preparing financial statements, we follow accounting principles generally accepted in the United States, which require us to make certain estimates and apply judgments that affect our financial position and results of operations. We regularly review our accounting policies and financial information disclosures. A summary of critical accounting estimates in preparing the financial statements was provided in our 2023 Form 10-K.
Recent Accounting Pronouncements
For the effect of recent accounting pronouncements, see Note 2, Significant Accounting Policies, to the unaudited condensed consolidated financial statements contained herein.
Item 3. Quantitative and Qualitative Disclosures about Market Risk
We are exposed to risks associated with changes in interest rates that could adversely affect our results of operations and financial condition. We do not hedge against interest rate risk.
The interest rate on our Term Loan Facility is determined quarterly based on the 1-month term SOFR. As of March 31, 2024, the interest rate on our Term Loan Facility was 7.9%. A 100 basis point change in SOFR would change our interest expense by $0.2 million on an annualized basis.
During the three months ended March 31, 2024, we incurred an immaterial decrease in incremental interest expense compared to the equivalent period in the prior year resulting from lower interest rates in our new term loan facility during the intervening period.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended, or the Exchange Act) as of the end of the period covered by this report. Based on that evaluation, our Chief
24


Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report were effective at a reasonable assurance level in ensuring that information required to be disclosed by us in reports that we file or submit under the Exchange Act (i) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely discussions regarding required disclosure. We believe that a control system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the control system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.
Changes in Internal Control over Financial Reporting
There was no change in our internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during the fiscal quarter ended March 31, 2024 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
25


PART II – OTHER INFORMATION

Item 1. Legal Proceedings
The Company and its subsidiaries are parties to numerous claims and lawsuits arising in the ordinary course of its business activities, some of which involve claims for substantial amounts. The ultimate outcome of these suits cannot be ascertained at this time. The description of the Welker v. MiMedx, et. Al case contained in Note 12, “Commitments and Contingencies,” to the unaudited condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report, is incorporated herein by reference.
Item 1A. Risk Factors
There have been no material changes to the Company’s risk factors included in its 2023 Form 10-K.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
(a) None.

(b) None.

(c) None.
Item 3. Defaults Upon Senior Securities
Not applicable.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
In March 2024, the Company made annual grants of restricted stock units (“RSUs”), performance stock units (“PSUs”) and stock options to its executive officers other than Joe Capper, its Chief Executive Officer. The forms of grant agreements are included as exhibits to this Quarterly Report. The following is a summary of certain of the key provisions of these agreements.

The RSUs granted to our executive officers in March 2024 vest on a “cliff” basis at the end of a three-year period and require the recipient to provide continuous service through the end of such period.

The PSUs granted to our executive officers other than Mr. Capper in March 2024 vest based on and to the extent that stipulated revenue targets for the year ended December 31, 2026 are achieved. Achievement of the performance goals allows for vesting of 50%, 100% and 150% (based on threshold, target or excellence performance) of the PSUs granted. If performance is below threshold, the PSUs do not vest. The PSUs also include a modifier on payments if the Company’s relative total shareholder return (“TSR”) percentile ranking over the three-year performance period is at or below the 50th percentile ranking, in which case vesting is limited to the target level, regardless of actual achievement against the stipulated revenue targets. In addition, vesting may increase if the Company’s relative TSR percentile ranking over the three-year performance period is above the 50th percentile ranking, up to a maximum of 20% if the Company’s relative TSR percentile ranking over the three-year performance period is at the 75th percentile ranking or above. The PSUs require recipients to continue employment with the Company through the vesting date, which will occur upon approval of the results with respect to the established targets by the Company’s Compensation Committee after December 31, 2026, but no later than March 15, 2027. The TSR is calculated as the average trading price of the Company’s common stock during the final 20 trading days of 2026, adjusted for dividends paid on the Company’s common stock, less the average trading price during the final 20 trading days of 2023, and the Company’s relative TSR percentile ranking is as compared to the TSR achieved by the Russell 2000 Index during the same period.

The stock options granted to our executive officers in March 2024 vest ratably annually over a period of four years and require the recipient to provide continuous service through the end of each applicable vesting period.

Insider Trading Arrangements and Policies
26


During the three months ended March 31, 2024, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

Item 6. Exhibits
Exhibit
Number
Description
10.1#
10.2#

10.3#
10.4#


10.5*
Fourth Amendment to Lease made as of January 26, 2024 between Georgia RE Fields, LLC, successor in interest to HUB Properties GA, LLC, and CPVF II West Oak LLC, and MiMedx Group, Inc., dated January 26, 2024 (incorporated by reference to Exhibit 10.2D to the Registrant’s Annual Report on Form 10-K filed on February 28, 2024).

31.1 #
Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2 #
Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1 #
Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2 #
Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS #XBRL Instance Document
101.SCH #XBRL Taxonomy Extension Schema Document
101.CAL #XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF #XBRL Taxonomy Extension Definition Linkbase Document
101.LAB #XBRL Taxonomy Extension Label Linkbase Document
101.PRE #XBRL Taxonomy Extension Presentation Linkbase Document
*Previously filed and incorporated herein by reference
#Filed or furnished herewith


SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
April 30, 2024
MIMEDX GROUP, INC.
   
 By:/s/ Doug Rice
  Doug Rice
  Chief Financial Officer

27
EX-10.1 2 ex101-formofrsuagreement20.htm EX-10.1 Document
EXHIBIT 10.1
MIMEDX GROUP, INC.
2016 EQUITY AND CASH INCENTIVE PLAN

Amended and Restated through May 2, 2023

Form of Restricted Stock Unit Agreement

THIS RESTRICTED STOCK UNIT AGREEMENT (this “Agreement”) dated as of the ____________ 202_, between MiMedx Group, Inc. (the “Company”) and Participant Name (the “Participant”), is made pursuant and subject to the provisions of the MiMedx Group, Inc. 2016 Equity and Cash Incentive Plan, as amended and restated through May 2, 2023 (the “Plan”), a copy of which is attached hereto. Unless otherwise defined herein, all terms used herein that are defined in the Plan have the same meaning given them in the Plan.

1.Grant of Restricted Stock Units. Pursuant to the Plan, the Company, on ____________, 202_ (the “Date of Grant”), granted to the Participant, subject to the terms and conditions of the Plan and subject further to the terms and conditions set forth herein, this Restricted Stock Unit Award for ____________ Restricted Stock Units (“RSUs”). Each RSU represents the right to receive one share of common stock, par value $0.001 per share (the “Common Stock”), of the Company (a “Share”) subject to the terms of this Agreement. The RSUs will vest as set forth in Section 2 below. The RSUs will vest as set forth in Section 2 below and, upon vesting, will be settled as set forth in Section 3.

2.Vesting of the RSUs. Subject to earlier expiration, termination or vesting as provided herein, the RSUs will become vested and nonforfeitable as follows:

(a)Vesting. The RSUs will become vested and nonforfeitable on the third anniversary of the Date of Grant, provided the Participant has been continuously employed by, or providing services to, the Company or an Affiliate from the Date of Grant until such date.

(b)Change in Control. Notwithstanding the foregoing, upon the occurrence of a Change in Control prior to the end of the applicable vesting period, any outstanding RSUs shall be treated in accordance with and governed by Section 14.05 of the Plan.

(c)Death and Disability. Additionally, if the Participant’s employment with the Company and its Affiliates is terminated on account of the Participant’s death or Disability prior to the end of the applicable vesting period, the RSUs shall become fully vested and nonforfeitable upon termination of the Participant’s employment with the Company and its Affiliates on account of the Participant’s death or Disability.

3.Settlement of RSUs.

(a)Timing and Amount. Except as otherwise required by applicable law or as set forth below or in the Plan, the Company shall cause one Share to be issued to the Participant for each vested RSU, with such Shares to be delivered to the Participant upon the applicable vesting date.

(b)Stock Holding Requirements. Notwithstanding any other provision of this Agreement, the Shares that are issued may not be sold, transferred or otherwise disposed of until the level of ownership provided in the Company’s Stock Ownership Guidelines is met, to the extent
1

EXHIBIT 10.1
applicable to the Participant. All Shares acquired hereunder (“net” shares acquired in case of any net exercise or withholding of shares) shall be subject to the terms and conditions of the Company’s Stock Ownership Guidelines, as they may be amended from time to time.

(c)Insider Trading Restrictions; Market Abuse Laws. Participant acknowledges that Participant may be subject to insider trading restrictions and/or market abuse laws in applicable jurisdictions, including but not limited to Participant’s country and the country or countries in which the Shares are or may be listed, which may affect his or her ability, directly or indirectly, to acquire, sell or attempt to sell or otherwise dispose of shares of Common Stock or rights to shares of Common Stock, under the Plan during such times as Participant is considered to have “inside information” regarding the Company. Furthermore, Participant understands that he or she may be prohibited from (i) disclosing the inside information to any third party, including fellow employees, and (ii) “tipping” third parties by sharing with them Company inside information, or otherwise causing third parties to buy or sell Company securities. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. Participant acknowledges that it is his or her responsibility to comply with any applicable restrictions as well as any applicable Company insider trading policy, and Participant should consult with his or her personal legal advisor on this matter.

4.Forfeiture of the Shares. RSUs that are not vested pursuant to Sections 2(a), (b) or (c) as of the date of termination of Participant’s employment by the Company and its Affiliates will be forfeited automatically at the close of business on that date (immediately upon notice of termination for Cause). In no event may the RSUs become vested, in whole or in part, after forfeiture pursuant to this Section 4.

5.Agreement to Terms of the Plan and this Agreement. The Participant has received a copy of the Plan, has read and understands the terms of the Plan and this Agreement, and agrees to be bound by their terms and conditions. All decisions and interpretations made by the Company or the Committee with regard to any question arising under this Agreement will be binding and conclusive on the Company and Participant and any other person who has any rights under this Agreement.

6.Tax Consequences. The Participant acknowledges (i) that there may be adverse tax consequences upon acquisition or disposition of the Shares received upon vesting of the RSUs and (ii) that Participant should consult a tax adviser prior to such acquisition or disposition. The Participant is solely responsible for determining the tax consequences of the Restricted Stock Unit Award and for satisfying the Participant’s tax obligations with respect to the Restricted Stock Unit Award (including, but not limited to, any income or excise tax as resulting from the application of Code Sections 409A or 4999 or related interest and penalties), and the Company and its Affiliates shall not be liable if this grant is subject to Code Sections 409A, 280G or 4999. The Company’s obligation to issue Shares is subject to the Participant’s satisfaction of any applicable federal, state and local income and employment tax and withholding requirements in a manner and form satisfactory to the Company. The Committee, to the extent applicable law permits, may allow the Participant to pay any such amounts as provided in the Plan.

7.Fractional Shares. Fractional shares shall not be issuable hereunder, and when any provision hereof may entitle the Participant to a fractional share such fractional share shall be disregarded.

2

EXHIBIT 10.1
8.Change in Common Stock. The RSUs are subject to adjustment as provided in Article XVI of the Plan.

9.Notice. Any notice or other communication given pursuant to this Agreement, or in any way with respect to the Shares, shall be in writing and shall be personally delivered or mailed by United States registered or certified mail, postage prepaid, return receipt requested, to the following addresses:

If to the Company:    MiMedx Group, Inc.
    1775 West Oak Commons Ct. NE
    Marietta, Georgia 30062
    Attn: General Counsel

If to the Participant:    The most current address of record on file with the     Company.

10.Shareholder Rights; Dividend Equivalents. Except as provided below, Participant shall have no rights as a Shareholder of the Company with respect to shares underlying the RSUs unless and until Shares are delivered to Participant in respect of such RSUs upon vesting. The RSUs will be entitled to accrue Dividend Equivalents, which will be subject to all conditions and restrictions applicable to the underlying RSUs to which they relate, and which may not be paid until and unless the underlying RSUs have vested. Dividend Equivalents will accrue prior to the issuance of Shares with respect to the RSUs or their earlier forfeiture. Dividend Equivalents will be earned only for RSUs that are earned or deemed earned under this Agreement. With respect to RSUs that are not earned (because the applicable vesting restrictions do not lapse or otherwise), Dividend Equivalents that were accrued for those RSUs will be cancelled and forfeited along with the RSUs and underlying Shares, without payment therefor by the Company or any Affiliate. Dividend Equivalents will be paid at such time as the underlying RSUs to which they relate are paid.

11.No Right to Continued Employment or Service. Neither the Plan, the granting of the RSUs nor any other action taken pursuant to the Plan or this Agreement constitutes or is evidence of any agreement or understanding, expressed or implied, that the Company or any Affiliate shall retain the Participant as an employee or other service provider for any period of time or at any particular rate of compensation.

12.Binding Effect. Subject to the limitations stated above and in the Plan, this Agreement shall be binding upon and inure to the benefit of the legatees, distributees, and personal representatives of the Participant and the successors of the Company.

13.Conflicts. In the event of any conflict between the provisions of the Plan and the provisions of this Agreement, the provisions of the Plan shall govern. All references herein to the Plan shall mean the Plan as in effect on the date hereof.

14.Counterparts. This Agreement may be executed in a number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one in the same instrument.

15.Miscellaneous. The parties agree to execute such further instruments and take such further actions as may be necessary to carry out the intent of the Plan and this Agreement. This Agreement and the Plan shall constitute the entire agreement of the parties with respect to the subject matter hereof.
3

EXHIBIT 10.1

16.Section 409A. Notwithstanding any of the provisions of this Agreement, it is intended that the RSUs granted pursuant to this Agreement be exempt from Section 409A of the Code as short-term deferrals, pursuant to Treasury regulation §1.409A-1(b)(4), or otherwise comply with Section 409A of the Code. Notwithstanding the preceding, neither the Company nor any Affiliate shall be liable to the Participant or any other person if the Internal Revenue Service or any court or other authority have any jurisdiction over such matter determines for any reason that the RSUs are subject to taxes, penalties or interest as a result of failing to be exempt from, or comply with, Section 409A of the Code. For the avoidance of doubt, the provisions of this Agreement shall be construed and interpreted consistent with Article XXII of the Plan.

17.Non-transferability and non-alienation. The Participant shall not assign or transfer any RSUs while such RSUs remain forfeitable, other than by will or the laws of descent and distribution. No right or interest of Participant or any transferee in the RSUs or Shares subject to the RSUs shall be subject to any lien or any obligation or liability of the Participant or any transferee.

18.Compensation Recoupment Policy. This Restricted Stock Unit Award shall be subject to the Company’s Compensation Recoupment Policy, any similar policy that the Company may adopt and applicable law related to compensation recoupment.

19.Governing Law. This Agreement shall be governed by the governing laws applicable to the Plan.


[Signature Page to Follow]

4

EXHIBIT 10.1
IN WITNESS WHEREOF, the Company has caused this Agreement to be signed by a duly authorized officer, and the Participant has affixed the Participant’s signature hereto.

COMPANY:
MIMEDX GROUP, INC.

___________________________________
    Name: Joseph H. Capper
    Title:    Chief Executive Office


ATTEST:


____________________________________
Name: William “Butch” Hulse
Title:     General Counsel and Chief Administrative Officer


PARTICIPANT:


    
[Participant’s Name]


5
EX-10.2 3 ex102-formofpsuagreement20.htm EX-10.2 Document
EXHIBIT 10.2
MIMEDX GROUP, INC.
2016 EQUITY AND CASH INCENTIVE PLAN
Amended and Restated through May 2, 2023
Form of Performance Stock Unit Agreement
THIS PERFORMANCE STOCK UNIT AGREEMENT (this “Agreement”) dated as of ____________, between MIMEDX Group, Inc. (the “Company”) and ____________ (the “Participant”), is made pursuant and subject to the provisions of the MiMedx Group, Inc. 2016 Equity and Cash Incentive Plan, as amended and restated through May 2, 2023 (the “Plan”). Unless otherwise defined herein, all terms used herein that are defined in the Plan have the same meaning given them in the Plan.
1.Grant of Performance Stock Units. Pursuant to the Plan, the Company, on _____, ___ (the “Date of Grant”), granted to the Participant, subject to the terms and conditions of the Plan and subject further to the terms and conditions set forth herein, this Award of Performance Stock Units (“PSUs”) in a target amount equal to ____________ of common stock, par value $0.001 (the “Common Stock”), of the Company (the “Shares”) subject to the terms of this Agreement. The PSUs will vest as set forth in Section 2 below and will be settled as set forth in Section 3 below. A Participant shall have no right to exchange the PSUs for cash, Common Stock or any other benefit and shall be an unsecured creditor of the Company with respect to such PSUs and any future rights to benefits.
2.Vesting of the PSUs. Subject to earlier expiration, termination or vesting as provided herein, the PSUs will become vested and may be earned based on achieving performance levels against pre-determined performance goals, and satisfying the conditions of employment, as described herein, and are forfeited if defined performance levels or conditions of employment are not achieved or satisfied.
(a)Performance Condition and Required Employment. Subject to Section 4, the total number of PSUs that may be earned by a Participant will be based on both (i) ____ Revenue, as described on Annex I, (the “Performance Condition”, with references to “Threshold,” “Target” and “Excellence” as included therein), limited as provided below and in Annex I, and (ii) satisfaction of the condition of employment, as set forth below.
(b)Applying Performance & Employment Conditions – Payout Formula. The PSUs will vest on ____________, 202_ (the “Performance Measurement Date”) in accordance with the following payout formula, provided that the Participant continues to be actively employed by the Company on the Payment Date and the Performance Condition is otherwise satisfied as follows: 50% of target number of Shares will be awarded at Threshold performance; 100% of target number of Shares will be awarded at Target performance; 150% of target number of Shares will be awarded at Excellence level; and 0% of target number of Shares will be awarded at performance below Threshold (the “Payout Formula”). Results between Threshold and Target and Target and Excellence will be prorated. Notwithstanding the foregoing, the Payout Formula may be modified based on the Company’s performance against the TSR Performance Condition (as described in Annex I).
3.Settlement of PSUs and Restricted Stock Units.
(a)Timing and Amount. Following the Performance Measurement Date, the Compensation Committee will determine the extent to which the applicable Performance Condition has



been achieved, as may be limited by the TSR Performance Condition (as described in Annex I). Vested PSUs, and if issued pursuant to Section 4(a) below, Restricted Stock Units, earned by a Participant will be settled and paid in Shares as soon as practicable following the Performance Measurement Date on a date determined in the Company’s discretion, provided that the Participant continues to be actively employed on such date, subject to Section 4, and in no event later than the last day of the “applicable 2½ month period” specified in Treas. Reg. §1.409A-1(b)(4) (the “Payment Date”).
(b)Stock Holding Requirements. Notwithstanding any other provision of this Agreement, the Shares that are issued may not be sold, transferred or otherwise disposed of until the level of ownership provided in the Company’s Stock Ownership Guidelines is met, to the extent applicable to the Participant. All Shares acquired hereunder (“net” Shares acquired in case of any net exercise or withholding of Shares) shall be subject to the terms and conditions of the Company’s Stock Ownership Guidelines, as they may be amended from time to time.
(c)Insider Trading Restrictions; Market Abuse Laws. Participant acknowledges that Participant may be subject to insider trading restrictions and/or market abuse laws in applicable jurisdictions, including but not limited to Participant’s country and the country or countries in which the Shares are or may be listed, which may affect his or her ability, directly or indirectly, to acquire, sell or attempt to sell or otherwise dispose of shares of Common Stock or rights to shares of Common Stock (e.g., PSUs), under the Plan during such times as Participant is considered to have “inside information” regarding the Company. Furthermore, Participant understands that he or she may be prohibited from (i) disclosing the inside information to any third party, including fellow employees, and (ii) “tipping” third parties by sharing with them Company inside information, or otherwise causing third parties to buy or sell Company securities. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. Participant acknowledges that it is his or her responsibility to comply with any applicable restrictions as well as any applicable Company insider trading policy, and Participant should consult with his or her personal legal advisor on this matter.
4.Forfeiture of the Shares. PSUs and/or Restricted Stock Units or other payments are forfeited and no amounts shall be paid to any employee whose services are terminated for any reason prior to Payment Date, as applicable, except for Participants whose employment is terminated without “Cause” or for “Good Reason” within two years following the occurrence of a Change in Control, or Participants who die or whose employment is terminated due to Disability before the end of the Performance Period (as defined in Annex I), each as set forth below.
(a)Change in Control. Notwithstanding the foregoing, upon the occurrence of a Change in Control prior to the end of the Performance Period, any outstanding PSUs shall be treated in accordance with and governed by Section 14.05 of the Plan. For PSUs which are then outstanding hereunder, the Target level of performance set forth with respect to the Performance Condition for such units shall be deemed to have been attained (or, if higher, the actual level of performance attained), and such Shares or units shall be converted into and remain outstanding as Restricted Stock Units, subject to forfeiture unless the Participant continues to be actively employed by the Company through the end of the original Performance Period, but subject to exception in the case of a termination of employment by the Company without Cause or, in the case of a Participant with an effective Key Employee Retention and Restrictive Covenant Agreement at the time of termination, a termination by the Participant with Good Reason, in either case during the two-year period following the Control Change Date.
        2


(b)Death and Disability. If the Participant’s employment with the Company and its Affiliates is terminated on account of the Participant’s death or Disability prior to the end of the Performance Period, a pro-rata portion of the PSUs shall vest in proportion to the number of days the Participant was employed in relation to the number of days in the Performance Period, reduced by the number of Restricted Stock Units issued to the Participant for the Performance Period, which PSUs may be earned subject to and based on the degree of attainment of the Performance Condition as may be limited by the TSR Performance Condition (as described in Annex I). Such vesting and payment of PSUs will occur after completion of the Performance Period as provided in Section 3(a).
5.Agreement to Terms of the Plan and this Agreement. The Participant has received a copy of the Plan, has read and understands the terms of the Plan and this Agreement, and agrees to be bound by their terms and conditions. All decisions and interpretations made by the Company or the Committee with regard to any question arising under this Agreement will be binding and conclusive on the Company and Participant and any other person who has any rights under this Agreement.
6.Tax Consequences. The Participant acknowledges (i) that there may be adverse tax consequences upon acquisition or disposition of the Shares received upon vesting of the PSUs and/or Restricted Stock Units and (ii) that Participant should consult a tax adviser prior to such acquisition or disposition. The Participant is solely responsible for determining the tax consequences of the Performance Stock Unit Award and for satisfying the Participant’s tax obligations with respect thereto (including, but not limited to, any income or excise tax as resulting from the application of Code Sections 409A or 4999 or related interest and penalties), and the Company and its Affiliates shall not be liable if this grant is subject to Code Sections 409A, 280G or 4999. The Company’s obligation to issue Shares is subject to the Participant’s satisfaction of any applicable federal, state and local income and employment tax and withholding requirements in a manner and form satisfactory to the Company. The Committee, to the extent applicable law permits, may allow the Participant to pay any such amounts as provided in the Plan.
7.Fractional Shares. Fractional Shares shall not be issuable hereunder, and when any provision hereof may entitle the Participant to a fractional share such fractional share shall be disregarded.
8.Change in Common Stock. The PSUs and Restricted Stock Units are subject to adjustment as provided in Article XVI of the Plan.
9.Notice. Any notice or other communication given pursuant to this Agreement, or in any way with respect to the Shares, shall be in writing and shall be personally delivered or mailed by United States registered or certified mail, postage prepaid, return receipt requested, to the following addresses:
If to the Company:    MIMEDX Group, Inc.
    1775 West Oak Commons Ct. NE
    Marietta, Georgia 30062
    Attn: General Counsel

If to the Participant:    The most current address of record on file with the     Company.

        3


10.Shareholder Rights; Dividend Equivalents. Except as provided below, Participant shall have no rights as a Shareholder of the Company with respect to Shares underlying the PSUs and Restricted Stock Units unless and until Shares are delivered to Participant in respect of such PSUs or Restricted Stock Units. The PSUs and Restricted Stock Units will be entitled to accrue Dividend Equivalents, which will be subject to all conditions and restrictions applicable to the underlying PSUs and Restricted Stock Units to which they relate, and which may not be paid until and unless the underlying PSUs and Restricted Stock Units are vested, earned and paid. Dividend Equivalents will accrue prior to the issuance of Shares with respect to the PSUs and Restricted Stock Units or their earlier forfeiture. Dividend Equivalents will be earned only for PSUs and Restricted Stock Units that are earned or deemed earned under this Agreement. With respect to PSUs and Restricted Stock Units that are not earned (because the applicable vesting restrictions do not lapse or otherwise), Dividend Equivalents that were accrued for those units will be cancelled and forfeited along with the PSUs, Restricted Stock Units and underlying Shares, without payment therefor by the Company or any Affiliate. Dividend Equivalents will be paid at such time as the underlying PSUs and Restricted Stock Units to which they relate are paid.
11.No Right to Continued Employment or Service. Neither the Plan, the granting of the PSUs or any Restricted Stock Units nor any other action taken pursuant to the Plan or this Agreement constitutes or is evidence of any agreement or understanding, expressed or implied, that the Company or any Affiliate shall retain the Participant as an employee or other service provider for any period of time or at any particular rate of compensation.
12.Binding Effect. Subject to the limitations stated above and in the Plan, this Agreement shall be binding upon and inure to the benefit of the legatees, distributees, and personal representatives of the Participant and the successors of the Company.
13.Conflicts. In the event of any conflict between the provisions of the Plan and the provisions of this Agreement, the provisions of the Plan shall govern. All references herein to the Plan shall mean the Plan as in effect on the date hereof.
14.Counterparts. This Agreement may be executed in a number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one in the same instrument.
15.Miscellaneous. The parties agree to execute such further instruments and take such further actions as may be necessary to carry out the intent of the Plan and this Agreement. This Agreement and the Plan shall constitute the entire agreement of the parties with respect to the subject matter hereof.
16.Section 409A. Notwithstanding any of the provisions of this Agreement, it is intended that the PSUs and Restricted Stock Units granted pursuant to this Agreement be exempt from Section 409A of the Code as short-term deferrals, pursuant to Treasury regulation §1.409A-1(b)(4), or otherwise comply with Section 409A of the Code. Notwithstanding the preceding, neither the Company nor any Affiliate shall be liable to the Participant or any other person if the Internal Revenue Service or any court or other authority have any jurisdiction over such matter determines for any reason that the PSUs or Restricted Stock Units are subject to taxes, penalties or interest as a result of failing to be exempt from, or comply with, Section 409A of the Code. For the avoidance of doubt, the provisions of this Agreement shall be construed and interpreted consistent with Article XXII of the Plan including, without limitation, the Key Employee Rule set forth in Section 1.07 thereunder.
        4


17.Non-transferability and non-alienation. The Participant shall not assign or transfer any PSUs or Restricted Stock Units while such units remain forfeitable, other than by will or the laws of descent and distribution. No right or interest of Participant or any transferee in the PSUs, Restricted Stock Units or Shares subject to the units shall be subject to any lien or any obligation or liability of the Participant or any transferee.
18.Compensation Recoupment Policy. This Award of PSUs shall be subject to the Company’s Compensation Recoupment Policy, any similar policy that the Company may adopt and applicable law related to compensation recoupment.
19.Governing Law. This Agreement shall be governed by the governing laws applicable to the Plan.
[Signature Page to Follow]
        5


IN WITNESS WHEREOF, the Company has caused this Agreement to be signed by a duly authorized officer, and the Participant has affixed the Participant’s signature hereto.

COMPANY:
COMPANY:
MIMEDX GROUP, INC.

____________________________________
    Name: Joseph H. Capper
    Title:    Chief Executive Office


ATTEST:


____________________________________
Name: William “Butch” Hulse
Title:     General Counsel and Chief Administrative Officer


PARTICIPANT:


    
____________
[Signature Page to PSU Award Agreement]
ACTIVE 693716423v6


Annex I
Threshold, Target and Excellence Levels
$(000)
Threshold
(50%) Payout
Target
(100% Payout)
Excellence
(150% Payout)
Total Revenue – Fiscal year ended December 31, ____$X$X$X

The number of PSUs earned determined based on the immediately preceding table may increase by up to 20% based on the Company’s Relative TSR Percentile Rank as follows:

(a)    if the Company’s Relative TSR Percentile Ranking is at the 50th percentile, then the TSR Modifier Percentage will be 100%; and

(b)    if the Company’s Relative TSR Percentile Ranking is at or above the 75th percentile, then the TSR Modifier Percentage will be 120%.

To the extent that the Company’s Relative TSR Percentile Ranking ranks in a percentile between the 50th and 75th percentile, then the TSR Modifier Percentage will be prorated between the corresponding TSR Modifier Percentages listed above.

Notwithstanding the foregoing, in order for PSUs to be earned (and Shares to be awarded) above the Target performance level and up to the Excellence performance level, the Company’s Relative TSR Percentile Ranking for the Performance Period must be at or above the 50th percentile.

For purposes of the above:
____ Revenue” means the Company’s total reported revenue for the year ended December 31, ____.
Relative TSR Percentile Ranking” means the percentile ranking of the Company’s Total Shareholder Return from January 1, ____ through December 31, ____ (the “Performance Period”) as compared to the Total Shareholder Return achieved by the Russell 2000 Index during such Performance Period.
Total Shareholder Return” means, with respect to any corporation, the increase in its stock price over the Performance Period plus reinvested dividends, divided by its stock price at the beginning of the Performance Period. For purposes of this definition, the beginning stock price will be the average closing price over the twenty (20) trading days up to and including January 1, ____ and the ending stock price will be the average closing price over the twenty (20) trading days up to and including December 31st ____.
ACTIVE 693716423v6
EX-10.3 4 ex103-formofstockoptionagr.htm EX-10.3 Document
EXHIBIT 10.3
MIMEDX GROUP, INC.
Form of Nonqualified Stock Option Agreement


THIS NONQUALIFIED STOCK OPTION AGREEMENT (this “Agreement”) dated as of ____________ (the “Date of Grant”), between MiMedx Group, Inc. (the “Company”), and ____________ (the “Participant”), is made pursuant and subject to the provisions of the MiMedx Group, Inc. 2016 Equity and Cash Incentive Plan, as amended and restated through May 2, 2023 (the “Plan”). Unless otherwise defined herein, all terms used herein that are defined in the Plan have the same meaning given them in the Plan.

1.    Grant of Option. Pursuant to, and subject to the terms and conditions of, the Plan and subject to the terms and conditions set forth herein, the Participant is hereby granted this Award of an option to purchase from the Company all or any part of an aggregate of ____________ shares of common stock of the Company, par value $0.001 per share (“Common Stock”), at the closing price per share of Common Stock on ____________ (this “Option”). The Option is subject to adjustment as provided in Article XVI of the Plan. No part of the Option granted hereby is intended to qualify as an “incentive stock option” under Section 422 of the Internal Revenue Code of 1986, as amended.

2.    Terms and Conditions. This Option is subject to the following terms and conditions:

(a)    Expiration Date. This Option shall expire at 11:59 p.m. on ____________, 203_ (the “Expiration Date”) or such earlier time as set forth in this Agreement. In no event shall the Expiration Date be later than seven (7) years after the Date of Grant.

(b)    Vesting of Option. This Option shall be vested and exercisable, in whole or in part, according to the following vesting schedule:

Twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Date of Grant, and twenty-five percent (25%) of the shares subject to the Option shall vest on each of the following three anniversaries thereafter, subject to Participant continuing to be an employee through each such date. On each vesting date, the number of shares vesting shall be rounded down to the nearest whole share, with the balance vesting on the last vesting date.

(c)    Change in Control. Upon the occurrence of a Change in Control, any outstanding Option shall be treated in accordance with and governed by Section 14.05 of the Plan, as if granted thereunder, and the terms provided in this Agreement.

(d)    Method of Exercise and Payment for Shares. To the extent then vested and exercisable, the Participant may exercise the Option by delivering written notice of exercise, along with the exercise price for the portion of the Option being exercised, to the attention of the Company’s Secretary at the Company’s address specified in Section 8 below. Notwithstanding the foregoing, no single exercise of the Option may be for less than 100 shares of Common Stock unless, at the time of



exercise, the maximum number of shares of Common Stock available for purchase under the Option is less than 100 shares, in which event the Option may be exercised, if at all, only for all of the shares of Common Stock then available for purchase. The exercise date shall be the date of the notice. The Participant shall pay the exercise price in cash or cash equivalent acceptable to the Committee. However, the Committee in its discretion may, but is not required to, allow the Participant to pay the exercise price (i) by surrendering shares of Common Stock the Participant already owns, (ii) by a cashless exercise through a broker, (iii) by means of a “net settlement” procedure, (iv) by such other medium of payment as the Committee shall authorize or (v) by any combination of the allowable methods of payment set forth herein. If payment is in the form of shares of Common Stock, then the certificate or certificates representing those shares must be duly executed in blank by the Participant or accompanied by a stock power duly executed in blank suitable for purposes of transferring those shares to the Company. Fractional shares of Common Stock will not be accepted in payment of the exercise price of the Option. The Company will not issue the shares of Common Stock until full payment of the exercise price for them has been made. As soon as administratively practicable upon the Company’s receipt of the exercise price, subject to the other terms of the Option, the Company shall direct the issuance of the applicable shares of Common Stock so purchased. In the case of the Participant’s death, the Option, to the extent vested and exercisable, may be exercised by the executor or administrator of the Participant’s estate or by any person or persons who have acquired the Option directly from the Participant by bequest or inheritance.

(e)    Non-Transferability of Option. The Participant shall not assign or transfer the Option, other than by will or the laws of descent and distribution. During the Participant’s lifetime, only the Participant (or, in the event of legal incapacity or incompetency, the Participant’s guardian or legal representative) may exercise the Option. No right or interest of the Participant or any transferee in this Option shall be liable for, or subject to, any lien, obligation or liability of the Participant or any transferee.

(f)    Stock Holding Requirements. Notwithstanding any other provision of this Agreement, shares of Common Stock acquired pursuant to this Option may not be sold, transferred or otherwise disposed of until the level of ownership provided in the Company’s Stock Ownership Guidelines is met, to the extent applicable to the Participant. All shares of Common Stock acquired hereunder (“net” shares acquired in case of any net exercise or withholding of shares) shall be subject to the terms and conditions of the Company’s Stock Ownership Guidelines, as they may be amended from time to time.

(g)    Insider Trading Restrictions; Market Abuse Laws. Participant acknowledges that Participant may be subject to insider trading restrictions and/or market abuse laws in applicable jurisdictions, including but not limited to Participant’s country and the country or countries in which the shares of Common Stock acquired pursuant to this Option may be listed, which may affect his or her ability, directly or indirectly, to acquire, sell or attempt to sell or otherwise dispose of shares of Common Stock or rights to shares of Common Stock, under the Plan during such times as Participant is considered to have “inside information” regarding the Company. Furthermore, Participant understands that he or she may be prohibited from (i) disclosing the inside information to any third party, including fellow employees, and (ii) “tipping” third parties by sharing with them Company inside information, or otherwise causing third parties to buy or sell Company securities. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any

2


applicable Company insider trading policy. Participant acknowledges that it is his or her responsibility to comply with any applicable restrictions as well as any applicable Company insider trading policy, and Participant should consult with his or her personal legal advisor on this matter.

3.    Termination of Option.

a.    Exercise in the Event of Death or Disability. This Option shall be exercisable for the number of shares of Common Stock subject to the Option only to the extent that the Participant is entitled to purchase pursuant to Section 2 as of the date of termination of the Participant’s employment by, or provision of services to, the Company and its Affiliates, reduced by the number of shares for which the Participant previously exercised the Option, and to the extent the Participant’s rights have not otherwise been terminated under this Agreement, if the Participant’s employment by, or provision of services to, the Company and its Affiliates terminates on account of the Participant's death or Disability, and the balance of the Option shall be forfeited with no consideration. In that event, to the extent exercisable, this Option may be exercised by the Participant, the Participant’s estate, or the person or persons to whom the Participant’s rights under this Option shall pass by will or the laws of descent and distribution (to the extent applicable), for the remainder of the period preceding the Expiration Date or until the date that is twelve (12) months after the Participant’s Termination Date due to death or Disability, whichever period is shorter.

b.    Exercise after a Change of Control. This Option shall be exercisable for the number of shares of Common Stock subject to the Option only to the extent that the Participant is entitled to purchase pursuant to Section 2 as of the date of termination of the Participant’s employment by, or provision of services to, the Company and its Affiliates on or after a Change in Control, reduced by the number of shares for which the Participant previously exercised the Option, and to the extent the Participant’s rights have not otherwise been terminated under this Agreement, if the Participant’s employment by, or provision of services to, the Company and its Affiliates terminates on or after a Change in Control (other than as described in Section 3(a) above), and the balance of the Option shall be forfeited with no consideration. In that event, to the extent exercisable the Participant may exercise this Option for the remainder of the period preceding the Expiration Date or until the date that is twelve (12) months after the Participant’s Termination Date, whichever period is shorter.

c.    Exercise after other Termination of Employment or Service. This Option shall be exercisable for the number of shares of Common Stock subject to the Option only to the extent that the Participant is entitled to purchase pursuant to Section 2 as of the date of termination of the Participant’s employment by, or provision of services to, the Company and its Affiliates, reduced by the number of shares for which the Participant previously exercised the Option, and to the extent the Participant’s rights have not otherwise terminated under this Agreement, if the Participant’s employment by, or provision of services to, the Company and its Affiliates terminates other than under any of the circumstances set forth in Sections 3(a) or (b) of this Agreement, for the remainder of the period preceding the Expiration Date or until the date that is twelve (12) months after the Participant's Termination Date, whichever period is shorter. The balance of the Option shall be forfeited with no consideration upon such Termination Date.


3


d.    Termination. The Option or portion thereof not either terminated or exercised at such time will terminate automatically and without further notice at the time the Option can no longer be exercised as set forth above.

e.    For Cause. Notwithstanding any other provision of this Agreement, the Option will terminate automatically upon the termination of the Participant’s employment by, or provision of services to, the Company and its Affiliates for Cause, as defined in the Participant’s Key Employee Retention Agreement, immediately upon notice of such termination (including any portion of the Option that may have become vested and exercisable previously).

4.    Agreement to Terms. The Participant has read and understands the terms of this Agreement, including the applicable provisions of the Plan, as if the Option was granted thereunder, and agrees to be bound by their terms and conditions. All decisions and interpretations made by the Company or the Committee with regard to any question arising under this Option will be binding and conclusive on the Company and the Participant and any other person entitled to exercise the Options as provided for in this Agreement.

5.    Tax Consequences. The Participant acknowledges (i) that there may be adverse tax consequences upon acquisition or disposition of the shares of Common Stock received upon exercise of this Option and (ii) that Participant should consult a tax adviser prior to such acquisition or disposition. The Participant is solely responsible for determining the tax consequences of the Option and for satisfying the Participant’s tax obligations with respect to the Option (including, but not limited to, any income or excise tax as resulting from the application of Code Sections 409A or 4999 or related interest and penalties), and the Company and its Affiliates shall not be liable if this Option is subject to Code Sections 409A, 280G or 4999. The Company’s obligation to deliver shares of Common Stock upon exercise of the Option is subject to the Participant’s satisfaction of any applicable federal, state and local income and employment tax and withholding requirements in a manner and form satisfactory to the Company. The Committee, to the extent applicable law permits, may allow the Participant to pay any such amounts (but only for the minimum required withholding or such other amounts as will not otherwise have negative accounting consequences) (i) by surrendering (actual or by attestation) shares of Common Stock that the Participant already owns; (ii) by a cashless exercise though a broker, (iii) by means of a “net exercise” procedure or (iv) by such other medium of payment as the Committee in its discretion shall authorize.

6.    Fractional Shares. Fractional shares shall not be issuable hereunder, and when any provision hereof may entitle the Participant to a fractional share such fractional share shall be disregarded.

7.    Change in Capital Structure. The terms of this Option shall be adjusted in the same manner as adjustments are made as set forth in Article XVI of the Plan as the Committee determines is

4


equitably required in the event the Company effects one or more stock dividends, stock splits, subdivisions or consolidations of shares or other similar changes in capitalization.

8.    Notice. Any notice or other communication given pursuant to this Agreement, or in any way with respect to this Option, shall be in writing and shall be personally delivered or mailed by United States registered or certified mail, postage prepaid, return receipt requested, to the following addresses:

If to the Company:    MiMedx Group, Inc.
1775 West Oak Commons Ct. NE
Marietta, Georgia 30062
Attn: General Counsel

If to the Participant:    At the Participant’s address on the Company’s records

or such other address as either party may have furnished to the other in writing in accordance herewith, except that notices of change of address shall be effective only upon receipt.

9.    Shareholder Rights. The Participant shall not have any rights as a shareholder with respect to shares of Common Stock subject to this Option until the issuance of the shares of the Common Stock upon exercise of the Option.

10.    No Right to Continued Employment or Service. Neither the Plan, the granting of this Option nor any other action taken pursuant to the Plan or this Option constitutes or is evidence of any agreement or understanding, expressed or implied, that the Company or any Affiliate shall retain the Participant as an employee or other service provider for any period of time or at any particular rate of compensation.

11.    Binding Effect. Subject to the limitations stated above and in the Plan, this Agreement shall be binding upon and inure to the benefit of the legatees, distributees, and personal representatives of the Participant and the successors of the Company.

12.    Conflicts. In the event of any conflict between the provisions of the Plan and the provisions of this Agreement, the provisions of the Plan shall govern. All references herein to the Plan shall mean the Plan as in effect on the date hereof.

13.    Counterparts. This Agreement may be executed in a number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one in the same instrument.

14.    Miscellaneous. The parties agree to execute such further instruments and take such further actions as may be necessary to carry out the intent of this Agreement. This Agreement, and any

5


provisions referenced herein, shall constitute the entire agreement of the parties with respect to the subject matter hereof.

15.    Section 409A. Notwithstanding any of the provisions of this Agreement, it is intended that the Option be exempt from Section 409A of the Code. Notwithstanding the preceding, neither the Company nor any Affiliate shall be liable to the Participant or any other person if the Internal Revenue Service or any court or other authority have any jurisdiction over such matter determines for any reason that the Option is subject to taxes, penalties or interest as a result of failing to be exempt from, or comply with, Section 409A of the Code.

16.    Compensation Recoupment Policy. This Award of the Option shall be subject to the Company’s Compensation Recoupment Policy, any similar policy that the Company may adopt and applicable law related to compensation recoupment.

17.    Governing Law. This Agreement shall be governed by the governing laws applicable to the Plan.

[Signatures continued on next page]


6


IN WITNESS WHEREOF, the Company has caused this Agreement to be signed by a duly authorized officer, and the Participant has affixed the Participant’s signature hereto.

COMPANY:

MIMEDX GROUP, Inc.

____________________________________
Name:    Joseph H. Capper
Title:    CEO



PARTICIPANT:


    



7
EX-10.4 5 ex104-mimedxxcreditagreeme.htm EX-10.4 Document
        EXHIBIT 10.4
Execution Version
CREDIT AGREEMENT
dated as of January 19, 2024
among
MIMEDX GROUP, INC.,
as the Borrower,
THE LENDERS PARTY HERETO,
CITIZENS BANK, N.A.,
as Administrative Agent,
and
BANK OF AMERICA, N.A.,
as Syndication Agent
    
CITIZENS BANK, N.A. and BANK OF AMERICA, N.A.
as Joint Lead Arrangers and Joint Bookrunners
4880-7517-6849 v.10

TABLE OF CONTENTS
Page




SCHEDULES:
Schedule 2.1Commitments
Schedule 4.1(f)Collateral Documents and Related Requirements
Schedule 5.6Disclosed Matters
Schedule 5.13Subsidiaries; Equity Interests
Schedule 5.14Insurance
Schedule 5.16(a)UCC Filing Offices
Schedule 5.19Healthcare and Regulatory Matters
Schedule 7.1Existing Indebtedness
Schedule 7.2Existing Liens
Schedule 7.4Existing Investments
Schedule 7.10Existing Restrictions
Schedule 10.1Notice Information

EXHIBITS:
Exhibit A
Form of Assignment and Assumption
Exhibit B-1
Form of Committed Loan Notice
Exhibit B-2
Form of Swingline Loan Notice
Exhibit C-1
Form of Revolving Loan Note
Exhibit C-2
Form of Term Loan Note
Exhibit C-3
Form of Swingline Loan Note
Exhibit D
Form of Compliance Certificate
Exhibit E
Form of Subsidiary Joinder Agreement
Exhibit F-1
Form of U.S. Tax Compliance Certificate For Foreign Lenders That Are Not Partnerships For U.S. Federal Income Tax Purposes
Exhibit F-2
Form of U.S. Tax Compliance Certificate For Foreign Participants That Are Not Partnerships For U.S. Federal Income Tax Purposes
Exhibit F-3
Form of U.S. Tax Compliance Certificate For Foreign Participants That Are Partnerships For U.S. Federal Income Tax Purposes
Exhibit F-4
Form of U.S. Tax Compliance Certificate For Foreign Lenders That Are Partnerships For U.S. Federal Income Tax Purposes
Exhibit G
Form of Master Intercompany Note
Exhibit H
Form of Solvency Certificate
Exhibit I
Form of Secured Obligation Designation Notice




CREDIT AGREEMENT
CREDIT AGREEMENT, dated as of January 19, 2024, among MIMEDX GROUP, INC., a Florida corporation (the “Borrower”), the other Loan Parties party hereto, the LENDERS party hereto and CITIZENS BANK, N.A., as Administrative Agent.
RECITALS
A.    The Borrower has requested that the Lenders make loans and other financial accommodations to the Borrower as more fully set forth herein.
B.    The Lenders have indicated their willingness to lend and the L/C Issuer has indicated its willingness to issue Letters of Credit, in each case, on the terms and subject to the conditions set forth herein.
In consideration of the mutual covenants and agreements herein contained, the parties hereto covenant and agree as follows:
Article 1

DEFINITIONS AND RULES OF CONSTRUCTION
Section 1.1Definitions. As used in this Credit Agreement, the following terms have the meanings specified below:
ABR Borrowing” means, as to any Borrowing, the ABR Loans comprising such Borrowing.
ABR Loan” means a Loan bearing interest based on the Alternate Base Rate.
Acquired EBITDA” means, with respect to any Acquired Entity or Business for any period, the historical Consolidated EBITDA of such Acquired Entity or Business for such period as certified by a Responsible Officer of the Borrower, which historical Consolidated EBITDA shall be calculated in a manner consistent with the definition of Consolidated EBITDA herein and to be based on financial statements for such Acquired Entity or Business prepared in accordance with GAAP (subject to the absence of footnote disclosures and year-end audit adjustments with respect to financial statements that are not annual audited financial statements), provided that when such Acquired EBITDA is included in Consolidated EBITDA it shall be on a Pro Forma Basis.
Acquired Entity or Business” means, for any period, any Person, property, business or asset acquired by the Borrower or any of its Subsidiaries in a Permitted Acquisition, to the extent not subsequently sold, transferred or otherwise Disposed of during such period.
Acquisition” means any transaction or series of related transactions resulting, directly or indirectly, in: (a) the acquisition by any Person of (i) all or substantially all of the assets of another Person or (ii) all or substantially all of any business line, unit or division of another Person, (b) the acquisition by any Person (i) of in excess of 50% of the Equity Interests of any other Person, or (ii) otherwise causing any other Person to become a subsidiary of such Person, or (c) a merger, amalgamation consolidation, or any other combination of any Person with another Person (other than a Person that is a Loan Party or a Subsidiary of a Loan Party) in which a Loan Party or any of its Subsidiaries is the surviving Person.



Administrative Agent” means Citizens Bank, in its capacity as administrative agent for the Lenders or any successor thereto.
Administrative Agent’s Payment Office” means the Administrative Agent’s office located at 28 State Street, Boston, Massachusetts 02109, or such other office as to which the Administrative Agent may from time to time notify the Borrower and the Lenders.
Administrative Questionnaire” means an Administrative Questionnaire in a form supplied by the Administrative Agent.
Affected Financial Institution” means (a) any EEA Financial Institution or (b) any UK Financial Institution.
Affiliate” means, with respect to a specified Person, another Person that directly, or indirectly through one or more intermediaries, Controls or is Controlled by or is under common Control with the Person specified.
Agent Parties” has the meaning assigned to such term in Section 10.1(d)(iii).
Alternate Base Rate” means, for any day, a rate per annum equal to the greatest of (a) the Prime Rate in effect on such day, (b) the Federal Funds Rate in effect on such day plus 0.50% per annum and (c) the Daily SOFR Rate on such day plus 1.00% per annum, provided that the Alternate Base Rate shall at no time be less than the Floor. If the Administrative Agent shall have determined (which determination shall be conclusive absent clearly manifest error) that it is unable to ascertain the Federal Funds Rate or the Daily SOFR Rate for any reason, including the inability or failure of the Administrative Agent to obtain sufficient quotations in accordance with the terms of the definition of the term Federal Funds Rate, the Alternate Base Rate shall be determined without regard to clause (b) or (c), as applicable, of the preceding sentence until the circumstances giving rise to such inability no longer exist. Any change in the Alternate Base Rate due to a change in the Prime Rate, the Federal Funds Rate or the Daily SOFR Rate, as applicable, shall be effective from and including the effective date of such change in the Prime Rate, the Federal Funds Rate or the Daily SOFR Rate, as applicable, respectively.
Anti-Corruption Laws” means all laws, rules, and regulations of any jurisdiction applicable to the Loan Parties or their respective Subsidiaries from time to time concerning or relating to bribery or corruption.
Anti-Terrorism Laws” has the meaning assigned to such term in Section 5.18(c).
Applicable Law” means, as to any Person, all applicable Laws binding upon such Person or to which such a Person is subject.
Applicable Lending Office” means for any Lender, such Lender’s office, branch or affiliate designated for SOFR Loans, ABR Loans, Swingline Loans or Letters of Credit or participations therein, as applicable, as notified to the Administrative Agent, any of which offices may be changed by such Lender.
Applicable Margin” means with respect to the Term Loans, the Revolving Loans, the Swingline Loans, L/C Participation Fees and Commitment Fees, during the applicable periods set forth below: in the case of (i) ABR Revolving Borrowings, the percentage set forth in the following table under the heading “ABR Margin”, (ii) SOFR Revolving Borrowings, Swingline Loans, and the L/C Participation Fees, the percentage set forth in the following table under the heading “SOFR Margin and L/C Participation Fee”,
- 2 -


and (iv) Commitment Fees, the percentage set forth in the following table under the heading “Commitment Fees”:
Pricing
Level
Consolidated Total Net Leverage RatioABR
Margin
SOFR
Margin
and L/C Participation Fee
Commitment Fees
IGreater than or equal to 3.00:1.00 2.50%3.50%0.50%
IIGreater than or equal to 2.50:1.00 but less than 3.00:1.002.00%3.00%0.375%
IIIGreater than or equal to 2.00:1.00 but less than 2.50:1.001.75%2.75%0.25%
IVGreater than or equal to 1.50:1.00 but less than 2.00:1.001.50%2.50%0.25%
VLess than 1.50:1.001.25%2.25%0.25%

The Applicable Margin shall be determined and adjusted quarterly on the date (each a “Margin Determination Date”) that is five (5) Business Days after receipt by the Administrative Agent of the Compliance Certificate pursuant to Section 6.1(c) for the most recently ended fiscal quarter of the Borrower (but in any event, not later than the 45th day after the end of each of the first three quarterly periods of each Fiscal Year or the 90th day after the end of each Fiscal Year, as the case may be); provided that (a) the Applicable Margin shall be based on Pricing Level IV until the Margin Determination Date for the first full fiscal quarter ending after the Closing Date, (b) if the Borrower fails to deliver the Compliance Certificate as required by Section 6.1(c) for the most recently ended fiscal quarter preceding the applicable Margin Determination Date, the Applicable Margin from such Margin Determination Date shall be based on Pricing Level I until the fifth Business Day after an appropriate Compliance Certificate is delivered, at which time the Pricing Level shall be determined by reference to the Consolidated Total Net Leverage Ratio as of the last day of the most recently ended fiscal quarter of the Borrower preceding such Margin Determination Date. The Applicable Margin shall be effective from one Margin Determination Date until the next Margin Determination Date. Any adjustment in the Applicable Margin shall be applicable to all Loans then existing or subsequently made during the applicable period for which the relevant Applicable Margin applies. Notwithstanding the foregoing, in the event that any financial statement delivered pursuant to Section 6.1(a) or (b) or any Compliance Certificate delivered pursuant to Section 6.1(c) is inaccurate (regardless of whether (i) this Credit Agreement is in effect, or (ii) any of the Commitments are in effect, or (iii) any Loans or Letters of Credit are outstanding when such inaccuracy is discovered or such financial statement or Compliance Certificate was delivered), and such inaccuracy, if corrected, would have led to the application of a higher Applicable Margin for any period (an “Applicable Period”) than the Applicable Margin applied for such Applicable Period, then (A) the Borrower shall immediately deliver to the Administrative Agent a corrected Compliance Certificate for such Applicable Period, (B) the Applicable Margin for such Applicable Period shall be determined as if the Consolidated Total Net Leverage Ratio in the corrected Compliance Certificate were applicable for such Applicable Period, and (C) the Borrower shall immediately pay to the Administrative Agent the accrued additional
- 3 -


interest and fees owing as a result of such increased Applicable Margin for such Applicable Period, which payment shall be promptly applied by the Administrative Agent in accordance with Section 2.8. Nothing in this paragraph shall limit the rights of the Administrative Agent and Lenders with respect to Section 3.1 and Section 8.1.
Notwithstanding the foregoing, the Applicable Margin in respect of any Class of Other Term Loans shall be the applicable percentages per annum set forth in the relevant Incremental Assumption Agreement.
Applicable Percentage” means, at any time (a) with respect to any Lender with a Commitment of any Class, the percentage equal to a fraction the numerator of which is the amount of such Lender’s Commitment of such Class and the denominator of which is the aggregate amount of all Commitments of such Class of all Lenders (provided that if the Commitments under the Revolving Facility have terminated or expired, the Applicable Percentages of the Lenders under the Revolving Facility shall be determined based upon the Revolving Exposure at such time of the determination pursuant to clause (b) below) and (b) with respect to the Loans of any Class, a percentage equal to a fraction the numerator of which is such Lender’s Outstanding Amount of the Loans of such Class and the denominator of which is the aggregate Outstanding Amount of all Loans of such Class.
Appropriate Lenders” means, at any time, (a) with respect to the Revolving Facility, the Revolving Lenders, (b) with respect to any Letters of Credit, the L/C Issuer and the Revolving Lenders, (c) with respect to any Swingline Loans, the Swingline Lender and the Revolving Lenders, and (d) with respect to the Term Facility, the Term Lenders, and (e) with respect to any Incremental Term Facility, the applicable Incremental Term Lenders.
Approved Fund” means any Fund that is administered or managed by (a) a Lender, (b) an Affiliate of a Lender or (c) an entity or an Affiliate of an entity that administers or manages a Lender.
Approved Line of Business” means, collectively, (a) those lines of business in which the Borrower and its Subsidiaries operate on the Closing Date (after giving effect to the Transactions occurring on the Closing Date) and (b) any business or activity that is the same, similar or otherwise reasonably related, ancillary, complementary or incidental thereto.
Arranger” has the meaning assigned to such term in Section 9.7.
Assignment and Assumption” means an assignment and assumption entered into by a Lender and an Eligible Assignee (with the consent of any party whose consent is required by Section 10.4) and accepted by the Administrative Agent, in substantially the form of Exhibit A or any other form acceptable to the Administrative Agent.
Attorney Costs” means with respect to (a) the Administrative Agent, all reasonable and documented fees and reasonable and documented out-of-pocket expenses, charges, disbursements and other charges of one law firm (and one local counsel in each relevant jurisdiction and one special or regulatory counsel for each relevant subject matter to the extent reasonably necessary) and (b) each Credit Party other than the Administrative Agent, all reasonable and documented fees and reasonable and documented out-of-pocket expenses, charges, disbursements and other charges of one counsel to each such Credit Party.
Attributable Indebtedness” means, at any date, (a) in respect of any Finance Lease of any Person, the capitalized amount thereof that would appear on a balance sheet of such Person prepared as of such date in accordance with GAAP, (b) in respect of any Synthetic Lease Obligation of any Person, the capitalized or principal amount of the remaining lease payments under the relevant lease that would
- 4 -


appear on a balance sheet of such Person prepared as of such date in accordance with GAAP if such lease or other agreement were accounted for as a Finance Lease, and (c) all Synthetic Debt of such Person.
Audit and Restatement” means (i) the investigation by the audit committee of the board of directors of the Borrower related to allegations of certain sales and distribution practices of the Borrower and other related matters, (ii) the restatement of the Borrower’s consolidated financial statements filed in their annual report for the Fiscal Year ended December 31, 2016 and certain unaudited condensed consolidated financial data as of and for the Fiscal Years ended December 31, 2015 and December 31, 2014 and (iii) directly related litigation.
Audited Financial Statements” means the Form 10-K containing the audited consolidated balance sheet of the Borrower and its Subsidiaries for the Fiscal Year ended December 31, 2022 and the related audited consolidated statements of income, comprehensive income, cash flows and shareholders’ equity of the Borrower and its Subsidiaries for the Fiscal Year ended December 31, 2022.
Auto-Renewal Letter of Credit” has the meaning assigned to such term in Section 2.4(b)(iii).
Availability Period” means, with respect to the Revolving Facility, the period from and including the Closing Date to but excluding the earlier of the Maturity Date with respect to the Revolving Facility and, if different, the date of the termination of the Revolving Commitments in accordance with the provisions of this Credit Agreement.
Available Tenor” means, as of any date of determination and with respect to the then-current Benchmark, as applicable, (x) if such Benchmark is a term rate, any tenor for such Benchmark (or component thereof) that is or may be used for determining the length of an Interest Period pursuant to this Credit Agreement or (y) otherwise, any payment period for interest calculated with reference to such Benchmark (or component thereof), as applicable, that is or may be used for determining any frequency of making payments of interest calculated with reference to such Benchmark pursuant to this Credit Agreement, in each case, as of such date and not including, for the avoidance of doubt, any tenor for such Benchmark that is then-removed from the definition of “Interest Period” pursuant to Section 3.8(d).
Back-to-Back Letter of Credit” means a letter of credit, in form and substance reasonably satisfactory to the L/C Issuer and issued by an issuer reasonably satisfactory to the L/C Issuer.
Backstopped” means, in respect of any Letter of Credit that remains outstanding on the applicable date, that the L/C Issuer shall have received (a) a Back-to-Back Letter of Credit and/or (b) cash or Cash Equivalents, provided that (i) the sum of the maximum drawable amount of such Back-to-Back Letter of Credit plus the amount of such cash and Cash Equivalents shall not be less than the Minimum Collateral Amount of the maximum drawable amount of such Letter of Credit, (ii) the arrangements with respect to such cash, Cash Equivalents and drawings on any Back-to-Back Letter of Credit allow the L/C Issuer to apply the same to reimburse itself with respect to drawings on, and other sums owing with respect to, such Letter of Credit, and (iii) the requirements under clauses (i) and (ii) of this defined term are reasonably satisfactory to the L/C Issuer.
Bail-In Action” means the exercise of any Write-Down and Conversion Powers by the applicable Resolution Authority in respect of any liability of an Affected Financial Institution.
Bail-In Legislation” means (a) with respect to any EEA Member Country implementing Article 55 of Directive 2014/59/EU of the European Parliament and of the Council of the European Union, the implementing law, regulation, rule or requirement for such EEA Member Country from time to time that is described in the EU Bail-In Legislation Schedule and (b) with respect to the United Kingdom, Part I of
- 5 -


the United Kingdom Banking Act 2009 (as amended from time to time) and any other law, regulation or rule applicable in the United Kingdom relating to the resolution of unsound or failing banks, investment firms or other financial institutions or their affiliates (other than through liquidation, administration or other insolvency proceedings).
Bankruptcy Code” means Title 11 of the United States Code or any similar federal or state law for the relief of debtors.
Benchmark” means, initially, the Term SOFR Reference Rate; provided that if a Benchmark Transition Event and its related Benchmark Replacement Date have occurred with respect to the Term SOFR Reference Rate or the then-current Benchmark, then “Benchmark” means the applicable Benchmark Replacement to the extent that such Benchmark Replacement has replaced such prior benchmark rate pursuant to Section 3.8(a). Any reference to “Benchmark” shall include, as applicable, the published component used in the calculation thereof.
Benchmark Replacement means, for any Available Tenor, the first alternative set forth in the order below that can be determined by the Administrative Agent for the applicable Benchmark Replacement Date:
(a)Daily Simple SOFR; or
(b)the sum of: (i) the alternate benchmark rate that has been selected by the Administrative Agent and the Borrower giving due consideration to (A) any selection or recommendation of a replacement benchmark rate or the mechanism for determining such a rate by the Relevant Governmental Body or (B) any evolving or then-prevailing market convention for determining a benchmark rate and an adjustment as a replacement to the then-current Benchmark for Dollar-denominated syndicated credit facilities at such time and (ii) the related Benchmark Replacement Adjustment;
provided, that any such Benchmark Replacement shall be administratively feasible as determined by the Administrative Agent in its sole discretion.
If the Benchmark Replacement as determined pursuant to clause (a) or (b) above would be less than the Floor, such Benchmark Replacement will be deemed to be the Floor for the purposes of this Credit Agreement and the other Loan Documents.
Benchmark Replacement Adjustment” means, with respect to any replacement of the then-current Benchmark with an Unadjusted Benchmark Replacement, the spread adjustment, or method for calculating or determining such spread adjustment (which may be a positive or negative value or zero) that has been selected by the Administrative Agent and the Borrower giving due consideration to (a) any selection or recommendation of a spread adjustment, or method for calculating or determining such spread adjustment, for the replacement of such Benchmark with the applicable Unadjusted Benchmark Replacement by the Relevant Governmental Body or (b) any evolving or then-prevailing market convention for determining a spread adjustment, or method for calculating or determining such spread adjustment, for the replacement of such Benchmark with the applicable Unadjusted Benchmark Replacement for Dollar-denominated syndicated credit facilities.
Benchmark Replacement Date” means a date and time determined by Administrative Agent, which date shall be no later than the earliest to occur of the following events with respect to the then-current Benchmark:
- 6 -


(c)in the case of clause (a) or (b) of the definition of “Benchmark Transition Event”, the later of (i) the date of the public statement or publication of information referenced therein and (ii) the date on which the administrator of such Benchmark (or the published component used in the calculation thereof) permanently or indefinitely ceases to provide all Available Tenors of such Benchmark (or such component thereof); or
(d)in the case of clause (c) of the definition of “Benchmark Transition Event”, the first date on which such Benchmark (or the published component used in the calculation thereof) has been determined and announced by or on behalf of the administrator of such Benchmark (or such component thereof) or the regulatory supervisor for the administrator of such Benchmark (or such component thereof) to be non-representative; provided that such non-representativeness will be determined by reference to the most recent statement or publication referenced in such clause (c) and even if any Available Tenor of such Benchmark (or such component thereof) continues to be provided on such date.
For the avoidance of doubt, the “Benchmark Replacement Date” will be deemed to have occurred in the case of clause (a) or (b) with respect to any Benchmark upon the occurrence of the applicable event or events set forth therein with respect to all then-current Available Tenors of such Benchmark (or the published component used in the calculation thereof).
Benchmark Transition Event” means the occurrence of one or more of the following events with respect to the then-current Benchmark:
(e)a public statement or publication of information by or on behalf of the administrator of such Benchmark (or the published component used in the calculation thereof) announcing that such administrator has ceased or will cease to provide all Available Tenors of such Benchmark (or such component thereof), permanently or indefinitely; provided that, at the time of such statement or publication, there is no successor administrator that will continue to provide any Available Tenor of such Benchmark (or such component thereof);
(f)a public statement or publication of information by the regulatory supervisor for the administrator of such Benchmark (or the published component used in the calculation thereof), the Federal Reserve Board, the Federal Reserve Bank of New York, an insolvency official with jurisdiction over the administrator for such Benchmark (or such component), a resolution authority with jurisdiction over the administrator for such Benchmark (or such component) or a court or an entity with similar insolvency or resolution authority over the administrator for such Benchmark (or such component), which states that the administrator of such Benchmark (or such component) has ceased or will cease to provide all Available Tenors of such Benchmark (or such component thereof) permanently or indefinitely; provided that, at the time of such statement or publication, there is no successor administrator that will continue to provide any Available Tenor of such Benchmark (or such component thereof); or
(g)a public statement or publication of information by or on behalf of the administrator of such Benchmark (or the published component used in the calculation thereof) or the regulatory supervisor for the administrator of such Benchmark (or such component thereof) announcing that all Available Tenors of such Benchmark (or such component thereof) are not, or as of a specified future date will not be, representative.
For the avoidance of doubt, a “Benchmark Transition Event” will be deemed to have occurred with respect to any Benchmark if a public statement or publication of information set forth above has occurred with respect to each then-current Available Tenor of such Benchmark (or the published component used in the calculation thereof).
- 7 -


Benchmark Unavailability Period” means, the period (if any) (a) beginning at the time that a Benchmark Replacement Date has occurred if, at such time, no Benchmark Replacement has replaced the then-current Benchmark for all purposes hereunder and under any Loan Document in accordance with Section 3.8 and (b) ending at the time that a Benchmark Replacement has replaced the then-current Benchmark for all purposes hereunder and under any Loan Document in accordance with Section 3.8.
Beneficial Ownership Certification” means, with respect to the Borrower, a certification regarding beneficial ownership as required by the Beneficial Ownership Regulation, which certification shall be substantially in the form provided by Administrative Agent or such other form reasonably satisfactory to the Administrative Agent.
Beneficial Ownership Regulation” means 31 C.F.R. § 1010.230.
Benefit Plan” means any of (a) an “employee benefit plan” (as defined in ERISA) that is subject to Title I of ERISA, (b) a “plan” as defined in Section 4975 of the Code or (c) any Person whose assets include (for purposes of ERISA Section 3(42) or otherwise for purposes of Title I of ERISA or Section 4975 of the Code) the assets of any such “employee benefit plan” or “plan”.
Bona Fide Debt Fund” means any bona fide debt fund, investment vehicle, regulated bank entity or unregulated lending entity that is primarily engaged in making, purchasing, holding or otherwise investing in commercial loans and similar extensions of credit in the ordinary course of business for financial investment purposes which is managed, sponsored or advised by any Person controlling, controlled by or under common control with (a) any Disqualified Institution or (b) any Affiliate of such Disqualified Institution, but, in each case, with respect to which no personnel involved with any investment in such Person or the management, control or operation of such Person directly or indirectly makes, has the right to make or participates with others in making any investment decisions, or otherwise causing the direction of the investment policies, with respect to such debt fund, investment vehicle, regulated bank entity or unregulated entity.
Borrower” has the meaning assigned to such term in the Preamble.
Borrowing” means a borrowing consisting of simultaneous Loans of the same Class, Type and, in the case of a SOFR Borrowing, having the same Interest Period, made by the Lenders.
Borrowing Minimum” means (a) in the case of a SOFR Borrowing (other than a Swingline Loan), $1,000,000, (b) in the case of an ABR Borrowing, $500,000, and (c) in the case of a Swingline Loan, $500,000.
Borrowing Multiple” means (a) in the case of a SOFR Borrowing (other than a Swingline Loan), $100,000, (b) in the case of an ABR Borrowing, $50,000, and (c) in the case of a Swingline Loan, $50,000.
Business Day” means any day other than a Saturday, Sunday or day on which banks in New York City, New York are authorized or required by law to close.
Capital Expenditures” means, for any period, with respect to any Person, the aggregate of all expenditures (whether paid in cash or other consideration or accrued as a liability) by such Person and its subsidiaries for the acquisition or leasing (pursuant to a Finance Lease) of fixed or capital assets or additions to equipment (including replacements, capitalized repairs and improvements during such period) that should be capitalized under GAAP on a consolidated balance sheet of such Person and its Subsidiaries (it being understood that “Capital Expenditures” shall not include any portion of the purchase
- 8 -


price of a Permitted Acquisition that is required to be capitalized under GAAP); provided that “Capital Expenditures” shall not include expenditures (a) in respect of normal replacements and maintenance which are properly charged to current operations, (b) made in connection with the replacement, substitution or restoration of assets to the extent financed (i) from insurance proceeds paid on account of the loss of or damage to the assets being replaced or restored or (ii) with awards of compensation arising from the taking by eminent domain or condemnation of the assets being replaced or (c) made as a tenant as leasehold improvements during such period to the extent reimbursed by the landlord during such period.
Cash Collateralize” means to deposit in a Controlled Account or to pledge and deposit with or deliver to the Administrative Agent, for the benefit of one or more of the L/C Issuer or the Lenders, as collateral for L/C Obligations or obligations of the Lenders to fund participations in respect of L/C Obligations, cash or deposit account balances or, if each of the Administrative Agent and the L/C Issuer shall agree in its sole discretion, other credit support, in each case pursuant to documentation in form and substance reasonably satisfactory to the Administrative Agent and the L/C Issuer. “Cash Collateral”, “Cash Collateralized” and “Cash Collateralization” shall have a meaning analogous to the foregoing and shall include the proceeds of such cash collateral and other credit support.
Cash Equivalents” means each of the following to the extent, except with respect to items described in clause (f) below:
(h)Dollars or money in foreign currencies received in the ordinary course of business that are readily convertible into Dollars;
(i)debt obligations maturing within one year from the date of acquisition thereof to the extent the principal thereof and interest thereon is backed by the full faith and credit of the United States;
(j)commercial paper maturing within 180 days from the date of acquisition thereof and having, at such date of acquisition, the highest credit rating obtainable from S&P or Moody’s;
(k)certificates of deposit, banker’s acceptances and time deposits maturing within 270 days from the date of acquisition thereof issued or guaranteed by or placed with, and money market deposit accounts issued or offered by, any domestic office of any commercial bank organized under the laws of the United States or any state, commonwealth or other political subdivision thereof that has a combined capital and surplus and undivided profits of not less than $250,000,000 or, to the extent not otherwise included, any Lender, and which is rated at least A-2 by S&P and P-2 by Moody’s in the note or commercial paper rating category;
(l)repurchase agreements with a term of not more than thirty (30) days for securities described in clause (a) of this definition and entered into with a financial institution satisfying the criteria described in clause (c) of this definition;
(m)money market mutual funds, substantially all of the investments of which are in cash or investments contemplated by clauses (a), (b) and (c) of this definition; and
(n)with respect to any Foreign Subsidiary, investments denominated in the currency of the jurisdiction in which such Subsidiary is organized or has its principal place of business which are similar and of comparable credit quality to the items specified in clauses (b) through (f) above.
- 9 -


Cash Management Obligations” means all obligations of the Loan Parties in respect of any Cash Management Services provided to any Loan Party or its Subsidiaries (whether absolute or contingent and howsoever and whenever created, arising, evidenced or acquired (including all renewals, extensions and modifications thereof and substitutions therefor)) that are (a) owed to the Administrative Agent or any of its Affiliates, (b) owed on the Closing Date to a Person that is a Lender or an Affiliate of a Lender as of the Closing Date or (c) owed to a Person that is a Lender or an Affiliate of a Lender at the time such obligations are incurred or becomes a Lender or an Affiliate of a Lender after it has incurred such obligations, provided that any such provider of Cash Management Services (other than the Administrative Agent or its Affiliates) executes and delivers a Secured Obligation Designation Notice to the Administrative Agent.
Cash Management Services” means, collectively, (a) commercial debit or credit cards, merchant card processing and other services, purchase or debit cards, including non-card e-payables services, (b) treasury management services (including cash pooling arrangements, controlled disbursement, netting, overdraft, lockbox and electronic or automatic clearing house fund transfer services, return items, sweep and interstate depository network services, foreign check clearing services), and (c) any other demand deposit or operating account relationships or other cash management services.
Casualty Event” means any event that (a) gives rise to the receipt by any Loan Party or any of its Subsidiaries of any insurance proceeds or condemnation awards arising from any damage to, destruction of, or other casualty or loss involving, or any seizure, condemnation, confiscation or taking under power of eminent domain of, or requisition of title or use of or relating to or in respect of any equipment, fixed assets or Real Property (including any improvements thereon) of such Loan Party or any of its Subsidiaries, and (b) provides Net Cash Proceeds in the aggregate in excess of $10,000,000 received by the Loan Parties and their Subsidiaries in any Fiscal Year; provided, that “Casualty Event” shall in no event include any event or circumstance which gives rise to the D&O Insurance Payment or the Petit Payment.
CEA Swap Obligation” means, with respect to any Guarantor, any obligation to pay or perform under any agreement, contract or transaction that constitutes a “swap” within the meaning of Section 1a(47) of the Commodity Exchange Act.
Change in Law” means the occurrence, after the Closing Date, of any of the following: (a) the adoption or taking effect of any law, rule, regulation or treaty, (b) any change in any law, rule, regulation or treaty or in the administration, interpretation, implementation or application thereof by any Governmental Authority or (c) the making or issuance of any request, rule, guideline or directive (whether or not having the force of law) by any Governmental Authority or the compliance therewith by any Credit Party (or, for purposes of Section 3.4(b), by any Applicable Lending Office of such Credit Party or such Credit Party’s holding company, if any); provided that notwithstanding anything herein to the contrary, (i) the Dodd-Frank Wall Street Reform and Consumer Protection Act and all requests, rules, guidelines and directives thereunder or issued in connection therewith or in the implementation thereof and (ii) all requests, rules, guidelines and directives promulgated by the Bank for International Settlements, the Basel Committee on Banking Supervision (or any successor or similar authority) or the United States or foreign regulatory authorities, in each case pursuant to Basel III, shall in each case be deemed to be a “Change in Law”, regardless of the date enacted, adopted, issued or implemented.
Change of Control” means an event or series of events by which (a) any Person or group (within the meaning of Rule 13d-5 of the Securities Exchange Act of 1934 as in effect on the Closing Date) shall own directly or indirectly, beneficially or of record, shares representing more than 35% of the aggregate ordinary voting power or economic interests represented by the issued and outstanding Equity Interests of
- 10 -


the Borrower on a fully diluted basis, (b) a majority of the seats (other than vacant seats) on the board of directors (or equivalent governing body) of the Borrower shall at any time be occupied by Persons who were neither (i) nominated, approved or appointed by the board of directors (or equivalent governing body) of the Borrower nor (ii) nominated, approved or appointed by individuals so nominated, approved, or appointed, (c) the Borrower shall fail to own, directly or indirectly, free and clear of all Liens or other encumbrances (other than Liens created pursuant to any Loan Document), 100% of the aggregate ordinary voting power and economic interests represented by the issued and outstanding Equity Interests of each of its Subsidiaries (or such lesser percentage as may be owned, directly or indirectly, as of the Closing Date or the later acquisition thereof) except where such failure is as a result of a transaction permitted by the Loan Documents or (d) any change in control (or similar event, however denominated) with respect to any Loan Party or any of its Subsidiaries shall occur under and as defined in any indenture or agreement in respect of Indebtedness in an outstanding principal amount in excess of the Threshold Amount to which any Loan Party or any of its Subsidiaries is a party.
Citizens Bank” means Citizens Bank, N.A., a national banking association.
Class”, when used in reference to any Loan or Borrowing, refers to whether such Loan, or the Loans comprising such Borrowing, are Revolving Loans, Term Loans, or Swingline Loans or Incremental Term Loans, and, when used in reference to any Commitment, refers to whether such Commitment is a Revolving Commitment, or Term Loan Commitment or Incremental Term Loan Commitment.
Closing Date” means January 19, 2024.
Code” means the Internal Revenue Code of 1986, as amended from time to time.
Collateral” means all the “Collateral” as defined in the Collateral Documents and all other property of whatever kind and nature pledged or charged, or purported to be pledged or charged, as collateral under any Collateral Document. For the avoidance of doubt, the assets of Excluded Subsidiaries shall not constitute “Collateral.”
Collateral and Guarantee Requirement” means, at any time, the requirement that:
(o)the Administrative Agent shall have received each Collateral Document required to be delivered on the Closing Date pursuant to Section 4.1 or Section 6.12, duly executed by each Loan Party that is a party thereto;
(p)all Secured Obligations shall have been unconditionally guaranteed jointly and severally on a senior basis by each of the Guarantors;
(q)except to the extent otherwise provided hereunder or under any Collateral Document, the Secured Obligations shall have been secured by a perfected first priority (subject to Liens expressly permitted pursuant to Section 7.2) security interest in, substantially all tangible and intangible assets of each Loan Party (including (i) accounts receivable, (ii) deposit accounts, commodity accounts and security accounts which shall be Controlled Accounts except that no Excluded Account be required to be a Controlled Account, (iii) inventory, (iv) machinery and equipment, (v) investment property, (vi) cash, (vii) Intellectual Property, (viii) other general intangibles, (ix) Pledged Debt, Pledged Debt Securities and Pledged Equity Interests (as such terms are defined in the Security Agreement), (x) motor vehicles (provided that no action shall be required to be taken to perfect the security interest therein other than the filing of a UCC financing statement) and (xi) the proceeds of the foregoing), it being understood that in the case of the pledge of Equity Interests, the Administrative Agent shall have received all stock certificates or other instruments (if any) representing such Equity Interests, together with stock powers or
- 11 -


other instruments of transfer with respect thereto endorsed in blank; provided that the pledge of any shares in respect of any Subsidiaries that are not Wholly-Owned Subsidiaries shall be limited to the shares actually owned by the applicable pledgor;
(r)the Secured Obligations shall have been secured by a first priority security interest in (i) all Indebtedness of the Borrower and each of its Subsidiaries that is owing to any Loan Party which shall be evidenced by a Master Intercompany Note and (ii) all other Indebtedness owed to a Loan Party, which if evidenced by a promissory note or other instrument, shall, to the extent required by the Security Agreement, have been pledged to the Administrative Agent, and in each case under clauses (i) and (ii), the Administrative Agent shall have received such Master Intercompany Note and such other promissory notes and other instruments together with note powers or other instruments of transfer with respect thereto endorsed in blank;
(s)none of the Collateral shall be subject to any Lien other than Liens expressly permitted by Section 7.2; and
(t)the Administrative Agent shall have received a Perfection Certificate from the Borrower with respect to each Loan Party.
The foregoing definition shall not require the creation or perfection of pledges of or security interests in particular assets, including the delivery of Foreign Pledge Agreements, if and for so long as the Administrative Agent and the Borrower agree in writing that the cost, burden, or consequences (including adverse tax consequences) of creating or perfecting such pledges or security interests in such assets shall be excessive in view of the benefits to be obtained by the Lenders therefrom.
The Administrative Agent may grant extensions of time for the perfection of security interests in and the other requirements pursuant to this definition with respect to particular assets (including extensions beyond the Closing Date for the perfection of security interests in the assets of the Loan Parties on such date) where it reasonably determines (and without the consent of any other Secured Party), that, except as may be required by law, perfection or other requirements cannot be accomplished without undue effort or expense by the time or times at which it would otherwise be required by this Credit Agreement or the Collateral Documents.
Notwithstanding the foregoing provisions of this definition or anything in this Credit Agreement or any other Loan Document to the contrary, (a) Liens required to be granted from time to time pursuant to the Collateral and Guarantee Requirement shall be subject to exceptions and limitations set forth herein and in the Collateral Documents and, to the extent appropriate in the applicable jurisdiction, as agreed between the Administrative Agent and the Borrower, (b) in no event shall the Collateral include any Excluded Assets and (c) notwithstanding anything to the contrary included in this definition, delivery of only the Collateral Documents required to be delivered by Section 4.1 shall be a condition precedent to the Credit Extensions on the Closing Date.
Collateral Documents” means, collectively, the Security Agreement, each Control Agreement, each Foreign Pledge Agreement, each Copyright Security Agreement, each Patent Security Agreement, each Trademark Security Agreement, each Perfection Certificate, each agreement creating or perfecting rights in Cash Collateral and each other security agreement, instrument or other document executed or delivered pursuant to the Collateral and Guarantee Requirement, Section 6.12 or the Security Agreement to secure any of the Secured Obligations.
Commitment” means with respect to any Lender, such Lender’s Revolving Commitment, Term Loan Commitment and Incremental Term Loan Commitment (if any).
- 12 -


Commitment Fee” has the meaning assigned to such term in Section 3.2(a).
Committed Loan Notice” means a notice of a Borrowing (other than a Swingline Borrowing), a conversion of Loans from one Type to the other, or a continuation of SOFR Loans pursuant to Section 2.2(a), which, if in writing, shall be substantially in the form of Exhibit B-1.
Commodity Exchange Act” means the Commodity Exchange Act (7 U.S.C. § 1 et seq.) and any successor statute.
Communications” means, collectively, any notice, demand, communication, information, document or other material provided by or on behalf of any Loan Party pursuant to any Loan Document or the transactions contemplated therein which is distributed to the Administrative Agent, any Lender or any L/C Issuer by means of electronic communications pursuant to Section 10.1, including through the Platform.
Competitor” means any Person that competes with the Borrower or any of its Subsidiaries.
Compliance Certificate” means a certificate, substantially in the form of Exhibit D.
Conforming Changes” means, with respect to either the use or administration of the Benchmark, or the use, administration, adoption or implementation of any Benchmark Replacement, any technical, administrative or operational changes (including, for example and not by way of limitation or prescription, changes to the definition of “Alternate Base Rate,” the definition of “Business Day,” the definition of “Interest Period” or any similar or analogous definition, the definition of “Government Securities Business Day,” timing and frequency of determining rates and making payments of interest, timing of borrowing requests or prepayment, conversion or continuation notices, the applicability and length of lookback periods, the applicability of Section 3.5, and other technical, administrative or operational matters) that the Administrative Agent decides may be appropriate in connection with the use or administration of the Benchmark or to reflect the adoption and implementation of any Benchmark Replacement or to permit the use and administration thereof by the Administrative Agent in a manner substantially consistent with market practice (or, if the Administrative Agent decides that adoption of any portion of such market practice is not administratively feasible or if the Administrative Agent determines that no market practice for the administration of any such rate exists, in such other manner of administration as the Administrative Agent decides is reasonably necessary in connection with the administration of this Credit Agreement and the other Loan Documents).
Connection Income Taxes” means Other Connection Taxes that are imposed on or measured by net income (however denominated) or that are franchise Taxes or branch profits Taxes.
Consolidated Depreciation and Amortization Expense” means, with respect to any Person for any period, the total amount of depreciation and amortization expense, including the amortization of deferred financing fees or costs, capitalized expenditures, customer acquisition costs and incentive payments, conversion costs and contract acquisition costs, the amortization of original issue discount, amortization of favorable or unfavorable lease assets or liabilities, and amortization, impairment, or write-off of intangibles of such Person and its Subsidiaries for such period on a consolidated basis and otherwise determined in accordance with GAAP.
Consolidated EBITDA” means, with respect to any Person for any period, the Consolidated Net Income of such Person and its Subsidiaries for such period:
- 13 -


(u)increased (without duplication of any addbacks set forth herein or in the definition of Pro Forma Basis) by the following, in each case, to the extent deducted (and not added back) in computing Consolidated Net Income for such Person for such period:
(i)provision for all taxes (whether or not paid, estimated, or accrued) based on income, profits, or capital and, without duplication, the aggregate amount of Permitted Tax Distributions made during such period; plus
(ii)Consolidated Interest Expense of such Person and its Subsidiaries to the extent paid or payable in cash or otherwise; plus
(iii)Impairment charges, asset write-off charges, and Consolidated Depreciation and Amortization Expense of such Person and its Subsidiaries; plus
(iv)non-cash losses and non-cash charges (excluding any non-cash charges that constitute an accrual of or a reserve for future cash charges or are reasonably likely to result in a cash outlay in a future period); plus
(v)in the case of the Borrower, reasonable and customary one-time, non-recurring fees, expenses and costs relating to the Transactions incurred within three months of the Closing Date; plus
(vi)one-time costs incurred in connection with (a) the severance, restructuring, termination and disbandment of the Borrower’s Regenerative Business Unit, (b) the Audit and Restatement, and (c) Permitted Acquisitions (including cash expenses relating to Earn-Out Obligations and similar obligations (in each case whether or not consummated)); provided that costs added back pursuant to this clause (vi) shall not exceed, in any twelve-month period when combined with any costs added back pursuant to clause (viii) below, 20% of Consolidated EBITDA determined before giving effect to this clause (vi); and provided further, that solely for the last twelve-month periods ending December 31, 2023 and March 31, 2024, the addbacks pursuant to this clause (vi) may exceed 20% of Consolidated EBITDA, but may not exceed $15,000,000 or $11,500,000, respectively, for each such twelve-month period; plus
(vii)the amount of any equity-based or non-cash compensation charges or expenses, including any such charges or expenses arising from grants of stock appreciation or similar rights, restricted stock units, performance stock units, stock options, restricted stock or other rights; plus
(viii)the amount of pro forma “run rate” cost savings, operating expenses, reductions, synergies and Consolidated EBITDA pursuant to contracted pricing (at the highest contracted rate) related to mergers and other business combinations, acquisitions, investments, dispositions, divestitures, restructuring, operating improvements, cost saving initiatives and other similar transaction or initiatives (including the modification and renegotiation of contracts and other arrangements) that are reasonably identifiable and factually supportable and projected by the Borrower or its Subsidiaries in good faith to result from actions that have been taken or with respect to which substantial steps have been taken (in each case, including any steps or actions taken in whole or in part prior to the Closing Date or the applicable consummation date of such transaction, initiative or event) or are expected to be taken (in the good faith determination of the Borrower or its Subsidiaries) within twelve (12) months after any such transaction, initiative or event is consummated, net of the amount of actual benefits realized during such period from such actions, calculated on a pro forma basis as though such cost savings, operating expense,
- 14 -


reductions, synergies and Consolidated EBITDA pursuant to contracted pricing (at the highest contracted rate) had been realized on the first day of such period for which Consolidated EBITDA is being determined as if such cost savings, operating expense reductions, synergies and Consolidated EBITDA Pursuant to contracted pricing were realized on the first day the applicable period for the entirety of such period; provided that no cost savings, operating expense reductions, synergies and Consolidated EBITDA pursuant to contracted pricing shall be added pursuant to this clause (viii) to the extent duplicative of any expenses or charges otherwise added to Consolidated EBITDA, whether through a pro forma adjustment or otherwise, for such period and provided further that addbacks pursuant to this clause (viii) shall not, when combined with any addbacks pursuant to clause (vi) above, exceed, in any twelve-month period, 20% of Consolidated EBITDA determined before giving effect to this clause (viii); plus
(ix)any net losses, charges, expenses, costs or other payments (including all fees, expenses or charges related thereto) (a) from closed, disposed, abandoned or discontinued operations, (b) in respect of facilities no longer used or useful in the conduct of the business of the Borrower and its Subsidiaries and any losses on disposal of abandoned, closed or discontinued operations and (c) attributable to business dispositions or asset dispositions (other than in the ordinary course of business); plus
(x)other add backs and adjustments reflected in any quality of earnings report made available to the Administrative Agent by (a) a nationally recognized accounting firm or (b) any other accounting firm that shall be reasonably acceptable to the Administrative Agent; and
(v)decreased (without duplication) by the following, in each case, to the extent taken into account (or added back) in computing Consolidated Net Income for such Person for such period:
(i)interest income to the extent received in cash or otherwise during such period; plus
(ii)any gain realized in connection with the sale or Disposition of assets (including Dispositions pursuant to Sale and Leaseback transactions) other than in the ordinary course of business or the Disposition of any securities or the extinguishment of any Indebtedness; plus
(iii)proceeds from the D&O Insurance Payment or the Petit Payment during such period.
For purposes of determining the Consolidated Total Net Leverage Ratio, (a) there shall be included in determining Consolidated EBITDA of the Borrower and its Subsidiaries for any period, without duplication, (i) the Acquired EBITDA of any Acquired Entity or Business on a Pro Forma Basis and (b) there shall be excluded in determining Consolidated EBITDA of the Borrower and its Subsidiaries for any period, the Disposed EBITDA of any Sold Entity or Business on a Pro Forma Basis. Notwithstanding the foregoing, but subject to any adjustment set forth above with respect to any transactions occurring after the Closing Date, Consolidated EBITDA shall be $7,312,000, $5,543,000, $14,101,000 and $17,596,000 for the fiscal quarters ended December 31, 2022, March 31, 2023, June 30, 2023, and September 30, 2023, respectively.
Consolidated Fixed Charge Coverage Ratio” means, with respect to any Measurement Period, the ratio of (a) the result of (i) the Consolidated EBITDA of the Borrower and its Subsidiaries, minus (ii) the aggregate amount of all Capital Expenditures of the Borrower and its Subsidiaries made in cash
- 15 -


(except to the extent financed with the proceeds of Indebtedness (other than a Revolving Borrowing)), minus (iii) federal, state, local and foreign income and franchise taxes paid in cash by the Borrower and its Subsidiaries determined on a consolidated basis to (b) Consolidated Fixed Charges of the Borrower and its Subsidiaries.
Consolidated Fixed Charges” means, for the Borrower and its Subsidiaries for any period, the sum, without duplication, of each of the following with respect to the Borrower and its Subsidiaries, determined on a consolidated basis in accordance with GAAP:
(a)Consolidated Interest Expense of the Borrower and its Subsidiaries for such period, plus
(b)the aggregate of all scheduled principal amounts that become payable during such period in respect of Indebtedness of the Borrower and its Subsidiaries (excluding the repayment of loans in connection with the Existing Credit Agreement Refinancing made on the Closing Date but including the principal portion of Finance Lease Obligations)
For purposes of this definition, “scheduled principal amounts” shall (i) be determined without giving effect to any reduction of such scheduled payments resulting from the application of any voluntary or mandatory prepayments made during the applicable period, (ii) be deemed to include the Attributable Indebtedness and (iii) not include any voluntary or mandatory prepayments.
Consolidated Interest Expense” means, with respect to any Person and its Subsidiaries for any period, the sum of (a) consolidated total interest expense of such Person and its Subsidiaries for such period, whether paid or accrued and whether or not capitalized (including (without duplication), amortization of debt issuance costs and original issue discount, premiums paid to obtain payment, financial assurance or similar bonds, interest capitalized during construction, non-cash interest payments, the interest component of any deferred payment obligations, the interest component of all payments under Finance Leases and the implied interest component of Synthetic Lease Obligations (regardless of whether accounted for as interest expense under GAAP), all commissions, discounts and other fees and charges owed with respect to letters of credit and bankers’ acceptances and net costs in respect of any obligations under any Swap Agreements constituting interest rate swaps, collars, caps or other arrangements requiring payments contingent upon interest rates of such Person and its Subsidiaries), plus (b) all cash dividends paid or payable on preferred stock during such period other than to such Person or a Loan Party, plus or minus, as applicable, to the extent they would otherwise be included in interest expense under GAAP, unrealized gains and losses arising from derivative financial instruments issued by such Person for the benefit of such Person or its Subsidiaries, in each case determined on a consolidated basis for such period.
Consolidated Net Income means, for any Person (the “first Person”) for any period, the sum of net income (or loss) for such period of such first Person and its subsidiaries determined on a consolidated basis in accordance with GAAP, excluding, without duplication, to the extent included in determining such net income (or loss) for such period: (a) any income (or loss) of any other Person (the “second Person”) if such second Person is not a subsidiary of such first Person, except that such first Person’s equity in the net income of any second Person for such period shall be included in the determination of Consolidated Net Income up to the aggregate amount of cash actually distributed by such second Person during such period to such first Person or any of its subsidiaries as a dividend or other distribution, (b) the income (or loss) of any second Person accrued prior to the date it became a subsidiary of such first Person or is merged into or consolidated with such first person or any of its subsidiaries or such second Person’s assets are acquired by such first person or any of its subsidiaries, (c) non-recurring gains (or losses), (d) the income of any subsidiary of such first Person to the extent that the declaration or payment of
- 16 -


dividends or similar distributions by such subsidiary of that income is prohibited by operation of the terms of its charter or any agreement, instrument, judgment, decree, statute, rule or governmental regulation applicable to such subsidiary, and (e) all non-cash adjustments made to translate foreign assets and liabilities for changes in foreign exchange rates made in accordance with ASC 830.
Consolidated Total Debt” means, with respect to any Person and its Subsidiaries at any time and as determined on a consolidated basis and without duplication, an amount equal to the sum of Indebtedness of the type set forth in clauses (a), (b), (c), (e), (g), (h) and (k) of the definition thereof.
Consolidated Total Net Leverage Ratio” means, with respect to any Measurement Period, the ratio of (a) Consolidated Total Debt of the Borrower and its Subsidiaries as of the last day of such Measurement Period minus an aggregate amount of Qualified Cash not to exceed $20,000,000 to (b) Consolidated EBITDA of the Borrower and its Subsidiaries for such Measurement Period.
Contested in Good Faith” means, with respect to any matter, that such matter is being contested in good faith by appropriate proceedings and for which adequate reserves have been provided in accordance with GAAP.
Contractual Obligation” means, as to any Person, any provision of any security issued by such Person or of any agreement, instrument or other undertaking to which such Person is a party or by which it or any of its property is bound.
Control” means the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of a Person, whether through the ability to exercise voting power, by contract or otherwise. “Controlling” and “Controlled” have meanings analogous thereto.
Controlled Account” means, as the context may require, a commodities account, deposit account and/or securities account that is subject to a Control Agreement in form and substance reasonably satisfactory to the Administrative Agent and, with respect to Cash Collateral, the L/C Issuer.
Control Agreement” has the meaning assigned to such term in the Security Agreement.
Copyright Security Agreement” has the meaning assigned to such term in the Security Agreement.
Credit Agreement” means this Credit Agreement.
Credit Extension” means the making of a Loan or a L/C Credit Extension.
Credit Facilities” means the Revolving Facility, the Term Facility and any Incremental Term Facility; each, a “Credit Facility”.
Credit Parties” means the Administrative Agent, the Swingline Lender, the L/C Issuer and the Lenders.
D&O Insurance Payment” means the cash or Cash Equivalent proceeds of any insurance payment received by the Borrower or its Subsidiaries as part of any director and officer’s insurance policy in connection with the litigation proceedings and investigation existing as of the Closing Date involving former CEO, Parker Petit, and other former members of management of the Borrower.
- 17 -


Daily Simple SOFR means, for any day, a rate per annum equal to the greater of (a) the sum of (i) SOFR, with the conventions for this rate (which will include a lookback) being established by the Administrative Agent in accordance with the conventions for this rate selected or recommended by the Relevant Governmental Body for determining “Daily Simple SOFR” for syndicated business loans; provided, that if the Administrative Agent decides that any such convention is not administratively feasible for the Administrative Agent, then the Administrative Agent may establish another convention in its reasonable discretion plus (ii) the Daily Simple SOFR Adjustment, and (b) the Floor.
Daily Simple SOFR Adjustment” means 0.10000%.
Daily SOFR Loan” means a Loan bearing interest based on the Daily SOFR Rate.
Daily SOFR Rate” means, for any day, a rate per annum equal to Term SOFR in effect on such day for a one-month Interest Period (subject to the Floor referred to in the definition of “Term SOFR”).
Debtor Relief Laws” means the Bankruptcy Code, and all other liquidation, conservatorship, bankruptcy, assignment for the benefit of creditors, moratorium, rearrangement, receivership, insolvency, reorganization, or similar debtor relief laws of the United States or other applicable jurisdictions from time to time in effect.
Debtor Relief Plan” means a plan of reorganization or plan of liquidation pursuant to any Debtor Relief Laws.
Default” means any event or condition which constitutes an Event of Default or that upon notice, lapse of time or both would, unless cured or waived, become an Event of Default.
Default Rate” means (a) when used with respect to the outstanding principal balance of any Loan, the sum of (i) the rate of interest otherwise applicable thereto plus (ii) 2.00% per annum, and (b) when used with respect to any L/C Borrowing or any interest, fee or other amount payable under the Loan Documents which shall not have been paid when due, the sum of (i) the Alternate Base Rate plus (ii) the Applicable Margin applicable to ABR Revolving Borrowings plus (iii) 2.00% per annum.
Defaulting Lender” means, subject to Section 2.9(b), any Lender that (a) has failed to (i) fund all or any portion of its Loans within two (2) Business Days of the date such Loans were required to be funded hereunder unless such Lender notifies the Administrative Agent and the Borrower in writing that such failure is the result of such Lender’s determination that one or more conditions precedent to funding (each of which conditions precedent, together with any applicable default, shall be specifically identified in such writing) has not been satisfied, or (ii) pay to the Administrative Agent, the L/C Issuer, the Swingline Lender or any other Lender any other amount required to be paid by it hereunder (including in respect of its participation in Letters of Credit or Swingline Loans) within two (2) Business Days of the date when due, (b) has notified the Borrower, the Administrative Agent or the L/C Issuer or Swingline Lender in writing that it does not intend to comply with its funding obligations hereunder, or has made a public statement to that effect (unless such writing or public statement relates to such Lender’s obligation to fund a Loan hereunder and states that such position is based on such Lender’s determination that a condition precedent to funding (which condition precedent, together with any applicable default, shall be specifically identified in such writing or public statement) cannot be satisfied), (c) has failed, within three (3) Business Days after written request by the Administrative Agent or the Borrower, or, to the extent an L/C Issuer has outstanding L/C obligations owed to it at such time, such L/C Issuer, to confirm in writing to the Administrative Agent and the Borrower that it will comply with its prospective funding obligations hereunder, provided that such Lender shall cease to be a Defaulting Lender pursuant to this clause (c) upon receipt of such written confirmation by the Administrative Agent, such L/C Issuer or the Borrower,
- 18 -


or (d) has, or has a direct or indirect holding company that has, (i) become the subject of a proceeding under any Debtor Relief Law, or (ii) had appointed for it a receiver, custodian, conservator, trustee, administrator, assignee for the benefit of creditors or similar Person charged with reorganization or liquidation of its business or assets, including the Federal Deposit Insurance Corporation or any other state or federal regulatory authority acting in such a capacity or (iii) become the subject of a Bail-In Action; provided that a Lender shall not be a Defaulting Lender solely by virtue of the ownership or acquisition of any equity interest in that Lender or any direct or indirect holding company thereof by a Governmental Authority so long as such ownership interest does not result in or provide such Lender with immunity from the jurisdiction of courts within the United States or from the enforcement of judgments or writs of attachment on its assets or permit such Lender (or such Governmental Authority) to reject, repudiate, disavow or disaffirm any contracts or agreements made with such Lender. Any determination by the Administrative Agent that a Lender is a Defaulting Lender under any one or more of clauses (a) through (d) above shall be conclusive and binding absent manifest error, and such Lender shall be deemed to be a Defaulting Lender (subject to Section 2.9(b)) upon delivery of written notice of such determination to the Borrower, the L/C Issuer, the Swingline Lender and each Lender.
Disclosed Matters” means the actions, suits, proceedings and environmental matters disclosed in Schedule 5.6.
Disposed EBITDA” means, with respect to any Sold Entity or Business for any period, the historical Consolidated EBITDA of such Sold Entity or Business for such period as certified by a Responsible Officer of the Borrower, which historical Consolidated EBITDA shall be calculated in a manner consistent with the definition of Consolidated EBITDA herein and to be based on financial statements for such Sold Entity or Business prepared in accordance with GAAP (subject to the absence of footnote disclosures and year-end audit adjustments with respect to financial statements that are not annual audited financial statements), provided that when such Disposed EBITDA is excluded from Consolidated EBITDA it shall be on a Pro Forma Basis).
Disposition” means, with respect to any Person, the sale, transfer, license, lease or other disposition (including by way of Division, Sale Leaseback or any sale or issuance of Equity Interests by way of a merger or otherwise) by such Person to any other Person, with or without recourse, of (a) any notes or accounts receivable or any rights and claims associated therewith, (b) any Equity Interests of any Subsidiary (other than directors’ qualifying shares), or (c) any other assets (other than Equity Interests of the Borrower), provided, however, that none of the following shall constitute a Disposition: (i) any sale, transfer, license, lease or other disposition by (A) a Loan Party to another Loan Party or (B) a Non-Loan Party Subsidiary to another Non-Loan Party Subsidiary, in each case, on terms which are no less favorable than are obtainable from any Person which is not one of its Affiliates, (ii) the collection of accounts receivable and other obligations in the ordinary course of business, (iii) sales of inventory in the ordinary course of business, (iv) dispositions of substantially worn out, damaged, uneconomical, surplus or obsolete equipment, equipment that is no longer useful in the business of the Borrower or its Subsidiaries, and (v) sales, transfers, licenses, leases or other Dispositions resulting in aggregate Net Cash Proceeds not exceeding $10,000,000 during any Fiscal Year. Each of the terms “Dispose” and “Disposed” when used as a verb shall have an analogous meaning.
Disqualified Equity Interest” means, with respect to any Person, any Equity Interest of such Person which, by its terms, or by the terms of any security or other Equity Interests into which it is convertible or for which it is exchangeable, or upon the happening of any event or condition, (a) matures or is mandatorily redeemable (other than solely for Qualified Equity Interests and cash in lieu of fractional shares of such Equity Interests) pursuant to a sinking fund obligation or otherwise (except as a result of a change in control or asset sale so long as any rights of the holders thereof upon the occurrence
- 19 -


of a change in control or asset sale event shall be subject to the prior occurrence of the Termination Date), (b) is redeemable at the option of the holder thereof (other than solely for Qualified Equity Interests), in whole or in part, (c) provides for the scheduled payments of dividends in cash, or (d) is or becomes convertible into or exchangeable for Indebtedness or any other Equity Interests that would constitute Disqualified Equity Interests, in each case, prior to the date that is 91 days after the Latest Maturity Date at the time such Equity Interests are issued.
Disqualified Institution” means (a) any Person designated by the Borrower as a “Disqualified Institution” by written notice delivered to the Administrative Agent on or prior to the date that is at least five (5) days prior to the Closing Date, (b) any other Person that is a Competitor of the Borrower or any of its Subsidiaries, which Person has been designated by the Borrower as a “Disqualified Institution” by written notice delivered to the Administrative Agent from time to time and (c) as to any entity referenced in either of clauses (a) and (b) above (the “Primary Disqualified Institution”), any of such Primary Disqualified Institution’s Affiliates designated by the Borrower by written notice delivered to the Administrative Agent from time to time or otherwise reasonably identifiable as an Affiliate of a Primary Disqualified Institution solely on the basis of the similarity of such Affiliate’s name to the name of any entity set forth on the DQ List, but excluding any Bona Fide Debt Fund.
Division” means the division of the assets, liabilities and/or obligations of a Person (the “Dividing Person”) among two or more Persons, whether pursuant to a “plan of division” or similar arrangement pursuant to Section 18-217 of the Delaware Limited Liability Company Act or any similar provision under the laws of any other applicable jurisdiction and pursuant to which the Dividing Person may or may not survive.
Dollars” or “$” refers to the lawful money of the United States.
Domestic Subsidiary” means a Subsidiary incorporated or organized under the laws of the United States, or any state, commonwealth or other political subdivision thereof (including, for the avoidance of doubt, the District of Columbia).
DQ List” has the meaning assigned to such term in Section 10.4(f)(iv).
Earn-Out Obligations” means, with respect to any Person, obligations of such Person that are recognized under GAAP as a liability of such Person, payable in cash or which may be payable in cash at the seller’s or obligee’s option arising from the acquisition of a business or a line of business (whether pursuant to an acquisition of Equity Interests or assets, the consummation of a merger or consolidation or otherwise) and payable to the seller or sellers thereof.
EEA Financial Institution” means (a) any credit institution or investment firm established in any EEA Member Country that is subject to the supervision of an EEA Resolution Authority, (b) any entity established in an EEA Member Country that is a parent of an institution described in clause (a) of this definition, or (c) any financial institution established in an EEA Member Country that is a subsidiary of an institution described in clauses (a) or (b) of this definition and is subject to consolidated supervision with its parent.
EEA Member Country” means any of the member states of the European Union, Iceland, Liechtenstein, and Norway.
EEA Resolution Authority” means any public administrative authority or any person entrusted with public administrative authority of any EEA Member Country (including any delegee) having responsibility for the resolution of any EEA Financial Institution.
- 20 -


Effective Yield” means, with respect to any Term Facility existing as of any date of determination, the sum of (a) the higher of (i) Term SOFR for an Interest Period closest to one month and (ii) the applicable Floor with respect thereto as of such date, (b) the Applicable Margin (or other applicable margin) as of such date for SOFR Loans (or other loans that accrue interest by reference to a similar reference rate) and (c) the amount of original issue discount and upfront fees thereon (converted to yield assuming the lesser of (x) a four year average life and (y) the remaining life to maturity, and without any present value discount), but excluding the effect of any arrangement, structuring, underwriting and syndication fees and other fees payable in connection therewith that are neither shared with nor generally paid to all Lenders.
Eligible Assignee” means any Person that meets the requirements to be an assignee under Section 10.4(b)(iii), (v) and (vi) (subject to such consents, if any, as may be required under Section 10.4(b)(iii)). For the avoidance of doubt, any Disqualified Institution is subject to Section 10.4(f).
Engagement Letter” means the Engagement Letter dated December 1, 2023, between the Borrower and Citizens Bank, as may be amended, restated, modified, supplemented or replaced from time to time.
Environmental Claims” means any and all administrative, regulatory or judicial actions, suits, demands, demand letters, claims, liens, notices of liability, non-compliance or violation, investigations, proceedings, settlements, consent decrees, consent orders, consent agreements and all costs and liabilities relating to or arising from or under any Environmental Law, including (a) any and all claims by Governmental Authorities for enforcement, investigation, corrective action, cleanup, removal, response, remedial or other actions, cost recovery, damages, natural resource damages or penalties pursuant to or arising under any Environmental Law, (b) any and all claims by any one or more Persons seeking damages, contribution, restitution, indemnification, cost recovery, compensation or injunctive relief directly or indirectly resulting from, based upon or arising under Environmental Law, pertaining to Hazardous Materials or, solely with respect to exposure to Hazardous Material, an alleged injury or threat of injury to human health, safety, natural resources, or the indoor or outdoor environment, and (c) all liabilities contingent or otherwise, expenses, obligations, losses, damages, fines and penalties arising under any Environmental Law.
Environmental Law” means, collectively and individually any and all federal, state, local, or foreign statute, rule, regulation, code, guidance, ordinance, order, judgment, directive, decree, injunction or common law as now or previously in effect and regulating, relating to or imposing liability or standards of conduct concerning: the environment; protection of the environment and natural resources; air emissions; water discharges; noise emissions; the Release, threatened Release or discharge into the environment and physical hazards of any Hazardous Material; the generation, handling, management, treatment, storage, transport or disposal of any Hazardous Material or otherwise concerning pollution or the protection of the outdoor or indoor environment, preservation or restoration of natural resources, employee or human health or safety with respect to protection from Hazardous Materials only, and potential or actual exposure to or injury from Hazardous Materials.
Environmental Liability” means, in respect of any Person, any statutory, common law or equitable liability, contingent or otherwise of such Person directly or indirectly resulting from, arising out of or based upon (a) the violation of any Environmental Law or Environmental Permit, or (b) an Environmental Claim.
- 21 -


Environmental Permit” means any permit, approval, authorization, certificate, license, variance, filing or permission required by or from any Governmental Authority pursuant to any Environmental Law.
Equity Interests” means, with respect to any Person, (a) shares of capital stock of (or other ownership or profit interests in) such Person, (b) warrants, options or other rights for the purchase or acquisition from such Person of shares of capital stock of (or other ownership or profit interests in) such Person, (c) securities (other than Indebtedness) convertible into or exchangeable for shares of capital stock of (or other ownership or profit interests in) such Person or warrants, rights or options for the purchase or acquisition from such Person of such shares (or such other interests), and (d) all other ownership or profit interests in such Person (including partnership, member or trust interests therein), whether voting or non-voting, and whether or not such shares, warrants, options, rights or other interests are outstanding on any date of determination.
ERISA” means the Employee Retirement Income Security Act of 1974, and the rules and regulations issued thereunder.
ERISA Affiliate” means any trade or business (whether or not incorporated) that, together with any Loan Party, is treated as a single employer under Section 414(b) or 414(c) of the Code or, solely for purposes of Sections 302 and 303 of ERISA and Sections 412 and 430 of the Code, is treated as a single employer under subsection (b), (c), (m) or (o) of Section 414 of the Code.
ERISA Event” means (a) any “reportable event”, as defined in Section 4043(c) of ERISA with respect to a Pension Plan (other than an event for which the 30-day notice period referred to in Section 4043 of ERISA is waived); (b) the existence with respect to any Pension Plan of a non-exempt “prohibited transaction,” as defined in Section 406 of ERISA or Section 4975(c)(1) of the Code; (c) any failure of any Pension Plan to satisfy the “minimum funding standard” applicable to such Pension Plan under Section 412 or Section 430 of the Code or Section 302 or Section 303 of ERISA, whether or not waived; (d) the filing pursuant to Section 412(c) of the Code or Section 302(c) of ERISA of an application for a waiver of the minimum funding standard with respect to any Pension Plan, the failure to make by its due date a required installment under Section 430(j)(3) of the Code with respect to any Pension Plan or the failure of any Loan Party or ERISA Affiliate to make any required contribution to any Multiemployer Plan; (e) a determination that any Pension Plan is, or is expected to be, in “at-risk” status (as defined in Section 430(i)(4) of the Code or Section 303(i)(4) of ERISA; (f) the incurrence by any Loan Party or any ERISA Affiliate of any liability under Title IV of ERISA with respect to the termination of any Pension Plan including the imposition of any Lien in favor of the PBGC or any Pension Plan(other than for PBGC premiums due but not delinquent under Section 4007 of ERISA); (g) the filing of a notice of intent to terminate, the treatment of a Pension Plan amendment as a termination under Section 4041 or Section 4041A or ERISA, the receipt by any Loan Party or any ERISA Affiliate from the PBGC or a Pension Plan administrator of any notice relating to an intention to terminate any Pension Plan or Pension Plans or to appoint a trustee to administer any Pension Plan under Section 4042 of ERISA or the occurrence of an event or condition which constitutes grounds under Section 4042 of ERISA or the termination of, or the appointment of a trustee to administrator, any Pension Plan; (h) any limitations under Section 436 of the Code become applicable; (i) the incurrence by any Loan Party or any of its ERISA Affiliates of any liability with respect to the withdrawal or partial withdrawal from any Pension Plan or Multiemployer Plan; (j) a withdrawal by any Loan Party or any ERISA Affiliate from a Pension Plan subject to Section 4063 of ERISA during a plan year in which it was a substantial employer (as defined in Section 4001(a)(2) of ERISA) or a cessation of operations that is treated as such a withdrawal under Section 4062(e) of ERISA; (k) the receipt by any Loan Party or any ERISA Affiliate of any notice, or the receipt by any Multiemployer Plan from any Loan Party or any ERISA Affiliate of any
- 22 -


notice, concerning the imposition of Withdrawal Liability or a determination that a Multiemployer Plan is, or is expected to be, insolvent or in reorganization, within the meaning of Title IV of ERISA or in endangered or critical status within the meaning of Section 432 of the Code or Section 305 or Title IV of ERISA; or (l) the imposition on any Loan Party or any ERISA Affiliate of any tax under Chapter 43 of Subtitle D of the Code, or the assessment of a civil penalty on any Loan Party or any ERISA Affiliate under Section 502(c) of ERISA.
Erroneous Payment” has the meaning assigned to such term in Section 9.13(a).
Erroneous Payment Deficiency Assignment” has the meaning assigned to such term in Section 9.13(d)(i).
Erroneous Payment Impacted Class” has the meaning assigned to such term in Section 9.13(d)(i).
Erroneous Payment Return Deficiency” has the meaning assigned to such term in Section 9.13(d)(i).
Erroneous Payment Subrogation Rights” has the meaning assigned to such term in Section 9.13(e).
EU Bail-In Legislation Schedule” means the EU Bail-In Legislation Schedule published by the Loan Market Association (or any successor person), as in effect from time to time.
Event of Default” has the meaning assigned to such term in Section 8.1.
Excluded Account” has the meaning assigned to such term in the Security Agreement.
Excluded Assets” has the meaning assigned to such term in the Security Agreement.
Excluded CEA Swap Obligation” means, with respect to any Guarantor, any CEA Swap Obligation if, and only to the extent that, all or a portion of the Guarantee of such Guarantor of, or the grant by such Guarantor of a security interest to secure, such CEA Swap Obligation (or any Guarantee thereof) is or becomes illegal under the Commodity Exchange Act or any rule, regulation or order of the Commodity Futures Trading Commission (or the application or official interpretation of any thereof), including by virtue of such Guarantor’s failure for any reason to constitute an “eligible contract participant” as defined in the Commodity Exchange Act (after giving effect to Section 10.20 and any other “keepwell”, support or other agreement for benefit of such Guarantor and any and all guarantees of such Guarantor’s CEA Swap Obligations by other Loan Parties) and the regulations thereunder at the time the Guarantee of such Guarantor or the grant of such security interest becomes effective with respect to such CEA Swap Obligation. If a CEA Swap Obligation arises under a master agreement governing more than one swap, such exclusion shall apply only to the portion of such CEA Swap Obligation that is attributable to swaps for which such Guarantee or security interest is or becomes illegal.
Excluded Collateral” has the meaning assigned to such term in the Security Agreement.
Excluded Subsidiary” means (a) any Subsidiary that is prohibited by Applicable Law, rule or regulation or by any contractual obligation (to the extent such contractual obligation is existing (i) on the Closing Date or (ii) at the time of acquisition of such Subsidiary so long as the prohibition or restriction in such contract is not entered into in contemplation thereof) from providing a Guarantee of the Secured Obligations or which would require governmental (including regulatory or any other Governmental
- 23 -


Authority’s) consent, approval, license or authorization to provide such a Guarantee unless such consent, approval, license or authorization has been received, (b) any Foreign Subsidiary (other than a Material Foreign Subsidiary), (c) any captive insurance company, (d) any other Subsidiary with respect to which the Borrower and the Administrative Agent reasonably determine in writing the cost, burden or other consequences (including adverse tax consequences) of providing such a Guarantee shall be excessive in view of the benefits of such Guarantee to be afforded to the Lenders therefrom and (e) any Immaterial Domestic Subsidiary.
Excluded Taxes” means any of the following Taxes imposed on or with respect to a Recipient or required to be withheld or deducted from a payment to a Recipient, (a) Taxes imposed on or measured by net income (however denominated), franchise Taxes, and branch profits Taxes, in each case, (i) imposed as a result of such Recipient being organized under the laws of, or having its principal office or, in the case of any Lender, its Applicable Lending Office located in, the jurisdiction imposing such Tax (or any political subdivision thereof) or (ii) that are Other Connection Taxes, (b) in the case of a Lender, U.S. federal withholding Taxes imposed on amounts payable to or for the account of such Lender with respect to an applicable interest in a Loan, Commitment or L/C Borrowing pursuant to a law in effect on the date on which (i) such Lender acquires such interest in the Loan, Commitment (other than pursuant to an assignment request by the Borrower under Section 3.7(b)) or L/C Borrowing or (ii) such Lender changes its Applicable Lending Office, except in each case to the extent that, pursuant to Section 3.6, amounts with respect to such Taxes were payable either to such Lender’s assignor immediately before such Lender became a party hereto or to such Lender immediately before it changed its Applicable Lending Office, (c) Taxes attributable to such Recipient’s failure to comply with Section 3.6(g) and (d) any U.S. federal withholding Taxes imposed under FATCA.
Existing Credit Agreement” means the Credit Agreement, dated as of June 30, 2020, among the Borrower, the lenders party thereto and Hayfin Services LLP, as agent (as amended, amended and restated, supplemented or otherwise modified prior to the date hereof), and all guarantees, notes and other documents, agreements and instruments entered into in connection therewith.
Existing Credit Agreement Refinancing” means the payment in full of all principal, premium, if any, interest, fees and other amounts due or outstanding under the Existing Credit Agreement, the termination of commitments thereunder and the discharge and release of all Guarantees and Liens existing in connection therewith.
FATCA” means Sections 1471 through 1474 of the Code, as of the date of this Credit Agreement (or any amended or successor version that is substantively comparable and not materially more onerous to comply with) and any current or future regulations or official interpretations thereof and any agreement entered into pursuant to Section 1471(b)(1) of the Code and any fiscal or regulatory legislation, rules or practices adopted pursuant to any intergovernmental agreement, treaty or convention among Governmental Authorities and implementing such Sections of the Code.
FDA” means the United States Food and Drug Administration and any successor agency or entity thereof or any analogous agency or entity in any other jurisdiction.
Federal Funds Rate” means, for any day, a rate per annum (expressed as a decimal, rounded upwards, if necessary, to the next higher 1/100 of 1%) equal to the weighted average of the rates on overnight federal funds transactions with members of the Federal Reserve System arranged by federal funds brokers on such day, as published by the Federal Reserve Bank of New York on the Business Day next succeeding such day, provided that (a) if the day for which such rate is to be determined is not a Business Day, the Federal Funds Rate for such day shall be such rate on such transactions on the next
- 24 -


preceding Business Day as so published on the next succeeding Business Day, (b) if such rate is not so published for any day, the Federal Funds Rate for such day shall be the average of the quotations for such day on such transactions received by the Administrative Agent from three federal funds brokers of recognized standing selected by it and (c) if the Federal Funds Rate shall be less than zero, such rate shall be deemed to be zero for purposes of this Credit Agreement.
Federal Reserve Board” means the Board of Governors of the Federal Reserve System of the United States.
Finance Lease Obligations” means, at the time any determination thereof is to be made, the amount of the liabilities in respect of Finance Leases that would at such time be required to be capitalized and reflected as a liability on a balance sheet (excluding the footnotes thereto) prepared in accordance with GAAP.
Finance Leases” means all leases that are required to be capitalized in accordance with GAAP.
Financial Covenants” means the covenants set forth in Sections 7.12(a) and (b).
Financial Officer” means, with respect to any Person, the chief financial officer, principal accounting officer, treasurer, comptroller, or controller of such Person (or such other financial officer as is acceptable to the Administrative Agent in its sole discretion.
Fiscal Year” means the four fiscal quarter period of the Borrower ending on December 31 of each calendar year.
Floor means 0.00% per annum.
Foreign Lender” means (a) if the Borrower is a U.S. Person, a Lender or L/C Issuer that is not a U.S. Person, and (b) if the Borrower is not a U.S. Person, a Lender or L/C Issuer that is resident or organized under the laws of a jurisdiction other than that in which the Borrower is resident for tax purposes.
Foreign Plan” means any employee pension benefit plan or arrangement (a) maintained or contributed to by any Loan Party or Subsidiary that is not subject to the laws of the United States, or (b) mandated by a government other than the United States for employees of any Loan Party or Subsidiary.
Foreign Pledge Agreement” means, collectively each local law pledge agreement executed and delivered by a Loan Party and the Administrative Agent to grant a security interest in the Equity Interests of a Material Foreign Subsidiary, each in form and substance reasonably satisfactory to the Administrative Agent.
Foreign Subsidiary” means any Subsidiary that is not a Domestic Subsidiary.
Fronting Exposure” means, at any time there is a Defaulting Lender, (a) with respect to the L/C Issuer, such Defaulting Lender’s L/C Exposure other than such Defaulting Lender’s L/C Exposure that has been reallocated to other Lenders or Cash Collateralized in accordance with the terms hereof, and (b) with respect to the Swingline Lender, such Defaulting Lender’s Swingline Exposure other than such Defaulting Lender’s Swingline Exposure that has been reallocated to other Lenders.
- 25 -


Fund” means any Person (other than a natural Person) that is (or will be) engaged in making, purchasing, holding or otherwise investing in commercial loans, bonds and similar extensions of credit in the ordinary course of its activities.
GAAP” means generally accepted accounting principles in effect from time to time in the United States.
Government Securities Business Day” means any day except for (a) a Saturday, (b) a Sunday or (c) a day on which the Securities Industry and Financial Markets Association (or any successor thereto) recommends that the fixed income departments of its members be closed for the entire day for purposes of trading in United States government securities.
Governmental Approval” means any consent, authorization, approval, order, license, franchise, permit, certificate, accreditation, registration, filing or notice, of, issued by, from or to, or other act by or in respect of, any Governmental Authority.
Governmental Authority” means the government of the United States or any other nation, or of any political subdivision thereof, whether state or local, and any department, commission, board, bureau, agency, authority, instrumentality, regulatory body, court, central bank or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative powers or functions of or pertaining to government (including any supra national bodies such as the European Union or the European Central Bank) and any group or body charged with setting financial accounting or regulatory capital rules or standards (including the Financial Accounting Standards Board, the Bank for International Settlements or the Basel Committee on Banking Supervision or any successor or similar authority to any of the foregoing).
Guarantee Agreement” means the Guarantee Agreement, dated as of the date Closing Date, among the Loan Parties and the Administrative Agent.
Guarantees” of or by any Person (the “guarantor”) means any obligation, contingent or otherwise, of the guarantor guaranteeing or having the economic effect of guaranteeing any Indebtedness or other obligation of any other Person (the “primary obligor”) in any manner, whether directly or indirectly, and including any obligation of the guarantor, direct or indirect, (a) to purchase or pay (or advance or supply funds for the purchase or payment of) such Indebtedness or other obligation or to purchase (or to advance or supply funds for the purchase of) any security for the payment thereof, (b) to purchase or lease property, securities or services for the purpose of assuring the owner of such Indebtedness or other obligation of the payment thereof, (c) to maintain working capital, equity capital or any other financial statement condition or liquidity of the primary obligor as to enable the primary obligor to pay such Indebtedness or other obligation or (d) as an account party in respect of any letter of credit or letter of guaranty issued to support such Indebtedness or obligation, provided that the term “Guarantee” shall not include endorsements for collection or deposit in the ordinary course of business. The term “Guaranteed” has a meaning analogous thereto. The amount of any Guarantee at any time shall be deemed to be an amount equal to the lesser at such time of (i) the stated or determinable amount of the primary obligation in respect of which such Guarantee is made (or, if not stated or determinable, the maximum reasonably anticipated amount of the obligations in respect of which such Guarantee is made) and (ii) the maximum amount for which the guarantor may be liable pursuant to the terms of the instrument embodying such Guarantee.
Guarantors” means (a) each Subsidiary Guarantor, and (b) each other Person that becomes a party to the Guarantee Agreement as a Guarantor.
- 26 -


Hazardous Materials” means all substances, wastes, chemicals, pollutants, or other contaminants, including petroleum or petroleum distillates, asbestos or asbestos containing materials, polychlorinated biphenyls, radon gas, mold, infectious, pharmaceutical or medical wastes and all other substances of any nature that are now or hereafter regulated under any Environmental Law or are now or hereafter defined, listed, classified, considered or described as hazardous, dangerous or toxic by any Governmental Authority or under any Environmental Law; provided, however, that the term “Hazardous Materials” shall not include materials that otherwise would be included in such definition but that are of kinds and in amounts ordinarily and customarily used or stored in similar properties, including, without limitation substances used for the purposes of cleaning, maintenance, or operations, substances typically used in construction, and typical products used in properties like the Real Property and which are otherwise in compliance with all Environmental Laws.
Health Care Compliance Program” has the meaning assigned to such term in Section 5.19(l).
Healthcare Law” means the laws, codes, policies and guidelines of all Governmental Authorities relating to the production, manufacturing, preparation, propagation, compounding, conversion, pricing, marketing, promotion, sale, distribution, coverage, or reimbursement of a drug, device, biological or other medical item, supply or service, including, without limitation, the U.S. Food, Drug and Cosmetic Act of 1938 (“FD&C Act”), 21 U.S.C. Ch. 9, as amended from time to time, and the rules, regulations, guidelines, guidance documents and compliance policy guides issued or promulgated thereunder, billing and collection practices relating to the payment for healthcare services, items or supplies, the federal False Claims Act (31 U.S.C. §§ 3729 et seq.), the federal healthcare program anti- kickback statute (42 U.S.C. § 1320a- 7b),the Stark law (42 U.S.C. § 1395nn), the Federal Program Fraud Civil Remedies Act (31 U.S.C. § 3801 et seq.) and the Federal Health Care Fraud Law (18 U.S.C. § 1347), the healthcare fraud, false statement and health information privacy and security provisions of the Health Insurance Portability and Accountability Act of 1996 (HIPAA), as amended by the Health Information Technology for Economic and Clinical Health (HITECH) Act ("HIPAA"), the federal healthcare program civil money penalty and exclusion authorities 42 U.S.C. § 1320a-7a), the Physician Payments Sunshine Act (42 U.S.C. § 1320a-7h), the statutes, regulations and binding directives of applicable federal healthcare programs of Medicare, Medicaid and other healthcare programs of other Governmental Authorities, including the Veterans Health Administration and United States Department of Defense healthcare and contracting programs, the Federal Trade Commission Act, as amended, and its implementing regulations, and the analogous Requirements of Law of any other jurisdiction.

HIPAA” has the meaning assigned to such term in the definition of Healthcare Laws.
Immaterial Domestic Subsidiary” means, at any date of determination, any Domestic Subsidiary of a Loan Party which as of such date (a) holds assets representing less than 2.5% or less of the Loan Parties’ consolidated total assets (excluding Investments in Subsidiaries and intercompany receivables that would be eliminated in consolidated financial statements, and goodwill) (determined in accordance with GAAP), (b) has generated less than 2.5% of the Loan Parties’ consolidated total revenues (excluding any intercompany revenue that would be eliminated in consolidated financial statements) determined in accordance with GAAP for the four fiscal quarter period ending on the last day of the most recent period for which financial statements have been delivered pursuant to Section 6.1(b); provided that all Subsidiaries that are individually “Immaterial Subsidiaries” shall not have aggregate consolidated total assets (excluding Investments in Subsidiaries and intercompany receivables that would be eliminated in consolidated financial statements, and goodwill) that would represent 5.0% or more of the Loan Parties consolidated total assets as of such date or have generated 5.0% or more of the Loan Parties’ consolidated total revenues (excluding any intercompany revenue that would be eliminated in consolidated financial statements) for such four fiscal quarter period, in each case determined in accordance with GAAP, and (c)
- 27 -


owns no material Intellectual Property. No Person may be a Loan Party and simultaneously be an Immaterial Domestic Subsidiary.
Incremental Assumption Agreement” means an Incremental Assumption Agreement in form and substance reasonably satisfactory to the Administrative Agent and the Borrower, among the Borrower, the Administrative Agent and each Incremental Term Lender and/or existing or additional Revolving Lender party thereto.
Incremental Commitments” has the meaning assigned to such term in Section 2.11(a).
Incremental Term Facilitymeans a term loan credit facility evidenced by Incremental Term Loan Commitments, if any.
Incremental Term Lendermeans a Lender with an Incremental Term Loan Commitment or an outstanding Incremental Term Loan.
Incremental Term Loan Commitment” means the commitment of any Lender, established pursuant to Section 2.11, to make an Incremental Term Loan to the Borrower.
Incremental Term Loan Maturity Date means the final maturity date of any Incremental Term Loan, as set forth in the applicable Incremental Assumption Agreement, provided that if such date is not a Business Day, the Incremental Term Loan Maturity Date shall be the Business Day immediately preceding such day.
Incremental Term Loan Repayment Date means each date regularly scheduled for the payment of principal of any Incremental Term Loan, as set forth in the applicable Incremental Assumption Agreement.
Incremental Term Loans means term loans made by one or more Lenders to the Borrower pursuant to Section 2.1(c). Incremental Term Loans may be made in the form of additional Term Loans or, to the extent permitted by Section 2.11 and provided for in the relevant Incremental Assumption Agreement, Other Term Loans.
Indebtedness” of any Person means, without duplication:
(c)all obligations of such Person for borrowed money;
(d)all obligations of such Person evidenced by bonds, debentures, notes, loan agreements or other similar instruments, including seller paper;
(e)the maximum amount (after giving effect to any prior drawings or reductions which have been reimbursed) of all letters of credit (including standby and commercial), banker’s acceptances, bank guaranties, surety bonds, and similar instruments issued or created by or for the account of such Person;
(f)the Swap Termination Value of each Swap Agreement (to the extent reflecting an amount owed by such Person or an amount that would be owing were such Swap Agreement terminated);
(g)the Attributable Indebtedness of such Person in respect of Finance Lease Obligations, Synthetic Debt and Synthetic Lease Obligations of such Person (regardless of whether accounted for as indebtedness under GAAP);
- 28 -


(h)all obligations of such Person to pay the deferred purchase price of property or services (other than (i) trade accounts payable in the ordinary course of business which are paid within 90 days of their respective due dates and (ii) any purchase price adjustments, earn out or similar obligation until such obligation becomes a liability on the balance sheet of such Person in accordance with GAAP and if not paid after becoming due and payable);
(i)indebtedness (excluding prepaid interest thereon) secured by a Lien (or for which the holder of such indebtedness has an existing right, contingent or otherwise, to be secured by a Lien) on property owned or being purchased by such Person (including indebtedness arising under conditional sales or other title retention agreements and mortgage, industrial revenue bond, industrial development bond and similar financings), whether or not such indebtedness shall have been assumed by such Person or is limited in recourse;
(j)all Earn-Out Obligations due and owing of such Person, but only at such time as such Earn-Out Obligation becomes a liquidated obligation of a Loan Party on its financial statements;
(k)all obligations of such Person in respect of Disqualified Equity Interests;
(l)all obligations of such Person to pay a specified purchase price for goods or services whether or not delivered or accepted (e.g., take or pay obligations) or similar obligations and, without duplication, all obligations of such Person under conditional sale or other title retention agreements relating to property or assets purchased by such Person; and
(m)all Guarantees by such Person of any of the foregoing.
The Indebtedness of any Person shall include the Indebtedness of any partnership or joint venture (other than a joint venture that is itself a corporation, company, or limited liability company) in which such Person is a general partner or a joint venturer, unless such Indebtedness is expressly made non-recourse to such Person. The amount of Indebtedness of any Person for purposes of clause (g) shall be deemed to be equal to the greater of (i) the aggregate unpaid amount of such Indebtedness and (ii) the fair market value of the property encumbered thereby as determined by such Person in good faith.
Indemnified Taxes” means (a) Taxes, other than Excluded Taxes, imposed on or with respect to any payment made by or on account of any obligation of any Loan Party under any Loan Document and (b) to the extent not otherwise described in clause (a), Other Taxes.
Indemnitee” has the meaning assigned to such term in Section 10.3(b).
Information” has the meaning assigned to such term in Section 10.14(b).
Information Memorandum” means the Confidential Executive Summary, dated December 4, 2023, relating to the Borrower, its Subsidiaries and the Transactions.
Intellectual Property” has the meaning assigned to such term in the Security Agreement.
Interest Payment Date” means (a) with respect to any ABR Loan, the last Business Day of each calendar month and the Maturity Date of the Credit Facility under which such ABR Loan was made, (b) with respect to any SOFR Loan (other than a Swingline Loan), the last day of the Interest Period therefor and, in the case of any Interest Period of more than three months’ duration, each day prior to the last day of such Interest Period that occurs at a three-month interval after the first day of such Interest Period, and the Maturity Date of the Credit Facility under which such SOFR Loan was made and (c) with respect to
- 29 -


any Swingline Loan, the last Business Day of each calendar month and the earlier of the maturity date selected therefor pursuant to Section 2.3(b)(iii) and the Revolving Maturity Date.
Interest Period” means, with respect to any applicable Loan or Borrowing, the period commencing on the date of such Loan or Borrowing and ending on the numerically corresponding day in the calendar month that is one, three or six months thereafter (in each case, subject to the availability thereof), as specified in the applicable Committed Loan Notice; provided that (i) if any Interest Period would end on a day other than a Business Day, such Interest Period shall be extended to the next succeeding Business Day unless such next succeeding Business Day would fall in the next calendar month, in which case such Interest Period shall end on the next preceding Business Day, (ii) any Interest Period that commences on the last Business Day of a calendar month (or on a day for which there is no numerically corresponding day in the last calendar month of such Interest Period) shall end on the last Business Day of the last calendar month of such Interest Period, (iii) no Interest Period shall extend beyond the Maturity Date and (iv) no tenor that has been removed from this definition pursuant to Section 3.8(d) shall be available for specification in such Committed Loan Notice. For purposes hereof, the date of a Loan or Borrowing initially shall be the date on which such Loan or Borrowing is made and thereafter shall be the effective date of the most recent conversion or continuation of such Loan or Borrowing. Interest shall accrue from and including the first day of an Interest Period to but excluding the last day of such Interest Period.
Investment” means, as to any Person, (a) any Acquisition by such Person, (b) any direct or indirect acquisition or investment by such Person in another Person, whether by means of the purchase or other acquisition of Equity Interests or debt or other securities of another Person (including any partnership or joint venture interest), or (c) any direct or indirect loan, advance or capital contribution to, Guarantee with respect to any Indebtedness or other obligation of, such other Person. For purposes of covenant compliance, the amount of any Investment on any date of determination shall be, in the case of any Investment in the form of (i) a loan or an advance, the principal amount thereof outstanding on such date, (ii) a Guarantee, the amount of such Guarantee as determined in accordance with the last sentence of the definition of such term, (iii) a transfer of Equity Interests or other property by the investor to the investee, including any such transfer in the form of a capital contribution, or the issuance of Equity Interests to such investor, the fair market value (as determined reasonably and in good faith by the Borrower) of such Equity Interests or other property as of the time of the transfer or issuance, without any adjustment for increases or decreases in value of, or write-ups, write-downs or write-offs with respect to, such Investment, and (iv) any Investment (other than any Investment referred to in clauses (i), (ii) or (iii) above) in the form of an Acquisition or a purchase or other acquisition for value of any evidences of Indebtedness or other securities of any other Person, the original cost of such Investment (including any Indebtedness assumed in connection therewith), plus the cost of all additions, as of such date, thereto, and minus the amount, as of such date, of any portion of such Investment repaid to the investor in cash as a repayment of principal or a return of capital, as the case may be, but without any other adjustment for increases or decreases in value of, or write-ups, write-downs or write-offs with respect to, such Investment.
IRS” means the United States Internal Revenue Service.
ISP” means the International Standby Practices, International Chamber of Commerce Publication No. 590 (or such later version thereof as may be in effect at the applicable time of issuance).
Latest Maturity Date” means, at any date of determination, the latest Maturity Date applicable to any Loan or Commitment hereunder at such time, including the latest Maturity Date of any Incremental
- 30 -


Term Loan, in each case as extended in accordance with this Credit Agreement or pursuant to any other Loan Document from time to time.
Laws” means, collectively, all international, foreign, federal, state and local statutes, treaties, rules, guidelines, regulations, ordinances, codes and administrative or judicial precedents or authorities, including the interpretation or administration thereof by any Governmental Authority charged with the enforcement, interpretation or administration thereof, and all applicable administrative orders, directed duties, requests, licenses, authorizations and permits of, and agreements with, any Governmental Authority.
L/C Advance” has the meaning assigned to such term in Section 2.4(c)(iii).
L/C Borrowing” means an extension of credit resulting from a drawing under any Letter of Credit which has not been reimbursed on the applicable L/C Honor Date or refinanced as a Revolving Borrowing.
L/C Credit Extension” means, with respect to any Letter of Credit, the issuance or renewal thereof or extension of the expiry date thereof, or the reinstatement or increase of the amount thereof or any amendment thereto.
L/C Disbursement” means a payment made by the L/C Issuer pursuant to a Letter of Credit.
L/C Exposure” means, with respect to any Revolving Lender at any time, its Applicable Percentage of the L/C Obligations.
L/C Fronting Fee” has the meaning assigned to such term in Section 3.2(b)(ii).
L/C Honor Date” has the meaning assigned to such term in Section 2.4(c)(i).
L/C Issuer” means Citizens Bank in its capacity as issuer of Letters of Credit hereunder.
L/C Obligations” means, at any time, with respect to all of the Revolving Lenders, the sum, without duplication, of (a) the undrawn portion of all Letters of Credit plus (b) the aggregate of all Unreimbursed Amounts in respect of Letters of Credit (unless refinanced as a Revolving Borrowing), including all L/C Borrowings.
L/C Participation Fee” has the meaning assigned to such term in Section 3.2(b)(i).
L/C Sublimit” means an amount equal to the lesser of (a) $10,000,000 and (b) the aggregate amount of the Revolving Commitments. The L/C Sublimit is a sublimit of the Revolving Commitments.
Lead Arrangers” means Citizens Bank and Bank of America, N.A. in their capacities as joint lead arrangers and joint bookrunners of the credit facilities established under this Credit Agreement.
Lenders” means (a) the financial institutions listed on Schedule 2.1 (other than any such financial institution that has ceased to be a party hereto pursuant to an Assignment and Acceptance) and (b) any financial institution that has become a party hereto pursuant to an Assignment and Assumption or pursuant to an Incremental Assumption Agreement. Unless the context clearly indicates otherwise, the term “Lenders” shall include the Swingline Lender but does not include the Administrative Agent or any L/C Issuer in their respective capacities as the Administrative Agent or as an L/C Issuer.
- 31 -


Letter of Credit” means any standby letter of credit issued hereunder providing for the payment of cash upon the honoring of a presentation thereunder.
Letter of Credit Application” means an application and agreement for the issuance or amendment of a Letter of Credit in the form from time to time in use by the L/C Issuer.
Letter of Credit Documents” means, with respect to each Letter of Credit, such Letter of Credit, any amendments thereto, any documents delivered in connection therewith, any Letter of Credit Application and any agreements, instruments, guarantees or other documents (whether general in application or applicable only to such Letter of Credit) governing or providing for (a) the rights and obligations of the parties concerned or (b) any collateral for such obligations.
Letter of Credit Expiration Date” means the day that is five (5) Business Days prior to the Maturity Date of the Revolving Facility (or, if such day is not a Business Day, the next preceding Business Day).
Lien” means, with respect to any asset, (a) any mortgage, deed of trust, lien, pledge, hypothecation, encumbrance, charge or security interest in, on or of such asset, (b) the interest of a vendor or a lessor under any conditional sale agreement, Finance Lease or title retention agreement relating to such asset, and (c) in the case of securities, any purchase option, call or similar right of a third party with respect to such securities.
Limited Condition Acquisition” means any Acquisition entered into after the Closing Date by the Borrower or one or more of its Subsidiaries permitted pursuant to the Loan Documents whose consummation is not conditioned on the availability of, or on obtaining, third party financing and which is consummated no more than one hundred eighty (180) days after the applicable Limited Condition Acquisition Agreement Signing Date.
Limited Condition Acquisition Agreement” means the applicable acquisition agreement pursuant to which a Limited Condition Acquisition is, or is to be, consummated.
Limited Condition Acquisition Agreement Signing Date” means the date the Limited Condition Acquisition Agreement is executed and effective.
Limited Condition Election” has the meaning set forth in Section 1.11.
Liquidity” means, as of any date of determination, (a) the aggregate amount of unrestricted and unencumbered (other than by Liens in favor of the Administrative Agent created by the Loan Documents or Liens permitted pursuant to clause (i) of the definition of “Permitted Encumbrances”) cash and Cash Equivalents of the Borrower and its Domestic Subsidiaries maintained in the United States in Controlled Accounts plus (b) the amount available to be borrowed under the Revolving Facility without creating a Default or Event of Default.
Loan” means an extension of credit by a Lender to the Borrower under Article 2 in the form of a Term Loan, a Revolving Loan or a Swingline Loan (including any Incremental Term Loans).
Loan Document Obligations” means the due and punctual payment and performance of all advances to, and debts, liabilities, obligations, covenants and duties of, any Loan Party under or pursuant to each of the Loan Documents or otherwise with respect to any Loan or Letter of Credit and all costs and expenses incurred in connection with enforcement and collection of the foregoing, including the fees, charges and disbursements of counsel, in each case whether direct or indirect (including those acquired by
- 32 -


assumption), absolute or contingent, due or to become due, now existing or hereafter arising and including interest, expenses and fees that accrue after the commencement by or against any Loan Party or any Affiliate thereof of any proceeding under any Debtor Relief Laws naming such Person as the debtor in such proceeding, regardless of whether such interest, expenses and fees are allowed claims in such proceeding.
Loan Documents” means, collectively, this Credit Agreement, the Notes, the Guarantee Agreement, each Incremental Assumption Agreement, each Letter of Credit Application, any agreement creating or perfecting rights in Cash Collateral pursuant to the provisions of Section 2.10, the Engagement Letter, the Collateral Documents and each other document entered into in connection herewith.
Loan Parties” means, collectively, (a) the Borrower, and (b) the Guarantors.
Margin Stock” has the meaning assigned to such term in Regulation U.
Master Agreement” has the meaning assigned to such term in the definition of “Swap Agreement.”
Master Intercompany Note” means a promissory note substantially in the form of Exhibit G.
Material Adverse Effect” means (a) a material adverse effect on the business, assets, operations, liabilities, or financial condition of the Loan Parties and their respective Subsidiaries, taken as a whole, (b) the condition that results when the legality, validity or enforceability of any Loan Document is affected in a manner that is material and adverse to the Lenders’ rights and remedies, or (c) the condition that results when the ability of (i) the Borrower or (ii) the Loan Parties and their Subsidiaries, taken as a whole, to perform any of their obligations under any Loan Document is affected in a manner that is material and adverse to the Lenders.
Material Foreign Subsidiary” means (a) any Foreign Subsidiary listed on Schedule 5.13 and (b) each other Foreign Subsidiary of a Loan Party which, as of the last day of any fiscal quarter, satisfies any of the following tests:
(n)such Foreign Subsidiary’s total tangible assets (after intercompany eliminations) exceeds 7.5% of consolidated total tangible assets of the Borrower and its Subsidiaries; or
(o)such Foreign Subsidiary’s income (not to include losses) for the last twelve months ending as of the last day of such fiscal quarter from continuing operations before income taxes, extraordinary items and the cumulative effect of a change in accounting principles of such Foreign Subsidiary for such period exceeds 7.5% of the income (not to include losses) for the last twelve months ending as of the last day of such fiscal quarter from continuing operations before income taxes, extraordinary items and the cumulative effect of a change in accounting principles of the Borrower and its Subsidiaries determined on a consolidated basis in accordance with GAAP.
Material Indebtedness” means, as of any date, Indebtedness (other than Indebtedness under the Loan Documents) or obligations in respect of one or more Swap Agreements, of any one or more of the Loan Parties or any of their Subsidiaries in an aggregate principal amount exceeding the Threshold Amount. For purposes of determining Material Indebtedness, the “principal amount” of the obligations in respect of any Swap Agreement at any time shall be its Swap Termination Value.
- 33 -


Maturity Date” means (a) with respect to the Revolving Facility, the Revolving Maturity Date, (b) with respect to the Term Loans, the Term Maturity Date, and (c) with respect to any Incremental Term Loan, the applicable Incremental Term Loan Maturity Date.
Measurement Period” means, at any date of determination, the most recently completed four consecutive fiscal quarters of the Borrower ending on or prior to such date for which financial statements have been or are required to be delivered pursuant to Section 6.1(a) or Section 6.1(b) or, prior to the first such requirement, the four-quarter period ended September 30, 2023. A Measurement Period may be designated by reference to the last day thereof (e.g. the June 30, 2023 Measurement Period refers to the period of four consecutive fiscal quarters of the Borrower ended June 30, 2023), and a Measurement Period shall be deemed to end on the last day thereof.
Minimum Collateral Amount” means, with respect to any L/C Obligations at any time, an amount equal to 103% of such L/C Obligations at such time.
Moody’s” means Moody’s Investors Service, Inc. and any successor to its rating agency business.
Multiemployer Plan” means a multiemployer plan as defined in Section 4001(a)(3) of ERISA.
Net Cash Proceeds” means, with respect to any (a) Disposition or Casualty Event by any Loan Party or any of its Subsidiaries, the cash proceeds (including cash proceeds subsequently received (as and when received) in respect of non-cash consideration initially received and including all insurance settlements and condemnation awards from any single event or series of related events) net of the sum, without duplication, of (i) transaction expenses (including reasonable broker’s fees or commissions, legal fees, accounting fees, investment banking fees and other professional fees, transfer and similar taxes and the Borrower’s good faith estimate of income taxes paid or payable in connection with the receipt of such cash proceeds), (ii) amounts set aside as a reserve, in accordance with GAAP, including pursuant to any escrow arrangement, against any liabilities under any indemnification obligations associated with such Disposition (provided that, to the extent and at the time any such amounts are released from such reserve, such amounts shall constitute Net Cash Proceeds), (iii) in the case of insurance settlements and condemnation awards related to a Casualty Event, amounts previously paid by such Loan Party or such Subsidiary to replace or restore the affected property, and (iv) the principal amount, premium or penalty, if any, interest and other amounts on any Indebtedness for borrowed money which is secured by a Lien on the asset sold in such Disposition which is senior in priority to the Liens securing Secured Obligations and is required to be repaid with such proceeds (other than any such Indebtedness assumed by the purchaser of such asset) ; provided, however, that if (A) the Borrower shall deliver a certificate of a Responsible Officer to the Administrative Agent at the time of receipt thereof setting forth the Borrower’s intent to reinvest such proceeds in productive assets of a kind then used or usable in the business of the Borrower and its Subsidiaries (or to repair any property damaged in a Casualty Event) within 365 days of receipt of such proceeds and (B) no Default or Event of Default shall have occurred and shall be continuing at the time of such certificate or at the proposed time of the application of such proceeds, such proceeds shall not constitute Net Cash Proceeds except to the extent not so used at the end of such 365-day period, at which time such proceeds shall be deemed to be Net Cash Proceeds.
Non-Consenting Lender” means any Lender that does not approve any consent, waiver or amendment that (a) requires the approval of all or all affected Lenders in accordance with the terms of Section 10.2 and (b) has been acceptable to the Required Lenders and, in the case of amendments that require the approval of all or all affected Lenders of a particular Class, Required Class Lenders of such Class.
- 34 -


Non-Defaulting Lender” means, at any time, each Lender that is not a Defaulting Lender at such time.
Non-Loan Party Subsidiary” means any Subsidiary of the Borrower that is not a Loan Party.
Nonrenewal Notice Date” has the meaning assigned to such term in Section 2.4(b)(iii).
Notes” means, collectively, the Revolving Loan Notes, the Term Loan Notes and the Swingline Loan Notes.
OFAC” means the U.S. Department of the Treasury’s Office of Foreign Assets Control, and any successor thereto.
Organizational Documents” means, (a) with respect to any corporation, the certificate or articles of incorporation and the bylaws (or equivalent or comparable constitutive documents with respect to any non-United States jurisdiction), (b) with respect to any limited liability company, the certificate or articles of formation or organization and operating or limited liability company agreement and (c) with respect to any partnership, joint venture, trust or other form of business entity, the partnership, joint venture or other applicable agreement of formation or organization and any agreement, instrument, filing or notice with respect thereto filed in connection with its formation or organization with the applicable Governmental Authority in the jurisdiction of its formation or organization and, if applicable, any certificate or articles of formation or organization of such entity.
Other Connection Taxes” means, with respect to any Recipient, Taxes imposed as a result of a present or former connection between such Recipient and the jurisdiction imposing such Tax (other than connections arising from such Recipient having executed, delivered, become a party to, performed its obligations under, received payments under, received or perfected a security interest under, engaged in any other transaction pursuant to or enforced any Loan Document, or sold or assigned an interest in any Loan or Loan Document).
Other Taxes” means all present or future stamp, court or documentary, intangible, recording, filing or similar Taxes that arise from any payment made under, from the execution, delivery, performance, enforcement or registration of, from the receipt or perfection of a security interest under, or otherwise with respect to, any Loan Document, except any such Taxes that are Other Connection Taxes imposed with respect to an assignment (other than an assignment made pursuant to Section 3.7(b)).
Other Term Loans” has the meaning assigned to such term in Section 2.11(a).
Outstanding Amount” means (a) with respect to any Loan on any date, the outstanding principal amount thereof after giving effect to any borrowings and prepayments or repayments thereof (including any refinancing of outstanding Unreimbursed Amounts under Letters of Credit or L/C Borrowings as a Revolving Borrowing) occurring on such date, and (b) with respect to any Letter of Credit, Unreimbursed Amount, L/C Borrowing or L/C Obligations on any date, the outstanding amount thereof on such date after giving effect to any related L/C Credit Extension occurring on such date and any other changes thereto as of such date, including as a result of any reimbursements of outstanding Unreimbursed Amounts under related Letters of Credit (including any refinancing of outstanding Unreimbursed Amounts under related Letters of Credit or related L/C Credit Extensions as a Revolving Borrowing) or any reductions in the maximum amount available for drawing under related Letters of Credit taking effect on such date.
Participant” has the meaning assigned to such term in Section 10.4(d).
- 35 -


Participant Register” has the meaning assigned to such term in Section 10.4(d).
Patent Security Agreement” has the meaning assigned to such term in the Security Agreement.
Payment Recipient” has the meaning assigned to such term in Section 9.13(a).
PBGC” means the Pension Benefit Guaranty Corporation referred to and defined in ERISA.
Pension Plan” means any employee pension benefit plan (other than a Multiemployer Plan) subject to the provisions of Title IV of ERISA or Section 412 or Section 430 of the Code or Section 302 or Section 303 of ERISA, and in respect of which any Loan Party or any ERISA Affiliate is (or, if such plan were terminated, would under Section 4069 of ERISA be deemed to be) an “employer” as defined in Section 3(5) of ERISA.
Perfection Certificate” means a perfection certificate in a form acceptable to the Administrative Agent.
Permits” means all licenses, certificates, accreditations, product clearances or approvals, provider numbers or provider authorizations, supplier numbers, provider numbers, marketing authorizations, other authorizations, registrations, permits, consents and approvals of the Borrower and each of its Subsidiaries required under any Applicable Law applicable to the business of any Loan Party or any of its Subsidiaries or necessary in the manufacturing, importing, exporting, possession, ownership, warehousing, marketing, promoting, sale, labeling, furnishing, distribution or delivery of goods or services under Applicable Law. Without limiting the generality of the foregoing, “Permits” includes all governmental authorizations and product authorizations of the Borrower and each of its Subsidiaries.
Permitted Acquisitions” means, collectively, each Acquisition which satisfies each of the following conditions:
(p)at the time of and immediately before and after giving Pro Forma Effect thereto, no Default or Event of Default shall have occurred and be continuing;
(q)such Acquisition shall be consensual and, if applicable, has been approved by the Acquisition target’s board of directors (or comparable governing body);
(r)the Person, assets or business unit acquired in the Acquisition shall be engaged in an Approved Line of Business;
(s)such Acquisition and all transactions related thereto shall be consummated in accordance with material laws, ordinances, rules, regulations and requirements of all Governmental Authorities;
(t)the Borrower shall give the Administrative Agent at least ten (10) Business Days’ prior written notice of any such acquisition;
(u)the Borrower shall provide to the Administrative Agent as soon as available, but in any event not later than five (5) Business Days (or such longer period as may acceptable to the Administrative Agent in its sole discretion) after the execution thereof, a copy of any executed purchase agreement or similar agreement with respect to any such acquisition and, to the extent required to be obtained under the terms of the purchase agreement or other similar agreement for such acquisition, the
- 36 -


applicable party under such acquisition agreements shall have received all required regulatory and third party approvals;
(v)if the consideration to be paid (or payable) in connection with such acquisition is greater than $25,000,000, the Borrower shall have delivered to the Administrative Agent not later than five (5) Business Days prior to the date on which any such acquisition is to be consummated (or such shorter period as may be acceptable to the Administrative Agent in its sole discretion) (A) a copy of all applicable business and financial due diligence information reasonably available to the Borrower, and (b) a certificate of a Responsible Officer of the Borrower, certifying that such purchase, investment or acquisition constitutes a Permitted Acquisition and demonstrating compliance with clause (j) below;
(w)if (A) the consideration to be paid (or payable) in connection with such acquisition is greater than $50,000,000 or (B) the person or assets being acquired has earnings before interest, taxes, depreciation and amortization of less than $0.00 for the trailing twelve month period most recently ended prior to the consummation of such acquisition, the Borrower shall have delivered to the Administrative Agent, at least five (5) Business Days prior to the date on which such acquisition is to be consummated (or such longer period as may be acceptable to the Administrative Agent in its sole discretion), updated projections demonstrating projected compliance with each of the Financial Covenants set forth in Sections 7.12(a) and (b) at the time such Acquisition is consummated;
(x)the aggregate cash consideration (excluding any amounts paid for with equity contributions from any direct or indirect equity holder of any Loan Party or any of its Subsidiaries) paid by any Loan Party or any of its Subsidiaries in connection with all such Acquisitions shall not exceed $75,000,000; and
(y)after giving Pro Forma Effect to such Acquisition and, if applicable, the making of a Credit Extension in connection with such Acquisition, the Consolidated Total Net Leverage Ratio shall not exceed 3.25:1.00 and (ii) Liquidity shall be at least $15,000,000.
Permitted Encumbrances” means:
(z)Liens imposed by law for taxes, assessments or other governmental charges that are not yet due or are being Contested in Good Faith, provided that enforcement of such Liens is stayed pending such contest;
(aa)landlords’, vendors’, carriers’, warehousemen’s, mechanics’, materialmen’s, repairmen’s and other like Liens imposed by law, arising in the ordinary course of business and securing obligations that are not overdue by more than thirty (30) days or are being Contested in Good Faith, provided that enforcement of such Liens is stayed pending such contest;
(ab)pledges and deposits made in the ordinary course of business in compliance with workers’ compensation, unemployment insurance and other social security laws or regulations;
(ac)deposits to secure the performance of bids, trade contracts (other than contracts for the payment of money), leases (other than Finance Lease Obligations), statutory obligations, surety and appeal bonds, performance bonds and other obligations of a like nature, in each case incurred in the ordinary course of business;
(ad)judgment liens in respect of judgments that do not constitute an Event of Default under Section 8.1(k);
- 37 -


(ae)easements, zoning restrictions, rights of way and similar encumbrances on real property imposed by law or arising in the ordinary course of business that do not secure any monetary obligation and do not materially detract from the value of the affected property or interfere with the ordinary conduct of business of the Loan Parties and their respective Subsidiaries;
(af)any interest or title of a licensor, sublicensor, lessor or sublessor with respect to any assets under any license or lease agreement entered into in the ordinary course of business, provided that the same do not in any material respect interfere with the business of the Loan Parties or their Subsidiaries or materially detract from the value of the relevant assets of the Loan Parties or its Subsidiaries;
(ag)licenses, sublicenses, leases or subleases with respect to any assets granted to third Persons in the ordinary course of business, provided that the same do not in any material respect interfere with the business of the Loan Parties or their Subsidiaries or materially detract from the value of the relevant assets of the Loan Parties or their Subsidiaries;
(ah)customary rights of set off, bankers’ liens, refunds or charge backs, under deposit agreements, the Uniform Commercial Code or common law, of banks or other financial institutions where any Loan Party or any of such Loan Party’s Subsidiaries maintains deposits (other than deposits intended as cash collateral) in the ordinary course of business;
(ai)Liens on Margin Stock to the extent that a prohibition on such Liens would violate Regulation U;
(aj)Liens (i) on earnest money deposits made in cash by the Borrower or any of its Subsidiaries in connection with any letter of intent or purchase agreement in connection with a Permitted Acquisition or other Investment permitted under this Credit Agreement or (ii) on amounts deposited as “security deposits” (or their equivalent) in the ordinary course of business in connection with actions or transactions not prohibited by this Credit Agreement;
(ak)Liens in favor of customs and revenue authorities arising in the ordinary course of business as a matter of law to secure payment of customs duties in connection with the importation of goods;
(al)Liens resulting from the filing of precautionary UCC-1 financing statements (or equivalent) with respect to operating leases;
(am)Liens arising out of conditional sale, title retention, consignment or similar arrangements for the sale of goods entered into by any Loan Party or any of its Subsidiaries in the ordinary course of business; and
(an)Liens incurred in the ordinary course of business imposed by law in connection with the purchase or shipping of goods or assets (or the related assets and proceeds thereof), which Liens are in favor of the seller or shipper of such goods or assets and only attach to such goods or assets;
provided that the term “Permitted Encumbrance” shall not include any Lien securing Indebtedness.
Permitted Tax Distributions” means, subject to the limitations and provisions herein, for each fiscal quarter (or portion thereof) of a Fiscal Year, a distribution by the Borrower to the holders of its Equity Interests in an amount of cash equal to (a) in the event that the Borrower is treated as an S corporation, partnership or disregarded entity for federal income tax purposes, the product of (i) the
- 38 -


taxable net income reportable by the Borrower for federal income tax purposes during such fiscal quarter (or portion thereof), times (ii) the highest combined marginal federal, state, and local income tax rate (for clarification, excluding self-employment and similar taxes) that is applicable to a holder of the Equity Interests of Borrower or (b) in the event the Borrower is a member of an affiliated group that files a federal consolidated income tax return, the product of (i) the net federal, state and local income tax payable by the consolidated taxpayer of such affiliated group, times (ii) a fraction, the numerator of which is the taxable net income of the Borrower, and the denominator of which is aggregate taxable net income of each member of the affiliated group that had taxable net income (and excluding any net losses of any member of the affiliated group). With respect to any fiscal quarter in which the Borrower’s federal reportable taxable net income is zero or a net loss (i) the Permitted Tax Distribution for such fiscal quarter shall be zero, and (ii) any such net loss shall reduce otherwise reportable taxable net income in subsequent fiscal quarters (whether in the same or a later calendar year) until all such net losses have been fully recouped by such reductions. If, upon the calculation of the annual reportable taxable net income or loss for any Fiscal Year of the Borrower, the aggregate Permitted Tax Distributions based on such annual reportable taxable net income or loss exceeds or is less than the aggregate Permitted Tax Distribution actually made with respect to such Fiscal Year, then the amount of Permitted Tax Distributions otherwise permitted for subsequent fiscal quarters shall be increased or reduced, as applicable, by the amount of such difference.
Person” means any natural person, corporation, limited liability company, trust, joint venture, association, company, partnership, Governmental Authority or other entity.
Petit Payment” means any cash or Cash Equivalent proceeds of any settlement or other negotiation with former CEO of the Borrower, Parker Petit, as a result of the January 2021 litigation filed by the Borrower against Parker Petit and William Taylor.
Platform” means DebtX, Debt Domain, Intralinks, Syndtrak or a substantially similar electronic transmission system.
Prime Rate” means a rate per annum equal to the prime rate of interest announced from time to time by Citizens Bank or its parent company (which is not necessarily the lowest rate charged to any customer), changing when and as said prime rate changes.
Pro Forma Basis” means, with respect to any transaction, that such transaction shall be deemed to have occurred as of the first day of the four-quarter period (or twelve month period, as applicable) ending as of the most recent quarter end (or month end, as applicable) preceding the date of such transaction for which financial statement information is available ; provided, however, with respect to any transaction occurring during the first fiscal quarter following the Closing Date, for purposes of determining whether the results of the Loan Parties and their Subsidiaries would be in compliance with the terms of this Credit Agreement on a Pro Forma Basis, compliance with each of the Financial Covenants set forth in Sections 7.12(a) and (b) shall be calculated based on the levels applicable at the end of the fiscal quarter ending September 30, 2023. Each of the terms “Pro Forma Compliance” and “Pro Forma Effect” shall have an analogous meaning.
Product” means any current or future service or product researched, designed, developed, manufactured, licensed, marketed, sole, performed, distributed or otherwise commercialized by the Borrower or any of its Subsidiaries, and any such product in development or which may be developed.
Protected Person” has the meaning assigned to such term in Section 10.3(d).
- 39 -


PTE” means a prohibited transaction class exemption issued by the U.S. Department of Labor, as any such exemption may be amended from time to time.
Public Lender” has the meaning assigned to such term in Section 10.1(d)(i).
Qualified Cash” means Unrestricted Cash held by the Loan Parties held in a Controlled Account.
Qualified ECP Guarantor” means, at any time, each Loan Party with total assets exceeding $10,000,000 or that qualifies at such time as an “eligible contract participant” under the Commodity Exchange Act and can cause another Person to qualify as an “eligible contract participant” at such time under Section 1a(18)(A)(v)(II) of the Commodity Exchange Act.
Qualified Equity Interests” means, with respect to the Equity Interests of any Person, any Equity Interests other than Disqualified Equity Interests of such Person.
Real Property” means, collectively, all right, title and interest in and to any and all parcels of or interests in real property owned or leased by any Person, together with, in each case, all easements, hereditaments and appurtenances relating thereto, all improvements and appurtenant fixtures and equipment, all general intangibles and contract rights and other property and rights incidental to the ownership thereof.
Recipient” means the Administrative Agent, any Lender or the L/C Issuer, as applicable.
Refinancing Indebtedness” means Indebtedness of any Loan Party or its Subsidiaries arising after the Closing Date issued in exchange for, or the proceeds of which are used to extend, refinance, refund, replace, renew, continue or substitute for other Indebtedness (such extended, refinanced, refunded, replaced, renewed, continued or substituted Indebtedness, the “Refinanced Obligations”); provided that (a) the principal amount of such Refinancing Indebtedness shall not exceed the principal amount of the Refinanced Obligations (plus any interest capitalized in connection with such Refinanced Obligations, the amount of prepayment premium, if any, original issue discount, if any, and reasonable fees, costs, and expenses incurred in connection therewith), (b) such Refinancing Indebtedness shall have a final maturity that is no earlier than the final maturity date of such Refinanced Obligations, (c) such Refinancing Indebtedness shall have a Weighted Average Life to Maturity not less than the weighted average life to maturity of the Refinanced Obligations, (d) such Refinancing Indebtedness shall rank in right of payment no more senior than, and be subordinated (if subordinated) to the Secured Obligations on terms, taken as a whole, not materially less favorable to the Secured Parties than the Refinanced Obligations, (e) [reserved], (f) if the Refinanced Obligations or any Guarantees thereof are unsecured, such Refinancing Indebtedness and any Guarantees thereof shall be unsecured, (g) if the Refinanced Obligations or any Guarantees thereof are secured, (1) such Refinancing Indebtedness and any Guarantees thereof shall be secured by substantially the same or less collateral, taken as a whole, as secured such Refinanced Obligations or any Guarantees thereof, on terms, taken as a whole, not materially less favorable to the Secured Parties , (2) the Liens to secure such Refinancing Indebtedness shall not have a priority, taken as a whole, more senior than the Liens securing the Refinanced Obligations and if subordinated to any other Liens on such property, shall be subordinated, taken as a whole, to the Administrative Agent’s Liens on terms and conditions, taken as a whole, not materially less favorable to the Secured Parties, and (3) such Refinancing Indebtedness and any Guarantees thereof shall be subject to an intercreditor agreement reasonably acceptable to the Administrative Agent, (h) the obligors in respect of the Refinanced Obligations immediately prior to such refinancing, refunding, extending, renewing, continuing, substituting or replacing thereof shall be the only obligors on such Refinancing Indebtedness, and (i) the terms and conditions (excluding as to pricing, premiums and optional prepayment or redemption
- 40 -


provisions) of any such Refinancing Indebtedness, taken as a whole, are not materially less favorable to the Loan Parties than the terms and conditions of the Refinanced Obligations.
Regenerative Business Unit” means the regenerative medicine segment of the Borrower’s business that acts as a research and development arm for the Borrower’s placental biologics platform.
Register” has the meaning assigned to such term in Section 10.4(c).
Regulation T, U or X” means Regulation T, U or X, respectively, of the Federal Reserve Board.
Related Parties” means, with respect to any Person, such Person’s Affiliates and the partners, members, directors, officers, employees, agents, trustees, administrators, managers, advisors, attorneys-in-fact and representatives, including accountants, auditors and legal counsel, of such Person and of such Person’s Affiliates.
Release” means any actual or threatened releasing, spilling, leaking, pumping, pouring, leaching, seeping, emitting, migration, emptying, discharging, injecting, escaping, depositing, disposing, or dumping of Hazardous Materials into the indoor or outdoor environment, including the movement of any Hazardous Material through the air, soil, surface water, groundwater or property and any other conditions resulting in potential or actual human exposure to Hazardous Materials within a structure.
Relevant Governmental Body means the Federal Reserve Board or the Federal Reserve Bank of New York, or a committee officially endorsed or convened by the Federal Reserve Board and/or the Federal Reserve Bank of New York.
Removal Effective Date” has the meaning assigned to such term in Section 9.6(b).
Request for Credit Extension” means (a) with respect to a Borrowing, conversion or continuation of Loans (other than Swingline Loans), a Committed Loan Notice, (b) with respect to a L/C Credit Extension, a Letter of Credit Application, and (c) with respect to a Swingline Loan, a Swingline Loan Notice.
Required Class Lenders” means, at any time with respect to any Class of Loans or Commitments, two or more unaffiliated Lenders having Total Credit Exposures with respect to such Class representing more than 50% of the Total Credit Exposures of all Lenders of such Class. The Total Credit Exposure of any Defaulting Lender with respect to such Class shall be disregarded in determining Required Class Lenders at any time.
Required Lenders” means, at any time, two or more unaffiliated Lenders having Total Credit Exposures representing more than 50% of the Total Credit Exposures of all Lenders. The Total Credit Exposure of any Defaulting Lender shall be disregarded in determining Required Lenders at any time.
Resignation Effective Date” has the meaning assigned to such term in Section 9.6(a).
Resolution Authority” means an EEA Resolution Authority or, with respect to any UK Financial Institution, a UK Resolution Authority.
Responsible Officer” means the chief executive officer, president, vice president, chief financial officer, treasurer, assistant treasurer, principal accounting officer, comptroller or other similar officer of a Loan Party. Any document delivered hereunder that is signed by a Responsible Officer of a Loan Party shall be conclusively presumed to have been authorized by all necessary corporate, partnership and/or
- 41 -


other action on the part of such Loan Party and such Responsible Officer shall be conclusively presumed to have acted on behalf of such Loan Party.
Restricted Payment” means, as to any Person, (a) any dividend or other distribution by such Person (whether in cash, securities or other property) with respect to any Equity Interests of such Person, (b) any payment (whether in cash, securities or other property), including any sinking fund or similar deposit, on account of the purchase, redemption, retirement, defeasance, acquisition, cancellation or termination of any such Equity Interest, or on account of any return of capital to the holders of Equity Interests of such Person, (c) the acquisition for value by such Person of any Equity Interests issued by such Person or any other Person that Controls such Person, (d) any payment with respect to any Earn-out Obligation, and (e) with respect to clauses (a) through (d) any transaction that has a substantially similar effect.
Revolving Borrowing” means a Borrowing consisting of Revolving Loans of the same Type made, converted or continued on the same date and, in the case of SOFR Loans, having the same Interest Period.
Revolving Commitment” means, with respect to each Revolving Lender, the commitment hereunder of such Revolving Lender to make Revolving Loans and to acquire participations in Letters of Credit and Swingline Loans in an aggregate outstanding amount not exceeding the amount of such Revolving Lender’s Revolving Commitment as set forth on Schedule 2.1 or in the Assignment and Assumption pursuant to which such Revolving Lender shall have assumed its Revolving Commitment in accordance with Section 10.4(b), as applicable, as such Revolving Commitment may be adjusted from time to time pursuant to Section 2.5 or Section 2.11 or pursuant to assignments by or to such Revolving Lender pursuant to Section 10.4. The initial aggregate amount of the Revolving Commitments on the Closing Date is $75,000,000.
Revolving Exposure” means, as to any Lender at any time, the sum of (a) the Outstanding Amount of its Revolving Loans, plus (b) its L/C Exposure, plus (c) its Swingline Exposure.
Revolving Facility” means the credit facility established hereunder and evidenced by the Revolving Commitments.
Revolving Lender” means a Lender having a Revolving Commitment or, if the Revolving Commitments have expired or terminated, having Revolving Exposure.
Revolving Loan” means a loan referred to in Section 2.1(a) and made pursuant to Section 2.2.
Revolving Loan Note” means with respect to a Revolving Lender, a promissory note evidencing the Revolving Loans of such Lender payable to the order of such Lender (or, if required by such Lender, to such Lender and its registered assigns) substantially in the form of Exhibit C-1.
Revolving Maturity Date” means the fifth anniversary of the Closing Date, provided that if such day is not a Business Day, the Revolving Maturity Date shall be the Business Day immediately preceding such day.
S&P” means Standard & Poor’s Financial Services LLC, a subsidiary of S&P Global Inc.
Sale and Leaseback” means any transaction or series of related transactions pursuant to which any Loan Party or any of its Subsidiaries (a) sells, transfers or otherwise disposes of any property, real or personal, whether now owned or hereafter acquired, and (b) as part of such transaction, thereafter rents or
- 42 -


leases such property or other property that it intends to use for substantially the same purpose or purposes as the property being sold, transferred or disposed.
Sanctioned Country” means any country, territory or region which is itself the subject or target of any comprehensive Sanctions (including, as of the date of this Credit Agreement, Cuba, Iran, North Korea, Syria, and the so-called Donetsk People’s Republic, so-called Luhansk People’s Republic, and Crimea regions of Ukraine).
Sanctioned Person” means (a) any Person or group listed in any Sanctions related list of designated Persons maintained by OFAC, including the List of Specially Designated Nationals and Blocked Persons, or the U.S. Department of State, the United Nations Security Council, the European Union, any EU member state or His Majesty’s Treasury of the United Kingdom, (b) any Person subject to any law that would prohibit all or substantially all financial or other transactions with that Person or would require that assets of that Person that come into the possession of a third-party be blocked (c) any legal entity organized or domiciled in a Sanctioned Country, (d) any agency, political subdivision or instrumentality of the government of a Sanctioned Country, (e) any natural person ordinarily resident in a Sanctioned Country, or (f) any Person 50% or more owned, directly or indirectly, individually or in the aggregate by any of the above.
Sanctions” means economic or financial sanctions or trade embargoes imposed, administered or enforced from time to time by (a) the U.S. government, including those administered by OFAC or the U.S. Department of State or (b) the United Nations Security Council, the European Union or any European Union member state, His Majesty’s Treasury of the United Kingdom or other relevant sanctions authority.
SEC” means the U.S. Securities and Exchange Commission, or any Governmental Authority succeeding to any of its principal functions.
Secured Obligation Designation Notice” means a notice substantially in the form of Exhibit I executed and delivered to the Administrative Agent by a counterparty (other than the Administrative Agent and its Affiliates) to a Swap Agreement or an agreement to provide Cash Management Services in order that the obligations in respect thereof constitute Swap Agreement Obligations or Cash Management Obligations.
Secured Obligations” means, collectively, (a) the Loan Document Obligations, (b) the Cash Management Obligations, (c) the Swap Agreement Obligations, and (d) the Erroneous Payment Subrogation Rights.
Secured Parties” means, collectively, (a) the Administrative Agent, (b) each Lender, (c) each L/C Issuer, (d) each Person to whom any Cash Management Obligations are owed, (e) each counterparty to any Swap Agreement the obligations under which constitute Swap Agreement Obligations, (f) the beneficiaries of each indemnification obligation undertaken by any Loan Party under any Loan Document and (g) the permitted successors and assigns of each of the foregoing.
Security Agreement” means the Pledge and Security Agreement, dated as of the Closing Date, among the Loan Parties and the Administrative Agent.
SOFR” means a rate equal to the secured overnight financing rate as published by the SOFR Administrator on the website of the SOFR Administrator, currently at http//www.newyorkfed.org (or any successor source for the secured overnight financing rate identified as such by the SOFR Administrator from time to time).
- 43 -


SOFR Administrator” means the Federal Reserve Bank of New York (or a successor administrator of the secured overnight financing rate).
SOFR Borrowing” means, as to any Borrowing, the SOFR Loans or Daily SOFR Loans comprising such Borrowing, as applicable.
SOFR Loan” means a Loan that bears interest at a rate based on Term SOFR, other than pursuant to clause (c) of the definition of “Alternate Base Rate” or the definition of “Daily SOFR Rate”.
Sold Entity or Business” means any Person or any property or assets constituting a line of business or a division of a Person Disposed of in a transaction permitted hereunder by the Borrower or any of its Subsidiaries.
Solvency Certificate” means a certificate, substantially in the form of Exhibit H.
Solvent” and “Solvency” means, with respect to any Person on any date of determination, that on such date (a) the fair value of the present assets of such Person and its Subsidiaries, taken as a whole, is not less than the sum of the debt (including contingent liabilities) of such Person and its Subsidiaries, taken as a whole, (b) the present fair salable value of the assets of such Person and its Subsidiaries, taken as a whole, is not less than the amount that will be required to pay the probable liabilities (including contingent liabilities) of such Person and its Subsidiaries, taken as a whole, on their debts as they become absolute and matured, (c) such Person and its Subsidiaries, on a consolidated basis, are able to pay their debts and liabilities, subordinated, contingent or otherwise, as such liabilities become absolute and matured and (d) such Person and its Subsidiaries, on a consolidated basis, are not engaged in, and are not about to engage in, business for which they have unreasonably small capital; provided that the amount of contingent liabilities at any time shall be computed as the amount that, in light of all the facts and circumstances existing at such time, represents the amount that can reasonably be expected to become an actual or matured liability.
Specified Loan Party” means any Loan Party that is not then an “eligible contract participant” under the Commodity Exchange Act (determined prior to giving effect to Section 10.20).
Specified Transaction” means any Investment, Disposition, incurrence or repayment of Indebtedness, Restricted Payment, Incremental Commitments incurred pursuant to Section 2.11(a) that by the terms of this Credit Agreement requires a test to be calculated on a “Pro Forma Basis”, be given in “Pro Forma Compliance” with, or after giving “Pro Forma Effect”; provided that any increase in the Revolving Commitments above the amount of Revolving Commitments in effect on the Closing Date, for purposes of this definition, shall be deemed to be fully drawn.
Subordinated Debt” means Indebtedness incurred by a Loan Party that is subordinated in right of payment to the prior payment of the Loan Document Obligations of such Loan Party and contains subordination and other terms acceptable to the Administrative Agent.
Subordinated Debt Documents” means any agreement, indenture or instrument pursuant to which any Subordinated Debt is issued, in each case as amended to the extent permitted under the Loan Documents.
Subsequent Transaction” has the meaning set forth in Section 1.11.
subsidiary” means, with respect to any Person (“Topco”), as of any date, any corporation, limited liability company, partnership, association or other entity the accounts of which would be
- 44 -


consolidated with those of Topco in Topco’s consolidated financial statements if such financial statements were prepared in accordance with GAAP as of such date, as well as any other corporation, limited liability company, partnership, association or other entity of which securities or other ownership interests representing more than 50% of the equity or more than 50% of the ordinary voting power is or, in the case of a partnership, more than 50% of the general partnership interests are, as of such date, owned, controlled or held by Topco or one or more subsidiaries of Topco.
Subsidiary” means any direct or indirect subsidiary of the Borrower or a Loan Party, as the context may require.
Subsidiary Guarantors” means each Subsidiary that executes and delivers the Guarantee Agreement and each other Subsidiary of the Borrower that becomes party thereto in by the execution and delivery of a Subsidiary Joinder Agreement, and the permitted successors and assigns of each such Person.
Subsidiary Joinder Agreement” means a Subsidiary Joinder Agreement, substantially in the form of Exhibit E, pursuant to which a Subsidiary (other than an Excluded Subsidiary) becomes a party to the Guarantee Agreement, to the Security Agreement and to each other applicable Loan Document.
Swap Agreement” means (a) any and all rate swap transactions, basis swaps, credit derivative transactions, forward rate transactions, commodity swaps, commodity options, forward commodity contracts, equity or equity index swaps or options, bond or bond price or bond index swaps or options or forward bond or forward bond price or forward bond index transactions, interest rate options, forward foreign exchange transactions, cap transactions, floor transactions, collar transactions, currency swap transactions, cross-currency rate swap transactions, currency options, spot contracts, or any other similar transactions or any combination of any of the foregoing (including any options to enter into any of the foregoing), whether or not any such transaction is governed by or subject to any master agreement, and (b) any and all transactions of any kind, and the related confirmations, which are subject to the terms and conditions of, or governed by, any form of master agreement published by the International Swaps and Derivatives Association, Inc., any International Foreign Exchange Master Agreement or any other master agreement (any such master agreement, together with any related schedules, a “Master Agreement”), including any such obligations or liabilities under any Master Agreement.
Swap Agreement Obligations” means all obligations of the Loan Parties under each Swap Agreement to which any Loan Party or its Subsidiary is a party and that that (a) is with a counterparty that is the Administrative Agent or any of its Affiliates, (b) is in effect on the Closing Date with a counterparty that is a Lender or an Affiliate of a Lender as of the Closing Date or (c) is entered into after the Closing Date with any counterparty that is a Lender or an Affiliate of a Lender at the time such Swap Agreement is entered into or becomes a Lender or an Affiliate of a Lender after it has entered into such agreement, provided that any such counterparty (other than the Administrative Agent or its Affiliates) executes and delivers a Secured Obligation Designation Notice to the Administrative Agent and, provided, further, that Swap Agreement Obligations shall not include, with respect to any Guarantor, Excluded CEA Swap Obligations of such Guarantor.
Swap Termination Value” means, in respect of any one or more Swap Agreements, after taking into account the effect of any legally enforceable netting agreement relating to such Swap Agreements, (a) for any date on or after the date such Swap Agreements have been closed out and termination value(s) determined in accordance therewith, such termination value(s), and (b) for any date prior to the date referenced in clause (a), the amount(s) determined as the mark-to-market value(s) for such Swap Agreements, as determined based upon one or more mid-market or other readily available quotations
- 45 -


provided by any recognized dealer in such Swap Agreements (which may include a Lender or any Affiliate of a Lender).
Swingline Exposure” means, with respect to any Revolving Lender at any time, its Applicable Percentage of the Outstanding Amount of the Swingline Loans.
Swingline Lender” means Citizens Bank in its capacity as lender of Swingline Loans.
Swingline Loan” means a loan referred to and made pursuant to Section 2.3.
Swingline Loan Note” means with respect to the Swingline Lender, a promissory note evidencing the Swingline Loans of such Lender payable to the order of such Lender (or, if required by such Lender, to such Lender and its registered assigns) substantially in the form of Exhibit C-3.
Swingline Loan Notice” means a notice of a Swingline Borrowing pursuant to Section 2.3(b), which, if in writing, shall be substantially in the form of Exhibit B-2.
Swingline Sublimit” means $10,000,000. The Swingline Sublimit is a sublimit of the Revolving Commitments.
Synthetic Debt” means, with respect to any Person as of any date of determination thereof, all obligations of such Person in respect of transactions entered into by such Person that are intended to function primarily as a borrowing of funds (including any minority interest transactions that function primarily as a borrowing) but are not otherwise included in the definition of “Indebtedness” or as a liability on the consolidated balance sheet of such Person and its Subsidiaries in accordance with GAAP).
Synthetic Lease Obligation” means the monetary obligation of a Person at any time of determination under (i) a so called synthetic, off balance sheet or tax retention lease, or (ii) an agreement for the use or possession of property, in each case, creating obligations that do not appear on the balance sheet of such Person but which could be characterized as the indebtedness of such Person (without regard to accounting treatment) (other than operating leases arising as a result of Sale and Leaseback transactions).
Taxes” means all present or future taxes, levies, imposts, duties, deductions, withholdings (including backup withholding), assessments, fees or other charges imposed by any Governmental Authority, including any interest, additions to tax or penalties applicable thereto.
Term Facility” means, the credit facility evidenced by the Term Loan Commitment. Unless the context shall otherwise require, the term “Term Facility” shall include Incremental Term Facilities.
Term Lender” means a Lender with a Term Loan Commitment or, if the Term Loan Commitments have expired or terminated, outstanding Term Loans. Unless the context shall otherwise require, the term “Term Lenders” shall include Incremental Term Lenders.
Term Loan” means a loan referred to in Section 2.1(b) and made pursuant to Section 2.2. Unless the context shall otherwise require, the term “Term Loans” shall include any Incremental Term Loans.
Term Loan Borrowing” means a Borrowing consisting of Term Loans of the same Type made, converted or continued on the same date and, in the case of SOFR Loans, having the same Interest Period.
- 46 -


Term Loan Commitment” means, with respect to each Term Lender, the commitment of such Term Lender to make a single Term Loan on the Closing Date pursuant to Section 2.1(b) in an aggregate amount not exceeding the amount of such Term Lender’s Term Loan Commitment as set forth on Schedule 2.1 or in the Assignment and Assumption pursuant to which such Term Lender shall have assumed its Term Loan Commitment, in accordance with Section 10.4(b), as applicable, as such Term Loan Commitment may be adjusted from time to time pursuant to Section 2.5 or Section 2.11 or pursuant to assignments by or to such Term Lender pursuant to Section 10.4. The aggregate amount of the Term Loan Commitments on the Closing Date is $20,000,000. Unless the context shall otherwise require, after the effectiveness of any Incremental Term Loan Commitment, the term “Term Loan Commitment” shall include such Incremental Term Loan Commitment.
Term Loan Note” means with respect to a Term Lender, a promissory note evidencing the Term Loans of such Lender payable to the order of such Lender (or, if required by such Lender, to such Lender and its registered assigns) substantially in the form of Exhibit C-2.
Term Maturity Date” means the fifth anniversary of the Closing Date, provided that if such day is not a Business Day, the Term Maturity Date shall be the Business Day immediately preceding such day.
Term SOFR” means a rate per annum equal to the greater of (a) the sum of (i) Term SOFR Reference Rate for a tenor comparable to the applicable Interest Period on the day (such day, the “Term SOFR Determination Day”) that is two (2) Government Securities Business Days prior to the first day of such Interest Period; provided, however, that if as of 5:00 p.m. (New York City time) on any Term SOFR Determination Day the Term SOFR Reference Rate for the applicable tenor has not been published by the Term SOFR Administrator and a Benchmark Replacement Date with respect to the Term SOFR Reference Rate has not occurred, then Term SOFR will be the Term SOFR Reference Rate for such tenor as published by the Term SOFR Administrator on the first preceding Government Securities Business Day for which such Term SOFR Reference Rate for such tenor was published by the Term SOFR Administrator so long as such first preceding Government Securities Business Day is not more than three (3) Government Securities Business Days prior to such Term SOFR Determination Day plus (ii) the Term SOFR Adjustment, and (b) the Floor.
Term SOFR Adjustment” means 0.10000%.
Term SOFR Administrator” means CME Group Benchmark Administration Limited (CBA) (or a successor administrator of the Term SOFR Reference Rate selected by the Administrative Agent in its reasonable discretion).
Term SOFR Determination Day” has the meaning specified in the definition of “Term SOFR”.
Term SOFR Reference Rate” means the forward-looking term rate based on SOFR published by the Term SOFR Administrator and displayed on CME’s Market Data Platform (or other commercially available source providing such quotations as may be selected by the Administrative Agent from time to time).
Termination Date” means the date upon which all Commitments have terminated, no Letters of Credit are outstanding (or if Letters of Credit remain outstanding, the same are Backstopped), and the Loans and L/C Obligations (other than with respect to the undrawn portion of outstanding Letters of Credit), together with all interest and fees related thereto and other Loan Document Obligations (other than unasserted contingent indemnification and unasserted expense reimbursement obligations in each case not yet due and payable), have been indefeasibly paid in full in cash.
- 47 -


Threshold Amount” means $10,000,000.
Total Credit Exposure” means, as to any Lender at any time, the unused Commitments, Revolving Exposure and outstanding Term Loans of such Lender at such time.
Total Revolving Outstandings” means at any time, the aggregate Outstanding Amount of all Revolving Loans, Swingline Loans and L/C Obligations at such time.
Trade Date” has the meaning assigned to such term in Section 10.4(f)(i).
Trademark Security Agreement” has the meaning assigned to such term in the Security Agreement.
Transaction Expenses” means any fees or expenses incurred or paid by the Borrower, or any Subsidiary in connection with the Transactions, this Credit Agreement and the other Loan Documents and the transactions contemplated hereby and thereby in connection therewith.
Transactions” means (a) the execution, delivery and performance by each Loan Party of each Loan Document to which it is a party, (b) the borrowing of the Loans and the issuance of the Letters of Credit, (c) the use of the proceeds of the Loans and the Letters of Credit, (d) the satisfaction of the Collateral and Guarantee Requirement, (e) the Existing Credit Agreement Refinancing and (f) the payment of Transaction Expenses.
Type”, when used in reference to any Loan or Borrowing, refers to whether the rate of interest on such Loan, or on the Loans comprising such Borrowing, is determined by reference to (i) Term SOFR or (ii) the Alternate Base Rate.
UK Financial Institution” means any BRRD Undertaking (as such term is defined under the PRA Rulebook (as amended from time to time) promulgated by the United Kingdom Prudential Regulation Authority) or any person falling within IFPRU 11.6 of the FCA Handbook (as amended from time to time) promulgated by the United Kingdom Financial Conduct Authority, which includes certain credit institutions and investment firms, and certain affiliates of such credit institutions or investment firms.
UK Resolution Authority” means the Bank of England or any other public administrative authority having responsibility for the resolution of any UK Financial Institution.
Unadjusted Benchmark Replacement means the applicable Benchmark Replacement excluding the related Benchmark Replacement Adjustment.
Unaudited Financial Statements” means the Form 10-Q containing the unaudited consolidated balance sheets and related statements of income, comprehensive income, changes in equity and cash flows of the Borrower and its Subsidiaries, covering any of the first three fiscal quarters that have ended after the most recent Fiscal Year covered by the Audited Financial Statements and at least forty-five (45) days before the Closing Date.
Uniform Commercial Code” or “UCC” means the Uniform Commercial Code as the same may from time to time be in effect in the State of New York; provided that, if perfection or the effect of perfection or non-perfection or the priority of any security interest in any Collateral is governed by the Uniform Commercial Code as in effect in a jurisdiction other than the State of New York, “Uniform Commercial Code” or “UCC” means the Uniform Commercial Code as in effect from time to time in
- 48 -


such other jurisdiction for purposes of the provisions hereof relating to such perfection, effect of perfection or non-perfection or priority.
United States” and “U.S.” mean the United States of America.
Unreimbursed Amount” has the meaning assigned to such term in Section 2.4(c)(i).
Unrestricted Cash” means unrestricted and unencumbered (other than by Liens in favor of the Administrative Agent created by the Loan Documents or Liens permitted pursuant to clause (i) of the definition of “Permitted Encumbrances”) cash and Cash Equivalents of the Loan Parties maintained in the United States in Controlled Accounts.
USA PATRIOT Act” means The Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (Title III of Pub. L. No. 107-56 (signed into law October 26, 2001)).
U.S. Person” means any Person that is a “United States Person” as defined in Section 7701(a)(30) of the Code.
U.S. Tax Compliance Certificate” has the meaning assigned to such term in Section 3.6(g)(ii)(B)(3).
Voting Equity Interests” means, with respect to any Person, shares of such Person’s Equity Interests having the right to vote for the election of the members of the board of directors or other managing person of such Person under ordinary circumstances.
Weighted Average Life to Maturity” means, when applied to any Indebtedness at any date, the number of years obtained by dividing: (a) the sum of the products obtained by multiplying (i) the amount of each then remaining installment, sinking fund, serial maturity or other required payments of principal, including payment at final maturity, in respect thereof, by (ii) the number of years (calculated to the nearest one-twelfth) that will elapse between such date and the making of such payment; by (b) the then outstanding principal amount of such Indebtedness.
Wholly-Owned” means, with respect to a Subsidiary of a Person, a Subsidiary of such Person all of the outstanding Equity Interests of which (other than (x) director’s qualifying shares and (y) shares issued to foreign nationals to the extent required by Applicable Law) are owned by such Person and/or by one or more wholly owned Subsidiaries of such Person.
Withdrawal Liability” means a liability to a Multiemployer Plan as a result of a complete or partial withdrawal from such Multiemployer Plan, as such terms are defined in Part I of Subtitle E of Title IV of ERISA.
Withholding Agent” means any Loan Party and the Administrative Agent.
Write-Down and Conversion Powers” means, (a) with respect to any EEA Resolution Authority, the write-down and conversion powers of such EEA Resolution Authority from time to time under the Bail-In Legislation for the applicable EEA Member Country, which write-down and conversion powers are described in the EU Bail-In Legislation Schedule, and (b) with respect to the United Kingdom, any powers of the applicable Resolution Authority under the Bail-In Legislation to cancel, reduce, modify or change the form of a liability of any UK Financial Institution or any contract or instrument under which that liability arises, to convert all or part of that liability into shares, securities or obligations of that
- 49 -


person or any other person, to provide that any such contract or instrument is to have effect as if a right had been exercised under it or to suspend any obligation in respect of that liability or any of the powers under that Bail-In Legislation that are related to or ancillary to any of those powers.
Yield Differential” has the meaning assigned to such term in Section 2.11(c).
Section 1.2Classification of Loans and Borrowings. For purposes of this Credit Agreement, Loans may be classified and referred to by Class (e.g., a “Revolving Loan”) or by Type (e.g., a “SOFR Loan”) or by Class and Type (e.g., a “SOFR Revolving Loan”). Borrowings may also be classified and referred to by Class (e.g., a “Revolving Borrowing”) or by Type (e.g., a “SOFR Borrowing”) or by Class and Type (e.g., a “SOFR Revolving Borrowing”).
Section 1.3Terms Generally. The definitions of terms herein shall apply equally to the singular and plural forms of the terms defined. Whenever the context may require, any pronoun shall include the corresponding masculine, feminine and neuter forms. The words “include,” “includes” and “including” shall be deemed to be followed by the phrase “without limitation.” The word “will” shall be construed to have the same meaning and effect as the word “shall.” In the computation of periods of time from a specified date to a later specified date, the word “from” means “from and including”; the words “to” and “until” each mean “to but excluding”; and the word “through” means “to and including.” Unless the context requires otherwise (a) any definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document as from time to time amended, restated, supplemented or otherwise modified (subject to any restrictions on such amendments, restatements, supplements or modifications set forth herein), (b) any reference herein to any Person shall be construed to include such Person’s successors and assigns, (c) the words “herein,” “hereof” and “hereunder,” and words of similar import, shall be construed to refer to this Credit Agreement in its entirety and not to any particular provision hereof, (d) all references herein to Articles, Sections, Exhibits and Schedules shall be construed to refer to Articles and Sections of, and Exhibits and Schedules to, this Credit Agreement, (e) any reference to any law or regulation herein shall, unless otherwise specified, refer to such law or regulation as amended, modified or supplemented from time to time, (f) the words “asset” and “property” shall be construed to have the same meaning and effect and to refer to any and all tangible and intangible assets and properties, including cash, securities, accounts and contract rights and (g) the words “renew”, “renewal” and variations thereof as used herein with respect to a Letter of Credit mean to extend the term of such Letter of Credit or to reinstate an amount drawn under such Letter of Credit or both. Any terms used in this Credit Agreement that are defined in the UCC shall be construed and defined as set forth in the UCC unless otherwise defined herein; provided, that to the extent that the UCC is used to define any term herein and such term is defined differently in different Articles of the UCC, the definition of such term contained in Article 9 of the UCC shall govern.
Section 1.4Accounting Terms; GAAP.
(a)All accounting terms not specifically or completely defined herein shall be construed in conformity with, and all financial data (including financial ratios and other financial calculations) required to be submitted pursuant to this Credit Agreement shall be prepared in conformity with, GAAP, applied in a manner consistent with that used in preparing the Audited Financial Statements, except as otherwise specifically prescribed herein.
(b)Notwithstanding anything to the contrary herein, for purposes of determining compliance with any test contained in this Credit Agreement with respect to any period during which any Specified Transaction occurs, Consolidated EBITDA, Consolidated Fixed Charge Coverage Ratio and Consolidated Total Net Leverage Ratio (and all component definitions of any of the foregoing) shall be
- 50 -


calculated with respect to such period and all Specified Transactions occurring during such period on a Pro Forma Basis.
(c)If at any time any change in GAAP would affect the computation of any financial ratio or requirement set forth in any Loan Document, and either the Borrower or the Required Lenders shall so request, the Administrative Agent, the Lenders and the Borrower shall negotiate in good faith to amend such ratio or requirement to preserve the original intent thereof in light of such change in GAAP (subject to the approval of the Required Lenders); provided that, until so amended, (i) such ratio or requirement shall continue to be computed in accordance with GAAP prior to such change therein and (ii) the Borrower shall provide to the Administrative Agent and the Lenders financial statements and other documents required under this Credit Agreement or as reasonably requested hereunder setting forth a reconciliation between calculations of such ratio or requirement made before and after giving effect to such change in GAAP. Notwithstanding any other provision contained herein, all terms of an accounting or financial nature used herein shall be construed, and all computations of amounts and ratios referred to herein, and the determination of Indebtedness hereunder, shall be made without giving effect to Financial Accounting Standards Board (FASB) Standard ASC 842 (Leases) (or any other applicable financial accounting standard having a similar result or effect) and related interpretations, in each case, to the extent any lease (or similar arrangement conveying the right to use) would be required to be treated as a capital lease thereunder where such lease (or similar arrangement) would have been treated as an operating lease under GAAP as in effect immediately prior to the effectiveness of the ASC 842.
Section 1.5Rounding. Any financial ratios required to be maintained by the Borrower pursuant to this Credit Agreement shall be calculated by dividing the appropriate component by the other component, carrying the result to one place more than the number of places by which such ratio is expressed herein and rounding the result up or down to the nearest number (with a rounding-up if there is no nearest number).
Section 1.6References to Time. Unless the context otherwise requires, references to a time shall refer to Eastern Standard Time or Eastern Daylight Savings Time, as applicable.
Section 1.7Resolution of Drafting Ambiguities. Each Loan Party acknowledges and agrees that it was represented by counsel in connection with the execution and delivery of the Loan Documents to which it is a party, that it and its counsel reviewed and participated in the preparation and negotiation hereof and thereof and that any rule of construction to the effect that ambiguities are to be resolved against the drafting party shall not be employed in the interpretation hereof or thereof.
Section 1.8Status of Loan Document Obligations. In the event that any Loan Party shall at any time issue or have outstanding any Subordinated Debt, the Borrower shall take or cause each other Loan Party to take all such actions as shall be necessary to cause the Loan Document Obligations to constitute senior indebtedness (however denominated) in respect of such Subordinated Debt and to enable the Administrative Agent and the Lenders to have and exercise any payment blockage or other remedies available or potentially available to holders of senior indebtedness under the terms of such Subordinated Debt. Without limiting the foregoing, the Loan Document Obligations are hereby designated as “senior indebtedness” and as “designated senior indebtedness” and words of similar import under and in respect of the Subordinated Debt Documents under which such Subordinated Debt is issued and are further given all such other designations as shall be required under the terms of any such Subordinated Debt in order that the Administrative Agent and the Lenders may have and exercise any payment blockage or other remedies available or potentially available to holders of senior indebtedness under the terms of such Subordinated Debt.
- 51 -


Section 1.9Rates Generally. The Administrative Agent does not warrant or accept responsibility for, and shall not have any liability with respect to (a) administration, construction, calculation, publication, continuation, discontinuation, movement, or regulation of, or any other matter related to, the Alternate Base Rate, the Benchmark, or any alternative, successor or replacement rate thereto (including any Benchmark Replacement), any component definition thereof or rates referred to in the definition thereof, including whether any Benchmark is similar to, or will produce the same value or economic equivalence of, any other rate or whether financial instruments referencing or underlying the Benchmark will have the same volume or liquidity as those referencing or underlying any other rate, (b) the impact of any regulatory statements about, or actions taken with respect to any Benchmark (or component thereof), (c) changes made by any administrator to the methodology used to calculate any Benchmark (or component thereof) or (d) the effect, implementation or composition of any Conforming Changes. The Administrative Agent and its affiliates or other related entities may engage in transactions that affect the calculation of the Alternate Base Rate, the Benchmark, any alternative, successor or replacement rate (including any Benchmark Replacement) or any relevant adjustments thereto, in each case, in a manner adverse to the Borrower. The Administrative Agent does not warrant or accept responsibility for, and shall not have any liability with respect to, such transactions. The Administrative Agent may select information sources or services in its reasonable discretion to ascertain the Alternate Base Rate, the Benchmark, or any alternative, successor or replacement rate (including any Benchmark Replacement), in each case pursuant to the terms of this Credit Agreement, and shall have no liability to the Borrower, any Lender or any other person or entity for damages of any kind, including direct or indirect, special, punitive, incidental or consequential damages, costs, losses or expenses (whether in tort, contract or otherwise and whether at law or in equity), for any error or calculation of any such rate (or component thereof) provided by any such information source or service.
Section 1.10Divisions. For all purposes under the Loan Documents, in connection with Division: (a) if any asset, right, obligation or liability of any Person becomes the asset, right, obligation or liability of a different Person, then it shall be deemed to have been transferred from the original Person to the subsequent Person, and (b) if any new Person comes into existence, such new Person shall be deemed to have been organized on the first date of its existence by the holders of its Equity Interests at such time.
Section 1.11Limited Condition Acquisitions. Notwithstanding anything to the contrary contained herein, for purposes of (a) determining compliance with any provision of this Credit Agreement or any other Loan Document which requires the calculation of any ratio (other than actual compliance with the Financial Covenants), (b) determining compliance with representations, warranties, Defaults or Events of Default contained herein or in any other Loan Document (other than the requirements contained in Section 4.2 and whether an Event of Default has occurred and is continuing under Sections 8.1(a), (b), (h) or (i)) or (c) testing availability under baskets (including baskets measured as a percentage of Consolidated EBITDA), in each case, in connection with any Limited Condition Acquisition, at the election of the Borrower (the Borrower’s election to exercise such option in connection with any Limited Condition Acquisition, a “Limited Condition Election”), the date of determination of whether any such action is permitted hereunder, shall be deemed to be the Limited Condition Acquisition Agreement Signing Date, and if, after giving pro forma effect thereto and the other transactions to be entered into in connection therewith the Borrower could have taken such action on the relevant test date in compliance with such ratio, test, basket or other condition, such ratio, test, basket or other condition shall be deemed to have been complied with. For the avoidance of doubt, if the Borrower has made a Limited Condition Election and any of the ratios, tests, baskets or other conditions for which compliance was determined or tested as of the Limited Condition Acquisition Agreement Signing Date are exceeded, or would not be complied with, at or prior to the consummation of the relevant Limited Condition Acquisition, such baskets, tests, ratios or other conditions will not be deemed to have been exceeded or failed. If the Borrower has made a Limited Condition Election for any Limited Condition Acquisition, then in
- 52 -


connection with any calculation of any ratio, test or basket availability with respect to the incurrence of Indebtedness or Liens, the making of Restricted Payments or the making of any Investment (a “Subsequent Transaction”) following the relevant Limited Condition Acquisition Agreement Signing Date and prior to the earliest of (x) the date on which such Limited Condition Acquisition is consummated, (y) the date that the relevant Limited Condition Acquisition Agreement is terminated or expires without consummation of such Limited Condition Acquisition or (z) the date that is one hundred eighty (180) days after the Limited Condition Acquisition Agreement Signing Date, for purposes of determining whether such Subsequent Transaction is permitted under this Credit Agreement, any such ratio, test or basket shall be required to be satisfied (A) on a pro forma basis assuming such Limited Condition Acquisition and other transactions in connection therewith (but excluding the Consolidated EBITDA of any acquisition target to be acquired in connection with such Limited Condition Acquisition unless and until such Limited Condition Acquisition is consummated) have been consummated and (B) in the case of any such ratio or basket related to a Restricted Payment, without giving effect to such Limited Condition Acquisition and other transactions in connection therewith (including any incurrence of Indebtedness and the use of proceeds thereof).
Section 1.12Letter of Credit Amounts. Unless otherwise specified herein, the amount of a Letter of Credit at any time shall be deemed to be the amount of such Letter of Credit available to be drawn at such time; provided that with respect to any Letter of Credit that, by its terms, provides for one or more automatic increases in the available amount thereof, the amount of such Letter of Credit shall be deemed to be the maximum amount of such Letter of Credit after giving effect to all such increases, whether or not such maximum amount is available to be drawn at such time.
Article 2

THE CREDITS
Section 1.1Commitments.
(a)Revolving Commitments. Subject to the terms and conditions hereof and relying upon the representations and warranties herein set forth, each Revolving Lender agrees, severally and not jointly, to make Revolving Loans to the Borrower in Dollars from time to time during the Availability Period in an aggregate principal amount that will not result in (i) such Revolving Lender’s Revolving Exposure exceeding such Revolving Lender’s Revolving Commitment or (ii) the Total Revolving Outstandings exceeding the aggregate Revolving Commitments. Within the foregoing limits and subject to the terms and conditions set forth herein, the Borrower may borrow, prepay and reborrow Revolving Loans. Revolving Loans may be ABR Loans or SOFR Loans, as further provided herein.
(b)Term Loan Commitments. Subject to the terms and conditions hereof and relying upon the representations and warranties herein set forth, each Term Lender agrees, severally and not jointly, to make a single loan (each such loan, a “Term Loan”) to the Borrower in Dollars on the Closing Date in a principal amount not exceeding such Term Lender’s Term Loan Commitment. Term Loans which are prepaid or repaid, in whole or in part, may not be reborrowed. Term Loans may be ABR Loans or SOFR Loans, as further provided herein.
(c)Incremental Term Loan Commitments. Subject to the terms and conditions hereof and relying upon the representations and warranties herein set forth, each Incremental Term Lender agrees, severally and not jointly, if such Incremental Term Lender has so committed pursuant to Section 2.11, to make Incremental Term Loans in Dollars to the Borrower in an aggregate principal amount not to exceed its Incremental Term Loan Commitment and otherwise on the terms and subject to
- 53 -


the conditions set forth in the Incremental Assumption Agreement to which such Lender is a party. Incremental Term Loans which are prepaid or repaid, in whole or in part, may not be reborrowed. Incremental Term Loans may be ABR Loans or SOFR Loans, as further provided herein.
Section 1.2Borrowings, Conversions and Continuations of Loans.
(a)Each Borrowing (other than a Swingline Borrowing which shall be made in accordance with Section 2.3), each conversion of Loans from one Type to the other, and each continuation of SOFR Loans shall be made upon the Borrower’s irrevocable notice, to the Administrative Agent, which may be given by telephone. Each such notice must be made in writing (or in the case of telephonic notice, promptly confirmed in writing) substantially in the form of a Committed Loan Notice appropriately completed and signed by a Responsible Officer of the Borrower and received by the Administrative Agent (i) in the case of an ABR Borrowing, not later than 11:00 a.m. on the date of the proposed Borrowing, or (ii) in the case of any other Borrowing, not later than 11:00 a.m. three (3) Government Securities Business Days before the date of the proposed Borrowing.
(b)Except as provided in Section 2.3(c) and Section 2.4(c), each Borrowing or conversion of Loans shall be in a principal amount of the Borrowing Minimum or a whole multiple of the Borrowing Multiple in excess thereof. Each Committed Loan Notice (whether telephonic or written) shall specify (A) whether the Borrower is requesting a Borrowing, a conversion of Loans from one Type to the other, or a continuation of SOFR Loans, (B) the requested date of the Borrowing, continuation or conversion, as the case may be (which shall be a Business Day), (C) the Class and principal amount of Loans to be borrowed, continued or converted, (D) the Type of Loans to be borrowed or to which existing Loans are to be converted, (E) if applicable, the duration of the Interest Period with respect thereto which shall be a period contemplated by the definition of the term “Interest Period”, and (F) the location and number of the Borrower’s account to which funds are to be disbursed, which shall comply with the requirements of Section 2.2. Notwithstanding anything in this Credit Agreement to the contrary, if the Borrower:
(i)requests a Borrowing of, conversion to, or continuation of SOFR Loans in any such Committed Loan Notice, but fails to specify an Interest Period, it will be deemed to have specified an Interest Period of one month; or
(ii)fails to specify a Type of Loan in a Committed Loan Notice or fails to give a timely notice requesting a conversion or continuation, then the applicable Loans shall be made as, continued as, or converted to, ABR Loans.
For avoidance of doubt, the Borrower and Lenders acknowledge and agree that any conversion or continuation of an existing Loan shall be deemed to be a continuation of that Loan with a converted interest rate methodology and not a new Loan. Any automatic conversion or continuation as provided above shall be effective as of the last day of the Interest Period then in effect with respect to the applicable SOFR Loans. No Swingline Loan may be converted into any Type of Loan other than a Daily SOFR Loan.
(c)Following receipt of a Committed Loan Notice, the Administrative Agent shall promptly notify each Appropriate Lender of the amount of its Applicable Percentage of the applicable Class of Loans, and if no timely notice of a conversion or continuation is provided by the Borrower, the Administrative Agent shall notify each Appropriate Lender of the details of any automatic conversion or continuation described in Section 2.2(b). In the case of each Borrowing, each Appropriate Lender shall make (or cause its Applicable Lending Office to make) the amount of its Loan available to the Administrative Agent, by transfer in immediately available funds to the account of the Administrative
- 54 -


Agent, not later than 1:00 p.m. on the Business Day specified in the applicable Committed Loan Notice. Upon satisfaction or waiver of the applicable conditions set forth in Section 4.2 (and, if such Borrowing is the initial Credit Extension, Section 4.1), the Administrative Agent shall make all funds so received available to the Borrower in like funds as received by transfer to the account of the Borrower designated in the Commitment Loan Notice the amount of such funds; provided that if, on the date the Committed Loan Notice with respect to such Borrowing is given by the Borrower, there are Swingline Loans or L/C Borrowings outstanding, then the proceeds of such Borrowing shall be applied first, to the payment in full of any such L/C Borrowings, second, to the payment in full of any such Swingline Loans, and third, to the Borrower as provided above.
(d)Except as otherwise provided herein, a SOFR Loan may be continued or converted only on the last day of the Interest Period for such Loan unless the Borrower pays the amount due, if any, under Section 3.5 in connection therewith. During the existence of an Event of Default, the Administrative Agent or the Required Lenders may require that (i) no Loans may be requested as, converted to or continued as SOFR Loans or Daily SOFR Loans and (ii) unless repaid, (X) each SOFR Loan be converted to an ABR Loan at the end of the Interest Period applicable thereto and (Y) each Daily SOFR Loan be immediately converted into an ABR Loan.
(e)The Administrative Agent shall promptly notify the Borrower and the Appropriate Lenders of the interest rate applicable to any Interest Period for SOFR Loans upon determination of such interest rate.
(f)The failure of any Appropriate Lender to make any Loan required to be made by it shall not relieve any other Appropriate Lender of its obligations hereunder, provided that the Commitments of the Lenders are several, and no Lender shall be responsible for any other Lender’s failure to make Loans as required. All Borrowings made on the Closing Date must be made as ABR Borrowings unless the Borrower shall have given a Committed Loan Notice requesting a SOFR Borrowing and provided an indemnity letter in form and substance reasonably satisfactory to the Administrative Agent extending the benefits of Section 3.5 to the Appropriate Lenders in respect of such Borrowings.
(g)Anything in clauses (a) through (d) above to the contrary notwithstanding, after giving effect to all Borrowings, all conversions of Loans from one Type to the other, and all continuations of Loans of the same Type, there shall not be more than six (6) Interest Periods in effect at any time for all Borrowings of SOFR Loans.
Section 1.3Swingline Loans.
(a)The Swingline. Subject to the terms and conditions hereof and relying upon the representations and warranties herein set forth and upon the agreements of the Revolving Lenders set forth in this Section 2.3, the Swingline Lender may in its sole discretion and without any obligation to do so make Swingline Loans to the Borrower in Dollars from time to time on any Business Day after the making of the initial Revolving Loans through the seventh Business Day preceding the Revolving Maturity Date; provided that after giving effect to each Swingline Loan, (i) the aggregate Outstanding Amount of Swingline Loans shall not exceed the Swingline Sublimit and (ii) the Total Revolving Outstandings shall not exceed the aggregate Revolving Commitments; provided, further, that the Borrower shall not use the proceeds of any Swingline Loan to refinance any outstanding Swingline Loan. Within the foregoing limits, and subject to the other terms and conditions hereof, the Borrower may borrow under this Section 2.3, prepay under Section 2.7, and reborrow under this Section 2.3.
- 55 -


(b)Borrowing Procedures. Each Swingline Borrowing shall be made upon the Borrower’s irrevocable notice to the Swingline Lender, which may be given by telephone. Each such notice must be received by the Swingline Lender not later than 1:00 p.m. on the requested borrowing date, and shall specify (i) the amount to be borrowed, which shall be in an aggregate amount that is an integral multiple of the Borrowing Multiple and not less than the Borrowing Minimum, (ii) the requested borrowing date, which shall be a Business Day and (iii) the maturity date of the requested Swingline Loan which shall be not later than seven Business Days after the making of such Swingline Loan. Each such telephonic notice must be confirmed promptly by hand delivery or facsimile (or transmitted by electronic communication, if arrangements for doing so have been acceptable to the Swingline Lender and the Administrative Agent) of a written Swingline Loan Notice to the Swingline Lender and the Administrative Agent, appropriately completed and signed by a Responsible Officer of the Borrower. Promptly after receipt by the Swingline Lender of any telephonic Swingline Loan Notice, the Swingline Lender will, if it is willing to make the requested Swingline Loan and provided that all applicable conditions in Section 4.2 are satisfied or waived, not later than 3:00 p.m. on the borrowing date specified in such Swingline Loan Notice, make the amount of its Swingline Loan available to the Borrower by crediting the account of the Borrower maintained with the Swingline Lender and notify the Administrative Agent thereof in writing.
(c)Refinancing of Swingline Loans. (i) The Swingline Lender at any time in its sole and absolute discretion may request, and shall request at least weekly at any time when Swingline Borrowings are outstanding, on behalf of the Borrower (which hereby irrevocably authorizes the Swingline Lender to so request on its behalf), that each Revolving Lender make an ABR Revolving Loan in Dollars in an amount equal to such Revolving Lender’s Applicable Percentage of the amount of Swingline Loans then outstanding. Such request shall be made in writing (which written request shall be deemed to be a Committed Loan Notice for purposes hereof) and in accordance with the requirements of Section 2.2, without regard to the minimum and multiples specified therein for the principal amount of ABR Loans. Each Revolving Lender shall make an amount equal to its Applicable Percentage of the amount specified in such Committed Loan Notice available to the Administrative Agent in immediately available funds in Dollars for the account of the Swingline Lender at the Administrative Agent’s Payment Office not later than 1:00 p.m. on the day specified in such Committed Loan Notice, whereupon, subject to Section 2.3(c)(ii), each Revolving Lender that so makes funds available shall be deemed to have made an ABR Revolving Loan to the Borrower in such amount. The Administrative Agent shall remit the funds so received to the Swingline Lender.
(i)If for any reason any Swingline Loan cannot be refinanced by a Revolving Borrowing in accordance with Section 2.3(c)(i), the request for ABR Revolving Loans submitted by the Swingline Lender as set forth therein shall be deemed to be a request by the Swingline Lender that each of the Revolving Lenders purchase for cash a risk participation in the relevant Swingline Loan in Dollars and each Revolving Lender hereby irrevocably and unconditionally agrees to make such purchase in an amount equal to the product of such Revolving Lender’s Applicable Percentage multiplied by the amount of such Swingline Loan. Each Revolving Lender’s payment to the Administrative Agent for the account of the Swingline Lender pursuant to Section 2.3(c)(i) shall be deemed payment in respect of such participation.
(ii)If any Revolving Lender fails to make available to the Administrative Agent for the account of the Swingline Lender any amount required to be paid by such Revolving Lender pursuant to the foregoing provisions of this Section 2.3(c) by the time specified in Section 2.3(c)(i), the Swingline Lender shall be entitled to recover from such Revolving Lender (acting through the Administrative Agent), on demand, such amount with interest thereon for the period from the date such payment is required to the date on which such payment is immediately
- 56 -


available to the Swingline Lender at the greater of the Federal Funds Rate and a rate determined by the Administrative Agent in accordance with banking industry rules on interbank compensation. A certificate of the Swingline Lender submitted to any Revolving Lender (through the Administrative Agent) with respect to any amounts owing under this clause (iii) shall be conclusive absent manifest error.
(iii)Each Revolving Lender’s obligation to make Revolving Loans or to purchase and fund risk participations in Swingline Loans pursuant to this Section 2.3(c) shall be absolute and unconditional and shall not be affected by any circumstance, provided that each Revolving Lender’s obligation to make Revolving Loans (but not to purchase and fund risk participations in Swingline Loans) pursuant to this Section 2.3(c) is subject to the conditions set forth in Section 4.2. No such funding of risk participations shall relieve or otherwise impair the obligation of the Borrower to repay Swingline Loans, together with interest as provided herein.
(d)Repayment of Participations. (i) At any time after any Revolving Lender has purchased and funded a risk participation in a Swingline Loan, if the Swingline Lender receives any payment on account of such Swingline Loan, the Swingline Lender will distribute to such Revolving Lender its Applicable Percentage of such payment (appropriately adjusted, in the case of interest payments, to reflect the period of time during which such Revolving Lender’s risk participation was funded) in the same funds as those received by the Swingline Lender.
(i)If any payment received by the Swingline Lender in respect of principal or interest on any Swingline Loan is required to be returned by the Swingline Lender under any of the circumstances described in Section 10.11 (including pursuant to any settlement entered into by the Swingline Lender in its discretion), each Revolving Lender shall pay to the Swingline Lender its Applicable Percentage thereof on demand by the Administrative Agent, plus interest thereon from the date of such demand to the date such amount is returned, at a rate per annum equal to the Federal Funds Rate. The Administrative Agent will make such demand upon the request of the Swingline Lender.
(e)Interest for Account of Swingline Lender. Until each Revolving Lender funds its ABR Revolving Loan or risk participation pursuant to this Section 2.3 to refinance such Revolving Lender’s Applicable Percentage of any Swingline Loan, interest in respect of such Applicable Percentage shall be solely for the account of the Swingline Lender.
(f)Payments Directly to Swingline Lender. The Borrower shall make all payments of principal and interest in respect of the Swingline Loans directly to the Swingline Lender and the Swingline Lender shall notify the Administrative Agent thereof.
Section 1.4Letters of Credit.
(a)The Letter of Credit Commitment. (i) Subject to the terms and conditions hereof and of any additional Letter of Credit Documents required by the L/C Issuer and relying upon the representations and warranties herein set forth (A) based upon the agreements of the Revolving Lenders set forth in this Section 2.4, the L/C Issuer agrees (1) from time to time on any Business Day during the Availability Period to issue Letters of Credit denominated in Dollars for the account of the Borrower (provided that any Letter of Credit may be for the joint account of the Borrower and any Subsidiary of the Borrower) and to amend or renew Letters of Credit previously issued by it, in accordance with Section 2.4(b), and (2) to honor conforming drafts under the Letters of Credit and (B) the Revolving Lenders severally agree to participate in Letters of Credit issued pursuant to this Section 2.4; provided that the L/C Issuer shall not be obligated to make any L/C Credit Extension with respect to any Letter of
- 57 -


Credit, and no Revolving Lender shall be obligated to participate in any such Letter of Credit if immediately after giving effect to such L/C Credit Extension, (w) the aggregate L/C Obligations would exceed the L/C Sublimit, (x) the Revolving Exposure of any Revolving Lender would exceed such Revolving Lender’s Revolving Commitment, or (y) the Total Revolving Outstandings would exceed the aggregate Revolving Commitments.
(i)The L/C Issuer shall be under no obligation to issue any Letter of Credit (and, in the case of clauses (B), (C) or (D) below, shall not issue any Letter of Credit) if:
(A)any order, judgment or decree of any Governmental Authority or arbitrator shall by its terms purport to enjoin or restrain the L/C Issuer from issuing such Letter of Credit, or any law applicable to the L/C Issuer or any directive (whether or not having the force of law) from any Governmental Authority with jurisdiction over the L/C Issuer shall prohibit, or direct that the L/C Issuer refrain from, the issuance of letters of credit generally or such Letter of Credit in particular or shall impose upon the L/C Issuer with respect to such Letter of Credit any restriction, reserve or capital requirement (for which the L/C Issuer is not otherwise compensated hereunder) not in effect on the Closing Date, or shall impose upon the L/C Issuer any unreimbursed loss, cost or expense which was not applicable on the Closing Date (for which the L/C Issuer is not otherwise compensated hereunder);
(B)subject to Section 2.4(b)(iii), the expiry date of such requested Letter of Credit would occur more than twelve months after the date of issuance or last renewal;
(C)the expiry date of such requested Letter of Credit would occur after the Letter of Credit Expiration Date;
(D)[reserved];
(E)the issuance of such Letter of Credit would violate one or more policies of the L/C Issuer applicable to letters of credit or any laws binding upon the L/C Issuer;
(F)the Letter of Credit is to be denominated in a currency other than Dollars;
(G)any Revolving Lender is at that time a Defaulting Lender, unless the L/C Issuer has entered into arrangements, including the delivery of Cash Collateral, satisfactory to the L/C Issuer (in its sole discretion) with the Borrower or such Defaulting Lender to eliminate the L/C Issuer’s actual or potential Fronting Exposure (after giving effect to Section 2.10(a)(iv)) with respect to such Defaulting Lender arising from either the Letter of Credit then proposed to be issued or such Letter of Credit and all other L/C Obligations as to which the L/C Issuer has actual or potential Fronting Exposure, as it may elect in its sole discretion; or
(H)the Letter of Credit is in an initial amount less than $50,000 (or such lesser amount as agreed to by the L/C Issuer and the Administrative Agent).
(ii)The L/C Issuer shall be under no obligation to amend any Letter of Credit if (A) the L/C Issuer would have no obligation at such time to issue such Letter of Credit
- 58 -


in its amended form under the terms hereof, or (B) the beneficiary of such Letter of Credit does not accept the proposed amendment to such Letter of Credit.
(b)Procedures for Issuance and Amendment of Letters of Credit; Auto-Renewal Letters of Credit. (i) Each Letter of Credit shall be issued or amended, as the case may be, upon the request of the Borrower hand delivered or sent by facsimile (or transmitted by electronic communication, if arrangements for doing so have been acceptable to the L/C Issuer) to the L/C Issuer (with a copy to the Administrative Agent) in the form of a Letter of Credit Application, appropriately completed and signed by a Responsible Officer of the Borrower. Such Letter of Credit Application must be received by the L/C Issuer and the Administrative Agent not later than 1:00 p.m. at least three (3) Business Days prior to the proposed issuance date or date of amendment, as the case may be; or, in each case, such later date and time as the L/C Issuer may agree in a particular instance in its sole discretion. In the case of a request for an initial issuance of a Letter of Credit, such Letter of Credit Application shall specify in form and detail reasonably satisfactory to the L/C Issuer: (A) the proposed issuance date of the requested Letter of Credit (which shall be a Business Day), (B) the amount thereof, (C) the expiry date thereof, (D) the name and address of the beneficiary thereof, (E) the documents to be presented by such beneficiary in case of any drawing thereunder, (F) the full text of any certificate to be presented by such beneficiary in case of any drawing thereunder, and (G) such other matters as the L/C Issuer may reasonably request. In the case of a request for an amendment of any outstanding Letter of Credit, such Letter of Credit Application shall specify in form and detail reasonably satisfactory to the L/C Issuer (1) the Letter of Credit to be amended, (2) the proposed date of amendment thereof (which shall be a Business Day), (3) the nature of the proposed amendment, and (4) such other matters as the L/C Issuer may reasonably request.
(i)Subject to the terms and conditions set forth herein, the L/C Issuer shall, on the requested date, issue a Letter of Credit for the account of the Borrower or enter into the applicable amendment, as the case may be. Immediately upon the issuance of each Letter of Credit, each Revolving Lender shall be deemed to have, and hereby irrevocably and unconditionally agrees to, acquire from the L/C Issuer a risk participation in such Letter of Credit in an amount equal to such Revolving Lender’s Applicable Percentage of the aggregate amount available to be drawn under such Letter of Credit. Each Lender acknowledges and agrees that its obligation to acquire risk participations pursuant to this paragraph in respect of Letters of Credit is absolute and unconditional and shall not be affected by any circumstance whatsoever, including any amendment, renewal or extension of any Letter of Credit or the occurrence and continuance of a Default or Event of Default or reduction or termination of the Commitments.
(ii)If the Borrower so requests in any applicable Letter of Credit Application, the L/C Issuer shall agree to issue a Letter of Credit that has automatic renewal provisions (each, an “Auto-Renewal Letter of Credit”); provided that any such Auto-Renewal Letter of Credit must permit the L/C Issuer to prevent any such renewal at least once in each twelve-month period (commencing with the date of issuance of such Auto-Renewal Letter of Credit) by giving prior notice to the beneficiary thereof not later than a day (the “Nonrenewal Notice Date”) in each such twelve-month period to be agreed upon at the time such Letter of Credit is issued. Unless otherwise directed by the L/C Issuer, the Borrower shall not be required to make a specific request to the L/C Issuer for any such renewal. Once an Auto-Renewal Letter of Credit has been issued, the Revolving Lenders shall be deemed to have authorized (but may not require) the L/C Issuer to permit the renewal of such Auto-Renewal Letter of Credit from time to time to an expiry date not later than the Letter of Credit Expiration Date; provided that the L/C Issuer shall not permit any such renewal if (A) the L/C Issuer has determined that it would have no obligation at such time to issue such Letter of Credit in its renewed form under the terms hereof (by reason of the provisions of Section 2.4(a)(ii) or otherwise), or (B) it has received
- 59 -


notice (which may be by telephone, followed promptly in writing, or in writing) on or before the day that is five (5) Business Days before the applicable Nonrenewal Notice Date from the Administrative Agent or any Revolving Lender, as applicable, or the Borrower that one or more of the applicable conditions specified in Section 4.2 is not then satisfied.
(iii)Promptly after its delivery of any Letter of Credit or any amendment to a Letter of Credit to an advising bank with respect thereto or to the beneficiary thereof, the L/C Issuer will also deliver to the Borrower and the Administrative Agent a true and complete copy of such Letter of Credit or amendment.
(c)Drawings and Reimbursements; Funding of Participations. (i) Upon receipt from the beneficiary of any Letter of Credit of any notice of a drawing under such Letter of Credit, the L/C Issuer shall notify promptly the Borrower and the Administrative Agent thereof. On the Business Day on which the Borrower shall have received notice of any payment by the L/C Issuer under a Letter of Credit or, if the Borrower shall have received such notice later than 3:00 p.m. on any Business Day, on the succeeding Business Day (such applicable Business Day, the “L/C Honor Date”), the Borrower shall (regardless of whether or not such Letter of Credit shall be for the sole account of the Borrower or for the joint account of the Borrower and any Subsidiary) reimburse the L/C Issuer through the Administrative Agent in an amount equal to such drawing in Dollars. If the Borrower fails to so reimburse the L/C Issuer on the L/C Honor Date (or if any such reimbursement payment is required to be refunded to the Borrower for any reason), then (x) the Borrower shall be deemed to have requested a Borrowing of ABR Revolving Loans in the amount of such drawing, and (y) the Administrative Agent shall promptly notify each Revolving Lender of the L/C Honor Date, the amount of the unreimbursed drawing (the “Unreimbursed Amount”), and the amount of such Revolving Lender’s Applicable Percentage thereof. Such Revolving Loans shall be made by the Revolving Lenders without regard to the Borrowing Minimums and Borrowing Multiples. Any notice given by the L/C Issuer or the Administrative Agent pursuant to this Section 2.4(c)(i) may be given by telephone if immediately confirmed in writing; provided that the lack of such an immediate confirmation shall not affect the conclusiveness or binding effect of such notice. For the avoidance of doubt, if any drawing occurs under a Letter of Credit and such drawing is not reimbursed on the same day, the Unreimbursed Amount of such drawing shall, without duplication, accrue interest for each day until the date of reimbursement at (x) prior to the third Business Day following the L/C Honor Date, the rate per annum applicable to the outstanding principal balance of ABR Revolving Loans pursuant to Section 3.1(a), and (y) thereafter, a rate per annum equal to the Default Rate applicable to the outstanding principal balance of ABR Revolving Loans.
(i)Each Revolving Lender (including the Revolving Lender acting as the L/C Issuer) shall upon any notice pursuant to Section 2.4(c)(i) make funds available to the Administrative Agent for the account of the L/C Issuer at the Administrative Agent’s Payment Office in an amount equal to its Applicable Percentage of any Unreimbursed Amount in respect of a Letter of Credit in Dollars not later than 1:00 p.m. on the Business Day specified in such notice by the Administrative Agent. The Administrative Agent shall remit the funds so received to the L/C Issuer, and may apply Cash Collateral provided for this purpose to such Unreimbursed Amount.
(ii)Each Revolving Lender that makes funds available pursuant to Section 2.4(c)(ii) shall be deemed to have made an ABR Revolving Loan in Dollars to the Borrower in such amount, provided that in the event the conditions for Revolving Borrowings set forth in Section 4.2 cannot be satisfied (and have not been waived) or for any other reason, then (A) the Borrower shall be deemed to have incurred from the L/C Issuer a L/C Borrowing in Dollars in the amount of the Unreimbursed Amount, which L/C Borrowing shall be due and
- 60 -


payable on demand (together with interest) and shall bear interest at the Default Rate, and (B) such Revolving Lender shall be deemed to have purchased a participation in such L/C Borrowing in an amount equal to its Applicable Percentage thereof (a “L/C Advance”).
(iii)Until each Revolving Lender funds its Revolving Loan or L/C Advance pursuant to this Section 2.4(c) to reimburse the L/C Issuer for any amount drawn under any Letter of Credit, interest in respect of such Revolving Lender’s Applicable Percentage of such amount shall be solely for the account of the L/C Issuer.
(iv)Each Revolving Lender’s obligation to make Revolving Loans or L/C Advances to reimburse the L/C Issuer for amounts drawn under Letters of Credit, as contemplated by this Section 2.4(c), shall be absolute and unconditional and shall not be affected by any circumstance; provided that each Revolving Lender’s obligation to make Revolving Loans (but not L/C Advances) pursuant to this Section 2.4(c) is subject to the conditions set forth in Section 4.2 (other than delivery by the Borrower of a Committed Loan Notice). No such making of a L/C Advance shall relieve or otherwise impair the obligation of the Borrower to reimburse the L/C Issuer for the amount of any payment made by the L/C Issuer under any Letter of Credit, together with interest as provided herein.
(v)If any Revolving Lender fails to make available to the Administrative Agent for the account of the L/C Issuer any amount required to be paid by such Revolving Lender pursuant to the foregoing provisions of this Section 2.4(c) by the time specified in Section 2.4(c)(ii), the L/C Issuer shall be entitled to recover from such Revolving Lender (acting through the Administrative Agent), on demand, such amount with interest thereon for the period from the date such payment is required to the date on which such payment is immediately available to the L/C Issuer at the greater of the Federal Funds Rate and a rate determined by the L/C Issuer in accordance with banking industry rules on interbank compensation. A certificate of the L/C Issuer submitted to any Revolving Lender (through the Administrative Agent) with respect to any amounts owing under this Section 2.4(c)(vi) shall be conclusive absent manifest error.
(vi)If, at any time after the L/C Issuer has made a payment under any Letter of Credit and has received from any Revolving Lender such Revolving Lender’s L/C Advance in respect of such payment in accordance with this Section 2.4(c), the Administrative Agent receives for the account of such Revolving Lender any payment in respect of the related Unreimbursed Amount or interest thereon (whether directly from the Borrower or otherwise, including proceeds of Cash Collateral applied thereto by the Administrative Agent), the Administrative Agent will distribute to such Revolving Lender its Applicable Percentage thereof (appropriately adjusted, in the case of interest payments, to reflect the period of time during which such Revolving Lender’s L/C Advance was outstanding) in the same funds as those received by the Administrative Agent.
(vii)If any payment received by the Administrative Agent for the account of the L/C Issuer pursuant to Section 2.4(c) is required to be returned under any of the circumstances described in Section 10.11, each Revolving Lender shall pay to the Administrative Agent its Applicable Percentage thereof on demand of the Administrative Agent, plus interest thereon from the date of such demand to the date such amount is returned by such Revolving Lender, at a rate per annum equal to the Federal Funds Rate.
(d)Obligations Absolute. The obligation of the Borrower to reimburse the L/C Issuer for each drawing under each Letter of Credit issued by it and to repay each L/C Borrowing shall
- 61 -


be absolute, unconditional and irrevocable, and shall be paid strictly in accordance with the terms of this Credit Agreement under all circumstances, including the following:
(i)any lack of validity or enforceability of such Letter of Credit, this Credit Agreement, or any other agreement or instrument relating thereto;
(ii)the existence of any claim, counterclaim, setoff, defense or other right that any Loan Party may have at any time against any beneficiary or any transferee of such Letter of Credit (or any Person for whom any such beneficiary or any such transferee may be acting), the L/C Issuer or any other Person, whether in connection with this Credit Agreement, the transactions contemplated hereby or by such Letter of Credit or any agreement or instrument relating thereto, or any unrelated transaction;
(iii)any draft, demand, certificate or other document presented under such Letter of Credit proving to be forged, fraudulent, invalid or insufficient in any respect or any statement therein being untrue or inaccurate in any respect; or any loss or delay in the transmission or otherwise of any document required in order to make a drawing under such Letter of Credit;
(iv)any payment by the L/C Issuer under such Letter of Credit against presentation of a draft or certificate that does not strictly comply with the terms of such Letter of Credit, or any payment made by the L/C Issuer under such Letter of Credit to any Person purporting to be a trustee in bankruptcy, debtor-in-possession, assignee for the benefit of creditors, liquidator, receiver or other representative of or successor to any beneficiary or any transferee of such Letter of Credit, including any arising in connection with (x) any proceeding under any Debtor Relief Law or (y) any Bail-In Action;
(v)any exchange, release or non-perfection of any Collateral, or any release or amendment or waiver of or consent to departure from the Guarantee Agreement or any other guarantee, for all or any of the Loan Document Obligations of any Loan Party in respect of such Letter of Credit; or
(vi)any other circumstance or happening whatsoever, whether or not similar to any of the foregoing, including any other circumstance that might otherwise constitute a defense available to, or a discharge of, any Loan Party;
provided that the foregoing shall not excuse the L/C Issuer from liability to the Borrower to the extent of any direct damages (as opposed to special, indirect, consequential or punitive damages, claims in respect of which are waived by the Borrower to the extent permitted by Applicable Law) suffered by the Borrower that are caused by the L/C Issuer’s gross negligence or willful misconduct when determining whether drafts and other documents presented under a Letter of Credit comply with the terms thereof.
(e)Role of L/C Issuer. Each Lender and the Borrower agree that, in paying any drawing under a Letter of Credit, the L/C Issuer shall not have any responsibility to obtain any document (other than any sight draft, certificates and documents expressly required by the Letter of Credit) or to ascertain or inquire as to the validity or accuracy of any such document or the authority of the Person executing or delivering any such document. None of the L/C Issuer, any of its Related Parties nor any of the correspondents, participants or assignees of the L/C Issuer shall be liable to any Lender for (i) any action taken or omitted in connection herewith at the request or with the approval of the Required Lenders or the Required Class Lenders in respect of the Revolving Facility, as applicable, (ii) any action taken or omitted in the absence of gross negligence or willful misconduct; or (iii) the due execution, effectiveness,
- 62 -


validity or enforceability of any document or instrument related to any Letter of Credit or Letter of Credit Application. The Borrower hereby assumes all risks of the acts or omissions of any beneficiary or transferee with respect to its use of any Letter of Credit; provided that this assumption is not intended to, and shall not, preclude the Borrower from pursuing such rights and remedies as it may have against the beneficiary or transferee at law or under any other agreement. None of the L/C Issuer, any of its Related Parties nor any of the correspondents, participants or assignees of the L/C Issuer shall be liable or responsible for any of the matters described in clauses (i) through (iii) of this Section 2.4(e); provided that anything in such clauses to the contrary notwithstanding, the Borrower may have a claim against the L/C Issuer, and the L/C Issuer may be liable to the Borrower, to the extent, but only to the extent, of any direct, as opposed to consequential or exemplary, damages suffered by the Borrower caused by the L/C Issuer’s willful misconduct or gross negligence or the L/C Issuer’s willful or grossly negligent failure to pay under any Letter of Credit after the presentation to it by the beneficiary of a sight draft and certificate(s) strictly complying with the terms and conditions of such Letter of Credit. In furtherance and not in limitation of the foregoing, the L/C Issuer may accept documents that appear on their face to be in order, without responsibility for further investigation, regardless of any notice or information to the contrary, and the L/C Issuer shall not be responsible for the validity or sufficiency of any instrument transferring or assigning or purporting to transfer or assign a Letter of Credit or the rights or benefits thereunder or proceeds thereof, in whole or in part, which may prove to be invalid or ineffective for any reason.
(f)Conflict with Letter of Credit Application. Notwithstanding anything else to the contrary in any Letter of Credit Document (including any Letter of Credit Application), in the event of any conflict between the terms hereof and the terms of any such Letter of Credit Document, the terms hereof shall control, provided that all non-conflicting terms of any such Letter of Credit Document shall remain in full force and effect.
(g)Applicability of ISP; Limitation of Liability. Unless otherwise expressly agreed by the L/C Issuer and the Borrower when a Letter of Credit is issued the rules of the ISP shall apply to each Letter of Credit. Notwithstanding the foregoing, the L/C Issuer shall not be responsible to any Loan Party for, and the L/C Issuer’s rights and remedies against any such Loan Party shall not be impaired by, any action or inaction of the L/C Issuer required or permitted under any law, order, or practice that is required or permitted to be applied to any Letter of Credit or this Credit Agreement, including the law or any order of a jurisdiction where the L/C Issuer or the beneficiary is located, the practice stated in the or in the decisions, opinions, practice statements, or official commentary of the ICC Banking Commission, the Bankers Association for Finance and Trade - International Financial Services Association (BAFT-IFSA), or the Institute of International Banking Law & Practice, whether or not any Letter of Credit chooses such law or practice.
Section 1.5Termination and Reduction of Commitments.
(a)Unless previously terminated, (i) the Term Loan Commitments (other than any Incremental Term Loan Commitments) shall automatically terminate upon the making of the Term Loans on the Closing Date, and (ii) the Revolving Commitments shall terminate on the last day of the Availability Period. Any Incremental Term Loan Commitment shall terminate as provided in the applicable Incremental Assumption Agreement.
(b)The Borrower may at any time terminate, or from time to time reduce, the Revolving Commitments, provided that (i) the Borrower shall not terminate or reduce the Revolving Commitments if, after giving effect to any concurrent prepayment or repayment of the Revolving Loans and the Swingline Loans in accordance with Section 2.7, the sum of the Revolving Exposures of all
- 63 -


Revolving Lenders would exceed the aggregate Revolving Commitments, (ii) each such reduction of the Revolving Commitments shall be in an amount that is an integral multiple of $1,000,000 and not less than $5,000,000, and (iii) any reduction of the Revolving Commitments to an amount below the L/C Sublimit or the Swingline Sublimit shall automatically reduce the L/C Sublimit or the Swingline Sublimit, as applicable, on a Dollar for Dollar basis. If at any time, as a result of such a partial reduction or termination as provided in Section 2.5(a), the Revolving Exposure of all Lenders would exceed the aggregate Revolving Commitments, then the Borrower shall on the date of such reduction or termination of Revolving Commitments, repay or prepay Revolving Borrowings or Swingline Loans (or a combination thereof) and/or Cash Collateralize Letters of Credit in an aggregate amount equal to such excess.
(c)[Reserved].
(d)The Borrower shall notify the Administrative Agent of any election to terminate or reduce the Revolving Commitments under paragraph (b) of this Section at least three (3) Business Days prior to the effective date of such termination or reduction, specifying such election and the effective date thereof. Promptly following receipt of any such notice, the Administrative Agent shall advise the Revolving Lenders of the contents thereof. Each notice delivered by the Borrower pursuant to this Section shall be irrevocable, provided that a notice of termination of the Revolving Commitments may state that such notice is conditioned upon the effectiveness of other credit facilities, in which case such notice may be revoked by the Borrower (by written notice to the Administrative Agent on or prior to the specified effective date) if such condition is not satisfied subject to the Borrower’s obligation to indemnify the Lenders pursuant to Section 3.5. Each reduction, and any termination, of the Revolving Commitments shall be permanent and each reduction of the Revolving Commitments shall be made ratably among the Revolving Lenders in accordance with their respective Revolving Commitments.
Section 1.6Repayment of Loans; Evidence of Debt.
(a)Payment at Maturity. The Borrower hereby unconditionally promises to pay (i) to the Administrative Agent for the account of (A) each Revolving Lender the then unpaid principal amount of each Revolving Loan together with all accrued interest thereon on the earlier of the Revolving Maturity Date and, if different, the date of the termination of the Revolving Commitments in accordance with the provisions of this Credit Agreement, (B) each Term Lender, the then unpaid principal amount of each Term Loan together with all accrued interest thereon on the earlier of the Maturity Date applicable to the Term Facility and, if different, the date of the acceleration of the Loans in accordance with Section 8.2, and (C) each Incremental Term Lender, the then unpaid principal amount of each Incremental Term Loan together with all accrued interest thereon on the earlier of the applicable Incremental Term Loan Maturity Date and, if different, the date of the acceleration of the Loans in accordance with Section 8.2, and (ii) to the Swingline Lender the then unpaid principal amount of each Swingline Loan together with all accrued interest thereon on the earliest of (A) the maturity date selected by the Borrower for such Swingline Loan, (B) the Revolving Maturity Date and (C) the date of the termination of the Revolving Commitments in accordance with the provisions of this Credit Agreement.
(b)Amortization Payments for Term Loans (other than Other Term Loans). On each date set forth below, the Borrower shall pay to the Administrative Agent, for the account of the Term Lenders (other than Incremental Term Lenders with respect to Other Term Loans), the aggregate unpaid principal balance of the Term Loans (other than Other Term Loans) in an amount equal to (i) the aggregate outstanding principal amount of the Term Loans on the Closing Date (as adjusted from time to time pursuant to Section 2.7(a), Section 2.7(b)(iii) and Section 2.11(f)) multiplied by (ii) the percentage set forth below adjacent to such date under the heading “Percentage”:
- 64 -


DatePercentage
March 31, 20241.25%
June 30, 20241.25%
September 30, 20241.25%
December 31, 20241.25%
March 31, 20251.25%
June 30, 20251.25%
September 30, 20251.25%
December 31, 20251.25%
March 31, 20261.875%
June 30, 20261.875%
September 30, 20261.875%
December 31, 2026
1.875%
March 31, 2027
1.875%
June 30, 2027
1.875%
September 30, 2027
1.875%
December 31, 2027
1.875%
March 31, 2028
2.5%
June 30, 2028
2.5%
September 30, 2028
2.5%
December 31, 2028
2.5%

(c)Amortization Payments for Other Term Loans. The Borrower shall pay to the Administrative Agent, for the account of the applicable Incremental Term Lenders with respect to Other Term Loans, on each Incremental Term Loan Repayment Date, a principal amount of the Other Term Loans (as adjusted from time to time pursuant to Section 2.7(a), Section 2.7(b)(iii) and Sections 2.11(d)) equal to the amount set forth in the applicable Incremental Assumption Agreement, together in each case with accrued and unpaid interest on the principal amount to be paid to, but excluding, the date of such payment.
(d)Notes. Any Lender may request through the Administrative Agent that Loans made by it be evidenced by a promissory note. In such event, the Borrower shall execute and deliver to (i) in the case of a Revolving Lender, a Revolving Loan Note, (ii) in the case of a Term Lender, a Term Loan Note and (iii) in the case of the Swingline Lender, a Swingline Loan Note. In addition, if requested by a Lender, its Note may be made payable to such Lender and its registered assigns in which case all Loans evidenced by such Note and interest thereon shall at all times (including after assignment pursuant to Section 10.4) be represented by one or more Notes in like form payable to the order of the payee named therein and its registered assigns.
(e)Lender Records. Each Lender shall maintain in accordance with its usual practice an account or accounts evidencing the indebtedness of the Borrower to such Lender resulting from each Loan owing to such Lender from time to time, including the amounts of principal and interest payable and paid to such Lender from time to time hereunder.
(f)Register. Entries made in good faith by the Administrative Agent in the Register pursuant to Section 10.4(c), and by each Lender in its account or accounts pursuant to Section 2.6(e), shall be prima facie evidence of the amount of principal and interest due and payable or to become due and payable from the Borrower to, in the case of the Register, each Lender and, in the case of such
- 65 -


account or accounts, such Lender, under this Credit Agreement, absent manifest error; provided, however, that the failure of the Administrative Agent or such Lender to make an entry, or any finding that an entry is incorrect, in the Register or such account or accounts shall not limit or otherwise affect the obligations of the Borrower under this Credit Agreement.
Section 1.7Prepayments.
(a)Optional Prepayments. (i) The Borrower may, upon written notice to the Administrative Agent, at any time and from time to time, voluntarily prepay any Borrowing of any Class (other than Swingline Loans) in whole or in part without premium or penalty (except as set forth in Section 3.5)), provided that (A) such notice must be received by the Administrative Agent not later than 1:00 p.m. (1) three (3) Government Securities Business Days prior to any date of prepayment of a SOFR Borrowing and (2) on the date of prepayment of an ABR Borrowing and (B) each prepayment shall be in a principal amount of the Borrowing Minimum or a whole multiple of the Borrowing Multiple in excess thereof or, in each case, the entire principal amount thereof then outstanding. Each such notice shall specify the date and amount of such prepayment and the Class(es) and Type(s) of Loans to be prepaid. The Administrative Agent will promptly notify each Appropriate Lender of its receipt of each such notice, and of the amount of such Lender’s Applicable Percentage of such prepayment. If such notice is given by the Borrower, the Borrower shall make such prepayment and the payment amount specified in such notice shall be due and payable on the date specified therein, provided that a notice of prepayment may state that such notice is conditioned upon the effectiveness of other credit facilities, in which case such notice may be revoked by the Borrower (by written notice to the Administrative Agent on or prior to the specified effective date) if such condition is not satisfied subject to the Borrower’s obligation to indemnify the Lenders pursuant to Section 3.5. Each prepayment of Term Loans pursuant to this Section 2.7(a) shall be applied to the installments thereof as directed by the Borrower (it being understood and agreed that if the Borrower does not so direct at the time of such prepayment, such prepayment shall be applied against the scheduled repayments of the Term Loans under Section 2.6 on a ratable basis and pro rata to the remaining installments and shall be paid to the Administrative Agent for the account of the Appropriate Lenders in accordance with their respective Applicable Percentages.
(i)The Borrower may, upon written notice to the Swingline Lender (with a copy to the Administrative Agent), at any time or from time to time, voluntarily prepay Swingline Loans in whole or in part without premium or penalty; provided that (A) such notice must be received by the Swingline Lender and the Administrative Agent not later than 1:00 p.m. on the date of the prepayment and (B) any such prepayment shall be in a principal amount of the Borrowing Minimum or a whole multiple of the Borrowing Multiple in excess thereof or the entire principal amount thereof then outstanding. Each such notice shall specify the date and amount of such prepayment. If such notice is given by the Borrower, the Borrower shall make such prepayment and the payment amount specified in such notice shall be due and payable on the date specified therein.
(b)Mandatory Prepayments.
(i)Net Cash Proceeds.
(A)Dispositions. In the event that any Loan Party or any of its Subsidiaries receives Net Cash Proceeds in respect of any Disposition, then, substantially simultaneously with (and in any event not later than the third Business Day next following) the receipt of such Net Cash Proceeds, the Borrower shall prepay the Term Loans in an aggregate principal amount equal to 100% of such Net Cash Proceeds.
- 66 -


(B)Reserved.
(C)Casualty Events. In the event that any Loan Party or any of its Subsidiaries receives Net Cash Proceeds in respect of any Casualty Event, then, substantially simultaneously with (and in any event not later than the third Business Day next following) the receipt of such Net Cash Proceeds, the Borrower shall prepay the Term Loans in an aggregate principal amount equal to 100% of such Net Cash Proceeds.
(ii)[Reserved].
(iii)Application of Mandatory Prepayments. Each prepayment of outstanding Term Loans required to be made pursuant to Section 2.7(b) shall be allocated pro rata among the Term Loans and applied against the remaining scheduled installments of principal due in respect of Term Loans under Section 2.6(b) and Section 2.6(c), respectively, pro rata against such remaining scheduled installments of principal; provided that if, after applying all or a portion of such prepayment to the Term Loans, the Term Loans have been paid in full, any unapplied portion thereof shall be applied to the prepayment of the Revolving Loans (without a corresponding reduction in Commitments).
(iv)Notice of Mandatory Prepayment. The Borrower shall deliver to the Administrative Agent, at the time of each prepayment required under this Section 2.7(b), (i) a certificate signed by a Responsible Officer of the Borrower setting forth in reasonable detail the calculation of the amount of such prepayment and (ii) to the extent practicable, at least three (3) Business Days’ prior written notice of such prepayment. Each notice of prepayment shall specify the prepayment date, the Type of each Loan being prepaid and the principal amount of each Loan (or portion thereof) to be prepaid.
(c)Prepayments of Revolving Loans. If for any reason the Total Revolving Outstandings at any time exceed the aggregate Revolving Commitments then in effect, the Borrower shall immediately prepay, without premium or penalty, Revolving Loans and Swingline Loans and/or Cash Collateralize the L/C Obligations in an aggregate amount equal to such excess.
(d)General Rules. All prepayments shall be subject to Section 3.5, but shall otherwise be without premium or penalty. Each prepayment of a Borrowing shall be applied ratably to the Loans included in the prepaid Borrowing. All prepayments shall be accompanied by accrued interest thereon and any additional amounts required pursuant to Section 3.5.
Section 1.8Payments Generally; Administrative Agent’s Clawback.
(a)General. Each Loan Party shall make each payment required to be made by it hereunder or under any other Loan Document (whether of principal of Loans, L/C Borrowings, interest or fees, or of amounts payable under Sections 3.4, 3.5, 3.6 or 10.3, or otherwise) prior to 12:00 noon on the date when due, in immediately available funds. In furtherance of the foregoing, the Borrower hereby irrevocably authorizes the Administrative Agent, in the Administrative Agent’s sole discretion, to request on behalf of the Borrower, Revolving Loans (which shall be ABR Loans) or Swingline Loans, in an amount sufficient to pay all principal, L/C Borrowings, interest, fees, or other amounts from time to time due and payable by any Loan Party to any Credit Party hereunder or under any other Loan Document. All payments to be made by a Loan Party hereunder shall be made free and clear of and without condition or deduction for any counterclaim, defense, recoupment or setoff, without setoff or counterclaim. Any amounts received after such time on any date may, in the discretion of the Administrative Agent, be deemed to have been received on the next succeeding Business Day for purposes of calculating interest
- 67 -


thereon. All such payments shall be made to the Administrative Agent’s Payment Office, except payments to be made to the L/C Issuer or the Swingline Lender as expressly provided herein and except that payments pursuant to Sections 3.4, 3.5, 3.6 or 10.3, shall be made directly to the Persons entitled thereto. The Administrative Agent shall distribute any such payments received by it for the account of any other Person to the appropriate recipient promptly following receipt thereof. If any payment hereunder shall be due on a day that is not a Business Day, the date for payment shall be extended to the next succeeding Business Day, and, in the case of any payment accruing interest, interest thereon shall be payable for the period of such extension. All payments hereunder shall be made in Dollars.
(b)Pro Rata Treatment. Except as otherwise provided in this Section 2.8 and as otherwise required under Section 3.4(e), each Borrowing, each payment or prepayment of principal of any Borrowing, each payment of interest on the Loans, each payment of fees, each reduction of the Revolving Commitments and each conversion of any Borrowing to or continuation of any Borrowing as a Borrowing of any Type shall be allocated pro rata among the Appropriate Lenders in accordance with their respective applicable Commitments (or, if such Commitments shall have expired or been terminated, in accordance with the respective principal amounts of their outstanding Loans of the applicable Class). Each Lender agrees that in computing such Lender’s portion of any Borrowing to be made hereunder, the Administrative Agent may, in its discretion, round each Lender’s percentage of such Borrowing to the next higher or lower whole Dollar amount.
(c)Administrative Agent’s Clawback. (i) Funding by Lenders; Presumption by Administrative Agent. Unless the Administrative Agent shall have received notice from a Lender prior to the proposed date of any Borrowing that such Lender will not make available to the Administrative Agent such Lender’s share of such Borrowing, the Administrative Agent may assume that such Lender has made such share available on such date in accordance with Section 2.2 and may, in reliance upon such assumption, make available to the Borrower a corresponding amount. In such event, if a Lender has not in fact made its share of the applicable Borrowing available to the Administrative Agent, then the Appropriate Lender and the Borrower severally agree to pay to the Administrative Agent forthwith on demand such corresponding amount with interest thereon for each day from and including the date such amount is made available to the Borrower to but excluding the date of payment to the Administrative Agent, at (A) in the case of a payment to be made by such Lender, the greater of the Federal Funds Rate and a rate determined by the Administrative Agent in accordance with banking industry rules on interbank compensation, and (B) in the case of a payment to be made by the Borrower, the interest rate applicable to ABR Loans. If the Borrower and such Lender shall pay such interest to the Administrative Agent for the same or an overlapping period, the Administrative Agent shall promptly remit to the Borrower the amount of such interest paid by the Borrower for such period. If such Lender pays its share of the applicable Borrowing to the Administrative Agent, then the amount so paid shall constitute such Lender’s Loan included in such Borrowing. Any payment by the Borrower shall be without prejudice to any claim the Borrower may have against a Lender that shall have failed to make such payment to the Administrative Agent.
(i)Payments by Borrower; Presumptions by Administrative Agent. Unless the Administrative Agent shall have received notice from the Borrower prior to the date on which any payment is due to the Administrative Agent for the account of the Lenders or the L/C Issuer hereunder that the Borrower will not make such payment, the Administrative Agent may assume that the Borrower has made such payment on such date in accordance herewith and may, in reliance upon such assumption, distribute to the Lenders or the L/C Issuer, as the case may be, the amount due. In such event, if the Borrower has not in fact made such payment, then each of the Lenders or the L/C Issuer, as the case may be, severally agrees to repay to the Administrative Agent forthwith on demand the amount so distributed to such Lender or the L/C Issuer, with
- 68 -


interest thereon, for each day from and including the date such amount is distributed to it to but excluding the date of payment to the Administrative Agent, at the greater of the Federal Funds Rate and a rate determined by the Administrative Agent in accordance with banking industry rules on interbank compensation.
(ii)Notice by Administrative Agent. A notice from the Administrative Agent to any Lender or the Borrower with respect to any amount owing under this paragraph (c) shall be conclusive, absent manifest error.
(d)Obligations of Lenders Several. The obligations of the Lenders hereunder to make Loans and purchase participations in Letters of Credit and Swingline Loans and to make payments pursuant to Section 10.3(c) are several and not joint. The failure of any Lender to make any Loan or purchase participations in Letters of Credit and Swingline Loans or make any payment under Section 10.3(c) on any date required hereunder shall not relieve any other Lender of its corresponding obligation to do so on such date, and no Lender shall be responsible for the failure of any other Lender to so make its Loan, purchase its participation in Letters of Credit and Swingline Loans or to make its payment under Section 10.3(c).
(e)Failure to Satisfy Conditions Precedent. If any Lender makes available to the Administrative Agent funds for any Loan to be made by such Lender as provided in the foregoing provisions of this Article 2, and such funds are not made available to the Borrower by the Administrative Agent because the conditions to the borrowing of Loans set forth in Article 5 are not satisfied or waived in accordance with the terms hereof, the Administrative Agent shall return such funds (in like funds as received from such Lender) to such Lender, without interest.
(f)Funding Source. Nothing herein shall be deemed to obligate any Lender to obtain the funds for any Loan in any particular place or manner or to constitute a representation by any Lender that it has obtained or will obtain the funds for any Loan in any particular place or manner.
(g)Insufficient Payment. Subject to the provisions of Article 8, whenever any payment received by the Administrative Agent under this Credit Agreement or any of the other Loan Documents is insufficient to pay in full all amounts due and payable to the Credit Parties under or in respect of this Credit Agreement and the other Loan Documents on any date, such payment shall be distributed by the Administrative Agent and applied by the Administrative Agent (i) first, towards payment of all fees and expenses due to the Administrative Agent under the Loan Documents, (ii) second, towards payment of all expenses then due hereunder, ratably among the parties entitled thereto in accordance herewith, (iii) third, towards payment of interest, fees and commissions then due hereunder, ratably among the parties entitled thereto in accordance with the amounts of interest, fees and commissions then due to such parties, and (iv) fourth, towards payment of principal of Loans and unreimbursed L/C Borrowings then due hereunder, ratably among the parties entitled thereto in accordance with the amounts of principal of Loans and unreimbursed L/C Borrowings then due to such parties.
(h)Sharing of Payments by Lenders. If any Lender shall, by exercising any right of setoff or counterclaim or otherwise, obtain payment in respect of any principal of or interest on any of its Loans or other obligations hereunder resulting in such Lender receiving payment of a proportion of the aggregate amount of its Loans and accrued interest thereon or other such obligations greater than its pro rata share thereof as provided herein, then such Lender shall (x) notify the Administrative Agent of such fact, and (y) purchase (for cash at face value) participations in the Loans and such other obligations of the other Lenders, or make such other adjustments as shall be equitable, so that the benefit of all such
- 69 -


payments shall be shared by the Lenders ratably in accordance with the aggregate amount of principal of and accrued interest on their respective Loans and other amounts owing them; provided that:
(i)if any such participations are purchased and all or any portion of the payment giving rise thereto is recovered, such participations shall be rescinded and the purchase price restored to the extent of such recovery, without interest; and
(ii)the provisions of this paragraph shall not be construed to apply to (x) any payment made by the Borrower pursuant to and in accordance with the express terms of this Credit Agreement (including the application of funds arising from the existence of a Defaulting Lender), or (y) any payment obtained by a Lender as consideration for the assignment of or sale of a participation in any of its Loans or participations in L/C Disbursements to any assignee or participant.
The Borrower consents to the foregoing and agrees, to the extent it may effectively do so under Applicable Law, that any Lender acquiring a participation pursuant to the foregoing arrangements may exercise against each Loan Party rights of setoff and counterclaim with respect to such participation as fully as if such Lender were a direct creditor of each Loan Party in the amount of such participation.
Section 1.9Defaulting Lenders.
(a)Defaulting Lender Adjustments. Notwithstanding anything to the contrary contained in this Credit Agreement, if any Lender becomes a Defaulting Lender, then, until such time as such Lender is no longer a Defaulting Lender, to the extent permitted by Applicable Law:
(i)Waivers and Amendments. Such Defaulting Lender’s right to approve or disapprove any amendment, waiver or consent with respect to this Credit Agreement shall be restricted as set forth in the definition of Required Lenders.
(ii)Defaulting Lender Waterfall. Any payment of principal, interest, fees or other amounts received by the Administrative Agent for the account of such Defaulting Lender (whether voluntary or mandatory, at maturity, pursuant to Article 8 or otherwise) or received by the Administrative Agent from a Defaulting Lender pursuant to Section 10.8 shall be applied at such time or times as may be determined by the Administrative Agent as follows: first, to the payment of any amounts owing by such Defaulting Lender to the Administrative Agent hereunder; second, to the payment on a pro rata basis of any amounts owing by such Defaulting Lender to the L/C Issuer or Swingline Lender hereunder; third, to Cash Collateralize the L/C Issuer’s Fronting Exposure with respect to such Defaulting Lender in accordance with Section 2.10; fourth, as the Borrower may request (so long as no Default or Event of Default exists), to the funding of any Loan in respect of which such Defaulting Lender has failed to fund its portion thereof as required by this Credit Agreement, as determined by the Administrative Agent; fifth, if so determined by the Administrative Agent and the Borrower, to be held in a deposit account and released pro rata in order to (x) satisfy such Defaulting Lender’s potential future funding obligations with respect to Loans under this Credit Agreement and (y) Cash Collateralize the L/C Issuer’s future Fronting Exposure with respect to such Defaulting Lender with respect to future Letters of Credit issued under this Credit Agreement, in accordance with Section 2.10; sixth, to the payment of any amounts owing to the Lenders, the L/C Issuer or Swingline Lender as a result of any judgment of a court of competent jurisdiction obtained by any Lender, the L/C Issuer or Swingline Lender against such Defaulting Lender as a result of such Defaulting Lender’s breach of its obligations under this Credit Agreement; seventh, so long as no Default or Event of Default exists, to the payment of any amounts owing to the Borrower as a
- 70 -


result of any judgment of a court of competent jurisdiction obtained by the Borrower against such Defaulting Lender as a result of such Defaulting Lender’s breach of its obligations under this Credit Agreement; and eighth, to such Defaulting Lender or as otherwise directed by a court of competent jurisdiction; provided that if (x) such payment is a payment of the principal amount of any Loans or L/C Borrowings in respect of which such Defaulting Lender has not fully funded its appropriate share, and (y) such Loans were made or the related Letters of Credit were issued at a time when the conditions set forth in Section 4.2 were satisfied or waived, such payment shall be applied solely to pay the Loans of, and L/C Borrowings owed to, all Non-Defaulting Lenders on a pro rata basis prior to being applied to the payment of any Loans of, or L/C Borrowings owed to, such Defaulting Lender until such time as all Loans and funded and unfunded participations in L/C Obligations and Swingline Loans are held by the Lenders pro rata in accordance with the Commitments under the applicable Facility without giving effect to Section 2.9(a)(iv). Any payments, prepayments or other amounts paid or payable to a Defaulting Lender that are applied (or held) to pay amounts owed by a Defaulting Lender or to post Cash Collateral pursuant to this Section 2.9(a)(ii) shall be deemed paid to and redirected by such Defaulting Lender, and each Lender irrevocably consents hereto.
(iii)Certain Fees.
(A)No Defaulting Lender shall be entitled to receive any Commitment Fee for any period during which that Lender is a Defaulting Lender (and the Borrower shall not be required to pay any such fee that otherwise would have been required to have been paid to that Defaulting Lender).
(B)Each Defaulting Lender shall be entitled to receive L/C Participation Fees for any period during which that Lender is a Defaulting Lender only to the extent allocable to its Applicable Percentage of the stated amount of Letters of Credit for which it has provided Cash Collateral pursuant to Section 2.10.
(C)With respect to any L/C Participation Fees not required to be paid to any Defaulting Lender pursuant to clause (A) or (B) above, the Borrower shall (x) pay to each Non-Defaulting Lender that portion of any such fee otherwise payable to such Defaulting Lender with respect to such Defaulting Lender’s participation in L/C Obligations or Swingline Loans that has been reallocated to such Non-Defaulting Lender pursuant to clause (iv) below, (y) pay to the L/C Issuer and Swingline Lender, as applicable, the amount of any such fee otherwise payable to such Defaulting Lender to the extent allocable to the L/C Issuer’s or Swingline Lender’s Fronting Exposure to such Defaulting Lender, and (z) not be required to pay the remaining amount of any such fee.
(iv)Reallocation of Participations to Reduce Fronting Exposure. If any L/C Obligations or Swingline Loans are outstanding at the time such Lender becomes a Defaulting Lender, then all or any part of the Swingline Exposure and L/C Exposure of such Defaulting Lender shall be reallocated among the non-Defaulting Lenders in accordance with their respective Applicable Percentages (calculated without regard to such Defaulting Lender’s Revolving Commitment) but only to the extent that such reallocation does not cause the aggregate Revolving Exposure of any Non-Defaulting Lender to exceed such Non-Defaulting Lender’s Revolving Commitment. Subject to Section 10.17, no reallocation hereunder shall constitute a waiver or release of any claim of any party hereunder against a Defaulting Lender arising from that Lender having become a Defaulting Lender, including any claim of a Non-Defaulting Lender as a result of such Non-Defaulting Lender’s increased exposure following such reallocation.
- 71 -


(v)Cash Collateral, Repayment of Swingline Loans. If the reallocation described in clause (iv) above cannot, or can only partially, be effected, the Borrower shall, without prejudice to any right or remedy available to it hereunder or under law, (x) first, prepay Swingline Loans in an amount equal to the Swingline Lender’s Fronting Exposure and (y) second, Cash Collateralize the L/C Issuer’s Fronting Exposure in accordance with the procedures set forth in Section 2.10.
(b)Defaulting Lender Cure. If the Borrower, the Administrative Agent and each Swingline Lender and L/C Issuer agree in writing that a Lender is no longer a Defaulting Lender, the Administrative Agent will so notify the parties hereto, whereupon as of the effective date specified in such notice and subject to any conditions set forth therein (which may include arrangements with respect to any Cash Collateral), that Lender will, to the extent applicable, purchase at par that portion of outstanding Loans of the other Lenders or take such other actions as the Administrative Agent may determine to be necessary to cause the Loans and funded and unfunded participations in Letters of Credit and Swingline Loans to be held pro rata by the Lenders in accordance with the Commitments under the applicable Facility (without giving effect to Section 2.9(a)(iv)), whereupon such Lender will cease to be a Defaulting Lender; provided that no adjustments will be made retroactively with respect to fees accrued or payments made by or on behalf of the Borrower while that Lender was a Defaulting Lender; and provided, further, that except to the extent otherwise expressly agreed by the affected parties, no change hereunder from Defaulting Lender to Lender will constitute a waiver or release of any claim of any party hereunder arising from that Lender’s having been a Defaulting Lender.
(c)New Swingline Loans/Letters of Credit. So long as any Lender is a Defaulting Lender, (i) the Swingline Lender shall not be required to fund any Swingline Loans unless it is satisfied that it will have no Fronting Exposure after giving effect to such Swingline Loan and (ii) the L/C Issuer shall not be required to issue, extend, increase, reinstate or renew any Letter of Credit unless it is satisfied that it will have no Fronting Exposure after giving effect thereto.
Section 1.10Cash Collateral.
(a)Certain Credit Support Events. The Borrower shall provide Cash Collateral to the L/C Issuer:
(i)if the L/C Issuer has honored any full or partial drawing request under any Letter of Credit and such drawing has resulted in a L/C Borrowing, within two (2) Business Days following any request by the Administrative Agent or the L/C Issuer, in an amount not less than the Minimum Collateral Amount of such L/C Borrowing,
(ii)if, as of the Letter of Credit Expiration Date, any L/C Obligation for any reason remains outstanding, immediately (without the necessity of any request), in an amount not less than the Minimum Collateral Amount of such L/C Obligation,
(iii)if the Borrower shall be required to provide Cash Collateral pursuant to Section 8.2, immediately upon any request by the Administrative Agent or the L/C Issuer, in an amount not less than the Minimum Collateral Amount of all L/C Obligations,
(iv)if there shall exist a Defaulting Lender, within two (2) Business Days following any request by the Administrative Agent or the L/C Issuer, in an amount not less than the Minimum Collateral Amount of the Fronting Exposure of the L/C Issuer with respect to such Defaulting Lender, and
- 72 -


(v)on any date, if the L/C Obligations exceed the L/C Sublimit, within two (2) Business Days following any request by the Administrative Agent or the L/C Issuer, in an amount not less than the Minimum Collateral Amount of such excess.
(b)Grant of Security Interest. As security for the obligations to which such Cash Collateral may be applied pursuant to Section 2.10(c), (i) the Borrower (and to the extent provided by any Defaulting Lender, such Defaulting Lender) hereby grants to (and subjects to the control of) the Administrative Agent, for the benefit of the Administrative Agent, the L/C Issuer and the Lenders, and agrees to maintain, a first priority security interest in all such cash, deposit accounts and all balances therein, and in all proceeds of the foregoing, and (ii) to the extent provided by any Defaulting Lender, such Defaulting Lender hereby grants to (and subjects to the control of) the Administrative Agent, for the benefit of the Administrative Agent, the L/C Issuer and the Lenders, and agrees to maintain, a first priority security interest in all such cash, deposit accounts and all balances therein, and in all proceeds of the foregoing. Borrower shall enter into documentation reasonably satisfactory to the Administrative Agent as may be requested in connection with the above-described grant of security. If at any time the Administrative Agent determines that Cash Collateral is subject to any right or claim of any Person other than the Administrative Agent or the L/C Issuer as herein provided, or that the total amount of such Cash Collateral is less than the Minimum Collateral Amount, the Borrower will, promptly upon demand by the Administrative Agent, pay or provide to the Administrative Agent additional Cash Collateral in an amount sufficient to eliminate such deficiency. All Cash Collateral (other than credit support not constituting funds subject to deposit) shall be maintained in blocked, non-interest bearing deposit accounts at the Administrative Agent. The Borrower shall pay on demand therefor from time to time all customary account opening, activity and other administrative fees and charges in connection with the maintenance and disbursement of Cash Collateral.
(c)Application. Notwithstanding anything to the contrary contained in this Credit Agreement, Cash Collateral provided under any of this Section 2.10 or Sections 2.4, 2.7, 2.10 or 8.2 in respect of Letters of Credit shall be held and applied to the satisfaction of the specific L/C Obligations, obligations to fund participations therein (including, as to Cash Collateral provided by a Lender that is a Defaulting Lender, any interest accrued on such obligation) and other obligations for which the Cash Collateral was so provided, prior to any other application of such property as may otherwise be provided for herein.
(d)Termination of Requirement. Cash Collateral (or the appropriate portion thereof) provided to reduce Fronting Exposure or to secure other obligations shall be released promptly following (i) the elimination of the applicable Fronting Exposure or other obligations giving rise thereto (including by the termination of Defaulting Lender status of the applicable Lender (or, as appropriate, its assignee following compliance with Section 10.4(b)(vii))) or (ii) the determination by the Administrative Agent and the L/C Issuer that there exists excess Cash Collateral; provided that, subject to this Section 2.10, the Person providing Cash Collateral and the L/C Issuer may agree that Cash Collateral shall be held to support future anticipated Fronting Exposure or other obligations and provided further that to the extent that such Cash Collateral was provided by the Borrower, such Cash Collateral shall remain subject to the security interest granted pursuant to the Loan Documents.
Section 1.11Incremental Commitments.
(a)The Borrower may, from time to time, by written notice to the Administrative Agent, request Incremental Term Loan Commitments and/or additional Revolving Commitments, as applicable (collectively, “Incremental Commitments”), from one or more Lenders (in the sole discretion of such Lenders) or Eligible Assignees who will become Lenders, in an aggregate principal amount of up
- 73 -


to an amount equal to the greater of $50,000,000 and 1.00x Consolidated EBITDA; provided that at the time of the incurrence of such Incremental Commitments and immediately after giving effect thereto and to the use of the proceeds thereof (assuming the full utilization thereof), (A) no Default or Event of Default shall have occurred and be continuing or would result therefrom and (B) the Borrower shall be in compliance, on a Pro Forma Basis, with each of the Financial Covenants set forth in Sections 7.12(a) and (b); provided, further, that each such person, if not already a Lender hereunder, shall be subject to the approval of the Administrative Agent and, in connection with any additional Revolving Commitment, the L/C Issuer and the Swingline Lender (which approvals shall not be unreasonably withheld or delayed). Such notice shall set forth (i) the amount of the Incremental Term Loan Commitments or additional Revolving Commitments being requested (which shall be in minimum increments of $5,000,000 and a minimum amount of $20,000,000), (ii) the date on which such Incremental Term Loan Commitments and/or additional Revolving Commitments are requested to become effective (which shall not be less than 10 Business Days nor more than 60 calendar days after the date of such notice, unless otherwise agreed to by the Administrative Agent) and (iii) in the case of Incremental Term Loan Commitments, whether such Incremental Term Loan Commitments are to be Term Loan Commitments or commitments to make term loans with terms different from the Term Loans (“Other Term Loans”). All Incremental Term Loans shall be made in Dollars.
(b)The Borrower and each Incremental Term Lender and/or additional Revolving Lender shall execute and deliver to the Administrative Agent an Incremental Assumption Agreement and such other documentation as the Administrative Agent shall reasonably specify to evidence the Incremental Commitment of such Lender. Subject to clause (c) below, each Incremental Assumption Agreement in respect of Incremental Term Loan Commitments shall specify the terms of the Incremental Term Loans to be made thereunder. The Administrative Agent shall promptly notify each Lender as to the effectiveness of each Incremental Assumption Agreement. Each of the parties hereto hereby agrees that, upon the effectiveness of any Incremental Assumption Agreement, this Credit Agreement shall be deemed amended to the extent (but only to the extent) necessary to reflect the existence and terms of the Incremental Commitments evidenced thereby and any increase to the Applicable Margins required by the foregoing provisions of this paragraph. Any such deemed amendment may be memorialized in writing by the Administrative Agent with the Borrower’s consent (not to be unreasonably withheld or delayed) and furnished to the other parties hereto.
(c)The terms of each Incremental Term Loan and, as applicable, each additional Revolving Commitment shall be reasonably satisfactory to the Administrative Agent and in any event:
(i)shall rank pari passu in right of payment and of security with the existing Revolving Loans and the existing Term Loans;
(ii)in the case of Incremental Term Loans, shall not mature earlier than the Latest Maturity Date of the Term Loans outstanding at the time of incurrence of such Incremental Term Loans;
(iii)in the case of Incremental Term Loans, shall have a Weighted Average Life to Maturity not shorter than the remaining Weighted Average Life to Maturity of then existing Term Loans;
(iv)in the case of Incremental Term Loans, subject to clauses (ii) and (iii) above, shall have amortization determined by the Borrower and the applicable Incremental Term Lenders;
- 74 -


(v)in the case of Incremental Term Loans, subject to clause (x) below, shall have an Applicable Margin determined by the Borrower and the applicable Incremental Term Lenders;
(vi)in the case of Incremental Term Loans, may participate on a pro rata basis or less than pro rata basis (but not on a greater than pro rata basis) in any voluntary or mandatory prepayments of initial Term Loans hereunder, as specified in the applicable Incremental Assumption Agreement;
(vii)without the prior written consent of any Loan Party or Credit Party, if the Effective Yield on any secured Other Term Loans (as determined by the Administrative Agent) exceeds by more than 50 basis points (the amount of such excess above 50 basis points being referred to herein as the “Yield Differential”) the Effective Yield (as determined by the Administrative Agent) on any then outstanding Class of Term Loans, then the Applicable Margin for each such Class of Term Loans shall automatically be increased by the Yield Differential, effective upon the making of such Other Term Loans; and
(viii)all material terms of any additional Revolving Commitments and Revolving Loans under such additional Revolving Commitments shall be identical to the existing Revolving Commitments and Revolving Loans.
(d)No Incremental Term Loan Commitments or additional Revolving Commitments shall become effective under this Section 2.11 unless, on the date of such effectiveness, (i) the conditions set forth in paragraphs (a) and (b) of Section 4.2 shall be satisfied as if it was a borrowing date and the Administrative Agent shall have received a certificate to that effect dated such date and executed by a Responsible Officer of the Borrower; and (ii) the Administrative Agent shall have received (with sufficient copies for each of the Incremental Term Lenders and/or additional Revolving Lenders) closing certificates, opinions of counsel and other customary documentation requested by the Administrative Agent.
(e)Each of the parties hereto hereby agrees that the Administrative Agent may take any and all action as may be reasonably necessary to ensure that all Incremental Term Loans (other than Other Term Loans), when originally made, are included in each Borrowing of outstanding Term Loans on a pro rata basis and that following the establishment of any additional Revolving Commitments, the outstanding Revolving Loans are held by the Revolving Lenders in accordance with their new Applicable Percentages. This may be accomplished at the discretion of the Administrative Agent by requiring each outstanding SOFR Borrowing of the relevant Class to be converted into an ABR Borrowing of such Class on the date of each Incremental Term Loan or additional Revolving Commitment, or by allocating a portion of each Incremental Term Loan to each outstanding SOFR Term Borrowing of the same Class on a pro rata basis, even though as a result thereof such Incremental Term Loan may effectively have a shorter Interest Period than the Term Loans included in the Borrowing of which they are a part (and notwithstanding any other provision of this Credit Agreement that would prohibit such an initial Interest Period), or requiring a prepayment and reborrowing of Revolving Loans.  Any conversion or prepayment made pursuant to the preceding sentence shall be subject to Section 3.5 (it being understood that, the Administrative Agent shall consult with the Borrower regarding the foregoing and, to the extent practicable, will attempt to pursue options that minimize breakage costs). In addition, to the extent any Incremental Term Loans are not Other Term Loans, the scheduled amortization payments under Section 2.6(b) required to be made after the making of such Incremental Term Loans shall be ratably increased by the aggregate principal amount of such Incremental Term Loans.
- 75 -


Article 3

INTEREST, FEES, YIELD PROTECTION, ETC.
Section 1.1Interest.
(a)Interest Rate Generally. All ABR Loans (other than Swingline Loans, which shall bear interest in accordance with the second following sentence) shall bear interest at a rate per annum equal to the Alternate Base Rate as in effect from time to time plus the Applicable Margin. All SOFR Loans shall bear interest at a rate per annum equal to Term SOFR for the Interest Period in effect for such Loans plus the Applicable Margin. Each Swingline Loan shall bear interest at a rate per annum equal to the Daily SOFR Rate as in effect from time to time plus the Applicable Margin.
(b)Default Rate.
(i)Notwithstanding the foregoing, if an Event of Default has occurred and is continuing then, any principal of or interest on any Loan, any reimbursement obligation in respect of any L/C Disbursement or any fee or other amount payable by the Borrower hereunder is not paid when due, whether at stated maturity, upon acceleration or otherwise, such overdue amount shall bear interest, after as well as before judgment, at a rate per annum equal to the Default Rate to the fullest extent permitted by Applicable Law.
(ii)Notwithstanding the foregoing, if an Event of Default has occurred and is continuing then, so long as such Event of Default is continuing, all outstanding principal of each Loan and all Unreimbursed Amounts in respect of L/C Disbursements (including L/C Borrowings) shall, without duplication of amounts payable under the preceding sentence, bear interest, after as well as before judgment, at a rate per annum equal to the Default Rate to the fullest extent permitted by Applicable Law.
(iii)Accrued and unpaid interest on past due amounts (including interest on past due interest) shall be due and payable upon demand.
(c)Interest Payment Dates. Accrued interest on each Loan shall be payable in arrears on each Interest Payment Date for such Loan and at such other times as may be specified herein, provided that (i) interest accrued pursuant to paragraph (b) of this Section shall be payable on demand, (ii) in the event of any repayment or prepayment of any Loan, accrued interest on the principal amount repaid or prepaid shall be payable on the date of such repayment or prepayment and (iii) in the event of any conversion of any SOFR Loan prior to the end of the current Interest Period therefor, accrued interest on such Loan shall be payable on the effective date of such conversion.
(d)Computation of Interest. All interest hereunder shall be computed on the basis of a year of 360 days (or in the case of interest computed by reference to the Alternate Base Rate at times when the Alternate Base Rate is based on the Prime Rate, such interest shall be computed on the basis of a year of 365 days (or 366 days in a leap year)), and in each case shall be payable for the actual number of days elapsed (including the first day but excluding the last day). All interest hereunder on any Loan shall be computed on a daily basis based upon the outstanding principal amount of such Loan as of the applicable date of determination. The applicable Alternate Base Rate, Daily SOFR Rate or Term SOFR shall be determined by the Administrative Agent, and such determination shall be conclusive absent clearly manifest error.
- 76 -


(e)Term SOFR Conforming Changes. In connection with the use or administration of Term SOFR, the Administrative Agent will have the right to make Conforming Changes from time to time and, notwithstanding anything to the contrary herein or in any other Loan Document, any amendments implementing such Conforming Changes will become effective without any further action or consent of any other party to this Credit Agreement or any other Loan Document. The Administrative Agent will promptly notify the Borrower and the Lenders of the effectiveness of any Conforming Changes in connection with the use or administration of Term SOFR.
Section 1.2Fees.
(a)Commitment Fee. The Borrower agrees to pay to the Administrative Agent for the account of each Revolving Lender, a commitment fee (the “Commitment Fee”), which shall accrue at a rate per annum equal to the Applicable Margin on the average daily unused amount of the Revolving Commitment of such Revolving Lender during the period from and including the date on which this Credit Agreement becomes effective pursuant to Section 10.6(a) to but excluding the date on which such Revolving Commitment terminates. For purposes of computing Commitment Fees, the Revolving Commitment of any Revolving Lender shall be deemed to be used to the extent of the aggregate principal amount at such time of its outstanding Revolving Loans and such Lender’s L/C Exposure. Accrued Commitment Fees shall be payable in arrears on the last day of March, June, September and December of each year, each date on which the Revolving Commitments are permanently reduced and on the date on which the Revolving Commitments terminate, commencing on the first such date to occur after the Closing Date. All Commitment Fees shall be computed on the basis of a year of 360 days and shall be payable for the actual number of days elapsed (including the first day but excluding the last day).
(b)L/C Fees. The Borrower agrees to pay (i) to the Administrative Agent for the account of the Revolving Lenders a fee (the “L/C Participation Fee”) in Dollars for each Letter of Credit, at a rate per annum equal to the Applicable Margin multiplied by the average daily amount available to be drawn under such Letter of Credit, and (ii) to the L/C Issuer for its own account a fee (the “L/C Fronting Fee”), which shall accrue at the rate or rates per annum separately agreed upon between the Borrower and the L/C Issuer on the average daily amount of the L/C Obligations (excluding any portion thereof attributable to unreimbursed L/C Disbursements) during the period from and including the Closing Date to but excluding the later of the date of termination of the Revolving Commitments and the date on which there ceases to be any L/C Obligations, as well as the L/C Issuer’s standard fees with respect to the issuance, amendment, renewal or extension of any Letter of Credit or processing of drawings thereunder. Accrued L/C Participation Fees and L/C Fronting Fees shall be payable in arrears on the last day of March, June, September and December of each year, commencing on the first such date to occur after the Closing Date; provided that all such fees shall be payable on the date on which the Revolving Commitments terminate and any such fees accruing after the date on which the Revolving Commitments terminate shall be payable on demand. Any other fees payable to the L/C Issuer pursuant to this paragraph shall be payable within 10 days after demand. All L/C Participation Fees and L/C Fronting Fees shall be computed on the basis of a year of 360 days and shall be payable for the actual number of days elapsed (including the first day but excluding the last day). Notwithstanding the foregoing, if an Event of Default has occurred and is continuing then, so long as such Event of Default is continuing, L/C Participation Fees and L/C Fronting Fees, as applicable, shall be calculated at a rate per annum equal to the Default Rate.
(c)Other Fees. The Borrower agrees to pay to each Credit Party, for its own account, fees and other amounts payable in the amounts and at the times separately agreed upon between the Borrower and such Credit Party.
- 77 -


(d)Payment of Fees Generally. All fees and other amounts payable hereunder shall be paid on the dates due, in immediately available funds. Fees and other amounts paid shall not be refundable under any circumstances.
Section 1.3Inability to Determine Rates. Subject to Section 3.8, if, on or prior to the first day of any Interest Period for any SOFR Loan or prior to setting the daily interest rate for a Daily SOFR Loan:
(a)the Administrative Agent determines (which determination shall be conclusive and binding absent manifest error) that “Term SOFR” cannot be determined pursuant to the definition thereof, or
(b)(i) the Required Lenders determine that for any reason in connection with any request for a SOFR Loan or a conversion thereto or a continuation thereof that Term SOFR for any requested Interest Period with respect to a proposed SOFR Loan does not adequately and fairly reflect the cost to such Lenders of funding such Loan, and the Required Lenders have provided notice of such determination to the Administrative Agent, or (ii) the Swingline Lender determines that the Daily SOFR Rate does not adequately and fairly reflect the cost of making or maintaining Swingline Loans, in each case,
the Administrative Agent will promptly so notify the Borrower and each Lender.
Upon notice thereof by the Administrative Agent to the Borrower, any obligation of the Lenders to make or maintain SOFR Loans or Daily SOFR Loans, and any right of the Borrower to continue SOFR Loans or to convert ABR Loans to SOFR Loans or Daily SOFR Loans shall be suspended (to the extent of the affected Interest Periods) until the Administrative Agent (with respect to clause (b) above, at the instruction of the Required Lenders) revokes such notice. Upon the Borrower’s receipt of such notice, (i) the Borrower may revoke any pending request for a borrowing of, conversion to or continuation of SOFR Loans (to the extent of the affected Interest Periods) or Daily SOFR Loans or, failing that, the Borrower will be deemed to have converted any such request into a request for a Borrowing of or conversion to ABR Loans in the amount specified therein, (ii) any outstanding affected SOFR Loans will be deemed to have been converted into ABR Loans at the end of the applicable Interest Period and (iii) in the case of clause(b)(ii) above, notwithstanding anything to the contrary in Section 3.1(a), each Swingline Loan shall bear interest at the Alternate Base Rate plus the Applicable Margin. Upon any such conversion, the Borrower shall also pay accrued interest on the amount so converted, together with any additional amounts required pursuant to Section 3.5. Subject to Section 3.8, if the Administrative Agent determines (which determination shall be conclusive and binding absent manifest error) that “Term SOFR” cannot be determined pursuant to the definition thereof on any given day, the interest rate on ABR Loans shall be determined by the Administrative Agent without reference to clause (c) of the definition of “Alternate Base Rate” until the Administrative Agent revokes such determination.
Section 1.4Increased Costs; Illegality.
(a)Increased Costs Generally. If any Change in Law shall:
(i)impose, modify or deem applicable any reserve (including pursuant to regulations issued from time to time by the Federal Reserve Board for determining any maximum reserve requirement (including any emergency, special, supplemental or other marginal reserve requirement)), special deposit, liquidity, compulsory loan, insurance charge or similar requirement against assets of, deposits with or for the account of, or credit extended or participated in by, any Lender or any L/C Issuer;
- 78 -


(ii)subject any Recipient to any Taxes (other than (A) Indemnified Taxes, (B) Taxes described in clauses (b) through (d) of the definition of Excluded Taxes and (C) Connection Income Taxes) on its loans, loan principal, letters of credit, commitments, or other obligations, or its deposits, reserves, other liabilities or capital attributable thereto; or
(iii)impose on any Lender or any L/C Issuer any other condition, cost or expense (other than Taxes) affecting this Credit Agreement or Loans made by such Lender or any Letter of Credit or participation in any such Loan or Letter of Credit;
and the result of any of the foregoing shall be to increase the cost to such Lender, such L/C Issuer or such other Recipient of making, converting to, continuing or maintaining any Loan or of maintaining its obligation to make any such Loan, or to increase the cost to such Lender, any L/C Issuer or such other Recipient of participating in, issuing or maintaining any Letter of Credit (or of maintaining its obligation to participate in or to issue any Letter of Credit), or to reduce the amount of any sum received or receivable by such Lender, L/C Issuer or other Recipient hereunder (whether of principal, interest or any other amount) then, upon written request of such Lender, L/C Issuer or other Recipient, the Borrower will pay to such Lender, L/C Issuer or other Recipient, as the case may be, such additional amount or amounts as will compensate such Lender, L/C Issuer or other Recipient, as the case may be, for such additional costs incurred or reduction suffered.
(b)Capital Requirements. If any Lender or the L/C Issuer determines that any Change in Law affecting such Lender or the L/C Issuer or any Applicable Lending Office of such Lender or such Lender’s or the L/C Issuer’s holding company, if any, regarding capital or liquidity requirements, has or would have the effect of reducing the rate of return on such Lender’s or the L/C Issuer’s capital or on the capital of such Lender’s or the L/C Issuer’s holding company, if any, as a consequence of this Credit Agreement, the Commitments of such Lender or the Loans made by, or participations in Letters of Credit or Swingline Loans held by, such Lender, or the Letters of Credit issued by the L/C Issuer, to a level below that which such Lender or the L/C Issuer or such Lender’s or the L/C Issuer’s holding company could have achieved but for such Change in Law (taking into consideration such Lender’s or the L/C Issuer’s policies and the policies of such Lender’s or the L/C Issuer’s holding company with respect to capital adequacy and liquidity), then from time to time the Borrower will pay to such Lender or the L/C Issuer, as the case may be, such additional amount or amounts as will compensate such Lender or the L/C Issuer or such Lender’s or the L/C Issuer’s holding company for any such reduction suffered.
(c)Certificates for Reimbursement. A certificate of a Lender or the L/C Issuer setting forth the amount or amounts necessary to compensate such Lender or the L/C Issuer or its holding company, as the case may be, as specified in paragraph (a) or (b) of this Section and delivered to the Borrower, shall be conclusive absent manifest error. The Borrower shall pay such Lender or the L/C Issuer, as the case may be, the amount shown as due on any such certificate within 10 days after receipt thereof.
(d)Delay in Requests. Failure or delay on the part of any Lender or the L/C Issuer to demand compensation pursuant to this Section shall not constitute a waiver of such Lender’s or the L/C Issuer’s right to demand such compensation; provided that the Borrower shall not be required to compensate a Lender or the L/C Issuer pursuant to this Section for any increased costs incurred or reductions suffered more than nine months prior to the date that such Lender or the L/C Issuer, as the case may be, notifies the Borrower of the Change in Law giving rise to such increased costs or reductions, and of such Lender’s or the L/C Issuer’s intention to claim compensation therefor (except that, if the Change in Law giving rise to such increased costs or reductions is retroactive, then the nine-month period referred to above shall be extended to include the period of retroactive effect thereof).
- 79 -


(e)Illegality. If any Lender determines that any Law has made it unlawful, or that any Governmental Authority has asserted that it is unlawful, for any Lender or its Applicable Lending Office to make, maintain or fund Loans whose interest is determined by reference to SOFR or Term SOFR, or to determine or charge interest rates based upon SOFR or Term SOFR, then, upon notice thereof by such Lender to the Borrower (through the Administrative Agent), (a) any obligation of the Lenders to make or maintain SOFR Loans or Daily SOFR Loans, and any right of the Borrower to continue SOFR Loans or to convert ABR Loans to SOFR Loans, shall be suspended, and (b) the interest rate on which ABR Loans shall, if necessary to avoid such illegality, be determined by the Administrative Agent without reference to clause (c) of the definition of “Alternate Base Rate”, in each case until such Lender notifies the Administrative Agent and the Borrower that the circumstances giving rise to such determination no longer exist. Upon receipt of such notice, (i) the Borrower shall, if necessary to avoid such illegality, upon demand from any Lender (with a copy to the Administrative Agent), prepay or, if applicable, convert all SOFR Loans and Daily SOFR Loans to ABR Loans (the interest rate on which ABR Loans of such Lender shall, if necessary to avoid such illegality, be determined by the Administrative Agent without reference to clause (c) of the definition of “Alternate Base Rate”), on the last day of the Interest Period therefor, in the case of SOFR Loans, and immediately, in the case of Daily SOFR Loans, if all affected Lenders may lawfully continue to maintain such Loans to such day, or immediately, if any Lender may not lawfully continue to maintain such Loans to such day, and (ii) if necessary to avoid such illegality, the Administrative Agent shall during the period of such suspension compute the Alternate Base Rate without reference to clause (c) of the definition of “Alternate Base Rate” in each case until the Administrative Agent is advised in writing by each affected Lender that it is no longer illegal for such Lender to determine or charge interest rates based upon SOFR or Term SOFR. Upon any such prepayment or conversion, the Borrower shall also pay accrued interest on the amount so prepaid or converted, together with any additional amounts required pursuant to Section 3.5.
Section 1.5Compensation for Losses. In the event of (a) the payment or prepayment of any principal of any SOFR Loan other than on the last day of the Interest Period applicable thereto whether voluntary, mandatory, automatic, by reason of acceleration (including as a result of an Event of Default), (b) the conversion of any SOFR Loan other than on the last day of the Interest Period applicable thereto (including as a result of an Event of Default), (c) the failure to borrow, convert, continue or prepay any SOFR Loan on the date specified in any notice delivered pursuant hereto (regardless of whether such notice may be revoked under Section 2.7(a) and is revoked in accordance therewith), or (d) the assignment of any SOFR Loan other than on the last day of the Interest Period applicable thereto or maturity date applicable thereto as a result of a request by the Borrower pursuant to Section 3.7(b), then, in any such event, the Borrower shall compensate each Lender for any loss, cost and expense attributable to such event, including any loss, cost or expense arising from the liquidation or redeployment of funds. A certificate of any Lender setting forth any amount or amounts that such Lender is entitled to receive pursuant to this Section shall be delivered to the Borrower and shall be conclusive absent manifest error. The Borrower shall pay such Lender the amount shown as due on any such certificate within 10 days after receipt thereof.
Section 1.6Taxes.
(a)Defined Terms. For purposes of this Section 3.6, the term “Lender” includes the L/C Issuer and the term “Applicable Law” includes FATCA.
(b)Payments Free of Taxes. Any and all payments by or on account of any obligation of any Loan Party under any Loan Document shall be made without deduction or withholding for any Taxes, except as required by Applicable Law. If any Applicable Law (as determined in the good faith discretion of an applicable Withholding Agent) requires the deduction or withholding of any Tax
- 80 -


from any such payment by a Withholding Agent, then the applicable Withholding Agent shall be entitled to make such deduction or withholding and shall timely pay the full amount deducted or withheld to the relevant Governmental Authority in accordance with Applicable Law and, if such Tax is an Indemnified Tax, then the sum payable by the applicable Loan Party shall be increased as necessary so that after such deduction or withholding has been made (including such deductions and withholdings applicable to additional sums payable under this Section) the applicable Recipient receives an amount equal to the sum it would have received had no such deduction or withholding been made.
(c)Payment of Other Taxes by the Loan Parties. Each of the Loan Parties shall timely pay to the relevant Governmental Authority in accordance with Applicable Law, or at the option of the Administrative Agent timely reimburse it for the payment of, any Other Taxes.
(d)Indemnification by the Loan Parties. Each of the Loan Parties shall jointly and severally indemnify each Recipient, within 10 days after demand therefor, for the full amount of any Indemnified Taxes (including Indemnified Taxes imposed or asserted on or attributable to amounts payable under this Section) payable or paid by such Recipient or required to be withheld or deducted from a payment to such Recipient and any reasonable expenses arising therefrom or with respect thereto, whether or not such Indemnified Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority. A certificate as to the amount of such payment or liability delivered to the Borrower by a Lender (with a copy to the Administrative Agent), or by the Administrative Agent on its own behalf or on behalf of a Lender, shall be conclusive absent manifest error.
(e)Indemnification by the Lenders. Each Lender shall severally indemnify the Administrative Agent, within 10 days after demand therefor, for (i) any Indemnified Taxes attributable to such Lender (but only to the extent that any Loan Party has not already indemnified the Administrative Agent for such Indemnified Taxes and without limiting the obligation of the Loan Parties to do so), (ii) any Taxes attributable to such Lender’s failure to comply with the provisions of Section 10.4(d) relating to the maintenance of a Participant Register and (iii) any Excluded Taxes attributable to such Lender, in each case, that are payable or paid by the Administrative Agent in connection with any Loan Document, and any reasonable expenses arising therefrom or with respect thereto, whether or not such Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority. A certificate as to the amount of such payment or liability delivered to any Lender by the Administrative Agent shall be conclusive absent manifest error. Each Lender hereby authorizes the Administrative Agent to set off and apply any and all amounts at any time owing to such Lender under any Loan Document or otherwise payable by the Administrative Agent to the Lender from any other source against any amount due to the Administrative Agent under this paragraph (e).
(f)Evidence of Payments. As soon as practicable after any payment of Taxes by any Loan Party to a Governmental Authority pursuant to this Section 3.6, such Loan Party shall deliver to the Administrative Agent the original or a certified copy of a receipt issued by such Governmental Authority evidencing such payment, a copy of the return reporting such payment or other evidence of such payment reasonably satisfactory to the Administrative Agent.
(g)Status of Lenders. (i) Any Lender that is entitled to an exemption from or reduction of withholding Tax with respect to payments made under any Loan Document shall deliver to the Borrower and the Administrative Agent, at the time or times reasonably requested by the Borrower or the Administrative Agent, such properly completed and executed documentation reasonably requested by the Borrower or the Administrative Agent as will permit such payments to be made without withholding or at a reduced rate of withholding. In addition, any Lender, if reasonably requested by the Borrower or the Administrative Agent, shall deliver such other documentation prescribed by Applicable Law or
- 81 -


reasonably requested by the Borrower or the Administrative Agent as will enable the Borrower or the Administrative Agent to determine whether or not such Lender is subject to backup withholding or information reporting requirements. Notwithstanding anything to the contrary in the preceding two sentences, the completion, execution and submission of such documentation (other than such documentation set forth in Section 3.6(g)(ii)(A), (ii)(B) and (ii)(D) below) shall not be required if in the Lender’s reasonable judgment such completion, execution or submission would subject such Lender to any material unreimbursed cost or expense or would materially prejudice the legal or commercial position of such Lender.
(i)Without limiting the generality of the foregoing,
(A)any Lender that is a U.S. Person shall deliver to the Borrower and the Administrative Agent on or about the date on which such Lender becomes a Lender under this Credit Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Administrative Agent), executed copies of IRS Form W-9 certifying that such Lender is exempt from U.S. federal backup withholding tax;
(B)any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to the Borrower and the Administrative Agent (in such number of copies as shall be requested by the recipient) on or about the date on which such Foreign Lender becomes a Lender under this Credit Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Administrative Agent), whichever of the following is applicable:
(1)in the case of a Foreign Lender claiming the benefits of an income tax treaty to which the United States is a party (A) with respect to payments of interest under any Loan Document, executed copies of IRS Form W-8BEN or IRS Form W-8BEN-E, as applicable, establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the “interest” article of such tax treaty and (B) with respect to any other applicable payments under any Loan Document, IRS Form W-8BEN or IRS Form W-8BEN-E, as applicable, establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the “business profits” or “other income” article of such tax treaty;
(2)executed copies of IRS Form W-8ECI;
(3)in the case of a Foreign Lender claiming the benefits of the exemption for portfolio interest under Section 881(c) of the Code, (A) a certificate substantially in the form of Exhibit F-1 to the effect that such Foreign Lender is not a “bank” within the meaning of Section 881(c)(3)(A) of the Code, a “10 percent shareholder” of the Borrower within the meaning of Section 881(c)(3)(B) of the Code, or a “controlled foreign corporation” related to any Loan Party described in Section 881(c)(3)(C) of the Code (a “U.S. Tax Compliance Certificate”) and (B) executed copies of IRS Form W-8BEN or IRS Form W-8BEN-E, as applicable; or
(4)to the extent a Foreign Lender is not the beneficial owner, executed copies of IRS Form W-8IMY, accompanied by IRS Form W-8ECI, IRS Form W-8BEN or IRS Form W-8BEN-E, as applicable, a U.S. Tax
- 82 -


Compliance Certificate substantially in the form of Exhibit F-2 or Exhibit F-3, IRS Form W-9, and/or other certification documents from each beneficial owner, as applicable; provided that if the Foreign Lender is a partnership and one or more direct or indirect partners of such Foreign Lender are claiming the portfolio interest exemption, such Foreign Lender may provide a U.S. Tax Compliance Certificate substantially in the form of Exhibit F-4 on behalf of each such direct and indirect partner;
(C)any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to the Borrower and the Administrative Agent (in such number of copies as shall be requested by the recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Credit Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Administrative Agent), executed copies of any other form prescribed by Applicable Law as a basis for claiming exemption from or a reduction in U.S. federal withholding Tax, duly completed, together with such supplementary documentation as may be prescribed by Applicable Law to permit the Borrower or the Administrative Agent to determine the withholding or deduction required to be made; and
(D)if a payment made to a Lender under any Loan Document would be subject to U.S. federal withholding Tax imposed by FATCA if such Lender were to fail to comply with the applicable reporting requirements of FATCA (including those contained in Section 1471(b) or 1472(b) of the Code, as applicable), such Lender shall deliver to the Borrower and the Administrative Agent at the time or times prescribed by law and at such time or times reasonably requested by the Borrower or the Administrative Agent such documentation prescribed by Applicable Law (including as prescribed by Section 1471(b)(3)(C)(i) of the Code) and such additional documentation reasonably requested by the Borrower or the Administrative Agent as may be necessary for the Borrower and the Administrative Agent to comply with their obligations under FATCA and to determine that such Lender has complied with such Lender’s obligations under FATCA or to determine the amount, if any, to deduct and withhold from such payment. Solely for purposes of this clause (D), “FATCA” shall include any amendments made to FATCA after the date of this Credit Agreement.
Each Lender agrees that if any form or certification it previously delivered expires or becomes obsolete or inaccurate in any respect, it shall update such form or certification or promptly notify the Borrower and the Administrative Agent in writing of its legal inability to do so.
(h)Treatment of Certain Refunds. If any party determines, in its sole discretion exercised in good faith, that it has received a refund of any Taxes as to which it has been indemnified pursuant to this Section 3.6 (including by the payment of additional amounts pursuant to this Section 3.6), it shall pay to the indemnifying party an amount equal to such refund (but only to the extent of indemnity payments made under this Section with respect to the Taxes giving rise to such refund), net of all out-of-pocket expenses (including Taxes) of such indemnified party and without interest (other than any interest paid by the relevant Governmental Authority with respect to such refund). Such indemnifying party, upon the request of such indemnified party, shall repay to such indemnified party the amount paid over pursuant to this paragraph (h) (plus any penalties, interest or other charges imposed by the relevant Governmental Authority) in the event that such indemnified party is required to repay such refund to such Governmental Authority. Notwithstanding anything to the contrary in this paragraph (h), in no event will the indemnified party be required to pay any amount to an indemnifying party pursuant to this paragraph
- 83 -


(h) the payment of which would place the indemnified party in a less favorable net after-Tax position than the indemnified party would have been in if the Tax subject to indemnification and giving rise to such refund had not been deducted, withheld or otherwise imposed and the indemnification payments or additional amounts with respect to such Tax had never been paid.
(i)Survival. Each party’s obligations under this Section 3.6 shall survive the resignation or replacement of the Administrative Agent or any assignment of rights by, or the replacement of, a Lender, the expiration or cancellation of all Letters of Credit and the Termination Date.
(j)Confidentiality. Nothing contained in Section 3.6(h) shall require any Credit Party or any other indemnified party to make available any of its Tax returns (or any other information that it deems to be confidential or proprietary) to the indemnifying party or any other Person.
Section 1.7Mitigation Obligations; Replacement of Lenders.
(a)Designation of a Different Lending Office. If any Lender requests compensation under Section 3.4, or requires the Borrower to pay any Indemnified Taxes or additional amounts to any Lender or any Governmental Authority for the account of any Lender pursuant to Section 3.6, then such Lender shall (at the request of the Borrower) use reasonable efforts to designate a different Applicable Lending Office for funding or booking its Loans hereunder or to assign its rights and obligations hereunder to another of its offices, branches or affiliates, if, in the judgment of such Lender, such designation or assignment (i) would eliminate or reduce amounts payable pursuant to Section 3.4 or Section 3.6, as the case may be, in the future, and (ii) would not subject such Lender to any unreimbursed cost or expense and would not otherwise be disadvantageous to such Lender. The Borrower hereby agrees to pay all reasonable costs and expenses incurred by any Lender in connection with any such designation or assignment.
(b)Replacement of Lenders. If any Lender requests compensation under Section 3.4 or if the Borrower is required to pay any Indemnified Taxes or additional amounts to any Lender or any Governmental Authority for the account of any Lender pursuant to Section 3.6 and, in each case, such Lender has declined or is unable to designate a different Applicable Lending Office in accordance with Section 3.7(a), or if any Lender is a Defaulting Lender or a Non-Consenting Lender, then the Borrower may, at its sole expense and effort, upon notice to such Lender and the Administrative Agent, require such Lender to assign and delegate, without recourse (in accordance with and subject to the restrictions contained in, and consents required by, Section 10.4), all of its interests, rights (other than its existing rights to payments pursuant to Section 3.4 or Section 3.6) and obligations under this Credit Agreement and the related Loan Documents to an Eligible Assignee that shall assume such obligations (which assignee may be another Lender, if a Lender accepts such assignment); provided that:
(i)unless waived by the Administrative Agent in its sole discretion, the Borrower shall have paid to the Administrative Agent the assignment fee (if any) specified in Section 10.4;
(ii)such Lender shall have received payment of an amount equal to the outstanding principal of its Loans and participations in L/C Obligations, accrued interest thereon, accrued fees and all other amounts payable to it hereunder and under the other Loan Documents (including any amounts under Section 3.5) from the assignee (to the extent of such outstanding principal and accrued interest and fees) or the Borrower (in the case of all other amounts);
- 84 -


(iii)in the case of any such assignment resulting from a claim for compensation under Section 3.4 or payments required to be made pursuant to Section 3.6, such assignment will result in a reduction in such compensation or payments thereafter;
(iv)such assignment does not conflict with Applicable Law; and
(v)in the case of any assignment resulting from a Lender becoming a Non-Consenting Lender, the applicable assignee shall have consented (or is willing to consent upon becoming a Lender) to the applicable amendment, waiver or consent.
A Lender shall not be required to make any such assignment or delegation if, prior thereto, as a result of a waiver by such Lender or otherwise, the circumstances entitling the Borrower to require such assignment and delegation cease to apply.
Section 1.8Benchmark Replacement Setting.
(a)Benchmark Replacement. Notwithstanding anything to the contrary herein or in any other Loan Document (and each Swap Agreement shall be deemed not to be a “Loan Document” for purposes of this Section 3.8), if a Benchmark Transition Event and its related Benchmark Replacement Date have occurred prior to any setting of the then-current Benchmark, then (x) if a Benchmark Replacement is determined in accordance with clause (a) of the definition of “Benchmark Replacement” for such Benchmark Replacement Date, such Benchmark Replacement will replace such Benchmark for all purposes hereunder and under any Loan Document in respect of such Benchmark setting and subsequent Benchmark settings without any amendment to, or further action or consent (subject to clause (y) below) of any other party to, this Credit Agreement or any other Loan Document and (y) if a Benchmark Replacement is determined in accordance with clause (b) of the definition of “Benchmark Replacement” for such Benchmark Replacement Date, such Benchmark Replacement will replace such Benchmark for all purposes hereunder and under any Loan Document in respect of any Benchmark setting at or after 5:00 p.m. (New York City time) on the fifth (5th) Business Day after the date notice of such Benchmark Replacement is provided to the Lenders without any amendment to, or further action or consent of any other party to, this Credit Agreement or any other Loan Document so long as the Administrative Agent has not received, by such time, written notice of objection to such Benchmark Replacement from Lenders comprising the Required Lenders. If the Benchmark Replacement is Daily Simple SOFR, all interest payments will be payable on a monthly basis.
(b)Benchmark Replacement Conforming Changes. In connection with the use, administration, adoption or implementation of a Benchmark Replacement, the Administrative Agent will have the right to make Conforming Changes from time to time and, notwithstanding anything to the contrary herein or in any other Loan Document, any amendments implementing such Conforming Changes will become effective without any further action or consent of any other party to this Credit Agreement or any other Loan Document.
(c)Notices; Standards for Decisions and Determinations. The Administrative Agent will promptly notify the Borrower and the Lenders of (i) the implementation of any Benchmark Replacement and (ii) the effectiveness of any Conforming Changes in connection with the use, administration, adoption or implementation of a Benchmark Replacement. The Administrative Agent will notify the Borrower of (x) the removal or reinstatement of any tenor of a Benchmark pursuant to Section 3.8(d) and (y) the commencement of any Benchmark Unavailability Period. Any determination, decision or election that may be made by the Administrative Agent or, if applicable, any Lender (or group of Lenders) pursuant to this Section 3.8, including any determination with respect to a tenor, rate or adjustment or of the occurrence or non-occurrence of an event, circumstance or date and any decision to
- 85 -


take or refrain from taking any action or selection, will be conclusive and binding absent manifest error and may be made in its or their sole discretion and without consent from any other party to this Credit Agreement or any other Loan Document, except, in each case, as expressly required pursuant to this Section 3.8.
(d)Unavailability of Tenor of Benchmark. Notwithstanding anything to the contrary herein or in any other Loan Document, at any time (including in connection with the implementation of a Benchmark Replacement), (i) if the then-current Benchmark is a term rate (including the Term SOFR Reference Rate) and either (A) any tenor for such Benchmark is not displayed on a screen or other information service that publishes such rate from time to time as selected by the Administrative Agent in its reasonable discretion or (B) the administrator of such Benchmark or the regulatory supervisor for the administrator of such Benchmark has provided a public statement or publication of information announcing that any tenor for such Benchmark is not or will not be representative, then the Administrative Agent may modify the definition of “Interest Period” (or any similar or analogous definition) for any Benchmark settings at or after such time to remove such unavailable or non-representative tenor and (ii) if a tenor that was removed pursuant to clause (i) above either (A) is subsequently displayed on a screen or information service for a Benchmark (including a Benchmark Replacement) or (B) is not, or is no longer, subject to an announcement that it is not or will not be representative for a Benchmark (including a Benchmark Replacement), then the Administrative Agent may modify the definition of “Interest Period” (or any similar or analogous definition) for all Benchmark settings at or after such time to reinstate such previously removed tenor.
(e)Benchmark Unavailability Period. Upon the Borrower’s receipt of notice of the commencement of a Benchmark Unavailability Period, the Borrower may revoke any pending request for a Borrowing of, conversion to or continuation of SOFR Loans to be made, converted or continued during any Benchmark Unavailability Period and, failing that, (i) the Borrower will be deemed to have converted any such request into a request for a Borrowing of or conversion to ABR Loans and (ii) any outstanding affected SOFR Loans will be deemed to have been converted into ABR Loans immediately. During a Benchmark Unavailability Period or at any time that a tenor for the then-current Benchmark is not an Available Tenor, the component of the Alternate Base Rate based upon the then-current Benchmark or such tenor for such Benchmark, as applicable, will not be used in any determination of the Alternate Base Rate.
Article 4

CONDITIONS PRECEDENT TO CREDIT EXTENSIONS
Section 1.1Conditions to Initial Credit Extensions. The effectiveness of this Credit Agreement and the obligation of each Lender and the L/C Issuer to make its initial Credit Extension hereunder on the Closing Date is subject to satisfaction or waiver of the following conditions precedent:
(a)Credit Agreement. The Administrative Agent (or its counsel) shall have received a counterpart of this Credit Agreement (which may include facsimile transmission or electronic mail transmission of a signed signature page of this Credit Agreement) that, when taken together, bear the signatures of the Borrower and each Lender.
(b)Notes. The Administrative Agent shall have received a Note for each Lender that shall have requested one, signed on behalf of the Borrower.
(c)Legal Opinion. The Administrative Agent shall have received a favorable written opinion (addressed to the Credit Parties and dated the Closing Date) from Greenberg Traurig,
- 86 -


P.A., special counsel to the Loan Parties, in form, scope and substance reasonably satisfactory to the Administrative Agent. The Borrower hereby requests such counsel to deliver such opinions.
(d)Officers’ Closing Certificate. The Administrative Agent shall have received a certificate of the President or a Vice President and the Secretary or Assistant Secretary of each Loan Party, executed by a Responsible Officer of such Loan Party and dated as of the Closing Date, which certificate shall (A) certify that attached thereto is a true and complete copy of the resolutions of written consents of its board of directors, members or other governing body, authorizing the execution, delivery and performance of the Loan Documents to which it is a party, and that such resolutions or written consents have not been modified, rescinded or amended and are in full force and effect, (B) identify by name and title and bear the signatures of the Responsible Officer or authorized signatory of such Loan Party authorized to sign the Loan Documents to which it is a party, (C) certify that attached thereto is a true and complete copy of the Organizational Documents of each Loan Party (which, with respect to such Loan Party’s certificate or articles of incorporation or certificate or articles of formation, are certified by the relevant authority of the jurisdiction of organization of such Loan Party), including, without limitation, all amendments thereto through the date hereof and (D) certify that attached hereto is a true and complete copy of a certificate of good standing, existence or its equivalent with respect to each Loan Party (which are certified by the relevant authority of the jurisdiction of organization of such Loan Party).
(e)Fees and Expenses. Substantially contemporaneously with the making of the Loans to be made on the Closing Date, the Borrower shall have paid all fees and expenses that under the terms hereof or of the Engagement Letter are due and payable on or prior to the Closing Date, as well as the reasonable fees, disbursements and other charges of counsel to the Administrative Agent and the Lead Arranger in connection with the Transactions to the extent invoiced on or prior to the Closing Date.
(f)Collateral and Guarantee Requirement.
(i)The Collateral Documents set forth in Schedule 4.1(f) shall have been duly executed and/or delivered by each Loan Party that is to be a party thereto and shall be in full force and effect. The Administrative Agent on behalf of the Secured Parties shall have a security interest in the Collateral of the type and the priority described in each such Collateral Document; and
(ii)The Administrative Agent shall have received a Perfection Certificate with respect to each Loan Party dated the Closing Date and duly executed by a Responsible Officer of the Borrower and shall have received the results of a search of the Uniform Commercial Code filings (or equivalent filings) made with respect to the Loan Parties in the states (or other jurisdictions) of formation of such persons, in each case as indicated on such Perfection Certificate, together with copies of the financing statements (or similar documents) disclosed by such search, and accompanied by evidence reasonably satisfactory to the Administrative Agent that the Liens indicated in any such financing statement (or similar document) would be permitted under Section 7.2 or have been or will be contemporaneously released or terminated.
(g)Guarantee Agreement. The Guarantee Agreement shall have been duly executed and delivered by each Loan Party that is to be a party thereto and shall be in full force and effect.
(h)Solvency Certificate. The Administrative Agent shall have received a Solvency Certificate attesting to the Solvency of each Loan Party and its Subsidiaries (taken as a whole) on the Closing Date immediately before and after giving effect to the Transactions, from the Financial Officer of the Borrower.
- 87 -


(i)Committed Loan Notice; Letter of Credit Application. The Administrative Agent shall have received a completed Committed Loan Notice and/or Letter of Credit Application, duly executed by a Responsible Officer of the Borrower with respect to any Credit Extensions to be made on the Closing Date.
(j)Insurance. The Administrative Agent shall have received evidence that all insurance required to be maintained pursuant to the Loan Documents has been obtained and is in effect and that the Administrative Agent has been named as lender’s loss payee and/or additional insured, as applicable, under each insurance policy with respect thereto and all endorsements thereto have been delivered, in each case, in accordance with the terms of the Loan Documents, and the Administrative Agent is otherwise satisfied with all of the insurance arrangements of the Loan Parties and their Subsidiaries.
(k)Pro-Forma Compliance Certificate. The Administrative Agent shall have received a certificate, dated the Closing Date and signed by a Financial Officer of the Borrower, setting forth reasonably detailed calculations demonstrating compliance with each of the Financial Covenants set forth in Sections 7.12(a) and (b) on a Pro Forma Basis immediately after giving effect to the Transactions occurring on the Closing Date.
(l)USA PATRIOT Act; KYC. To the extent requested, at least five (5) days prior to the Closing Date, each Lender shall have received:
(i)any and all documentation and other information requested by such Lender in connection with applicable “know your customer” and anti-money-laundering rules and regulations, including the USA PATRIOT Act; and
(ii)to the extent the Borrower constitutes a “legal entity customer” under the Beneficial Ownership Regulation, a completed Beneficial Ownership Certification in relation to the Borrower.
(m)Financial Statements and Projections. The Administrative Agent shall have received (i) the Audited Financial Statements, (ii) the Unaudited Financial Statements and (iii) the financial projections for the Borrower and its Subsidiaries through the Fiscal Year ending December 31, 2028.
(n)Legal Impediments. No law or regulation shall be applicable that restrains, prevents or imposes materially adverse conditions upon the Credit Facilities.
(o)No Material Adverse Effect. There shall not have occurred a Material Adverse Effect or any event or circumstance that could reasonably be expected to result in a Material Adverse Effect and the Administrative Agent shall have received a certificate of a Responsible Officer of the Borrower to the foregoing effect.
(p)Responsible Officer Certificate. The Administrative Agent shall have received a certificate, dated the Closing Date and signed by a Responsible Officer of the Borrower confirming that the conditions set forth in paragraph (o) of this Section 4.1 and clauses (a) and (b) of Section 4.2 shall be satisfied.
(q)Approvals. All Governmental Approvals and consents and approvals of, or notices to, any other Person (including the holders of any Equity Interests issued by any Loan Party) required in connection with the execution, delivery and performance of the Loan Documents and the
- 88 -


consummation of the transactions contemplated hereby shall have been obtained and be in full force and effect.
(r)Existing Credit Agreement Refinancing. The Existing Credit Agreement Refinancing shall have been consummated substantially contemporaneously with the funding of the Loans to be made on the Closing Date. The Existing Credit Agreement (and each related loan document) and all commitments thereunder shall have been terminated, all obligations thereunder shall have been paid in full (other than obligations that are contingent in nature or unliquidated at such time, which under the terms of the Existing Credit Agreement or related loan documents expressly survive such payment and termination) and all documentation necessary to release or terminate, as applicable, security interests and guarantees in respect thereof shall have been delivered to the Administrative Agent or its counsel.
For purposes of determining whether the Closing Date has occurred, each Lender that has executed this Credit Agreement shall be deemed to have consented to, approved or accepted, or to be satisfied with, each document or other matter required hereunder to be consented to or approved by or acceptable or satisfactory to the Lead Arranger, Administrative Agent or such Lender, as the case may be, unless such Lender has notified the Administrative Agent of any disagreement prior to the initial Credit Extensions hereunder.
Section 1.2Conditions to All Credit Extensions. The obligation of each Lender or the L/C Issuer, as the case may be, to honor any Request for Credit Extension (other than (x) as may be limited in respect of certain conditions precedent as set forth in Section 1.11 with respect to any extension of Credit in connection with a Limited Condition Acquisition and (y) a Committed Loan Notice requesting only a conversion of Loans to the other Type, or a continuation of SOFR Loans) is subject to the satisfaction of the conditions in Section 4.1 and the following additional conditions precedent:
(a)Each of the representations and warranties of the Loan Parties set forth in the Loan Documents shall be true and correct in all material respects, in each case on and as of such date as if made on and as of such date, provided that to the extent that such representations and warranties specifically refer to an earlier date, they shall be true and correct in all respects as of such earlier date; provided further that any representation and warranty that is qualified as to “materiality”, “Material Adverse Effect” or similar language shall be true and correct (after giving effect to any qualification therein) in all respects on such respective dates.
(b)No Default or Event of Default shall exist, or would result from such proposed Credit Extension or from the application of the proceeds therefrom.
(c)The Administrative Agent and, if applicable, the L/C Issuer or the Swingline Lender shall have received a Request for Credit Extension in accordance with the requirements hereof.
(d)In the case of a Borrowing under an Incremental Facility, each of the applicable requirements set forth in Section 2.11 shall have been satisfied.
Each Request for Credit Extension (other than a Committed Loan Notice requesting only a conversion of Loans to the other Type or a continuation of SOFR Loans) submitted by the Borrower shall be deemed to be a representation and warranty that the applicable conditions specified in Sections 4.2(a) and, if applicable, (b) have been satisfied on and as of the date of the applicable Credit Extension.
Article 5

REPRESENTATIONS AND WARRANTIES
- 89 -


The Borrower represent and warrant to the Administrative Agent and the Lenders that:
Section 1.1Existence, Qualification and Power; Compliance with Laws. Each Loan Party and each of its Subsidiaries (a) is duly incorporated, organized or formed, and validly existing and, where applicable, in good standing under the laws of the jurisdiction of its incorporation or organization, (b) has all requisite power and authority to (i) own or lease its assets and carry on its business as now conducted and (ii) execute, deliver and perform its obligations under the Loan Documents to which it is a party, (c) is duly qualified and, where applicable, in good standing under the laws of each jurisdiction where its ownership, lease or operation of properties or the conduct of its business requires such qualification, and (d) has all requisite governmental licenses, authorizations, consents and approvals and is in compliance with all applicable statutes and regulations imposed by any Governmental Authority, to operate its business as currently conducted; except in each case referred to in clause (c) or (d), to the extent that failure to do so could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. The Borrower and its Subsidiaries are in compliance with all laws, rules, regulations and orders of any Governmental Authority applicable to it or its property and maintains all permits and licenses necessary to conduct its business, except where the failure to do so, individually or in the aggregate, could not reasonably be expected to result in a Material Adverse Effect.
Section 1.2Authorization; No Contravention. The execution, delivery and performance by each Loan Party of each Loan Document to which such Loan Party is a party, and the consummation of the Transactions, are within such Loan Party’s corporate, limited liability company or other analogous powers, have been duly authorized by all necessary corporate, limited liability company or other analogous action, and do not and will not (a) contravene the terms of any of such Person’s Organizational Documents, (b) conflict with or result in any breach or contravention of, or the creation of any Lien under (other than under the Loan Documents), or require any payment to be made under (i) any Contractual Obligation to which such Person is a party or affecting such Person or the properties of such Person or any of its Subsidiaries or (ii) any order, injunction, writ or decree of any Governmental Authority or any arbitral award to which such Person or its property is subject; or (c) violate any law; except with respect to any conflict, breach or contravention or payment (but not creation of Liens) referred to in clause (b)(i), to the extent that such conflict, breach, contravention or payment could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.
Section 1.3Governmental Authorization; Other Consents. No approval, consent, exemption, authorization, or other action by, or notice to, or filing with, any Governmental Authority or any other Person is necessary or required in connection with (a) the execution, delivery or performance by, or enforcement against, any Loan Party of any Loan Document to which it is a party, or for the consummation of the Transactions, (b) the grant by any Loan Party of the Liens granted by it pursuant to the Collateral Documents, (c) the perfection or maintenance of the Liens created under the Collateral Documents (including the priority thereof) or (d) the exercise by the Administrative Agent or any Lender of its rights under the Loan Documents or the remedies in respect of the Collateral pursuant to the Loan Documents, except for (i) filings and recordings necessary to satisfy the Collateral and Guarantee Requirement, and (ii) the approvals, consents, exemptions, authorizations, actions, notices and filings which have been duly obtained, taken, given or made and are in full force and effect.
Section 1.4Binding Effect. Each Loan Document has been duly executed and delivered by each Loan Party that is party thereto and constitutes a legal, valid and binding obligation of each such Loan Party, enforceable in accordance with its terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium or other similar laws affecting creditors’ rights generally and subject to general principles of equity, regardless of whether considered in a proceeding in equity or at law.
- 90 -


Section 1.5Financial Statements; No Material Adverse Effect.
(a)The Audited Financial Statements and Unaudited Financial Statements:
(i)fairly present the financial condition of the Borrower and its Subsidiaries, as applicable, as of the dates thereof and its results of operations for the period covered thereby in accordance with GAAP consistently applied throughout the periods covered thereby, subject, in the case of the Unaudited Financial Statements, to normal year-end audit adjustments and the absence of footnotes; and
(ii)show all material Indebtedness and other liabilities, direct or contingent, of the Borrower and its Subsidiaries, as applicable, as of the date thereof, including liabilities for Taxes, material commitments and contingent obligations.
(b)Since December 31, 2022, there has been no event or circumstance, either individually or in the aggregate, that has had or would reasonably be expected to have a Material Adverse Effect.
Section 1.6Litigation. There are no actions, suits or proceedings by or before any arbitrator or Governmental Authority pending against any Loan Party or, to the knowledge of the Borrower, threatened in writing against or affecting the Loan Parties or any of their Subsidiaries (a) as to which there is a reasonable possibility of an adverse determination and that, if adversely determined, could reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect (other than the Disclosed Matters) or (b) that involve or affect, or that purport to or could reasonably be expected to involve or affect, any Loan Document or the Transactions.
Section 1.7Environmental Matters.
(a)Except for the Disclosed Matters and except for Environmental Claims that have been fully resolved in compliance with Environmental Laws with no remaining obligations or conditions:
(i)except where any of the following would not reasonably be expected to result in a Material Adverse Effect, each Loan Party and its Subsidiaries possess all Environmental Permits required under applicable Environmental Law to conduct their respective businesses and are, and within applicable statutes of limitation, have been, in material compliance with the terms of such Environmental Permits. No Loan Party or any of its Subsidiaries has received written notice that any Environmental Permits possessed by any of them will be revoked, suspended or will not be renewed;
(ii)[reserved];
(iii)to each of the Loan Parties’ and their Subsidiaries’ knowledge, each of the Loan Parties and their Subsidiaries are currently, and within applicable statutes of limitation, have been, in material compliance with all applicable Environmental Law such that noncompliance would not be reasonably expected to result in a Material Adverse Effect;
(iv)no Loan Party nor any of its Subsidiaries has received (A) notice of any Environmental Claim, or (B) notice of actual or potential liability by a third-party under any Environmental Law including any Environmental Liability that such Loan Party or Subsidiary may have retained or assumed either contractually or by operation of law or of any Environmental Claim, in either case with respect to clauses (A) or (B) that reasonably could be
- 91 -


expected to result in a Material Adverse Effect. No Loan Party or any of its Subsidiaries has knowledge of any circumstances that reasonably could be expected to result in an Environmental Liability that could be reasonably expected to result in a Material Adverse Effect;
(v)as of the Closing Date: (A) no property or facility currently, or to the knowledge of each Loan Party, formerly owned, operated or leased by any Loan Party or any of its current or former Subsidiaries, and (B) no property at which Hazardous Materials generated, owned or controlled by any Loan Party, any of its present or former Subsidiaries or any predecessor in interest have been stored, treated or disposed of, have been identified by a Governmental Authority as recommended for or requiring or potentially requiring any Loan Party or any of its current or former Subsidiaries to perform environmental assessment and/or response actions under Environmental Law that would reasonably be expected to result in a Material Adverse Effect;
(vi)to each Loan Party’s and its Subsidiaries’ knowledge, (A) there has been no disposal, spill, discharge or Release of any Hazardous Material generated, used, owned, stored or controlled by any Loan Party, any of its Subsidiaries, on, at or under any property currently or formerly owned, leased or operated by any Loan Party, any of its current or former Subsidiaries, (B) there are no Hazardous Materials located in, at, on or under such facility or property, or at any other location, in either case (A) or (B), that reasonably could be expected to require investigation, removal, remedial or corrective measures by any Loan Party or any of its Subsidiaries or that reasonably could result in a Material Adverse Effect, and (C) neither the Loan Parties nor any of their Subsidiaries has retained or assumed any liability contractually or by operation of law with regard to the generation, treatment, storage or disposal of Hazardous Materials or compliance with Environmental Law that could reasonably be expected to result in a Material Adverse Effect;
(vii)to each Loan Party’s and its Subsidiaries’ knowledge, (A) there are no underground or aboveground storage tank or other underground storage receptacle or related piping, or any impoundment or other disposal area in each case containing Hazardous Materials located on any facility or property currently, or formerly owned, leased or operated by any Loan Party or any of its Subsidiaries, and (B) no asbestos or polychlorinated biphenyls have been used or disposed of by any Loan Party or their Subsidiaries at any such facility or property, in either case (A) or (B) except in material compliance with applicable Environmental Laws and as would not result in Environmental Liability that could reasonably be expected to result in a Material Adverse Effect.
(viii)no Lien has been recorded against any properties, assets or facilities currently owned, leased or operated by any Loan Party or any of its Subsidiaries under any Environmental Law.
(b)The Loan Parties and their Subsidiaries have provided to the Administrative Agent and its authorized representatives all material records and files, including all material assessments, reports, studies, analyses, audits, tests and data, in their possession or under their control concerning any Environmental Claim, the existence of Hazardous Materials or any other environmental concern at properties, assets or facilities currently or formerly owned, operated or leased by any Loan Party or any of their present or former Subsidiaries or predecessor in interest, or concerning compliance by any Loan Party or any such Subsidiary with, or liability under any Environmental Law.
- 92 -


Section 1.8Ownership of Properties; Liens; Intellectual Property. Each Loan Party and its Subsidiaries (a) has good title to, or valid leasehold interests in, all its real and personal property material to its business, except for minor defects in title that do not interfere with its ability to conduct its business as currently conducted or to utilize such properties for their intended purposes, (b) owns, or is entitled to use, all trademarks, service marks, trade names, domain names, copyrights, patents, patent rights, technology, software, know-how database rights, design rights and other intellectual property rights necessary to the conduct of its business, and the use thereof by the Loan Parties and their respective Subsidiaries does not infringe upon or otherwise violate the rights of any other Person, except for any such infringements that, individually or in the aggregate, could not reasonably be expected to result in a Material Adverse Effect, (c) has complied in all material respects with all obligations under all material leases to which it is a party and all such leases are in full force and effect and (d) enjoys peaceful and undisturbed possession under all such material leases. No claim has been asserted and is pending by any Person challenging or questioning any Loan Party’s use of any Intellectual Property or the validity or effectiveness of any Loan Party’s Intellectual Property unless such claim would not reasonably be expected to have a Material Adverse Effect. No holding, decision or judgment has been rendered by any Governmental Authority and no action or proceeding is pending or threatened in writing, which would limit, cancel or question the validity of, or the rights of any Loan Party in, any Intellectual Property or Intellectual Property license that would reasonably be expected to have a Material Adverse Effect.
Section 1.9Casualty, Etc. Neither the businesses nor the properties of any Loan Party or any of its Subsidiaries are affected by any fire, explosion, accident, strike, lockout or other labor dispute, drought, storm, hail, earthquake, embargo, act of God or of the public enemy or other casualty (whether or not covered by insurance) that, either individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect.
Section 1.10Investment Company Status, Etc. No Loan Party or any of its Subsidiaries is (a) an “investment company” as defined in, or subject to regulation under, the Investment Company Act of 1940 or (b) otherwise subject to any other regulatory scheme limiting its ability to incur debt.
Section 1.11Taxes. Each Loan Party and its Subsidiaries has timely filed or caused to be filed all federal, provincial, state, municipal, foreign and other Tax returns and reports required to be filed, and have timely paid all federal, provincial, state, municipal, foreign and Taxes levied or imposed upon them or their properties, income or assets otherwise due and payable, except (a) those which are being Contested in Good Faith and (b) failures to file or pay as could not, either individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect. There are no Tax audits, deficiencies, assessments or other claims with respect to any Loan Party or any of its Subsidiaries that could, either individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect.
Section 1.12ERISA.
(a)Each Benefit Plan sponsored by any Loan Party or any of their respective ERISA Affiliates is in compliance in all material respects with the applicable provisions of ERISA and the Code and the regulations and published interpretations thereunder. No ERISA Event has occurred or is reasonably expected to occur that, when taken together with all other such ERISA Events for which liability is reasonably expected to occur, would reasonably be expected to result in a Material Adverse Effect. No event described in Section 4062(e) of ERISA has occurred and is continuing with respect to any Pension Plan. The present value of all accumulated benefit obligations under each Pension Plan (based on the assumptions used for purposes of Statement of Financial Accounting Standards No. 87) did not, as of the date of the most recent financial statements reflecting such amounts, exceed the fair market value of the assets of such Pension Plan.
- 93 -


(b)Each Pension Plan that is intended to qualify under Section 401(a) of the Code is subject to a favorable determination letter from the IRS or an application for such a letter is currently being processed by the IRS with respect thereto and, to the knowledge of the Loan Parties, nothing has occurred which would prevent, or cause the loss of, such qualification. Each Loan Party and ERISA Affiliate has made all required contributions to each Pension Plan subject to Section 412 of the Code, and no application for a funding waiver pursuant to Section 412 of the Code has been made with respect to any Pension Plan.
(c)There are no pending or, to the knowledge of the Loan Parties, threatened claims, actions, or lawsuits, or action by any Governmental Authority, with respect to any Pension Plan that would reasonably be expected to have a Material Adverse Effect. There has been no violation of the fiduciary responsibility rules of ERISA with respect to any Pension Plan that has resulted in or would reasonably be expected to have a Material Adverse Effect.
(d)No Loan Party or ERISA Affiliate (i) has incurred, or reasonably expects to incur, any liability under Title IV of ERISA with respect to any Pension Plan (other than premiums due and not delinquent under Section 4007 of ERISA), (ii) has incurred, or reasonably expects to incur, any liability (and no event has occurred which, with the giving of notice under Section 4219 of ERISA, would result in such liability) under Section 4201 of ERISA with respect to a Multiemployer Plan, and (iii) has engaged in a transaction that could be subject to Section 4069 or Section 4212(c) of ERISA.
(e)No such Pension Plan or trust created thereunder, or party in interest (as defined in Section 3(14) of ERISA), or any fiduciary (as defined in Section 3(21) of ERISA), has engaged in a “prohibited transaction” (as such term is defined in Section 406 of ERISA or Section 4975 of the Code) which would subject such Pension Plan or any other plan of any Loan Party or any of its ERISA Affiliates, any trust created thereunder, or any such party in interest or fiduciary, or any party dealing with any such Pension Plan or any such trust, to any material penalty or tax on “prohibited transactions” imposed by Section 502 of ERISA or Section 4975 of the Code.
(f)No Loan Party nor any ERISA Affiliate sponsors, maintains, or contributes to, or has any obligation under, any Foreign Plan.
Section 1.13Subsidiaries; Equity Interests. As of the Closing Date, no Loan Party has any direct or indirect Subsidiaries or investments (other than Cash Equivalents) in, or joint ventures or partnerships with, any Person, except as disclosed in Schedule 5.13. Such Schedule sets forth (a) the name and jurisdiction of organization or incorporation of each Subsidiary and identifies each Subsidiary that is an Excluded Subsidiary, Subsidiary Guarantor and/or a Material Foreign Subsidiary on the Closing Date, (b) the ownership interest of each Loan Party and tier respective Subsidiaries in each of their respective Subsidiaries, including the percentage of such ownership and (c) identifies each Person the Equity Interests of which are required to be pledged on the Closing Date pursuant to the Collateral and Guarantee Requirement. Except as set forth on Schedule 5.13, neither any Loan Party nor any of its Subsidiaries has issued any Disqualified Equity Interests and there are no outstanding options or warrants to purchase Equity Interests of any Loan Party or any of its Subsidiaries of any class or kind, and there are no agreements, voting trusts or understandings with respect thereto or affecting in any manner the sale, pledge, assignment or other disposition thereof, including any right of first refusal, option, redemption, call or other rights with respect thereto, whether similar or dissimilar to any of the foregoing. All of the issued and outstanding Equity Interests owned by any Loan Party in its Subsidiaries have been duly authorized and issued and are fully paid and non-assessable and are free and clear of all Liens other than Liens in favor of the Administrative Agent under the Collateral Documents.
- 94 -


Section 1.14Insurance. Schedule 5.14 sets forth a description of all insurance maintained by or on behalf of the Loan Parties and their Subsidiaries on the Closing Date (including names of carriers, policy number, expiration dates, insurance types and coverage amounts). As of the Closing Date, all premiums in respect of such insurance that are due and payable have been paid.
Section 1.15Federal Reserve Regulations, Etc. Neither any Loan Party nor any of its Subsidiaries is engaged principally, or as one of their important activities, in the business of extending credit for the purpose of buying or carrying Margin Stock. Immediately before and after giving effect to the making of each Loan and the issuance of each Letter of Credit, Margin Stock will constitute less than 25% of each Loan Party’s assets as determined in accordance with Regulation U. No part of the proceeds of any Loan or any Letter of Credit will be used, whether directly or indirectly, and whether immediately, incidentally or ultimately, to purchase, acquire or carry any Margin Stock or for any purpose that entails a violation of, or that is inconsistent with, the provisions of the regulations of the Federal Reserve Board, including Regulation T, U or X.
Section 1.16Collateral Documents. The Security Agreement, upon execution and delivery thereof by the parties thereto, will create in favor of the Administrative Agent, for the ratable benefit of the Secured Parties, a legal, valid and enforceable security interest in the Collateral (as defined in the Security Agreement) and the proceeds thereof and (i) when the Pledged Equity Interests (other than uncertificated Equity Interests) and the Pledged Debt Securities (as each such term is defined in the Security Agreement) are delivered to the Administrative Agent together with the proper endorsements, the Lien created under Security Agreement shall constitute a fully perfected first priority Lien on, and security interest in, all right, title and interest of the Loan Parties in such Pledged Equity Interests and Pledged Debt Securities to the extent that the laws of the United States or any state, commonwealth or other political subdivision thereof govern the creation and perfection of any such security interest, in each case prior and superior in right to any other Lien or right of any other person and (ii) when financing statements in appropriate form are filed in the offices specified on Schedule 5.16(a) and, with respect to Collateral consisting of Intellectual Property registered or owned under the applicable copyright, trademark, and/or patent laws of the United States, when the Security Agreement (or Copyright Security Agreements, Patent Security Agreements and/or Trademark Security Agreements, as applicable) are filed with the United States Patent and Trademark Office or the United States Copyright Office, as applicable, and in each case, all applicable filing fees have been paid, the Lien created under the Security Agreement will constitute a fully perfected Lien on, and security interest in, all right, title and interest of the Loan Parties in the Collateral to the extent such security interest may be perfected by the filing of a UCC financing statement and, with respect to Intellectual Property, the filing of such Copyright Security Agreements, Patent Security Agreements and/or Trademark Security Agreements with the United States Patent and Trademark Office or the United States Copyright Office, as applicable, in each case prior and superior in right to any other Lien or right of any other person, other than Liens expressly permitted by Section 7.2 which by operation of law or contract have priority over the Liens securing the Secured Obligations.
Section 1.17Solvency. Immediately before and after giving effect to the consummation of each Transaction, each of the Loan Parties and its Subsidiaries are Solvent.
Section 1.18Anti-Corruption Laws; Sanctions; Anti-Terrorism Laws.
(a)No Loan Party, its Subsidiaries and, to the knowledge of such Loan Party or Subsidiary, their respective officers and employees and their directors and agents, are in compliance with Anti-Corruption Laws and applicable Sanctions. Neither any Loan Party, any of its Subsidiaries or, to the knowledge of such Loan Party or Subsidiary, any of their respective directors, officers or employees is a
- 95 -


Sanctioned Person. Each Loan Party and each of its Subsidiaries has implemented and maintains in effect policies and procedures reasonably designed to ensure compliance by the Loan Party, its Subsidiaries and their respective directors, officers, employees and agents with Anti-Corruption Laws and all applicable Sanctions.
(b)No Loan or Letter of Credit, use of the proceeds of any Loan or Letter of Credit or other transactions contemplated hereby will violate Anti-Corruption Laws or applicable Sanctions. No part of the proceeds of the Loans or the Letters of Credit will be used, directly or, to the knowledge of the Borrower, indirectly, for any payments to any governmental official or employee, political party, official of a political party, candidate for political office, or anyone else acting in an official capacity, in order to obtain, retain or direct business or obtain any improper advantage, in violation of Anti-Corruption Laws.
(c)Neither the making of the Loans hereunder nor the use of the proceeds thereof will violate the any regulations passed under the USA PATRIOT Act or will violate the Trading with the Enemy Act, the International Emergency Economic Powers Act, or any regulations passed thereunder, including the foreign assets control regulations of the United States Treasury Department (31 C.F.R., Subtitle B, Chapter V) or any enabling legislation or executive order relating thereto or successor statute thereto (together with Sanctions, “Anti-Terrorism Laws”). Each Loan Party and each of its Subsidiaries are in compliance with applicable Anti-Terrorism Laws.
Section 1.19Regulatory Matters.
(a)Except as set forth on Schedule 5.19, each Loan Party is, and for the last six (6) years, has been, conducting its business in compliance in all material respects with all Healthcare Laws applicable to the Loan Party, its property, any Product or other asset of such Loan Party.
(b)Each Loan Party and its Subsidiaries is in compliance in all material respects with Applicable Law governing the reporting and recordkeeping of Product modifications, adverse event reporting, recordkeeping for each Product, reporting of corrections and removals, and all other manufacturing and release documents and records are true in all material respects, and no Loan Party or any of its Subsidiaries has received or been subject to any written or oral communications from the FDA or any other Governmental Authority asserting that any Loan Party or any of its Subsidiaries was not in compliance with Applicable Law or any Permit which would reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect.
(c)Each Loan Party and its Subsidiaries owns, free and clear of all Liens, except Liens permitted under this Credit Agreement, all Permits that are necessary (i) for the research, development and commercialization of the Products, including without limitation, all Permits necessary in connection with testing, manufacturing, marketing or selling any of the Products, and (ii) to carry on the business of the Loan Parties and their Subsidiaries. Each Permit is valid and in full force and effect and the Loan Parties and their Subsidiaries are in material compliance with all of the terms and conditions of such Permits and has made all declarations and filings with the applicable Governmental Authorities reasonably necessary to the conduct of the business of such Loan Party or Subsidiary. None of the Loan Parties or their Subsidiaries has received any notice from any Governmental Authority that any Permit has been or is being revoked, withdrawn, suspended or challenged or that such Governmental Authority is conducting an investigation or review thereof, has issued an order or recommendation stating that the development, testing and/or manufacturing of such Product should cease or that any Product should be withdrawn from the market which would reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect.
- 96 -


(d)No Loan Party nor any of its Subsidiaries has made any material untrue statement of fact and no Loan Party or any of its Subsidiaries or any of their respective agents or representatives has made any fraudulent statement to the FDA or any other Governmental Authority, and no Loan Party nor any of its Subsidiaries has failed to disclose any material fact otherwise required to be disclosed to the FDA or any other Governmental Authority.
(e)Each Product (whether manufactured by the Borrower or any of its Subsidiaries, any of their respective Affiliates or a third party manufacturer under the direction of the Borrower or any of its Subsidiaries) has been, and currently is, being researched, developed, designed, investigated, manufactured, made, assembled, stored, packaged, labeled, marketed and distributed by the Borrower and its Subsidiaries or third parties on their behalf, in compliance with all Applicable Laws, including, without limitation, all Healthcare Laws and all required Permits.
(f)There have been no adverse clinical test results, clinical holds, serious adverse health events or injuries, or enforcement actions by any Governmental Authority with respect to any of the Products, and there have been no recalls or voluntary market withdrawal from any market, except as set forth on Schedule 5.19. No investigational Product or product candidate that has not yet received the requisite FDA marketing approval or clearance has been, or is being, marketed, sold, commercialized, or promoted in the United States.
(g)To the knowledge of the Loan Parties, none of the clinical investigators who is providing or has provided services in connection with any clinical trial sponsored by any Loan Party or any of their Subsidiaries has been or is disqualified, debarred, or otherwise sanctioned by the FDA, the Department of Health and Human Services, or any Governmental Authority and, to the knowledge of the Loan Parties, no such disqualification, or other sanction of any such clinical investigator is pending or threatened. None of the Loan Parties or any of their Subsidiaries has received from the FDA or other applicable Governmental Authority any notices or correspondence requiring or threatening the termination, suspension, material modification or clinical hold of any studies, tests or clinical trials with respect to or in connection with the Products.
(h)Except as set forth on Schedule 5.19 (other than routine surveillance audits and inspections), no investigation by any Governmental Authority with respect to the Borrower or any of its Subsidiaries is pending or, to the knowledge, threatened in writing. None of the Borrower or any of its Subsidiaries has received any written or oral communications from any Governmental Authority of any noncompliance with any Applicable Laws or any written or oral communication from any Governmental Authority of any material issues, problems, or concerns regarding the quality or performance of the Products which would reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect. No Loan Party nor any of their Subsidiaries has been served with or received any search warrant, subpoena, or civil investigative demand from any Governmental Authority regarding any actual or alleged violation of Healthcare Laws, except as set forth on Schedule 5.19.
(i)Except as set forth on Schedule 5.19, no Loan Party nor any of its Subsidiaries has been the subject of any “for cause” inspection, investigation or audit by any Governmental Authority in connection with any improper activity. No Loan Party, nor any of its Subsidiaries, nor any officer, director, employee, or any other personnel of any Loan Party or Subsidiary is a party to a corporate integrity agreement or has any reporting obligations pursuant to a settlement agreement, plan of correction, deferred prosecution agreement, consent decree or other remedial measure entered into with any Governmental Authority.
- 97 -


(j)No Loan Party or any of its Subsidiaries, and to the knowledge of such Loan Party or Subsidiary, nor any officer, director, employee, or contractor of any Loan Party or Subsidiary (except with respect to the actions of former employees and officers of any Loan Party or Subsidiary which are public knowledge or have otherwise been disclosed in writing to the Administrative Agent and the Lenders), in such capacity on behalf of any such Person, directly or indirectly, has: (i) offered or paid or solicited or received any remuneration, in cash or in kind, or made any financial arrangements, in material violation of any applicable Healthcare Law; (ii) given any gift or gratuitous payment of any kind, nature or description (whether in money, property or services) in material violation of any applicable Healthcare Law; (iii) established or maintained any unrecorded fund or asset for any purpose or made any misleading, false or artificial entries on any of its books or records in material violation of applicable Healthcare Laws; or (iv) knowingly or willfully offered, paid, solicited or received any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind (A) in return for referring an individual to a person for the furnishing or arranging of any item or service for which payment may be made in whole or in part by any “federal health care program” (as defined in 42 U.S.C. § 1320a-7b(f)), commercial health insurer, or self-pay patient, or (B) in return for purchasing, leasing, ordering or arranging for or recommending purchasing, leasing or ordering any good, facility, service or item for which payment may be made in whole or in part by any “federal health care program” (as defined in 42 U.S.C. § 1320a-7b(f)), commercial health insurer, or self-pay patient, or otherwise made any payment to any Person with the intention that any part of such payment would be in material violation of any applicable Healthcare Law. To the knowledge of any Loan Party, no Person has filed, or has threatened in writing to file, against any Loan Party or any Subsidiary, an action under any federal or state whistleblower statute related to alleged noncompliance with applicable Healthcare Laws, including under the False Claims Act of 1863 (31 U.S.C. § 3729 et seq.).
(k)Except where any of the following would not be reasonably expected, individually or in the aggregate, to result in a Material Adverse Effect, no Loan Party or any of its Subsidiaries, nor any officer, director, employee, contractor, or Person with a “direct or indirect ownership interest” (as that phrase is defined in 42 C.F.R. § 420.201) in any Loan Party or Subsidiary, is: (i) excluded, debarred, disqualified, or suspended from any “federal health care program” (as such term is defined in 42 U.S.C. § 1320a-7b(f)) or any other medical reimbursement program; (ii) “suspended” or “debarred” from selling products to the U.S. government or its agencies pursuant to the Federal Acquisition Regulation, relating to debarment and suspension applicable to federal government agencies generally (42 C.F.R. Subpart 9.4); (iii) listed on the General Services Administration list of excluded parties; or (iv) made a party to any other action by any Governmental Authority that may prohibit it from selling products or providing services to any governmental or other purchaser pursuant to any Applicable Law. To the knowledge of any Loan Party, no such debarment, disqualification, suspension, exclusion, or prohibition is threatened or pending.
(l)Each of the Loan Parties and their Subsidiaries maintains and adheres to, in all material respects, compliance policies and procedures that are designed to promote compliance with and to detect, prevent, and address material violations of Laws, including all material Healthcare Laws, applicable to it and/or its assets, business or operations (collectively, “Health Care Compliance Program”). No Loan Party or any of its Subsidiaries is aware of any complaints from employees, independent contractors, vendors, physicians, customers, patients or other Persons that could reasonably be considered to indicate a violation of any Applicable Law, including any applicable Healthcare Law, which would be reasonably expected, individually or in the aggregate, to result in a Material Adverse Effect.
(m)The Loan Parties and their Subsidiaries are and have been for the last six (6) years, to the extent directly applicable, conducting their business in material compliance with all
- 98 -


regulations promulgated under HIPAA. To the extent the Loan Parties or any of their Subsidiaries create any de-identified protected health information, the Loan Parties and their Subsidiaries do so in compliance with the HIPAA regulations. No Loan Party nor any of its Subsidiaries have (i) suffered any breach of unsecured health protected health information (except as would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect), or (ii) failed to notify any individual or required third party, including any appropriate Governmental Authority, of an event that triggered a notification or reporting requirement under any contract to which any Loan Party or any of its Subsidiaries is a party, or any applicable requirement related to the unauthorized access, use or disclosure of protected health information. The Loan Parties have no knowledge of any complaints to or investigations by any Governmental Authority with respect to HIPAA compliance by the Loan Parties or any of their Subsidiaries, have not received any notice or audit request from the United States Department of Health and Human Services Office for Civil Rights, is currently conducting their businesses in material compliance with all Applicable Laws governing the privacy, security or confidentiality of health information and/or other records generated in the course of providing or paying for health care services, including without limitation, all laws to the extent not preempted by HIPAA, and has conducted its businesses in material compliance with such laws since such laws first became applicable to it.
Section 1.20Accuracy of Information, Etc.
(a)Each Loan Party has disclosed to the Credit Parties all agreements, instruments and corporate or other restrictions to which it or any of its Subsidiaries is subject, and all other matters known to it, that, individually or in the aggregate, would reasonably be expected to result in a Material Adverse Effect. Neither the Information Memorandum nor any of the other reports, financial statements, certificates or other information furnished (whether in writing or orally) by or on behalf of any Loan Party to any Credit Party in connection with the transactions contemplated hereby and the negotiation of this Credit Agreement or delivered hereunder or under any other Loan Document (in each case as modified or supplemented by other information so furnished) contains any material misstatement of fact or omits to state any material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, provided that, with respect to projected financial information, the Loan Parties represent only that such information was prepared in good faith based upon assumptions believed to be reasonable at the time.
(b)As of the Closing Date, the information included in the Beneficial Ownership Certification is true and correct in all respects.
Section 1.21Labor Matters. There are no strikes, lockouts or slowdowns against any Loan Party or any of its Subsidiaries pending or, to the knowledge of any Loan Party, threatened. The hours worked by and payments made to employees of the Loan Parties and their Subsidiaries have not been in violation in any material respect of the Fair Labor Standards Act or any other applicable Federal, state, local or foreign law dealing with such matters. All material payments due from the Loan Parties or any of their Subsidiaries, or for which any claim may be made against any of the Loan Parties or any of their Subsidiaries, on account of wages and employee health and welfare insurance and other benefits, have been paid or accrued as a liability on the books of such Loan Party or such Subsidiary. The consummation of the Transactions will not give rise to any right of termination or right of renegotiation on the part of any union under any collective bargaining agreement to which any of the Loan Parties or any of their Subsidiaries is bound.
Section 1.22Absence of Certain Restrictions. No indenture, certificate of designation for preferred stock, agreement or instrument to which any Loan Party or any of its Subsidiaries is a party (other than this Credit Agreement), prohibits or limits in any way, directly or indirectly the ability of any
- 99 -


Subsidiary to make Restricted Payments or loans to, to make any advance on behalf of, or to repay any Indebtedness to, any Loan Party or to another Subsidiary.
Section 1.23No Default. No Loan Party nor any of its Subsidiaries is in default in the performance, observance or fulfillment of any of the obligations, covenants or conditions contained in any agreement, instrument or other undertaking to which such Person is a party or by which it or any of its property is bound in any respect that would reasonably be expected to have a Material Adverse Effect.
Section 1.24Common Enterprise. The successful operation and condition of each of the Loan Parties is dependent on the continued successful performance of the functions of the group of the Loan Parties as a whole and the successful operation of each of the Loan Parties is dependent on the successful performance and operation of each other Loan Party. Each Loan Party expects to derive benefit (and its board of directors or other governing body has determined that it may reasonably be expected to derive benefit), directly and indirectly, from (a) successful operations of each of the other Loan Parties and (b) the credit extended by the Lenders to the Borrower hereunder, both in their separate capacities and as members of the group of companies. Each Loan Party has determined that execution, delivery, and performance of this Credit Agreement and any other Loan Documents to be executed by such Loan Party is within its purpose, will be of direct and indirect benefit to such Loan Party, and is in its best interest.
Section 1.25Brokers’ Fees. None of the Loan Parties or their Subsidiaries has any obligation to any Person in respect of any finder’s, broker’s, investment banking or other similar fee in connection with any of the transactions contemplated under the Loan Documents other than the closing and other fees payable pursuant to this Credit Agreement and as set forth in the Fee Letter.
Section 1.26Affected Financial Institutions. No Loan Party is an Affected Financial Institution.
Article 6

AFFIRMATIVE COVENANTS
Until the Termination Date, the Borrower covenants and agrees with the Credit Parties that:
Section 1.1Financial Statements and Other Information. The Borrower will furnish or caused to be furnished to the Administrative Agent and each Lender either in hard copy or by electronic communication (including by email, internet and intranet websites) pursuant to procedures acceptable to the Administrative Agent:
(a)as soon as available, but in any event within ninety (90) days after the end of each Fiscal Year of the Borrower, beginning with the fiscal year ending on December 31, 2023, the Borrower’s Form 10-K containing the audited consolidated balance sheet of the Borrower and its Subsidiaries together with the related statements of income, comprehensive income, stockholders’ equity and cash flows as of the end of and for such year, setting forth in each case in comparative form the figures for the previous Fiscal Year, all reported on by Deloitte & Touche LLP or another registered independent public accounting firm of recognized national standing (without a “going concern” or like qualification or exception and without any qualification or exception as to the scope of such audit) to the effect that such consolidated financial statements present fairly in all material respects the financial condition and results of operations of the Borrower and its Subsidiaries on a consolidated basis in accordance with GAAP consistently applied;
- 100 -


(b)as soon as available, but in any event within forty-five (45) days after the end of each of the first three fiscal quarters of each Fiscal Year, the Borrower’s Form 10-Q containing the unaudited consolidated balance sheet of the Borrower and its Subsidiaries and the related unaudited statements of income, comprehensive income, stockholders’ equity and cash flows as of the end of and for such fiscal quarter and the then elapsed portion of the Fiscal Year, setting forth in each case in comparative form the figures for the corresponding period or periods of (or, in the case of the balance sheet, as of the end of) the previous Fiscal Year, all certified by one of its Financial Officers as presenting fairly in all material respects the financial condition and results of operations of the Borrower and its Subsidiaries on a consolidated basis in accordance with GAAP consistently applied, subject to normal year-end audit adjustments and the absence of footnotes
(c)concurrently with any delivery of financial statements under clause (a) or (b) above, a Compliance Certificate signed by a Financial Officer of the Borrower (i) stating whether any change in GAAP or in the application thereof has occurred since the Closing Date and, if any such change has occurred, specifying the effect of such change on the financial statements accompanying such Compliance Certificate, (ii) containing either a certification that no Default or Event of Default exists or, specifying the nature of each such Default, the nature and status thereof and any action taken or proposed to be taken with respect thereto, (iii) certifying that there have been no changes to the jurisdiction of organization or legal name of any Loan Party since the date of the last Compliance Certificate delivered pursuant to the Credit Agreement, (iv) attaching reasonably detailed calculations demonstrating compliance with Section 7.12, and (v) certifying that the Borrower has no Subsidiaries other than (A) those that existed on the Closing Date and were reflected in the Perfection Certificate on such date, (B) those formed or acquired after the Closing Date with respect to which the Administrative Agent was previously notified either pursuant to Section 6.12 of the Credit Agreement, in an additional Perfection Certificate or in a previous Compliance Certificate, and (C) those other Subsidiaries set forth on the relevant Schedule to such Compliance Certificate, which Schedule sets forth for each such Subsidiary whether such Subsidiary is (w) a Domestic Subsidiary, (x) a Subsidiary Guarantor (including the basis for it not being a Subsidiary Guarantor, if applicable), (y) a Foreign Subsidiary and in such case, whether such Foreign Subsidiary is a Material Foreign Subsidiary or (z) an Excluded Subsidiary (including the basis for its constituting an Excluded Subsidiary).
(d)[reserved];
(e)(i) within forty-five (45) days after the beginning of each Fiscal Year, an annual consolidated forecast for the Borrower and its Subsidiaries for such Fiscal Year, including projected consolidated balance sheet of the Borrower and its Subsidiaries as of the end of each fiscal quarter for such Fiscal Year, the related consolidated statements of projected cash flow and projected income and a description of the underlying assumptions applicable thereto, all in reasonable detail acceptable to the Administrative Agent and (ii) promptly upon preparation thereof, such other forecasts that the Borrower or any Subsidiary may prepare and any revisions that may be made to any forecast previously delivered to the Administrative Agent and the Lenders
(f)concurrently with the delivery of any Compliance Certificate under clause (c) above, to the extent any of the Loan Parties have registered, applied for registration of, acquired, or otherwise obtained ownership of any new Intellectual Property since the Closing Date or since the last update pursuant to this clause (f), a description of such new Intellectual Property; and
(g)promptly following any request therefor, (i) such other information and documentation reasonably requested by the Administrative Agent or any Lender for purposes of compliance with applicable “know your customer” requirements under the USA Patriot Act, the
- 101 -


Beneficial Ownership Regulation or other applicable Anti-Corruption and Anti-Terrorism Laws (including those passed pursuant to the USA PATRIOT Act), and (ii) such other information regarding the operations, business affairs and financial condition of the Borrower or any Subsidiary, or compliance with the terms of the Loan Documents, as any Credit Party may reasonably request.
Additionally, documents required to delivered pursuant to this Section 6.1 (to the extent any such documents are included in materials otherwise filed with the SEC) may be delivered electronically and if so, shall be deemed to have been delivered on the date on which the Borrower posts such documents, or provides a link thereto, either: (i) on the Borrower’s website on the Internet at the website address: https://www.mimedx.com/; or (ii) when such documents are posted electronically on the Borrower’s behalf on an internet or intranet website to which each Credit Party and the Administrative Agent have access (whether a commercial, third-party website or whether sponsored by the Administrative Agent) if any; provided that: (A) the Borrower shall deliver paper copies of such documents to the Administrative Agent or any Credit Party upon written request to the Borrower to deliver such paper copies until written request to cease delivering paper copies is given by the Administrative Agent or such Credit Party and (B) the Borrower shall notify (which may be by facsimile or electronic mail) the Administrative Agent of the posting of any such documents.
Section 1.2Notices of Material Events. The Borrower will furnish or caused to be furnished to the Administrative Agent for distribution to each Lender prompt written notice of the following:
(a)the occurrence of any Default or Event of Default, specifying the nature and extent thereof;
(b)the filing or commencement of, or any threat or notice of intention of any Person to file or commence, any action, suit or proceeding, whether at law or in equity or by or before any Governmental Authority, against, or affecting, any Loan Party or any of its Subsidiaries that would reasonably be expected to result in a Material Adverse Effect;
(c)if requested by Administrative Agent from time to time, copies of any annual report required to be filed in connection with each Pension Plan or Foreign Plan, and as soon as possible after, and in any event within ten (10) Business Days after any Loan Party or any ERISA Affiliate knows or has reason to know that, any ERISA Event (or any similar event with respect to a Foreign Plan) has occurred that, alone or together with any other ERISA Event (or any similar event with respect to a Foreign Plan) would reasonably be expected to result in liability of any Loan Party or any ERISA Affiliate in an aggregate amount exceeding the Threshold Amount;
(d)as soon as reasonably possible and in no event later than five (5) Business Days after the receipt by any Loan Party or any of its Subsidiaries, of a copy of any notice, summons, citation or other written communication concerning any actual, alleged, suspected or threatened violation of any Environmental Law by, Environmental Claim against or Environmental Liability of, any Loan Party or any of its Subsidiaries, in each case, which would reasonably be expected to have a Material Adverse Effect;
(e)promptly upon receipt by the Borrower or any of its Subsidiaries obtaining knowledge that the Borrower or any of its Subsidiaries has become subject to any federal, state, or local government or civil or criminal investigations or audits involving or related to its compliance with Healthcare Laws (including, without limitation, an inquiry or investigation of any Person having “ownership, financial or control interest” ( as that phrase is defined in 42 C.F.R. §420.201 et seq.) in the Borrower or any of its Subsidiaries (other than routine audits in the ordinary course of business that are not the result of any actual or alleged violations of Healthcare Laws) and any fines or penalties imposed
- 102 -


by any Governmental Authority (including under any Healthcare Laws), that would reasonably be expected to have a Material Adverse Effect, written notice thereof prepared in reasonably detail;
(f)[reserved];
(g)[reserved];
(h)promptly, and in any event within five (5) Business Days after receipt thereof by the Borrower or any of its Subsidiaries, copies of each notice or other correspondence received from the SEC (or comparable agency) concerning any investigation by such agency regarding financial or other operational results of the Borrower or any of its Subsidiaries (other than routine comment letters from the staff of the SEC relating to the Borrower’s filings with the SEC);
(i)promptly upon written request by the Administrative Agent, copies of all reports, documents, filings or correspondence with any Governmental Authority regarding compliance with or maintenance of Governmental Approvals, Permits or any Applicable Law;
(j)promptly after the furnishing thereof, copies of any statement or report furnished to any holder of debt securities of any Loan Party or of any of its Subsidiaries pursuant to the terms of any indenture, loan or credit or similar agreement and not otherwise required to be furnished to the Lenders pursuant to any other clause of this Section 6.2;
(k)[reserved]; and
(l)promptly after any Person becomes, or ceases to be, a Subsidiary or a Guarantor, an updated list of Subsidiaries or Guarantors, as the case may be.
Each notice delivered under this Section shall be accompanied by a statement of a Responsible Officer of the Borrower or other executive officer of the Borrower setting forth the details of the event or development requiring such notice and any action taken or proposed to be taken with respect thereto.
Section 1.3Existence; Conduct of Business. The Borrower will, and will cause each of its Subsidiaries to, do or cause to be done all things necessary to preserve, renew and keep in full force and effect (a) its legal existence, (b) all Permits, and (iii) all Governmental Approvals (including the rights, licenses, permits, privileges and franchises material to the conduct of its business), provided that the foregoing shall not prohibit any merger, consolidation, liquidation or dissolution permitted under Section 7.3 or any sale, lease, transfer or other disposition permitted by Section 7.5.
Section 1.4Payment and Performance of Obligations. The Borrower will, and will cause each of its Subsidiaries to, pay or perform its obligations, including Tax liabilities, that, if not paid or performed, could reasonably be expected to result in a Material Adverse Effect before the same shall become delinquent or in default, except where (a) the validity or amount thereof is being Contested in Good Faith and (b) the failure to make payment pending such contest could not reasonably be expected to result in a Material Adverse Effect, provided that nothing in this Section shall be deemed to require any Loan Party to pay any Subordinated Debt in violation of the subordination provisions applicable thereto.
Section 1.5Maintenance of Properties. The Borrower will, and will cause each of its Subsidiaries to, keep and maintain all property material to the conduct of its business in good working order and condition, ordinary wear and tear excepted.
- 103 -


Section 1.6Books and Records; Inspection Rights. The Borrower will, and will cause each of its Subsidiaries to, (a) keep proper books of record and account in which full, true and correct entries are made of all dealings and transactions in relation to its business and activities and (b) permit any representatives designated by any Credit Party, upon reasonable prior notice, to visit and inspect its properties, to examine and make extracts from its books and records, and to discuss its affairs, finances and condition with its officers and independent accounting firm, all at the expense of the Borrower and at such reasonable times and as often as reasonably requested; provided, however, during the existence of an Event of Default, the Administrative Agent or any Lender (or any of their respective representatives or independent contractors) may do any of the foregoing at the expense of the Borrower at any time during normal business hours and without advance notice.
Section 1.7Compliance with Laws. The Borrower will, and will cause each of its Subsidiaries to, comply with all laws, rules, regulations and orders of any Governmental Authority (including all Healthcare Laws) applicable to it or its property and maintain all permits and licenses necessary to conduct its business, except where the failure to do so, individually or in the aggregate, could not reasonably be expected to result in a Material Adverse Effect. In addition, and without limiting the foregoing sentence, each Loan Party will, and will cause each of its Subsidiaries to, comply with all applicable Environmental Laws in all material respects, and with applicable Anti-Corruption Laws, applicable Sanctions and the USA PATRIOT Act and the regulations promulgated thereunder in all respects. The Borrower will maintain a Health Care Compliance Program that includes: (a) regular compliance training for all directors, officers, employees, and contractors; (b) reasonable monitoring on a regular basis to ensure adherence to, and effectiveness of, the Health Care Compliance Program; and (c) modification of the compliance program from time to time as may be necessary to promote continuing material compliance with all Applicable Laws, including all applicable Healthcare Laws.
Section 1.8Use of Proceeds.
(a)On the Closing Date, the proceeds of the Term Loans and Revolving Loans will be used to consummate the Existing Credit Agreement Refinancing and to pay Transaction Expenses, and thereafter, the proceeds of the Revolving Loans and Letters of Credit will be used only for general corporate and working capital purposes not inconsistent with the terms hereof or in contravention of any Law or any Loan Document, including Permitted Acquisitions.
(b)No part of the proceeds of any Loan or any Letter of Credit will be used, whether directly or indirectly, and whether immediately, incidentally or ultimately, (a) to purchase, acquire or carry any Margin Stock or (b) for any purpose that entails a violation of any of the regulations of the Federal Reserve Board, including Regulations T, U and X. The Borrower will not request any Credit Extension, and the Borrower shall not use, and shall ensure that each Loan Party, their respective Subsidiaries and to the knowledge of any such Loan Party, respective directors, officers, employees and agents shall not use, the proceeds of any credit extension hereunder, (i) in furtherance of an offer, payment, promise to pay, or authorization of the payment or giving of money, or anything else of value, to any person in violation of any anti-corruption laws or (ii) in any matter that would result in the violation of any applicable Sanctions or applicable Anti-Terrorism Laws by any Person, including any Credit Party.
Section 1.9Information Concerning Collateral. The Borrower will furnish to the Administrative Agent at least 10 days prior written notice of any change in (a) the legal name or jurisdiction of incorporation or formation of any Loan Party, (b) the location of the chief executive office of any Loan Party, (c) the identity or organizational structure of any Loan Party such that a filed financing statement becomes misleading or (d) the Federal Taxpayer Identification Number or company
- 104 -


organizational number of any Loan Party. The Borrower agrees not to effect or permit any change referred to in the preceding sentence unless all filings have been made under the UCC or otherwise that are required in order for the Administrative Agent to continue at all times following such change to have a valid, legal and perfected security interest in all the Collateral. The Borrower also agrees promptly to notify the Administrative Agent if any material portion of the Collateral is damaged or destroyed.
Section 1.10Insurance.
(a)The Borrower will, and will cause each of its Subsidiaries to, maintain, with financially sound and reputable insurance companies, adequate insurance for its insurable properties, all to such extent and against such risks, including fire, casualty, business interruption and other risks insured against by extended coverage, as is customary with companies in the same or similar businesses operating in the same or similar locations and of same or similar size, including public liability insurance against claims for personal injury or death or property damage occurring upon, in, about or in connection with the use of any properties owned, occupied or controlled by it (including the insurance required pursuant to the Collateral Documents); and maintain such other insurance as may be required by law.
(b)[reserved].
(c)The Borrower will, and will cause each of its Subsidiaries to, (i) cause all such policies of such Loan Party and its Subsidiaries to be endorsed or otherwise amended to include an additional insured endorsement or a lender’s loss payable endorsement, as appropriate, each in form and substance reasonably satisfactory to the Administrative Agent, (ii) cause all such policies to provide that neither such Loan Party, any Subsidiary or the Administrative Agent nor any other party shall be a co-insurer thereunder, and such other provisions as the Administrative Agent may reasonably require from time to time to protect its interests, (iii) deliver copies of all such policies to the Administrative Agent (which, except as set forth in clause (v) below or with respect to evidence of annual renewals, shall be not more than once per calendar year), (iv) cause each such policy to provide that it shall not be canceled, modified or not renewed for any other reason upon not less than thirty (30) days’ (ten (10) days for non-payment of premium) prior written notice thereof by the insurer to the Administrative Agent, and (v) deliver to the Administrative Agent, prior to the cancellation, modification or non-renewal of any such policy of insurance, a copy of a renewal or replacement policy (or other evidence of renewal of a policy previously delivered to the Administrative Agent) together with evidence satisfactory to the Administrative Agent of payment of the premium therefor.
(d)[Reserved].
(e)The Borrower will, and will cause each of its Subsidiaries to, notify the Administrative Agent immediately whenever any separate insurance concurrent in form or contributing in the event of loss with that required to be maintained under this Section 6.10 is taken out by any Loan Party; and promptly deliver to the Administrative Agent a copy of such policy or policies.
(f)In connection with the covenants set forth in this Section 6.10, it is understood and agreed that:
(i)no Credit Party or any of its Related Parties shall be liable for any loss or damage insured by the insurance policies required to be maintained under this Section 6.10, it being understood that (A) each Loan Party shall look solely to its insurance companies or any other parties other than the aforesaid parties for the recovery of such loss or damage and (B) such insurance companies shall have no rights of subrogation against any Credit Party or any of their Related Parties, provided, however, that if the insurance policies do not provide waiver of
- 105 -


subrogation rights against such parties, as required above, then the Borrower (for itself and each of its Subsidiaries) hereby agrees, to the extent permitted by law, to waive its right of recovery, if any, against the Credit Parties and their Related Parties; and
(ii)the designation of any form, type or amount of insurance coverage by the Administrative Agent or the Required Lenders under this Section 6.10 shall in no event be deemed a representation, warranty or advice by any Credit Party that such insurance is adequate for the purposes of the business of any Loan Party or its Subsidiaries or the protection of their properties and the Administrative Agent and the Required Lenders shall have the right from time to time to require the Loan Parties and their respective Subsidiaries to keep other insurance in such form and amount as the Administrative Agent or the Required Lenders may reasonably request; provided that such insurance shall be obtainable on commercially reasonable terms.
Section 1.11Casualty Events.
(a)     The Borrower will, and will cause each of its Subsidiaries to, furnish to the Administrative Agent prompt written notice of each Casualty Event or the commencement of any action or proceeding for the condemnation or other taking of any such property or any part thereof or interest therein under power of eminent domain or by condemnation or similar proceeding.
(a)
(b)If any Casualty Event results in Net Cash Proceeds (whether in the form of insurance proceeds, condemnation award or otherwise), the Administrative Agent is authorized to collect such Net Cash Proceeds and, if received by any Loan Party or any of its Subsidiaries, shall be held in trust for the benefit of the Administrative Agent hereunder and shall be forthwith paid over to the Administrative Agent, provided that (i) to the extent that any Loan Party or any of its Subsidiaries intends to use any such Net Cash Proceeds to repair, restore, reinvest or replace assets of the Borrower or any of its Subsidiaries as provided in the definition of Net Cash Proceeds, the Administrative Agent shall, subject to the terms and conditions of such proviso, deliver such Net Cash Proceeds to the Borrower on behalf of the applicable Loan Party, (ii) otherwise, the Administrative Agent shall, and each Loan Party hereby authorizes the Administrative Agent to, apply such Net Cash Proceeds to prepay the Loans in accordance with Section 2.7 and (iii) all proceeds of business interruption insurance shall be paid over to the Borrower unless a Default or an Event of Default has occurred and is continuing.
(c)All proceeds received by or paid to the Administrative Agent that do not constitute Net Cash Proceeds shall be paid over to the Borrower on behalf of the applicable Loan Party unless a Default or Event of Default has occurred and is continuing.
Section 1.12Covenant to Guarantee and Provide Security.
(a)Subsidiary Guarantors. If any Subsidiary of a Loan Party (other than an Excluded Subsidiary or a Subsidiary that that is a party to this Credit Agreement and the Collateral Documents) is formed or acquired after the Closing Date or if an Excluded Subsidiary ceases to be an Excluded Subsidiary, the Borrower will notify the Credit Parties in writing thereof within thirty (30) days following the date on which such Subsidiary is formed or acquired or such Excluded Subsidiary ceases to be an Excluded Subsidiary (or such later date as may be acceptable to the Administrative Agent in its sole discretion) and, by such date:
(i)the Borrower will cause each such Subsidiary to (A) execute and deliver a Subsidiary Joinder Agreement and a Perfection Certificate and (B) promptly take such actions
- 106 -


to create and perfect Liens on such Subsidiary’s assets to secure the Secured Obligations as the Administrative Agent shall reasonably request, (including the execution and delivery of any collateral document necessary or appropriate to create and perfect Liens with respect to such Subsidiary’s owned or leased real property in form and substance reasonably satisfactory to the Administrative Agent,
(ii)if any Equity Interests issued by any such Subsidiary are owned or held by or on behalf of any Loan Party, the Borrower will cause such Equity Interests to be pledged pursuant to the Collateral Documents not later than the 30th day after the date on which such Subsidiary is formed or acquired,
(iii)the Borrower will cause each such Subsidiary to become a party to any Master Intercompany Note not later than the 30th day after the date on which such Subsidiary is formed or acquired, and
(iv)the Borrower will deliver or cause to be delivered to the Administrative Agent such certificates and legal opinions as would have been required had such Subsidiary been a Subsidiary Guarantor on the Closing Date.
(b)[Reserved].
(c)Further Assurances.
(i)The Borrower will, and will cause each of the Loan Parties to, grant to the Administrative Agent, for the benefit of the Secured Parties, security interests in such of its assets and properties as are not covered by the Collateral Documents in order that the Borrower be in compliance with the Collateral and Guarantee Requirement. Such security interests shall (i) be granted pursuant to documentation reasonably satisfactory in form and substance to the Administrative Agent and (ii) constitute valid and enforceable perfected security interests superior to and prior to the rights of all third Persons, and subject to no other Liens, except Liens permitted by Section 7.2. Such additional collateral documents and the other instruments related thereto shall have been duly recorded or filed in such manner and in such places as are required by law to establish, perfect, preserve and protect the Liens in favor of the Administrative Agent required to be granted pursuant to such additional collateral documents and all taxes, fees and other charges payable in connection therewith shall have been paid in full.
(ii)The Borrower will, and will cause each of the Loan Parties to, at its own expense, make, execute, endorse, acknowledge, file or deliver to the Administrative Agent from time to time such vouchers, invoices, schedules, confirmatory assignments, conveyances, financing statements, transfer endorsements, powers of attorney, certificates, surveys, reports and other assurances or instruments, and take such further steps relating to the Collateral covered by any of the Collateral Documents as the Administrative Agent may reasonably require. The Borrower shall cause to be delivered to the Administrative Agent such opinions of counsel and other related documents as may be reasonably requested by the Administrative Agent.
(iii)Each action required by this Section 6.12(c) shall be completed as soon as possible, but in no event later than thirty (30) days (or such longer period in the case of actions involving third parties as determined by the Administrative Agent in its reasonable discretion) after any such assets or properties are acquired or such action is requested to be taken by the Administrative Agent, as the case may be.
- 107 -


Section 1.13Environmental Matters. The Borrower will, and will cause each of its Subsidiaries to, (a) conduct its operations in material compliance with all applicable Environmental Laws, (b) implement any and all investigation, remediation, removal and response actions that either are necessary to materially comply with Environmental Laws pertaining to the presence, generation, treatment, storage, use, disposal, transportation or Release of any Hazardous Material by any Loan Party or any of its Subsidiaries on, at, under, or from any of their owned or leased property or are requested by Government Authorities pursuant to Environmental Law, (c) notify the Administrative Agent promptly upon becoming aware of any violation of Environmental Laws by any Loan Party or any of its Subsidiaries or any Release of Hazardous Materials on, at, under, or from, any property that is reasonably likely to result in an Environmental Claim against any Loan Party or any of its Subsidiaries or that would reasonably be expected to result in a Material Adverse Effect and promptly forward to the Administrative Agent a copy of any written communication received in connection therewith. If the Administrative Agent at any time has a reasonable basis to believe that there may be a violation of any Environmental Laws by any Loan Party or any of its Subsidiaries or a Release of Hazardous Materials on, at, under, or from any property owned or leased by any Loan Party or any of its Subsidiaries that would reasonably be expected to have a Material Adverse Effect, then, subject to Section 9.3(d), upon written request by the Administrative Agent the Borrower shall cause such Loan Party to permit the Administrative Agent to appoint a nationally-recognized independent environmental testing firm or such other consultant as the Administrative Agent shall determine, at the Loan Parties’ expense, to have access to the property owned or leased by each Loan Party and each of its Subsidiaries that is subject to the suspected violation or Release for the purpose of conducting an environmental investigation, which, at the environmental professionals’ judgment, may include testing of environmental media, including soil and groundwater.
Section 1.14Post-Closing Obligations.
(a)Deposit Account Control Agreements. The Loan Parties shall deliver, or cause to be delivered, to the Administrative Agent, within thirty (30) days after the Closing Date (or such later date as the Administrative Agent shall agree in its sole discretion), duly executed control agreements in favor of the Administrative Agent for the benefit of the Secured Parties for all Deposit Accounts, Securities Accounts and Commodity Accounts owned by the Loan Parties in the United States (other than to the extent constituting Excluded Accounts (as defined in the Security Agreement)).
(b)Insurance Endorsements. The Loan Parties shall deliver, or cause to be delivered, to the Administrative Agent, within thirty (30) days after the Closing Date (or such later date as the Administrative Agent shall agree in its sole discretion), insurance endorsements (a) naming the Administrative Agent as lender’s loss payable on all property insurance policies of the Loan Parties as required under Section 6.10, (b) naming the Administrative Agent as additional insured on all liability policies of the Loan Parties as required under Section 6.10, and (c) providing the Administrative Agent with thirty (30) days (or ten (10) days’ notice for non-payment of premium) prior written notice before any such policy or policies shall be altered or cancelled on all insurance policies of the Loan Parties.
(c)Patent Filings. The Loan Parties shall, within forty-five (45) days after the Closing Date (or such later date as the Administrative Agent shall agree in its sole discretion), ensure that all chain of title issues with respect to any Patent ownership have been corrected such that the Administrative Agent may properly record, and if necessary, perfect a security interest in all Patents subject to the patent law of the United States, in each case for the benefit of the Secured Parties.
(d)Patent Security Agreement and Perfection Certificate. The Loan Parties shall, within five (5) days after the Closing Date (or such later date as the Administrative Agent shall agree in its sole discretion) deliver to the Administrative Agent (i) a Patent Security Agreement covering any
- 108 -


Patents owned by any Loan Party not otherwise included in the Patent Security Agreement delivered to the Administrative Agent on the Closing Date, and (ii) a Perfection Certificate with an updated Schedule 12(a) thereto reflecting any such additional Patents owned by any Loan Party not otherwise included on Schedule 12(a) of the Perfection Certificate delivered to the Administrative Agent on the Closing Date.

Article 7

NEGATIVE COVENANTS
Until the Termination Date, the Borrower covenants and agrees with the Credit Parties that:
Section 1.1Indebtedness; Equity Interests.
(a)The Borrower will not, and will not permit any of its Subsidiaries to, create, incur, assume or permit to exist any Indebtedness, except:
(i)Indebtedness created under the Loan Documents;
(ii)Indebtedness existing on the Closing Date and set forth in Schedule 7.1, and any and any Refinancing Indebtedness with respect thereto;
(iii)Indebtedness of the Borrower or any of its Subsidiaries incurred to finance the acquisition, construction or improvement of any fixed or capital assets, including Finance Lease Obligations and any Indebtedness assumed in connection with the acquisition of any such assets or secured by a Lien on any such assets prior to the acquisition thereof, and any Refinancing Indebtedness with respect thereto, provided that (A) such Indebtedness is incurred prior to or within 90 days after such acquisition or the completion of such construction or improvement and (B) the aggregate outstanding principal amount of Indebtedness permitted by this clause (iii) shall not, without duplication, exceed $5,000,000 at any time;
(iv)Indebtedness of any Person that becomes a Subsidiary of the Borrower after the Closing Date, and any Refinancing Indebtedness with respect thereto, provided that (A) such Indebtedness exists at the time such Person becomes a Subsidiary and is not created in contemplation of or in connection with such Person becoming a Subsidiary and (B) the aggregate outstanding principal amount of Indebtedness permitted by this clause (iv) shall not, without duplication, exceed $10,000,000 at any time;
(v)intercompany Indebtedness of the Borrower or any Subsidiary owing to and held by the Borrower or any Subsidiary; provided, however, that (A) if the Borrower or any Subsidiary Guarantor is the obligor on such Indebtedness and any Subsidiary (other than a Subsidiary Guarantor) is the obligee thereof, such Indebtedness must be unsecured and expressly subordinated to the prior payment in full in cash of all Secured Obligations (including, with respect to any Subsidiary Guarantor, its obligations under the Security Agreement), (B) Indebtedness owed to the Borrower or any Subsidiary Guarantor must be evidenced by a Master Intercompany Note or an unsubordinated promissory note pledged to the Administrative Agent under the Security Agreement and (C) Indebtedness (excluding any ordinary course out-of-pocket expenses)of Subsidiaries (other than Subsidiary Guarantors) owed to the Borrower and/or a Subsidiary Guarantor may not exceed $5,000,000 in the aggregate at any time outstanding;
- 109 -


(vi)Guarantees by (A) any Loan Party of Indebtedness of any other Loan Party, (B) any Non-Loan Party Subsidiary of Indebtedness of any other Non-Loan Party Subsidiary, and (C) any Non-Loan Party Subsidiary of any Indebtedness of any Loan Party, provided that, in each case, such Indebtedness is otherwise permitted by this Section 7.1(a);
(vii)obligations under any Swap Agreements permitted by Section 7.7;
(viii)Indebtedness arising from the honoring by a bank or other financial institution of a check, draft or other similar instrument drawn against insufficient funds in the ordinary course of business;
(ix)unsecured guarantees arising as a result of customary indemnification obligations to purchasers that are not Affiliates of a Loan Party in connection with any Disposition permitted by Section 7.5;
(x)Indebtedness incurred in the ordinary course of business under (A) appeal bonds or similar instruments and (B) surety bonds, payment bonds, performance bonds, bid bonds, completion guarantees and similar obligations, workers’ compensation claims, health, disability or other employee benefits, and bankers acceptances issued for the account of any Loan Party or its Subsidiaries and unsecured guarantees thereof;
(xi)Earn-Out Obligations owing to sellers incurred in connection with a Permitted Acquisition; provided that the amount of such Earn-Out Obligations shall be deemed to be part of the cost of such Investment (the amount of which shall be deemed to be the amount required to be accrued as a liability in accordance with GAAP or the amount actually paid);
(xii)contingent payment obligations and contingent liabilities in respect of any indemnification obligations and adjustments of purchase price, in each case in connection with a Permitted Acquisition;
(xiii)other Indebtedness not to exceed $2,500,000 in the aggregate principal amount at any time outstanding; provided that any Liens securing such Indebtedness shall rank junior in priority to the liens securing the Indebtedness under the Loan Documents;
(xiv)other Indebtedness not to exceed $2,500,000 in the aggregate at any time outstanding; provided that such Indebtedness (A) shall rank junior in priority to the Liens securing the Indebtedness under the Loan Documents pursuant to a subordination or intercreditor agreement in form and substance reasonably satisfactory to the Administrative Agent, (B) shall at the time such Indebtedness is incurred, have a scheduled maturity date that is at least ninety-one (91) days following the Latest Maturity Date and (C) shall not require payments of principal thereon prior to a date that is, at the time such Indebtedness is incurred, at least ninety-one (91) days following the Latest Maturity Date; and
(xv)deferred compensation or similar arrangement payable to future, present or former directors, officers, employees, members of management or consultants of any Loan Party and its Subsidiaries in an aggregate amount not to exceed $3,000,000 outstanding at any one time.
(b)the Borrower will not, and will not permit any of its Subsidiaries to, (i) issue any Disqualified Equity Interests, or (ii) be or become liable in respect of any obligation (contingent or
- 110 -


otherwise) to purchase, redeem, retire, acquire or make any other payment in respect of any Equity Interests of any Loan Party or any of its Subsidiaries, except as permitted under Section 7.8.
Section 1.2Liens. The Borrower will not, and will not permit any of its Subsidiaries to, create, incur, assume or permit to exist any Lien on any property or asset now owned or hereafter acquired by it, or assign or sell any income or revenues (including accounts receivable) or rights in respect of any thereof, except:
(a)Liens created under the Loan Documents;
(b)Permitted Encumbrances;
(c)any Lien on any property or asset of the Borrower or any Subsidiary existing on the Closing Date and set forth in Schedule 7.2, provided that (i) such Lien shall not apply to any other property or asset of the Borrower or any Subsidiary and (ii) such Lien shall secure only those obligations which it secures on the Closing Date and any extensions, renewals and replacements thereof that do not increase the outstanding principal amount thereof;
(d)any Lien on fixed or capital assets acquired, constructed or improved by the Borrower or any Subsidiary, provided that (i) such Lien secures Indebtedness permitted by Section 7.1(a)(iii), (ii) such Lien and the Indebtedness secured thereby are incurred prior to or within 90 days after such acquisition or the completion of such construction or improvement, (iii) the Indebtedness secured thereby does not exceed the cost of acquiring, constructing or improving such fixed or capital assets and (iv) such Lien shall not apply to any other property or assets of the Borrower or any Subsidiary;
(e)any Lien existing on any property or asset prior to the acquisition thereof by the Borrower or any Subsidiary or existing on any property or asset of any Person that becomes a Subsidiary after the Closing Date prior to the time such Person becomes a Subsidiary, provided that (i) such Lien secures Indebtedness permitted by Section 7.1(a)(iv), (ii) such Lien is not created in contemplation of or in connection with such acquisition or such Person becoming a Subsidiary, as applicable, (iii) such Lien shall not apply to any other property or assets of the Borrower or any Subsidiary and (iv) such Lien shall secure only the Indebtedness and other obligations that it secures on the date of such acquisition or the date such Person becomes a Subsidiary, as applicable, and any extensions, renewals and replacements thereof that do not increase the outstanding principal amount thereof;
(f)Liens of a depository bank or securities intermediary permitted by any Control Agreement;
(g)Liens constituting deposits to secure real property lease obligations as lessee incurred by any Loan Party in the ordinary course of business;
(h)Liens to secure Indebtedness permitted under Section 7.1(a)(xiv), provided that such Liens only secure Indebtedness incurred pursuant thereto; and
(i)other Liens so long as the aggregate outstanding principal amount of the obligations secured thereby does not exceed $10,000,000 at any one time.
- 111 -


Section 1.3Fundamental Changes; Business; Fiscal Year.
(a)The Borrower will not, and will not permit any of its Subsidiaries to, merge into or consolidate with any other Person, or permit any other Person to merge into or consolidate with it, or sell, transfer, lease or otherwise Dispose of (in one transaction or in a series of transactions) all or substantially all of its assets, or all or substantially all of the Equity Interests issued by any of its Subsidiaries (in each case, whether now owned or hereafter acquired), or liquidate or dissolve or consummate a Division, provided that, if at the time thereof and immediately after giving effect thereto, no Default or Event of Default shall or would have occurred and be continuing:
(i)any Wholly-Owned Subsidiary of the Borrower may merge into or consolidate with (A) the Borrower in a transaction in which the Borrower is the surviving entity, (B) any Subsidiary Guarantor in a transaction in which such Subsidiary Guarantor is the surviving entity, and (C) to the extent such Subsidiary is a Non-Loan Party Subsidiary, any other Non-Loan Party Subsidiary;
(ii)the Borrower or any Subsidiary may merge into or consolidate with any Person in a transaction that is not permitted by Section 7.3(a)(i), provided that (x) in the case of a merger involving the Borrower, the Borrower shall be the surviving entity of such merger, (y) such merger is permitted by Section 7.4 and either (A) the Subsidiary Guarantor shall be the surviving entity or (B) such other Person shall become a Subsidiary Guarantor pursuant to Section 6.12, and (z) such merger shall not be prohibited by Section 7.5;
(iii)(A) any Subsidiary of a Loan Party may sell, transfer, lease or otherwise Dispose of all or substantially all of its assets to the Borrower or to any Subsidiary Guarantor and (B) any Non-Loan Party Subsidiary may sell, transfer, lease or otherwise Dispose of all or substantially all of its assets to the Borrower or any Subsidiary of the Borrower;
(iv)the Borrower or any of its Subsidiaries may sell, transfer, lease or otherwise Dispose of its assets in a transaction that is not permitted by Section 7.3(a)(iii), provided that such sale, transfer, lease or other Disposition is permitted by Section 7.5; and
(v)(A) any Non-Loan Party Subsidiary may liquidate or dissolve so long as any remaining assets are transferred to another Non-Loan Party Subsidiary or a Loan Party and (B) any Subsidiary Guarantor may liquidate or dissolve so long as any remaining assets of such Subsidiary Guarantor are transferred to another Loan Party; provided that, in each case, the Borrower determines in good faith that such liquidation or dissolution is in the best interests of Borrower and its Subsidiaries and is not disadvantageous to the Administrative Agent or any Lender in any material respect;
(b)The Borrower will not, and will not permit any of its Subsidiaries to, engage to any material extent in any business other than an Approved Line of Business; and
(c)The Borrower will not, and will not permit any of its Subsidiaries to, change its Fiscal Year.
Section 1.4Investments, Loans, Advances, Guarantees and Acquisitions. The Borrower will not, and will not permit any of its Subsidiaries to, purchase, hold or acquire (including pursuant to any merger or Division) any Investment, make or permit to exist any Guarantees of any obligations of, or make or permit to exist any investment or any other interest in, any other Person, make any Acquisition or purchase or otherwise enter into or become party to any derivative transaction, except:
- 112 -


(a)Investments in cash and Cash Equivalents;
(b)investments existing on the Closing Date and set forth in Schedule 5.13 and Schedule 7.4;
(c)equity Investments made by the Borrower in the Equity Interests of any Subsidiary Guarantor or any Non-Loan Party Subsidiary and made by any Subsidiary Guarantor in the Equity Interests of any other Subsidiary Guarantor or any Non-Loan Party Subsidiary; provided that Investments pursuant to this Section 7.4(c) in any Non-Loan Party Subsidiary shall not exceed $7,500,000 in the aggregate after the Closing Date less any amounts expended pursuant to subsection (e) below;
(d)Investments constituting Indebtedness made by (i) any Loan Party to any Subsidiary thereof or (ii) any Subsidiary to any Loan Party or another Subsidiary, in each case subject to the limitations set forth in Section 7.1(a)(v) and (vi);
(e)acquisitions made by (i) any Loan Party from any other Loan Party, (ii) any Non-Loan Party Subsidiary from any other Non-Loan Party Subsidiary and (iii) any Non-Loan Party Subsidiary from any Loan Party; provided that, with respect to this clause (iii), the amount of any such Investments shall not exceed $7,500,000 in the aggregate after the Closing Date less any amounts expended pursuant to subsection (c) above;
(f)Guarantees permitted by Section 7.1(a);
(g)Swap Agreements permitted by Section 7.7;
(h)Permitted Acquisitions;
(i)payroll, commission, travel and other similar cash advances made to directors (or comparable Persons), officers or employees in the ordinary course of business;
(j)(i) promissory notes and other non-cash consideration received in connection with Dispositions permitted by Section 7.5 and (ii) Investments received in settlement of amounts due to any Loan Party or any of its Subsidiaries effected in the ordinary course of business as a result of insolvency, bankruptcy, reorganization, or other similar proceeding involving an account debtor or upon the foreclosure or enforcement of any Lien in favor of a Loan Party or its Subsidiaries;
(k)Investments of any Person existing at the time such Person becomes a Subsidiary or consolidates or merges with Borrower or any Subsidiary thereof (including in connection with a Permitted Acquisition) so long as such Investments were not made in contemplation of such Person becoming a Subsidiary or of such consolidation or merger;
(l)deposits of cash made in the ordinary course of business to secure performance of (i) operating leases and (ii) other contractual obligations that do not constitute Indebtedness, including earnest money deposits made in cash in connection with any letter of intent or purchase agreement in connection with a Permitted Acquisition;
(m)Investments in negotiable instruments deposited or to be deposited for collection in the ordinary course of business;
- 113 -


(n)so long as no Default or Event of Default shall have occurred and be continuing or would immediately result therefrom, other Investments by the Borrower and its Subsidiaries after the Closing Date in an aggregate amount not to exceed $20,000,000;
(o)Investments constituting (i) accounts arising, (ii) trade debt granted or (iii) deposits made, in connection with the purchase price of goods or services, in each case in the ordinary course of business; and
(p)Guarantees by any Loan Party of leases of its Subsidiaries, or by any Subsidiary of a Loan Party of leases of such Loan Party, in each case, solely to the extent not constituting Indebtedness.
In determining the amount of Investments, acquisitions, loans, and advances permitted under this Section 7.4, Investments and acquisitions shall always be taken at the original cost thereof (regardless of any subsequent appreciation or depreciation therein) minus all returns of principal, capital, dividends, distributions and other cash returns thereof and minus all liabilities expressly assumed by another Person in connection with the sale or other Disposition of any Investment, and loans and advances shall be taken at the principal amount thereof then remaining unpaid.
Section 1.5Dispositions. The Borrower will not, and will not permit any of its Subsidiaries to, Dispose of any of its assets except:
(a)issuances of Qualified Equity Interests by (i) any Wholly-Owned Subsidiary of a Loan Party to a Loan Party, in each case subject to the Collateral and Guarantee Requirement;
(b)the sale or lease of inventory in the ordinary course of business;
(c)the use or transfer of money, cash or Cash Equivalents in a manner that is not prohibited by the terms of this Credit Agreement or the other Loan Documents;
(d)the licensing and sublicensing on a non-exclusive basis of patents, trademarks, copyrights, and other intellectual property rights in the ordinary course of business, and the leasing and subleasing of any other property;
(e)the granting of Liens permitted hereunder and the other transactions permitted by Section 7.2;
(f)any Casualty Event and the Disposition of any property subject thereto;
(g)the abandonment, cancellation or lapse of issued patents, registered trademarks and other registered intellectual property of a Loan Party or Subsidiary thereof to the extent, in such Loan Party’s reasonable business judgment, not economically desirable in the conduct of such Loan Party’s business or so long as such lapse is not materially adverse to the interests of the Lenders and (ii) the expiration of patents in accordance with their statutory terms;
(h)the sale of assets (other than Equity Interests of any Wholly-Owned Subsidiary, unless all of the Equity Interests of such Wholly-Owned Subsidiary (other than the Borrower) are sold in accordance with this clause (i)) for at least fair market value, so long as (A) no Default or Event of Default then exists or would immediately result therefrom, (B) at least 75% of the consideration received by the applicable Loan Party consists of cash or Cash Equivalents and is paid at the time of the closing of such sale, (C) the Net Cash Proceeds therefrom are applied and/or reinvested as (and to the extent)
- 114 -


required by Section 2.7(b)(i)(A) and (D) the aggregate amount of the cash and non-cash proceeds received from all assets sold pursuant to this clause (i) shall not exceed $10,000,000 in the aggregate in any Fiscal Year (for this purpose, using the fair market value of property other than cash and Cash Equivalents);
(i)any trade in of equipment in exchange for other equipment in the ordinary course of business;
(j)the unwinding or terminating of hedging arrangements or transactions contemplated by any Swap Agreement which are not prohibited hereunder;
(k)is by any Loan Party or Subsidiary thereof to any Loan Party;
(l)is by any Non-Loan Party Subsidiary to any Loan Party or any other Non-Loan Party Subsidiary; and
(m)any leases, subleases, licenses or sublicenses of property in the ordinary course of business.
To the extent the Required Lenders or all the Lenders, as applicable, waive the provisions of this Section 7.5 with respect to the sale of any Collateral, or any Collateral is sold as permitted by this Section 7.5, such Collateral (unless sold to a Loan Party) shall be sold automatically free and clear of the Liens created by the Collateral Documents and, at the expense of the Loan Parties, the Administrative Agent shall take all reasonable actions any Loan Party reasonably requests in writing in order to effect the foregoing.
Section 1.6Sale and Lease Back Transactions. The Borrower will not, and will not permit any of its Subsidiaries to, enter into any Sale and Leaseback arrangement, directly or indirectly, with any Person.
Section 1.7Swap Agreements. The Borrower will not, and will not permit any of its Subsidiaries to, enter into any Swap Agreement, except (a) Swap Agreements entered into in the ordinary course of business to hedge or mitigate risks to which the Borrower or any Subsidiary has actual exposure (other than those in respect of Equity Interests of the Borrower or any Subsidiary) and that are not for speculative purposes, and (b) Swap Agreements entered into in order to effectively cap, collar or exchange interest rates (from fixed to floating rates, from one floating rate to another floating rate or otherwise) with respect to any interest-bearing liability or investment of such Loan Party or Subsidiary.
Section 1.8Restricted Payments. The Borrower will not, and will not permit any of its Subsidiaries to, declare or make, or agree to pay for or make, directly or indirectly, any Restricted Payment, or incur any obligation (contingent or otherwise) to do so, except:
(a)subject to the Collateral and Guarantee Requirement, any Subsidiary of the Borrower may declare and pay, and agree to pay, dividends and other distributions with respect to its Equity Interests payable solely in perpetual common Equity Interests (other than Disqualified Equity Interests),
(b)any Subsidiary of the Borrower may declare and pay dividends or other distributions with respect to its Equity Interests to the Borrower or any Subsidiary Guarantor,
- 115 -


(c)so long as no Default or Event of Default shall have occurred and be continuing or would result therefrom, the Borrower may declare and pay Permitted Tax Distributions;
(d)the making of dividends or distributions by a Non-Loan Party Subsidiary to a Loan Party or another Non-Loan Party Subsidiary;
(e)the Borrower may make dividends payable solely in Equity Interests (other than Disqualified Equity Interests);
(f)so long as no Default or Event of Default shall have occurred and be continuing at the time of such purchase or would arise after giving effect thereto, the Borrower and its Subsidiaries may purchase common stock or common stock options from present or former officers, directors, employees or consultants of the Borrower and its Subsidiaries upon the death, disability or termination of employment of such person or otherwise in accordance with any stock option or stock appreciation rights plan or any stock ownership or subscription plan or equity incentive or other similar plan or termination agreement; provided that the aggregate amount of payments made under this clause shall not exceed $2,500,000 during any Fiscal Year of the Borrower;
(g)(i) the Borrower may make cashless repurchase of Equity Interests deemed to occur upon the exercise of stock options or warrants if such repurchased Equity Interests represents a portion of the exercise price of such options or warrants, and (ii) the Borrower may make repurchase of Equity Interests deemed to occur upon the withholding of a portion of the Equity Interests granted or awarded to a current or former officer, director, employee or consultant to pay for the Taxes payable by such Person upon such grant or award (or vesting thereof);
(h)the Borrower or any of its Subsidiaries may purchase, redeem or otherwise acquired Equity Interests issued by it with the proceeds received from the substantially concurrent issue of new shares of its Equity Interests (other than Disqualified Equity Interests); provided that any such issuance is otherwise permitted hereunder;
(i)payment of Earn-Out Obligations so long as (i) immediately before and immediately after giving effect to such payment, no Default or Event of Default shall have occurred and be continuing, (ii) immediately after giving effect to such payment, the Borrower and its Subsidiaries shall be in pro forma compliance with the Financial Covenants set forth in Sections 7.12(a) and (b), in each case, as of the last day of the most recent fiscal quarter for which financial statements have been delivered under Section 6.1, and (iii) immediately after giving effect to such payment, Liquidity shall be at least $20,000,000; and
(j)so long as (i) immediately before and immediately after giving effect to such payment, no Default or Event of Default shall have occurred and be continuing, the Borrower may make additional Restricted Payments in an aggregate amount not to exceed $10,000,000 in any Fiscal Year.
Section 1.9Transactions with Affiliates. The Borrower will not, and will not permit any of its Subsidiaries to, Dispose (including pursuant to a merger or Division) of any property or assets to, or purchase, lease or otherwise acquire (including pursuant to a merger or Division) any property or assets from, or otherwise engage in any other transactions with, any of its Affiliates involving aggregate payments or consideration in excess of $2,500,000, except (a) transactions in the ordinary course of business and at prices and on terms and conditions not less favorable to such Loan Party or such Subsidiary than could be obtained on an arm’s-length basis from unrelated third parties (it being understood that this Section shall not apply to any transaction that is expressly permitted under Sections 7.1, 7.3, 7.4, 7.5 or 7.8 of this Credit Agreement between or among the Loan Parties and not
- 116 -


involving any other Affiliate), (b) the Transactions, (c) the payment of customary fees and reasonable out-of-pocket costs to, and indemnities provided on behalf of, directors, officers and employees of any Loan Party and any of their respective Subsidiaries, (d) the payment of reasonable and customary compensation, severance and indemnification arrangements and benefit plans for officers and employees of any Loan Party and any of their respective Subsidiaries in the ordinary course of business and (e) any arrangement, transaction and contract with or among any other Loan Party in the ordinary course of business.
Section 1.10Restrictive Agreements. The Borrower will not, and will not permit any of its Subsidiaries to, directly or indirectly, enter into, incur or permit to exist any agreement or other arrangement that prohibits, restricts or imposes any condition upon (a) the ability of any Loan Party or any of its Subsidiaries to create, incur or permit to exist any Lien upon any of its property or assets (unless such agreement or arrangement does not prohibit, restrict or impose any condition upon the ability of any Loan Party to create, incur or permit to exist, or the ability of the Administrative Agent to exercise any right or remedy with respect to, any Lien in favor of the Secured Parties created under the Loan Documents) or (b) the ability of any Subsidiary to pay dividends or make other distributions with respect to any of its Equity Interests or to make or repay loans or advances to the Borrower or any other Subsidiary or to Guarantee Indebtedness of the Borrower or any other Subsidiary, provided that (i) the foregoing shall not apply to (A) restrictions and conditions imposed by law or by the Loan Documents, (B) restrictions and conditions existing on the Closing Date identified on Schedule 7.10 (but shall apply to any extension or renewal of, or any amendment or modification expanding the scope of, any such restriction or condition), and (C) customary restrictions and conditions contained in agreements relating to the sale of a subsidiary pending such sale provided that such restrictions and conditions apply only to its Subsidiary that is to be sold and such sale is permitted hereunder, (ii) clause (a) of this Section shall not apply to restrictions or conditions imposed by any agreement relating to secured Indebtedness permitted by this Credit Agreement if such restrictions or conditions apply only to the property or assets securing such Indebtedness, and (iii) clause (a) of this Section shall not apply to customary provisions in agreements restricting the assignment thereof.
Section 1.11Amendment of Material Documents. The Borrower will not, and will not permit any of its Subsidiaries to, amend, supplement modify or waive any of its rights under any Subordinated Debt Document or any of its Organizational Documents, other than immaterial amendments, modifications or waivers that could not reasonably be expected to adversely affect the Credit Parties, provided that the Borrower shall deliver or cause to be delivered to the Administrative Agent and each Lender a copy of all amendments, modifications or waivers thereto (other than immaterial or ministerial amendments, modifications and waivers) together with the next Compliance Certificate required to be delivered pursuant to Section 6.1(c).
Section 1.12Financial Covenants.
(a)Maximum Consolidated Total Net Leverage Ratio. The Borrower will not permit the Consolidated Total Net Leverage Ratio as of the end of any fiscal quarter to be greater than 3.50:1.00.
(b)Minimum Consolidated Fixed Charge Coverage Ratio. The Borrower will not permit the Consolidated Fixed Charge Coverage Ratio as of the end of any fiscal quarter to be less than 1.25:1.00:
Section 1.13Payments on Subordinated Debt. The Borrower will not, and will not permit any of its Subsidiaries to, declare or make, or agree to pay for or make, directly or indirectly, any payment of principal or interest or any purchase, redemption, retirement, acquisition or defeasance with respect to any
- 117 -


Indebtedness of such Person which is subordinated to the payment of the Loan Document Obligations except that so long as no Default or Event of Default shall have occurred and shall be continuing or would immediately result therefrom, the Borrower or any Subsidiary may make payments of Subordinated Debt to the extent permitted by the subordination provisions applicable thereto.
Section 1.14Government Regulation. The Borrower will not, and will not permit any of its Subsidiaries to, (a) at any time be or become the subject of any law, regulation, or list of any government agency (including the United States Office of Foreign Asset Control list) that prohibits or limits any Lender from making any loans or extension of credit (including the Loans and the Letters of Credit) to any Loan Party or from otherwise conducting business with any Loan Party, or (b) fail to provide documentary and other evidence of any Loan Party’s identity as may be requested by any Credit Party at any time to enable such Credit Party to verify any Loan Party’s identity or to comply with any Applicable Law or regulation, including Section 326 of the USA PATRIOT Act.
Section 1.15Hazardous Materials. The Borrower will not, and will not permit any of its Subsidiaries or agents to, cause or permit a Release or threat of Release of Hazardous Materials on, at, in, above, to, from or about any of the property where such Release or threat of Release would (a) violate, or form the basis for any Environmental Claims under, any Environmental Law or any Environmental Permit or (b) otherwise adversely impact the value or marketability of any property of any Loan Party or any of its Subsidiaries or any of the Collateral, other than such Release, violation or Environmental Claim as could not reasonably be expected to result in an Environmental Liability having a Material Adverse Effect.
Article 8

EVENTS OF DEFAULT
Section 1.1Events of Default. Any of the following shall constitute an Event of Default:
(a)Non-Payment of Principal or L/C Disbursement. Any Loan Party shall fail to pay any principal of any Loan or any reimbursement obligation in respect of any L/C Disbursement when and as the same shall become due and payable, whether at the due date thereof or at a date fixed for prepayment thereof or otherwise.
(b)Other Non-Payment. Any Loan Party shall fail to pay any interest on any Loan or on any reimbursement obligation in respect of any L/C Disbursement or any fee, commission or any other amount (other than an amount referred to in clause (a) of this Section) payable under any Loan Document, when and as the same shall become due and payable, and such failure shall continue unremedied for a period of three (3) Business Days.
(c)Representations and Warranties. Any representation or warranty made or deemed made by or on behalf of any Loan Party or any of its Subsidiaries in or in connection with any Loan Document or any amendment or modification hereof or waiver thereunder, or in any report, certificate, financial statement or other document furnished pursuant to or in connection with any Loan Document or any amendment or modification thereof or waiver thereunder, shall prove to have been incorrect in any material respect when made or deemed made.
(d)Specific Covenants. Any Loan Party shall fail to observe or perform any covenant, condition or agreement contained in Sections 6.1 (a)-(f), 6.2(a), 6.3(a) (solely with respect to the Borrower), 6.8, 6.12, or in Article 7.
- 118 -


(e)Other Covenants. Any Loan Party shall fail to observe or perform any covenant, condition or agreement contained in any Loan Document to which it is a party (other than those specified in clause (a), (b) or (d) of this Article), and such failure shall continue unremedied for a period of thirty (30) days after the occurrence thereof.
(f)Cross Default - Payment Default on Material Indebtedness. Any Loan Party shall fail to make any payment (whether of principal, interest or otherwise and regardless of amount) in respect of any Material Indebtedness when and as the same shall become due and payable (after giving effect to any applicable grace period).
(g)Other Cross-Defaults. (i) Any event or condition occurs that results in any Material Indebtedness becoming due prior to its scheduled maturity or payment date, or that enables or permits (with or without the giving of notice, the lapse of time or both) the holder or holders of any Material Indebtedness or any trustee or agent on its or their behalf to cause any Material Indebtedness to become due prior to their scheduled maturity or payment date or to require the prepayment, repurchase, redemption or defeasance thereof prior to their scheduled maturity or payment date (in each case after giving effect to any applicable notice and any applicable cure period), provided that this clause (g) shall not apply to secured Indebtedness that becomes due solely as a result of the voluntary sale, transfer or other disposition of the property or assets securing such Indebtedness; or (ii) any Loan Party or any of its Subsidiaries shall breach or default on any payment obligation constituting a Swap Agreement Obligation.
(h)Involuntary Proceedings. An involuntary proceeding shall be commenced or an involuntary petition shall be filed seeking (i) liquidation, reorganization or other relief in respect of any Loan Party or any of its Subsidiaries or its debts, or of a substantial part of its assets, under any Debtor Relief Law now or hereafter in effect or (ii) the appointment of a receiver, trustee, custodian, sequestrator, conservator or similar official for any Loan Party or any of its Subsidiaries or for a substantial part of its assets, and, in any such case, such proceeding or petition shall continue undismissed for 60 days or an order or decree approving or ordering any of the foregoing shall be entered.
(i)Voluntary Proceedings. Any Loan Party or any of its Subsidiaries shall (i) voluntarily commence any proceeding or file any petition seeking liquidation, reorganization or other relief under any Debtor Relief Law now or hereafter in effect, (ii) consent to the institution of, or fail to contest in a timely and appropriate manner, any proceeding or petition described in clause (h) of this Article, (iii) apply for or consent to the appointment of a receiver, trustee, custodian, sequestrator, conservator or similar official for any Loan Party or any of its Subsidiaries or for a substantial part of its assets, (iv) file an answer admitting the material allegations of a petition filed against it in any such proceeding, (v) make a general assignment for the benefit of creditors or (vi) take any action for the purpose of effecting any of the foregoing.
(j)Inability to Pay Debts. Any Loan Party or any of its Subsidiaries shall become unable, admit in writing its inability or fail generally to pay its debts as they become due.
(k)Judgments. One or more (i) non-monetary judgments which could, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, or (ii) judgments for the payment of money in an aggregate amount in excess of the Threshold Amount shall be rendered against any Loan Party or any of its Subsidiaries or any combination thereof (which shall not be fully covered (without taking into account any applicable deductibles) by insurance from an unaffiliated insurance company with an A.M. Best financial strength rating of at least A-, it being understood that even if such amounts are covered by insurance from such an insurance company, such amounts shall count against
- 119 -


such basket if responsibility for such amounts has been denied by such insurance company) and the same shall remain undischarged or unbonded for a period of 30 consecutive days during which execution shall not be effectively stayed, or any action shall be legally taken by a judgment creditor to attach or levy upon any assets of any Loan Party or any of its Subsidiaries to enforce any such judgment.
(l)ERISA Events. (i) An ERISA Event shall have occurred that, in the opinion of the Required Lenders, when taken together with all other ERISA Events that have occurred, would reasonably be expected to result in liability of any Loan Party or any of its Subsidiaries in an aggregate amount exceeding the Threshold Amount, (ii) an ERISA Event shall occur with respect to a Pension Plan or Multiemployer Plan that constitutes grounds for appointment of a trustee for or termination by the PBGC of any Pension Plan or Multiemployer Plan; (iii) a Loan Party or ERISA Affiliate shall fail to pay when due any installment payment with respect to its Withdrawal Liability under Section 4201 of ERISA under a Multiemployer Plan; (iv) any event similar to (i), (ii), or (iii) above shall occur or exist with respect to a Foreign Plan; or (v) there shall be at any time a Lien imposed against the assets of any Loan Party or ERISA Affiliate under Section 412 or Section 430 of the Code or Sections 302, Section 303, or Section 4068 of ERISA.
(m)Invalidity of Loan Documents. Any Loan Document or any material provision thereof shall cease, for any reason, to be in full force and effect, or any Loan Party shall so assert in writing or shall disavow any of its obligations thereunder.
(n)Liens. Any Lien purported to be created under any Collateral Document (other than Collateral consisting of Intellectual Property that is registered or owned pursuant to the applicable copyright, trademark, or patent laws of any country other than the United States) shall cease to be, or shall be asserted by any Loan Party not to be, a valid and perfected Lien on any Collateral, with the priority required by the applicable Collateral Document, except (i) as a result of the sale or other disposition of the applicable Collateral in a transaction permitted under the Loan Documents or (ii) as a result of the Administrative Agent’s failure (x) to maintain possession of any stock certificates, promissory notes or other instruments delivered to it under the Security Agreement, (y) to renew or continue any UCC financing statement filed against any of the Loan Parties to perfect its security interest in the Collateral of such Loan Party and/or (z) to file any necessary amendments to any of the UCC financing statements filed by the Administrative Agent against any of the Loan Parties subsequent to the timely notification under Section 6.9 by any Loan Party of a legal change in name or jurisdiction of organization or formation, change in chief executive office address, or Federal Taxpayer Identification Number.
(o)Licenses. There shall occur the loss, suspension or revocation of, or failure to renew any license or permit now held or hereafter acquired if such loss, suspension, revocation or failure to renew would reasonably be expected to have a Material Adverse Effect.
(p)Change of Control. A Change of Control shall occur.
(q)Cessation of Business. There shall occur a cessation of a substantial part of the business of any Loan Party which would reasonably be expected to have a Material Adverse Effect.
(r)Governmental Approvals. Any material Governmental Approvals necessary for any Loan Party to operate in the ordinary course shall have been revoked, rescinded, suspended, modified in adverse manner or not renewed in the ordinary course for a full term, and such decision or revocation, recission, suspension, modification or renewal has, or would reasonably be expected to have, a Material Adverse Effect.
- 120 -


Section 1.2Remedies Upon Event of Default. If any Event of Default occurs and is continuing, then, and in every such event (other than an event described in Section 8.1(h) or (i)), and at any time thereafter during the continuance of such event, the Administrative Agent may, and at the request of the Required Lenders shall, by notice to the Borrower, take either or both of the following actions (whether before or after the Closing Date), at the same or different times: (i) terminate the Commitments, and thereupon the Commitments shall terminate immediately, (ii) declare the Loans then outstanding to be due and payable in whole (or in part, in which case any principal not so declared to be due and payable may thereafter be declared to be due and payable), and thereupon the principal of the Loans so declared to be due and payable, together with accrued interest thereon and all fees and other obligations of each Loan Party accrued under the Loan Documents, shall become due and payable immediately, without presentment, demand, protest or other notice of any kind, all of which are hereby waived by the Borrower, and (iii) require that the Borrower Cash Collateralize the L/C Obligations (in an amount equal to the Minimum Collateral Amount with respect thereto) and thereupon such Cash Collateral shall become due and payable immediately, without presentment, demand, protest or other notice of any kind, all of which are hereby waived by the Borrower, and in case of any event described in Section 8.1(h) or (i), the Commitments shall automatically terminate (whether before or after the Closing Date) the principal of the Loans then outstanding, together with accrued interest thereon and all fees and other obligations of each Loan Party accrued under the Loan Documents, shall automatically become due and payable, without presentment, demand, protest or other notice of any kind, all of which are hereby waived by the Borrower and Cash Collateral for the L/C Obligations as described above shall automatically become due and payable, without presentment, demand, protest or other notice of any kind, all of which are hereby waived by the Borrower.
Section 1.3Application of Funds. After the exercise of remedies provided for in Section 8.2 (or after the Loans have automatically become immediately due and payable and the L/C Obligations have automatically been required to be Cash Collateralized as set forth in Section 2.10), any amounts received on account of the Secured Obligations shall be applied by the Administrative Agent in the following order:
First, to the payment of that portion of the Secured Obligations constituting fees, indemnities, expenses and other amounts (including fees, charges and disbursements of counsel to the Administrative Agent and amounts payable under Article 3), in each case payable to the Administrative Agent in its capacity as such;
Second, to the extent of any excess of such proceeds, to the payment of that portion of the Secured Obligations constituting fees, indemnities, expenses and other amounts (including fees, charges and disbursements of counsel to the L/C Issuer and the L/C Fronting Fee), in each case payable to the L/C Issuer in its capacity as such;
Third, to the extent of any excess of such proceeds, to the payment of that portion of the Secured Obligations constituting fees, indemnities and other amounts, payable to the Credit Parties (including fees, charges and disbursements of counsel to the respective Credit Parties and amounts payable under Article 3), ratably among them in proportion to the respective amounts described in this clause Third payable to them;
Fourth, to the extent of any excess of such proceeds, to the payment of that portion of the Secured Obligations constituting accrued and unpaid interest on the Loans, L/C Obligations and other Secured Obligations, ratably among the Credit Parties in proportion to the respective amounts described in this clause Fourth payable to them;
- 121 -


Fifth, to the extent of any excess of such proceeds, to the payment of that portion of the Secured Obligations constituting unpaid principal of the Loans and L/C Obligations, the Cash Management Obligations and the Swap Agreement Obligations, ratably among the Secured Parties in proportion to the respective amounts described in this clause Fifth held by them;
Sixth, to the extent of any excess of such proceeds, to the Administrative Agent for the account of the L/C Issuer, to Cash Collateralize that portion of L/C Obligations comprised of the aggregate undrawn amount of Letters of Credit;
Seventh, to the extent of any excess of such proceeds, to the payment of all other Secured Obligations of the Loan Parties owing under or in respect of the Loan Documents that are due and payable to the Secured Parties, or any of them, on such date, ratably based on the respective aggregate amounts of all such Secured Obligations owing to the Secured Parties on such date; and
Last, to the extent of any excess of such proceeds, the balance, if any, after all of the Secured Obligations (other than unasserted contingent indemnification and unasserted expense reimbursement obligations in each case not yet due and payable) have been paid in full, to the Borrower or as otherwise required by law.
Subject to Section 2.10, amounts used to Cash Collateralize the aggregate undrawn amount of Letters of Credit pursuant to clause Fifth above shall be applied to satisfy drawings under such Letters of Credit as they occur. If any amount remains on deposit as Cash Collateral after all Letters of Credit have either been fully drawn or expired, such remaining amount shall be applied to the Secured Obligations, if any, in the order set forth above. The Administrative Agent shall have no obligation to calculate the amount of any Swap Agreement Obligations or Cash Management Obligations and may request a reasonably detailed calculation thereof from the provider of such Secured Obligations. If the provider of any Swap Agreement Obligations or Cash Management Obligations fails to deliver the calculation of such Secured Obligations within five (5) days following request thereof by the Administrative Agent, then the Administrative Agent may assume the amount of such Secured Obligations are zero. Notwithstanding anything to the contrary set forth above, Excluded CEA Swap Obligations with respect to any Guarantor shall not be paid with amounts received from such Guarantor or its assets, but appropriate adjustments shall be made with respect to payments from other Loan Parties to preserve the allocation to Secured Obligations otherwise set forth above in this Section.
Article 9

THE ADMINISTRATIVE AGENT
Section 1.1Appointment and Authority. Each of the Lenders and the L/C Issuer hereby irrevocably appoints Citizens Bank to act on its behalf as the Administrative Agent hereunder and under the other Loan Documents and authorizes the Administrative Agent to take such actions on its behalf and to exercise such powers as are delegated to the Administrative Agent by the terms hereof or thereof, together with such actions and powers as are reasonably incidental thereto. The provisions of this Article are solely for the benefit of the Administrative Agent, the Lenders and the L/C Issuer, and neither the Borrower nor any other Loan Party shall have rights as a third-party beneficiary of any of such provisions. It is understood and agreed that the use of the term “agent” herein or in any other Loan Documents (or any other similar term) with reference to the Administrative Agent is not intended to connote any fiduciary or other implied (or express) obligations arising under agency doctrine of any Applicable Law. Instead such term is used as a matter of market custom, and is intended to create or reflect only an administrative relationship between contracting parties.
- 122 -


Section 1.2Rights as a Lender or L/C Issuer. The Person serving as the Administrative Agent hereunder shall have the same rights and powers in its capacity as a Lender or L/C Issuer as any other Lender or L/C Issuer and may exercise the same as though it were not the Administrative Agent, and the term “Lender” or “Lenders” shall, unless otherwise expressly indicated or unless the context otherwise requires, include the Person serving as the Administrative Agent hereunder in its individual capacity. Such Person and its branches and Affiliates may accept deposits from, lend money to, own securities of, act as the financial advisor or in any other advisory capacity for, and generally engage in any kind of business with, the Borrower or any Subsidiary or other Affiliate thereof as if such Person were not the Administrative Agent hereunder and without any duty to account therefor to the Lenders.
Section 1.3Exculpatory Provisions.
(a)The Administrative Agent shall not have any duties or obligations except those expressly set forth herein and in the other Loan Documents, and its duties hereunder shall be administrative in nature. Without limiting the generality of the foregoing, the Administrative Agent:
(i)shall not be subject to any fiduciary or other implied duties, regardless of whether a Default or Event of Default has occurred and is continuing;
(ii)shall not have any duty to take any discretionary action or exercise any discretionary powers, except discretionary rights and powers expressly contemplated hereby or by the other Loan Documents that the Administrative Agent is required to exercise as directed in writing by the Required Lenders (or such other number or percentage of the Lenders as shall be expressly provided for herein or in the other Loan Documents); provided that the Administrative Agent shall not be required to take any action that, in its opinion or the opinion of its counsel, may expose the Administrative Agent to liability or that is contrary to any Loan Document or Applicable Law, including for the avoidance of doubt any action that may be in violation of the automatic stay under any Debtor Relief Law or that may effect a forfeiture, modification or termination of property of a Defaulting Lender in violation of any Debtor Relief Law; and
(iii)shall not, except as expressly set forth herein and in the other Loan Documents, have any duty to disclose, and shall not be liable for the failure to disclose, any information relating to the Borrower or any of its Affiliates that is communicated to or obtained by the Person serving as the Administrative Agent or any of its branches or Affiliates in any capacity.
(b)The Administrative Agent shall not be liable for any action taken or not taken by it (i) with the consent or at the request of the Required Lenders (or such other number or percentage of the Lenders as shall be necessary, or as the Administrative Agent shall believe in good faith shall be necessary, under the circumstances as provided in Section 8.2 and Section 10.2), or (ii) in the absence of its own gross negligence, willful misconduct, or breach in bad faith as determined by a court of competent jurisdiction by final and nonappealable judgment. The Administrative Agent shall be deemed not to have knowledge of any Default or Event of Default unless and until notice describing such Default or Event of Default is given to the Administrative Agent in writing by the Borrower, a Lender or the L/C Issuer.
(c)The Administrative Agent shall not be responsible for or have any duty to ascertain or inquire into (i) any statement, warranty or representation made in or in connection with this Credit Agreement or any other Loan Document, (ii) the contents of any certificate, report or other document delivered hereunder or thereunder or in connection herewith or therewith, (iii) the performance or observance of any of the covenants, agreements or other terms or conditions set forth herein or therein or the occurrence of any Default, (iv) the validity, enforceability, effectiveness or genuineness of this
- 123 -


Credit Agreement, any other Loan Document or any other agreement, instrument or document, or (v) the satisfaction of any condition set forth in Article 5 or elsewhere herein, other than to confirm receipt of items expressly required to be delivered to the Administrative Agent.
(d)The Administrative Agent shall not be responsible or have any liability for, or have any duty to investigate a violation or potential violation of an Environmental Law or a Release or threat of Release of a Hazardous Material pursuant to Section 6.13, nor shall it have any liability for any action it takes or does not take in connection with any such investigation.
Section 1.4Reliance by Administrative Agent. The Administrative Agent shall be entitled to rely upon, and shall not incur any liability for relying upon, any notice, request, certificate, consent, statement, instrument, document or other writing (including any electronic message, Internet or intranet website posting or other distribution) believed by it to be genuine and to have been signed, sent or otherwise authenticated by the proper Person. The Administrative Agent also may rely upon any statement made to it orally or by telephone and believed by it to have been made by the proper Person, and shall not incur any liability for relying thereon. In determining compliance with any condition hereunder to the making of a Loan, or the issuance, extension, amendment, increase, reinstatement or renewal of a Letter of Credit, that by its terms must be fulfilled to the satisfaction of a Lender or the L/C Issuer, the Administrative Agent may presume that such condition is satisfactory to such Lender or the L/C Issuer unless the Administrative Agent shall have received notice to the contrary from such Lender or the L/C Issuer prior to the making of such Loan or the issuance of such Letter of Credit. The Administrative Agent may consult with legal counsel (who may be counsel for the Borrower), independent accountants and other experts selected by it, and shall not be liable for any action taken or not taken by it in accordance with the advice of any such counsel, accountants or experts.
Section 1.5Delegation of Duties. The Administrative Agent may perform any and all of its duties and exercise its rights and powers hereunder or under any other Loan Document by or through any one or more sub-agents appointed by the Administrative Agent. The Administrative Agent and any such sub-agent may perform any and all of its duties and exercise its rights and powers by or through their respective Related Parties. The exculpatory provisions of this Article shall apply to any such sub-agent and to the Related Parties of the Administrative Agent and any such sub-agent, and shall apply to their respective activities in connection with the syndication of the Credit Facilities as well as activities as Administrative Agent. The Administrative Agent shall not be responsible for the negligence or misconduct of any sub-agents except to the extent that a court of competent jurisdiction determines in a final and nonappealable judgment that the Administrative Agent acted with gross negligence or willful misconduct in the selection of such sub-agents.
Section 1.6Resignation of Administrative Agent.
(a)The Administrative Agent may at any time give notice of its resignation to the Lenders, the L/C Issuer and the Borrower. Upon receipt of any such notice of resignation, the Required Lenders shall have the right, in consultation with the Borrower, to appoint a successor, which shall be a bank with an office in New York, New York, or an Affiliate of any such bank with an office in New York, New York. If no such successor shall have been so appointed by the Required Lenders and shall have accepted such appointment within thirty (30) days after the retiring Administrative Agent gives notice of its resignation (or such earlier day as shall be agreed by the Required Lenders) (the “Resignation Effective Date”), then the retiring Administrative Agent may (but shall not be obligated to), on behalf of the Lenders and the L/C Issuer, appoint a successor Administrative Agent meeting the qualifications set forth above, provided that in no event shall any such successor Administrative Agent be a Defaulting
- 124 -


Lender. Whether or not a successor has been appointed, such resignation shall become effective in accordance with such notice on the Resignation Effective Date.
(b)If the Person serving as Administrative Agent is a Defaulting Lender pursuant to clause (d) of the definition thereof, the Required Lenders may, to the extent permitted by Applicable Law, by notice in writing to the Borrower and such Person remove such Person as Administrative Agent and, in consultation with the Borrower, appoint a successor. If no such successor shall have been so appointed by the Required Lenders and shall have accepted such appointment within thirty (30) days (or such earlier day as shall be agreed by the Required Lenders) (the “Removal Effective Date”), then such removal shall nonetheless become effective in accordance with such notice on the Removal Effective Date.
(c)With effect from the Resignation Effective Date or the Removal Effective Date (as applicable) (i) the retiring or removed Administrative Agent shall be discharged from its duties and obligations hereunder and under the other Loan Documents and (ii) except for any indemnity payments owed to the retiring or removed Administrative Agent, all payments, communications and determinations provided to be made by, to or through the Administrative Agent shall instead be made by or to each Lender and the L/C Issuer directly, until such time, if any, as the Required Lenders appoint a successor Administrative Agent as provided for above. Upon the acceptance of a successor’s appointment as Administrative Agent hereunder, such successor shall succeed to and become vested with all of the rights, powers, privileges and duties of the retiring or removed Administrative Agent (other than any rights to indemnity payments owed to the retiring or removed Administrative Agent), and the retiring or removed Administrative Agent shall be discharged from all of its duties and obligations hereunder or under the other Loan Documents. The fees payable by the Borrower to a successor Administrative Agent shall be the same as those payable to its predecessor unless otherwise agreed between the Borrower and such successor. After the retiring or removed Administrative Agent’s resignation or removal hereunder and under the other Loan Documents, the provisions of this Article and Section 10.3 shall continue in effect for the benefit of such retiring or removed Administrative Agent, its sub-agents and their respective Related Parties in respect of any actions taken or omitted to be taken by any of them while the retiring or removed Administrative Agent was acting as Administrative Agent. To the extent the retiring or removed Administrative Agent is holding cash, deposit account balances or other credit support as collateral for Cash Collateralized Letters of Credit, the retiring or removed Administrative Agent shall on or reasonably promptly following the Resignation Effective Date or the Removal Effective Date (as applicable) cause such collateral to be transferred to the successor Administrative Agent or, if no successor Administrative Agent has been appointed and accepted such appointment, to the respective L/C Issuers ratably according to the outstanding amount of Cash Collateralized Letters of Credit issued by them, in each case to be held as collateral for such Cash Collateralized Letters of Credit in accordance with this Credit Agreement.
Section 1.7Non-Reliance on Administrative Agent, L/C Issuers and Other Lenders. Each Lender and L/C Issuer expressly acknowledges that that none of the Administrative Agent nor any arranger or bookrunner (collectively the “Arranger”) has made any representation or warranty to it, and that no act by the Administrative Agent or the Arranger hereafter taken, including any consent to, and acceptance of any assignment or review of the affairs of any Loan Party or any Affiliate thereof, shall be deemed to constitute any representation or warranty by the Administrative Agent or the Arranger to any Lender or L/C Issuer as to any matter, including whether the Administrative Agent or the Arranger have disclosed material information in their (or their Related Parties’) possession. Each Lender and L/C Issuer represents to the Administrative Agent and the Arranger that it has, independently and without reliance upon the Administrative Agent, any Arranger, or any other Lender or any of their Related Parties and based on such documents and information as it has deemed appropriate, made its own credit analysis of, appraisal of, and investigation into, the business, prospects, operations, property, financial and other condition and creditworthiness of the Loan Parties and their Subsidiaries, and all applicable bank or other
- 125 -


regulatory Laws relating to the transactions contemplated hereby, and made its own decision to enter into this Credit Agreement and to extend credit to the Borrower hereunder. Each Lender and L/C Issuer also acknowledges that it will, independently and without reliance upon the Administrative Agent, any Arranger, or any other Lender or any of their Related Parties and based on such documents and information as it shall from time to time deem appropriate, continue to make its own credit analyses, appraisals and decisions in taking or not taking action under or based upon this Credit Agreement, any other Loan Document or any related agreement or any document furnished hereunder or thereunder, and to make such investigations as it deems necessary to inform itself as to the business, prospects, operations, property, financial and other condition and creditworthiness of the Loan Parties. Each Lender and L/C Issuer represents and warrants that (i) the Loan Documents set forth the terms of a commercial lending facility and (ii) it is engaged in making, acquiring and/or holding commercial loans in the ordinary course and is entering into this Credit Agreement as a Lender or L/C Issuer for the purpose of making, acquiring or holding commercial loans and providing other facilities set forth herein as may be applicable to such Lender or L/C Issuer, and not for the purpose of purchasing, acquiring or holding any other type of financial instrument, and each Lender and L/C Issuer agrees not to assert a claim in contravention of the foregoing. Each Lender and L/C Issuer represents and warrants that it is sophisticated with respect to decisions to make, acquire and/or hold commercial loans and to provide other facilities set forth herein, as may be applicable to such Lender or such L/C Issuer, and either it, or the Person exercising discretion in making its decision to make, acquire and/or hold such commercial loans or to provide such other facilities, is experienced in making, acquiring and/or holding such commercial loans or providing such other facilities.
Section 1.8No Other Duties, Etc. Anything herein to the contrary notwithstanding, none of the Lead Arranger or any agent listed on the cover page hereof shall have any powers, duties or responsibilities under this Credit Agreement or any of the other Loan Documents, except in its capacity, as applicable, as the Administrative Agent, a Lender or the L/C Issuer hereunder.
Section 1.9Administrative Agent May File Proofs of Claims; Credit Bidding. In case of the pendency of any proceeding under any Debtor Relief Law or any other judicial proceeding relative to any Loan Party, the Administrative Agent (irrespective of whether the principal of any Loan or reimbursement for any L/C Disbursement shall then be due and payable as herein expressed or by declaration or otherwise and irrespective of whether the Administrative Agent shall have made any demand on the Borrower) shall be entitled and empowered (but not obligated) by intervention in such proceeding or otherwise:
(a)to file and prove a claim for the whole amount of the principal and interest owing and unpaid in respect of the Loans, L/C Obligations and all other Loan Document Obligations that are owing and unpaid and to file such other documents as may be necessary or advisable in order to have the claims of the Lenders, the L/C Issuer and the Administrative Agent (including any claim for the reasonable compensation, expenses, disbursements and advances of the Lenders, the L/C Issuer and the Administrative Agent and their respective agents and counsel and all other amounts due the Lenders, the L/C Issuer and the Administrative Agent under Section 10.3) allowed in such judicial proceeding; and
(b)to collect and receive any monies or other property payable or deliverable on any such claims and to distribute the same;
and any custodian, receiver, assignee, trustee, liquidator, sequestrator or other similar official in any such judicial proceeding is hereby authorized by each Lender and the L/C Issuer to make such payments to the Administrative Agent and, in the event that the Administrative Agent shall consent to the making of such payments directly to the Lenders and the L/C Issuer, to pay to the Administrative Agent any amount due
- 126 -


for the reasonable compensation, expenses, disbursements and advances of the Administrative Agent and its agents and counsel, and any other amounts due to the Administrative Agent under Section 10.3.
        (c)    The Secured Parties hereby irrevocably authorize the Administrative Agent, at the direction of the Required Lenders, to credit bid all or any portion of the Secured Obligations (including accepting some or all of the Collateral in satisfaction of some or all of the Secured Obligations pursuant to a deed in lieu of foreclosure or otherwise) and in such manner purchase (either directly or through one or more acquisition vehicles) all or any portion of the Collateral (i) at any sale thereof conducted under the provisions of the Bankruptcy Code of the United States, including under Sections 363, 1123 or 1129 of the Bankruptcy Code of the United States, or any similar Laws in any other jurisdictions to which a Loan Party is subject, (ii) at any other sale or foreclosure or acceptance of collateral in lieu of debt conducted by (or with the consent or at the direction of) the Administrative Agent (whether by judicial action or otherwise) in accordance with any Applicable Law. In connection with any such credit bid and purchase, the Secured Obligations owed to the Secured Parties shall be entitled to be, and shall be, credit bid on a ratable basis (with Secured Obligations with respect to contingent or unliquidated claims receiving contingent interests in the acquired assets on a ratable basis that would vest upon the liquidation of such claims in an amount proportional to the liquidated portion of the contingent claim amount used in allocating the contingent interests) in the asset or assets so purchased (or in the Equity Interests or debt instruments of the acquisition vehicle or vehicles that are used to consummate such purchase). In connection with any such bid (A) the Administrative Agent shall be authorized to form one or more acquisition vehicles to make a bid, (B) to adopt documents providing for the governance of the acquisition vehicle or vehicles (provided that any actions by the Administrative Agent with respect to such acquisition vehicle or vehicles, including any disposition of the assets or Capital Stock thereof shall be governed, directly or indirectly, by the vote of the Required Lenders, irrespective of the termination of this Agreement and without giving effect to the limitations on actions by the Required Lenders contained in Section 10.02(b)), and (C) to the extent that Secured Obligations that are assigned to an acquisition vehicle are not used to acquire Collateral for any reason (as a result of another bid being higher or better, because the amount of Secured Obligations assigned to the acquisition vehicle exceeds the amount of debt credit bid by the acquisition vehicle or otherwise), such Secured Obligations shall automatically be reassigned to the Lenders pro rata and the Capital Stock and/or debt instruments issued by any acquisition vehicle on account of the Secured Obligations that had been assigned to the acquisition vehicle shall automatically be cancelled, without the need for any Secured Party or any acquisition vehicle to take any further action.
Section 1.10Collateral and Guarantee Matters.
(a)The Secured Parties irrevocably authorize the Administrative Agent, at its option and in its discretion,
(i)to release any Lien on any property granted to or held by the Administrative Agent under any Loan Document (A) at the Termination Date, (B) that is sold or otherwise Disposed of or to be sold or otherwise Disposed of as part of or in connection with any sale or other Disposition permitted under the Loan Documents to a Person that is not and is not required to become a Loan Party; provided, however, any sale or Disposition of all or substantially all of the Collateral or all or substantially all of the value of the Guarantees under the Guarantee Agreement shall be subject to Section 10.2(b), or (C) subject to Section 10.2, if approved, authorized or ratified in writing by the Required Lenders;
- 127 -


(ii)to subordinate any Lien on any property granted to or held by the Administrative Agent under any Loan Document to the holder of any Lien on such property that is permitted by Section 7.2(d); and
(iii)to release any Guarantor from its obligations under the Loan Documents if such Person ceases to be a Subsidiary as a result of a transaction permitted under the Loan Documents, provided, however, that the release of all or substantially all of the Collateral or all or substantially all of the value of the Guarantees under the Guarantee Agreement shall be subject to Section 10.2(b).
Upon request by the Administrative Agent at any time, the Required Lenders will confirm in writing the Administrative Agent’s authority to release or subordinate its interest in particular types or items of property, or to release any Guarantor from its obligations under the Loan Documents pursuant to this Section 9.10.
(b)The Administrative Agent shall not be responsible for or have a duty to ascertain or inquire into any representation or warranty regarding the existence, value or collectability of the Collateral, the existence, priority or perfection of the Administrative Agent’s Lien thereon, or any certificate prepared by any Loan Party in connection therewith, nor shall the Administrative Agent be responsible or liable to the Lenders for any failure to monitor or maintain any portion of the Collateral.
Section 1.11[Reserved].
Section 1.12Cash Management Obligations and Swap Agreement Obligations. Except as otherwise expressly set forth herein or in the Security Agreement, any other Collateral Document or any other Loan Document, no Person holding Cash Management Obligations or Swap Agreement Obligations that obtains the benefits of any Guarantee under the Guarantee Agreement or any Collateral by virtue of the provisions hereof or of any Loan Document shall have any right to notice of any action or to consent to, direct or object to any action hereunder or under any other Loan Document or otherwise in respect of the Collateral (including the release or impairment of any Collateral or amendment to any Loan Document (including any Collateral Document) other than in its capacity as a Lender or Administrative Agent and, in such case, only to the extent expressly provided in the Loan Documents. Notwithstanding any other provision of this Article 9 to the contrary, the Administrative Agent shall not be required to verify the payment of, or that other satisfactory arrangements have been made with respect to, Cash Management Obligations or Swap Agreement Obligations except to the extent expressly required hereunder, provided that the Administrative Agent has received a Secured Obligation Designation Notice, together with such supporting documentation as the Administrative Agent may request, from the applicable Person holding such Secured Obligations. The Administrative Agent shall not be required to verify the payment of, or that other satisfactory arrangements have been made with respect to, Cash Management Obligations and Swap Agreement Obligations.
Section 1.13Erroneous Payments.
(a)If the Administrative Agent (x) notifies a Lender, L/C Issuer or Secured Party, or any Person who has received funds on behalf of a Lender, L/C Issuer or Secured Party (any such Lender, L/C Issuer, Secured Party or other recipient (and each of their respective successors and assigns), a “Payment Recipient”) that the Administrative Agent has determined in its sole discretion (whether or not after receipt of any notice under Section 9.13(b)) that any funds (as set forth in such notice from the Administrative Agent) received by such Payment Recipient from the Administrative Agent or any of its Affiliates were erroneously or mistakenly transmitted to, or otherwise erroneously or mistakenly received by, such Payment Recipient (whether or not known to such Lender, L/C Issuer, Secured Party or other
- 128 -


Payment Recipient on its behalf) (any such funds, whether transmitted or received as a payment, prepayment or repayment of principal, interest, fees, distribution or otherwise, individually and collectively, an “Erroneous Payment”) and (y) demands the return of such Erroneous Payment (or a portion thereof), such Erroneous Payment shall at all times remain the property of the Administrative Agent pending its return or repayment as contemplated below in this Section 9.13 and held in trust for the benefit of the Administrative Agent, and such Lender, L/C Issuer or Secured Party shall (or, with respect to any Payment Recipient who received such funds on its behalf, shall cause such Payment Recipient to) promptly, but in no event later than two (2) Business Days thereafter (or such later date as the Administrative Agent may, in its sole discretion, specify in writing), return to the Administrative Agent the amount of any such Erroneous Payment (or portion thereof) as to which such a demand was made, in same day funds (in the currency so received), together with interest thereon (except to the extent waived in writing by the Administrative Agent) in respect of each day from and including the date such Erroneous Payment (or portion thereof) was received by such Payment Recipient to the date such amount is repaid to the Administrative Agent in same day funds at the greater of the Federal Funds Rate and a rate determined by the Administrative Agent in accordance with banking industry rules on interbank compensation from time to time in effect. A notice of the Administrative Agent to any Payment Recipient under this Section 9.13(a) shall be conclusive, absent manifest error.
(b)Without limiting the provisions of Section 9.13(a), each Payment Recipient (and each of their respective successors and assigns) hereby further agrees that if it receives a payment, prepayment or repayment (whether received as a payment, prepayment or repayment of principal, interest, fees, distribution or otherwise) from the Administrative Agent (or any of its Affiliates) (x) that is in a different amount than, or on a different date from, that specified in this Credit Agreement or in a notice of payment, prepayment or repayment sent by the Administrative Agent (or any of its Affiliates) with respect to such payment, prepayment or repayment, (y) that was not preceded or accompanied by a notice of payment, prepayment or repayment sent by the Administrative Agent (or any of its Affiliates), or (z) that such Payment Recipient otherwise becomes aware was transmitted, or received, in error or by mistake (in whole or in part), in each case:
(i)it acknowledges and agrees that (A) in the case of immediately preceding clauses (x) or (y), an error shall be presumed to have been made (absent written confirmation from the Administrative Agent to the contrary) or (B) in the case of immediately preceding clause (z), an error and mistake has been made, in each case, with respect to such payment, prepayment or repayment; and
(ii)such Lender, L/C Issuer or Secured Party shall (and shall cause any other recipient that receives funds on its respective behalf to) promptly (and, in all events, within one (1) Business Day of its knowledge of the occurrence of any of the circumstances described in immediately preceding clauses (x), (y) and (z)) notify the Administrative Agent of its receipt of such payment, prepayment or repayment, the details thereof (in reasonable detail) and that it is so notifying the Administrative Agent pursuant to this Section 9.13(b). For the avoidance of doubt, the failure to deliver a notice to the Administrative Agent pursuant to this Section 9.13(b) shall not have any effect on a Payment Recipient’s obligations pursuant to Section 9.13(a) or on whether or not an Erroneous Payment has been made.
(c)Each Lender, L/C Issuer or Secured Party hereby authorizes the Administrative Agent to set off, net and apply any and all amounts at any time owing to such Lender, L/C Issuer or Secured Party under any Loan Document, or otherwise payable or distributable by the Administrative Agent to such Lender, L/C Issuer or Secured Party under any Loan Document with respect to any
- 129 -


payment of principal, interest, fees, or other amounts, against any amount that the Administrative Agent has demanded to be returned under Section 9.13(a).
(d)(i)    In the event that an Erroneous Payment (or portion thereof) is not recovered by the Administrative Agent for any reason, after demand therefor in accordance with Section 9.13(a), from any Lender that has received such Erroneous Payment (or portion thereof) (and/or from any Payment Recipient who received such Erroneous Payment (or portion thereof) on its respective behalf) (such unrecovered amount, an “Erroneous Payment Return Deficiency”), upon the Administrative Agent’s notice to such Lender at any time, then effective immediately (with the consideration therefor being acknowledged by the parties hereto), (A) such Lender shall be deemed to have assigned its Loans (but not its Commitments) of the relevant Class with respect to which such Erroneous Payment was made (the “Erroneous Payment Impacted Class”) in an amount equal to the Erroneous Payment Return Deficiency (or such lesser amount as the Administrative Agent may specify) (such assignment of the Loans (but not Commitments) of the Erroneous Payment Impacted Class, the “Erroneous Payment Deficiency Assignment”) (on a cashless basis and such amount calculated at par plus any accrued and unpaid interest (with the assignment fee to be waived by the Administrative Agent in such instance), and is hereby (together with the Borrower) deemed to execute and deliver an Assignment and Assumption with respect to such Erroneous Payment Deficiency Assignment, and such Lender shall deliver any Notes evidencing such Loans to the Borrower or the Administrative Agent (but the failure of such Person to deliver any such Notes shall not affect the effectiveness of the foregoing assignment), (B) the Administrative Agent as the assignee Lender shall be deemed to have acquired the Erroneous Payment Deficiency Assignment, (C) upon such deemed acquisition, the Administrative Agent as the assignee Lender shall become a Lender hereunder with respect to such Erroneous Payment Deficiency Assignment and the assigning Lender shall cease to be a Lender hereunder with respect to such Erroneous Payment Deficiency Assignment, excluding, for the avoidance of doubt, its obligations under the indemnification provisions of this Credit Agreement and its applicable Commitments which shall survive as to such assigning Lender, (D) the Administrative Agent and the Borrower shall be deemed to have waived any consents required under this Credit Agreement to any such Erroneous Payment Deficiency Assignment, and (E) the Administrative Agent may reflect in the Register its ownership interest in the Loans subject to the Erroneous Payment Deficiency Assignment. For the avoidance of doubt, no Erroneous Payment Deficiency Assignment will reduce the Commitments of any Lender and such Commitments shall remain available in accordance with the terms of this Credit Agreement.
(i)The Administrative Agent may, in its discretion, sell any Loans acquired pursuant to an Erroneous Payment Deficiency Assignment and upon receipt of the proceeds of such sale, the Erroneous Payment Return Deficiency owing by the applicable Lender shall be reduced by the net proceeds of the sale of such Loan (or portion thereof), and the Administrative Agent shall retain all other rights, remedies and claims against such Lender (and/or against any recipient that receives funds on its respective behalf). In addition, an Erroneous Payment Return Deficiency owing by the applicable Lender (x) shall be reduced by the proceeds of prepayments or repayments of principal and interest or other distribution in respect of principal and interest, received by the Administrative Agent on or with respect to any such Loans acquired from such Lender pursuant to an Erroneous Payment Deficiency Assignment (to the extent that any such Loans are then owned by the Administrative Agent) and (y) may in the sole discretion of the Administrative Agent be reduced by any amount specified by the Administrative Agent in writing to the applicable Lender from time to time.
(e)The parties hereto agree (x) irrespective of whether the Administrative Agent may be equitably subrogated, in the event that an Erroneous Payment (or portion thereof) is not recovered from any Payment Recipient that has received such Erroneous Payment (or portion thereof) for any
- 130 -


reason, the Administrative Agent shall be subrogated to all the rights and interests of such Payment Recipient (and, in the case of any Payment Recipient who has received funds on behalf of a Lender, L/C Issuer or Secured Party, to the rights and interests of such Lender, L/C Issuer or Secured Party, as the case may be) under the Loan Documents with respect to such amount (the “Erroneous Payment Subrogation Rights”) (provided that the Loan Parties’ Secured Obligations under the Loan Documents in respect of the Erroneous Payment Subrogation Rights shall not be duplicative of such Secured Obligations in respect of Loans that have been assigned to the Administrative Agent under an Erroneous Payment Deficiency Assignment) and (y) that an Erroneous Payment shall not pay, prepay, repay, discharge or otherwise satisfy any Secured Obligations owed by the Borrower or any other Loan Party; provided that this Section 9.13 shall not be interpreted to increase (or accelerate the due date for) the Obligations of the Borrower relative to the amount (and/or timing for payment) of the Obligations that would have been payable had such Erroneous Payment not been made by the Administrative Agent; provided, further, that for the avoidance of doubt, immediately preceding clauses (x) and (y) shall not apply to the extent any such Erroneous Payment is, and solely with respect to the amount of such Erroneous Payment that is, comprised of funds received by the Administrative Agent from the Borrower for the purpose of making such Erroneous Payment.
(f)To the extent permitted by Applicable Law, no Payment Recipient shall assert any right or claim to an Erroneous Payment, and hereby waives, and is deemed to waive, any claim, counterclaim, defense or right of set-off or recoupment with respect to any demand, claim or counterclaim by the Administrative Agent for the return of any Erroneous Payment received, including without limitation any defense based on “discharge for value” or any similar doctrine.
(g)Each party’s obligations, agreements and waivers under this Section 9.13 shall survive the resignation or replacement of the Administrative Agent, any transfer of rights or obligations by, or the replacement of, a Lender or L/C Issuer, the termination of the Commitments and/or the repayment, satisfaction or discharge of all Secured Obligations (or any portion thereof).
Article 10

MISCELLANEOUS
Section 1.1Notices.
(a)Notices Generally. Except in the case of notices and other communications expressly permitted to be given by telephone (and except as provided in paragraph (b) below), all notices and other communications provided for herein shall be in writing and shall be delivered by hand or overnight courier service, mailed by certified or registered mail or sent by facsimile as follows:
(i)if to any Loan Party, MiMedx Group, Inc., 1775 West Oak Commons, Ct., NE, Marietta, GA 30062, Attention: Legal Department, Email: legaldept@mimedx.com, with a copy to (which shall not constitute notice), Greenberg Traurig, LLP, Terminus 200, 3333 Piedmont Road NE, Suite 2500, Atlanta, GA 30305, Attention: Bethani Oppenheimer, Email: oppenheimerb@gtlaw.com;
(ii)if to the Administrative Agent, the L/C Issuer or the Swingline Lender, to the address, facsimile number, electronic mail address or telephone number specified for such Person on Schedule 10.1 (Committed Loan Notices and Letter of Credit Applications shall additionally be delivered to the addressees set forth therein); and
- 131 -


(iii)if to any other Credit Party, the address, facsimile number, electronic mail address or telephone number specified in its Administrative Questionnaire.
Notices sent by hand or overnight courier service, or mailed by certified or registered mail, shall be deemed to have been given when received; notices sent by facsimile shall be deemed to have been given when sent (except that, if not given during normal business hours for the recipient, shall be deemed to have been given at the opening of business on the next Business Day for the recipient). Notices delivered through electronic communications to the extent provided in paragraph (b) below, shall be effective as provided in said paragraph (b).
(b)Electronic Communications. Notices and other communications hereunder may be delivered or furnished by electronic communication (including e-mail and Internet or intranet websites) pursuant to procedures acceptable to the Administrative Agent, provided that the foregoing shall not apply to notices to any Credit Party pursuant to Article 2 if such Credit Party has notified the Administrative Agent that it is incapable of receiving notices under such Article by electronic communication.
Unless the Administrative Agent otherwise prescribes, (i) notices and other communications sent to an e-mail address shall be deemed received upon the sender’s receipt of an acknowledgement of transmission to the intended recipient (such as by the “delivery receipt requested” function, return e-mail, confirmation of system-generated posting notices by a Platform or other written acknowledgement) and (ii) notices or communications posted to a Platform or an Internet or intranet website shall be deemed received upon the deemed receipt by the intended recipient at its e-mail address as described in the foregoing clause (i) of notification that such notice or communication is available and identifying the website address therefor; provided that for both clauses (i) and (ii) above, if such notice or other communication is not sent during the normal business hours of the recipient, such notice or communication shall be deemed to have been sent at the opening of business on the next Business Day for the recipient. Notwithstanding anything to the contrary herein, borrowing requests and other notices to Administrative Agent, a Swing Line Lender or an L/C Issuer sent by email or posted to a Platform or an Internet or intranet website shall only be effective against such party if receipt of such transmission is affirmatively acknowledged by such party.
(c)Change of Address, Etc. Any party hereto may change its address or facsimile number for notices and other communications hereunder by notice to the other parties hereto.
(d)Platform.
(i)The Borrower agrees that the Administrative Agent may, but shall not be obligated to, make the Communications available to the L/C Issuer and the other Lenders by posting the Communications on the Platform and that certain of the Lenders (each, a “Public Lender”) may have personnel who do not wish to receive material non-public information with respect to the Loan Parties or their Affiliates, or the respective securities of any of the foregoing, and who may be engaged in investment and other market-related activities with respect to such Persons’ securities.
(ii)The Borrower hereby agrees that so long as any Loan Party is the issuer of any outstanding debt or equity securities that are registered or issued pursuant to a private offering or is actively contemplating issuing any such securities it will use commercially reasonable efforts to identify that portion of the Communications that may be distributed to the Public Lenders and that: (A) all such (i) shall be clearly and conspicuously marked “PUBLIC” which, at a minimum, means that the word “PUBLIC” shall appear prominently on the first page thereof; (B) by marking (ii) “PUBLIC,” the Borrower shall be deemed to have authorized the
- 132 -


Administrative Agent, Lead Arranger and the Lenders to treat such Communications as not containing any material non-public information (although it may be sensitive and proprietary) with respect to any Loan Party or its securities for purposes of United States Federal and state securities laws (provided, however, that to the extent such Communications constitute Information, they shall be treated as set forth in Section 10.14); (C) all Communications marked “PUBLIC” are permitted to be made available through a portion of the Platform designated “Public Side Information”; and (D) the Administrative Agent and the Lead Arrangers shall be entitled to treat any Communications that are not marked “PUBLIC” as being suitable only for posting on a portion of the Platform not designated “Public Side Information”. The Borrower acknowledges and agrees that the DQ List shall be deemed suitable for posting and may be posted by the Administrative Agent on the Platform, including the portion of the Platform designated for Public Lenders. The Borrower acknowledges and agrees that the DQ List shall be deemed suitable for posting and may be posted by the Administrative Agent on the Platform, including the portion of the Platform that is designated for Public Lenders.
(iii)The Platform is provided “as is” and “as available.” The Agent Parties (as defined below) do not warrant the adequacy of the Platform and expressly disclaim liability for errors or omissions in the Communications. No warranty of any kind, express, implied or statutory, including any warranty of merchantability, fitness for a particular purpose, non-infringement of third-party rights or freedom from viruses or other code defects, is made by any Agent Party in connection with the Communications or the Platform. In no event shall the Administrative Agent or any of its Related Parties (collectively, the “Agent Parties”) have any liability to the Borrower or the other Loan Parties, any Lender or any other Person or entity for damages of any kind, including direct or indirect, special, incidental or consequential damages, losses or expenses (whether in tort, contract or otherwise) arising out of any Loan Party’s or the Administrative Agent’s transmission of communications through the Platform.
Section 1.2Waivers; Amendments.
(a)No failure or delay by any Credit Party in exercising any right or power under any Loan Document shall operate as a waiver thereof, nor shall any single or partial exercise of any such right or power, or any abandonment or discontinuance of steps to enforce such a right or power, preclude any other or further exercise thereof or the exercise of any other right or power. The rights and remedies of the Credit Parties under the Loan Documents are cumulative and are not exclusive of any rights or remedies that they would otherwise have. No waiver of any provision of any Loan Document or consent to any departure by any Loan Party therefrom shall in any event be effective unless the same shall be permitted by paragraph (b) of this Section, and then such waiver or consent shall be effective only in the specific instance and for the purpose for which given. Without limiting the generality of the foregoing, the making of a Loan and/or the issuance, amendment, extension or renewal of a Letter of Credit shall not be construed as a waiver of any Default, regardless of whether any Credit Party may have had notice or knowledge of such Default at the time.
(b)Except as expressly provided by Section 2.11, Section 3.1(e), Section 3.8 or in the other paragraphs of this Section 10.2, neither this Credit Agreement, any other Loan Document (other than the Engagement Letter) nor any provision thereof may be waived, amended or modified except pursuant to an agreement or agreements in writing entered into by the Loan Parties and the Required Lenders (or, in the case of waivers of any condition precedent to any Revolving Borrowing set forth in Section 4.2, the Required Class Lenders in respect of the Revolving Facility), or by the Borrower and the Administrative Agent with the consent of the Required Lenders; provided that no such agreement shall:
- 133 -


(i)extend or increase any Commitment of any Lender without the written consent of such Lender or increase the L/C Sublimit without the consent of the L/C Issuer (it being understood that a waiver of any condition precedent set forth in Article 4 or the waiver of any Default or Event of Default shall not constitute an extension or increase of any Commitment of any Lender or an increase of the L/C Sublimit);
(ii)reduce the principal amount of any Loan or any reimbursement obligation with respect to a L/C Disbursement, or reduce the rate of any interest, or reduce any fees or other amounts, payable under the Loan Documents, without the written consent of each Credit Party directly and adversely affected thereby; provided that only the consent of the Required Lenders shall be necessary to amend or modify any Financial Covenant, any defined terms used therein or the definition of “Default Rate” or to waive any obligation of the Borrower to pay interest at the Default Rate, in each case, notwithstanding the fact that any such amendment or modification actually results in reduction in the rate of interest or fees;
(iii)postpone any date scheduled for any payment of principal of, or interest on, any Loan or reimbursement obligation with respect to any L/C Disbursement, or any fees or other amounts payable hereunder or under any other Loan Document, or reduce the amount of, waive or excuse any such payment, or postpone the stated termination or expiration of the Revolving Commitments or reduce the amount of or postpone the date of any prepayment required by Section 2.7(b) without the written consent of each Credit Party directly and adversely affected thereby;
(iv)except as provided in Section 2.10 and subsection (c) below change any provision hereof in a manner that would alter the pro rata sharing of payments required by Section 2.8(b) or the pro rata reduction of Revolving Commitments required by Section 2.5(d), without the written consent of each Credit Party directly and adversely affected thereby;
(v)change any of the provisions of this Section or the definition of the terms “Required Lenders” or “Required Class Lenders” or any other provision hereof specifying the number or percentage of Lenders required to waive, amend or modify any rights hereunder or make any determination or grant any consent hereunder;
(vi)amend, modify or waive any provision of Section 2.10 without the written consent of the Administrative Agent, the Swingline Lender and the L/C Issuer;
(vii)change the currency in which any Commitment or Loan is, or is to be, denominated, Letters of Credit are to be issued or payment under the Loan Documents is to be made without the written consent of each Lender directly affected thereby;
(viii)release any Guarantor from its Guarantee under the Guarantee Agreement (except as expressly provided therein or in Section 9.10), or limit its liability in respect of such Guarantee, without the written consent of each Lender; or
(ix)release all or substantially all of the Collateral from the Liens of the Loan Documents (except as expressly provided in the applicable Collateral Document or in connection with a transaction permitted by Section 7.3), without the consent of each Lender; and
provided, further, that no such amendment, waiver or consent shall amend, modify or otherwise affect the rights or duties hereunder or under any other Loan Document of (A) the Administrative Agent, unless in writing executed by the Administrative Agent, (B) any Issuing Bank, unless in writing executed by such
- 134 -


Issuing Bank and (C) any Swingline Lender, unless in writing executed by such Swingline Lender, in each case in addition to the Borrower and the Lenders required above.
(c)Notwithstanding anything herein to the contrary, no Defaulting Lender shall have any right to approve or disapprove any amendment, waiver or consent hereunder (and any amendment, waiver or consent that by its terms requires the consent of all the Lenders or each affected Lender may be effected with the consent of the applicable Lenders other than Defaulting Lenders, except that (x) the Commitment of any Defaulting Lender may not be increased or extended, or the maturity of any of its Loan may not be extended, the rate of interest on any of its Loans may not be reduced and the principal amount of any of its Loans may not be forgiven, in each case without the consent of such Defaulting Lender and (y) any amendment, waiver or consent requiring the consent of all the Lenders or each affected Lender that by its terms affects any Defaulting Lender more adversely than the other affected Lenders shall require the consent of such Defaulting Lender.
(d)In addition, notwithstanding anything in this Section to the contrary, if the Administrative Agent and the Borrower shall have jointly identified an obvious error or any error or omission of a technical nature, in each case, in any provision of the Loan Documents, then the Administrative Agent and the Borrower shall be permitted to amend such provision, and, in each case, such amendment shall become effective without any further action or consent of any other party to any Loan Document if the same is not objected to in writing by the Required Lenders to the Administrative Agent within 10 Business Days following receipt of notice thereof.
Section 1.3Expenses; Indemnity; Damage Waiver.
(a)Costs and Expenses. The Loan Parties, jointly and severally, shall pay (i) all reasonable out-of-pocket expenses incurred by the Administrative Agent, Lead Arrangers and their respective Affiliates (including Attorney Costs which shall be limited to one primary counsel and one local or foreign counsel, if applicable, as reasonably necessary in each relevant jurisdiction material to the interests of the Lenders taken as a whole), in connection with the syndication of the credit facilities provided for herein, the preparation, negotiation, execution, delivery and administration of this Credit Agreement and the other Loan Documents or any amendments, modifications or waivers of the provisions hereof or thereof (whether or not the transactions contemplated hereby or thereby shall be consummated), (ii) all reasonable out-of-pocket expenses incurred by the L/C Issuer in connection with the issuance, amendment, renewal or extension of any Letter of Credit or any demand for payment thereunder and (iii) all out-of-pocket expenses incurred by the Administrative Agent, Lead Arrangers or any Credit Party (including Attorney Costs (but limited in the case of such legal fees and expenses to the reasonable and documented out-of-pocket fees, disbursements and other charges of one counsel to the Administrative Agent, Lead Arrangers and Credit Parties, taken as a whole and, if reasonably necessary, one local counsel or foreign counsel for the Administrative Agent, Lead Arrangers and Credit Parties taken as a whole in each relevant jurisdiction that is material the interests of the Credit Parties, and solely in the case of a conflict of interest, one additional counsel in each relevant jurisdiction that is material to each group of similarly situated affected Persons) of the Administrative Agent or any Credit Party, in connection with the enforcement or protection of its rights (whether through negotiations, legal proceedings or otherwise) (A) in connection with this Credit Agreement and the other Loan Documents, including its rights under this Section, or (B) in connection with the Loans made or Letters of Credit issued hereunder, including all such out-of-pocket expenses incurred during any workout, restructuring or negotiations in respect of such Loans or Letters of Credit.
(b)Indemnification by Loan Parties. The Loan Parties, jointly and severally, shall indemnify the Administrative Agent (and any sub-agent thereof), each Credit Party, and each Related
- 135 -


Party of any of the foregoing Persons (each such Person being called an “Indemnitee”) against, and hold each Indemnitee harmless from, any and all losses, claims, damages, liabilities and related expenses (including Attorney Costs (but limited in the case of legal fees and expenses, to the reasonable and documented out-of-pocket fees, disbursements and other charges of one additional counsel to all Indemnitees taken as a whole, and, if reasonably necessary, one local counsel for all Indemnitees taken as a whole in each relevant jurisdiction that is material to the interests of such Indemnitees, and solely in the case of a conflict of interest, one additional counsel in each relevant jurisdiction that is material to each group of similarly situated affected Indemnitees)), incurred by any Indemnitee or asserted against any Indemnitee by any third party or by any Loan Party arising out of, in connection with, or as a result of (i) the execution or delivery of this Credit Agreement, any other Loan Document or any agreement or instrument contemplated hereby or thereby, the performance by the parties hereto of their respective obligations hereunder or thereunder or the consummation of the transactions contemplated hereby or thereby, (ii) any Loan or Letter of Credit or the use or proposed use of the proceeds therefrom (including any refusal by the L/C Issuer to honor a demand for payment under a Letter of Credit if the documents presented in connection with such demand do not strictly comply with the terms of such Letter of Credit), (iii) any actual or alleged presence or Release of Hazardous Materials at, on, under or from any property owned or operated by any Loan Party or any of its Subsidiaries, or any Environmental Claim or Environmental Liability related in any way to any Loan Party or any of its Subsidiaries, (iv) any actual or prospective claim, litigation, investigation or proceeding relating to any of the foregoing, whether based on contract, tort or any other theory, whether brought by a third party or by any Loan Party, and regardless of whether any Indemnitee is a party thereto or (v) any government investigation, audit, hearing or enforcement action resulting from any Loan Party’s or any of its Affiliate’s noncompliance (or purported noncompliance) with any applicable Sanctions, other Anti-Terrorism Laws or Anti-Corruption Laws (it being understood and agreed that the Indemnitees shall be entitled to indemnification pursuant to this clause (including indemnification for fines, penalties and other expenses) regardless of whether any adverse finding is made against any Loan Party or any of its Affiliates), provided that such indemnity shall not, as to any Indemnitee, be available to the extent that such losses, claims, damages, liabilities or related expenses (x) are determined by a court of competent jurisdiction by final and non-appealable judgment to have resulted from the gross negligence or willful misconduct of such Indemnitee or (y) result from a claim brought by any Loan Party against an Indemnitee for breach in bad faith of such Indemnitee’s obligations hereunder or under any other Loan Document, if such Loan Party has obtained a final and non-appealable judgment in its favor on such claim as determined by a court of competent jurisdiction. To the extent that the indemnity set forth above in this paragraph shall be held to be unenforceable in whole or in part because it is violative of any law or public policy, the Borrower shall contribute the maximum portion that it is permitted to pay and satisfy under Applicable Law to the payment and satisfaction of all indemnified amounts incurred by Indemnitees or any of them. Notwithstanding anything contained in this Agreement to the contrary, the Loan Parties’ liability and obligations with respect to any indemnified liability arising out of any Environmental Law, Environmental Claim or Environmental Liability shall be released on the date which is the earlier of (A) the one (1) year anniversary of the date on which the earliest of the following occurs: (i) the payment in full of the Loan Document Obligations, or (ii) the Administrative Agent or its nominee or assignee have exercised its foreclosure rights under this Agreement (any of (i) or (ii), the “Release Date”) provided that the Administrative Agent has received an environmental investigation report, which includes an ASTM E1527-21 Phase I and a compliance audit, prepared on the Administrative Agent’s behalf by environmental professionals selected by the Loan Parties and approved by the Administrative Agent in its reasonable discretion, at the cost of the Loan Parties, that indicates that the Real Property is free from any circumstance, condition, Hazardous Materials, Release or threat of Release of Hazardous Materials that constitutes a “recognized environmental condition” (as that term is defined in the ASTM standard practice for Phase I Environmental Site Assessments) and has no violations that would reasonably be expected to
- 136 -


have a Material Adverse Effect and that were not disclosed to the Administrative Agent in connection with the closing of the Credit Facilities.
(c)Reimbursement by Lenders. To the extent that the Borrower for any reason fails to indefeasibly pay any amount required under paragraph (a) or (b) of this Section to be paid by it to the Administrative Agent (or any sub-agent thereof), the L/C Issuer, the Swingline Lender or any Related Party of any of the foregoing, each Lender severally agrees to pay to the Administrative Agent (or any such sub-agent), the L/C Issuer, the Swingline Lender or such Related Party, as the case may be, such Lender’s pro rata share (determined as of the time that the applicable unreimbursed expense or indemnity payment is sought based on each Lender’s share of the Total Credit Exposure at such time) of such unpaid amount (including any such unpaid amount in respect of a claim asserted by such Lender); provided that with respect to such unpaid amounts owed to the L/C Issuer or the Swingline Lender solely in its capacity as such, only the Revolving Lenders shall be required to pay such unpaid amounts, such payment to be made severally among them based on such Revolving Lender’s Applicable Percentage (determined as of the time that the applicable unreimbursed expense or indemnity payment is sought) provided, further, that the unreimbursed expense or indemnified loss, claim, damage, liability or related expense, as the case may be, was incurred by or asserted against the Administrative Agent (or any such sub-agent), the L/C Issuer or the Swingline Lender in its capacity as such, or against any Related Party of any of the foregoing acting for the Administrative Agent (or any such sub-agent), the L/C Issuer or the Swingline Lender in connection with such capacity. The obligations of the Lenders under this paragraph (c) are subject to the provisions of Section 2.8(d).
(d)Waiver of Consequential Damages, Etc. To the fullest extent permitted by Applicable Law, no Loan Party shall assert, and each Loan Party hereby waives, any claim against the Administrative Agent (and any sub-agent thereof), any Lender and any L/C Issuer, and any Related Party of any of the foregoing Persons (each such Person being called a “Protected Person”), on any theory of liability, for special, indirect, consequential or punitive damages (as opposed to direct or actual damages) arising out of, in connection with, or as a result of, this Credit Agreement, any other Loan Document or any agreement or instrument contemplated hereby or thereby, the transactions contemplated hereby or thereby, any Loan or Letter of Credit or the use of the proceeds thereof. No Protected Person shall be liable for any damages arising from the use by unintended recipients of any information or other materials distributed by it through telecommunications, electronic or other information transmission systems in connection with this Credit Agreement or the other Loan Documents or the transactions contemplated hereby or thereby.
(e)Payments. All amounts due under this Section shall be payable promptly and in no event later than 10 days after demand therefor.
Section 1.4Successors and Assigns.
(a)Successors and Assigns Generally. The provisions of this Credit Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns permitted hereby, except that no Loan Party may assign or otherwise transfer any of its rights or obligations hereunder without the prior written consent of the Administrative Agent, each L/C Issuer and each Lender (and any other attempted assignment or transfer by any party hereto shall be null and void) and no Lender may assign or otherwise transfer any of its rights or obligations hereunder except (i) to an assignee in accordance with the provisions of paragraph (b) of this Section, (ii) by way of participation in accordance with the provisions of paragraph (d) of this Section or (iii) by way of pledge or assignment of a security interest subject to the restrictions of paragraph (e) of this Section. Nothing in this Credit Agreement, expressed or implied, shall be construed to confer upon any Person (other than the parties
- 137 -


hereto, their respective successors and assigns permitted hereby, Participants to the extent provided in paragraph (d) of this Section and, to the extent expressly contemplated hereby, the Related Parties of each Credit Party) any legal or equitable right, remedy or claim under or by reason of this Credit Agreement.
(b)Assignments by Lenders. Any Lender may at any time assign to one or more assignees all or a portion of its rights and obligations under this Credit Agreement (including all or a portion of its applicable Commitments and the applicable Loans at the time owing to it); provided that any such assignment shall be subject to the following conditions:
(i)Minimum Amounts.
(A)in the case of an assignment of the entire remaining amount of the assigning Lender’s applicable Commitment and/or the applicable Loans at the time owing to it (in each case with respect to any Credit Facility) or contemporaneous assignments to or by related Approved Funds (determined after giving effect to such assignments) that equal at least the amount specified in paragraph (b)(i)(B) of this Section in the aggregate or in the case of an assignment to a Lender, an Affiliate of a Lender or an Approved Fund, no minimum amount need be assigned; and
(B)in any case not described in paragraph (b)(i)(A) of this Section, the aggregate amount of the applicable Commitment (which for this purpose includes Loans outstanding thereunder) or, if the applicable Commitment is not then in effect, the principal outstanding balance of the applicable Loans of the assigning Lender subject to each such assignment (determined as of the date the Assignment and Assumption with respect to such assignment is delivered to the Administrative Agent or, if “Trade Date” is specified in the Assignment and Assumption, as of the Trade Date) shall not be less than $5,000,000, in the case of any assignment in respect of a Revolving Facility, or $1,000,000, in the case of any assignment in respect of a Term Facility, unless each of the Administrative Agent and, so long as no Event of Default has occurred and is continuing, the Borrower otherwise consents (each such consent not to be unreasonably withheld or delayed).
(ii)Proportionate Amounts. Each partial assignment shall be made as an assignment of a proportionate part of all the assigning Lender’s rights and obligations under this Credit Agreement with respect to the applicable Loan or the applicable Commitment assigned, except that this clause (ii) shall not prohibit any Lender from assigning all or a portion of its rights and obligations among separate Tranches on a non-pro rata basis.
(iii)Required Consents. No consent shall be required for any assignment except to the extent required by paragraph (b)(i)(B) of this Section and, in addition:
(A)the consent of the Borrower (such consent not to be unreasonably withheld or delayed) shall be required unless (x) an Event of Default under Sections 8.1(a), (b), (h), or (i) has occurred and is continuing at the time of such assignment or (y) such assignment is to a Lender (other than a Defaulting Lender), an Affiliate of a Lender (other than a Defaulting Lender) or an Approved Fund, provided that the Borrower shall be deemed to have consented to any such assignment unless it shall object thereto by written notice to the Administrative Agent within five (5) Business Days after written notice of such assignment shall have delivered to the Borrower; and provided, further, that the Borrower’s consent shall not be required during the primary syndication of the Credit Facilities;
- 138 -


(B)the consent of the Administrative Agent (such consent not to be unreasonably withheld or delayed) shall be required for assignments in respect of (i) the Revolving Facility or any unfunded Term Loan Commitment if such assignment is to a Person that is not a Lender with a Commitment in respect of such facility, an Affiliate of such Lender or an Approved Fund with respect to such Lender or (ii) a funded Term Facility to a Person who is not a Lender, an Affiliate of a Lender or an Approved Fund; and
(C)the consent of the L/C Issuer and the Swingline Lender shall be required for any assignment in respect of the Revolving Facility.
(iv)Assignment and Assumption. The parties to each assignment shall execute and deliver to the Administrative Agent an Assignment and Assumption, together with a processing and recordation fee of $3,500, and the assignee, if it is not a Lender, shall deliver to the Administrative Agent an Administrative Questionnaire. In addition, each assignee shall, on or before the effective date of such assignment, deliver to the Borrower and the Administrative Agent certification as to exemption from deduction or withholding of any United States Taxes in accordance with Section 3.6(g).
(v)No Assignment to Certain Persons. No such assignment shall be made to (A) the Borrower or any of the Borrower’s Affiliates or Subsidiaries, (B)any Defaulting Lender or any of its Subsidiaries, or any Person who, upon becoming a Lender hereunder, would constitute a Defaulting Lender or a Subsidiary thereof or (C) a Person who, at the time of such assignment, is a Sanctioned Person if such assignment would violate Applicable Law.
(vi)No Assignment to Natural Persons. No such assignment shall be made to a natural person (or a holding company, investment vehicle or trust for, or owned and operated for the primary benefit of, a natural person).
(vii)Certain Additional Payments. In connection with any assignment of rights and obligations of any Defaulting Lender hereunder, no such assignment shall be effective unless and until, in addition to the other conditions thereto set forth herein, the parties to the assignment shall make such additional payments to the Administrative Agent in an aggregate amount sufficient, upon distribution thereof as appropriate (which may be outright payment, purchases by the assignee of participations or subparticipations, or other compensating actions, including funding, with the prior written consent of the Borrower and the Administrative Agent, the applicable pro rata share of Loans previously requested but not funded by the Defaulting Lender, to each of which the applicable assignee and assignor hereby irrevocably consent), to (x) pay and satisfy in full all payment liabilities then owed by such Defaulting Lender to the Administrative Agent or any Lender hereunder (and interest accrued thereon) and (y) acquire (and fund as appropriate) its full pro rata share of all Loans and participations in Letters of Credit and Swingline Loans, as applicable, in accordance with its Applicable Percentage. Notwithstanding the foregoing, in the event that any assignment of rights and obligations of any Defaulting Lender hereunder shall become effective under Applicable Law without compliance with the provisions of this paragraph, then the assignee of such interest shall be deemed to be a Defaulting Lender for all purposes of this Credit Agreement until such compliance occurs.
Subject to acceptance and recording thereof by the Administrative Agent pursuant to paragraph (c) of this Section, from and after the effective date specified in each Assignment and Assumption, the assignee thereunder shall be a party to this Credit Agreement and, to the extent of the interest assigned by such
- 139 -


Assignment and Assumption, have the rights and obligations of a Lender under this Credit Agreement, and the assigning Lender thereunder shall, to the extent of the interest assigned by such Assignment and Assumption, be released from its obligations under this Credit Agreement (and, in the case of an Assignment and Assumption covering all of the assigning Lender’s rights and obligations under this Credit Agreement, such Lender shall cease to be a party hereto) but shall continue to be entitled to the benefits of Section 3.5 and Section 10.3 with respect to facts and circumstances occurring prior to the effective date of such assignment. Any assignment or transfer by a Lender of rights or obligations under this Credit Agreement that does not comply with this paragraph shall be treated for purposes of this Credit Agreement as a sale by such Lender of a participation in such rights and obligations in accordance with paragraph (d) of this Section.
(c)Register. The Administrative Agent, acting solely for this purpose as a non-fiduciary agent of the Borrower, shall maintain, at one of its offices in the United States, a copy of each Assignment and Assumption delivered to it and a register for the recordation of the names and addresses of the applicable Lenders, and the applicable Commitments of, and principal amounts of the applicable Loans owing to, each Lender pursuant to the terms hereof from time to time (the “Register”). The entries in the Register shall be conclusive, and the Borrower, the Administrative Agent, the L/C Issuers and the applicable Lenders may treat each Person whose name is recorded in the Register pursuant to the terms hereof as a Lender hereunder for all purposes of this Credit Agreement, notwithstanding notice to the contrary. The Register shall be available for inspection by the Borrower and any L/C Issuer or Lender, at any reasonable time and from time to time upon reasonable prior notice.
(d)Participations. Any Lender may at any time, without the consent of, or notice to, the Borrower, any L/C Issuer or the Administrative Agent, sell participations to any Person (other than (w) a natural person (or a holding company, investment vehicle or trust for, or owned and operated for the primary benefit of, a natural person), (x) the Borrower or any of the Borrower’s Affiliates or Subsidiaries, (y) any Defaulting Lender or any of its subsidiaries or (z) a Person who, at the time of such participation, is a Sanctioned Person if the sale of such participation would violate Applicable Law) (each, a “Participant”) in all or a portion of such Lender’s rights and/or obligations under this Credit Agreement (including all or a portion of its applicable Revolving Commitment and/or the applicable Loans owing to it); provided that (i) such Lender’s obligations under this Credit Agreement shall remain unchanged, (ii) such Lender shall remain solely responsible to the other parties hereto for the performance of such obligations and (iii) the Borrower, the Administrative Agent and each Credit Party shall continue to deal solely and directly with such Lender in connection with such Lender’s rights and obligations under this Credit Agreement.
Any agreement or instrument pursuant to which a Lender sells such a participation shall provide that such Lender shall retain the sole right to enforce this Credit Agreement and to approve any amendment, modification or waiver of any provision of this Credit Agreement; provided that such agreement or instrument may provide that such Lender will not, without the consent of the Participant, agree to any amendment, modification or waiver described in Section 10.2(b) that affects such Participant. The Borrower agrees that each Participant shall be entitled to the benefits of Sections 3.4, 3.5 and 3.6 (subject to the requirements and limitations therein, including the requirements under Section 3.6 (it being understood that the documentation required under Section 3.6(g) shall be delivered to the participating Lender)) to the same extent as if it were a Lender and had acquired its interest by assignment pursuant to paragraph (b) of this Section; provided that such Participant (A) agrees to be subject to the provisions of Sections 3.7 as if it were an assignee under paragraph (b) of this Section; and (B) shall not be entitled to receive any greater payment under Sections 3.5 or 3.6, with respect to any participation, than its participating Lender would have been entitled to receive, except to the extent such entitlement to receive a greater payment results from a Change in Law that occurs after the Participant acquired the applicable
- 140 -


participation. Each Lender that sells a participation agrees, at the Borrower’s request and expense, to use reasonable efforts to cooperate with the Borrower to effectuate the provisions of Section 3.7(b) with respect to any Participant. To the extent permitted by law, each Participant also shall be entitled to the benefits of Section 10.8 as though it were a Lender; provided that such Participant agrees to be subject to Section 2.8(h) as though it were a Lender. Each Lender that sells a participation shall, acting solely for this purpose as a non-fiduciary agent of the Borrower, maintain a register on which it enters the name and address of each Participant and the principal amounts (and stated interest) of each Participant’s interest in the Loans or other obligations under the Loan Documents (the “Participant Register”); provided that no Lender shall have any obligation to disclose all or any portion of the Participant Register (including the identity of any Participant or any information relating to a Participant’s interest in any commitments, loans, letters of credit or its other obligations under any Loan Document) to any Person except to the extent that such disclosure is necessary to establish that such commitment, loan, letter of credit or other obligation is in registered form under Section 5f.103-1(c) of the United States Treasury Regulations. The entries in the Participant Register shall be conclusive absent manifest error, and such Lender shall treat each Person whose name is recorded in the Participant Register as the owner of such participation for all purposes of this Credit Agreement notwithstanding any notice to the contrary. For the avoidance of doubt, the Administrative Agent (in its capacity as Administrative Agent) shall have no responsibility for maintaining a Participant Register.
(e)Certain Pledges. Any Lender may at any time pledge or assign a security interest in all or any portion of its rights under this Credit Agreement and the Loan Documents to secure obligations of such Lender, including any pledge or assignment to secure obligations to a Federal Reserve Bank; provided that no such pledge or assignment shall release such Lender from any of its obligations hereunder or substitute any such pledgee or assignee for such Lender as a party hereto.
(f)Disqualified Institutions.
(i)    No assignment or participation shall be made to any Person that was a Disqualified Institution as of the date (the “Trade Date”) on which the assigning Lender entered into a binding agreement to sell and/or assign all or a portion of its rights and obligations under this Credit Agreement (including through a participation) to such Person (unless the Borrower has consented to such assignment or participation in writing in its sole and absolute discretion, in which case such Person will not be considered a Disqualified Institution for the purpose of such assignment). For the avoidance of doubt, with respect to any assignee or participant that becomes a Disqualified Institution after the Trade Date or any Person that the Borrower removes from the DQ List (including as a result of the delivery of a notice pursuant to the definition of “Disqualified Institution”), (x) any additional designation or removal permitted by the foregoing shall not apply retroactively to any prior or pending assignment or participation, as applicable, to any Lender or Participant and (y) any designation or removal after the Closing Date of a Person as a Disqualified Institution shall become effective three (3) Business Days after such designation or removal. Any assignment or participation in violation of this clause (h)(i) shall not be void, but the other provisions of this clause (h) shall apply.
(ii)    If any assignment or participation is made to any Disqualified Institution without the Borrower’s prior written consent in violation of clause (i) above, or if any Person becomes a Disqualified Institution after the applicable Trade Date, the Borrower may, at its sole expense and effort, upon notice to the applicable Disqualified Institution and the Administrative Agent, (A) terminate any Revolving Commitment of such Disqualified Institution or terminate any Revolving Commitment of a Lender which has sold a participation to a Participant which is a Disqualified Institution and repay all obligations of the Borrower owing to such Disqualified
- 141 -


Institution in connection with such Revolving Commitment, (B) in the case of outstanding Term Loans held by Disqualified Institutions, purchase or prepay such Term Loan by paying the lesser of (x) the principal amount thereof and (y) the amount that such Disqualified Institution paid to acquire such Term Loans or such participation in such Term Loans, in each case plus accrued interest, accrued fees and all other amounts (other than principal amounts) payable to it hereunder and/or (C) require such Disqualified Institution to assign, without recourse (in accordance with and subject to the restrictions contained in this Section 10.4, all of its interest, rights and obligations under this Credit Agreement to one or more Eligible Assignees at the lesser of (x) the principal amount thereof and (y) the amount that such Disqualified Institution paid to acquire such interests, rights and obligations, in each case plus accrued interest, accrued fees and all other amounts (other than principal amounts) payable to it hereunder.
(iii)    Notwithstanding anything to the contrary contained in this Credit Agreement, Disqualified Institutions (A) will not (x) have the right to receive information, reports or other materials provided to Lenders or L/C Issuers by the Borrower, the Administrative Agent or any other Lender or L/C Issuer, (y) attend or participate in meetings attended by the Lenders, L/C Issuers and the Administrative Agent, or (z) access any electronic site established for the Lenders or L/C Issuers or confidential communications from counsel to or financial advisors of the Administrative Agent or the Lenders or L/C Issuers and (B) (x) for purposes of any consent to any amendment, waiver or modification of, or any action under, and for the purpose of any direction to the Administrative Agent or any Lender or any L/C Issuer to undertake any action (or refrain from taking any action) under this Credit Agreement or any other Loan Document, each Disqualified Institution will be deemed to have consented in the same proportion as the Lenders or L/C Issuers that are not Disqualified Institutions consented to such matter, and (y) for purposes of voting on any Debtor Relief Plan, each Disqualified Institution party hereto hereby agrees (1) not to vote on such Debtor Relief Plan, (2) if such Disqualified Institution does vote on such Debtor Relief Plan notwithstanding the restriction in the foregoing clause (1), such vote will be deemed not to be in good faith and shall be “designated” pursuant to Section 1126(e) of the Bankruptcy Code (or any similar provision in any other Debtor Relief Laws), and such vote shall not be counted in determining whether the applicable class has accepted or rejected such Debtor Relief Plan in accordance with Section 1126(c) of the Bankruptcy Code (or any similar provision in any other Debtor Relief Laws) and (3) not to contest any request by any party for a determination by the Bankruptcy Court (or other applicable court of competent jurisdiction) effectuating the foregoing clause (2).
(iv)    The Administrative Agent shall have the right, and the Borrower hereby expressly authorizes the Administrative Agent, to (A) post the list of Disqualified Institutions provided by the Borrower and any updates thereto from time to time (collectively, the “DQ List”) on the Platform, including that portion of the Platform that is designated for Public Lenders and/or (B) provide the DQ List to each Lender requesting the same.
(g)Cashless Settlement. Notwithstanding anything to the contrary contained in this Credit Agreement, any Lender may exchange, continue or rollover all or a portion of its Loans in connection with any refinancing, extension, loan modification or similar transaction permitted by the terms of this Credit Agreement, pursuant to a cashless settlement mechanism acceptable to the Borrower, the Administrative Agent and such Lender.
Section 1.5Survival. All covenants, agreements, representations and warranties made by the Borrower herein and in the certificates or other instruments prepared or delivered in connection with or pursuant to this Credit Agreement or any other Loan Document shall be considered to have been relied
- 142 -


upon by the other parties hereto and shall survive the execution and delivery of any Loan Document and the making of any Loans and the issuance of any Letter of Credit, regardless of any investigation made by any such other party or on its behalf and notwithstanding that any Credit Party may have had notice or knowledge of any Default or Event of Default or incorrect representation or warranty at the time any credit is extended hereunder, and shall continue in full force and effect as long as the principal of or any accrued interest on any Loan or any L/C Obligation or any fee or any other amount payable under the Loan Documents is outstanding and unpaid or any Letter of Credit is outstanding and so long as the Commitments have not expired or terminated. The provisions of Sections 3.4, 3.5, 3.6, 10.3, 10.9, and 10.10 and Article 9 shall survive and remain in full force and effect regardless of the consummation of the transactions contemplated hereby or the Termination Date.
Section 1.6Counterparts; Integration; Effectiveness; Electronic Execution. This Credit Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Except as provided in Section 4.1, this Credit Agreement shall become effective when it shall have been executed by the Administrative Agent and when the Administrative Agent shall have received counterparts hereof that, when taken together, bear the signatures of each of the other parties hereto. Delivery of an executed signature page counterpart hereof by telecopy, emailed .pdf or any other electronic means that reproduces an image of the actual executed signature page shall be effective as delivery of a manually executed counterpart hereof. The words “execution,” “signed,” “signature,” “delivery,” and words of like import in or relating to any document to be signed in connection with this Credit Agreement and the transactions contemplated hereby shall be deemed to include electronic signatures, the electronic association of signatures and records on electronic platforms, deliveries or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature, physical delivery thereof or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any Applicable Law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, any other similar state laws based on the Uniform Electronic Transactions Act or the Uniform Commercial Code, each as amended, and the parties hereto hereby waive any objection to the contrary, provided that (x) nothing herein shall require Administrative Agent to accept electronic signature counterparts in any form or format and (y) Administrative Agent reserves the right to require, at any time and at its sole discretion, the delivery of manually executed counterpart signature pages to any Loan Document and the parties hereto agree to promptly deliver such manually executed counterpart signature pages. This Credit Agreement and the other Loan Documents, and any separate letter agreements with respect to fees payable to Administrative Agent, Lead Arranger or any Lender, constitute the entire contract among the parties relating to the subject matter hereof and supersede any and all previous agreements and understandings, oral or written, relating to the subject matter hereof.
Section 1.7Severability. In the event any one or more of the provisions contained in this Credit Agreement should be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby (it being understood that the invalidity of a particular provision in a particular jurisdiction shall not in and of itself affect the validity of such provision in any other jurisdiction). The parties shall endeavor in good faith negotiations to replace the invalid, illegal or unenforceable provisions with valid provisions the economic effect of which comes as close as possible to that of the invalid, illegal or unenforceable provisions.
Section 1.8Setoff. If an Event of Default shall have occurred and be continuing, each Credit Party and each of their respective branches and Affiliates is hereby authorized at any time and from time to time, to the fullest extent permitted by Applicable Law, to set off and apply any and all deposits
- 143 -


(general or special, time or demand, provisional or final, in whatever currency) at any time held and other obligations (in whatever currency) at any time owing by such Credit Party or any such branch or Affiliate to or for the credit or the account of any Loan Party or any of its Subsidiaries against any and all of the obligations of such Loan Party or such Subsidiary now or hereafter existing under this Credit Agreement or any other Loan Document to such Credit Party or such branch or Affiliate, irrespective of whether or not such Credit Party, branch or Affiliate shall have made any demand under this Credit Agreement or any other Loan Document and although such obligations of such Loan Party or Subsidiary may be contingent or unmatured or are owed to a branch, office or Affiliate of such Credit Party different from the branch, office or Affiliate holding such deposit or obligated on such indebtedness, provided, that in the event that any Defaulting Lender shall exercise any right of setoff, (x) all amounts so set off shall be paid over immediately to the Administrative Agent for further application in accordance with the provisions of Section 2.8 and, pending such payment, shall be segregated by such Defaulting Lender from its other funds and deemed held in trust for the benefit of the Administrative Agent and the Lenders, and (y) the Defaulting Lender shall provide promptly to the Administrative Agent a statement describing in reasonable detail the Secured Obligations owing to such Defaulting Lender as to which it exercised such right of setoff. The rights of each Credit Party and its branches and Affiliates under this Section are in addition to other rights and remedies (including other rights of setoff) that such Credit Party and its branches and Affiliates may have. Each Credit Party agrees to notify the Borrower and the Administrative Agent promptly after any such setoff and application, provided that the failure to give such notice shall not affect the validity of such setoff and application.
Section 1.9Governing Law; Jurisdiction; Consent to Service of Process.
(a)Governing Law. This Credit Agreement shall be governed by, and construed in accordance with, the laws of the State of New York.
(b)Submission to Jurisdiction. Each of the parties hereto irrevocably and unconditionally submits, for itself and its property, to the exclusive jurisdiction of the courts of the State of New York sitting in New York County and of the United States District Court of the for the Southern District of New York and any appellate court from any thereof, in any action or proceeding arising out of or relating to this Credit Agreement or any other Loan Document, or for recognition or enforcement of any judgment, and each of the parties hereto irrevocably and unconditionally agrees that all claims in respect of any such action or proceeding may be heard and determined in such New York State court or, to the fullest extent permitted by Applicable Law, in such Federal court. Each of the parties hereto agrees that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law. Nothing in this Credit Agreement or in any other Loan Document shall (i) affect any right that any Credit Party may otherwise have to bring any action or proceeding relating to this Credit Agreement or any other Loan Document against the Borrower or any other Loan Party or its properties in the courts of any jurisdiction, (ii) waive any statutory, regulatory, common law, or other rule, doctrine, legal restriction, provision or the like providing for the treatment of bank branches, bank agencies, or other bank offices as if they were separate juridical entities for certain purposes, including Uniform Commercial Code Sections 4-106, 4-A-105(1)(b), and 5-116(b), UCP 600 Article 3 and ISP98 Rule 2.02, and URDG 758 Article 3(a), or (iii) affect which courts have or do not have personal jurisdiction over the issuing bank or beneficiary of any Letter of Credit or any advising bank, nominated bank or assignee of proceeds thereunder or proper venue with respect to any litigation arising out of or relating to such Letter of Credit with, or affecting the rights of, any Person not a party to this Credit Agreement, whether or not such Letter of Credit contains its own jurisdiction submission clause.
- 144 -


(c)Waiver of Objection to Venue. Each of the parties hereto irrevocably and unconditionally waives, to the fullest extent permitted by Applicable Law, any objection that it may now or hereafter have to the laying of venue of any action or proceeding arising out of or relating to this Credit Agreement or any other Loan Document in any court referred to in paragraph (b) of this Section. Each of the parties hereto hereby irrevocably waives, to the fullest extent permitted by Applicable Law, the defense of an inconvenient forum to the maintenance of such action or proceeding in any such court.
(d)Service of Process. Each of the parties hereto irrevocably consents to service of process in the manner provided for notices in Section 10.1. Nothing in this Credit Agreement will affect the right of any party to this Credit Agreement to serve process in any other manner permitted by Applicable Law.
Section 1.10WAIVER OF JURY TRIAL. EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS CREDIT AGREEMENT OR ANY OTHER LOAN DOCUMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY). EACH PARTY HERETO HEREBY (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PERSON HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PERSON WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS CREDIT AGREEMENT AND THE OTHER LOAN DOCUMENTS BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION.
Section 1.11Payments Set Aside. To the extent that any payment by or on behalf of the Borrower is made to the Administrative Agent or any Lender, or the Administrative Agent or any Lender exercises its right of setoff, and such payment or the proceeds of such setoff or any part thereof is subsequently invalidated, declared to be fraudulent or preferential, set aside or required (including pursuant to any settlement entered into by the Administrative Agent or such Lender in its discretion) to be repaid to a trustee, receiver or any other party, in connection with any proceeding under any Debtor Relief Law or Fraudulent Transfer Law, then (a) to the extent of such recovery, the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such payment had not been made or such setoff had not occurred, and (b) each Lender severally agrees to pay to the Administrative Agent upon demand its applicable share of any amount so recovered from or repaid by the Administrative Agent, plus interest thereon from the date of such demand to the date such payment is made at a rate per annum equal to the greater of the Federal Funds Rate from time to time in effect and a rate determined by the Administrative Agent in accordance with banking industry rules on interbank compensation.
Section 1.12Headings. Article and Section headings and the Table of Contents used herein are for convenience of reference only, are not part of this Credit Agreement and shall not affect the construction of, or be taken into consideration in interpreting, this Credit Agreement.
Section 1.13Interest Rate Limitation. Notwithstanding anything herein to the contrary, if at any time the interest rate applicable to any Loan or L/C Obligation, together with all fees, charges and other amounts that are treated as interest thereon under Applicable Law (collectively the “charges”), shall exceed the maximum lawful rate (the “maximum rate”) that may be contracted for, charged, taken, received or reserved by the Lender holding an interest in such Loan or L/C Obligation in accordance with
- 145 -


Applicable Law, the rate of interest payable in respect of such Loan or L/C Obligation hereunder, together with all of the charges payable in respect thereof, shall be limited to the maximum rate and, to the extent lawful, the interest and the charges that would have been payable in respect of such Loan or L/C Obligation but were not payable as a result of the operation of this Section shall be cumulated, and the interest and the charges payable to such Lender in respect of other Loans or L/C Obligations or periods shall be increased (but not above the maximum rate therefor) until such cumulated amount, together with interest thereon at the Federal Funds Rate to the date of repayment, shall have been received by such Lender.
Section 1.14Confidentiality; Treatment of Certain Information.
(a)Each Credit Party agrees to maintain the confidentiality of the Information (as defined below), except that Information may be disclosed (i) to its Affiliates and to its and its Affiliates’ respective partners, directors, officers, employees, agents, advisors and other representatives (it being understood that the Persons to whom such disclosure is made will be informed of the confidential nature of such Information and instructed to keep such Information confidential), (ii) to the extent requested by any regulatory authority purporting to have jurisdiction over it (including any self-regulatory authority, such as the National Association of Insurance Commissioners), (iii) to the extent required by Applicable Law or regulations or by any subpoena or similar legal process, (iv) to any other party hereto, (v) in connection with the exercise of any remedies hereunder or under any other Loan Document or any action or proceeding relating to this Credit Agreement or any other Loan Document or the enforcement of rights hereunder or thereunder, (vi) subject to an agreement containing provisions substantially the same as those of this Section, to (A) any assignee of or Participant in, or any prospective assignee of or Participant in, any of its rights or obligations under this Credit Agreement (other than Disqualified Institutions, except solely to the extent such disclosure was made to a Disqualified Institution who was not known by such Credit Party to be a Disqualified Institution at the time such disclosure was made) or (B) any actual or prospective party (or its Related Parties) to any swap, derivative or other transaction under which payments are to be made by reference to the Borrower and its obligations, this Credit Agreement or payments hereunder, (vii) on a confidential basis to (A) any rating agency in connection with rating the Borrower ,its Subsidiaries or the Credit Facilities or (B) the CUSIP Service Bureau or any similar agency in connection with the issuance and monitoring of CUSIP numbers with respect to the Credit Facilities, (viii) with the consent of the Borrower or (ix) to the extent such Information (A) becomes publicly available other than as a result of a breach of this Section or (B) becomes available to the Administrative Agent, any Credit Party or any of their respective Affiliates on a non-confidential basis from a source other than the Borrower or (z) is independently generated by the Administrative Agent, any Credit Party or any of their respective Affiliates. . In addition, the Administrative Agent and the Lenders may disclose the existence of this Credit Agreement and information about this Credit Agreement and the Loan Documents to (i) market data collectors, league table providers and other similar service providers to the lending industry and (ii) service providers to the Administrative Agent or any Lender in connection with the administration of this Credit Agreement, the other Loan Documents, and the Commitments.
(b)For purposes of this Section, “Information” means all information received from any Loan Party or any of its Subsidiaries relating to any Loan Party or any of its Subsidiaries or any of their respective businesses, other than any such information that is available to the Administrative Agent or any other Credit Party on a non-confidential basis prior to disclosure by any Loan Party or any Subsidiary or that is independently prepared by the Administrative Agent or any other Credit Party, provided that, in the case of information received from any Loan Party or any of its Subsidiaries after the Closing Date, such information is clearly identified at the time of delivery as confidential. Any Person required to maintain the confidentiality of Information as provided in this Section shall be considered to have complied with its obligation to do so if such Person has exercised the same degree of care to
- 146 -


maintain the confidentiality of such Information as such Person would accord to its own confidential information. Notwithstanding anything herein to the contrary, “Information” shall not include, and each Credit Party (and their Affiliates and respective partners, directors, officers, employees, agents, advisors and representatives) may disclose to any and all persons, without limitation of any kind, any information with respect to the U.S. federal income tax treatment and U.S. federal income tax structure of the transactions contemplated hereby and all materials of any kind (including opinions or other tax analyses) that are provided to such Credit Party relating to such tax treatment and tax structure.
(c)The Loan Parties agree, on behalf of themselves and their Affiliates, that they will not in the future issue any press releases or other public disclosure using the name of the Administrative Agent or any Lender or their respective Affiliates or referring to this Credit Agreement or any of the other Loan Documents without the prior written consent of such Person, unless (and only to the extent that) the Loan Parties or such Affiliate is required to do so under law and then, in any event, the Loan Parties or such Affiliate will consult with such Person before issuing such press release or other public disclosure.
(d)The Loan Parties consent to the publication by the Administrative Agent or any Lender of customary advertising material relating to the Transactions (including, without limitation amount and type of facility) using the names, product photographs, logos or trademarks of the Loan Parties.
Section 1.15USA PATRIOT Act. Each Lender that is subject to the USA PATRIOT Act and the Administrative Agent (for itself and not on behalf of any Lender) hereby notifies the Borrower that pursuant to the requirements of the USA PATRIOT Act, it is required to obtain, verify and record information that identifies each Loan Party, which information includes the name and address of each Loan Party and other information that will allow such Lender or the Administrative Agent, as applicable, to identify each Loan Party in accordance with the USA PATRIOT Act. The Borrower shall, and shall cause each Subsidiary to, provide such information and take such actions as are reasonably requested by the Administrative Agent or any Lender in order to assist the Administrative Agent and the Lenders in maintaining compliance with the USA PATRIOT Act.
Section 1.16No Fiduciary Duty. Each Loan Party agrees that in connection with all aspects of the transactions contemplated hereby and any communications in connection therewith, such Loan Party and its Affiliates, on the one hand, and the Administrative Agent, the Lead Arrangers, the Documentation Agent, the Syndication Agent, the other Credit Parties and their respective Affiliates, on the other hand, will have a business relationship that does not create, by implication or otherwise, any fiduciary duty on the part of the Administrative Agent, the Lead Arrangers, the Documentation Agent, the Syndication Agent, the other Credit Parties or their respective Affiliates and no such duty will be deemed to have arisen in connection with any such transactions or communications.
Section 1.17Acknowledgement and Consent to Bail-In of Affected Financial Institutions. Notwithstanding anything to the contrary in any Loan Document or in any other agreement, arrangement or understanding among any such parties, each party hereto acknowledges that any liability of any Affected Financial Institution arising under any Loan Document, to the extent such liability is unsecured, may be subject to the Write-Down and Conversion Powers of the applicable Resolution Authority and agrees and consents to, and acknowledges and agrees to be bound by:
(a)the application of any Write-Down and Conversion Powers by the applicable Resolution Authority to any such liabilities arising hereunder which may be payable to it by any party hereto that is an Affected Financial Institution; and
- 147 -


(b)the effects of any Bail-In Action on any such liability, including, if applicable:
(i)a reduction in full or in part or cancellation of any such liability;
(ii)a conversion of all, or a portion of, such liability into shares or other instruments of ownership in such Affected Financial Institution, its parent undertaking, or a bridge institution that may be issued to it or otherwise conferred on it, and that such shares or other instruments of ownership will be accepted by it in lieu of any rights with respect to any such liability under this Credit Agreement or any other Loan Document; or
(iii)the variation of the terms of such liability in connection with the exercise of the Write-Down and Conversion Powers of any applicable Resolution Authority.
Section 1.18Certain ERISA Matters.
(a)Each Lender (x) represents and warrants, as of the date such Person became a Lender party hereto, to, and (y) covenants, from the date such Person became a Lender party hereto to the date such Person ceases being a Lender party hereto, for the benefit of, the Administrative Agent and the Lead Arrangers and their respective Affiliates, and not, for the avoidance of doubt, to or for the benefit of the Borrower or any other Loan Party, that at least one of the following is and will be true:
(i)such Lender is not using “plan assets” (within the meaning of 29 CFR § 2510.3-101, as modified by Section 3(42) of ERISA) of one or more Benefit Plans in connection with the Loans, the Letters of Credit or the Commitments,
(ii)the transaction exemption set forth in one or more PTEs, such as PTE 84-14 (a class exemption for certain transactions determined by independent qualified professional asset managers), PTE 95-60 (a class exemption for certain transactions involving insurance company general accounts), PTE 90-1 (a class exemption for certain transactions involving insurance company pooled separate accounts), PTE 91-38 (a class exemption for certain transactions involving bank collective investment funds) or PTE 96-23 (a class exemption for certain transactions determined by in-house asset managers), is applicable with respect to such Lender’s entrance into, participation in, administration of and performance of the Loans, the Letters of Credit, the Commitments and this Credit Agreement,
(iii)(A) such Lender is an investment fund managed by a “Qualified Professional Asset Manager” (within the meaning of Part VI of PTE 84-14), (B) such Qualified Professional Asset Manager made the investment decision on behalf of such Lender to enter into, participate in, administer and perform the Loans, the Letters of Credit, the Commitments and this Credit Agreement, (C) the entrance into, participation in, administration of and performance of the Loans, the Letters of Credit, the Commitments and this Credit Agreement satisfies the requirements of sub-sections (b) through (g) of Part I of PTE 84-14 and (D) to the best knowledge of such Lender, the requirements of subsection (a) of Part I of PTE 84-14 are satisfied with respect to such Lender’s entrance into, participation in, administration of and performance of the Loans, the Letters of Credit, the Commitments and this Credit Agreement, or
(iv)such other representation, warranty and covenant as may be agreed in writing between the Administrative Agent, in its sole discretion, and such Lender.
(b)In addition, unless sub-clause (i) in the immediately preceding clause (a) is true with respect to a Lender or such Lender has not provided another representation, warranty and covenant
- 148 -


as provided in sub-clause (iv) in the immediately preceding clause (a), such Lender further (x) represents and warrants, as of the date such Person became a Lender party hereto, to, and (y) covenants, from the date such Person became a Lender party hereto to the date such Person ceases being a Lender party hereto, for the benefit of, the Administrative Agent and the Lead Arrangers, their respective Affiliates, and not, for the avoidance of doubt, to or for the benefit of the Borrower or any other Loan Party, that:
(i)none of the Administrative Agent or the Lead Arrangers or any of their respective Affiliates is a fiduciary with respect to the assets of such Lender (including in connection with the reservation or exercise of any rights by the Administrative Agent under this Credit Agreement, any Loan Document or any documents related to hereto or thereto),
(ii)the Person making the investment decision on behalf of such Lender with respect to the entrance into, participation in, administration of and performance of the Loans, the Letters of Credit, the Commitments and this Credit Agreement is independent (within the meaning of 29 CFR § 2510.3-21) and is a bank, an insurance carrier, an investment adviser, a broker-dealer or other person that holds, or has under management or control, total assets of at least $50 million, in each case as described in 29 CFR § 2510.3-21(c)(1)(i)(A)-(E),
(iii)the Person making the investment decision on behalf of such Lender with respect to the entrance into, participation in, administration of and performance of the Loans, the Letters of Credit, the Commitments and this Credit Agreement is capable of evaluating investment risks independently, both in general and with regard to particular transactions and investment strategies (including in respect of the Loan Document Obligations),
(iv)the Person making the investment decision on behalf of such Lender with respect to the entrance into, participation in, administration of and performance of the Loans, the Letters of Credit, the Commitments and this Credit Agreement is a fiduciary under ERISA or the Code, or both, with respect to the Loans, the Letters of Credit, the Commitments and this Credit Agreement and is responsible for exercising independent judgment in evaluating the transactions hereunder, and
(v)no fee or other compensation is being paid directly to the Administrative Agent or the Lead Arrangers or any their respective Affiliates for investment advice (as opposed to other services) in connection with the Loans, the Letters of Credit, the Commitments or this Credit Agreement.
(c)The Administrative Agent and the Lead Arrangers hereby inform the Lenders that each such Person is not undertaking to provide impartial investment advice, or to give advice in a fiduciary capacity, in connection with the transactions contemplated hereby, and that such Person has a financial interest in the transactions contemplated hereby in that such Person or an Affiliate thereof (i) may receive interest or other payments with respect to the Loans, the Letters of Credit, the Commitments and this Credit Agreement, (ii) may recognize a gain if it extended the Loans, the Letters of Credit or the Commitments for an amount less than the amount being paid for an interest in the Loans, the Letters of Credit or the Commitments by such Lender or (iii) may receive fees or other payments in connection with the transactions contemplated hereby, the Loan Documents or otherwise, including structuring fees, commitment fees, arrangement fees, facility fees, upfront fees, underwriting fees, ticking fees, agency fees, administrative agent or collateral agent fees, utilization fees, minimum usage fees, letter of credit fees, fronting fees, deal-away or alternate transaction fees, amendment fees, processing fees, term out premiums, banker’s acceptance fees, breakage or other early termination fees or fees similar to the foregoing.
- 149 -


Section 1.19Acknowledgement Regarding Any Supported QFCs. To the extent that the Loan Documents provide support, through a guarantee or otherwise, for Swap Agreements or any other agreement or instrument that is a QFC (such support, “QFC Credit Support” and each such QFC a “Supported QFC”), the parties acknowledge and agree as follows with respect to the resolution power of the Federal Deposit Insurance Corporation under the Federal Deposit Insurance Act and Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act (together with the regulations promulgated thereunder, the “U.S. Special Resolution Regimes”) in respect of such Supported QFC and QFC Credit Support (with the provisions below applicable notwithstanding that the Loan Documents and any Supported QFC may in fact be stated to be governed by the laws of the State of New York and/or of the United States or any other state of the United States):
(a)In the event a Covered Entity that is party to a Supported QFC (each, a “Covered Party”) becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer of such Supported QFC and the benefit of such QFC Credit Support (and any interest and obligation in or under such Supported QFC and such QFC Credit Support, and any rights in property securing such Supported QFC or such QFC Credit Support) from such Covered Party will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if the Supported QFC and such QFC Credit Support (and any such interest, obligation and rights in property) were governed by the laws of the United States or a state of the United States. In the event a Covered Party or a BHC Act Affiliate of a Covered Party becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under the Loan Documents that might otherwise apply to such Supported QFC or any QFC Credit Support that may be exercised against such Covered Party are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if the Supported QFC and the Loan Documents were governed by the laws of the United States or a state of the United States. Without limitation of the foregoing, it is understood and agreed that rights and remedies of the parties with respect to a Defaulting Lender shall in no event affect the rights of any Covered Party with respect to a Supported QFC or any QFC Credit Support.
(b)As used in this Section 10.19, the following terms have the following meanings:
BHC Act Affiliate” of a party means an “affiliate” (as such term is defined under, and interpreted in accordance with, 12 U.S.C. 1841(k)) of such party.
Covered Entity” means any of the following:
(i)    a “covered entity” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 252.82(b);
(ii)    a “covered bank” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 47.3(b); or
(iii)    a “covered FSI” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 382.2(b).
Default Right” has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. §§ 252.81, 47.2 or 382.1, as applicable.
QFC” has the meaning assigned to the term “qualified financial contract” in, and shall be interpreted in accordance with, 12 U.S.C. 5390(c)(8)(D).
- 150 -


Section 10.20    Keepwell. Each Loan Party that is a Qualified ECP Guarantor at the time the Guarantee or the grant of a Lien under the Loan Documents, in each case, by any Specified Loan Party becomes effective with respect to any CEA Swap Obligation, hereby jointly and severally, absolutely, unconditionally and irrevocably undertakes to provide such funds or other support to each Specified Loan Party with respect to such CEA Swap Obligation as may be needed by such Specified Loan Party from time to time to honor all of its obligations under the Loan Documents in respect of such CEA Swap Obligation (but, in each case, only up to the maximum amount of such liability that can be hereby incurred without rendering such Qualified ECP Guarantor’s obligations and undertakings under this Article X voidable under Applicable Law relating to fraudulent conveyance or fraudulent transfer, and not for any greater amount). The obligations and undertakings of each Qualified ECP Guarantor under this Section 10.20 shall remain in full force and effect until the Secured Obligations have been indefeasibly paid and performed in full. Each Loan Party intends this Section 10.20 to constitute, and this Section 10.20 shall be deemed to constitute, a guarantee of the obligations of, and a “keepwell, support, or other agreement” for the benefit of, each Specified Loan Party for all purposes of the Commodity Exchange Act.

[Signature pages follow]
- 151 -


IN WITNESS WHEREOF, the parties hereto have caused this Credit Agreement to be duly executed by their respective authorized officers as of the day and year first above written.
MIMEDX GROUP, INC., as the Borrower
By:/s/ Joseph H. Capper
Name:Joseph H. Capper
Title:Chief Executive Officer

MIMEDX TISSUE SERVICES, LLC., as a Guarantor
By:/s/ Joseph H. Capper
Name: Joseph H. Capper
Title: Chief Executive Officer

MIMEDX PROCESSING SERVICES, LLC, as a Guarantor
By:/s/ Joseph H. Capper
Name:
Title: Chief Executive Officer

MIMEDX SUPPLY LLC, as a Guarantor
By:/s/ Douglas Rice
Name: Douglas Rice
Title: Chief Financial Officer




CITIZENS BANK, N.A. as the Administrative
Agent, the L/C Issuer, the Swingline Lender

and a Lender
By:/s/ Luis Gutierrez
Name:Luis Gutierrez
Title:Vice President




BANK OF AMERICA, NATIONAL
ASSOCIATION, as a Lender
By:/s/ H. Hope Walker
Name:H. Hope Walker
Title:Senior Vice President



EX-31.1 6 ex311ceosox.htm EX-31.1 Document

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO RULES 13a-14(A) AND 15d-14(A)
OF THE SECURITIES EXCHANGE ACT OF 1934
 
I, Joseph H. Capper, certify that:
 
1. I have reviewed this Quarterly Report on Form 10-Q of MiMedx Group, Inc. (the “Report”); 
2. Based on my knowledge, this Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Report;
3. Based on my knowledge, the financial statements, and other financial information included in this Report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this Report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this Report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this Report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this Report based on such evaluation; and
(d) Disclosed in this Report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:April 30, 2024/s/ Joseph H. Capper
 Joseph H. Capper
 Chief Executive Officer


EX-31.2 7 ex312cfosox.htm EX-31.2 Document

Exhibit 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO RULES 13a-14(A) AND 15d-14(A)
OF THE SECURITIES EXCHANGE ACT OF 1934
 
I, Doug Rice, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of MiMedx Group, Inc. (the “Report”);
2. Based on my knowledge, this Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Report;
3. Based on my knowledge, the financial statements, and other financial information included in this Report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this Report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this Report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this Report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this Report based on such evaluation; and
(d) Disclosed in this Report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date:April 30, 2024/s/ Doug Rice
 Doug Rice
 Chief Financial Officer


EX-32.1 8 ex321ceosox.htm EX-32.1 Document

Exhibit 32.1
 
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
    The undersigned Joseph H. Capper, the Chief Executive Officer of MiMedx Group, Inc. (the “Company”), has executed this certification in connection with the filing with the Securities and Exchange Commission of the Company’s Quarterly Report on Form 10-Q for the period ending March 31, 2024 (the “Report”). Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned hereby certifies, to his knowledge, that:

(1)the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date:April 30, 2024/s/ Joseph H. Capper
 Joseph H. Capper
 Chief Executive Officer


EX-32.2 9 ex322cfosox.htm EX-32.2 Document

 Exhibit 32.2
 
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
    The undersigned, Doug Rice, the Chief Financial Officer of MiMedx Group, Inc. (the “Company”), has executed this certification in connection with the filing with the Securities and Exchange Commission of the Company’s Quarterly Report on Form 10-Q for the period ending March 31, 2024 (the “Report”). Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned hereby certifies, to his knowledge, that:

(1)the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date:April 30, 2024/s/ Doug Rice
 Doug Rice
 Chief Financial Officer


EX-101.SCH 10 mdxg-20240331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 0000007 - Disclosure - Nature of Business link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Accounts Receivable, Net link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Property and Equipment, Net link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Intangible Assets, Net link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Long Term Debt, Net link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Net Income (Loss) Per Common Share link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Discontinued Operations link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Accounts Receivable, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Property and Equipment, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Intangible Assets, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Long Term Debt, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Net Income (Loss) Per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Discontinued Operations (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Accounts Receivable, Net - Accounts Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Accounts Receivable, Net - Schedule of Activity Related to the Allowance for Doubtful Accounts (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Intangible Assets, Net - Activity Summary (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Intangible Assets, Net - Activity Summary (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Intangible Assets, Net - Estimated Future Amortization Expense for Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Long Term Debt, Net - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Long Term Debt, Net - Schedule of Extinguishment of Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Long Term Debt, Net - Schedule of Term Loan Facility Balances (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Long Term Debt, Net - Schedule of Term Loan Balances (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Long Term Debt, Net - Schedule of Interest Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Long Term Debt, Net - Term Loan Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Net Income (Loss) Per Common Share - Schedule of Basic Net Loss Per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Net Income (Loss) Per Common Share - Schedule of Diluted Net Loss Per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Net Income (Loss) Per Common Share - Antidilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Revenue - Summary of Revenue by Site Of Service (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Revenue - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Revenue - Summary of Revenue by Product Type (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Discontinued Operations - Schedule Of Disposal Groups Including Discontinued Operations Income Statement (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 11 mdxg-20240331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 12 mdxg-20240331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 13 mdxg-20240331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Variable Rate [Domain] Variable Rate [Domain] Accounts Receivable, Net Accounts and Nontrade Receivable [Text Block] Pay vs Performance Disclosure [Line Items] Schedule of Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Accrued expenses Accrued expenses Accrued Liabilities, Current Discontinued operations- diluted (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share Statistical Measurement [Domain] Statistical Measurement [Domain] Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Research and development Research and Development Expense Increase (decrease) in cash resulting from changes in: Increase (Decrease) in Operating Capital [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Award Type [Domain] Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Long Term Debt, Net Debt Disclosure [Text Block] Impairment of intangible assets Impairment of Intangible Assets (Excluding Goodwill) Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Revolving Credit Facility Revolving Credit Facility [Member] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Performance stock unit awards Performance Shares [Member] Accounts payable Accounts Payable, Current Discontinued Operations and Disposal Groups [Abstract] Restatement Determination Date: Restatement Determination Date [Axis] Commitments and contingencies (Note 12) Commitments and Contingencies Insider Trading Policies and Procedures [Line Items] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Regenerative Medicine Regenerative Medicine Business Unit [Member] Regenerative Medicine Business Unit Total adjustments Dilutive Securities, Effect on Basic Earnings Per Share Error Corrections and Prior Period Adjustments Restatement [Line Items] Error Corrections and Prior Period Adjustments Restatement [Line Items] Income Taxes Income Tax Disclosure [Text Block] Schedule of Revenue by Major Customers, by Reporting Segments [Table] Schedule of Revenue by Major Customers, by Reporting Segments [Table] Issuance of restricted stock, net (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Property and equipment, gross Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization Hospital Hospital Site Of Service [Member] Hospital Site Of Service [Member] Current liabilities: Liabilities, Current [Abstract] Number of sites of service Revenue From Contract With Customer, Number Service Sites Revenue From Contract With Customer, Number Service Sites Deferred financing, noncurrent Deferred financing costs Debt Issuance Costs, Noncurrent, Net Diluted net (loss) income per common share (in dollars per share) Earnings Per Share, Diluted PEO Total Compensation Amount PEO Total Compensation Amount Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Accounts receivable, net Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Supplemental Cash Flow Elements [Abstract] Supplemental Cash Flow Elements [Abstract] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Treasury stock, beginning balance (in shares) Treasury stock, ending balance (in shares) Treasury Stock, Common, Shares Line of Credit Line of Credit [Member] Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Trading Symbol Trading Symbol Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Fair value of term loan Long-Term Debt, Fair Value Net income (loss) Net income (loss) Net Income (Loss) Net Income (Loss) Basic Net Income (Loss) Per Common Share Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table Text Block] Total current liabilities Liabilities, Current Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Intangible assets, gross carrying amount Intangible Assets, Gross (Excluding Goodwill) Property and equipment, net Property and equipment, net Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Accretion of original issue discount Amortization of Debt Discount (Premium) Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Employee stock purchase plan Employee Stock [Member] Hayfin Loan Agreement Term Loan Hayfin Loan Agreement Term Loan [Member] Hayfin Loan Agreement Term Loan [Member] Stockholders' equity Equity, Attributable to Parent [Abstract] Exercise of stock options (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Cost of sales Cost of Goods and Services Sold Executive Category: Executive Category [Axis] Schedule of Intangible Assets Activity Summary - Indefinite-lived Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Significant Accounting Policies Significant Accounting Policies [Text Block] Name Measure Name Patents and know-how Patents [Member] Name Forgone Recovery, Individual Name Goodwill Goodwill Summary of Property and Equipment Property, Plant and Equipment [Table Text Block] Equity Components [Axis] Equity Components [Axis] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Accrued expenses Increase (Decrease) in Accrued Liabilities Asset Acquisition [Domain] Asset Acquisition [Domain] 2026 Long-Term Debt, Maturity, Year Two Underlying Securities Award Underlying Securities Amount Entity Small Business Entity Small Business 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Four Local Phone Number Local Phone Number Accounts receivable Increase (Decrease) in Accounts Receivable Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Letter of Credit Letter of Credit [Member] 2024 (excluding the three months ended March 31, 2024) Long-Term Debt, Maturity, Remainder of Fiscal Year RSU Restricted Stock Units (RSUs) [Member] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Depreciation Depreciation Deferred financing cost Payments of Debt Issuance Costs Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Debt Amortization, Year Four Debt Amortization, Year Four [Member] Debt Amortization, Year Four Revision of Prior Period, Reclassification, Adjustment Revision of Prior Period, Reclassification, Adjustment [Member] Total adjustments (in shares) Weighted Average Number of Shares Outstanding, Diluted, Adjustment Asset retirement cost Asset Retirement Cost [Member] Asset Retirement Cost [Member] Payables and Accruals [Abstract] Payables and Accruals [Abstract] Product and Service [Domain] Product and Service [Domain] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Other Performance Measure, Amount Other Performance Measure, Amount Interest expense Interest Expense, Debt Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Inventory Increase (Decrease) in Inventories Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Potential common shares (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Award Type [Axis] Award Type [Axis] Accrued Group Purchasing Organization fees Accrued Administrative Fees, Current Accrued Administrative Fees, Current Document Quarterly Report Document Quarterly Report Prepayment premium on Hayfin term loan Payment for Debt Extinguishment or Debt Prepayment Cost Purchases of equipment in accounts payable Capital Expenditures Incurred but Not yet Paid Loss on extinguishment of debt Loss on extinguishment of debt Gain (Loss) on Extinguishment of Debt Finite-lived intangible assets acquired Finite-Lived Intangible Assets Acquired Term loan Notes Payable, Other Payables [Member] Property and equipment, gross Property, Plant and Equipment, Gross Right of use assets arising from operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 2024 (excluding the three months ended March 31, 2024) Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Allowance for Doubtful Accounts Accounts Receivable, Allowance for Credit Loss [Roll Forward] Trading Arrangement: Trading Arrangement [Axis] Use of Estimates Use of Estimates, Policy [Policy Text Block] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Adjustments to reconcile to income (loss) available to common stockholders: Preferred Stock Dividends and Other Adjustments [Abstract] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity File Number Entity File Number Summary of Antidilutive Securities [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Original issue discount Debt Instrument, Unamortized Discount Prepaid expenses Prepaid Expense, Current 2027 Long-Term Debt, Maturity, Year Three Employee stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Amortization of intangible assets Amortization of Intangible Assets Entity Shell Company Entity Shell Company Line of credit facility, optional increase, EBITDA multiplier Line of Credit Facility, Accordion Feature, EBITDA Multiplier Line of Credit Facility, Accordion Feature, EBITDA Multiplier Total amortized intangible assets Finite-Lived Intangible Assets, Net Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Recently Issued Accounting Standards Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Restatement Determination Date Restatement Determination Date Prepaid expenses Increase (Decrease) in Prepaid Expense Original issue discount, noncurrent Original issue discount Debt Instrument, Unamortized Discount, Noncurrent Other liabilities Increase (Decrease) in Other Operating Liabilities Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Term Loan Facility and Hayfin Loan Agreement Term Loan Facility and Hayfin Loan Agreement [Member] Term Loan Facility and Hayfin Loan Agreement Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Debt Amortization Period [Axis] Debt Amortization Period [Axis] Debt Amortization Period Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Common stock, shares issued (in shares) Balance beginning of period (in shares) Balance end of period (in shares) Common Stock, Shares, Issued Gross profit Gross Profit Profit sharing payment liability, current Asset Acquisition, Contingent Consideration, Liability, Current Security Exchange Name Security Exchange Name Current portion of long term debt Long-Term Debt, Current Maturities [Abstract] Selling, general and administrative Selling, General and Administrative Expense 2028 Long-Term Debt, Maturity, Year Four Outstanding stock options Employee Stock Option [Member] Asset Acquisition [Table] Asset Acquisition [Table] Accrued rebates Accrued Rebates Accrued Rebates Maximum Maximum [Member] Document Type Document Type Tabular List, Table Tabular List [Table Text Block] Discontinued operations - basic (in dollars per share) Discontinued operations - basic (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share Entity Address, Address Line One Entity Address, Address Line One Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Debt Amortization, Year Three Debt Amortization, Year Three [Member] Debt Amortization, Year Three Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Less: allowance for doubtful accounts Beginning balance Ending balance Accounts Receivable, Allowance for Credit Loss, Current Tradenames and trademarks Trademarks and Trade Names [Member] Other current liabilities Other current liabilities Other Liabilities, Current Variable Rate [Axis] Variable Rate [Axis] Income Statement [Abstract] Income Statement [Abstract] Raw materials Inventory, Raw Materials, Net of Reserves Title of 12(b) Security Title of 12(b) Security Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Asset Acquisition [Line Items] Asset Acquisition [Line Items] Gross carrying value, indefinite lived Indefinite-Lived Intangible Assets (Excluding Goodwill) Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Other current assets Other Assets, Current Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Schedule of Accounts, Notes, Loans and Financing Receivable Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Diluted net income (loss) per common share: Diluted net income (loss) per common share: Earnings Per Share, Diluted [Abstract] Entity Tax Identification Number Entity Tax Identification Number Inventory Inventory Inventory, Net Statistical Measurement [Axis] Statistical Measurement [Axis] Stated interest Interest Expense, Debt, Excluding Amortization Discontinued Operations Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Entity Interactive Data Current Entity Interactive Data Current Total Shareholder Return Amount Total Shareholder Return Amount Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Non-cash activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Future payments for remaining product inventory Asset Acquisition, Consideration Transferred, Future Payment to Acquire Remaining Product Inventory Asset Acquisition, Consideration Transferred, Future Payment to Acquire Remaining Product Inventory Accumulated deficit Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Issuance of restricted stock (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Gross Name Outstanding Recovery, Individual Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current assets: Assets, Current [Abstract] Accounts receivable, gross Accounts Receivable, before Allowance for Credit Loss, Current Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Continuing operations - basic (in dollars per share) Income (Loss) from Continuing Operations, Per Basic Share Deferred financing, current Deferred financing costs Debt Issuance Costs, Current, Net 2025 Finite-Lived Intangible Asset, Expected Amortization, Year One Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Disposal Group Name [Domain] Disposal Group Name [Domain] Basic net income (loss) per common share: Basic net income (loss) per common share: Earnings Per Share, Basic [Abstract] Number of product lines Contract with Customer, Number of Product Lines Contract with Customer, Number of Product Lines PEO PEO [Member] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Net cash flows used in investing activities Net Cash Provided by (Used in) Investing Activities Schedule of Inventory Schedule of Inventory, Current [Table Text Block] Debt Instrument [Axis] Debt Instrument [Axis] Net income (loss) from continuing operations Net income (loss) from continuing operations Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent Schedule of Original Discount and Deferred Financing Costs Schedule of Original Discount and Deferred Financing Costs [Table Text Block] Schedule of Original Discount and Deferred Financing Costs Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Effective tax rate Effective Income Tax Rate Reconciliation, Percent Patents in Process Patents in Process [Member] Patents in Process Credit Facility [Axis] Credit Facility [Axis] Schedule of Extinguishment of Debt Schedule of Extinguishment of Debt [Table Text Block] Series B Preferred Stock Series B Preferred Stock [Member] Summary of Principal Payments for the Term Loan Facility Schedule of Maturities of Long-Term Debt [Table Text Block] Total liabilities Liabilities Net sales over the period Asset Acquisition, Consideration Transferred, Contingent Consideration Period Asset Acquisition, Consideration Transferred, Contingent Consideration Period Asset Acquisition [Axis] Asset Acquisition [Axis] Nature of Business Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Schedule of Interest Expense Schedule of Interest Expense [Table Text Block] Schedule of Interest Expense [Table Text Block] Property and Equipment, Net Property, Plant and Equipment Disclosure [Text Block] All Executive Categories All Executive Categories [Member] Repayment of Citizens Revolving Credit Facility Repayments of initial line of credit draw Repayments of Long-Term Lines of Credit Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Accrued Expenses Accounts Payable and Accrued Liabilities Disclosure [Text Block] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Common stock; $0.001 par value; 250,000,000 shares authorized; 147,528,596 issued and outstanding at March 31, 2024 and 146,227,639 issued and outstanding at December 31, 2023 Common Stock, Value, Issued Adjustments: Earnings Per Share, Diluted, Other Disclosure [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Legal and settlement costs Accrued Professional Fees, Current Non-cash lease expenses Operating Lease, Right-of-Use Asset, Periodic Reduction Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Total current assets Assets, Current Estimated sales returns Contract with Customer, Refund Liability, Current Principal payments on finance lease Finance Lease, Principal Payments Revenue from Contract with Customer [Abstract] All Individuals All Individuals [Member] Other (expense) income, net Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Proceeds from Citizens Term Loan Facility Proceeds from term loan Proceeds from Issuance of Secured Debt Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date Other Other Site Of Service [Member] Other Site Of Service [Member] PEO Name PEO Name Diluted Net Income (Loss) Per Common Share Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table Text Block] Base Rate Base Rate [Member] Thereafter Long-Term Debt, Maturity, after Year Four Long-Term Debt, Maturity, after Year Four Less: antidilutive adjustments Preferred Stock Dividends, Antidilutive Adjustments, Net of Tax Preferred Stock Dividends, Antidilutive Adjustments, Net of Tax Net cash flows provided by (used in) operating activities Net Cash Provided by (Used in) Operating Activities Schedule of Estimated Future Amortization Expense for Intangible Assets Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Restricted stock shares canceled/forfeited Stock Issued During Period, Value, Restricted Stock Award, Forfeitures Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Other Other Accrued Liabilities, Current Furniture and equipment Furniture and Fixtures [Member] Interest rate Debt Instrument, Interest Rate, Stated Percentage Net income (loss) from continuing operations available to common stockholders Net income (loss) available to common stockholders from continuing operations Net income (loss) available to common stockholders from continuing operations Net Income (Loss) from Continuing Operations Available to Common Shareholders, Basic Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Accrued compensation Increase (Decrease) in Employee Related Liabilities Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Total stockholders' equity Balance, beginning of period Balance, end of period Equity, Attributable to Parent Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] RSA Restricted Stock [Member] Dividends on Series B Preferred Stock Convertible Preferred Dividends, Net of Tax Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Revision of Prior Period [Domain] Revision of Prior Period [Domain] Income (loss) from continuing operations before income tax Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Debt Amortization Period [Domain] Debt Amortization Period [Domain] Debt Amortization Period [Domain] Commissions to sales agents Accrued Sales Commission, Current Contingent consideration Asset Acquisition, Consideration Transferred, Contingent Consideration Outstanding principal Long-Term Debt, Gross, Excluding Current Maturities Long-Term Debt, Gross, Excluding Current Maturities Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Entity Emerging Growth Company Entity Emerging Growth Company Deferred financing Debt Issuance Costs, Net Intangible assets, net Intangible assets, net carrying amount Intangible Assets, Net (Excluding Goodwill) Disposal Group Classification [Domain] Disposal Group Classification [Domain] Interest rate, effective percentage (percent) Debt Instrument, Interest Rate, Effective Percentage Consideration payable to TELA Unpaid Inventory From Asset Purchase Agreement Unpaid Inventory From Asset Purchase Agreement Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Unamortized original issue discount Unamortized Issuance Discount, Writeoff Unamortized Issuance Discount, Writeoff Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Title Trading Arrangement, Individual Title Wound Wound [Member] Wound Share-based compensation Share-Based Payment Arrangement, Noncash Expense Consideration paid pursuant to TELA APA (Note 12) Initial consideration paid Payments to Acquire Other Productive Assets Common Stock Issued Common Stock [Member] Numerator Net Income (Loss) Available to Common Stockholders, Diluted, Operations [Abstract] Individual: Individual [Axis] Finance lease right-of-use asset Finance Lease, Right-of-Use Asset, before Accumulated Amortization City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Product and Service [Axis] Product and Service [Axis] Net Income (Loss) Per Common Share Earnings Per Share [Text Block] Repayment of Hayfin term loan Repayments of term loan Repayments of Secured Debt Document Fiscal Year Focus Document Fiscal Year Focus Disbanded Discontinued Operations, Disposed of by Means Other than Sale, Abandonment [Member] Minimum Minimum [Member] Receivables [Abstract] Exercise Price Award Exercise Price Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Private Office Private Office Site Of Service [Member] Private Office Site Of Service [Member] Disposal Group Classification [Axis] Disposal Group Classification [Axis] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] ASSETS Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Long term debt, net Long-Term Debt, by Current and Noncurrent [Abstract] Stock repurchased for tax withholdings on vesting of restricted stock units Payment, Tax Withholding, Share-Based Payment Arrangement Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Net cash flows used in financing activities Net Cash Provided by (Used in) Financing Activities Deferred tax asset, net Deferred Income Tax Assets, Net Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Continuing operations- diluted(in dollars per share) Income (Loss) from Continuing Operations, Per Diluted Share Accumulated Deficit Retained Earnings [Member] Current portion of long term debt Long term debt, net Long-Term Debt, Current Maturities Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Total liabilities and stockholders’ equity Liabilities and Equity Other expense, net Nonoperating Income (Expense) [Abstract] Other assets Other Assets, Noncurrent Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Research and development expense Disposal Group, Including Discontinued Operation, Research And Development Expense Disposal Group, Including Discontinued Operation, Research And Development Expense Basic net income (loss) per common share (in dollars per share) Earnings Per Share, Basic Right of use asset Operating Lease, Right-of-Use Asset Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Employee stock purchase plan Issuance of shares pursuant to employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Accounting Policies [Abstract] Accounting Policies [Abstract] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Citizens Credit Agreement Citizens Credit Agreement [Member] Citizens Credit Agreement Indefinite-lived Intangible Assets [Line Items] Indefinite-Lived Intangible Assets [Line Items] Arrangement Duration Trading Arrangement Duration Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Debt Amortization, Year One Debt Amortization, Year One [Member] Debt Amortization, Year One Cash paid for income taxes Income Taxes Paid Principles of Consolidation Consolidation, Policy [Policy Text Block] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Thereafter Finite-Lived Intangible Asset, Expected Amortization, After Year Four Finite-Lived Intangible Asset, Expected Amortization, After Year Four Termination Date Trading Arrangement Termination Date TELA APA TELA APA [Member] TELA APA Accounts payable Increase (Decrease) in Accounts Payable Common stock, shares authorized (in shares) Common Stock, Shares Authorized Indefinite-lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Outstanding principal Long-Term Debt, Gross Adjustments to reconcile net income (loss) from continuing operations to net cash flows provided by (used in) operating activities from continuing operations: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Accrued travel Accrued Travel Accrued Travel All Trading Arrangements All Trading Arrangements [Member] Present value of minimum earn out Fair value of minimum contingent consideration Asset Acquisition, Consideration Transferred, Fair Value of Minimum Contingent Consideration Asset Acquisition, Consideration Transferred, Fair Value of Minimum Contingent Consideration Bridge Loan Bridge Loan [Member] Distribution rights Distribution Rights [Member] Less: accumulated depreciation and amortization Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization All Adjustments to Compensation All Adjustments to Compensation [Member] Award Timing Disclosures [Line Items] Compensation Amount Outstanding Recovery Compensation Amount Principal payments on Citizens Term Loan Facility Principal Payments of Secured Debt Principal Payments of Secured Debt Bad debt expense Accounts Receivable, Credit Loss Expense (Reversal) Additional paid-in capital Additional Paid in Capital Issuance of restricted stock Stock Issued During Period, Value, Restricted Stock Award, Gross Proceeds from exercise of stock options Proceeds from Stock Options Exercised Net cash flows provided by operating activities from continuing operations Net Cash Provided by (Used in) Operating Activities, Continuing Operations Surgical & Other Surgical [Member] Surgical Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities Cash Flow, Supplemental Disclosures [Text Block] 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Three Insider Trading Arrangements [Line Items] 2025 Long-Term Debt, Maturity, Year One Revenue, Major Customer [Line Items] Revenue, Major Customer [Line Items] Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Stock-based awards (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Other assets Increase (Decrease) in Other Operating Assets Prepayment premium on Hayfin term loan Debt Prepayment Premium Debt Prepayment Premium 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Two Adjustment to Compensation, Amount Adjustment to Compensation Amount Document Period End Date Document Period End Date Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Adoption Date Trading Arrangement Adoption Date Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Issuance of restricted stock, net Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Disposal Group Name [Axis] Disposal Group Name [Axis] Schedule of Activity Related to the Allowance for Doubtful Accounts Accounts Receivable, Allowance for Credit Loss [Table Text Block] Treasury Stock Treasury Stock, Common [Member] Entity Central Index Key Entity Central Index Key Amortization of deferred financing costs Amortization of Debt Issuance Costs and Discounts Loss on fixed asset disposal Gain (Loss) on Disposition of Property Plant Equipment Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Adjustments: Net Income (Loss) Available to Common Stockholders, Diluted [Abstract] Gross Carrying Amount Finite-Lived Intangible Assets, Gross Income tax expense from continuing operations Income Tax Expense (Benefit) Finished goods Inventory, Finished Goods, Net of Reserves Write-offs Accounts Receivable, Allowance for Credit Loss, Writeoff Accrued compensation Employee-related Liabilities, Current Name Trading Arrangement, Individual Name Net cash flows used in operating activities of discontinued operations Cash Provided by (Used in) Operating Activities, Discontinued Operations Unamortized deferred financing costs Deferred Debt Issuance Cost, Writeoff Schedule of Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Payments for legal settlements Payments for Legal Settlements Accretion of asset retirement obligation Asset Retirement Obligation, Accretion Expense Inventory Inventory Disclosure [Text Block] Net sales Revenue from Contract with Customer, Excluding Assessed Tax Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Accumulated dividend on previously converted Series B Preferred Stock Preferred Stock Dividends, Income Statement Impact Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Amendment Flag Amendment Flag Commitment fee Interest Expense, Commitment Fees Interest Expense, Commitment Fees Intangible Assets, Net Intangible Assets Disclosure [Text Block] Change in deferred income taxes Increase (Decrease) in Deferred Income Taxes Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Licenses Licensing Agreements [Member] Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Interest expense, net Interest Income (Expense), Net Credit Facility [Domain] Credit Facility [Domain] Current liabilities of discontinued operations Disposal Group, Including Discontinued Operation, Liabilities, Current Basis spread on variable rate (percent) Debt Instrument, Basis Spread on Variable Rate Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Long term debt, net Long term debt, net Long-Term Debt, Excluding Current Maturities Leasehold improvements Leasehold Improvements [Member] Patent application costs Payments For Application Costs, Patent Payments For Application Costs, Patent Weighted average shares outstanding - diluted (in shares) Weighted average shares outstanding adjusted for potential common shares (in shares) Weighted Average Number of Shares Outstanding, Diluted Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Original issue discount, current Original issue discount Debt Instrument, Unamortized Discount, Current Asset acquisition, inventory Asset Acquisition, Inventory Asset Acquisition, Inventory Schedule of Assets And Liabilities of the Discontinued Operations Disposal Groups, Including Discontinued Operations [Table Text Block] Operating expenses: Operating Expenses [Abstract] Revenue Revenue from Contract with Customer [Text Block] Company Selected Measure Amount Company Selected Measure Amount Additional Paid-in Capital Additional Paid-in Capital [Member] Potential common shares Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract] Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Revision of Prior Period [Axis] Revision of Prior Period [Axis] Cover [Abstract] Cover [Abstract] SOFR Secured Overnight Financing Rate (SOFR) [Member] Secured Overnight Financing Rate (SOFR) Laboratory and clean room equipment Equipment [Member] Debt Amortization, Year Two Debt Amortization, Year Two [Member] Debt Amortization, Year Two Share-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Amortization of deferred financing costs Amortization of Debt Issuance Costs Other liabilities Other Liabilities, Noncurrent Non-NEOs Non-NEOs [Member] Schedule of Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Construction in progress Construction in Progress [Member] Consideration transferred Asset Acquisition, Consideration Transferred Unpaid deferred financing costs Unpaid Deferred Financing Costs Unpaid Deferred Financing Costs Schedule of Error Corrections and Prior Period Adjustment Restatement [Table] Schedule of Error Corrections and Prior Period Adjustment Restatement [Table] Net change in cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Term Loan Secured Debt [Member] Non-PEO NEO Non-PEO NEO [Member] Equity Component [Domain] Equity Component [Domain] Outstanding principal Long-Term Debt, Gross, Current Maturities Long-Term Debt, Gross, Current Maturities Adjustment to Compensation: Adjustment to Compensation [Axis] Purchases of equipment Payments to Acquire Machinery and Equipment Work in process Inventory, Work in Process, Net of Reserves Investigation, restatement and related Investigation, Restatement And Related Investigation, Restatement And Related Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Debt Instrument [Line Items] Debt Instrument [Line Items] Weighted average common shares outstanding - basic (in shares) Weighted average common shares outstanding (in shares) Weighted average shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Selling, general and administrative expense Disposal Group, Including Discontinued Operation, General and Administrative Expense Debt Amortization, Year Five Debt Amortization, Year Five [Member] Debt Amortization, Year Five Operating income (loss) Operating Income (Loss) Reclassifications Reclassification, Comparability Adjustment [Policy Text Block] Schedule of Indefinite-Lived Intangible Assets [Table] Schedule of Indefinite-Lived Intangible Assets [Table] Restricted stock canceled/forfeited (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Forfeited Line of credit facility, optional increase Line of Credit Facility, Accordion Feature, Increase Limit Line of Credit Facility, Accordion Feature, Increase Limit Estimated future amortization expense [Abstract] Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Undrawn commitment fee percentage Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Statement [Line Items] Statement [Line Items] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Schedule of the Balances of the Loan Facility and Agreement Schedule of Debt [Table Text Block] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Long term debt, net Long-Term Debt, Excluding Current Maturities [Abstract] Proceeds from Citizens Revolving Credit Facility Proceeds from revolving credit facility Proceeds from Long-Term Lines of Credit Income (loss) from discontinued operations, net of tax Income (loss) from discontinued operations, net of tax Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent EX-101.PRE 14 mdxg-20240331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 16 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cover - shares
3 Months Ended
Mar. 31, 2024
Apr. 24, 2024
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2024  
Document Transition Report false  
Entity File Number 001-35887  
Entity Registrant Name MIMEDX GROUP, INC.  
Entity Incorporation, State or Country Code FL  
Entity Tax Identification Number 26-2792552  
Entity Address, Address Line One 1775 West Oak Commons Ct NE  
Entity Address, City or Town Marietta  
Entity Address, State or Province GA  
Entity Address, Postal Zip Code 30062  
City Area Code 770  
Local Phone Number 651-9100  
Title of 12(b) Security Common Stock, par value $0.001 per share  
Trading Symbol MDXG  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   147,603,955
Entity Central Index Key 0001376339  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q1  
Amendment Flag false  
XML 17 R2.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 48,487 $ 82,000
Accounts receivable, net 57,016 53,871
Inventory 24,454 21,021
Prepaid expenses 6,095 5,624
Other current assets 2,801 1,745
Total current assets 138,853 164,261
Property and equipment, net 7,340 6,974
Right of use asset 3,499 2,132
Deferred tax asset, net 38,747 40,777
Goodwill 19,441 19,441
Intangible assets, net 12,550 5,257
Other assets 1,251 205
Total assets 221,681 239,047
Current liabilities:    
Current portion of long term debt 1,000 1,000
Accounts payable 9,697 9,048
Accrued compensation 17,913 22,353
Accrued expenses 9,196 9,361
Current liabilities of discontinued operations 344 1,352
Other current liabilities 4,071 2,894
Total current liabilities 42,221 46,008
Long term debt, net 18,453 48,099
Other liabilities 5,276 2,223
Total liabilities 65,950 96,330
Commitments and contingencies (Note 12)
Stockholders' equity    
Common stock; $0.001 par value; 250,000,000 shares authorized; 147,528,596 issued and outstanding at March 31, 2024 and 146,227,639 issued and outstanding at December 31, 2023 148 146
Additional paid-in capital 280,000 276,249
Accumulated deficit (124,417) (133,678)
Total stockholders' equity 155,731 142,717
Total liabilities and stockholders’ equity $ 221,681 $ 239,047
XML 18 R3.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Mar. 31, 2024
Dec. 31, 2023
Statement of Financial Position [Abstract]    
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 250,000,000 250,000,000
Common stock, shares issued (in shares) 147,528,596 146,227,639
Common stock, shares outstanding (in shares) 147,528,596 146,227,639
XML 19 R4.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]    
Net sales $ 84,709 $ 71,676
Cost of sales 12,987 12,419
Gross profit 71,722 59,257
Operating expenses:    
Selling, general and administrative 55,129 52,250
Research and development 2,841 3,484
Investigation, restatement and related 311 3,673
Amortization of intangible assets 189 190
Impairment of intangible assets 54 0
Operating income (loss) 13,198 (340)
Other expense, net    
Interest expense, net (1,690) (1,553)
Other (expense) income, net (99) 2
Income (loss) from continuing operations before income tax 11,409 (1,891)
Income tax expense from continuing operations (2,348) (51)
Net income (loss) from continuing operations 9,061 (1,942)
Income (loss) from discontinued operations, net of tax 200 (3,041)
Net income (loss) 9,261 (4,983)
Net income (loss) from continuing operations available to common stockholders $ 9,061 $ (3,626)
Basic net income (loss) per common share:    
Continuing operations - basic (in dollars per share) $ 0.06 $ (0.03)
Discontinued operations - basic (in dollars per share) 0 (0.03)
Basic net income (loss) per common share (in dollars per share) 0.06 (0.06)
Diluted net income (loss) per common share:    
Continuing operations- diluted(in dollars per share) 0.06 (0.03)
Discontinued operations- diluted (in dollars per share) 0 (0.03)
Diluted net (loss) income per common share (in dollars per share) $ 0.06 $ (0.06)
Weighted average common shares outstanding - basic (in shares) 146,404,587 114,398,813
Weighted average shares outstanding - diluted (in shares) 150,028,107 114,398,813
XML 20 R5.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT) - USD ($)
$ in Thousands
Total
Common Stock Issued
Additional Paid-in Capital
Treasury Stock
Accumulated Deficit
Balance beginning of period (in shares) at Dec. 31, 2022   113,705,447      
Balance, beginning of period at Dec. 31, 2022 $ (17,988) $ 114 $ 173,804 $ 0 $ (191,906)
Treasury stock, beginning balance (in shares) at Dec. 31, 2022       0  
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Share-based compensation expense 4,345   4,345    
Issuance of restricted stock (in shares)   1,439,676   (57,770)  
Issuance of restricted stock 0 $ 1 (179) $ 178  
Restricted stock shares canceled/forfeited 0   179 $ (179)  
Restricted stock canceled/forfeited (in shares)       58,104  
Employee stock purchase plan (in shares)   235,419      
Employee stock purchase plan 680   680    
Net income (loss) (4,983)       (4,983)
Balance end of period (in shares) at Mar. 31, 2023   115,380,542      
Balance, end of period at Mar. 31, 2023 $ (17,946) $ 115 178,829 $ (1) (196,889)
Treasury stock, ending balance (in shares) at Mar. 31, 2023       334  
Balance beginning of period (in shares) at Dec. 31, 2023 146,227,639 146,227,639      
Balance, beginning of period at Dec. 31, 2023 $ 142,717 $ 146 276,249 $ 0 (133,678)
Treasury stock, beginning balance (in shares) at Dec. 31, 2023       0  
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Share-based compensation expense 4,340   4,340    
Exercise of stock options (in shares)   109,920      
Exercise of stock options 766   766    
Employee stock purchase plan (in shares)   121,783      
Employee stock purchase plan 797   797    
Issuance of restricted stock, net (in shares)   1,069,254      
Issuance of restricted stock, net (2,150) $ 2 (2,152)    
Net income (loss) $ 9,261       9,261
Balance end of period (in shares) at Mar. 31, 2024 147,528,596 147,528,596      
Balance, end of period at Mar. 31, 2024 $ 155,731 $ 148 $ 280,000 $ 0 $ (124,417)
Treasury stock, ending balance (in shares) at Mar. 31, 2024       0  
XML 21 R6.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Cash flows from operating activities:    
Net income (loss) from continuing operations $ 9,061 $ (1,942)
Adjustments to reconcile net income (loss) from continuing operations to net cash flows provided by (used in) operating activities from continuing operations:    
Share-based compensation 4,340 3,904
Change in deferred income taxes 2,031 0
Loss on extinguishment of debt 1,401 0
Depreciation 558 714
Non-cash lease expenses 317 334
Bad debt expense 199 (60)
Amortization of intangible assets 189 190
Loss on fixed asset disposal 185 0
Accretion of asset retirement obligation 22 22
Amortization of deferred financing costs 69 121
Increase (decrease) in cash resulting from changes in:    
Accounts receivable (3,344) (1,551)
Inventory (2,941) (1,474)
Prepaid expenses (471) 934
Other assets (1,001) 1,030
Accounts payable 283 (686)
Accrued compensation (4,440) (2,494)
Accrued expenses 522 1,956
Other liabilities (195) (398)
Net cash flows provided by operating activities from continuing operations 6,785 600
Net cash flows used in operating activities of discontinued operations (807) (4,648)
Net cash flows provided by (used in) operating activities 5,978 (4,048)
Cash flows from investing activities:    
Consideration paid pursuant to TELA APA (Note 12) (5,000) 0
Purchases of equipment (1,144) (633)
Patent application costs 120 (44)
Net cash flows used in investing activities (6,024) (677)
Cash flows from financing activities:    
Proceeds from Citizens Revolving Credit Facility 30,000 0
Proceeds from Citizens Term Loan Facility 19,783 0
Proceeds from exercise of stock options 766 0
Principal payments on finance lease (13) (4)
Prepayment premium on Hayfin term loan (500) 0
Deferred financing cost (1,101) 0
Repayment of Hayfin term loan (50,000) 0
Repayment of Citizens Revolving Credit Facility (30,000) 0
Principal payments on Citizens Term Loan Facility (250) 0
Stock repurchased for tax withholdings on vesting of restricted stock units (2,152) 0
Net cash flows used in financing activities (33,467) (4)
Net change in cash (33,513) (4,729)
Cash and cash equivalents, beginning of period 82,000 65,950
Cash and cash equivalents, end of period $ 48,487 $ 61,221
XML 22 R7.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Nature of Business
3 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Nature of Business Nature of Business
MiMedx Group, Inc. (together with its subsidiaries, except where the context otherwise requires, “MIMEDX,” or the “Company”) is a pioneer and leader in placental biologics focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. All of our products sold in the United States are regulated by the United States Food and Drug Administration (“FDA”).
The Company’s product portfolio and product development focuses on Wound and Surgical markets.
The Company’s business is focused primarily on the United States of America but the Company also has a small commercial presence in several international locations, including Japan.
XML 23 R8.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Significant Accounting Policies
3 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
Significant Accounting Policies Significant Accounting Policies
Please see Note 2, Significant Accounting Policies, to the Company’s Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Form 10-K”), filed with the Securities and Exchange Commission (“SEC”) on February 28, 2024 for a description of all significant accounting policies.
Basis of Presentation
The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations for the periods presented have been included. The operating results for the three months ended March 31, 2024 and 2023 are not necessarily indicative of the results that may be expected for the full fiscal year. The balance sheet as of December 31, 2023 was derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.
These unaudited condensed consolidated financial statements should be read in conjunction with the historical consolidated financial statements of the Company included in the 2023 Form 10-K.
Reclassifications
Current portion of long term debt of $1.0 million as of December 31, 2023, which was presented in other current liabilities in previously-issued financial statements, has been reclassified to be presented in a separate line item still within current liabilities in the March 31, 2024 balance sheet presentation.
Principles of Consolidation
The consolidated financial statements include the accounts of MiMedx Group, Inc. and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation.
Use of Estimates
GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported consolidated statements of operations during the reporting period. Actual results could differ from those estimates. Significant estimates include estimated useful lives and potential impairment of property and equipment, estimates of impairment for goodwill and intangible assets, estimates of useful lives for intangible assets, estimates of loss for contingent liabilities, estimate of allowance for doubtful accounts, estimate of fair value and the probable achievement of share-based payments, estimates of returns and allowances, and valuation of deferred tax assets.
Recently Issued Accounting Standards Not Yet Adopted
In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, “Segment Reporting: Improvements to Reportable Segment Disclosures (Topic 280)”. The standard improves disclosures about a public entity’s reportable segments and addresses requests from investors for additional, more detailed information about a reportable segment’s expenses. Additionally, ASU 2023-07 extends the disclosure requirements under Accounting Standards Codification (“ASC”) Topic 280 to entities with a single reportable segment. ASU 2023-07 is effective for annual reporting periods beginning after December 15, 2023, and interim periods in fiscal years beginning after December 15, 2024. As of March 31, 2024, the Company is evaluating the impact of this standard on its consolidated financial statements.
In December 2023, the FASB issued ASU 2023-09, “Improvement to Income Tax Disclosures (Topic 740)”, which requires additional disclosures for income tax rate reconciliations, income taxes paid, and certain other tax disclosures. ASU 2023-09 is intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to the rate reconciliation and income taxes paid information. Adoption is required for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures.
All other ASUs issued and not yet effective as of March 31, 2024, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company’s current and future financial position and results of operations.
XML 24 R9.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Accounts Receivable, Net
3 Months Ended
Mar. 31, 2024
Receivables [Abstract]  
Accounts Receivable, Net Accounts Receivable, Net
Accounts receivable, net, consisted of the following (in thousands):
 March 31, 2024December 31, 2023
Accounts receivable, gross$60,282 $57,015 
Less: allowance for doubtful accounts(3,266)(3,144)
Accounts receivable, net$57,016 $53,871 
Activity related to the Company’s allowance for doubtful accounts for the three months ended March 31, 2024 was as follows (in thousands):
Allowance for Doubtful Accounts
Balance at December 31, 2023
$3,144 
Bad debt expense199 
Write-offs(77)
Balance at March 31, 2024
$3,266 
Allowance for Doubtful Accounts
Balance at December 31, 2022
$3,783 
Bad debt expense reversal
(60)
Write-offs(122)
Balance at March 31, 2023
$3,601 
XML 25 R10.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Inventory
3 Months Ended
Mar. 31, 2024
Inventory Disclosure [Abstract]  
Inventory Inventory
Inventory consisted of the following (in thousands):
 March 31, 2024December 31, 2023
Raw materials$1,136 $825 
Work in process8,609 8,521 
Finished goods14,709 11,675 
Inventory$24,454 $21,021 
XML 26 R11.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Property and Equipment, Net
3 Months Ended
Mar. 31, 2024
Property, Plant and Equipment [Abstract]  
Property and Equipment, Net Property and Equipment, Net
Property and equipment, net, consisted of the following (in thousands):
 March 31, 2024December 31, 2023
Laboratory and clean room equipment$14,504 $13,954 
Furniture and equipment2,205 1,989 
Leasehold improvements8,141 8,141 
Construction in progress1,870 1,791 
Asset retirement cost889 938 
Finance lease right-of-use asset189 189 
Property and equipment, gross27,798 27,002 
Less: accumulated depreciation and amortization(20,458)(20,028)
Property and equipment, net$7,340 $6,974 
XML 27 R12.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Intangible Assets, Net
3 Months Ended
Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets, Net Intangible Assets, Net
Intangible assets, net, are summarized as follows (in thousands):
March 31, 2024December 31, 2023
Gross Carrying AmountAccumulated AmortizationNet Carrying AmountGross Carrying AmountAccumulated AmortizationNet Carrying Amount
Amortized intangible assets
Patents and know-how$9,968 $(7,949)$2,019 $10,039 $(7,818)$2,221 
Licenses1,000 (67)933 1,000 (54)$946 
Distribution rights7,602 — 7,602 — — — 
Total amortized intangible assets$18,570 $(8,016)$10,554 $11,039 $(7,872)$3,167 
Unamortized intangible assets:
Tradenames and trademarks$1,008 $1,008 $1,008 $1,008 
Patents in Process988 988 1,082 1,082 
Total intangible assets$20,566 $12,550 $13,129 $5,257 
The Company recognized $0.1 million of impairment of intangible assets during the three months ended March 31, 2024 related to patents which were abandoned.
Expected future amortization of intangible assets as of March 31, 2024, is as follows (in thousands):
Year ending December 31,Estimated
Amortization
Expense
2024 (excluding the three months ended March 31, 2024)
$1,708 
20251,883 
20261,729 
20271,728 
20281,726 
Thereafter1,780 
Total amortized intangible assets$10,554 
XML 28 R13.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Accrued Expenses
3 Months Ended
Mar. 31, 2024
Payables and Accruals [Abstract]  
Accrued Expenses Accrued Expenses
Accrued expenses consisted of the following (in thousands):
March 31, 2024December 31, 2023
Commissions to sales agents$2,954 $4,136 
Accrued rebates1,380 745 
Legal and settlement costs1,235 834 
Accrued Group Purchasing Organization fees
1,235 1,338 
Estimated sales returns1,085 1,096 
Accrued travel142 433 
Other1,165 779 
Accrued expenses$9,196 $9,361 
XML 29 R14.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Long Term Debt, Net
3 Months Ended
Mar. 31, 2024
Debt Disclosure [Abstract]  
Long Term Debt, Net Long Term Debt, Net
Citizens Credit Agreement
On January 19, 2024, the Company entered into a Credit Agreement (the “Citizens Credit Agreement”) with certain lenders party thereto, and Citizens Bank, N.A., as administrative agent (the “Agent”). The Citizens Credit Agreement provides for senior secured credit facilities in an aggregate principal amount of up to $95.0 million consisting of: (i) a $75.0 million senior secured revolving credit facility (the “Revolving Credit Facility”) with a $10.0 million letter of credit sublimit and a $10.0 million swingline loan sublimit, and (ii) a $20.0 million senior secured term loan facility (the “Term Loan Facility” and, together with the Revolving Credit Facility, the “Credit Facilities”). All obligations are required to be paid in full on January 19, 2029 (the “Maturity Date”). The Company has the option to obtain one or more incremental Term Loan Facilities and/or increase the commitments under the Revolving Credit Facility in an aggregate principal amount equal to the greater of (i) $50.0 million and (ii) 1.00 times the Company’s Consolidated EBITDA (as defined therein), each subject to the existing or any new lenders’ election to extend additional term loans or revolving commitments.
At the Company’s option, borrowings under the Citizens Credit Agreement (other than any swingline loan) will bear interest at a rate per annum equal to (i) the Alternate Base Rate, as defined therein, or (ii) a Term SOFR as defined therein, in each case plus an applicable margin ranging from 1.25% and 2.50% with respect to Alternate Base Rate borrowings and 2.25% and 3.50% for Term SOFR borrowings, plus a fallback provision of 0.1%. Swingline loans will bear interest at a rate per annum equal to one-month Term SOFR plus the applicable margin. The applicable margin will be determined based on the Company’s consolidated total net leverage ratio.
The Company is required to pay a quarterly commitment fee on any unused portion of the Revolving Credit Facility, letter of credit fees, and other customary fees to the Agent and the Lenders. The Term Loan Facility will amortize on a quarterly basis at 1.25% (for year one and two), 1.88% (for year three and four), and 2.5% (for year five) based on the aggregate principal amount outstanding under the Term Loan Facility, with the remainder due on the Maturity Date. The Company must make mandatory prepayments in connection with certain asset dispositions and casualty events, subject in each case to customary reinvestment rights. The Company may prepay borrowings under the Credit Facilities at any time, without premium or penalty, and may, at its option, reduce the aggregate unused commitments under the Revolving Credit Facility in whole or in part, in each case subject to the terms of the Credit Agreement. The Company must also comply with certain financial covenants, including a maximum total net leverage ratio and a minimum consolidated fixed charge coverage ratio, as well as other customary restrictive covenants.
On January 19, 2024, the Company borrowed $30.0 million under the Revolving Credit Facility and $20.0 million under the Term Loan Facility. Proceeds from the initial drawings under the Credit Facilities together with cash on hand were used to repay in full the $50.0 million principal amount and other outstanding obligations under the Company’s prior senior secured term loan with Hayfin (the “Hayfin Loan Agreement”) and to pay related fees, premiums, costs and expenses (collectively with the entry into the Citizens Credit Agreement and the initial borrowings thereunder, the “Debt Refinancing Transactions”). The Company recorded a loss on extinguishment of debt of $1.4 million. This amount is reflected as a part of interest expense, net on the unaudited condensed consolidated statement of operations for the three months ended March 31, 2024. The composition of the loss on extinguishment of debt was as follows (amounts in thousands):
January 19, 2024
Unamortized deferred financing costs
$781 
Unamortized original issue discount
120 
Prepayment premium
500 
Loss on extinguishment of debt
$1,401 
In addition, on February 27, 2024, the Company repaid the initial $30.0 million drawing under the Revolving Credit Facility and had no outstanding borrowings under this facility as of March 31, 2024. Deferred financing costs and original issue discount allocated to the Revolving Credit Facility are amortized straight-line through the expiration of the commitment term. The Revolving Credit Facility is currently subject to a commitment fee of 0.25% per annum of the amount undrawn, which is recognized as interest expense.
Original issue discount and deferred financing costs incurred as part of the Credit Facilities were allocated between the Term Loan Facility and the Revolving Credit Facility on the basis of the maximum potential principal outstanding permitted under the Citizens Credit Agreement. The allocation of the deferred financing costs and original issue discount between the Term Loan Facility and the Revolving Credit Facility were as follows (in thousands):
January 19, 2024
Term Loan Facility
Revolving Credit Facility
Total
Long term debt
Other assets
Original issue discount
$224 $839 $1,063 
Deferred financing
54 202 256 
The balances of the Term Loan Facility as of March 31, 2024 and the Hayfin Loan Agreement as of December 31, 2023 were as follows (in thousands):
March 31, 2024December 31, 2023
Current portion of long term debt
Long term debt, netCurrent portion of long term debtLong term debt, net
Outstanding principal$1,000 $18,750 $1,000 $49,000 
Deferred financing costs— (82)— (781)
Original issue discount— (215)— (120)
Long term debt, net$1,000 $18,453 $1,000 $48,099 
The Citizens Term Loan Facility bears interest at a rate per annum equal to (i) the Alternate Base Rate, as defined therein, or (ii) a Term SOFR as defined therein, in each case plus an applicable margin ranging from 1.25% and 2.50% with respect to Alternate Base Rate borrowings and 2.25% and 3.50% for Term SOFR borrowings, plus a fallback provision of 0.1%. The applicable margin is determined based on the Company’s consolidated total net leverage ratio. The Term Loan Facility carried an interest rate of 7.9% as of March 31, 2024. Interest expense related to the Term Loan Facility and the Hayfin Loan Agreement included in interest expense, net in the unaudited condensed consolidated statements of operations, was as follows (amounts in thousands):
Three Months Ended March 31,
20242023
Stated interest$661 $1,436 
Amortization of deferred financing costs29 105 
Accretion of original issue discount13 16 
Interest expense$703 $1,557 
Interest expense related to the Revolving Credit Facility included in interest expense, net in the unaudited condensed consolidated statements of operations, was as follows (amounts in thousands):
Three Months Ended March 31,
2024
Commitment fee
$30 
Amortization of deferred financing costs16 
Accretion of original issue discount42 
Interest expense$88 
A summary of principal payments due on the Term Loan Facility, by year, from March 31, 2024 through maturity are as follows (in thousands):
Year ending December 31,Principal
2024 (excluding the three months ended March 31, 2024)
$750 
2025
1,000 
2026
1,500 
2027
1,500 
2028
2,000 
Thereafter13,000 
Outstanding principal$19,750 
As of March 31, 2024, the fair value of the Term Loan Facility was $19.3 million. This valuation was calculated based on a series of Level 2 and Level 3 inputs, including a discount rate based on the credit risk spread of debt instruments of similar risk character in reference to U.S. Treasury instruments with similar maturities, with an incremental risk premium for risk factors specific to the Company. Fair value was calculated by discounting the remaining cash flows associated with the Term Loan Facility to March 31, 2024 using this discount rate.
XML 30 R15.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Net Income (Loss) Per Common Share
3 Months Ended
Mar. 31, 2024
Earnings Per Share [Abstract]  
Net Income (Loss) Per Common Share Net Income (Loss) Per Common Share
Net income (loss) per common share is calculated using two methods: basic and diluted.
Basic Net Income (Loss) Per Common Share
The following table provides a reconciliation of net income (loss) to net income (loss) available to common stockholders and calculation of basic net income (loss) per common share for each of the three months ended March 31, 2024 and 2023 (in thousands, except share and per share amounts):
 Three Months Ended March 31,
 20242023
Net income (loss) from continuing operations$9,061 $(1,942)
Income (loss) from discontinued operations, net of tax$200 $(3,041)
Net income (loss)9,261 (4,983)
Adjustments to reconcile to income (loss) available to common stockholders:
Accumulated dividend on previously converted Series B Preferred Stock— 1,684 
Net income (loss) available to common stockholders from continuing operations$9,061 $(3,626)
Weighted average common shares outstanding146,404,587 114,398,813 
Basic net income (loss) per common share:
Continuing operations$0.06 $(0.03)
Discontinued operations— (0.03)
Basic net income (loss) per common share$0.06 $(0.06)
Diluted Net Income (Loss) Per Common Share
The following table sets forth the computation of diluted net income (loss) per common share (in thousands, except share and per share amounts):
 Three Months Ended March 31,
 20242023
Net income (loss) available to common stockholders from continuing operations$9,061 $(3,626)
Adjustments:
Dividends on Series B Preferred Stock— 1,684 
Less: antidilutive adjustments— (1,684)
Total adjustments— — 
Numerator
Net income (loss) available to common shareholders from continuing operations9,061 (3,626)
Income (loss) from discontinued operations, net of tax200 (3,041)
Weighted average shares outstanding146,404,587 114,398,813 
Adjustments:
Potential common shares (a)
Restricted stock unit awards2,016,109 — 
Outstanding stock options1,499,970 — 
Performance stock unit awards106,802 — 
Employee stock purchase plan639 — 
Total adjustments3,623,520 — 
Weighted average shares outstanding adjusted for potential common shares150,028,107 114,398,813 
Diluted net income (loss) per common share:
Continuing operations$0.06 $(0.03)
Discontinued operations— (0.03)
Diluted net income (loss) per common share$0.06 $(0.06)
(a) Weighted average common shares outstanding for the calculation of diluted net income (loss) per common share does not include the following adjustments for potential common shares below because their effects were determined to be antidilutive for the periods presented.
Three Months Ended March 31,
20242023
Series B Preferred Stock— 29,559,946 
Restricted stock unit awards— 567,167 
Restricted stock awards— 5,152 
Employee stock purchase plan— 5,740 
Performance stock unit awards— 13,133 
Outstanding stock options— — 
Potential common shares— 30,151,138 
XML 31 R16.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Income Taxes
3 Months Ended
Mar. 31, 2024
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
On a continuing operations basis, the effective tax rates for the Company were 20.6% and (2.7)% for the three months ended March 31, 2024 and 2023, respectively. Restricted stock vestings impacted the effective tax rate for the three months ended March 31, 2024. Net operating losses generated for the three months ended March 31, 2023 were offset by a valuation allowance.
XML 32 R17.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities
3 Months Ended
Mar. 31, 2024
Supplemental Cash Flow Elements [Abstract]  
Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities
Selected cash payments, receipts, and non-cash activities are as follows (in thousands):
Three Months Ended March 31,
 20242023
Cash paid for interest$1,403 $1,452 
Cash paid for income taxes— 
Non-cash activities:
Present value of minimum earn out
2,731 — 
Right of use assets arising from operating lease liabilities1,820 — 
Issuance of shares pursuant to employee stock purchase plan797 680 
Purchases of equipment in accounts payable626 223 
Consideration payable to TELA
366 — 
Unpaid deferred financing costs149 — 
XML 33 R18.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Commitments and Contingencies
3 Months Ended
Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
TELA and Regenity Agreements
On March 15, 2024, the Company entered into an Asset Purchase Agreement (the “TELA APA”) with TELA Bio, Inc. (“TELA”) to obtain exclusive rights to sell and market a 510(k)-cleared collagen particulate xenograft product in the United States pursuant to a preexisting Manufacturing and Supply Agreement (the “TELA-Regenity Supply Agreement”) between TELA and Regenity Biosciences, Inc. (“Regenity”), which retains all intellectual property rights and regulatory clearances related to the product. Pursuant to the TELA APA, the Company paid $5.0 million of initial consideration to TELA and will be required to make future payments of $0.4 million to acquire TELA’s remaining product inventory, as well as future profit share payments (the “Profit Share Payments”) of between a minimum of $3.0 million and a maximum of $7.0 million based on MIMEDX’s net sales of the product over the two-years following its commercialization of the product.
Simultaneously with entry into the TELA APA, the Company executed a new Manufacturing and Supply Agreement (the “Supply Agreement”) with Regenity, replacing the previous TELA-Regenity Supply Agreement. The Supply Agreement maintains MIMEDX’s exclusive right to sell and market the product in the United States and requires MIMEDX to purchase a minimum amount of the xenograft product from Regenity annually through December 31, 2033. Should MIMEDX fail to meet a purchasing minimum in any one period, it has the option (among others) to amend its distribution rights under the Supply Agreement to be non-exclusive.
The transaction was accounted for as an acquisition of assets. The cost to acquire the assets on the transaction date was assessed to be $8.1 million, reflecting the $5.0 million of initial consideration, $0.4 million to acquire inventory, and $2.7 million, reflecting the fair value of the minimum amount of the Profit Share Payments, were allocated amongst the assets acquired. The Company assigned $7.6 million to the distribution rights acquired and $0.5 million to inventory. These amounts are reflected in the consolidated balance sheets as part of intangible assets, net and inventory, respectively, on the unaudited condensed consolidated balance sheet as of March 31, 2024.
The $2.7 million fair value for the minimum amount of Profit Share Payments reflects the anticipated timing of such Profit Share Payments, discounted to present value at a discount rate approximating the Company’s borrowing rate plus a risk premium.
Of the minimum Profit Share Payment, $1.1 million is reflected as part of other current liabilities in the unaudited condensed consolidated balance sheet as of March 31, 2024, reflecting the extent of the obligation that is anticipated to be repaid within twelve months of that date. The remaining balance is reflected in other liabilities.
Litigation and Regulatory Matters
In the ordinary course of business, the Company and its subsidiaries may be a party to pending and threatened legal, regulatory, and governmental actions and proceedings (including those described below). In view of the inherent difficulty of predicting the outcome of such matters, particularly where the plaintiffs or claimants seek very large or indeterminate damages or where the matters present novel legal theories or involve a large number of parties, the Company generally cannot predict what the eventual outcome of the pending matters will be, what the timing of the ultimate resolution of these matters will be, or what the
eventual recovery, loss, fines or penalties related to each pending matter may be. The Company's unaudited condensed consolidated balance sheet as of March 31, 2024 reflects the Company's current best estimate of probable losses associated with these matters, including costs to comply with various settlement agreements, where applicable. For more information regarding the Company’s legal proceedings, refer to Note 16, “Commitments and Contingencies” in the 2023 Form 10-K.
The Company has not accrued for any potential losses related to legal matters as of March 31, 2024. The Company made no payments toward the resolution of legal matters involving the Company during the three months ended March 31, 2024. The Company paid $0.2 million during the three months ended March 31, 2023.
The following is a description of certain litigation and regulatory matters to which the Company is a party:
Welker v. MiMedx, et. al.
On November 4, 2022, Troy Welker and Min Turner, former optionholders of the Company, brought a lawsuit in Fulton County State Court against the Company, former directors Terry Dewberry and Charles Evans, and former officers Parker H. “Pete” Petit, William C. Taylor, and Michael Senken alleging violations of the Georgia Racketeer Influenced and Corrupt Organizations (“RICO”) Act against all defendants, and conspiracy to violate the Georgia RICO Act and breach of fiduciary duty against the individual defendants. On motion by the Company, the case has been moved to the Fulton County Business Court. The Company and the individual defendants filed answers and motions to dismiss, which were denied on the RICO claims, but granted with respect to the breach of fiduciary duty claims against the individual defendants. The Company is defending against the allegations and is obligated to indemnify certain of its current and former officers and directors who are party to this proceeding.
Former Employee Litigation and Related Matters
On January 12, 2021, the Company filed suit in the Circuit Court of the Eleventh Judicial District in and for Miami-Dade County, Florida (MiMedx Group, Inc. v. Petit, et. al.) against its former CEO, Parker H. “Pete” Petit, and its former COO, William C. Taylor, seeking a determination of its rights and obligations under indemnification agreements with Petit and Taylor following a federal jury’s guilty verdict against Petit for securities fraud and Taylor for conspiracy to commit securities fraud. On March 26, 2024, the Company filed an amended complaint against only Petit as the Company previously reached as settlement with Taylor. The Company is seeking a declaratory judgment that Petit is not entitled to indemnification in connection with certain cases and the Company is also seeking to recoup amounts previously paid on behalf of Petit in connection with such cases.
As noted above, the Company and Mr. Taylor reached an agreement to settle the matter between them. Negotiations with Mr. Petit are ongoing.
XML 34 R19.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Revenue
3 Months Ended
Mar. 31, 2024
Revenue from Contract with Customer [Abstract]  
Revenue Revenue
Net Sales by Site of Service
MIMEDX has three main sites of service for its products (1) Hospital settings and wound care clinics, which are stable reimbursement settings in which products are used for surgical applications, (2) Private offices, which generally represents doctors and practitioners with independent operations, and (3) Other, which includes federal facilities, international sales, and other sites of service.
Below is a summary of net sales by site of service (in thousands):
Three Months Ended March 31,
20242023
Hospital$43,757 $42,171 
Private Office30,332 21,487 
Other10,620 8,018 
Total$84,709 $71,676 
Net Sales by Product Line
MIMEDX has two product lines (1) Wound, which reflects products typically used in Advanced Wound Care settings, including the treatment of chronic, non-healing wounds, and (2) Surgical, which reflects products principally used in surgical
settings, including the closure of acute wounds or to protect and reinforce tissues and/or regions of interest. The Company manages its product portfolio and pipeline, based upon opportunities in each of these settings.
Below is a summary of net sales by product line (in thousands):
Three Months Ended March 31,
20242023
Wound
$57,049 $45,206 
Surgical
27,660 26,470 
Total$84,709 $71,676 
The Company did not have significant foreign operations or a single external customer from which 10% or more of revenues were derived during the three months ended March 31, 2024 or 2023.
AXIOFILL
The Company received a determination letter on March 25, 2024 reaffirming the FDA’s position that AXIOFILL does not meet the regulatory classification requirements of a Human Cell, Tissue or Cellular or Tissue-based Product under Section 361 of the Public Health Service Act. The Company strongly disagrees with this determination and has filed suit in the U.S. District Court for the Northern District of Georgia against the FDA on this matter.
XML 35 R20.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Discontinued Operations
3 Months Ended
Mar. 31, 2024
Discontinued Operations and Disposal Groups [Abstract]  
Discontinued Operations Discontinued Operations
Disbanding of Regenerative Medicine Business Unit
On June 20, 2023, the Company announced the disbanding of its Regenerative Medicine business unit and the suspension of its Knee Osteoarthritis clinical trial program. During the fourth quarter of 2023, the Company materially completed the regulatory obligations associated with the clinical trial.
Financial Statement Impact of Discontinued Operations
The income and expenses of the discontinued operation have been classified as income (loss) from discontinued operations in the consolidated statements of operations for the three months ended March 31, 2024 and 2023 as follows (in thousands):
Three Months Ended March 31,
20242023
Selling, general and administrative expense
— 29 
Research and development expense
$(200)3,012 
Income (loss) from discontinued operations
$200 $(3,041)
XML 36 R21.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Pay vs Performance Disclosure - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Pay vs Performance Disclosure    
Net Income (Loss) $ 9,261 $ (4,983)
XML 37 R22.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Insider Trading Arrangements
3 Months Ended
Mar. 31, 2024
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 38 R23.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Significant Accounting Policies (Policies)
3 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations for the periods presented have been included. The operating results for the three months ended March 31, 2024 and 2023 are not necessarily indicative of the results that may be expected for the full fiscal year. The balance sheet as of December 31, 2023 was derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.
These unaudited condensed consolidated financial statements should be read in conjunction with the historical consolidated financial statements of the Company included in the 2023 Form 10-K.
Reclassifications
Reclassifications
Current portion of long term debt of $1.0 million as of December 31, 2023, which was presented in other current liabilities in previously-issued financial statements, has been reclassified to be presented in a separate line item still within current liabilities in the March 31, 2024 balance sheet presentation.
Principles of Consolidation
Principles of Consolidation
The consolidated financial statements include the accounts of MiMedx Group, Inc. and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation.
Use of Estimates
Use of Estimates
GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported consolidated statements of operations during the reporting period. Actual results could differ from those estimates. Significant estimates include estimated useful lives and potential impairment of property and equipment, estimates of impairment for goodwill and intangible assets, estimates of useful lives for intangible assets, estimates of loss for contingent liabilities, estimate of allowance for doubtful accounts, estimate of fair value and the probable achievement of share-based payments, estimates of returns and allowances, and valuation of deferred tax assets.
Recently Issued Accounting Standards Not Yet Adopted
Recently Issued Accounting Standards Not Yet Adopted
In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, “Segment Reporting: Improvements to Reportable Segment Disclosures (Topic 280)”. The standard improves disclosures about a public entity’s reportable segments and addresses requests from investors for additional, more detailed information about a reportable segment’s expenses. Additionally, ASU 2023-07 extends the disclosure requirements under Accounting Standards Codification (“ASC”) Topic 280 to entities with a single reportable segment. ASU 2023-07 is effective for annual reporting periods beginning after December 15, 2023, and interim periods in fiscal years beginning after December 15, 2024. As of March 31, 2024, the Company is evaluating the impact of this standard on its consolidated financial statements.
In December 2023, the FASB issued ASU 2023-09, “Improvement to Income Tax Disclosures (Topic 740)”, which requires additional disclosures for income tax rate reconciliations, income taxes paid, and certain other tax disclosures. ASU 2023-09 is intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to the rate reconciliation and income taxes paid information. Adoption is required for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures.
All other ASUs issued and not yet effective as of March 31, 2024, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company’s current and future financial position and results of operations.
XML 39 R24.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Accounts Receivable, Net (Tables)
3 Months Ended
Mar. 31, 2024
Receivables [Abstract]  
Schedule of Accounts, Notes, Loans and Financing Receivable
Accounts receivable, net, consisted of the following (in thousands):
 March 31, 2024December 31, 2023
Accounts receivable, gross$60,282 $57,015 
Less: allowance for doubtful accounts(3,266)(3,144)
Accounts receivable, net$57,016 $53,871 
Schedule of Activity Related to the Allowance for Doubtful Accounts
Activity related to the Company’s allowance for doubtful accounts for the three months ended March 31, 2024 was as follows (in thousands):
Allowance for Doubtful Accounts
Balance at December 31, 2023
$3,144 
Bad debt expense199 
Write-offs(77)
Balance at March 31, 2024
$3,266 
Allowance for Doubtful Accounts
Balance at December 31, 2022
$3,783 
Bad debt expense reversal
(60)
Write-offs(122)
Balance at March 31, 2023
$3,601 
XML 40 R25.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Inventory (Tables)
3 Months Ended
Mar. 31, 2024
Inventory Disclosure [Abstract]  
Schedule of Inventory
Inventory consisted of the following (in thousands):
 March 31, 2024December 31, 2023
Raw materials$1,136 $825 
Work in process8,609 8,521 
Finished goods14,709 11,675 
Inventory$24,454 $21,021 
XML 41 R26.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Property and Equipment, Net (Tables)
3 Months Ended
Mar. 31, 2024
Property, Plant and Equipment [Abstract]  
Summary of Property and Equipment
Property and equipment, net, consisted of the following (in thousands):
 March 31, 2024December 31, 2023
Laboratory and clean room equipment$14,504 $13,954 
Furniture and equipment2,205 1,989 
Leasehold improvements8,141 8,141 
Construction in progress1,870 1,791 
Asset retirement cost889 938 
Finance lease right-of-use asset189 189 
Property and equipment, gross27,798 27,002 
Less: accumulated depreciation and amortization(20,458)(20,028)
Property and equipment, net$7,340 $6,974 
XML 42 R27.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Intangible Assets, Net (Tables)
3 Months Ended
Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Intangible Assets Activity Summary - Indefinite-lived
Intangible assets, net, are summarized as follows (in thousands):
March 31, 2024December 31, 2023
Gross Carrying AmountAccumulated AmortizationNet Carrying AmountGross Carrying AmountAccumulated AmortizationNet Carrying Amount
Amortized intangible assets
Patents and know-how$9,968 $(7,949)$2,019 $10,039 $(7,818)$2,221 
Licenses1,000 (67)933 1,000 (54)$946 
Distribution rights7,602 — 7,602 — — — 
Total amortized intangible assets$18,570 $(8,016)$10,554 $11,039 $(7,872)$3,167 
Unamortized intangible assets:
Tradenames and trademarks$1,008 $1,008 $1,008 $1,008 
Patents in Process988 988 1,082 1,082 
Total intangible assets$20,566 $12,550 $13,129 $5,257 
Schedule of Estimated Future Amortization Expense for Intangible Assets
Expected future amortization of intangible assets as of March 31, 2024, is as follows (in thousands):
Year ending December 31,Estimated
Amortization
Expense
2024 (excluding the three months ended March 31, 2024)
$1,708 
20251,883 
20261,729 
20271,728 
20281,726 
Thereafter1,780 
Total amortized intangible assets$10,554 
XML 43 R28.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Accrued Expenses (Tables)
3 Months Ended
Mar. 31, 2024
Payables and Accruals [Abstract]  
Schedule of Accrued Liabilities
Accrued expenses consisted of the following (in thousands):
March 31, 2024December 31, 2023
Commissions to sales agents$2,954 $4,136 
Accrued rebates1,380 745 
Legal and settlement costs1,235 834 
Accrued Group Purchasing Organization fees
1,235 1,338 
Estimated sales returns1,085 1,096 
Accrued travel142 433 
Other1,165 779 
Accrued expenses$9,196 $9,361 
XML 44 R29.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Long Term Debt, Net (Tables)
3 Months Ended
Mar. 31, 2024
Debt Disclosure [Abstract]  
Schedule of Extinguishment of Debt The composition of the loss on extinguishment of debt was as follows (amounts in thousands):
January 19, 2024
Unamortized deferred financing costs
$781 
Unamortized original issue discount
120 
Prepayment premium
500 
Loss on extinguishment of debt
$1,401 
Schedule of Original Discount and Deferred Financing Costs
Original issue discount and deferred financing costs incurred as part of the Credit Facilities were allocated between the Term Loan Facility and the Revolving Credit Facility on the basis of the maximum potential principal outstanding permitted under the Citizens Credit Agreement. The allocation of the deferred financing costs and original issue discount between the Term Loan Facility and the Revolving Credit Facility were as follows (in thousands):
January 19, 2024
Term Loan Facility
Revolving Credit Facility
Total
Long term debt
Other assets
Original issue discount
$224 $839 $1,063 
Deferred financing
54 202 256 
Schedule of the Balances of the Loan Facility and Agreement
The balances of the Term Loan Facility as of March 31, 2024 and the Hayfin Loan Agreement as of December 31, 2023 were as follows (in thousands):
March 31, 2024December 31, 2023
Current portion of long term debt
Long term debt, netCurrent portion of long term debtLong term debt, net
Outstanding principal$1,000 $18,750 $1,000 $49,000 
Deferred financing costs— (82)— (781)
Original issue discount— (215)— (120)
Long term debt, net$1,000 $18,453 $1,000 $48,099 
Schedule of Interest Expense Interest expense related to the Term Loan Facility and the Hayfin Loan Agreement included in interest expense, net in the unaudited condensed consolidated statements of operations, was as follows (amounts in thousands):
Three Months Ended March 31,
20242023
Stated interest$661 $1,436 
Amortization of deferred financing costs29 105 
Accretion of original issue discount13 16 
Interest expense$703 $1,557 
Interest expense related to the Revolving Credit Facility included in interest expense, net in the unaudited condensed consolidated statements of operations, was as follows (amounts in thousands):
Three Months Ended March 31,
2024
Commitment fee
$30 
Amortization of deferred financing costs16 
Accretion of original issue discount42 
Interest expense$88 
Summary of Principal Payments for the Term Loan Facility
A summary of principal payments due on the Term Loan Facility, by year, from March 31, 2024 through maturity are as follows (in thousands):
Year ending December 31,Principal
2024 (excluding the three months ended March 31, 2024)
$750 
2025
1,000 
2026
1,500 
2027
1,500 
2028
2,000 
Thereafter13,000 
Outstanding principal$19,750 
XML 45 R30.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Net Income (Loss) Per Common Share (Tables)
3 Months Ended
Mar. 31, 2024
Earnings Per Share [Abstract]  
Basic Net Income (Loss) Per Common Share
The following table provides a reconciliation of net income (loss) to net income (loss) available to common stockholders and calculation of basic net income (loss) per common share for each of the three months ended March 31, 2024 and 2023 (in thousands, except share and per share amounts):
 Three Months Ended March 31,
 20242023
Net income (loss) from continuing operations$9,061 $(1,942)
Income (loss) from discontinued operations, net of tax$200 $(3,041)
Net income (loss)9,261 (4,983)
Adjustments to reconcile to income (loss) available to common stockholders:
Accumulated dividend on previously converted Series B Preferred Stock— 1,684 
Net income (loss) available to common stockholders from continuing operations$9,061 $(3,626)
Weighted average common shares outstanding146,404,587 114,398,813 
Basic net income (loss) per common share:
Continuing operations$0.06 $(0.03)
Discontinued operations— (0.03)
Basic net income (loss) per common share$0.06 $(0.06)
Diluted Net Income (Loss) Per Common Share
The following table sets forth the computation of diluted net income (loss) per common share (in thousands, except share and per share amounts):
 Three Months Ended March 31,
 20242023
Net income (loss) available to common stockholders from continuing operations$9,061 $(3,626)
Adjustments:
Dividends on Series B Preferred Stock— 1,684 
Less: antidilutive adjustments— (1,684)
Total adjustments— — 
Numerator
Net income (loss) available to common shareholders from continuing operations9,061 (3,626)
Income (loss) from discontinued operations, net of tax200 (3,041)
Weighted average shares outstanding146,404,587 114,398,813 
Adjustments:
Potential common shares (a)
Restricted stock unit awards2,016,109 — 
Outstanding stock options1,499,970 — 
Performance stock unit awards106,802 — 
Employee stock purchase plan639 — 
Total adjustments3,623,520 — 
Weighted average shares outstanding adjusted for potential common shares150,028,107 114,398,813 
Diluted net income (loss) per common share:
Continuing operations$0.06 $(0.03)
Discontinued operations— (0.03)
Diluted net income (loss) per common share$0.06 $(0.06)
(a) Weighted average common shares outstanding for the calculation of diluted net income (loss) per common share does not include the following adjustments for potential common shares below because their effects were determined to be antidilutive for the periods presented.
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
Three Months Ended March 31,
20242023
Series B Preferred Stock— 29,559,946 
Restricted stock unit awards— 567,167 
Restricted stock awards— 5,152 
Employee stock purchase plan— 5,740 
Performance stock unit awards— 13,133 
Outstanding stock options— — 
Potential common shares— 30,151,138 
XML 46 R31.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities (Tables)
3 Months Ended
Mar. 31, 2024
Supplemental Cash Flow Elements [Abstract]  
Schedule of Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities
Selected cash payments, receipts, and non-cash activities are as follows (in thousands):
Three Months Ended March 31,
 20242023
Cash paid for interest$1,403 $1,452 
Cash paid for income taxes— 
Non-cash activities:
Present value of minimum earn out
2,731 — 
Right of use assets arising from operating lease liabilities1,820 — 
Issuance of shares pursuant to employee stock purchase plan797 680 
Purchases of equipment in accounts payable626 223 
Consideration payable to TELA
366 — 
Unpaid deferred financing costs149 — 
XML 47 R32.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Revenue (Tables)
3 Months Ended
Mar. 31, 2024
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue
Below is a summary of net sales by site of service (in thousands):
Three Months Ended March 31,
20242023
Hospital$43,757 $42,171 
Private Office30,332 21,487 
Other10,620 8,018 
Total$84,709 $71,676 
Below is a summary of net sales by product line (in thousands):
Three Months Ended March 31,
20242023
Wound
$57,049 $45,206 
Surgical
27,660 26,470 
Total$84,709 $71,676 
XML 48 R33.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Discontinued Operations (Tables)
3 Months Ended
Mar. 31, 2024
Discontinued Operations and Disposal Groups [Abstract]  
Schedule of Assets And Liabilities of the Discontinued Operations
The income and expenses of the discontinued operation have been classified as income (loss) from discontinued operations in the consolidated statements of operations for the three months ended March 31, 2024 and 2023 as follows (in thousands):
Three Months Ended March 31,
20242023
Selling, general and administrative expense
— 29 
Research and development expense
$(200)3,012 
Income (loss) from discontinued operations
$200 $(3,041)
XML 49 R34.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Significant Accounting Policies (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Error Corrections and Prior Period Adjustments Restatement [Line Items]    
Other current liabilities $ (4,071) $ (2,894)
Current portion of long term debt 1,000 $ 1,000
Revision of Prior Period, Reclassification, Adjustment    
Error Corrections and Prior Period Adjustments Restatement [Line Items]    
Other current liabilities 1,000  
Current portion of long term debt $ 1,000  
XML 50 R35.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Accounts Receivable, Net - Accounts Receivable (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Mar. 31, 2023
Dec. 31, 2022
Receivables [Abstract]        
Accounts receivable, gross $ 60,282 $ 57,015    
Less: allowance for doubtful accounts (3,266) (3,144) $ (3,601) $ (3,783)
Accounts receivable, net $ 57,016 $ 53,871    
XML 51 R36.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Accounts Receivable, Net - Schedule of Activity Related to the Allowance for Doubtful Accounts (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Allowance for Doubtful Accounts    
Beginning balance $ 3,144 $ 3,783
Bad debt expense 199 (60)
Write-offs (77) (122)
Ending balance $ 3,266 $ 3,601
XML 52 R37.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Inventory (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Inventory Disclosure [Abstract]    
Raw materials $ 1,136 $ 825
Work in process 8,609 8,521
Finished goods 14,709 11,675
Inventory $ 24,454 $ 21,021
XML 53 R38.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Property and Equipment, Net - Summary of Property and Equipment (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Property, Plant and Equipment [Line Items]    
Finance lease right-of-use asset $ 189 $ 189
Property and equipment, gross 27,798 27,002
Less: accumulated depreciation and amortization (20,458) (20,028)
Property and equipment, net 7,340 6,974
Laboratory and clean room equipment    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 14,504 13,954
Furniture and equipment    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 2,205 1,989
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 8,141 8,141
Construction in progress    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 1,870 1,791
Asset retirement cost    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 889 $ 938
XML 54 R39.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Intangible Assets, Net - Activity Summary (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount $ 18,570 $ 11,039
Accumulated Amortization (8,016) (7,872)
Total amortized intangible assets 10,554 3,167
Indefinite-lived Intangible Assets [Line Items]    
Intangible assets, gross carrying amount 20,566 13,129
Intangible assets, net carrying amount 12,550 5,257
Tradenames and trademarks    
Indefinite-lived Intangible Assets [Line Items]    
Gross carrying value, indefinite lived 1,008 1,008
Patents in Process    
Indefinite-lived Intangible Assets [Line Items]    
Gross carrying value, indefinite lived 988 1,082
Patents and know-how    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 9,968 10,039
Accumulated Amortization (7,949) (7,818)
Total amortized intangible assets 2,019 2,221
Licenses    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 1,000 1,000
Accumulated Amortization (67) (54)
Total amortized intangible assets 933 946
Distribution rights    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 7,602 0
Accumulated Amortization 0 0
Total amortized intangible assets $ 7,602 $ 0
XML 55 R40.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Intangible Assets, Net - Estimated Future Amortization Expense for Intangible Assets (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Estimated future amortization expense [Abstract]    
2024 (excluding the three months ended March 31, 2024) $ 1,708  
2025 1,883  
2026 1,729  
2027 1,728  
2028 1,726  
Thereafter 1,780  
Total amortized intangible assets $ 10,554 $ 3,167
XML 56 R41.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Accrued Expenses (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Payables and Accruals [Abstract]    
Commissions to sales agents $ 2,954 $ 4,136
Accrued rebates 1,380 745
Legal and settlement costs 1,235 834
Accrued Group Purchasing Organization fees 1,235 1,338
Estimated sales returns 1,085 1,096
Accrued travel 142 433
Other 1,165 779
Accrued expenses $ 9,196 $ 9,361
XML 57 R42.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Long Term Debt, Net - Narrative (Details)
3 Months Ended
Feb. 27, 2024
USD ($)
Jan. 19, 2024
USD ($)
Mar. 31, 2024
USD ($)
Mar. 31, 2023
USD ($)
Debt Instrument [Line Items]        
Proceeds from revolving credit facility     $ 30,000,000 $ 0
Proceeds from term loan     19,783,000 0
Repayments of term loan     50,000,000 0
Loss on extinguishment of debt   $ 1,401,000 1,401,000 0
Repayments of initial line of credit draw     30,000,000 $ 0
Citizens Credit Agreement | Line of Credit        
Debt Instrument [Line Items]        
Maximum borrowing capacity   $ 95,000,000    
Citizens Credit Agreement | Line of Credit | Minimum | Base Rate        
Debt Instrument [Line Items]        
Basis spread on variable rate (percent)   1.25%    
Citizens Credit Agreement | Line of Credit | Minimum | SOFR        
Debt Instrument [Line Items]        
Basis spread on variable rate (percent)   2.25%    
Citizens Credit Agreement | Line of Credit | Maximum | Base Rate        
Debt Instrument [Line Items]        
Basis spread on variable rate (percent)   2.50%    
Citizens Credit Agreement | Line of Credit | Maximum | SOFR        
Debt Instrument [Line Items]        
Basis spread on variable rate (percent)   3.50%    
Citizens Credit Agreement | Line of Credit | Revolving Credit Facility        
Debt Instrument [Line Items]        
Maximum borrowing capacity   $ 75,000,000    
Line of credit facility, optional increase   $ 50,000,000    
Line of credit facility, optional increase, EBITDA multiplier   1.00    
Proceeds from revolving credit facility   $ 30,000,000    
Repayments of initial line of credit draw $ 30,000,000      
Undrawn commitment fee percentage 0.25%      
Citizens Credit Agreement | Line of Credit | Letter of Credit        
Debt Instrument [Line Items]        
Maximum borrowing capacity   10,000,000    
Citizens Credit Agreement | Line of Credit | Bridge Loan        
Debt Instrument [Line Items]        
Maximum borrowing capacity   $ 10,000,000    
Citizens Credit Agreement | Line of Credit | Bridge Loan | SOFR        
Debt Instrument [Line Items]        
Basis spread on variable rate (percent)   0.10%    
Citizens Credit Agreement | Line of Credit | Term Loan        
Debt Instrument [Line Items]        
Maximum borrowing capacity   $ 20,000,000    
Proceeds from term loan   $ 20,000,000    
Fair value of term loan     $ 19,300,000  
Citizens Credit Agreement | Line of Credit | Term Loan | Debt Amortization, Year One        
Debt Instrument [Line Items]        
Interest rate   1.25%    
Citizens Credit Agreement | Line of Credit | Term Loan | Debt Amortization, Year Two        
Debt Instrument [Line Items]        
Interest rate   1.25%    
Citizens Credit Agreement | Line of Credit | Term Loan | Debt Amortization, Year Three        
Debt Instrument [Line Items]        
Interest rate   1.88%    
Citizens Credit Agreement | Line of Credit | Term Loan | Debt Amortization, Year Four        
Debt Instrument [Line Items]        
Interest rate   1.88%    
Citizens Credit Agreement | Line of Credit | Term Loan | Debt Amortization, Year Five        
Debt Instrument [Line Items]        
Interest rate   2.50%    
Citizens Credit Agreement | Line of Credit | Term Loan | Minimum | Base Rate        
Debt Instrument [Line Items]        
Basis spread on variable rate (percent)   1.25%    
Citizens Credit Agreement | Line of Credit | Term Loan | Minimum | SOFR        
Debt Instrument [Line Items]        
Basis spread on variable rate (percent)   2.25%    
Interest rate, effective percentage (percent)     7.90%  
Citizens Credit Agreement | Line of Credit | Term Loan | Maximum | Base Rate        
Debt Instrument [Line Items]        
Basis spread on variable rate (percent)   2.50%    
Citizens Credit Agreement | Line of Credit | Term Loan | Maximum | SOFR        
Debt Instrument [Line Items]        
Basis spread on variable rate (percent)   3.50%    
Hayfin Loan Agreement Term Loan | Term loan        
Debt Instrument [Line Items]        
Repayments of term loan   $ 50,000,000    
XML 58 R43.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Long Term Debt, Net - Schedule of Extinguishment of Debt (Details) - USD ($)
$ in Thousands
3 Months Ended
Jan. 19, 2024
Mar. 31, 2024
Mar. 31, 2023
Debt Disclosure [Abstract]      
Unamortized deferred financing costs $ 781    
Unamortized original issue discount 120    
Prepayment premium on Hayfin term loan 500    
Loss on extinguishment of debt $ 1,401 $ 1,401 $ 0
XML 59 R44.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Long Term Debt, Net - Schedule of Term Loan Facility Balances (Details) - Line of Credit - Citizens Credit Agreement - USD ($)
$ in Thousands
Mar. 31, 2024
Jan. 19, 2024
Long term debt, net    
Original issue discount   $ 1,063
Deferred financing   256
Term Loan    
Long term debt, net    
Original issue discount, noncurrent $ 215 224
Deferred financing, noncurrent 82 54
Current portion of long term debt    
Original issue discount, current 0  
Deferred financing, current $ 0  
Revolving Credit Facility    
Current portion of long term debt    
Original issue discount, current   839
Deferred financing, current   $ 202
XML 60 R45.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Long Term Debt, Net - Schedule of Term Loan Balances (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Jan. 19, 2024
Dec. 31, 2023
Current portion of long term debt      
Long term debt, net $ 1,000   $ 1,000
Long term debt, net      
Long term debt, net 18,453   48,099
Line of Credit | Citizens Credit Agreement | Term Loan      
Current portion of long term debt      
Outstanding principal 1,000    
Deferred financing costs 0    
Original issue discount 0    
Long term debt, net 1,000    
Long term debt, net      
Outstanding principal 18,750    
Deferred financing costs (82) $ (54)  
Original issue discount (215) $ (224)  
Long term debt, net $ 18,453    
Term loan | Hayfin Loan Agreement Term Loan      
Current portion of long term debt      
Outstanding principal     1,000
Deferred financing costs     0
Original issue discount     0
Long term debt, net     1,000
Long term debt, net      
Outstanding principal     49,000
Deferred financing costs     (781)
Original issue discount     (120)
Long term debt, net     $ 48,099
XML 61 R46.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Long Term Debt, Net - Schedule of Interest Expense (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Term Loan Facility and Hayfin Loan Agreement    
Debt Instrument [Line Items]    
Stated interest $ 661 $ 1,436
Amortization of deferred financing costs 29 105
Accretion of original issue discount 13 16
Interest expense 703 $ 1,557
Line of Credit | Citizens Credit Agreement | Revolving Credit Facility    
Debt Instrument [Line Items]    
Amortization of deferred financing costs 16  
Accretion of original issue discount 42  
Commitment fee 30  
Interest expense $ 88  
XML 62 R47.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Long Term Debt, Net - Term Loan Maturity (Details) - Term Loan - Citizens Credit Agreement - Line of Credit
$ in Thousands
Mar. 31, 2024
USD ($)
Debt Instrument [Line Items]  
2024 (excluding the three months ended March 31, 2024) $ 750
2025 1,000
2026 1,500
2027 1,500
2028 2,000
Thereafter 13,000
Outstanding principal $ 19,750
XML 63 R48.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Net Income (Loss) Per Common Share - Schedule of Basic Net Loss Per Common Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Earnings Per Share [Abstract]    
Net income (loss) from continuing operations $ 9,061 $ (1,942)
Income (loss) from discontinued operations, net of tax 200 (3,041)
Net income (loss) 9,261 (4,983)
Adjustments to reconcile to income (loss) available to common stockholders:    
Accumulated dividend on previously converted Series B Preferred Stock 0 1,684
Net income (loss) available to common stockholders from continuing operations $ 9,061 $ (3,626)
Weighted average common shares outstanding (in shares) 146,404,587 114,398,813
Basic net income (loss) per common share:    
Continuing operations - basic (in dollars per share) $ 0.06 $ (0.03)
Discontinued operations - basic (in dollars per share) 0 (0.03)
Basic net income (loss) per common share (in dollars per share) $ 0.06 $ (0.06)
XML 64 R49.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Net Income (Loss) Per Common Share - Schedule of Diluted Net Loss Per Common Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Net income (loss) available to common stockholders from continuing operations $ 9,061 $ (3,626)
Adjustments:    
Dividends on Series B Preferred Stock 0 1,684
Less: antidilutive adjustments 0 (1,684)
Total adjustments 0 0
Numerator    
Net income (loss) available to common stockholders from continuing operations 9,061 (3,626)
Income (loss) from discontinued operations, net of tax $ 200 $ (3,041)
Weighted average shares outstanding (in shares) 146,404,587 114,398,813
Potential common shares    
Total adjustments (in shares) 3,623,520 0
Weighted average shares outstanding adjusted for potential common shares (in shares) 150,028,107 114,398,813
Diluted net income (loss) per common share:    
Continuing operations- diluted(in dollars per share) $ 0.06 $ (0.03)
Discontinued operations- diluted (in dollars per share) 0 (0.03)
Diluted net (loss) income per common share (in dollars per share) $ 0.06 $ (0.06)
RSU    
Potential common shares    
Stock-based awards (in shares) 2,016,109 0
Outstanding stock options    
Potential common shares    
Stock-based awards (in shares) 1,499,970 0
Performance stock unit awards    
Potential common shares    
Stock-based awards (in shares) 106,802 0
Employee stock purchase plan    
Potential common shares    
Stock-based awards (in shares) 639 0
XML 65 R50.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Net Income (Loss) Per Common Share - Antidilutive Securities (Details) - shares
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potential common shares (in shares) 0 30,151,138
Series B Preferred Stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potential common shares (in shares) 0 29,559,946
RSU    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potential common shares (in shares) 0 567,167
RSA    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potential common shares (in shares) 0 5,152
Employee stock purchase plan    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potential common shares (in shares) 0 5,740
Performance stock unit awards    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potential common shares (in shares) 0 13,133
Outstanding stock options    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potential common shares (in shares) 0 0
XML 66 R51.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Income Taxes (Details)
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Tax Disclosure [Abstract]    
Effective tax rate 20.60% (2.70%)
XML 67 R52.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Supplemental Cash Flow Elements [Abstract]    
Cash paid for interest $ 1,403 $ 1,452
Cash paid for income taxes 8 0
Non-cash activities:    
Present value of minimum earn out 2,731 0
Right of use assets arising from operating lease liabilities 1,820 0
Issuance of shares pursuant to employee stock purchase plan 797 680
Purchases of equipment in accounts payable 626 223
Consideration payable to TELA 366 0
Unpaid deferred financing costs $ 149 $ 0
XML 68 R53.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Commitments and Contingencies (Details) - USD ($)
3 Months Ended
Mar. 15, 2024
Mar. 31, 2024
Mar. 31, 2023
Asset Acquisition [Line Items]      
Initial consideration paid   $ 5,000,000 $ 0
Fair value of minimum contingent consideration   2,731,000 0
Payments for legal settlements   0 $ 200,000
TELA APA      
Asset Acquisition [Line Items]      
Initial consideration paid $ 5,000,000    
Future payments for remaining product inventory $ 400,000    
Net sales over the period 2 years    
Consideration transferred $ 8,100,000    
Fair value of minimum contingent consideration 2,700,000    
Asset acquisition, inventory 500,000    
Profit sharing payment liability, current   $ 1,100,000  
TELA APA | Distribution rights      
Asset Acquisition [Line Items]      
Finite-lived intangible assets acquired 7,600,000    
TELA APA | Minimum      
Asset Acquisition [Line Items]      
Contingent consideration 3,000,000    
TELA APA | Maximum      
Asset Acquisition [Line Items]      
Contingent consideration $ 7,000,000    
XML 69 R54.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Revenue - Summary of Revenue by Site Of Service (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenue, Major Customer [Line Items]    
Net sales $ 84,709 $ 71,676
Hospital    
Revenue, Major Customer [Line Items]    
Net sales 43,757 42,171
Private Office    
Revenue, Major Customer [Line Items]    
Net sales 30,332 21,487
Other    
Revenue, Major Customer [Line Items]    
Net sales $ 10,620 $ 8,018
XML 70 R55.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Revenue - Narrative (Details)
3 Months Ended
Mar. 31, 2024
service_site
product_line
Revenue from Contract with Customer [Abstract]  
Number of sites of service | service_site 3
Number of product lines | product_line 2
XML 71 R56.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Revenue - Summary of Revenue by Product Type (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenue, Major Customer [Line Items]    
Net sales $ 84,709 $ 71,676
Wound    
Revenue, Major Customer [Line Items]    
Net sales 57,049 45,206
Surgical & Other    
Revenue, Major Customer [Line Items]    
Net sales $ 27,660 $ 26,470
XML 72 R57.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Discontinued Operations - Schedule Of Disposal Groups Including Discontinued Operations Income Statement (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Income (loss) from discontinued operations, net of tax $ 200 $ (3,041)
Regenerative Medicine | Disbanded    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Selling, general and administrative expense 0 29
Research and development expense (200) 3,012
Income (loss) from discontinued operations, net of tax $ 200 $ (3,041)
EXCEL 73 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 74 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 75 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 77 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 118 263 1 false 51 0 false 6 false false R1.htm 0000001 - Document - Cover Sheet http://mimedx.com/role/Cover Cover Cover 1 false false R2.htm 0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY (DEFICIT) Sheet http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY (DEFICIT) Statements 5 false false R6.htm 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 0000007 - Disclosure - Nature of Business Sheet http://mimedx.com/role/NatureofBusiness Nature of Business Notes 7 false false R8.htm 0000008 - Disclosure - Significant Accounting Policies Sheet http://mimedx.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 8 false false R9.htm 0000009 - Disclosure - Accounts Receivable, Net Sheet http://mimedx.com/role/AccountsReceivableNet Accounts Receivable, Net Notes 9 false false R10.htm 0000010 - Disclosure - Inventory Sheet http://mimedx.com/role/Inventory Inventory Notes 10 false false R11.htm 0000011 - Disclosure - Property and Equipment, Net Sheet http://mimedx.com/role/PropertyandEquipmentNet Property and Equipment, Net Notes 11 false false R12.htm 0000012 - Disclosure - Intangible Assets, Net Sheet http://mimedx.com/role/IntangibleAssetsNet Intangible Assets, Net Notes 12 false false R13.htm 0000013 - Disclosure - Accrued Expenses Sheet http://mimedx.com/role/AccruedExpenses Accrued Expenses Notes 13 false false R14.htm 0000014 - Disclosure - Long Term Debt, Net Sheet http://mimedx.com/role/LongTermDebtNet Long Term Debt, Net Notes 14 false false R15.htm 0000015 - Disclosure - Net Income (Loss) Per Common Share Sheet http://mimedx.com/role/NetIncomeLossPerCommonShare Net Income (Loss) Per Common Share Notes 15 false false R16.htm 0000016 - Disclosure - Income Taxes Sheet http://mimedx.com/role/IncomeTaxes Income Taxes Notes 16 false false R17.htm 0000017 - Disclosure - Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities Sheet http://mimedx.com/role/SupplementalDisclosureofCashFlowandNoncashInvestingandFinancingActivities Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities Notes 17 false false R18.htm 0000018 - Disclosure - Commitments and Contingencies Sheet http://mimedx.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 18 false false R19.htm 0000019 - Disclosure - Revenue Sheet http://mimedx.com/role/Revenue Revenue Notes 19 false false R20.htm 0000020 - Disclosure - Discontinued Operations Sheet http://mimedx.com/role/DiscontinuedOperations Discontinued Operations Notes 20 false false R21.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 21 false false R22.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 22 false false R23.htm 9954471 - Disclosure - Significant Accounting Policies (Policies) Sheet http://mimedx.com/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://mimedx.com/role/SignificantAccountingPolicies 23 false false R24.htm 9954472 - Disclosure - Accounts Receivable, Net (Tables) Sheet http://mimedx.com/role/AccountsReceivableNetTables Accounts Receivable, Net (Tables) Tables http://mimedx.com/role/AccountsReceivableNet 24 false false R25.htm 9954473 - Disclosure - Inventory (Tables) Sheet http://mimedx.com/role/InventoryTables Inventory (Tables) Tables http://mimedx.com/role/Inventory 25 false false R26.htm 9954474 - Disclosure - Property and Equipment, Net (Tables) Sheet http://mimedx.com/role/PropertyandEquipmentNetTables Property and Equipment, Net (Tables) Tables http://mimedx.com/role/PropertyandEquipmentNet 26 false false R27.htm 9954475 - Disclosure - Intangible Assets, Net (Tables) Sheet http://mimedx.com/role/IntangibleAssetsNetTables Intangible Assets, Net (Tables) Tables http://mimedx.com/role/IntangibleAssetsNet 27 false false R28.htm 9954476 - Disclosure - Accrued Expenses (Tables) Sheet http://mimedx.com/role/AccruedExpensesTables Accrued Expenses (Tables) Tables http://mimedx.com/role/AccruedExpenses 28 false false R29.htm 9954477 - Disclosure - Long Term Debt, Net (Tables) Sheet http://mimedx.com/role/LongTermDebtNetTables Long Term Debt, Net (Tables) Tables http://mimedx.com/role/LongTermDebtNet 29 false false R30.htm 9954478 - Disclosure - Net Income (Loss) Per Common Share (Tables) Sheet http://mimedx.com/role/NetIncomeLossPerCommonShareTables Net Income (Loss) Per Common Share (Tables) Tables http://mimedx.com/role/NetIncomeLossPerCommonShare 30 false false R31.htm 9954479 - Disclosure - Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities (Tables) Sheet http://mimedx.com/role/SupplementalDisclosureofCashFlowandNoncashInvestingandFinancingActivitiesTables Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities (Tables) Tables http://mimedx.com/role/SupplementalDisclosureofCashFlowandNoncashInvestingandFinancingActivities 31 false false R32.htm 9954480 - Disclosure - Revenue (Tables) Sheet http://mimedx.com/role/RevenueTables Revenue (Tables) Tables http://mimedx.com/role/Revenue 32 false false R33.htm 9954481 - Disclosure - Discontinued Operations (Tables) Sheet http://mimedx.com/role/DiscontinuedOperationsTables Discontinued Operations (Tables) Tables http://mimedx.com/role/DiscontinuedOperations 33 false false R34.htm 9954482 - Disclosure - Significant Accounting Policies (Details) Sheet http://mimedx.com/role/SignificantAccountingPoliciesDetails Significant Accounting Policies (Details) Details http://mimedx.com/role/SignificantAccountingPoliciesPolicies 34 false false R35.htm 9954483 - Disclosure - Accounts Receivable, Net - Accounts Receivable (Details) Sheet http://mimedx.com/role/AccountsReceivableNetAccountsReceivableDetails Accounts Receivable, Net - Accounts Receivable (Details) Details 35 false false R36.htm 9954484 - Disclosure - Accounts Receivable, Net - Schedule of Activity Related to the Allowance for Doubtful Accounts (Details) Sheet http://mimedx.com/role/AccountsReceivableNetScheduleofActivityRelatedtotheAllowanceforDoubtfulAccountsDetails Accounts Receivable, Net - Schedule of Activity Related to the Allowance for Doubtful Accounts (Details) Details 36 false false R37.htm 9954485 - Disclosure - Inventory (Details) Sheet http://mimedx.com/role/InventoryDetails Inventory (Details) Details http://mimedx.com/role/InventoryTables 37 false false R38.htm 9954486 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment (Details) Sheet http://mimedx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails Property and Equipment, Net - Summary of Property and Equipment (Details) Details 38 false false R39.htm 9954487 - Disclosure - Intangible Assets, Net - Activity Summary (Details) Sheet http://mimedx.com/role/IntangibleAssetsNetActivitySummaryDetails Intangible Assets, Net - Activity Summary (Details) Details 39 false false R40.htm 9954488 - Disclosure - Intangible Assets, Net - Estimated Future Amortization Expense for Intangible Assets (Details) Sheet http://mimedx.com/role/IntangibleAssetsNetEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails Intangible Assets, Net - Estimated Future Amortization Expense for Intangible Assets (Details) Details 40 false false R41.htm 9954489 - Disclosure - Accrued Expenses (Details) Sheet http://mimedx.com/role/AccruedExpensesDetails Accrued Expenses (Details) Details http://mimedx.com/role/AccruedExpensesTables 41 false false R42.htm 9954490 - Disclosure - Long Term Debt, Net - Narrative (Details) Sheet http://mimedx.com/role/LongTermDebtNetNarrativeDetails Long Term Debt, Net - Narrative (Details) Details 42 false false R43.htm 9954491 - Disclosure - Long Term Debt, Net - Schedule of Extinguishment of Debt (Details) Sheet http://mimedx.com/role/LongTermDebtNetScheduleofExtinguishmentofDebtDetails Long Term Debt, Net - Schedule of Extinguishment of Debt (Details) Details 43 false false R44.htm 9954492 - Disclosure - Long Term Debt, Net - Schedule of Term Loan Facility Balances (Details) Sheet http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanFacilityBalancesDetails Long Term Debt, Net - Schedule of Term Loan Facility Balances (Details) Details 44 false false R45.htm 9954493 - Disclosure - Long Term Debt, Net - Schedule of Term Loan Balances (Details) Sheet http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanBalancesDetails Long Term Debt, Net - Schedule of Term Loan Balances (Details) Details 45 false false R46.htm 9954494 - Disclosure - Long Term Debt, Net - Schedule of Interest Expense (Details) Sheet http://mimedx.com/role/LongTermDebtNetScheduleofInterestExpenseDetails Long Term Debt, Net - Schedule of Interest Expense (Details) Details 46 false false R47.htm 9954495 - Disclosure - Long Term Debt, Net - Term Loan Maturity (Details) Sheet http://mimedx.com/role/LongTermDebtNetTermLoanMaturityDetails Long Term Debt, Net - Term Loan Maturity (Details) Details 47 false false R48.htm 9954496 - Disclosure - Net Income (Loss) Per Common Share - Schedule of Basic Net Loss Per Common Share (Details) Sheet http://mimedx.com/role/NetIncomeLossPerCommonShareScheduleofBasicNetLossPerCommonShareDetails Net Income (Loss) Per Common Share - Schedule of Basic Net Loss Per Common Share (Details) Details http://mimedx.com/role/NetIncomeLossPerCommonShareTables 48 false false R49.htm 9954497 - Disclosure - Net Income (Loss) Per Common Share - Schedule of Diluted Net Loss Per Common Share (Details) Sheet http://mimedx.com/role/NetIncomeLossPerCommonShareScheduleofDilutedNetLossPerCommonShareDetails Net Income (Loss) Per Common Share - Schedule of Diluted Net Loss Per Common Share (Details) Details http://mimedx.com/role/NetIncomeLossPerCommonShareTables 49 false false R50.htm 9954498 - Disclosure - Net Income (Loss) Per Common Share - Antidilutive Securities (Details) Sheet http://mimedx.com/role/NetIncomeLossPerCommonShareAntidilutiveSecuritiesDetails Net Income (Loss) Per Common Share - Antidilutive Securities (Details) Details http://mimedx.com/role/NetIncomeLossPerCommonShareTables 50 false false R51.htm 9954499 - Disclosure - Income Taxes (Details) Sheet http://mimedx.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://mimedx.com/role/IncomeTaxes 51 false false R52.htm 9954500 - Disclosure - Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities (Details) Sheet http://mimedx.com/role/SupplementalDisclosureofCashFlowandNoncashInvestingandFinancingActivitiesDetails Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities (Details) Details http://mimedx.com/role/SupplementalDisclosureofCashFlowandNoncashInvestingandFinancingActivitiesTables 52 false false R53.htm 9954501 - Disclosure - Commitments and Contingencies (Details) Sheet http://mimedx.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://mimedx.com/role/CommitmentsandContingencies 53 false false R54.htm 9954502 - Disclosure - Revenue - Summary of Revenue by Site Of Service (Details) Sheet http://mimedx.com/role/RevenueSummaryofRevenuebySiteOfServiceDetails Revenue - Summary of Revenue by Site Of Service (Details) Details 54 false false R55.htm 9954503 - Disclosure - Revenue - Narrative (Details) Sheet http://mimedx.com/role/RevenueNarrativeDetails Revenue - Narrative (Details) Details 55 false false R56.htm 9954504 - Disclosure - Revenue - Summary of Revenue by Product Type (Details) Sheet http://mimedx.com/role/RevenueSummaryofRevenuebyProductTypeDetails Revenue - Summary of Revenue by Product Type (Details) Details 56 false false R57.htm 9954505 - Disclosure - Discontinued Operations - Schedule Of Disposal Groups Including Discontinued Operations Income Statement (Details) Sheet http://mimedx.com/role/DiscontinuedOperationsScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementDetails Discontinued Operations - Schedule Of Disposal Groups Including Discontinued Operations Income Statement (Details) Details 57 false false All Reports Book All Reports mdxg-20240331.htm mdxg-20240331.xsd mdxg-20240331_cal.xml mdxg-20240331_def.xml mdxg-20240331_lab.xml mdxg-20240331_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 79 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "mdxg-20240331.htm": { "nsprefix": "mdxg", "nsuri": "http://mimedx.com/20240331", "dts": { "inline": { "local": [ "mdxg-20240331.htm" ] }, "schema": { "local": [ "mdxg-20240331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" ] }, "calculationLink": { "local": [ "mdxg-20240331_cal.xml" ] }, "definitionLink": { "local": [ "mdxg-20240331_def.xml" ] }, "labelLink": { "local": [ "mdxg-20240331_lab.xml" ] }, "presentationLink": { "local": [ "mdxg-20240331_pre.xml" ] } }, "keyStandard": 236, "keyCustom": 27, "axisStandard": 16, "axisCustom": 1, "memberStandard": 29, "memberCustom": 18, "hidden": { "total": 5, "http://xbrl.sec.gov/dei/2023": 5 }, "contextCount": 118, "entityCount": 1, "segmentCount": 51, "elementCount": 494, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 544, "http://xbrl.sec.gov/dei/2023": 29, "http://xbrl.sec.gov/ecd/2023": 4 }, "report": { "R1": { "role": "http://mimedx.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true } }, "R2": { "role": "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "longName": "0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true } }, "R3": { "role": "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "longName": "0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true } }, "R4": { "role": "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "longName": "0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "unique": true } }, "R5": { "role": "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT", "longName": "0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY (DEFICIT)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY (DEFICIT)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-17", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-17", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true } }, "R6": { "role": "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "longName": "0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeLossFromContinuingOperations", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "unique": true } }, "R7": { "role": "http://mimedx.com/role/NatureofBusiness", "longName": "0000007 - Disclosure - Nature of Business", "shortName": "Nature of Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true } }, "R8": { "role": "http://mimedx.com/role/SignificantAccountingPolicies", "longName": "0000008 - Disclosure - Significant Accounting Policies", "shortName": "Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true } }, "R9": { "role": "http://mimedx.com/role/AccountsReceivableNet", "longName": "0000009 - Disclosure - Accounts Receivable, Net", "shortName": "Accounts Receivable, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsAndNontradeReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsAndNontradeReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true } }, "R10": { "role": "http://mimedx.com/role/Inventory", "longName": "0000010 - Disclosure - Inventory", "shortName": "Inventory", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true } }, "R11": { "role": "http://mimedx.com/role/PropertyandEquipmentNet", "longName": "0000011 - Disclosure - Property and Equipment, Net", "shortName": "Property and Equipment, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true } }, "R12": { "role": "http://mimedx.com/role/IntangibleAssetsNet", "longName": "0000012 - Disclosure - Intangible Assets, Net", "shortName": "Intangible Assets, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true } }, "R13": { "role": "http://mimedx.com/role/AccruedExpenses", "longName": "0000013 - Disclosure - Accrued Expenses", "shortName": "Accrued Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true } }, "R14": { "role": "http://mimedx.com/role/LongTermDebtNet", "longName": "0000014 - Disclosure - Long Term Debt, Net", "shortName": "Long Term Debt, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true } }, "R15": { "role": "http://mimedx.com/role/NetIncomeLossPerCommonShare", "longName": "0000015 - Disclosure - Net Income (Loss) Per Common Share", "shortName": "Net Income (Loss) Per Common Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true } }, "R16": { "role": "http://mimedx.com/role/IncomeTaxes", "longName": "0000016 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true } }, "R17": { "role": "http://mimedx.com/role/SupplementalDisclosureofCashFlowandNoncashInvestingandFinancingActivities", "longName": "0000017 - Disclosure - Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities", "shortName": "Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true } }, "R18": { "role": "http://mimedx.com/role/CommitmentsandContingencies", "longName": "0000018 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true } }, "R19": { "role": "http://mimedx.com/role/Revenue", "longName": "0000019 - Disclosure - Revenue", "shortName": "Revenue", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true } }, "R20": { "role": "http://mimedx.com/role/DiscontinuedOperations", "longName": "0000020 - Disclosure - Discontinued Operations", "shortName": "Discontinued Operations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true } }, "R21": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true }, "uniqueAnchor": null }, "R22": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true } }, "R23": { "role": "http://mimedx.com/role/SignificantAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - Significant Accounting Policies (Policies)", "shortName": "Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true } }, "R24": { "role": "http://mimedx.com/role/AccountsReceivableNetTables", "longName": "9954472 - Disclosure - Accounts Receivable, Net (Tables)", "shortName": "Accounts Receivable, Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true } }, "R25": { "role": "http://mimedx.com/role/InventoryTables", "longName": "9954473 - Disclosure - Inventory (Tables)", "shortName": "Inventory (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true } }, "R26": { "role": "http://mimedx.com/role/PropertyandEquipmentNetTables", "longName": "9954474 - Disclosure - Property and Equipment, Net (Tables)", "shortName": "Property and Equipment, Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true } }, "R27": { "role": "http://mimedx.com/role/IntangibleAssetsNetTables", "longName": "9954475 - Disclosure - Intangible Assets, Net (Tables)", "shortName": "Intangible Assets, Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true } }, "R28": { "role": "http://mimedx.com/role/AccruedExpensesTables", "longName": "9954476 - Disclosure - Accrued Expenses (Tables)", "shortName": "Accrued Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true } }, "R29": { "role": "http://mimedx.com/role/LongTermDebtNetTables", "longName": "9954477 - Disclosure - Long Term Debt, Net (Tables)", "shortName": "Long Term Debt, Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfExtinguishmentOfDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfExtinguishmentOfDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true } }, "R30": { "role": "http://mimedx.com/role/NetIncomeLossPerCommonShareTables", "longName": "9954478 - Disclosure - Net Income (Loss) Per Common Share (Tables)", "shortName": "Net Income (Loss) Per Common Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true } }, "R31": { "role": "http://mimedx.com/role/SupplementalDisclosureofCashFlowandNoncashInvestingandFinancingActivitiesTables", "longName": "9954479 - Disclosure - Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities (Tables)", "shortName": "Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true } }, "R32": { "role": "http://mimedx.com/role/RevenueTables", "longName": "9954480 - Disclosure - Revenue (Tables)", "shortName": "Revenue (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true } }, "R33": { "role": "http://mimedx.com/role/DiscontinuedOperationsTables", "longName": "9954481 - Disclosure - Discontinued Operations (Tables)", "shortName": "Discontinued Operations (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true } }, "R34": { "role": "http://mimedx.com/role/SignificantAccountingPoliciesDetails", "longName": "9954482 - Disclosure - Significant Accounting Policies (Details)", "shortName": "Significant Accounting Policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:OtherLiabilitiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-31", "name": "us-gaap:OtherLiabilitiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "us-gaap:LongTermDebtCurrent", "span", "div", "ix:continuation", "us-gaap:PriorPeriodReclassificationAdjustmentDescription", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "unique": true } }, "R35": { "role": "http://mimedx.com/role/AccountsReceivableNetAccountsReceivableDetails", "longName": "9954483 - Disclosure - Accounts Receivable, Net - Accounts Receivable (Details)", "shortName": "Accounts Receivable, Net - Accounts Receivable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AccountsReceivableGrossCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AccountsReceivableGrossCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true } }, "R36": { "role": "http://mimedx.com/role/AccountsReceivableNetScheduleofActivityRelatedtotheAllowanceforDoubtfulAccountsDetails", "longName": "9954484 - Disclosure - Accounts Receivable, Net - Schedule of Activity Related to the Allowance for Doubtful Accounts (Details)", "shortName": "Accounts Receivable, Net - Schedule of Activity Related to the Allowance for Doubtful Accounts (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "unique": true } }, "R37": { "role": "http://mimedx.com/role/InventoryDetails", "longName": "9954485 - Disclosure - Inventory (Details)", "shortName": "Inventory (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true } }, "R38": { "role": "http://mimedx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails", "longName": "9954486 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment (Details)", "shortName": "Property and Equipment, Net - Summary of Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:PropertyPlantAndEquipmentTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:PropertyPlantAndEquipmentTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true } }, "R39": { "role": "http://mimedx.com/role/IntangibleAssetsNetActivitySummaryDetails", "longName": "9954487 - Disclosure - Intangible Assets, Net - Activity Summary (Details)", "shortName": "Intangible Assets, Net - Activity Summary (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true } }, "R40": { "role": "http://mimedx.com/role/IntangibleAssetsNetEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails", "longName": "9954488 - Disclosure - Intangible Assets, Net - Estimated Future Amortization Expense for Intangible Assets (Details)", "shortName": "Intangible Assets, Net - Estimated Future Amortization Expense for Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true } }, "R41": { "role": "http://mimedx.com/role/AccruedExpensesDetails", "longName": "9954489 - Disclosure - Accrued Expenses (Details)", "shortName": "Accrued Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AccruedSalesCommissionCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AccruedSalesCommissionCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true } }, "R42": { "role": "http://mimedx.com/role/LongTermDebtNetNarrativeDetails", "longName": "9954490 - Disclosure - Long Term Debt, Net - Narrative (Details)", "shortName": "Long Term Debt, Net - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProceedsFromLongTermLinesOfCredit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-52", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "unique": true } }, "R43": { "role": "http://mimedx.com/role/LongTermDebtNetScheduleofExtinguishmentofDebtDetails", "longName": "9954491 - Disclosure - Long Term Debt, Net - Schedule of Extinguishment of Debt (Details)", "shortName": "Long Term Debt, Net - Schedule of Extinguishment of Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-70", "name": "us-gaap:WriteOffOfDeferredDebtIssuanceCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-70", "name": "us-gaap:WriteOffOfDeferredDebtIssuanceCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true } }, "R44": { "role": "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanFacilityBalancesDetails", "longName": "9954492 - Disclosure - Long Term Debt, Net - Schedule of Term Loan Facility Balances (Details)", "shortName": "Long Term Debt, Net - Schedule of Term Loan Facility Balances (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-52", "name": "us-gaap:DebtInstrumentUnamortizedDiscount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mdxg:ScheduleOfOriginalDiscountAndDeferredFinancingCostsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-52", "name": "us-gaap:DebtInstrumentUnamortizedDiscount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mdxg:ScheduleOfOriginalDiscountAndDeferredFinancingCostsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true } }, "R45": { "role": "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanBalancesDetails", "longName": "9954493 - Disclosure - Long Term Debt, Net - Schedule of Term Loan Balances (Details)", "shortName": "Long Term Debt, Net - Schedule of Term Loan Balances (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LongTermDebtCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-72", "name": "mdxg:LongTermDebtGrossCurrentMaturities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "unique": true } }, "R46": { "role": "http://mimedx.com/role/LongTermDebtNetScheduleofInterestExpenseDetails", "longName": "9954494 - Disclosure - Long Term Debt, Net - Schedule of Interest Expense (Details)", "shortName": "Long Term Debt, Net - Schedule of Interest Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-79", "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-79", "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true } }, "R47": { "role": "http://mimedx.com/role/LongTermDebtNetTermLoanMaturityDetails", "longName": "9954495 - Disclosure - Long Term Debt, Net - Term Loan Maturity (Details)", "shortName": "Long Term Debt, Net - Term Loan Maturity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-72", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-72", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true } }, "R48": { "role": "http://mimedx.com/role/NetIncomeLossPerCommonShareScheduleofBasicNetLossPerCommonShareDetails", "longName": "9954496 - Disclosure - Net Income (Loss) Per Common Share - Schedule of Basic Net Loss Per Common Share (Details)", "shortName": "Net Income (Loss) Per Common Share - Schedule of Basic Net Loss Per Common Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeLossFromContinuingOperations", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PreferredStockDividendsIncomeStatementImpact", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "unique": true } }, "R49": { "role": "http://mimedx.com/role/NetIncomeLossPerCommonShareScheduleofDilutedNetLossPerCommonShareDetails", "longName": "9954497 - Disclosure - Net Income (Loss) Per Common Share - Schedule of Diluted Net Loss Per Common Share (Details)", "shortName": "Net Income (Loss) Per Common Share - Schedule of Diluted Net Loss Per Common Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ConvertiblePreferredDividendsNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "unique": true } }, "R50": { "role": "http://mimedx.com/role/NetIncomeLossPerCommonShareAntidilutiveSecuritiesDetails", "longName": "9954498 - Disclosure - Net Income (Loss) Per Common Share - Antidilutive Securities (Details)", "shortName": "Net Income (Loss) Per Common Share - Antidilutive Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true } }, "R51": { "role": "http://mimedx.com/role/IncomeTaxesDetails", "longName": "9954499 - Disclosure - Income Taxes (Details)", "shortName": "Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true } }, "R52": { "role": "http://mimedx.com/role/SupplementalDisclosureofCashFlowandNoncashInvestingandFinancingActivitiesDetails", "longName": "9954500 - Disclosure - Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities (Details)", "shortName": "Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InterestPaidNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InterestPaidNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true } }, "R53": { "role": "http://mimedx.com/role/CommitmentsandContingenciesDetails", "longName": "9954501 - Disclosure - Commitments and Contingencies (Details)", "shortName": "Commitments and Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PaymentsToAcquireOtherProductiveAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PaymentsForLegalSettlements", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "unique": true } }, "R54": { "role": "http://mimedx.com/role/RevenueSummaryofRevenuebySiteOfServiceDetails", "longName": "9954502 - Disclosure - Revenue - Summary of Revenue by Site Of Service (Details)", "shortName": "Revenue - Summary of Revenue by Site Of Service (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-107", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "unique": true } }, "R55": { "role": "http://mimedx.com/role/RevenueNarrativeDetails", "longName": "9954503 - Disclosure - Revenue - Narrative (Details)", "shortName": "Revenue - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-3", "name": "mdxg:RevenueFromContractWithCustomerNumberServiceSites", "unitRef": "service_site", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "mdxg:RevenueFromContractWithCustomerNumberServiceSites", "unitRef": "service_site", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true, "unique": true } }, "R56": { "role": "http://mimedx.com/role/RevenueSummaryofRevenuebyProductTypeDetails", "longName": "9954504 - Disclosure - Revenue - Summary of Revenue by Product Type (Details)", "shortName": "Revenue - Summary of Revenue by Product Type (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-113", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "unique": true } }, "R57": { "role": "http://mimedx.com/role/DiscontinuedOperationsScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementDetails", "longName": "9954505 - Disclosure - Discontinued Operations - Schedule Of Disposal Groups Including Discontinued Operations Income Statement (Details)", "shortName": "Discontinued Operations - Schedule Of Disposal Groups Including Discontinued Operations Income Statement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-117", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mdxg-20240331.htm", "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsAndNontradeReceivableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsAndNontradeReceivableTextBlock", "presentation": [ "http://mimedx.com/role/AccountsReceivableNet" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable, Net", "label": "Accounts and Nontrade Receivable [Text Block]", "documentation": "The entire disclosure for accounts receivable, contract receivable, receivable held-for-sale, and nontrade receivable." } } }, "auth_ref": [ "r255", "r260" ] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://mimedx.com/role/AccruedExpenses" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued Expenses", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r20" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r19", "r548" ] }, "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock", "presentation": [ "http://mimedx.com/role/AccountsReceivableNetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Activity Related to the Allowance for Doubtful Accounts", "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]", "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r655" ] }, "us-gaap_AccountsReceivableGrossCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableGrossCurrent", "crdr": "debit", "calculation": { "http://mimedx.com/role/AccountsReceivableNetAccountsReceivableDetails": { "parentTag": "us-gaap_AccountsReceivableNetCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://mimedx.com/role/AccountsReceivableNetAccountsReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, gross", "label": "Accounts Receivable, before Allowance for Credit Loss, Current", "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r181", "r256", "r257", "r524" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 }, "http://mimedx.com/role/AccountsReceivableNetAccountsReceivableDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://mimedx.com/role/AccountsReceivableNetAccountsReceivableDetails", "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net", "totalLabel": "Accounts receivable, net", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r256", "r257" ] }, "mdxg_AccruedAdministrativeFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://mimedx.com/20240331", "localname": "AccruedAdministrativeFeesCurrent", "crdr": "credit", "calculation": { "http://mimedx.com/role/AccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://mimedx.com/role/AccruedExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued Group Purchasing Organization fees", "label": "Accrued Administrative Fees, Current", "documentation": "Accrued Administrative Fees, Current" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 }, "http://mimedx.com/role/AccruedExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://mimedx.com/role/AccruedExpensesDetails", "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses", "totalLabel": "Accrued expenses", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r23" ] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://mimedx.com/role/AccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://mimedx.com/role/AccruedExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal and settlement costs", "label": "Accrued Professional Fees, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r23" ] }, "mdxg_AccruedRebates": { "xbrltype": "monetaryItemType", "nsuri": "http://mimedx.com/20240331", "localname": "AccruedRebates", "crdr": "credit", "calculation": { "http://mimedx.com/role/AccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://mimedx.com/role/AccruedExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued rebates", "label": "Accrued Rebates", "documentation": "Accrued Rebates" } } }, "auth_ref": [] }, "us-gaap_AccruedSalesCommissionCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedSalesCommissionCurrent", "crdr": "credit", "calculation": { "http://mimedx.com/role/AccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://mimedx.com/role/AccruedExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commissions to sales agents", "label": "Accrued Sales Commission, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r23", "r526" ] }, "mdxg_AccruedTravel": { "xbrltype": "monetaryItemType", "nsuri": "http://mimedx.com/20240331", "localname": "AccruedTravel", "crdr": "credit", "calculation": { "http://mimedx.com/role/AccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://mimedx.com/role/AccruedExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued travel", "label": "Accrued Travel", "documentation": "Accrued Travel" } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r598" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r101", "r548", "r692" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r370", "r371", "r372", "r461", "r649", "r650", "r651", "r677", "r693" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r604" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r604" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r604" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r604" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation\u00a0expense", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r62", "r63", "r342" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net income (loss) from continuing operations to net cash flows provided by (used in) operating activities from continuing operations:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r569", "r580", "r590", "r615" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r572", "r583", "r593", "r618" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r604" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r611" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r576", "r584", "r594", "r611", "r619", "r623", "r631" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r629" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "calculation": { "http://mimedx.com/role/AccountsReceivableNetAccountsReceivableDetails": { "parentTag": "us-gaap_AccountsReceivableNetCurrent", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://mimedx.com/role/AccountsReceivableNetAccountsReceivableDetails", "http://mimedx.com/role/AccountsReceivableNetScheduleofActivityRelatedtotheAllowanceforDoubtfulAccountsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: allowance for doubtful accounts", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r182", "r258", "r265" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivableRollforward", "presentation": [ "http://mimedx.com/role/AccountsReceivableNetScheduleofActivityRelatedtotheAllowanceforDoubtfulAccountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Allowance for Doubtful Accounts", "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs", "crdr": "debit", "presentation": [ "http://mimedx.com/role/AccountsReceivableNetScheduleofActivityRelatedtotheAllowanceforDoubtfulAccountsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Write-offs", "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff", "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance." } } }, "auth_ref": [ "r267" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://mimedx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfDebtDiscountPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfDebtDiscountPremium", "crdr": "debit", "calculation": { "http://mimedx.com/role/LongTermDebtNetScheduleofInterestExpenseDetails": { "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://mimedx.com/role/LongTermDebtNetScheduleofInterestExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accretion of original issue discount", "label": "Amortization of Debt Discount (Premium)", "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense." } } }, "auth_ref": [ "r7", "r68", "r118", "r319" ] }, "us-gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfFinancingCosts", "crdr": "debit", "calculation": { "http://mimedx.com/role/LongTermDebtNetScheduleofInterestExpenseDetails": { "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://mimedx.com/role/LongTermDebtNetScheduleofInterestExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of deferred financing costs", "label": "Amortization of Debt Issuance Costs", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } }, "auth_ref": [ "r113", "r319", "r411", "r645" ] }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of deferred financing costs", "label": "Amortization of Debt Issuance Costs and Discounts", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r319", "r411", "r539", "r540", "r645" ] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 2.0 }, "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of intangible assets", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r7", "r48", "r53" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://mimedx.com/role/NetIncomeLossPerCommonShareAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Potential common shares (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r235" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://mimedx.com/role/NetIncomeLossPerCommonShareAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r42" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://mimedx.com/role/NetIncomeLossPerCommonShareAntidilutiveSecuritiesDetails", "http://mimedx.com/role/NetIncomeLossPerCommonShareScheduleofDilutedNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://mimedx.com/role/NetIncomeLossPerCommonShareAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r42" ] }, "us-gaap_AssetAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionAxis", "presentation": [ "http://mimedx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition [Axis]", "label": "Asset Acquisition [Axis]", "documentation": "Information by asset acquisition." } } }, "auth_ref": [ "r673" ] }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionConsiderationTransferred", "crdr": "credit", "calculation": { "http://mimedx.com/role/CommitmentsandContingenciesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://mimedx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Consideration transferred", "label": "Asset Acquisition, Consideration Transferred", "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer." } } }, "auth_ref": [ "r546", "r674", "r675", "r676" ] }, "us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionConsiderationTransferredContingentConsideration", "crdr": "credit", "presentation": [ "http://mimedx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration", "label": "Asset Acquisition, Consideration Transferred, Contingent Consideration", "documentation": "Amount of contingent consideration recognized as part of consideration transferred in asset acquisition." } } }, "auth_ref": [ "r674", "r675", "r676" ] }, "mdxg_AssetAcquisitionConsiderationTransferredContingentConsiderationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://mimedx.com/20240331", "localname": "AssetAcquisitionConsiderationTransferredContingentConsiderationPeriod", "presentation": [ "http://mimedx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net sales over the period", "label": "Asset Acquisition, Consideration Transferred, Contingent Consideration Period", "documentation": "Asset Acquisition, Consideration Transferred, Contingent Consideration Period" } } }, "auth_ref": [] }, "mdxg_AssetAcquisitionConsiderationTransferredFairValueOfMinimumContingentConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://mimedx.com/20240331", "localname": "AssetAcquisitionConsiderationTransferredFairValueOfMinimumContingentConsideration", "crdr": "credit", "calculation": { "http://mimedx.com/role/CommitmentsandContingenciesDetails": { "parentTag": "us-gaap_AssetAcquisitionConsiderationTransferred", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://mimedx.com/role/CommitmentsandContingenciesDetails", "http://mimedx.com/role/SupplementalDisclosureofCashFlowandNoncashInvestingandFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Present value of minimum earn out", "terseLabel": "Fair value of minimum contingent consideration", "label": "Asset Acquisition, Consideration Transferred, Fair Value of Minimum Contingent Consideration", "documentation": "Asset Acquisition, Consideration Transferred, Fair Value of Minimum Contingent Consideration" } } }, "auth_ref": [] }, "mdxg_AssetAcquisitionConsiderationTransferredFuturePaymentToAcquireRemainingProductInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://mimedx.com/20240331", "localname": "AssetAcquisitionConsiderationTransferredFuturePaymentToAcquireRemainingProductInventory", "crdr": "credit", "calculation": { "http://mimedx.com/role/CommitmentsandContingenciesDetails": { "parentTag": "us-gaap_AssetAcquisitionConsiderationTransferred", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://mimedx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Future payments for remaining product inventory", "label": "Asset Acquisition, Consideration Transferred, Future Payment to Acquire Remaining Product Inventory", "documentation": "Asset Acquisition, Consideration Transferred, Future Payment to Acquire Remaining Product Inventory" } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionContingentConsiderationLiabilityCurrent", "crdr": "credit", "presentation": [ "http://mimedx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Profit sharing payment liability, current", "label": "Asset Acquisition, Contingent Consideration, Liability, Current", "documentation": "Amount of liability recognized from contingent consideration in asset acquisition, classified as current." } } }, "auth_ref": [ "r673" ] }, "us-gaap_AssetAcquisitionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionDomain", "presentation": [ "http://mimedx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition [Domain]", "label": "Asset Acquisition [Domain]", "documentation": "Asset acquisition." } } }, "auth_ref": [ "r673" ] }, "mdxg_AssetAcquisitionInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://mimedx.com/20240331", "localname": "AssetAcquisitionInventory", "crdr": "debit", "presentation": [ "http://mimedx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset acquisition, inventory", "label": "Asset Acquisition, Inventory", "documentation": "Asset Acquisition, Inventory" } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionLineItems", "presentation": [ "http://mimedx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition [Line Items]", "label": "Asset Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r673" ] }, "us-gaap_AssetAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionTable", "presentation": [ "http://mimedx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition [Table]", "label": "Asset Acquisition [Table]", "documentation": "Disclosure of information about asset acquisition." } } }, "auth_ref": [ "r673" ] }, "mdxg_AssetRetirementCostMember": { "xbrltype": "domainItemType", "nsuri": "http://mimedx.com/20240331", "localname": "AssetRetirementCostMember", "presentation": [ "http://mimedx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset retirement cost", "label": "Asset Retirement Cost [Member]", "documentation": "Asset Retirement Cost [Member]" } } }, "auth_ref": [] }, "us-gaap_AssetRetirementObligationAccretionExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetRetirementObligationAccretionExpense", "crdr": "debit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Accretion of asset retirement obligation", "label": "Asset Retirement Obligation, Accretion Expense", "documentation": "Amount of accretion expense recognized during the period that is associated with an asset retirement obligation. Accretion expense measures and incorporates changes due to the passage of time into the carrying amount of the liability." } } }, "auth_ref": [ "r280", "r281" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r147", "r178", "r202", "r240", "r246", "r250", "r259", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r390", "r392", "r404", "r428", "r485", "r548", "r560", "r665", "r666", "r679" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r171", "r186", "r202", "r259", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r390", "r392", "r404", "r548", "r665", "r666", "r679" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r626" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r627" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r622" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r622" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r622" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r622" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r622" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r622" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://mimedx.com/role/NetIncomeLossPerCommonShareScheduleofDilutedNetLossPerCommonShareDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r625" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r624" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r623" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r623" ] }, "us-gaap_BaseRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BaseRateMember", "presentation": [ "http://mimedx.com/role/LongTermDebtNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Base Rate", "label": "Base Rate [Member]", "documentation": "Minimum rate investor will accept." } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://mimedx.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BridgeLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BridgeLoanMember", "presentation": [ "http://mimedx.com/role/LongTermDebtNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bridge Loan", "label": "Bridge Loan [Member]", "documentation": "Financing which is expected to be replaced by a medium to long-term loan. The loan \"bridges\" the gap in time when otherwise no financing would be in place." } } }, "auth_ref": [] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [ "http://mimedx.com/role/SupplementalDisclosureofCashFlowandNoncashInvestingandFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchases of equipment in accounts payable", "label": "Capital Expenditures Incurred but Not yet Paid", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": [ "r37", "r38", "r39" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r35", "r173", "r522" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents, beginning of period", "periodEndLabel": "Cash and cash equivalents, end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r35", "r123", "r199" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net change in cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r123" ] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": [ "http://mimedx.com/role/SupplementalDisclosureofCashFlowandNoncashInvestingandFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash activities:", "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashFlowSupplementalDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowSupplementalDisclosuresTextBlock", "presentation": [ "http://mimedx.com/role/SupplementalDisclosureofCashFlowandNoncashInvestingandFinancingActivities" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities", "label": "Cash Flow, Supplemental Disclosures [Text Block]", "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r121" ] }, "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "crdr": "debit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Net cash flows used in operating activities of discontinued operations", "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations", "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r91", "r123" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r602" ] }, "mdxg_CitizensCreditAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://mimedx.com/20240331", "localname": "CitizensCreditAgreementMember", "presentation": [ "http://mimedx.com/role/LongTermDebtNetNarrativeDetails", "http://mimedx.com/role/LongTermDebtNetScheduleofInterestExpenseDetails", "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanBalancesDetails", "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanFacilityBalancesDetails", "http://mimedx.com/role/LongTermDebtNetTermLoanMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Citizens Credit Agreement", "label": "Citizens Credit Agreement [Member]", "documentation": "Citizens Credit Agreement" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://mimedx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r603" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r603" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (Note 12)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r28", "r72", "r429", "r472" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://mimedx.com/role/CommitmentsandContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r138", "r282", "r283", "r518", "r662" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock Issued", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r551", "r552", "r553", "r555", "r556", "r557", "r558", "r649", "r650", "r677", "r691", "r693" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r100" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r100", "r473" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (in shares)", "periodStartLabel": "Balance beginning of period (in shares)", "periodEndLabel": "Balance end of period (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r100" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r11", "r100", "r473", "r491", "r693", "r694" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock; $0.001 par value; 250,000,000 shares authorized; 147,528,596 issued and outstanding at March\u00a031, 2024 and 146,227,639 issued and outstanding at December\u00a031, 2023", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r100", "r430", "r548" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r608" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r607" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r609" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r606" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://mimedx.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Principles of Consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r67", "r530" ] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConstructionInProgressMember", "presentation": [ "http://mimedx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Construction in progress", "label": "Construction in Progress [Member]", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "mdxg_ContractWithCustomerNumberOfProductLines": { "xbrltype": "integerItemType", "nsuri": "http://mimedx.com/20240331", "localname": "ContractWithCustomerNumberOfProductLines", "presentation": [ "http://mimedx.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of product lines", "label": "Contract with Customer, Number of Product Lines", "documentation": "Contract with Customer, Number of Product Lines" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerRefundLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerRefundLiabilityCurrent", "crdr": "credit", "calculation": { "http://mimedx.com/role/AccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://mimedx.com/role/AccruedExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated sales returns", "label": "Contract with Customer, Refund Liability, Current", "documentation": "Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer, classified as current." } } }, "auth_ref": [ "r671" ] }, "us-gaap_ConvertiblePreferredDividendsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertiblePreferredDividendsNetOfTax", "crdr": "credit", "calculation": { "http://mimedx.com/role/NetIncomeLossPerCommonShareScheduleofDilutedNetLossPerCommonShareDetails": { "parentTag": "us-gaap_DilutiveSecurities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://mimedx.com/role/NetIncomeLossPerCommonShareScheduleofDilutedNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Dividends on Series B Preferred Stock", "label": "Convertible Preferred Dividends, Net of Tax", "documentation": "The after-tax amount of any dividends on convertible preferred stock." } } }, "auth_ref": [ "r223", "r224", "r230", "r234", "r327" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of sales", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r116", "r422" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": [ "http://mimedx.com/role/LongTermDebtNetNarrativeDetails", "http://mimedx.com/role/LongTermDebtNetScheduleofInterestExpenseDetails", "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanBalancesDetails", "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanFacilityBalancesDetails", "http://mimedx.com/role/LongTermDebtNetTermLoanMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": [ "http://mimedx.com/role/LongTermDebtNetNarrativeDetails", "http://mimedx.com/role/LongTermDebtNetScheduleofInterestExpenseDetails", "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanBalancesDetails", "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanFacilityBalancesDetails", "http://mimedx.com/role/LongTermDebtNetTermLoanMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://mimedx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "mdxg_DebtAmortizationPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://mimedx.com/20240331", "localname": "DebtAmortizationPeriodAxis", "presentation": [ "http://mimedx.com/role/LongTermDebtNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Amortization Period [Axis]", "label": "Debt Amortization Period [Axis]", "documentation": "Debt Amortization Period" } } }, "auth_ref": [] }, "mdxg_DebtAmortizationPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://mimedx.com/20240331", "localname": "DebtAmortizationPeriodDomain", "presentation": [ "http://mimedx.com/role/LongTermDebtNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Amortization Period [Domain]", "label": "Debt Amortization Period [Domain]", "documentation": "Debt Amortization Period [Domain]" } } }, "auth_ref": [] }, "mdxg_DebtAmortizationYearFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://mimedx.com/20240331", "localname": "DebtAmortizationYearFiveMember", "presentation": [ "http://mimedx.com/role/LongTermDebtNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Amortization, Year Five", "label": "Debt Amortization, Year Five [Member]", "documentation": "Debt Amortization, Year Five" } } }, "auth_ref": [] }, "mdxg_DebtAmortizationYearFourMember": { "xbrltype": "domainItemType", "nsuri": "http://mimedx.com/20240331", "localname": "DebtAmortizationYearFourMember", "presentation": [ "http://mimedx.com/role/LongTermDebtNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Amortization, Year Four", "label": "Debt Amortization, Year Four [Member]", "documentation": "Debt Amortization, Year Four" } } }, "auth_ref": [] }, "mdxg_DebtAmortizationYearOneMember": { "xbrltype": "domainItemType", "nsuri": "http://mimedx.com/20240331", "localname": "DebtAmortizationYearOneMember", "presentation": [ "http://mimedx.com/role/LongTermDebtNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Amortization, Year One", "label": "Debt Amortization, Year One [Member]", "documentation": "Debt Amortization, Year One" } } }, "auth_ref": [] }, "mdxg_DebtAmortizationYearThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://mimedx.com/20240331", "localname": "DebtAmortizationYearThreeMember", "presentation": [ "http://mimedx.com/role/LongTermDebtNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Amortization, Year Three", "label": "Debt Amortization, Year Three [Member]", "documentation": "Debt Amortization, Year Three" } } }, "auth_ref": [] }, "mdxg_DebtAmortizationYearTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://mimedx.com/20240331", "localname": "DebtAmortizationYearTwoMember", "presentation": [ "http://mimedx.com/role/LongTermDebtNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Amortization, Year Two", "label": "Debt Amortization, Year Two [Member]", "documentation": "Debt Amortization, Year Two" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://mimedx.com/role/LongTermDebtNet" ], "lang": { "en-us": { "role": { "terseLabel": "Long Term Debt, Net", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r139", "r201", "r297", "r303", "r304", "r305", "r306", "r307", "r308", "r313", "r320", "r321", "r323" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://mimedx.com/role/LongTermDebtNetNarrativeDetails", "http://mimedx.com/role/LongTermDebtNetScheduleofInterestExpenseDetails", "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanBalancesDetails", "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanFacilityBalancesDetails", "http://mimedx.com/role/LongTermDebtNetTermLoanMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r16", "r97", "r98", "r148", "r149", "r204", "r298", "r299", "r300", "r301", "r302", "r304", "r309", "r310", "r311", "r312", "r314", "r315", "r316", "r317", "r318", "r319", "r412", "r536", "r537", "r538", "r539", "r540", "r646" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://mimedx.com/role/LongTermDebtNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basis spread on variable rate (percent)", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://mimedx.com/role/LongTermDebtNetTermLoanMaturityDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://mimedx.com/role/LongTermDebtNetTermLoanMaturityDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Outstanding principal", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r16", "r149", "r324" ] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://mimedx.com/role/LongTermDebtNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate, effective percentage (percent)", "label": "Debt Instrument, Interest Rate, Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r25", "r69", "r325", "r412" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://mimedx.com/role/LongTermDebtNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r25", "r299" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://mimedx.com/role/LongTermDebtNetNarrativeDetails", "http://mimedx.com/role/LongTermDebtNetScheduleofInterestExpenseDetails", "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanBalancesDetails", "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanFacilityBalancesDetails", "http://mimedx.com/role/LongTermDebtNetTermLoanMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r204", "r298", "r299", "r300", "r301", "r302", "r304", "r309", "r310", "r311", "r312", "r314", "r315", "r316", "r317", "r318", "r319", "r322", "r412", "r536", "r537", "r538", "r539", "r540", "r646" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://mimedx.com/role/LongTermDebtNetNarrativeDetails", "http://mimedx.com/role/LongTermDebtNetScheduleofInterestExpenseDetails", "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanBalancesDetails", "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanFacilityBalancesDetails", "http://mimedx.com/role/LongTermDebtNetTermLoanMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r26", "r204", "r298", "r299", "r300", "r301", "r302", "r304", "r309", "r310", "r311", "r312", "r314", "r315", "r316", "r317", "r318", "r319", "r412", "r536", "r537", "r538", "r539", "r540", "r646" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://mimedx.com/role/LongTermDebtNetNarrativeDetails", "http://mimedx.com/role/LongTermDebtNetScheduleofInterestExpenseDetails", "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanBalancesDetails", "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanFacilityBalancesDetails", "http://mimedx.com/role/LongTermDebtNetTermLoanMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r26", "r59", "r60", "r68", "r69", "r71", "r73", "r140", "r141", "r204", "r298", "r299", "r300", "r301", "r302", "r304", "r309", "r310", "r311", "r312", "r314", "r315", "r316", "r317", "r318", "r319", "r322", "r412", "r536", "r537", "r538", "r539", "r540", "r646" ] }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedDiscount", "crdr": "debit", "calculation": { "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanFacilityBalancesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanFacilityBalancesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Original issue discount", "label": "Debt Instrument, Unamortized Discount", "documentation": "Amount, after accumulated amortization, of debt discount." } } }, "auth_ref": [ "r68", "r71", "r668" ] }, "us-gaap_DebtInstrumentUnamortizedDiscountCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedDiscountCurrent", "crdr": "debit", "calculation": { "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanFacilityBalancesDetails": { "parentTag": "us-gaap_DebtInstrumentUnamortizedDiscount", "weight": 1.0, "order": 2.0 }, "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanBalancesDetails": { "parentTag": "us-gaap_LongTermDebtCurrent", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanBalancesDetails", "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanFacilityBalancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Original issue discount, current", "negatedTerseLabel": "Original issue discount", "label": "Debt Instrument, Unamortized Discount, Current", "documentation": "Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer." } } }, "auth_ref": [ "r68", "r71" ] }, "us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedDiscountNoncurrent", "crdr": "debit", "calculation": { "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanFacilityBalancesDetails": { "parentTag": "us-gaap_DebtInstrumentUnamortizedDiscount", "weight": 1.0, "order": 1.0 }, "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanBalancesDetails": { "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanBalancesDetails", "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanFacilityBalancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Original issue discount, noncurrent", "negatedTerseLabel": "Original issue discount", "label": "Debt Instrument, Unamortized Discount, Noncurrent", "documentation": "Amount of debt discount to be amortized after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r68", "r71" ] }, "mdxg_DebtPrepaymentPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://mimedx.com/20240331", "localname": "DebtPrepaymentPremium", "crdr": "debit", "calculation": { "http://mimedx.com/role/LongTermDebtNetScheduleofExtinguishmentofDebtDetails": { "parentTag": "us-gaap_GainsLossesOnExtinguishmentOfDebt", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://mimedx.com/role/LongTermDebtNetScheduleofExtinguishmentofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepayment premium on Hayfin term loan", "label": "Debt Prepayment Premium", "documentation": "Debt Prepayment Premium" } } }, "auth_ref": [] }, "us-gaap_DeferredFinanceCostsCurrentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFinanceCostsCurrentNet", "crdr": "debit", "calculation": { "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanFacilityBalancesDetails": { "parentTag": "us-gaap_DeferredFinanceCostsNet", "weight": 1.0, "order": 1.0 }, "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanBalancesDetails": { "parentTag": "us-gaap_LongTermDebtCurrent", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanBalancesDetails", "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanFacilityBalancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred financing, current", "negatedTerseLabel": "Deferred financing costs", "label": "Debt Issuance Costs, Current, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r70" ] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "calculation": { "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanFacilityBalancesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanFacilityBalancesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Deferred financing", "label": "Debt Issuance Costs, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r70", "r668" ] }, "us-gaap_DeferredFinanceCostsNoncurrentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFinanceCostsNoncurrentNet", "crdr": "debit", "calculation": { "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanFacilityBalancesDetails": { "parentTag": "us-gaap_DeferredFinanceCostsNet", "weight": 1.0, "order": 2.0 }, "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanBalancesDetails": { "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanBalancesDetails", "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanFacilityBalancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred financing, noncurrent", "negatedTerseLabel": "Deferred financing costs", "label": "Debt Issuance Costs, Noncurrent, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r70" ] }, "us-gaap_DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax asset, net", "label": "Deferred Income Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": [ "r376", "r377" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r7", "r54" ] }, "us-gaap_DilutiveSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DilutiveSecurities", "crdr": "credit", "calculation": { "http://mimedx.com/role/NetIncomeLossPerCommonShareScheduleofDilutedNetLossPerCommonShareDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://mimedx.com/role/NetIncomeLossPerCommonShareScheduleofDilutedNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total adjustments", "label": "Dilutive Securities, Effect on Basic Earnings Per Share", "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities." } } }, "auth_ref": [ "r40" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://mimedx.com/role/RevenueTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Disaggregation of Revenue", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r670" ] }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "lang": { "en-us": { "role": { "label": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember", "presentation": [ "http://mimedx.com/role/DiscontinuedOperationsScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disbanded", "label": "Discontinued Operations, Disposed of by Means Other than Sale, Abandonment [Member]", "documentation": "Component or group of components disposed of by means of abandonment and representing a strategic shift that has or will have a major effect on operations and financial results." } } }, "auth_ref": [ "r78" ] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupClassificationAxis", "presentation": [ "http://mimedx.com/role/DiscontinuedOperationsScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Axis]", "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": [ "r169" ] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupClassificationDomain", "presentation": [ "http://mimedx.com/role/DiscontinuedOperationsScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Domain]", "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://mimedx.com/role/DiscontinuedOperationsScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementDetails": { "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://mimedx.com/role/DiscontinuedOperationsScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative expense", "label": "Disposal Group, Including Discontinued Operation, General and Administrative Expense", "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r90" ] }, "mdxg_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://mimedx.com/20240331", "localname": "DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://mimedx.com/role/DiscontinuedOperationsScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementDetails": { "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://mimedx.com/role/DiscontinuedOperationsScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development expense", "label": "Disposal Group, Including Discontinued Operation, Research And Development Expense", "documentation": "Disposal Group, Including Discontinued Operation, Research And Development Expense" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "presentation": [ "http://mimedx.com/role/DiscontinuedOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Discontinued Operations", "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r76", "r133" ] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": [ "http://mimedx.com/role/DiscontinuedOperationsScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Domain]", "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": [ "r543", "r544" ] }, "us-gaap_DistributionRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DistributionRightsMember", "presentation": [ "http://mimedx.com/role/CommitmentsandContingenciesDetails", "http://mimedx.com/role/IntangibleAssetsNetActivitySummaryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Distribution rights", "label": "Distribution Rights [Member]", "documentation": "Legal rights, generally of a limited duration, to distribute a product or products, often within specific geographic areas or supply channels." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://mimedx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://mimedx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://mimedx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://mimedx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r564" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://mimedx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r597" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://mimedx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://mimedx.com/role/NetIncomeLossPerCommonShareScheduleofBasicNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Basic net income (loss) per common share (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r192", "r210", "r211", "r213", "r214", "r216", "r222", "r225", "r232", "r233", "r234", "r238", "r402", "r403", "r426", "r436", "r531" ] }, "us-gaap_EarningsPerShareBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasicAbstract", "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://mimedx.com/role/NetIncomeLossPerCommonShareScheduleofBasicNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Basic net income (loss) per common share:", "terseLabel": "Basic net income (loss) per common share:", "label": "Earnings Per Share, Basic [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://mimedx.com/role/NetIncomeLossPerCommonShareScheduleofDilutedNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Diluted net (loss) income per common share (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r192", "r210", "r211", "r213", "r214", "r216", "r225", "r232", "r233", "r234", "r238", "r402", "r403", "r426", "r436", "r531" ] }, "us-gaap_EarningsPerShareDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDilutedAbstract", "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://mimedx.com/role/NetIncomeLossPerCommonShareScheduleofDilutedNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Diluted net income (loss) per common share:", "terseLabel": "Diluted net income (loss) per common share:", "label": "Earnings Per Share, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDilutedOtherDisclosuresAbstract", "presentation": [ "http://mimedx.com/role/NetIncomeLossPerCommonShareScheduleofDilutedNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments:", "label": "Earnings Per Share, Diluted, Other Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://mimedx.com/role/NetIncomeLossPerCommonShare" ], "lang": { "en-us": { "role": { "verboseLabel": "Net Income (Loss) Per Common Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r221", "r235", "r236", "r237" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://mimedx.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective tax rate", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r379" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued compensation", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r23" ] }, "us-gaap_EmployeeStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockMember", "presentation": [ "http://mimedx.com/role/NetIncomeLossPerCommonShareAntidilutiveSecuritiesDetails", "http://mimedx.com/role/NetIncomeLossPerCommonShareScheduleofDilutedNetLossPerCommonShareDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Employee stock purchase plan", "label": "Employee Stock [Member]", "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://mimedx.com/role/NetIncomeLossPerCommonShareAntidilutiveSecuritiesDetails", "http://mimedx.com/role/NetIncomeLossPerCommonShareScheduleofDilutedNetLossPerCommonShareDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding stock options", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://mimedx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://mimedx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://mimedx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://mimedx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://mimedx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r562" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://mimedx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://mimedx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://mimedx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r562" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://mimedx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://mimedx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r562" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://mimedx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://mimedx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r636" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://mimedx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r562" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://mimedx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r562" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://mimedx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r562" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://mimedx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r562" ] }, "us-gaap_EntityWideRevenueMajorCustomerLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EntityWideRevenueMajorCustomerLineItems", "presentation": [ "http://mimedx.com/role/RevenueSummaryofRevenuebyProductTypeDetails", "http://mimedx.com/role/RevenueSummaryofRevenuebySiteOfServiceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue, Major Customer [Line Items]", "label": "Revenue, Major Customer [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquipmentMember", "presentation": [ "http://mimedx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Laboratory and clean room equipment", "label": "Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services." } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r11", "r166", "r189", "r190", "r191", "r205", "r206", "r207", "r209", "r217", "r219", "r239", "r261", "r264", "r328", "r370", "r371", "r372", "r383", "r384", "r394", "r395", "r396", "r397", "r398", "r399", "r401", "r405", "r406", "r407", "r408", "r409", "r410", "r419", "r445", "r446", "r447", "r461", "r510" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r605" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r569", "r580", "r590", "r615" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r566", "r577", "r587", "r612" ] }, "us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems", "presentation": [ "http://mimedx.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Error Corrections and Prior Period Adjustments Restatement [Line Items]", "label": "Error Corrections and Prior Period Adjustments Restatement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r210", "r211", "r212", "r216", "r217", "r218", "r219", "r238" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r611" ] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Principal payments on finance lease", "label": "Finance Lease, Principal Payments", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": [ "r415", "r416" ] }, "us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization", "crdr": "debit", "calculation": { "http://mimedx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://mimedx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Finance lease right-of-use asset", "label": "Finance Lease, Right-of-Use Asset, before Accumulated Amortization", "documentation": "Amount, before accumulated amortization, of right-of-use asset from finance lease." } } }, "auth_ref": [ "r637" ] }, "mdxg_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://mimedx.com/20240331", "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour", "crdr": "debit", "calculation": { "http://mimedx.com/role/IntangibleAssetsNetEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://mimedx.com/role/IntangibleAssetsNetEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four", "documentation": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://mimedx.com/role/IntangibleAssetsNetActivitySummaryDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://mimedx.com/role/IntangibleAssetsNetActivitySummaryDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accumulated Amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r176", "r277" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "calculation": { "http://mimedx.com/role/IntangibleAssetsNetEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://mimedx.com/role/IntangibleAssetsNetEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r131" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit", "calculation": { "http://mimedx.com/role/IntangibleAssetsNetEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://mimedx.com/role/IntangibleAssetsNetEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024 (excluding the three months ended March 31, 2024)", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "calculation": { "http://mimedx.com/role/IntangibleAssetsNetEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://mimedx.com/role/IntangibleAssetsNetEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r131" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "calculation": { "http://mimedx.com/role/IntangibleAssetsNetEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://mimedx.com/role/IntangibleAssetsNetEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r131" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "calculation": { "http://mimedx.com/role/IntangibleAssetsNetEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://mimedx.com/role/IntangibleAssetsNetEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r131" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://mimedx.com/role/CommitmentsandContingenciesDetails", "http://mimedx.com/role/IntangibleAssetsNetActivitySummaryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r273", "r276", "r277", "r279", "r423", "r424" ] }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract", "presentation": [ "http://mimedx.com/role/IntangibleAssetsNetEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated future amortization expense [Abstract]", "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://mimedx.com/role/IntangibleAssetsNetActivitySummaryDetails": { "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://mimedx.com/role/IntangibleAssetsNetActivitySummaryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Carrying Amount", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r130", "r424" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://mimedx.com/role/IntangibleAssetsNetActivitySummaryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets [Line Items]", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r423" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://mimedx.com/role/CommitmentsandContingenciesDetails", "http://mimedx.com/role/IntangibleAssetsNetActivitySummaryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r49", "r52" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://mimedx.com/role/IntangibleAssetsNetActivitySummaryDetails_1": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 1.0 }, "http://mimedx.com/role/IntangibleAssetsNetActivitySummaryDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://mimedx.com/role/IntangibleAssetsNetEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://mimedx.com/role/IntangibleAssetsNetActivitySummaryDetails", "http://mimedx.com/role/IntangibleAssetsNetEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total amortized intangible assets", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r130", "r423" ] }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinitelivedIntangibleAssetsAcquired1", "crdr": "debit", "presentation": [ "http://mimedx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-lived intangible assets acquired", "label": "Finite-Lived Intangible Assets Acquired", "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition." } } }, "auth_ref": [ "r274" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r573", "r584", "r594", "r619" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r573", "r584", "r594", "r619" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r573", "r584", "r594", "r619" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r573", "r584", "r594", "r619" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r573", "r584", "r594", "r619" ] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://mimedx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Furniture and equipment", "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnSaleOfPropertyPlantEquipment", "crdr": "credit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Loss on fixed asset disposal", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property." } } }, "auth_ref": [ "r7" ] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 19.0 }, "http://mimedx.com/role/LongTermDebtNetScheduleofExtinguishmentofDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://mimedx.com/role/LongTermDebtNetNarrativeDetails", "http://mimedx.com/role/LongTermDebtNetScheduleofExtinguishmentofDebtDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Loss on extinguishment of debt", "negatedTotalLabel": "Loss on extinguishment of debt", "label": "Gain (Loss) on Extinguishment of Debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": [ "r7", "r56", "r57" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r175", "r271", "r425", "r535", "r548", "r656", "r657" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]", "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r114", "r202", "r240", "r245", "r249", "r251", "r259", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r404", "r533", "r665" ] }, "mdxg_HayfinLoanAgreementTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://mimedx.com/20240331", "localname": "HayfinLoanAgreementTermLoanMember", "presentation": [ "http://mimedx.com/role/LongTermDebtNetNarrativeDetails", "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanBalancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hayfin Loan Agreement Term Loan", "label": "Hayfin Loan Agreement Term Loan [Member]", "documentation": "Hayfin Loan Agreement Term Loan [Member]" } } }, "auth_ref": [] }, "mdxg_HospitalSiteOfServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://mimedx.com/20240331", "localname": "HospitalSiteOfServiceMember", "presentation": [ "http://mimedx.com/role/RevenueSummaryofRevenuebySiteOfServiceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hospital", "label": "Hospital Site Of Service [Member]", "documentation": "Hospital Site Of Service [Member]" } } }, "auth_ref": [] }, "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill", "crdr": "debit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of intangible assets", "label": "Impairment of Intangible Assets (Excluding Goodwill)", "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value." } } }, "auth_ref": [ "r7", "r14" ] }, "us-gaap_IncomeLossFromContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperations", "crdr": "credit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 }, "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://mimedx.com/role/NetIncomeLossPerCommonShareScheduleofBasicNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net income (loss) from continuing operations", "terseLabel": "Net income (loss) from continuing operations", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent", "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent." } } }, "auth_ref": [ "r66", "r115", "r125", "r210", "r211", "r213", "r214", "r231", "r234" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "totalLabel": "Income (loss) from continuing operations before income tax", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r110", "r152", "r240", "r245", "r249", "r251", "r427", "r434", "r533" ] }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_EarningsPerShareBasic", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://mimedx.com/role/NetIncomeLossPerCommonShareScheduleofBasicNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Continuing operations - basic (in dollars per share)", "label": "Income (Loss) from Continuing Operations, Per Basic Share", "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r109", "r151", "r153", "r192", "r208", "r210", "r211", "r213", "r214", "r225", "r232", "r233", "r403", "r426", "r689" ] }, "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsPerDilutedShare", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_EarningsPerShareDiluted", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://mimedx.com/role/NetIncomeLossPerCommonShareScheduleofDilutedNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Continuing operations- diluted(in dollars per share)", "label": "Income (Loss) from Continuing Operations, Per Diluted Share", "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r109", "r192", "r208", "r210", "r211", "r213", "r214", "r225", "r232", "r233", "r234", "r403", "r426", "r689" ] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "crdr": "credit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://mimedx.com/role/DiscontinuedOperationsScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://mimedx.com/role/DiscontinuedOperationsScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementDetails", "http://mimedx.com/role/NetIncomeLossPerCommonShareScheduleofBasicNetLossPerCommonShareDetails", "http://mimedx.com/role/NetIncomeLossPerCommonShareScheduleofDilutedNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income (loss) from discontinued operations, net of tax", "totalLabel": "Income (loss) from discontinued operations, net of tax", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent", "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": [ "r79", "r80", "r81", "r82", "r83", "r89", "r94", "r145" ] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_EarningsPerShareBasic", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://mimedx.com/role/NetIncomeLossPerCommonShareScheduleofBasicNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discontinued operations - basic (in dollars per share)", "verboseLabel": "Discontinued operations - basic (in dollars per share)", "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share", "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation." } } }, "auth_ref": [ "r111", "r192", "r229", "r232", "r233", "r688", "r689" ] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_EarningsPerShareDiluted", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://mimedx.com/role/NetIncomeLossPerCommonShareScheduleofDilutedNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discontinued operations- diluted (in dollars per share)", "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share", "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation." } } }, "auth_ref": [ "r146", "r229", "r232", "r233" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "presentation": [ "http://mimedx.com/role/DiscontinuedOperationsScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Axis]", "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": [ "r543", "r544" ] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "presentation": [ "http://mimedx.com/role/DiscontinuedOperationsScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "presentation": [ "http://mimedx.com/role/DiscontinuedOperationsScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]", "label": "Disposal Groups, Including Discontinued Operations [Table]", "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r10", "r13", "r17", "r77", "r84", "r85", "r86", "r87", "r88", "r93", "r95", "r96", "r137" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://mimedx.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "verboseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r203", "r375", "r380", "r381", "r382", "r385", "r387", "r388", "r389", "r460" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "negatedLabel": "Income tax expense from continuing operations", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r156", "r164", "r218", "r219", "r243", "r378", "r386", "r437" ] }, "us-gaap_IncomeTaxesPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaid", "crdr": "credit", "presentation": [ "http://mimedx.com/role/SupplementalDisclosureofCashFlowandNoncashInvestingandFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for income taxes", "label": "Income Taxes Paid", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income." } } }, "auth_ref": [ "r34", "r36" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses", "label": "Increase (Decrease) in Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInDeferredIncomeTaxes", "crdr": "credit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 18.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Change in deferred income taxes", "label": "Increase (Decrease) in Deferred Income Taxes", "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "crdr": "debit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued compensation", "label": "Increase (Decrease) in Employee Related Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Inventory", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) in cash resulting from changes in:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other assets", "label": "Increase (Decrease) in Other Operating Assets", "documentation": "Amount of increase (decrease) in operating assets classified as other." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Other liabilities", "label": "Increase (Decrease) in Other Operating Liabilities", "documentation": "Amount of increase (decrease) in operating liabilities classified as other." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidExpense", "crdr": "credit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 17.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Prepaid expenses", "label": "Increase (Decrease) in Prepaid Expense", "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "calculation": { "http://mimedx.com/role/NetIncomeLossPerCommonShareScheduleofDilutedNetLossPerCommonShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://mimedx.com/role/NetIncomeLossPerCommonShareScheduleofDilutedNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based awards (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r226", "r227", "r228", "r234", "r343" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://mimedx.com/role/IntangibleAssetsNetActivitySummaryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets [Axis]", "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r275", "r278" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "presentation": [ "http://mimedx.com/role/IntangibleAssetsNetActivitySummaryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets [Line Items]", "label": "Indefinite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "calculation": { "http://mimedx.com/role/IntangibleAssetsNetActivitySummaryDetails": { "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill", "weight": 1.0, "order": 2.0 }, "http://mimedx.com/role/IntangibleAssetsNetActivitySummaryDetails_1": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://mimedx.com/role/IntangibleAssetsNetActivitySummaryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross carrying value, indefinite lived", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r132" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://mimedx.com/role/IntangibleAssetsNetActivitySummaryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": [ "r50", "r132" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r576", "r584", "r594", "r611", "r619", "r623", "r631" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r629" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r565", "r635" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r565", "r635" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r565", "r635" ] }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsDisclosureTextBlock", "presentation": [ "http://mimedx.com/role/IntangibleAssetsNet" ], "lang": { "en-us": { "role": { "verboseLabel": "Intangible Assets, Net", "label": "Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for all or part of the information related to intangible assets." } } }, "auth_ref": [ "r272" ] }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsGrossExcludingGoodwill", "crdr": "debit", "calculation": { "http://mimedx.com/role/IntangibleAssetsNetActivitySummaryDetails": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://mimedx.com/role/IntangibleAssetsNetActivitySummaryDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Intangible assets, gross carrying amount", "label": "Intangible Assets, Gross (Excluding Goodwill)", "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill." } } }, "auth_ref": [ "r175" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 }, "http://mimedx.com/role/IntangibleAssetsNetActivitySummaryDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://mimedx.com/role/IntangibleAssetsNetActivitySummaryDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://mimedx.com/role/IntangibleAssetsNetActivitySummaryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, net", "totalLabel": "Intangible assets, net carrying amount", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r47", "r51" ] }, "mdxg_InterestExpenseCommitmentFees": { "xbrltype": "monetaryItemType", "nsuri": "http://mimedx.com/20240331", "localname": "InterestExpenseCommitmentFees", "crdr": "debit", "calculation": { "http://mimedx.com/role/LongTermDebtNetScheduleofInterestExpenseDetails": { "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://mimedx.com/role/LongTermDebtNetScheduleofInterestExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commitment fee", "label": "Interest Expense, Commitment Fees", "documentation": "Interest Expense, Commitment Fees" } } }, "auth_ref": [] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseDebt", "crdr": "debit", "calculation": { "http://mimedx.com/role/LongTermDebtNetScheduleofInterestExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://mimedx.com/role/LongTermDebtNetScheduleofInterestExpenseDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Interest expense", "label": "Interest Expense, Debt", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": [ "r118", "r317", "r326", "r539", "r540" ] }, "us-gaap_InterestExpenseDebtExcludingAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseDebtExcludingAmortization", "crdr": "debit", "calculation": { "http://mimedx.com/role/LongTermDebtNetScheduleofInterestExpenseDetails": { "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://mimedx.com/role/LongTermDebtNetScheduleofInterestExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stated interest", "label": "Interest Expense, Debt, Excluding Amortization", "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs." } } }, "auth_ref": [ "r120", "r318", "r539", "r540" ] }, "us-gaap_InterestIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeExpenseNet", "crdr": "credit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense, net", "label": "Interest Income (Expense), Net", "documentation": "The net amount of operating interest income (expense)." } } }, "auth_ref": [ "r155" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://mimedx.com/role/SupplementalDisclosureofCashFlowandNoncashInvestingandFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r195", "r197", "r198" ] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Inventory Disclosure [Abstract]", "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://mimedx.com/role/Inventory" ], "lang": { "en-us": { "role": { "verboseLabel": "Inventory", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r268" ] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://mimedx.com/role/InventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://mimedx.com/role/InventoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": [ "r129", "r527" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 }, "http://mimedx.com/role/InventoryDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://mimedx.com/role/InventoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory", "totalLabel": "Inventory", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r183", "r523", "r548" ] }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "calculation": { "http://mimedx.com/role/InventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://mimedx.com/role/InventoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Inventory, Raw Materials, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": [ "r129", "r529" ] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://mimedx.com/role/InventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://mimedx.com/role/InventoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Work in process", "label": "Inventory, Work in Process, Net of Reserves", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": [ "r129", "r528" ] }, "mdxg_InvestigationRestatementAndRelated": { "xbrltype": "monetaryItemType", "nsuri": "http://mimedx.com/20240331", "localname": "InvestigationRestatementAndRelated", "crdr": "debit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Investigation, restatement and related", "label": "Investigation, Restatement And Related", "documentation": "Investigation, Restatement And Related" } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://mimedx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leasehold improvements", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r135" ] }, "us-gaap_LetterOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LetterOfCreditMember", "presentation": [ "http://mimedx.com/role/LongTermDebtNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Letter of Credit", "label": "Letter of Credit [Member]", "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r22", "r202", "r259", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r391", "r392", "r393", "r404", "r471", "r532", "r560", "r665", "r679", "r680" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r105", "r150", "r432", "r548", "r647", "r654", "r678" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r24", "r172", "r202", "r259", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r391", "r392", "r393", "r404", "r548", "r665", "r679", "r680" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "verboseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "credit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities of discontinued operations", "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r2", "r77", "r92", "r134", "r136", "r169", "r170" ] }, "us-gaap_LicensingAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LicensingAgreementsMember", "presentation": [ "http://mimedx.com/role/IntangibleAssetsNetActivitySummaryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Licenses", "label": "Licensing Agreements [Member]", "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory)." } } }, "auth_ref": [ "r65", "r374", "r672" ] }, "mdxg_LineOfCreditFacilityAccordionFeatureEBITDAMultiplier": { "xbrltype": "pureItemType", "nsuri": "http://mimedx.com/20240331", "localname": "LineOfCreditFacilityAccordionFeatureEBITDAMultiplier", "presentation": [ "http://mimedx.com/role/LongTermDebtNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility, optional increase, EBITDA multiplier", "label": "Line of Credit Facility, Accordion Feature, EBITDA Multiplier", "documentation": "Line of Credit Facility, Accordion Feature, EBITDA Multiplier" } } }, "auth_ref": [] }, "mdxg_LineOfCreditFacilityAccordionFeatureIncreaseLimit": { "xbrltype": "monetaryItemType", "nsuri": "http://mimedx.com/20240331", "localname": "LineOfCreditFacilityAccordionFeatureIncreaseLimit", "crdr": "credit", "presentation": [ "http://mimedx.com/role/LongTermDebtNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility, optional increase", "label": "Line of Credit Facility, Accordion Feature, Increase Limit", "documentation": "Line of Credit Facility, Accordion Feature, Increase Limit" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://mimedx.com/role/LongTermDebtNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum borrowing capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r21" ] }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "presentation": [ "http://mimedx.com/role/LongTermDebtNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Undrawn commitment fee percentage", "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditMember", "presentation": [ "http://mimedx.com/role/LongTermDebtNetNarrativeDetails", "http://mimedx.com/role/LongTermDebtNetScheduleofInterestExpenseDetails", "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanBalancesDetails", "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanFacilityBalancesDetails", "http://mimedx.com/role/LongTermDebtNetTermLoanMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit", "label": "Line of Credit [Member]", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://mimedx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtByCurrentAndNoncurrentAbstract", "presentation": [ "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanBalancesDetails", "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanFacilityBalancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long term debt, net", "label": "Long-Term Debt, by Current and Noncurrent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 }, "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanBalancesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanBalancesDetails", "http://mimedx.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of long term debt", "totalLabel": "Long term debt, net", "label": "Long-Term Debt, Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r179" ] }, "us-gaap_LongTermDebtCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtCurrentAbstract", "presentation": [ "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanBalancesDetails", "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanFacilityBalancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of long term debt", "label": "Long-Term Debt, Current Maturities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtFairValue", "crdr": "credit", "presentation": [ "http://mimedx.com/role/LongTermDebtNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of term loan", "label": "Long-Term Debt, Fair Value", "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission." } } }, "auth_ref": [] }, "mdxg_LongTermDebtGrossCurrentMaturities": { "xbrltype": "monetaryItemType", "nsuri": "http://mimedx.com/20240331", "localname": "LongTermDebtGrossCurrentMaturities", "crdr": "credit", "calculation": { "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanBalancesDetails": { "parentTag": "us-gaap_LongTermDebtCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanBalancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding principal", "label": "Long-Term Debt, Gross, Current Maturities", "documentation": "Long-Term Debt, Gross, Current Maturities" } } }, "auth_ref": [] }, "mdxg_LongTermDebtGrossExcludingCurrentMaturities": { "xbrltype": "monetaryItemType", "nsuri": "http://mimedx.com/20240331", "localname": "LongTermDebtGrossExcludingCurrentMaturities", "crdr": "credit", "calculation": { "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanBalancesDetails": { "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanBalancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding principal", "label": "Long-Term Debt, Gross, Excluding Current Maturities", "documentation": "Long-Term Debt, Gross, Excluding Current Maturities" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": { "http://mimedx.com/role/LongTermDebtNetTermLoanMaturityDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://mimedx.com/role/LongTermDebtNetTermLoanMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Long-Term Debt, Maturity, Year One", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r9", "r204", "r315" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "calculation": { "http://mimedx.com/role/LongTermDebtNetTermLoanMaturityDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://mimedx.com/role/LongTermDebtNetTermLoanMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Long-Term Debt, Maturity, Year Four", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r9", "r204", "r315" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "calculation": { "http://mimedx.com/role/LongTermDebtNetTermLoanMaturityDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://mimedx.com/role/LongTermDebtNetTermLoanMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Long-Term Debt, Maturity, Year Three", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r9", "r204", "r315" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": { "http://mimedx.com/role/LongTermDebtNetTermLoanMaturityDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://mimedx.com/role/LongTermDebtNetTermLoanMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Long-Term Debt, Maturity, Year Two", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r9", "r204", "r315" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://mimedx.com/role/LongTermDebtNetTermLoanMaturityDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://mimedx.com/role/LongTermDebtNetTermLoanMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024 (excluding the three months ended March\u00a031, 2024)", "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year." } } }, "auth_ref": [ "r648" ] }, "mdxg_LongTermDebtMaturityAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://mimedx.com/20240331", "localname": "LongTermDebtMaturityAfterYearFour", "crdr": "credit", "calculation": { "http://mimedx.com/role/LongTermDebtNetTermLoanMaturityDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://mimedx.com/role/LongTermDebtNetTermLoanMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Long-Term Debt, Maturity, after Year Four", "documentation": "Long-Term Debt, Maturity, after Year Four" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 }, "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanBalancesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanBalancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long term debt, net", "totalLabel": "Long term debt, net", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r180" ] }, "us-gaap_LongTermDebtNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtNoncurrentAbstract", "presentation": [ "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanFacilityBalancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long term debt, net", "label": "Long-Term Debt, Excluding Current Maturities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://mimedx.com/role/LongTermDebtNetNarrativeDetails", "http://mimedx.com/role/LongTermDebtNetScheduleofInterestExpenseDetails", "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanBalancesDetails", "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanFacilityBalancesDetails", "http://mimedx.com/role/LongTermDebtNetTermLoanMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r26" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://mimedx.com/role/LongTermDebtNetNarrativeDetails", "http://mimedx.com/role/LongTermDebtNetScheduleofInterestExpenseDetails", "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanBalancesDetails", "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanFacilityBalancesDetails", "http://mimedx.com/role/LongTermDebtNetTermLoanMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r26", "r55" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://mimedx.com/role/CommitmentsandContingenciesDetails", "http://mimedx.com/role/LongTermDebtNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r284", "r285", "r286", "r287", "r341", "r421", "r444", "r463", "r464", "r513", "r514", "r515", "r516", "r517", "r519", "r520", "r534", "r541", "r545", "r550", "r667", "r681", "r682", "r683", "r684", "r685", "r686" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r603" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r603" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://mimedx.com/role/CommitmentsandContingenciesDetails", "http://mimedx.com/role/LongTermDebtNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r284", "r285", "r286", "r287", "r341", "r421", "r444", "r463", "r464", "r513", "r514", "r515", "r516", "r517", "r519", "r520", "r534", "r541", "r545", "r550", "r667", "r681", "r682", "r683", "r684", "r685", "r686" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r622" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r630" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r604" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash flows used in financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r196" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash flows used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r196" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash\u00a0flows from investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash flows provided by (used in) operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r123", "r124", "r125" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash flows provided by operating activities from continuing operations", "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations", "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r123", "r124", "r125" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://mimedx.com/role/NetIncomeLossPerCommonShareScheduleofBasicNetLossPerCommonShareDetails": { "parentTag": "us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic", "weight": 1.0, "order": 1.0 }, "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT", "http://mimedx.com/role/NetIncomeLossPerCommonShareScheduleofBasicNetLossPerCommonShareDetails", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net income (loss)", "netLabel": "Net income (loss)", "terseLabel": "Net Income (Loss)", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r112", "r125", "r154", "r170", "r187", "r188", "r191", "r202", "r208", "r210", "r211", "r213", "r214", "r218", "r219", "r231", "r240", "r245", "r249", "r251", "r259", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r403", "r404", "r435", "r493", "r508", "r509", "r533", "r559", "r665" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract", "presentation": [ "http://mimedx.com/role/NetIncomeLossPerCommonShareScheduleofDilutedNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments:", "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersOperationsDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersOperationsDilutedAbstract", "presentation": [ "http://mimedx.com/role/NetIncomeLossPerCommonShareScheduleofDilutedNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Numerator", "label": "Net Income (Loss) Available to Common Stockholders, Diluted, Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic", "crdr": "credit", "calculation": { "http://mimedx.com/role/NetIncomeLossPerCommonShareScheduleofBasicNetLossPerCommonShareDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://mimedx.com/role/NetIncomeLossPerCommonShareScheduleofBasicNetLossPerCommonShareDetails", "http://mimedx.com/role/NetIncomeLossPerCommonShareScheduleofDilutedNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Net income (loss) from continuing operations available to common stockholders", "totalLabel": "Net income (loss) available to common stockholders from continuing operations", "terseLabel": "Net income (loss) available to common stockholders from continuing operations", "label": "Net Income (Loss) from Continuing Operations Available to Common Shareholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) from continuing operations available to common shareholders." } } }, "auth_ref": [ "r223", "r234" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://mimedx.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recently Issued Accounting Standards Not Yet Adopted", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r603" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r573", "r584", "r594", "r611", "r619" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r601" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r600" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r611" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r630" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r630" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Other expense, net", "label": "Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NotesPayableOtherPayablesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesPayableOtherPayablesMember", "presentation": [ "http://mimedx.com/role/LongTermDebtNetNarrativeDetails", "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanBalancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term loan", "label": "Notes Payable, Other Payables [Member]", "documentation": "A written promise to pay a note to a third party." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses:", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "totalLabel": "Operating income (loss)", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r240", "r245", "r249", "r251", "r533" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Right of use asset", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r414" ] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash lease expenses", "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": [ "r645" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://mimedx.com/role/NatureofBusiness" ], "lang": { "en-us": { "role": { "terseLabel": "Nature of Business", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r75", "r144", "r455", "r456" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://mimedx.com/role/AccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://mimedx.com/role/AccruedExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r23" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r185", "r548" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r177" ] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://mimedx.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities", "negatedTerseLabel": "Other current liabilities", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r23", "r548" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r27" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Other (expense) income, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r119" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r603" ] }, "mdxg_OtherSiteOfServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://mimedx.com/20240331", "localname": "OtherSiteOfServiceMember", "presentation": [ "http://mimedx.com/role/RevenueSummaryofRevenuebySiteOfServiceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Site Of Service [Member]", "documentation": "Other Site Of Service [Member]" } } }, "auth_ref": [] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r571", "r582", "r592", "r617" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r574", "r585", "r595", "r620" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r574", "r585", "r595", "r620" ] }, "us-gaap_PatentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PatentsMember", "presentation": [ "http://mimedx.com/role/IntangibleAssetsNetActivitySummaryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Patents and know-how", "label": "Patents [Member]", "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law." } } }, "auth_ref": [ "r143" ] }, "mdxg_PatentsinProcessMember": { "xbrltype": "domainItemType", "nsuri": "http://mimedx.com/20240331", "localname": "PatentsinProcessMember", "presentation": [ "http://mimedx.com/role/IntangibleAssetsNetActivitySummaryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Patents in Process", "label": "Patents in Process [Member]", "documentation": "Patents in Process" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r599" ] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Payables and Accruals [Abstract]", "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "mdxg_PaymentsForApplicationCostsPatent": { "xbrltype": "monetaryItemType", "nsuri": "http://mimedx.com/20240331", "localname": "PaymentsForApplicationCostsPatent", "crdr": "credit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Patent application costs", "label": "Payments For Application Costs, Patent", "documentation": "Payments For Application Costs, Patent" } } }, "auth_ref": [] }, "us-gaap_PaymentsForLegalSettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForLegalSettlements", "crdr": "credit", "presentation": [ "http://mimedx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments for legal settlements", "label": "Payments for Legal Settlements", "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period." } } }, "auth_ref": [ "r5" ] }, "us-gaap_PaymentsOfDebtExtinguishmentCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDebtExtinguishmentCosts", "crdr": "credit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Prepayment premium on Hayfin term loan", "label": "Payment for Debt Extinguishment or Debt Prepayment Cost", "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest." } } }, "auth_ref": [ "r4" ] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Deferred financing cost", "label": "Payments of Debt Issuance Costs", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": [ "r33" ] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Stock repurchased for tax withholdings on vesting of restricted stock units", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r194" ] }, "us-gaap_PaymentsToAcquireMachineryAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireMachineryAndEquipment", "crdr": "credit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchases of equipment", "label": "Payments to Acquire Machinery and Equipment", "documentation": "The cash outflow for acquisition of machinery and equipment." } } }, "auth_ref": [ "r122" ] }, "us-gaap_PaymentsToAcquireOtherProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireOtherProductiveAssets", "crdr": "credit", "calculation": { "http://mimedx.com/role/CommitmentsandContingenciesDetails": { "parentTag": "us-gaap_AssetAcquisitionConsiderationTransferred", "weight": 1.0, "order": 1.0 }, "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://mimedx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Consideration paid pursuant to TELA APA (Note 12)", "terseLabel": "Initial consideration paid", "label": "Payments to Acquire Other Productive Assets", "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other." } } }, "auth_ref": [ "r122" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r602" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r602" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r601" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r611" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r604" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r600" ] }, "us-gaap_PerformanceSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PerformanceSharesMember", "presentation": [ "http://mimedx.com/role/NetIncomeLossPerCommonShareAntidilutiveSecuritiesDetails", "http://mimedx.com/role/NetIncomeLossPerCommonShareScheduleofDilutedNetLossPerCommonShareDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Performance stock unit awards", "label": "Performance Shares [Member]", "documentation": "Share-based payment arrangement awarded for meeting performance target." } } }, "auth_ref": [] }, "us-gaap_PreferredStockDividendsAndOtherAdjustmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockDividendsAndOtherAdjustmentsAbstract", "presentation": [ "http://mimedx.com/role/NetIncomeLossPerCommonShareScheduleofBasicNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile to income (loss) available to common stockholders:", "label": "Preferred Stock Dividends and Other Adjustments [Abstract]" } } }, "auth_ref": [] }, "mdxg_PreferredStockDividendsAntidilutiveAdjustmentsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://mimedx.com/20240331", "localname": "PreferredStockDividendsAntidilutiveAdjustmentsNetOfTax", "crdr": "debit", "calculation": { "http://mimedx.com/role/NetIncomeLossPerCommonShareScheduleofDilutedNetLossPerCommonShareDetails": { "parentTag": "us-gaap_DilutiveSecurities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://mimedx.com/role/NetIncomeLossPerCommonShareScheduleofDilutedNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: antidilutive adjustments", "label": "Preferred Stock Dividends, Antidilutive Adjustments, Net of Tax", "documentation": "Preferred Stock Dividends, Antidilutive Adjustments, Net of Tax" } } }, "auth_ref": [] }, "us-gaap_PreferredStockDividendsIncomeStatementImpact": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockDividendsIncomeStatementImpact", "crdr": "debit", "calculation": { "http://mimedx.com/role/NetIncomeLossPerCommonShareScheduleofBasicNetLossPerCommonShareDetails": { "parentTag": "us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://mimedx.com/role/NetIncomeLossPerCommonShareScheduleofBasicNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated dividend on previously converted Series B Preferred Stock", "label": "Preferred Stock Dividends, Income Statement Impact", "documentation": "The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders." } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses", "label": "Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r184", "r269", "r270", "r525" ] }, "mdxg_PrincipalPaymentsOfSecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://mimedx.com/20240331", "localname": "PrincipalPaymentsOfSecuredDebt", "crdr": "debit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Principal payments on Citizens Term Loan Facility", "label": "Principal Payments of Secured Debt", "documentation": "Principal Payments of Secured Debt" } } }, "auth_ref": [] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": [ "http://mimedx.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassifications", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": [ "r641" ] }, "mdxg_PrivateOfficeSiteOfServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://mimedx.com/20240331", "localname": "PrivateOfficeSiteOfServiceMember", "presentation": [ "http://mimedx.com/role/RevenueSummaryofRevenuebySiteOfServiceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Private Office", "label": "Private Office Site Of Service [Member]", "documentation": "Private Office Site Of Service [Member]" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfSecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfSecuredDebt", "crdr": "debit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://mimedx.com/role/LongTermDebtNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from Citizens Term Loan Facility", "verboseLabel": "Proceeds from term loan", "label": "Proceeds from Issuance of Secured Debt", "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt." } } }, "auth_ref": [ "r31" ] }, "us-gaap_ProceedsFromLongTermLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromLongTermLinesOfCredit", "crdr": "debit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://mimedx.com/role/LongTermDebtNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from Citizens Revolving Credit Facility", "verboseLabel": "Proceeds from revolving credit facility", "label": "Proceeds from Long-Term Lines of Credit", "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer." } } }, "auth_ref": [ "r31" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercise of stock options", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r3", "r12" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://mimedx.com/role/RevenueSummaryofRevenuebyProductTypeDetails", "http://mimedx.com/role/RevenueSummaryofRevenuebySiteOfServiceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r252", "r422", "r438", "r439", "r440", "r441", "r442", "r443", "r521", "r542", "r549", "r640", "r663", "r664", "r670", "r690" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://mimedx.com/role/RevenueSummaryofRevenuebyProductTypeDetails", "http://mimedx.com/role/RevenueSummaryofRevenuebySiteOfServiceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r252", "r422", "r438", "r439", "r440", "r441", "r442", "r443", "r521", "r542", "r549", "r640", "r663", "r664", "r670", "r690" ] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Abstract]", "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization", "crdr": "credit", "calculation": { "http://mimedx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://mimedx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: accumulated depreciation and amortization", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization", "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease." } } }, "auth_ref": [ "r638", "r639", "r660" ] }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "crdr": "debit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 }, "http://mimedx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://mimedx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization", "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset." } } }, "auth_ref": [ "r639", "r658" ] }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "crdr": "debit", "calculation": { "http://mimedx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://mimedx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Property and equipment, gross", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization", "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset." } } }, "auth_ref": [ "r637", "r642", "r659" ] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://mimedx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r8" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://mimedx.com/role/PropertyandEquipmentNet" ], "lang": { "en-us": { "role": { "terseLabel": "Property and Equipment, Net", "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r133", "r159", "r162", "r163" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://mimedx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://mimedx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, gross", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r135", "r174", "r433" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://mimedx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://mimedx.com/role/PropertyandEquipmentNetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Property and Equipment", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r8" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://mimedx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r135" ] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://mimedx.com/role/AccountsReceivableNetScheduleofActivityRelatedtotheAllowanceforDoubtfulAccountsDetails", "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "verboseLabel": "Bad debt expense", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": [ "r193", "r266" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r599" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r599" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://mimedx.com/role/CommitmentsandContingenciesDetails", "http://mimedx.com/role/LongTermDebtNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r284", "r285", "r286", "r287", "r340", "r341", "r366", "r367", "r368", "r420", "r421", "r444", "r463", "r464", "r513", "r514", "r515", "r516", "r517", "r519", "r520", "r534", "r541", "r545", "r550", "r553", "r661", "r667", "r682", "r683", "r684", "r685", "r686" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://mimedx.com/role/CommitmentsandContingenciesDetails", "http://mimedx.com/role/LongTermDebtNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r284", "r285", "r286", "r287", "r340", "r341", "r366", "r367", "r368", "r420", "r421", "r444", "r463", "r464", "r513", "r514", "r515", "r516", "r517", "r519", "r520", "r534", "r541", "r545", "r550", "r553", "r661", "r667", "r682", "r683", "r684", "r685", "r686" ] }, "us-gaap_ReceivablesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReceivablesAbstract", "lang": { "en-us": { "role": { "label": "Receivables [Abstract]" } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r566", "r577", "r587", "r612" ] }, "mdxg_RegenerativeMedicineBusinessUnitMember": { "xbrltype": "domainItemType", "nsuri": "http://mimedx.com/20240331", "localname": "RegenerativeMedicineBusinessUnitMember", "presentation": [ "http://mimedx.com/role/DiscontinuedOperationsScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Regenerative Medicine", "label": "Regenerative Medicine Business Unit [Member]", "documentation": "Regenerative Medicine Business Unit" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfLongTermLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfLongTermLinesOfCredit", "crdr": "credit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://mimedx.com/role/LongTermDebtNetNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repayment of Citizens Revolving Credit Facility", "terseLabel": "Repayments of initial line of credit draw", "label": "Repayments of Long-Term Lines of Credit", "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer." } } }, "auth_ref": [ "r32" ] }, "us-gaap_RepaymentsOfSecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfSecuredDebt", "crdr": "credit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://mimedx.com/role/LongTermDebtNetNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repayment of Hayfin term loan", "terseLabel": "Repayments of term loan", "label": "Repayments of Secured Debt", "documentation": "The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt." } } }, "auth_ref": [ "r32" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r74", "r373", "r687" ] }, "srt_RestatementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RestatementAxis", "presentation": [ "http://mimedx.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revision of Prior Period [Axis]", "label": "Revision of Prior Period [Axis]" } } }, "auth_ref": [ "r167", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r215", "r216", "r217", "r218", "r219", "r220", "r238", "r262", "r263", "r384", "r400", "r401", "r402", "r403", "r413", "r418", "r419", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r457" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r567", "r578", "r588", "r613" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r568", "r579", "r589", "r614" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r575", "r586", "r596", "r621" ] }, "srt_RestatementDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RestatementDomain", "presentation": [ "http://mimedx.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revision of Prior Period [Domain]", "label": "Revision of Prior Period [Domain]" } } }, "auth_ref": [ "r167", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r215", "r216", "r217", "r218", "r219", "r220", "r238", "r262", "r263", "r384", "r400", "r401", "r402", "r403", "r413", "r418", "r419", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r457" ] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockMember", "presentation": [ "http://mimedx.com/role/NetIncomeLossPerCommonShareAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "RSA", "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r42" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://mimedx.com/role/NetIncomeLossPerCommonShareAntidilutiveSecuritiesDetails", "http://mimedx.com/role/NetIncomeLossPerCommonShareScheduleofDilutedNetLossPerCommonShareDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "RSU", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "verboseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r102", "r142", "r431", "r449", "r454", "r459", "r474", "r548" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r166", "r205", "r206", "r207", "r209", "r217", "r219", "r261", "r264", "r370", "r371", "r372", "r383", "r384", "r394", "r396", "r397", "r399", "r401", "r445", "r447", "r461", "r693" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://mimedx.com/role/RevenueSummaryofRevenuebyProductTypeDetails", "http://mimedx.com/role/RevenueSummaryofRevenuebySiteOfServiceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net sales", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r241", "r242", "r244", "r247", "r248", "r252", "r253", "r254", "r337", "r338", "r422" ] }, "mdxg_RevenueFromContractWithCustomerNumberServiceSites": { "xbrltype": "integerItemType", "nsuri": "http://mimedx.com/20240331", "localname": "RevenueFromContractWithCustomerNumberServiceSites", "presentation": [ "http://mimedx.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of sites of service", "label": "Revenue From Contract With Customer, Number Service Sites", "documentation": "Revenue From Contract With Customer, Number Service Sites" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://mimedx.com/role/Revenue" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r165", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r339" ] }, "srt_RevisionOfPriorPeriodReclassificationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RevisionOfPriorPeriodReclassificationAdjustmentMember", "presentation": [ "http://mimedx.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revision of Prior Period, Reclassification, Adjustment", "label": "Revision of Prior Period, Reclassification, Adjustment [Member]" } } }, "auth_ref": [ "r168" ] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://mimedx.com/role/LongTermDebtNetNarrativeDetails", "http://mimedx.com/role/LongTermDebtNetScheduleofInterestExpenseDetails", "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanFacilityBalancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Facility", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://mimedx.com/role/SupplementalDisclosureofCashFlowandNoncashInvestingandFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right of use assets arising from operating lease liabilities", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r417", "r547" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r630" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r630" ] }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "presentation": [ "http://mimedx.com/role/AccountsReceivableNetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables." } } }, "auth_ref": [ "r30" ] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://mimedx.com/role/AccruedExpensesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accrued Liabilities", "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://mimedx.com/role/NetIncomeLossPerCommonShareAntidilutiveSecuritiesDetails", "http://mimedx.com/role/NetIncomeLossPerCommonShareScheduleofDilutedNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Antidilutive Securities [Table]", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r42" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://mimedx.com/role/NetIncomeLossPerCommonShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r42" ] }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "presentation": [ "http://mimedx.com/role/SupplementalDisclosureofCashFlowandNoncashInvestingandFinancingActivitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtTableTextBlock", "presentation": [ "http://mimedx.com/role/LongTermDebtNetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of the Balances of the Loan Facility and Agreement", "label": "Schedule of Debt [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "presentation": [ "http://mimedx.com/role/DiscontinuedOperationsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Assets And Liabilities of the Discontinued Operations", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r10", "r13", "r17", "r77", "r84", "r85", "r86", "r87", "r88", "r93", "r95", "r96", "r137" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "presentation": [ "http://mimedx.com/role/NetIncomeLossPerCommonShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Basic Net Income (Loss) Per Common Share", "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table Text Block]", "documentation": "Tabular disclosure of the effect of income (loss) on basic earnings per share." } } }, "auth_ref": [ "r41", "r43", "r652" ] }, "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock", "presentation": [ "http://mimedx.com/role/NetIncomeLossPerCommonShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted Net Income (Loss) Per Common Share", "label": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table Text Block]", "documentation": "Tabular disclosure of the effect of income (loss) on an entity's diluted earnings per share." } } }, "auth_ref": [ "r41", "r43", "r652" ] }, "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable", "presentation": [ "http://mimedx.com/role/RevenueSummaryofRevenuebyProductTypeDetails", "http://mimedx.com/role/RevenueSummaryofRevenuebySiteOfServiceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]", "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]", "documentation": "Tabular disclosure about the extent of the entity's reliance on its major customers." } } }, "auth_ref": [ "r127" ] }, "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable", "presentation": [ "http://mimedx.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]", "label": "Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]", "documentation": "Schedule of prior period adjustments to correct an error in previously issued financial statements. The disclosure may include, but is not limited to: (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustment (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made. This table can be used to disclose the amounts as previously reported and the effect of the correction or other adjustment on per line item or per share amount basis. This table uses as its line items financial statement line items that are affected by prior period adjustments." } } }, "auth_ref": [ "r210", "r211", "r212", "r216", "r217", "r218", "r219", "r238" ] }, "us-gaap_ScheduleOfExtinguishmentOfDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfExtinguishmentOfDebtTextBlock", "presentation": [ "http://mimedx.com/role/LongTermDebtNetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Extinguishment of Debt", "label": "Schedule of Extinguishment of Debt [Table Text Block]", "documentation": "Tabular disclosure of debt extinguished which may include, amount of gain (loss), the income tax effect and the per share amount of the aggregate gain (loss), net of the related income tax." } } }, "auth_ref": [ "r58" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://mimedx.com/role/IntangibleAssetsNetActivitySummaryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r49", "r52", "r423" ] }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable", "presentation": [ "http://mimedx.com/role/IntangibleAssetsNetActivitySummaryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]", "label": "Schedule of Indefinite-Lived Intangible Assets [Table]", "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity." } } }, "auth_ref": [ "r15", "r132" ] }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://mimedx.com/role/IntangibleAssetsNetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Intangible Assets Activity Summary - Indefinite-lived", "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment." } } }, "auth_ref": [ "r15", "r132" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://mimedx.com/role/InventoryTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Inventory", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r18", "r106", "r107", "r108" ] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [ "http://mimedx.com/role/LongTermDebtNetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Principal Payments for the Term Loan Facility", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": [ "r9" ] }, "mdxg_ScheduleOfOriginalDiscountAndDeferredFinancingCostsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://mimedx.com/20240331", "localname": "ScheduleOfOriginalDiscountAndDeferredFinancingCostsTableTextBlock", "presentation": [ "http://mimedx.com/role/LongTermDebtNetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Original Discount and Deferred Financing Costs", "label": "Schedule of Original Discount and Deferred Financing Costs [Table Text Block]", "documentation": "Schedule of Original Discount and Deferred Financing Costs" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://mimedx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r8" ] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": [ "http://mimedx.com/role/IntangibleAssetsNetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Estimated Future Amortization Expense for Intangible Assets", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": [ "r52" ] }, "mdxg_ScheduleofInterestExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://mimedx.com/20240331", "localname": "ScheduleofInterestExpenseTableTextBlock", "presentation": [ "http://mimedx.com/role/LongTermDebtNetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Interest Expense", "label": "Schedule of Interest Expense [Table Text Block]", "documentation": "Schedule of Interest Expense [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_SecuredDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuredDebtMember", "presentation": [ "http://mimedx.com/role/LongTermDebtNetNarrativeDetails", "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanBalancesDetails", "http://mimedx.com/role/LongTermDebtNetScheduleofTermLoanFacilityBalancesDetails", "http://mimedx.com/role/LongTermDebtNetTermLoanMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan", "label": "Secured Debt [Member]", "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets." } } }, "auth_ref": [] }, "mdxg_SecuredOvernightFinancingRateSOFRMember": { "xbrltype": "domainItemType", "nsuri": "http://mimedx.com/20240331", "localname": "SecuredOvernightFinancingRateSOFRMember", "presentation": [ "http://mimedx.com/role/LongTermDebtNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SOFR", "label": "Secured Overnight Financing Rate (SOFR) [Member]", "documentation": "Secured Overnight Financing Rate (SOFR)" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://mimedx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r561" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://mimedx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r563" ] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r117" ] }, "us-gaap_SeriesBPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesBPreferredStockMember", "presentation": [ "http://mimedx.com/role/NetIncomeLossPerCommonShareAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Series B Preferred Stock", "label": "Series B Preferred Stock [Member]", "documentation": "Series B preferred stock." } } }, "auth_ref": [ "r643", "r644", "r669" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r6" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://mimedx.com/role/NetIncomeLossPerCommonShareScheduleofDilutedNetLossPerCommonShareDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://mimedx.com/role/SignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r126", "r200" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r11", "r29", "r166", "r189", "r190", "r191", "r205", "r206", "r207", "r209", "r217", "r219", "r239", "r261", "r264", "r328", "r370", "r371", "r372", "r383", "r384", "r394", "r395", "r396", "r397", "r398", "r399", "r401", "r405", "r406", "r407", "r408", "r409", "r410", "r419", "r445", "r446", "r447", "r461", "r510" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r205", "r206", "r207", "r239", "r422", "r458", "r462", "r465", "r466", "r467", "r468", "r469", "r470", "r473", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r486", "r487", "r488", "r489", "r490", "r492", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r510", "r554" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r205", "r206", "r207", "r239", "r422", "r458", "r462", "r465", "r466", "r467", "r468", "r469", "r470", "r473", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r486", "r487", "r488", "r489", "r490", "r492", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r510", "r554" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r570", "r581", "r591", "r616" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Employee stock purchase plan (in shares)", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": [ "r11", "r99", "r100", "r142" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited", "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock canceled/forfeited (in shares)", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited", "documentation": "Number of shares related to Restricted Stock Award forfeited during the period." } } }, "auth_ref": [ "r11", "r99", "r100", "r142" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of restricted stock (in shares)", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards." } } }, "auth_ref": [ "r11", "r142" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of restricted stock, net (in shares)", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": [ "r11", "r99", "r100", "r142" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of stock options (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r11", "r99", "r100", "r142", "r352" ] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT", "http://mimedx.com/role/SupplementalDisclosureofCashFlowandNoncashInvestingandFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee stock purchase plan", "verboseLabel": "Issuance of shares pursuant to employee stock purchase plan", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": [ "r11", "r99", "r100", "r142" ] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures", "crdr": "debit", "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Restricted stock shares canceled/forfeited", "label": "Stock Issued During Period, Value, Restricted Stock Award, Forfeitures", "documentation": "Value of stock related to Restricted Stock Awards forfeited during the period." } } }, "auth_ref": [ "r11", "r99", "r100", "r142" ] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "crdr": "credit", "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of restricted stock", "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross", "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period." } } }, "auth_ref": [ "r11", "r99", "r100", "r142" ] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "crdr": "credit", "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of restricted stock, net", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth_ref": [ "r11", "r142" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of stock options", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r11", "r29", "r142" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders' equity", "periodStartLabel": "Balance, beginning of period", "periodEndLabel": "Balance, end of period", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r100", "r103", "r104", "r128", "r475", "r491", "r511", "r512", "r548", "r560", "r647", "r654", "r678", "r693" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "verboseLabel": "Stockholders' equity", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowElementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowElementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Supplemental Cash Flow Elements [Abstract]", "label": "Supplemental Cash Flow Elements [Abstract]" } } }, "auth_ref": [] }, "mdxg_SurgicalMember": { "xbrltype": "domainItemType", "nsuri": "http://mimedx.com/20240331", "localname": "SurgicalMember", "presentation": [ "http://mimedx.com/role/RevenueSummaryofRevenuebyProductTypeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Surgical & Other", "label": "Surgical [Member]", "documentation": "Surgical" } } }, "auth_ref": [] }, "mdxg_TELAAPAMember": { "xbrltype": "domainItemType", "nsuri": "http://mimedx.com/20240331", "localname": "TELAAPAMember", "presentation": [ "http://mimedx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "TELA APA", "label": "TELA APA [Member]", "documentation": "TELA APA" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r610" ] }, "mdxg_TermLoanFacilityAndHayfinLoanAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://mimedx.com/20240331", "localname": "TermLoanFacilityAndHayfinLoanAgreementMember", "presentation": [ "http://mimedx.com/role/LongTermDebtNetScheduleofInterestExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan Facility and Hayfin Loan Agreement", "label": "Term Loan Facility and Hayfin Loan Agreement [Member]", "documentation": "Term Loan Facility and Hayfin Loan Agreement" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r602" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r609" ] }, "us-gaap_TrademarksAndTradeNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TrademarksAndTradeNamesMember", "presentation": [ "http://mimedx.com/role/IntangibleAssetsNetActivitySummaryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tradenames and trademarks", "label": "Trademarks and Trade Names [Member]", "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": [ "r64" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r629" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r631" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://mimedx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r632" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r633" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r631" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r631" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r634" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r632" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonMember", "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r61" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonShares", "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "periodStartLabel": "Treasury stock, beginning balance (in shares)", "periodEndLabel": "Treasury stock, ending balance (in shares)", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r61" ] }, "mdxg_UnamortizedIssuanceDiscountWriteoff": { "xbrltype": "monetaryItemType", "nsuri": "http://mimedx.com/20240331", "localname": "UnamortizedIssuanceDiscountWriteoff", "crdr": "debit", "calculation": { "http://mimedx.com/role/LongTermDebtNetScheduleofExtinguishmentofDebtDetails": { "parentTag": "us-gaap_GainsLossesOnExtinguishmentOfDebt", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://mimedx.com/role/LongTermDebtNetScheduleofExtinguishmentofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unamortized original issue discount", "label": "Unamortized Issuance Discount, Writeoff", "documentation": "Unamortized Issuance Discount, Writeoff" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r628" ] }, "mdxg_UnpaidDeferredFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://mimedx.com/20240331", "localname": "UnpaidDeferredFinancingCosts", "crdr": "credit", "presentation": [ "http://mimedx.com/role/SupplementalDisclosureofCashFlowandNoncashInvestingandFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unpaid deferred financing costs", "label": "Unpaid Deferred Financing Costs", "documentation": "Unpaid Deferred Financing Costs" } } }, "auth_ref": [] }, "mdxg_UnpaidInventoryFromAssetPurchaseAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://mimedx.com/20240331", "localname": "UnpaidInventoryFromAssetPurchaseAgreement", "crdr": "credit", "presentation": [ "http://mimedx.com/role/SupplementalDisclosureofCashFlowandNoncashInvestingandFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consideration payable to TELA", "label": "Unpaid Inventory From Asset Purchase Agreement", "documentation": "Unpaid Inventory From Asset Purchase Agreement" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://mimedx.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r44", "r45", "r46", "r157", "r158", "r160", "r161" ] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateAxis", "presentation": [ "http://mimedx.com/role/LongTermDebtNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Axis]", "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateDomain", "presentation": [ "http://mimedx.com/role/LongTermDebtNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Domain]", "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "calculation": { "http://mimedx.com/role/NetIncomeLossPerCommonShareScheduleofDilutedNetLossPerCommonShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://mimedx.com/role/NetIncomeLossPerCommonShareScheduleofDilutedNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total adjustments (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation." } } }, "auth_ref": [ "r653" ] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract", "presentation": [ "http://mimedx.com/role/NetIncomeLossPerCommonShareScheduleofDilutedNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Potential common shares", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://mimedx.com/role/NetIncomeLossPerCommonShareScheduleofDilutedNetLossPerCommonShareDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://mimedx.com/role/NetIncomeLossPerCommonShareScheduleofDilutedNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average shares outstanding - diluted (in shares)", "totalLabel": "Weighted average shares outstanding adjusted for potential common shares (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r224", "r234" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://mimedx.com/role/NetIncomeLossPerCommonShareScheduleofDilutedNetLossPerCommonShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://mimedx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://mimedx.com/role/NetIncomeLossPerCommonShareScheduleofBasicNetLossPerCommonShareDetails", "http://mimedx.com/role/NetIncomeLossPerCommonShareScheduleofDilutedNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average common shares outstanding - basic (in shares)", "terseLabel": "Weighted average common shares outstanding (in shares)", "netLabel": "Weighted average shares outstanding (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r222", "r234" ] }, "mdxg_WoundMember": { "xbrltype": "domainItemType", "nsuri": "http://mimedx.com/20240331", "localname": "WoundMember", "presentation": [ "http://mimedx.com/role/RevenueSummaryofRevenuebyProductTypeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Wound", "label": "Wound [Member]", "documentation": "Wound" } } }, "auth_ref": [] }, "us-gaap_WriteOffOfDeferredDebtIssuanceCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WriteOffOfDeferredDebtIssuanceCost", "crdr": "debit", "calculation": { "http://mimedx.com/role/LongTermDebtNetScheduleofExtinguishmentofDebtDetails": { "parentTag": "us-gaap_GainsLossesOnExtinguishmentOfDebt", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://mimedx.com/role/LongTermDebtNetScheduleofExtinguishmentofDebtDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Unamortized deferred financing costs", "label": "Deferred Debt Issuance Cost, Writeoff", "documentation": "Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt." } } }, "auth_ref": [ "r118" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-10" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b),(d)", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.3,4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "25", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481244/470-50-50-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-31" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-18" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205-20/tableOfContent" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-11" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1B" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3A" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3B" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-4" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3A" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4A" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4B" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5A" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5D" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1,2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.13)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//230/tableOfContent" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-9" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3A" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 5.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479836/810-10-S99-5" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.10)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483504/205-10-50-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//310/tableOfContent" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//326/tableOfContent" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350-30/tableOfContent" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "410", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481879/410-20-45-1" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "410", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481850/410-20-50-1" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-15" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-3" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r522": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8" }, "r527": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r531": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r532": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r533": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r534": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r535": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r536": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r537": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r538": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r539": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r540": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r541": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r542": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r543": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r544": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r545": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r546": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479908/805-50-55-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r548": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r549": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r550": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r551": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r553": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r557": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r558": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r559": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r560": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r561": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r562": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r563": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r565": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r566": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r567": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r568": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r569": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r570": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r571": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r572": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r573": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r574": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r575": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r576": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r577": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r578": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r579": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r580": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r581": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r582": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r583": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r584": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r585": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r586": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r587": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r588": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r589": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r590": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r591": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r592": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r593": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r594": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r595": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r596": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r597": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r599": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r600": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r601": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r602": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r603": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r604": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r605": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r606": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r607": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r608": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r609": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r610": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r611": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r612": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r613": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r614": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r615": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r616": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r617": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r618": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r619": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r620": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r621": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r622": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r623": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r624": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r625": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r626": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r627": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r628": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r629": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r630": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r631": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r632": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r633": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r634": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r635": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r636": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r637": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r638": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4" }, "r639": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r640": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r641": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483504/205-10-50-1" }, "r642": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r643": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r644": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r645": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r646": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r647": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r648": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r649": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r650": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r651": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r652": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r653": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r654": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r655": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r656": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r657": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r658": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r659": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r660": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r661": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r662": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r663": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r664": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r665": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r666": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r667": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r668": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r669": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r670": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r671": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-27" }, "r672": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1" }, "r673": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480123/805-50-15-3" }, "r674": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480060/805-50-25-1" }, "r675": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-1" }, "r676": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-2" }, "r677": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r678": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r679": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r680": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r681": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r682": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r683": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r684": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r685": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r686": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r687": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r688": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r689": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r690": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r691": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r692": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r693": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r694": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 80 0001376339-24-000033-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001376339-24-000033-xbrl.zip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

    [*5%KOFO#V-:/P8$^YKG=9*G!^=;AW$SF>+*MF3$H65)Q,Z4!C51DEQ.P*I&24 M5ZB#*JUSV1Z LI?0Q<6[SIUA23M\S,:!R;6>& L)/"/C,+"DZ/- AF%KCVUC MD$/RZUIP:*L QM92ZRDN]F08[P;@R&AE>R^AL%(+EPFLB7T24#@KO!;&]WR2 MMA'<(ZG[-BZ/W__GJS]O.W?\QK1Z,K.^ H+<:?SR]@^D2RE2F +:2HE? ((1H&,DL9$BI=7;Z;HB' MI'#WQ,H]BKC=56@"?*O;2XTU=N-$YL%%-YB;'US[)AD2XUEMF=?5%DDO\?R_ M5U6/C[^F3V'Z$=^%!1Z7@FDQ*O6:-],UG8*3B4,+$$+ !#(X7W,W3%:MHSW[ M'>'^MHF1=S:6Q&K=1R[(9JRW'[1+4 R+R$J.[>=R6Q5^6*4T8(YOOX5L)/Z^ MM=C%6<4-?-:1#V&3!V"(B>(VC!4(42K5.M\]C61S&])V]:*VRHZ\GPM)Z_;69Y;5S9;']V0,O9_?'KN*OY# MT-.HB"4R"=DE5@L!UMI(*@$KGJ";D$KSLL/;TG.;,YVS\&U5Z^6DO,>T[&HI MSTBREREEPV5TJS9;* M]1;N;[LQC?.L%@@^QS?**4JA> 9F?,UZJ?E^J>)2LI9\938UO_;R**!!92+M MB2[M)-2N5>#%VR_R8S[,/H2O]29Y+5-% W\UN\I/)44U.ZWGEJL)'6E"Y*S6 M$$2N)?23)+18*V]F0R9V(2W4ND+$ME@'E?"T)ZKM1:X-,Q:^[Z.797[?C*>U M.]0+VE/'BY&S)C*E/3#-5.W80':'"A%X((LYBLAE\_3R)T$-*DWJ !IO=TDU M['@Z2XAY=9+W>CY?UFWVIDJ67.D0? >>;5>G25>)P$B.U/;?M FV_J(_TE0 M0^K0LZ]]J:F@>N'/_;06VF-.VH!3WH 2)D%<=:4A2AN4SA+:'OFS]0:TKQX^ M!^#/[H)J;D:=E,KAXZ\ULK,:M$\2?Q)4.M0Q_]Q]=7N@FIS'>E.Z.&F 5;OY_-:%@A] M]0"M(0->1 %!8\L%2]D?PPVM)[VH:38R"(8)WL=7$ZR MVNH!@O("BB?4/LJ KG7.>,L4FZVR?V\=R]SJD3Y*L0BM90'&;3W$4QYBK!UI MNAK40B@X@I?". M'!PN8_.KIH\!^A%"[H=19=M*K4 -[9V]\922U]' MX%JQE%RQ6?10@W%=>#] 6/XP'&LCT':=&,)X6J]OG4S?APF>%)HDPK;X]G82 MIHN:4;6Z;#NR7/.I!C M,XZ]Q+,.T_A"09-[;R+#>M>T(E"UI&U6];I!"KKHZ&]'1G9FTO7W;QBN_Z/2 M96N1]*CJR)'LEIAO;(D>#:^@.-9L7H<&@K<>&.V.WL1"'D'K&E#KX-HP?/]' M)5%S$?9+KE64XATF'']>!2HDN0.\EHIPKNZ%I=Y[CA)!&EH!R3D;L?5IXCJX M-@SP_V$U6G,9MCPX^CR>TP!?S;J7LV5JU36=W7Z3PI-R"KV=3TP=EGIA@LO MI:K*.?+:TDJ4NI-*D-9Y$845W+5V^#;%N!;;_@VBY+W*=F_1AHLH+$_2!\4U M(&>TQ\J:%B2$ !VTX&0R$O8>RE^O@6PMMATZ_WT(488M!-DCR8Y/SR:S;X@7 M:=77C45>0JT0B"!L;4;)O8=0T'L:W%N'^#6+OOF6?@+??@68E,,6-$ZN$ J$'#8_[O$:%O*;]V M.UC5V>]P,>Y6Y9=/XN2B)G.-L>!UVS$D6:SV&6Q!\EZT)"L2HP,TW&OR7DP. MK0M'K0UN+98=.+U^+WM8+]+LT4A[V^%9&.=+5$JD(G@.X&1MIVQ3 %^4AYRB MR*YDF7GK!A-/85J+6H?.O#^,-;:#\'JDU$LLV'5U5JY:I8UO0&?J'(=>N8FQZ=#VOBAOG)].;EU#.[QB, MD%M;M(H$JU8V9<5"9);V4NMJ8S8D8?1Q:OTHJ+68]>\0WV\KOD.4FA(B&).9 M!.M- 16#!B\MUF:MW**W.HL]%4MYLM34]I>I/LR.TK^69+?\&M*G\12[;^1S M?4\H8-9D4YO?)FMHY3-+7)",EG]"U%9DSGCK8(3L#!0,M0\X(+@ M6$B.//:8;G?$>^@"UE.O^A$JH[0B1@^3WU-E][NY C0U=S]\B8LPGLQO@EFO MNON&;]BMPOLNPVE4Y?U>""^6Y J0Q)54.H@D@*'CH'B4$%QP8'@DN\TD+4/K MRB"/X=DY^#:9S+[4Z\GW9 M\?]_EX"TW3A69P*E:.Q UARAH.15-%FPHUB5L M?KMH$X"#,H6:T>A.B*TWF;6+Z=Z!LVK&>8F)B?IR&G.*U2ZCK1*\$0QH*\7@ ME+16MTY(>QS1D&ZI]<>;=D+I29==7DOYMH.VNO.,W?31XY ::9RKEY"D1TSG M['0U+7/2H%0]?S$U+)"\X_"EU_)2NK&87+>&:>V M-^O(/!N%9+#VK@:1BJ%Q,3+(R+*&$!@K.@0C>/M;ST^A&M*UYZWY<#>HV508 M#6/F%[A^GW7_K&'\6<+Y+6#>1AN"]8"Y2% Y1_!H$))$+9TH@>SVOECR,*PA M:8KV-&DDCO8\>55;,W_"7'MEW@(FK7&UW"FPVHA5.5:#M*Y =@H50V)Q:IW8 ML@:L(5U>;L^31N+HR8RXO!(6KL4"">3[.EW=MUFY[]]WL#AV>=UNQDFS@3:R M8V[B:6_7R]G?#M/N)!F(NMT>;I<)=5=O[-5&[-?2XL:$;-*U(J!-!)K MQ5E>CV0,%*&994(HC*T3)_L?58-[&ELA7&_*DW:%]H4"PCG:,1@*<$+5ML2) M5KH.RK0OWMSG@ 85)1C8DKGG-LE F-7R4M,V0_H9RZS#-0=F2B["F@*\>$5* MT >(,CNPREMO,$=9!K)D-AG6D&S?/^:ZZ8UD/]3J\F JM M&]-MB_4/H-'VQM&]\*&W@X6;!?=69\JK!(%O%\[R3B<.ZSY\UZ.(K0;1[(SB MSMN/OUZTF:MAH"_CR63DC2(>20F)8[W=6ZL4\%6*?P@N>Y.$:1^+>QI7@ZV0 MUNZ;\>>:8G+S=0^1/K.L)6W-X(DIM3AH345/N=[8TLHRHU+SNRJ;HQR4)]R< M8/=L8'U*L6'0^R:XE0UP=RH$\I"M0/)'D(P"94S-:]1@C8\\"L.DZ'NMW8]L M2$JU=U+U(*R6%MQ#A*\G 57?"V$3<"\]&0/H(8:DH?A2G'&S<7S3X6 MR(,:01N60@Z )090PEEPL2#X5-%SJ]&VCDWTH]?WEL)]&%:UD-^^-7KR.>6< M/1#9:SBA8@\5*#;#.&3SN =B]2K"0X>+1KPH9W1[(/H-&5LCLD!7@ M52\K%0*QJP20!A.3$5T.[=?L08-&U>[1(I0H,0,OB48=12VSXBVLV.^\-"FV M+C:WB?;"N=PR@X=,TYR1Q8L,Z"0US)WR9'IG% I*4IIWJ7X MCZ3LFI.J5P'N3]4=SQ?CT^HXO5HNEAW>4\6SS+K;O]?V_&0G",U59KL)::16 MG]B]F'0R!5Z@,-K"E!"%=J_ 0".*HM&A-ZU;P!XLL'>/,/XOAN[5;-F-?""7 MGJ8"4JTPJT0QX%WM-5]*]-%QYE7K_7$[I$-2O0VYM4FXII$8]Q(:O(OU'9Z& M,2WLKI9MG), *_B1-%*P(,E1CIGF2N<"40L%29>@$R_1FM;WG!K 'I+*'@P9 M=Q?P@9A9<7[X,AM)%WD-L),;G=(Y5)\+61ZIN,)-;4"X1YWP,- AW9L9#/NV M$>*!^/8;F3@?ON#D,_XZFRX^S4?,>=0E.K"&15 \.(C,!4A*\F(4B\ZUSDO< M#?&&70/_/1BXDUC;E,)Y&'#%F&X=]*P2O:],"&:U+-J3S1 )LHJ&U;PW#](; M6C;9%;RMB1\HDK,#B"$U"NR!5WN5T2&5*?$#1T8%#,PB6%H%H K/X%6TX(-/ MPOMCW3X%V5\%I]I+[ +:+I&4!YZT4>'BIW3$1!HR0' MHKJ[3$ TBM9#2FCI?UJFUE&+QQ$-*3K1AB%WNABUDT@SS53+T'8A+7X?+SZ] M6,X7LU/L:#=93J\0?KO$EZ)"SK@EY]/4LOW.@-."01::\\*,+ZYUKO'ZZ(84 M3NB'/3U)JHW5?#'DHWQ:2S8L:CWCS_@*OX]<&8VD_PRPE#TH0Q97I-D [0R2 M:5^N@&%R'5,I(G(7-$3AJ\V- M')P,%C*OS251Y\1ZJ&;X"*(A.=_][!8-)=*:);6A]OS%[/1TO )V54&05%^H MI]\.0VULZZIUK&N&IHQ!FFA5\TK%CP(:DB/=*T<:R*.I$GF',2QP/LK.FV!= M@IA4S=76DK183N!XP)R%\#FO%TVY^=PA>:K]*8AM)K&I%#]TX3-.1NA%UO4J MJ,J!3!%3:Z.;HL!$SX276+O6;2+$\\<.J>M\?S+<8@I[BAV\F4T_?L#NM+:1 MJ)6?TB?,RPG.RLT^$[-5GXD=(@M;O6>WN,/N0VL4E5BC?X<,Y"(: U:I>H,E M.W"9F!6*4K7-P-WP\K[;KVP^ZM\[6ETGI=2GG??!J4]]/9\OZRWP6@1]E )W M.3I7DX')5JGUWB*7&43MA*DX2BE:IS ^C6I0=UK;4N>VF=!81&VTS#^FX3S> MBOD2R67CRA7>62DCEHVFO5. %'7W++1Q1I0%:#=&J3P7F:WGJ' M#[W,>QLVU#&MFK2M.BG0WT['R],1:LZ%+ *<$K4&)9(%RUT$[PB$]=XP+&O) M_]['#ZI/18\2WWUN]VV4U _?S,+T54BKL-C/85)YNLN1Q];OZLDXV6B(C0R4 MU:X_G2^Z927"M8W@<@,8,>V%]8*)9[:5JWL%@7VY!.7 Y,IVVD MU9!+YT;Y1>&L5=^HFN:0A%:I]M:62AM0S$@(WC%P#)VV,3(TV)PZ]T+I8X07 M4UX'&ID-6C$+]7BC%M#T$*TTH$E_1ZT9"M[Z8M_CB(:UT>[.CKOKH9D\^ET% M5[M\A945;>O19]#>U12">0Y+%QA2"Q-@ZH?$>&#O%&JX_ M[WIGJU_#8MF=MX(,7BH3;8%2ZNU.F6G)D(,-O+@D;,&BW'J!AZ??-21=LZO M;X0=&D_S 4QW*UB]XPN(R=2ZV0@A,0_5I3#%A(#-NQCV9+KW&[IJQ9I>!=2K MG7+-=A(E:^X8#3>;4 =N(!86(1O+)4N&J^;5%G>W9?<6Y6Q/E6;":$:0&ZK[ M>YC">BE9T(6,ZD!D%ZRK1AU\Z5&VZ)1$>5ZB-YGY_FO7:+&A9ZF@3 MB%A\+1554RMHZ6N+Y%J;YKD43:(!!]&US6C34BK[C@:\GBZPP_GBXH92'\& !U[1 M4RQ@G0&U*]!V\U61F,18\=E(,-H3DX*JM\S)$!?,QER,Y$RW;[QZ!\;..A"(A6:9#DV@ANHF3YR3WE MZ=<,*=;<2N:-)[=E)>;;X[NRMF_4B=8\!"]\!!4YH2O.@W/) >E1H;U,2C>_ M]+ NMB%=I&J]1_0BGW;W9&[L8.?64G73JKTT"C$+5/4FN:KV="!F1T%_))-$ M2$Z:TEQM/H9G2#>I^M4D.\AA/Z;JY=G.A1^_2Z^I-9_WO:JV![B6\_@?KU]*IJCRLIL% XL%0#DHP%<$)G0%5;"IJ2A6Z=S+05T"$9 MV4,@WI8B/ S;[E0?$PF3$<+3U-2&J,H+< 'K7MZK":&2TVB%P45L(Q6QJ6FD$QZR/-=!J79\G?NOB')(#, S.;2/ M-F&F>V!^NUG]3@CGN>$:2FTVH(Q0X%E6D *6S"6/+IFGG(/U7C6D\@G->='# M;!]PLUE5J!-<9F4]!T>"8M]9N:MCW1(]1L&M.%L+,2> M@A+DR;^>TD]8;R.^Q:Z&8V?3]Y]"A]^/GGX.\W&B;][]S@Y!BT9OWBVHT?Z?TA3O##[!JL3[,)K:OY"O>(<:5I MSCTD6^MG(CF0/M6+OJ9(PY,J5K6^D]0(^JY;ZPT8(ZYS]IX\&-KC0SU9*.!U M8,"$$2X+YH)J'2>Z 6!(08Y#<.OVGKF]=)KIWK?=18K#^\4L_?/E^/,XT\J= MG\-ZOP@TA[1[OSX]"VDQ$M:[(*R&Y%(!I37I![01; S.&_KU8.YJ//1."/^-OR--8 M[06OG)\O%?!&F]5QR)*..W&L/DKM4>PH+1,RH8A)Z-R\_NJ&$'OI>B ]-QE'^?\OY*J%D5"3I!^\(HC?ZO%B MRZ#%MI;QC4KS:]G; EU M2 <1!R=?8\FV2U.NN,:?\3VFR\Q[A4IZ62)$;PPMA^+!E6"!1\]*\LF7W+J! MTET4#8J*T_0O:F^$*Z/IREXB/7M2/H2OHV+0);*20'B::*5JLJ_3A>PDD4SQ M-4#:^DQO+6!#VK=W9,@]-<0;"Z9-X/H!T_J(;/Q\,0/?U^IWH$9RK'L"V&!2 MK8P9P6E3R+CWGK.LZMI=*YJ]W?L'Y2$U8LJ^Q'%P55Y-BT0S!*1H!*C:=CYR MYB$8B\IA*;IYO+N)*M\F&35U*]?486&>:WYR'F MHZX+TX^KWYN/A,F*TW35:F^VUGQQE-WBSQL"KM5:Z/:BNHH_6LYGH\K M7'KQG#;O\P#9!Y+L_'QC'XGLDQ3*U7Q5#BKI5-TN!)&(<3+):$/K?HGK8MLY M"'MQ1O9AMGI9AZN^.V^[65ZFE>I:M>L:11%7' 89L=06[*0=4VV]Y3> M]FVD..U#D@PED6KE"2$8^&03F(2TLXI4:#QKV:T] 1Q2\*!7!@Y&RGOF:QAW M_Q4F2SPIOQ+VT^7IE8):W/B=419>!E0%-,/:)Z:X6AW30[91&&4TJZ MT(:4ZS@@CO8BV9Y,N]6]S-4Q'N;OIWB7!S,U0#@_F\W#Y)=NMCRKYVSG%[3N M_[5;QW [V(;[@+6;<;GWB6MV#?SZ$>[]<"ZC"3?=E'=X5N]B33\>TR\LOHUT ML$Q)$T"HVL57UZH2(2%DK9.)Y+(8UMIX:P9^]ZCQ->D^+MQ?<$I_FQQ-;S6, MN[@A-U(EY&0-^9,B,5"A]FU@9%P5QU*MZ!!B;IUCW []H%IP'(;:=RIL'(8: MC9HXK _^')T+_$SSB9G=6MZQ*ZJ&&UL[7U9 CYA?N7$>X>?OSK__Q^>_ M_?S[I]?@?OZ?__8O__*O_PW@_SS_\/:GEY-T>H+C^4\OIACFF'_Z8S3_\M/\ M"_[TC\GTGZ-OX:?WQV%>)M,3@'];_+,7DZ]GT]'G+_.?!!/JXMC\;__&O](X89_D3+&\\67_[MYR_S^=>__O++'W_\\9?O<7K\E\GT\R^" M,?G+Q6__?/[KWU=^_P^Y^&WNO?]E\=,?OSH;K?M%^EC^R__Y]>W'] 5/ HS& MLWD8I\L'T./S_,<_O(I&_[+\(?WJ;/37V>+?OYVD,%\HZ,XE_+3Q-^I7_UT_[96=,7PC( M-)U&!/HNCBO%&V)<]^F[8_[Q69"QA-/C>4/$JY_=%._D)(Q:"GCEHQN@77P0 MG.!)Q&E+J-<^]PK."Y W$9[0VO+WOZ3)R2\+8"_>_?;RU6\?7[VDOWQ\]_;- MRV>?7KW\^(G^_/75;Y\^OGO]\=.[%__KW]^]??GJP\=7__OW-Y_^\^6KUV]> MO/ET]RI.\O?/4/=>)I=O^W_?X6E7UD8D&HU'=5]Z2U^>/[*NIO=5XO3=.V7CNNF.?FAY>,0\7CQW:/3&7P.X>O1QSF=8/4P(_SXAOXZ.^+% M#Z[^$Y5 MA%PH83.*I9 ;K.M3B,=X9)/*AHD$440.RJ '+S4'S651Z)P41O:UI@6"Z^NY MI,VSZ<7*SM_/3L=,F4Y.FNIS/FDFQJ6F"/3//TVF&:=D6=&/%IO&7]/Q9(;Y M;S_/IZ=X^$ZL?G6\>""]Q_BY_J49$U[]W]/1_.S%Y.3K9$Q?SIY]'\V. M4";T42)X%3PH'1T$GP*XI$EDC"7F>R/[.D ->7++T7\+;^ZAZ$V+A4N&:G[I\)783= P,(SLED_'$^2?_\=6&^'HD<>MH'H[/P1E:4-#. <,@02F>B=DE ME,6O#"$Z;6:K\5T&.@ M0#N)]_#F?YIBF)U.SQ8,79+U')ADVD4?,G"6:DA.&EIRT* XELA2L=&VWO\W M@GD,-&@CZ54*B%TI\ 'GM#;,K\)T/!I_GIVC\MJ(E$P&H:T"6I\"QPT2/B>8 M153"B<;Z7X_D,2B_@8Q7-2]WU?R;<:JDQ)>X_/\WRX/JR^28/G^VE,*'R?'Q MZ\GTCS#-1Y9LGFP"D@2L( ED UZH0N@+DS:[&$MK7[$CQ.&YTCC>T*=*>K F MKI@W'[^$*<[>S&:GF(]H0RM$; ':Q @J*@D^QP1.E.1S)A-9M3X\-D 9GA&] MJG"S>7EO^?=@5:PN^,@&GECPM$H9#2@7$L28#)F])04?0\K*-H\SW43QN,FP MH]1[,"W6V#Q+FAX97:SVVD.1A8!%+< 7R4!GQ[F/EIOS>3TZ9Y\F&YRD!=)Z5YVK-8;CV>(*_ .2A&:C.7[$Z;=1PO@?6 DU':N4"^K7(9E#&% MY&,C ;9([FY&55H[^YU!/DF6-=+9*LE,KYO9!YS-IZ,TQ[SXM6=5/'^?3F:S M(YVR",8R$"HRH!4$B)Q%(,Q>EYRXX6[(#6TCTB=)MY;:6^6<[7-CVPPZ2"5* M+!D".@W*HH<0@P=T)@3#4O&B?>[+/8 ^2<8UU-TJX=S0A"-!%1S-3ZM[)5$G M#%I!2CK1N^(91*MJ^)@'%8MT4;7/K+DWW#_)UT*/JQ3T@Y^SY]C)0N ,F:C" M*I;L B4E)S,TDKMCT$3!K/%Q(*MN"[1/DH"MM;@FEKMSC/]6Z*].OAY/SG!I MHKX_G:8O),CWQV$\.XI2Z: P0 ID(2BT$F(,G/[F2Y-;YQ+<$^H3IEXC M_:WA79M+A U[]D;81P6U2$P'P%1(4HZ\[ECS.(,5RD:C>$$UX*F[$>B3Y%Q# MW:UAW,[7%9TWZ=]P_JY=KF'ESO2!%P:YU.+*Q J$K!D8+4T)T9+7/F1P[T]. M#JK1-93<^2*# )&\)B?XMOKH):(F-\B!3ZS>(Y)[[C2) B5)PJJ0+6MMZ%T# M\+C)E:2Z&,UPP;R#KP$ 9+L'Y MZ"!R47+@V89LALW%^-=?;KS*;^G+[@6U'T>?QZ,R2F$\?Y;2Y'0\KWOMY'B4 M1CA[65,RCV?77Y;M2F>W^MR=BF2[(V]4#OMJ.IU,7TRF4TR+ZZ9GX_R>SJ;I M\H2Z&?40Q7S#L?& M%1-M6,WNNU9X-IT?75G HLJ-+,GB)3DZ6M2H3TX"G(@9@B#D/-$2U%;I4_39 M5UA)7UTRG@W[J 3>61WKU;J# M+'M7L':(T1@'V7G:)5$$"-%SB$HY:VD+E=MEF!V&8C?4]?:KURXB;*[/;Z.Z M\G?ERA[U =-QF,T6!N1"I#_VK/.Z(\N"TS8G\DC$$?')&23\>=/.#UYB7%^ M 2G:;%FQ'AP/]2W):KEYLL 5LB2Y\;PQ0=; >$KDV%4+&P^>1L&6]],)F=OS MLS#.-6#UM:[\-YQ_/#TY"=.S25GW\QUB,+L\;J?03+-U-HK87#ROWJ#.GUUY MZ"7MF#/&%NU!:T&.20BYIJ,[X)G\DV!TD+YU$<'=J-K%7C8^:^F6*:6C2DJ! M\(R!*I'.R:CT]"HI^I.@,@?:*5V, M8"R%UF6N>Z/.'6W;#H$Y7=314S._KU<##"4HRW,&;DUMF>XD[;$Z 9WI@0?M MN66M';4;$(9WTIJK:4T/O_O*N ?__/7I=+Q(#**EOAY]7Z0(G2-+*4GCN($L M/5EUD3.@Y18HVB6M1.3"I<;:WXSF\1&AD>1[V ;>UK2DFC_RYN3K=/)M81)? M0,L\&4[;'#BK:O88,=4QAL!=*2D[8WUN38I;X#P^5K22?0\-65Y,QC-RFA:Q MJS=C$L1G8NP%-B>"1N0:W*)J7?!"+F )P)"GP$0NJ%L?%;?A>7S$:";]AMU8 M:F3MZ-ELAO,/.!]-%V1],9E='&VE]KDKGH.7QH!B/H/3MM#1%@RF%+E,-_:* MU5#=[8]X/&IN*,H>FH]L7/6RT-8H3,$3_8HB3$ID!3XE@IB%"UP5LFI:W_C< MCNB >-$F2M90 7T8D:-Q'4ZT.+L^U$E-[\KO,URP^3F6"9DX*9V>G![7>4_/ M3B;3^>C_+6XTCUPQ1M?$T<7P)56[BT7))&"1@=%_-"NM<_[NB_7146H0I0T9 MUEC8T=NOZ25^G6(:+:_6Q]>7*$TJ(3H%4LE2[\8T1$][+D-=$KEE0KK66.>$'NUQKMJH_ M6=XO$38Z4(VR7=Z,YV'\>12/E\N8_59?V/GHVVA^=IX)LD-NR_8?OE,FRSW7 MT"AOY75%BV]'WS#?!'+)2"-$S,H@.6KH-KG:Y M*[<\;7E'SGB0MEY7:2F(](*1!*(VP%FQ7!>F9&X=E-L>W5#Y*\VYLCF#I:E" M#B6'Y99%/3_[-?S79/JBIBDO[D>]UIDVV !H+:]-."Q$D2-@-)(+C.AM#_[\ MMO#VG]/2EB"K#GTOBNK!A[\%ZB70W\+)141U&[@]9;ITA+J?K)?>5+\]Q9KI M[0#HENJ]B;(:R,6O/:O(3@Q.)\ 4DS9&),/88Z39'1DRA\JR+NKJ(R!)OL?E M)2U*RR6KPYBDEM6G3A ,=V"99B0%I4MI'CJ\"F!XY[!7==WT%.\MZSYJ6T:I MOCGCS\\^3_':3;V362:,$9P0M$2^&!.0R9S4+CEI5+*V=5K=1C"/FQ!M=-## MKO!R5'LQQ=/%A(D:M[C I:P(!CD#XVKU#D\2@@RU26+ $+C36;>^+-V$Y7%3 MHXD&>@CIWR*#Y6TN,=-'VMI 8ZXSX((%5W0 I9A6T1;'FM?'W87IH)C2QFUO MJH9^+M4WX=MT,RN5U[2S6;#!&J*S8>"<%Y"<4*E$4GH9D#@'X_2M^>+"N#FOM36@_&PAUP MUSINVT#N*6)_#[C[B=KW2H-NE&NFPP.AGQ*>:Z49H,OT=IKLR'JR"3PKFJL2 MG8JMH[ '0[L[HOB'SKHNJNN!;9^F(>-)F/ZSMN=9?%&Q782.A,Z!Z1BA".-J M)("LC6@=U; >VC?7G/*ET90=U*'PUC-(MJG?.[B%$MQDJ7 MM5@"DT=!CELLGH&27$-(!>:GN 6-,-HRW@2+_DS">16*S)DJTC<5TQ'AR1VOM_ MO:IMXW;2*$OT:L^VWW#^6YA.PYR6L4-NZ%T?N5-&:">\C?) Z[/>+.IBKRS"+@ASCR7@VO("4)L9<9,BQ=>O*88EP1YQC*!YT MD7-#_2^\I1:F"\&58H@,];64JPN5W+@Y#J9;"TS M4MUE,M[]F.']B#:JF/0BQ]9!AG\/9R30MY,P_H&J&MGU&Q=)D)XMIHP#BKAH M#5*]ESKG60NI;"9SR,BMM'SGHQZ#IMO*LX_F6^1&S<_=J!]]!T4P*7(L0$KC MA,D0'&X3:"ZSTCX$X?KHF'X3QV,QZW:6<0\)%SW'J-M= M8W=08 =Q#[ )G*/CIA@=BP>'6#,2BP''; :ILE6)_.'V_3B'),$=!MU0'.@B MY3YT/QKCN[*T1"X,D,(E)BG 9E?#DF2*!"\89&>#I1,O6=?:IU]%,?SIWT(_ M*^4".PFWAS3?WR9SG+T/9_506\QP.?_[QA1$:"GV'C:!)4-?AU2G^9PM*^J\P>*= VE-G0--C'5>5H/' M,.FD"09;%R6NHG@L%N".\NVA&=3?H2 M>!\UQ3@G2^>&B3WI"H0H(^1LA67)YF):'_WK<#P"W>\LWAXV M@.?34?Z,5R*0)OO ? QT-"H'2@H%02+923J$*(J+6K1.,KR)X1&H>B>Q]A#@ M^XCI=%J;U,4?HS]L,BJB(L^SCK!"^-!= ML_M+KV'#^Q\@+H)#6\!H.<'^\M%[F%U_/^'?5-\.DFMXN-Z$XVWT.HA0'0;Z M@YY/ISV= "H3#F.R4G:K;(A]*_"V&?5-]==%8(WU]BM)ZN3TY!R(--P[ZSSH M'.KC:5=RW$>P*?#H;#:YM)@W?^VA \^1OZ_8)RUDUM")60 )WZ\ B=HA.>:R M3BNJT\=-ALBUAIAU$59XE=56B;AW*>_J0Q^@\NXMLQ[ M0LZK:/83<-Y-2[>H? <1]_RBGR,+@4B<$R'+EARG$!UXQ5-M4J.#9$G&YO-X MAE+Z'8'FOG7>1;)]Q)AJ]WQ"/\CKKUGJ^ MCF#XL,.N.KD97;J_0%NGB)['/]Y]P^FXMKE;3DP8C3]7?!_?O?YPT?9.1V0Z MB3JW&,FXR+%.LN&0#?K$/*&7VXWCV_*!#U;'O4FU=?IW-4^N=A5[C]/1)"^V M+Z1=BB$M681%@FQDX!39E#XK)YCEM)6QK92]^1D/W2AK*<)5S9H>-'O.Z6V MK3?1.NEX'R984YW<=!#K,NWP.L.3"=? 2 M9-QL0(01<$P3D++GA?!#]0 M36^PN_:CZ"YR[%O!_XEA^FY\84#8[%-FPH+SM?)_[TT M?.TQPQW)C75QFX;O+\C6EM@Z9)_^F%S8B$FK%*V#(G(F4T369I'%0=:Z>&6* M(&_CWBK^\9A'J^+["7*(M_@3:>L'_:P19/^1E8F%L/'H@2BG(-4;3F&TU+B# MDB\?]'C5?$]A-KRQWXCM]>1T>C&0.QDCG$ PS%A0D;P^)P5QD!44KBC%;DXZ MZJ#GR^<\6C7?4Y0-;^LW0QM]NR"@SFA2JG6%T6%-)"@0&1I@5DF/Y#JFO)W+ M?/MS'J^6[R?*AA?ZZPH_?F3\+:]=GD^FT\D?-1\P?*6?S,^.4.KL$35XAAY4 MI@,FBBA!%CIG$ITQS+0.CW7!M^\ZW+=->K#TII'65MTZH,]2HL\FF;_&,#^= MXIMQFM8)I6]')Z/Y$<%SW-1!NDES4-H%"!X3E*SK(%0F2PE;;1N='_VPJ3& MN%O;@]N@??7\S:>7SWX]/9Z/OAZ/ZEX81&T/'Z!@[>U>+9SHV2)=+2=DL2ZA M&3]N/OV)4&0GH?>0_GE=",_#;#3[^)5(G-^-KX:M^9&2.:+(JE[Z!W)@=08O M30!/=!8Q9"=MZ]D+VV)[V-3I51,]5(1=Q_EF/,,2S"DQA!&^XJ-Q&(/'465=!&<^#IA.S5\[=4S'/7I-< M+IHR5AG,+K;,HX12NDC&-U\43G$4$!P1.[I0NZC$.GZF,5WN!/4X6-)6]CUD M_%P%^&8V.PWC1$?IE13Z(UV*3X(\<2,#F=J.]C\O+8/D6;)%6TWF5(_D6 OJ M\9%C=]DWO'*\K(S[&LX6,Q2OPV*2,Z%#AB1Y34LDXM:6:70DHE(AF!Q%:R'E5_797]?^=Y#%[.YG-:+L:O_H^)P?\=#3[4H&^*PN &;-0FC.P M5M>3K2:X2AZ)KC$+1Q@=5XV)<">HQT&)MK)?)8=KN3>L/]FDLI8IQL"%4F=U M!@4!4X1H)7>)''%[\PJSZ2[QB*V*MK)?)8?O([KZ^_ATAODB@O=B(VJ>4NK^X)]'&0:1E=KXFP[U\9O M=L%>E8*I-IN_@C:0AYY<3A"58=66JJF\B4.(R6D5L^'-Q^YU O@XV-2?3M8P MJ$E?O8L9!:_#:/H?X?@4CVQ!SK.+P),ELRN02^935" %MXKL;^U5:X]G+9#' MP8C=9;Q&\Z+/T1H7D_\FY:(5[,6^^#P<5R=MUF[FQO;/:CF,XYXK['E*!\-<=BR%[A#K0)@9=B',/60]H&G-(A2\@^F@1%RX4S)R'4)@0Z+,;6 MB,!\ZTOD YS2T47'VTSIZ"+50YG2L;9QJ=?<:Q8">$$./^VK53", ]J<9$;A M+&_>T^? 6SIWTNTV+9V[R'BX+K[;H'JJ+9T[:6R[=K[W$?=P9"C1,*%+!EEJ M?5(V$J+V9&ZEG(SB2J!H?=M[Z"V=>^! %RD/T])9\N1*< @E!0Z*9X206(& MQB>C;>UFV&/?FLFSR"=:-%%#3$D,H-<'2&24X 4 M,FJEDX^NWZ2.QW36[RC?WI-[KLPIV0;74YW*U4EGVTYCNH_ >]CQ-^(SEG"8 M("!$E4 AC^"8-\!39%))5*9Y,Y5#G\K5"P^ZR+EU3NCMTZ3((:Z] A0$P6MS M0BS@C71D[6"0*%+2X49?P <^E:N3*K:?RM5%CCT<\FLZ4V>C7,D:P;/:_DDP M!\XPLF(R#T(*'UGS[BF'W:%_ET-^1_D.U:%_&TQ/L4-_)UUMTZ7]/H(>JD-_ ME-F%X@6D$C1YK$*"Y[X."RF!Y BS&'9A0#N!]Q2R_7&).AD35Z?59XEDY(0T/[)8 MLN1$4X^+9IV6UAV"(ZX*SXN5MMC6=+@=T;YM_K=-;OT:2KWWV-[OX["L>*9- M;#1+D]/Q%*4+LRQU0T2X'U>[]]*[S]!'];:?;6 M.$ [M?02&BI(0/*RH1R^F,SFLTMTO^'\B+GH.2,_J1BDY<=,II-)I:;@)"WI M'6*F?>;:': >&5M:JJ"'>/+5M;^XL7#AA MT#(+()1%]5:%#D<[(8HH-A@DG M,],MP%%(;7,D-9O:X(3I$X4'M:NA?$^7[S M73=CV^_FL9-"NYXS]]'&0(?,B\OM+6?G49"'GB+]H6A/@\@%N>F"<6Z=IG^] MU32,'4^8%P=RO+1E2#/)]WRP/#^[6/FSCX M\;/?7:6E1KL>0YW4,9230]L?=S%D+A$X6=%U0HHGWRL6,$[Y''QAV+SSP 8H MCY@;NXM^XPXR5 '&$(47PQ9<[+/0PEJ-Z*2%7-OY*8T>G-,,N HL)J6\\JG7 MO?EMGX46V>EHA5"@ _>@9#3TLKA4FTAFHG9*,K0W9@^NT**+CK"!Q9%BH(K&73K4^+0"RUZX$ 7 M*0]3:!&R\]%*!RGF.I^GEA84LH(3.4""E\B3:%[A11?A]G 9 M^]MDCK/WX:P>:N_F7W!Z_O?9Q: ;8M&\G]Y\064(FY[7X$R[94E_Y@\HL:Z MOP/2HR!"2['W?F.RV.E4YJ6PHFEY18+B.A&B$"&R8!WYOH8%[-5%>$P6X([R M';+\9AM<3[7\II/.MBV[N(_ ARR_T4EPS#7C@]5HO<@"@JU=:"QCSDIZ&W*_ M4>K#*[_IA0==Y#QL^8W,J(LH!C+SHC:+YQ"=EE P. (LHA(WDK(>>/E-)U5L M7W[318ZM)S+\>S@C@=:HZ@]4%V'6L@\D7DC10&750V@BV"*-RK< MG."Q0\@Q59H- :9,@19+*AB:W,0VN?08W0REA384RFV MZJ2;.XNMN@BVA^C=;1EX47%>PB7?+7.L>)Y(RS(QXS*D\R[K M5,1VTY'O?M9A9:)VTLND/Z$.GZ*<0L@BT][FM*@)U'8Q+[* $(QEYU,NS9OR M/J04Y?L0HP?)[R/5]"+%7C)2H"D.=*0343$>P(E0OR1'6"2'0?0;U'\H!0^[ M<:4';?3@+ZY9_Y&QGB$92:!=)B(75;N-NPC&2:F]XD:Y/@MT'QT7=I7QJMIW M'^N[?4ZMT\AD2A:$BYR0>@'1,08FIV@2R]HW3U!_B/4,K2S,AMIH?4&P8AN] M^IZ.3W/M0K!B) D1@Y2%A%#G,BG-,A R"YJA9MYZC?+.3.2N#SWHU/1.BKO5 M(FTD];V4:)LDN4C1"4)-N9%6ZT-:I]9LF!EVCW0)M^U+$/D_5* M]P&96/#>U##]XB;%C0!@V/MF?- FD+TRJ%^5-2S*7L5E8I,<)TA MBL1KFP,-9'(1/L]%R%DJ)_M(8%U%\F@YTD#P&TW-;5DQ&)'-(5B; ["U9/"S03HD.!+)"IE;V(;5N87?H55,]<*"+E(>IFDJN)&>B M BX(ELJT2!?HA(PE:M3D!$G>O&CV<*NF.NGG[JJI+L(=9CR-Y3+R(BV=95A; M]"=)"ZS-7!V7UOO@M>NW0L2"I!;%&K!'@=)%SZ^NOFR. GXWSF@* M\[-*9YN2KC7B1MHH%-)UTM4T1Q7T$ M/50!3;3&)?) 08AJT# 5P2O/01C%M--$# M8ZYB>5>6.5>5W#7KZHB%F"03$21&"RK3RQ(26C#1TK=#MDJVC@O?AN=Q,*.9 MQ'LX3:YCJZN_2)AZ/\63T>G)40K<9649!,YK!G@A&1B=@9!QM$%:;D6OE%@# MZC'R8E?9-XPK+_S=&_O9B\G)R6A>%_\:<7:DHU0Q2@;HR'E6SA1P 36@XD[K M(F*)VU7LW?J8AZWGQF+LP8E<2[\#IAC^:PBPS]<_:91EN^N26R85;H>\YIY .\X(R>]"U4XO2 M=2*#+ E85!@Q%.5TZ\-RP)Q"7V+.DDGPTA%U7>9$71[(L\;BD!OA_!/(*>RB MXVUR"KM(]5!R"M?$67P2NNB"(*4F6\4Q#[70&$P)A;-LM6X^,_FPX\V=]'IW MO+F+?(<*-6Z#Z2G&FSOI:IN8XWT$/1@)E,52.Y&E8LQRFEI(TA#/?:'-4:;$ M6I]YAQQO;J_[#O(=I&&3L,:';"+!J*TA!=-U"E4 ;1CS,3,K;S9??+0-FSKI MYLZ&35T$.TSB((LE&"4Y&3>&T_IB 9_*PO31R4A%GE'K2^3#3AS=)'SL(VU@XJ!*U6GR22R:XR@8\H;!P6CRUJ+P,N-U-$'GBG6217; M9XIUD6-/71E7:EZ\29BDQMIHDH&29+-ZA?2E2C$[EJ6/3ZT:<)>#?F<9]]1U M8$WIRS:HGFHU8">-;5<)=A]Q#U@:ZBRG'8]#4,K7+)D WM$F%3T7:.F-P.:. MW:%7 _; @2Y2'J8:T*M"VYK+$!4+==9# D=G%-0%!H&!!VS>>N1PJP$[Z>?N M:L NPNVY"_-E!ZX/^#6R M>,>X2$!#!!*'YK5,4DAI8]#6M [O[8IYWT9DF[NB036W7^:]&?^&W^>? M_L#C;_CK9#S_,CLR+!OGM0-KZ[6[M @A%GHI=48T#'5J7K*Z$^ GQ[D===:3 M5;,U^/J&?/ICG>-\@O2ZCX9Z MB)%VQTPTP2/F):I4RXMLRJ 24Q!1*O IE1 EE]B\_]+]D#Y59G764L^M +=" M_7IR.CT*3/L8"H$VCGP25WLR\^JBI*RD$LY8W6>GXZV!/E%F==91P[[9*YUX M+Y+AGA7R='Z@(\H[R8T%]"Z2/4A'=B@^@I4Y2)532.Y&B=@678_7/NIA]M'D1IM.S9<%#V?/SRY_Y_W2IUFLX'(9 MX_S^.(RO)BMML::>+HW[6,]^KIQWH,G-3?!0=/Q0^,L+4[2"!,AK-PB1$T1R MT4 &](4\=U50/5G>WG%+?N"T[:+:7IJSD%,X2N1+?)Q/TC]_)X7,/GS\_2*_ MFV=I-#K(7$DZ59P!KX. :!BR&$*2KG5^Q:V AG?&]Z_SE>8NK136PPWJ*W*S M)V>("VCOOE91G0.SWHMLC0$C"BX'(OFH+?T- R]DYTC?^G9T(Y@_6=1(43WL M1V35ELGTI([56@AD=@Z+.ZMYT $DEY78]3K-Z0(I..:8E\;GUL6:&Z#\R9XF M2NKAXO,:J2\VQ%KLE$4 ;CC1.6L%,60+P6KGF.1EOAQ]&V4:28"E!]H+7@;H( ;,'XPPO4J!0I75Y MWE; AF?;0(J^6;C?7$NMB_M^P%J(X >VJR_GL_Q?I[-%;[)+R-FG;!4)A251 MR&N1$:*M>>R&@">6O!,W0A8;,D7N]_S'SI^A5--'[?C*EGYD=4XQ10[2A=H+ M5V<()C'0.4O'&6JEFA<)KZ!X[)1I)/^^'8!;Y7!I%MZ4"'=TPJ/5P$,D*H>< MP1LE:<=4T1.[A5&M!](U@/VG436(PGO8Q5KY+C&II)27)$;F:3/."IP."")J MCL)F87+K1BF].*W=)7@=PZ*#[0(&YDL4%V?6L_E\.HK$R@6@#_BU-L =?WY% M_V!^=D22BLI&#UFRVE!!$PNYD^#(,I(QJF!4Z^N19N /^=1I]/*M]#;=A]Y[ MV +^@://7ZI4R((/G_&WTRKW=V49BGUW.I_-P[@V<5^^Z+IP$QAFT$72BU[0 M@.?)D02+)= Z6MDZ.M4)X!,]BOI38@^&TDT1G+^6[^9?<%I?I./)[)1@_WA- M=2P!);T6.M>1M+75F-?!U[$!)E2'4C3G7$>(3Y1U?2JR857(K2_).>:5-^72 MY;QT5TRQR4@2E:O7X4+1<5$P@&%1RHRQR.;)A3M"'IZ7O5)BFTVO)WWV$-HD M"V*ZN#P+QU=LT]EU8V'U5NW*I=N1M,YE50)@KF9WR@57 Y,>>^#P];DO"?4 M/[?)7?4WG%^R"?B1\5YE%Q6(5&>)8'$0R'T"LF.$UMK2:]JZ!J@CQ"=J)?:I MR![*23>\FC]>17*9G,5D@&5?TU9TA%", R>S5S9(Z7-KGMT!Z8GRJJ6B-A:B MM@H,K@M.OK^^#1]IE5%+(K[ALH"20D!$=+5\WCGI$G?8N@UE9Y '3\VW M!O%:ZZ@?GV'KJ.--Z&2[\LAB';MN%+UK/$'DW$#FF(6-6F3=?@3FO>$^9J+U MI[<^\F#7BX6V;DN;MU.0LZF-_31Y)?1F (;B-:NS &3KQG@;H#PNJK20]\:@ M;?]]%=:;!OWT4;C]67WU3>BPPD/KDV *9R4F3;P,$E2V2)14$C"W9[[)'11_L'T M2=AMX<_/UG_ H@R6JU"$J$9QHD-."9O!)18@*V.*JBT#\,#:K]RVG$?2PZ$3 M26_V<#@0LO3@0:U'=K4L:0M\/75WN O;GCHU' H9MB+ICIK1W_1?E\XS6HW M?YU*)*LI./#(!6@7O2%SJFC9W$[=#.=0(M7WU=W*",,V@N^AFN_VQ@X,$^-U MHH=5AL!I'L"S4CL]!4:+]HGL@\:L.+!.'+WRHIWP^^_1<@XJZ2)M-A8XLEI- M0WBB5 A,6\*C:>MDK1.XUP)YW$RXA[ 'ZFQ@0V0RYTPLK+<96@N(T1E@RF3I MA94EM3XG#J*S0:_:WU70/>3>;FJV81)RVI4D<,=2[00OZ;B2'K1B,G#:G[AM MG=MX,!U1>N5 "X'WD N[N65/K'<4ANSCP@0M5AB$&"0'2^>63-ZB+ZU/@@/J MK330\[*CYW7>^1NC<9CKI$@7-%$:Z^0P1^3VR41K@LFN=?Y"$^"' MPK*!@^+#*WVCG]/H6K)>THV69>)AG)?I')]QG':[@-SB4W>Z:NR*NM6EXFR& M\V?I_YZ.9A=PSTEE%4]DDT@H!!D;-\@S>GI/BJ\= WPTM(EG1B\0[;K1.RF;]_%:"V2P2[@FNE[90':6[<%< MCMU8R2)D&$,H"9,BMZSV)\M,TQX7ZR +IE I[S)KW61R'8Y]74N9@ME%Q=->T\!"<( M;)!.)ADQB]:QD2%)<->MS$ _ R&@AZTD1*#2\X9M/YT8=:&[?@HJ5UY*^NGPEKSWPX1_&]Y=?PTCT#Q 7 MP; M8'0Y;K=19_NW\NYS=0?AWU3?#I)KN'O>A,.##T)H![YH#8I[!4%) 3X) ME8U)7,6M7,=]*W##F=A>?UT$UEAOOY*D3DY/+H!X.KH33X"F5MVE5(!.<01K MG8C>IL*W:[)QA^:N/72X(W$GL4]:R*SQ$?AK^'X%B%2\2!8C6(]T$!!X\$Q$ MR%IXA\&S9'T+Y5U]Z -4WKUEUH.O\;J*"]^.OF%^,Y[3ZFKSU,4Q/WM^]FOX MK\GTQ7&8+9.7K%,J2V_ 1!9K16R&J,GR$@Z94RA=,:V'\G6 ]_!MHKYUTL,] M[BU0+X%>N;;:!FY/ 8V.4/<3Z>A-]=M3K)G>AMVMUL)&#"DG7<"46$"56L-O M:9MU$>D%#3G[U/HJ\"!H=DTEC/VR'-/DT6 M!_T4%QURWD\G^30M&H,OQ'&4I"^I#BCU&1&4" F"B1D,V>#,6<.X;AVAW0[9 M_H-^;:[Z>M!#0[8LHI,W%_YB0GMR/B^N_S0-X]DR2?OUZ?QTBN<+^K&>#UBE M.QI_/E_3F_$W^O%D>G;$4RX,+8*V+M9:;@F!W/SZEHF"]'986@S!,T>Y;4\6+M+4%5PF.ZXRZ[TR, MCI ?.AOWH;F&@?5.+],&[.]Q.IKD(V:4#+2A0\XU43G12Q1RDB M>='!..G8 MG:E3[> \=%[M23$]1!ZV7<11<*%>+@H@7T4#^3)D-<;"01=DV25M0VD]%FQ; M; ^=3;WJHF&V>;>S/8RF_Q&.3_%=.0^S;]I834RW-M<4ZWV3K85:=;X81&X#E!@M MS\A,<>%>V\WC]N'N)\!5M=H>+)9UN]3;48BCX]'\[,4I[6[C^1$KP6<1/:3( M";97#**G+UF,0NK,@XQ]9XEO"?6A\V=(3:T2S+6*4KZ>3-_BYW#\$>?SX_/F M[=$S$:+(8%E,H(CLX)*O_0!KFV-K-7V[I]#D&CB/A2BM)+Y*!M^T(ND#TAYX MBA]/3T["]&Q2SK^.9Q_I,'Q7/N+TVRCA#L5)W1ZP4YW2#FMI5+*T')CU#]H' MSI^]O G6MX];0FO7Q7#E M@1<7B.>/G#T_^S%H[..R2F:VS)"P/-)6R1PP[0HH1\:X"]& T62,.Q6M:#Z7 MH0'LH4JE^N#8YG:$PVAQWV56-?GJ/#3_;GJ^3RSNN'V4Z&RTH+*JS1"L!R^3 MAQBT+\()36MLD+>V[MG[[_(WD.XG#770. /U',_LV3B?(YJ=WV5O ZIA0OA& M(,.GA^^NHU6%-Q+P8-I7')-%K8&5K$$%92&0-4CFO)9*IJ2\:)%%/K#6;\DI M'TCI7>3:NL3JWR>SKZ,Y6>I7C<6+A%Z,]-]B@!?/0'%EP&-F@":')(-*:LL MRRT/&39=N9$.)CT(L'7>Q?OIZ%NHD KA60NUB>AZ: 1W;G=>S+ZIHRO^,9I_N3! EZU@ZE"XV0SI?_E3^'YD M3*)%.P5&5AYJ+B'6"@PD"Y08F%W,K>-9]X"YAY$@ _B-?>NK[_X\&R-(Y^_< M)WI^'[&P-1_?3R3LKG4,' ?+P2#S-=TMAD0;%D9P@GEPW@81RL"\?ZB(-UT>+!QL%L9D&J M0H="HI.!H)-=Y[4 K9*HX[U\-%O-TGIB<;!.NK\K#M9%!X-%0K8!]83B8)UT MM%5(Y#X"'DS[TJ!)7$M@9.2 DK3+.L9B_5($SWV6:JN)C8>E]:YQL/9*[R+7 MUF[T/R:GXWQ1@AY#R4)X2%C[!^C:]=47#5:K: ,7)NCM\ABO?.BA.,N=9#QI M(*#6<:V/I]//HQ2.SZ%@R5QGR8&<-'+5!:]GC7,0%#H1FNK M[XC&^DF^E[8M_?SK9!:._SZ=G'Z=O1F?+V?]/UL.'/TX#_.%N[%#)&0(6#M% M4 :76Z/(RXU'/0_'R\;^B'/:4Y_EO)!".*Y R:$\G2)Y+YT6<^6]0L-*Q !% M&CK\N$/:2B72X>>+\C8GX5OGZ0RXO#:3T/N$NO0QM;8I\ZA >^]H=]-JF9(N ME#0!513!MHYW#[2TH2))A_K.K)_1?EB,VG?$:CC9+%P]%DLP=*R3^HH'A3E" MM$F!"(@B!QZ"WA\BBU28[@U'@@!AL-/+HD4'2C+PT7VN/:5\ RY)4F45OL?6F?E#,O:,G MV",F;A?-MXZS?L#/.%Y@^H:_8AXELA&?G\[HS]FL#N2\R*@B@U$9PR!S43L6 MN=H@1@G:;T2.@EO&PG9=+K9[WO!1G$%T-^E7\#TT%KLFED4GM5$9I844%J^+ M4XH78P0XB;XV4Z/E,U^ 1^G(H<@YFUXWK55(?YJ0FTW(EMKL(<_N%G@7,QFV M #B$E;<.W'[LN:8JW9XN.^BC;Y-K+5#O$:U4"82DPUR5&G=7H6;[*2\X;=.^ M^+)F7UW"IN^4YV>_8AC/%GG(G[Z$\<=PC,]B&.?) MN.[I%W=WWEI$G<"77$U$VH:=YYY.:$3FI;?Z9AE&"R[M#GS/1M7NA%BEV\#: M[-O NMT ^/O"7CQ>6!,GI+O9?&D]OOK^E5Y^/,(HLS)2D,-"1@&9HF0J!O)? M1$3IA;:!8^L0?#OTPY/SH<3;]\20UGDB'9;Q 6=(#_Y"ZWB)W_!X\K4JZ'(1 M)@5-+VQ"3[*4@A8A9 ;EE+'<LXQ;S5^IO.U30/P?Y+\]GN9H?FQT?V^9\;.0ELS3'_Y//GV"Z;\R[,_PC37 M"IUWX^.SNY-KKC'UZNO?W*G_)@N*!NELBR&N#\/L]IN]J1N2$M? M:3JMDY862?;/SRY_Y[SAT@+6#VQ$U_=$WBL!]+8O>2\0=\XPK),2TASSQ_DD M_;-&-&=0JO4.T/?1]?47;^>0,<4&A7A2Y[@F/6HFWB'1C0]8-)_?YM^L? MD8#]V[_\?U!+ P04 " !]@)Y8;**(]WC3 "D-P@ %0 &UD>&W/<.I(G^O]^"MR>B%UWA-"'#Y $>F=F0WZ=<5P? M2VOK]&S'B1L5(!XRITM%#5EE6_?37X!D/50/$@!!RG,GIGULB41F_JHRD4CD MXY__UX^')?@FJKHH5__RI_ OP9^ 6+&2%ZO[?_G3[W?O(?[3__K7__;?_OG_ M@O#_O/[\$;PMV>9!K-;@327H6G#PO5A_!>NO OQ[6?VC^$;![9*N95D]0/BO MS6MORL>GJKC_N@91$*'M8]O?5G\5&)&$1A)&G#.(4, @C2B%.8DQSN,D26)^ M=?_70*0I$S* 81[&$/$L@EC_02@7J124"?4/O>BR6/WCK_J/G-8"*/%6=?// M?_G3U_7Z\:^__/+]^_>__,BKY5_*ZOZ7* CB7[9/_ZE[_,?)\]_CYNF0$/)+ M\]O=HW5Q[D&U;/C+__GMXQ?V53Q06*SJ-5TQ3: N_EHW/_Q8,KIN4!_D"UQ\ M0O\+;A^#^D*0LAIF?X@,QHEMLO MU+L5G^N[NR,UFO7I.?;UM2C7=#G#UV)/YH#EI?[!1_6WCHQ>J,>8-G0ZTWW MJOBQ%BLN6FOY;&E0\'_YD_K;8E/#>TH?%U_6)?O']>-C)5C1F.[/>ENKOUQ_ M_O*;>,A%M5COOK\+L8*_?]F2:M:S7.Q/%F*M+ZAG)>IR4[%V8U-Q? M&_K@D '0<@!>*1[J/__S+WO.?4"SG!^5I5= P!\M!__/161*]HS64F_P974L M;;O%E-Q1_(M8KNOM3Z#^2:-&YO1^.?FHKZNM5+1B M ZAW3_S"2N7K/*[ALP] 5N6#H_CKTO%;TGX0BJT_@;+BHE(>[AD13[[-?Z-5 M07-E$)7Q>5L^T&*UB*(TX2'CD&4T@$AYI9"*D,*,\Q#E(A(RC&S4_Y3$Q/J^ M)0@T1?!'2_/R=]D4%S.U'B>MG1Y;"FJMM)=E\:2E9PC,JI:7!3S6PYXGW13O MFK%RLUK7URO^J5RM*W6V^RR84.=%1>5.;=6O%:/_6*@C8Y1@@2"21$!$"8.Y ME"E,@C3.LQQE08AME-&,[,0*NF4"[$E? >7!VZFH(8)F:NL?%SM5WD%"5QQL M.3C !_RAF0 -%QXUW$YL3UIO2'162V 'Q+%UL'S;SF((QA>W].EOM3I[Z6B3 MCJZ\+6JV+.M-)=2I0'Q8BX=ZX(MNN,ITWW!%''RKP0%YL*?Y2ML*>SVNVO[FMLVIZ."?+,4-U+I M2+51QW&UC1;+8EV(^NZYH::I3%.<*IAI&D.$$@GSC(10ICR0+!+$\?IH#:G@.G00FRP-I/T)J\VOVP$FV0'OY?1U1S0G/ M>U:U!N3DT&J_@K,3?;3\FTU5B=5Z06."8\8PE%&60Q0C BD*$*3JGR*F"+'HUC5ML;B,CZ"9"G*HQQ*AC-UN, 8YG$2P4PA)9"D0@J% MSRX8.1,^%V*L+X"/\:EAO-36!X5C\W@%.JI>SP7]@OD["ER@,[?WWR_N&8=_ MX 4W@_9AQ*2>V.J>-$L5*D;AY%U00 :W50OI%W](?RV]X6R\U: M\"]?:246("EXF-XB$OH-PQ M P%O>0"OBA7@Y7))JQJH7X-:,V49YQ_S49A9CYD MK,O+5/@E6;KST"K"G@& M]YZU)E2A?O=8UG2I/;<+SS6A'?U[)<:5/O^!3A+0B.+/:'G TY-9&\/)K(;/ M V3'IM''DG;&LZ[6B\_J.RRZ^S=!XDRD>08Y(APB(2-(\DS"D(M<4"SBB(8F MAO!HW+59E/*""%L%N_1K-T]#!WANY)M*\&+]GC+MQ3S]1G\4#YN' MUV55E=^+U?T;^JA^LWY:R)Q$+(P1Y#(B$*4RAWDJ4QBG@< DR1(LC33*A?C$ M:M>1!?F6+F =83MWP0I/,_]@*I3L5+<)S*K=N^4#;!FY EOD=KR -T/(66_I M+A!XVL.M2,^Z:;N K_A;\4TLRT=M^M^U!_9%3). MQ*&$)*%$GUH"2,,P@3(5DD5IS$,A;$Q++[6);9Z?"& M@IVM> ; 6'04?9G&(P$]&0)^FG-JOI&8A_KNME+S@&+2OESXJUH__MAU7GY MC?DHUG1YG=?KBK+U0F19E"4LAP+%$424)5#I?@JS/*(ICH,DP-0R/F%(>F*U MWS("7O&.E3^#8J7\B/HK4*]MEIJE]BC-OFH'KE:__JMU-,(49^/@PP3H6<<: M.N#>'@*W8P1TG( _MKQXO/>Q!\!?<,"4\-RQ $M SAS];5>P3X7X?<6KY=/] M%\$VE79:_K&^K0HFWGQ=W=^J;[^! 1E>96*#H8@+15U_P[<,*&^Z^H=8@X8+ M\*8Q$V86P@"3?HO@%PX["V"(1!,V9%YN.,RE=R/UZZ?],[?T2?_L^CNM>//'G:*JO)=; M]=WY1!^V";DI"[,@S!GDH400I1&#.,<$\C@,XC")4X&(5<+(!$Q.?3VL"0-- MV3'/>9(/QLP#>6FX+>]=+9"VST&9$ I?V2I3L#AO7LN$()]DP$Q)R]YG:A;] M51%?OZ5K\9X6U=_H"1E9N.=7* SL1)^+)5K?B>J!Z#I.U1I7(+'S$?P M(+2=$FJ"S_+2)\DY'1#+TY9]BE[7J/O9$?5FOU M@1?Y4ES7M5C7[WZPY48W ?FU+/GW8KE-$[:K'C1FVQFAW+H*05K(9QR:G L@Q-/L-ISPAH.0&O M=KR +3.7\\OL8Y,N(/@*3UK1GC="Z0++29#2:1''L,=:.1HMJ::0^VNY5"_7 M[_YS4ZR?=@'[)(W2*$("1,=[>,D(]O$B3[ S"R"-QCL+,%%!"9HQ6(DHK?4B3Y:,Z=.&(A]FCIA\I)] M0.ZWU6.ACSEWQ8/@[\M*1PG_1I?OE_3>-"C7L\3$ZOK;I]L/AV?DA@,@RPH< M!CL'(E=6D Q'ZSRA8:>U-D" /S0OGFK;#:1UBN;UK3M;1,] N,.HGLGC;AOP M06%\$ZNONYTDRE@49B*">1I+B$0H(*8AA0SC &5QS/(DMMEZ+]"96(L/&S'4 M34.PS4IM/%0'22WC )> ,MMR/8AOI[:'DK<4)]AE!Z3RM+]>HC+KSCH@ZO&> M.O3XN'Y*M_1)5YAOZW@18@*S+(I;^X1R7.?HR,B M+]+7Z+R@E_H877C:\8+L; F@3D;N:D=_K*^J>SG8]8 MPS-)"0/=I:^RC-NHT:B'R\99J\8K\]?EC5A7KRKJ+ZCO:V7!9ZP=NJ9!\M MNF :K#)A7D%+''34P99\\Y75/ B^:0(2'WWWP[00VVF?,5E_MGW'0MC#? M? -/;[3DEL[>H-!>@_G]XKGY?.>7G,_MZQ7IF>?7_^2X(U0I:N4"?1;_N2DJ MW9"Y_":JIWT*JL/)JG_%&0]<7'$"5N4:5"TO8,N,V[%K "F[TY@_D$8.?89OVQF$!_[C7E%1GF<3M?DF?A-< M;>DK\7I3JS_K^O=5L=YV#5.'012F*9241A#EN8 XBQ"D>4I33CE*8J/VB18T M)[<7>R; E@LS^V #7+]QF @.6\MP!@FPY0!H%H:O )T!XMT@R29@-#=0SXC[ M!&R\[720N#6<^D5M&U$0M_,?_\EFJ5F,HX-L6\OH\JKKSN"@7>T6JE#;#-QPW>GUKM6.B$P\\W1)0%/+XP %S71!-L0=: M_L !@^#P>& 47IO@XS&S);.!;F=VIL;;V@QYP!]X9.S/LW6I= MK)_^O=#C]+Z)U4:\?OJ-_H>R,\J8*.I5_?KILW@L*WV[^$7<-_:E&3"TR 4A M:10%,(YU#W@6!S#7LS%$G@S3],B/V*@V6BLO$\Z<^?HA4:@C8;P M\FRT\4N[%J4K$_VAKC>"OU5'UM5]ZZ*UN?C:.ZL*IB=R-)/'=35(,ZWC?5E) M4:QUP/I*CB4VK9JVI%E$* M7NW8::MFKL!*K)N!0\V0H=HRV6K\AV%H0.>$V-)\-L5'+6^@9:X[3EYUY3E7 M8,]A6R6?[&.QL]M;YJ] P_Y5\\GL M)&C^UDO9(M^B#Y5^@^M35CLKN24*-%5P(T%'UR7? MI$]^BR033SBX99:XXV&75V(@9&\R2=_[\V60&$CQ+&W$Y'G7>8''HXYW!;L\ MC6E I,R\ M0C_2VYFI<^/$)RE7'A;.V_R^BX1FGM8W)/#I;+[!-YS28)L@HQ[*J^NQ]'+_ M7JR_;J.-GS;:2'060YN/>A&$>9BC)(!!1A*(.$]@CJ( 8B%)E@<4)]@HE\2- M_,3N1TM0!X]J3:WY2TO=*@'4%E,#-V52I.RLPO8V0_,"MLP SVN[ZIQIN(X2'V7DNJ[B.E= "F7\ MMZ?1-V6]KC\I:=L=X9-8+Z(X2E@01#"(J51^5\P@#@,,61;01#E?(N'2;L+ M ,6)3?*6/I - \7J_@JL=O1MQPX,H9BE:98A MB8B,%RMQKT_Y=W.#2%H03\B/P!(PS8IO%,T\6J_?++LMK!GHL+O :R@K\[JC MW3_1PF&P@Z&@WD8\#-&;>=B#H?BG8Q],7W1,JNZ2X6^5B=;W1$W6MN +'HJ< M8BIT%V7EXHI PIQAY?$R%HLTH%F06Y4[7* S\=U(1Z6]B5Z6=:W'J#8Y2B[Z^GFHIJ7RR6MZN:7S4\M[ZPO@6EF"SQ 9&,20\-2J]_QB^NA> M>F2FZP"D9GO@%$!9*N\HC$;DI)H)[#WQ=(#L"V67FH%Q.874\/UQ'94_"R:* M;WI!Y8=O.P?S+&5QG >0I$B=G@75/= SY3TG-$Y11.(TM!H_TD=L8G.Q:S=< M[6@W29UN'9;/HI5F.6*2I#"6 8.(9JCM+8$S)K.4(XR$53J7-[3LSQHSH&5F M0WUA8&=QS=K,WCX[*I8U2.&ZV_OE!KZ5YY1LK,1 M'@"R=[ L)/;E7)F0G->QL@#AQ*FR>=<^9M&UE+RNJM=/'U:\/2P8!B[.O3NQ MCF_;DQY.K&\*V!3]XEO!-Z9Y>Q=E'PYDC!7;3FD-)/9W+!H2SRG <7;!V:(< M?>(M-]=14?+QIHMUM,<@BH@0'7'G; J4ZP"$#2!E/8<*) MD%D2Q)@GB\>V?&1-J[79'GR1GLVW\YBJQ1>UI;XM/\O%?;'2$5:0TV7C?CH7 MHUT&,@Q2@I.4PS335\T291"+-(,Y9AEA"0^$B#L@WZWX[#!N:3J#*%9\8@3- M'!.R##+[@F[J[$C6R/ MH[L* AQF+$Y@3*(0H@0K14ZY3O&3&48X$PFQBON>DIC8/=$$=<9>2](V/?<$ M#S/='">EG5(^%W""\727A?&6?GM"8.:TVTL"GJ;;7GS2:X%],P:T^=W-8],B MZ=T/4;&B%GQ!J4AYFDF8Y9':7C,10"(Y@3S)DH31E)#$KEN)+0<3Z^N63I-E MV]1OERT#7HKE>X U#!=,"9=E[*"G&+[AYZHK@.]8 CN>)B]\'X9CVD+W'OH_ M0V'[,#R&A>P&"]G9)2Z*[;'KR]-#7BX7/$1I$B0AS+)4.0 A09"0F$$28BX3 M+DB44A-[<[+R3&&)EIB9\3B5OM\HC)+)+>8P((ZQ E]DO2>>H-YI=5+]9:^* MIRO-HF(7!=BJSN4'[$-RG\K5K2@_B?+ZVWV3>,'6&[IB^.TG$Z=H#FQSK]: BCX2B>1WCLE,LO,E:A/4.9G:)\ M0VO/%O S%/(P]F?ZBN-!MUS=ZQ$].N/[/2VJ9A]=Q$&8J*U.AP"##"*:8DA# MAF&(,RQCC$E$[+,%]UKK$NK;Y/L[?3O.1 I M)6D@4 1I'"*(.,X@H4(!$?KSVK_3PKUK'=//_0Z.;' M1X43S5B/UT_MU<";):WK??ON(&%9%L@(IDSY-DA0#BE#&,I8!@E!0J#8*AW3 MB8N)U;(=:W+R%6[*>EIV!L:<>,3;,*XX-8J6L<6#/L7GBJ(:IIJ1=1@28I!7[*/3\=RZVX.&E>A7;P]33G=AA,5^= MA18YC;%(0@IY&$<0X2"'.0YBY34F*\J3UL'3=DOR/M%Y0F!%^X/=/FB\N*3]M'/-U]UFAN_%:+ZM2HWC^]7 MUH-Q>Y:8V!7H* --&C2TK\#[LERORK7A]C\$P7!@TY/T=KK6)_@$DVT-9'0* M8O:M.UL TT"XP^"ER>,.:EA^$4NA^U7_UJ3_B$_TP3@Q^.S+4ZM>^?!(5T]@ M2QETI(&F;:%[9^4VT+JQ(EOJFY.T=CK6)Y&;=IU=<3Z]ZA/HF4;U/N@Z"HP+ M6:R*M?A8?!/\PVJM/LY"G5&:]KUU.V!#>Z^:UMOR@1:K18+2*.X[@4K,$]CRUC;B5Y]:-JVE.=YHQ\$?+ MFF45C\L'8.;33@RKG6$X0/2C/T0=QI4Y8^)MBID]!S,/-W.&Z'3FF?M2KN;L M.8E?];2#=S^Z>,RO9Y8G=K4NS:JS;),SPX24YRQDF"4QC(M76H3Y!@E(" M: M0A1F7.T06/TS21#-49A29EDM:$9XXDWZXX?KUQ\^?KC[\.X+N/[T%GRYNWGS M?__;S<>W[SY_^>__A*,P^Y_@W?_^_SOJJ[7'B MX2!&POJ_ NPG^U(7@T9@]%P7FKWOV";NP"3=2)TZJB?"ZX/Y;24>BLV#,B B ME%)(&"1)DYS$($FX@"BB+& L(A%/K'K%#5&>/ZK&O.D+QN+0MW3J'CYG"CY3:3K]W K<="OPW M+>F1QM> A3,4YAVN<%G$D\$*/8^ZC!RF3[)8?2SIZOJ^$DT#/%T+IG^P'3%+ MLX0HO801D3K.3P.(TS2"F,4\RN*,AV9%!F;D)M;.EC[0],". ] 4'7XTKJTT M!*Y?5_W#8:>V T@X#2H>_BY9C"OV"8WCT.*Q$%G.+C:5N'^"\> J,\XQ-I7H M^31CX[=&-&JZ$/3,)%%.1@*3.$ET1R8!\R -H< \"' 8LI01NYG&?D)W3C.- M#TG_C^9.:_WDT'EI3!CS)0*7+9TK<+U>5T6^63>E2NL2W-+)IAO/%K+\68*4 M]F')R0*1%]HIM4T4S[<'DWF6I+F^_":Z_6&,0H@))S"(0I$)]4,D[+JS6[,P M]1GD4N,U]Q:G#C!;F(C)P+,S'0U1^%H=U_A1TYA]>VA=*'GXW"U]:GY\_9U6 M_&K;H.UJUZ&M!@KR5J;)>[49@#9ML[8^!GZ&;FT& !FV:S-9RAVERG;ND"3=B?81@6SI,!Z"$TJZ(/"WRL MT 9OV!=T*>5GFW7Q3;RA:W%?5D_7/PJC3B<77Y[>16AI@BW1OYJ7<9V7ME_] MO AJ>1(XD5%Y_XJBIS+)7FF<2KC.KSA;"5>O0(V)?L MI@01PB,$PRP,(:(QASA,)"2,))#K B\4BA32 M7)FZ5(08)P1%F3IPVU@Y([)3&[4]$V#/!=BR86FRS( TM%#>X;$T2/W(>.[Y MX":U+U-C1G1>RV(%Q(DAL7O;_K#AT#-BODX1=@TA[-I S-+\P7^O!U\='EZD MK\- -P=_/1QNU5EBM:Z[FV)*19!'(H:2Z-G)A'.8IZ&$>19BD25!@)BTJBX\ M7'UB%>AH-7&>?ZS*[_!K^=VRB.P9%F9[EK.$=NJQ%]YB MI'-BG=0-G7W(?FMXK[@L5^*S8.4W4>E1BS:[Q/FW?ZH-XX* PWO'>-GL]*2C M![8$KPY'BOK;6_K%LC\^ M7G->Z&0FND1!]$U7B"Y+'=ZQ;A(]N-#$^KJG#Q0#K[[]&>QY,#]L#L,Q?.[T MBH2=SO:!,$';:&-)G4ZEPZO/=D U%O3PK&K^DFO/2*9'R8NWHOWOAY5N6+ 1 M_* AQ(*E81;D&,-,8 Z13!#,8YE"$G*)(I[&2%@-C#$A.K6FMP2!^*'3=6UO M#8U0,]N8?6-AI^M;ZN#5EOZ?=>+Q%IV/!K,H'!I"FDOLK1VD 6F;B^T?9.57IE\=58Y3V3>=BJ]@I[T M4.E_>OS\VM_H>E,U6O]9/+9U)?6-O*V*%2L>Z?+#ZN^"5G??RT7.XR -B#I5 M$RP@8F$",6&Q4E^DI[YQR>+0=;RM*1,3*[?ZOJ3NHVZ-D313\JGQL3,!QX-R M.XZ>KH FK<>U33,PUU;R">;I&K/P8N-V;4'JF\9KO9;#B5^7K?V^XM7RZ?Z+ M8!TY/>3=]*1_:8&)[8,B*11-G1:W)VMQM+\HM\&1WH?(EKN^)@G.RNQUAOV@ M:&YG]XNKSG=F'Q+LV5E]\&$[1>.B6+Q;K96)_O) E\O7F[I8B;I>"!$$.>)AS"3$G,8QRR:*0,A;F1MOXA?6GCHDW%$%#$FQIFFG@)4#Z=<^#F)9! M;RL)C15M0(X>%5-OMBJF_K)7L4OKS:)< \)LU6KH,>]=!P\;'KYK8T-ZMWRO M/NL%9[F,<$(@YXDZ_:81@42F&,9Q++.,*A\Z\]6'L(>-Z1UH[*WE8!^:9B[T M]!C9Z79O6T)=OO_8CGX[9*YSL#5CL[0J- !F^N:%?4S\+.T,#8"R:'!HLIJ] M _!1?1.6MU_+E?BT:=)ZDRR2*" IY"P,( H)AC0,!$RYQ(CCF,?2*,7YW.(3 MVY:&'&CH@9:@^;Y_@L/PIC]&.MNCM;%@5MO])0F<]OJ3Q6;;Z"^)<;C+7WS& MX[V6/O"H,S$3Q3>=>;2(HD!DB(>0$XPA"E &:<8Y)#SCB(5,TB18K,2]GJUP M-_)ZZXBVT7>1M-_%$PYL;KD:NJ#:$?9PT74,XXB++A=4/%]TM0!]'@;(ST77 M!8FGO.@Z)OGR%UT70#"ZZ+KTKGT0:YL ?B/?595.AME?KW\T[)5MNLQT7^PM M=9UWJN@K^UENZN53VUCJN"'582+'1Y\-M&UQ<(H'&1&8+31D(^YAE,CJ/Y(R4U=*;/!)S@J*Y/H%\W;^<(S'O_4J/D"?W)WW/ M3GY%^UGH*V&N&7BOK %=ZH/C@L5QRC@-8"A3JC0V%DIW<:;[VV=I2)6'RJV* M6<+=OU5J/]50H"'NDF>,>(MCXM*TWPZD5NAGM1F?^6^#P[/^N-<2]X M(VZ/^]=ULY2?1;VN"ATW;3IC_KXJE(?_Y??M< \L4:2#[3)-E.,BU'D=!S*! M(:A/;.$7'SE;U0V-FB+P);'LRV9+M9GPTA,$K1;K^\P0^ MC9&8GLQ&/ZU9;8*1V,<*;_;2Z$8";S?BKOQ;42Z[ 6+_5CZ(-_H 7SU]I-\M MTD5LUYU8C8^K] '?-,WB=RSI[5,S!3JN@&+K:BCE8CR:P\&**8&TO$F;!,,Q M71",P?#1'V&8V$MU3C"&H:>G@OD:;AZ#=E0^K)0-:^:SZ/8-7?:U9'F0"*%@ DE64(EX@+E-L[")4(3&YAF(.:>[E73^L,Q3_TB5F;>@P\$ M["R#H_#6#L.09)Y\A8MD9G43AH0]]A &GW=5W/V(\D42IR+#>D1XG F(TA!! MG%$*4\RRD(>4IYE58_K#Q2=7T#TI6W4\0,!4!=WDLE4[ Y$)>!,U.]L3@X-LMK MB>Y&8V_I@H:PS]YY@])YZZ1WF=+,??4&13[MLC?\BG.6BG*,=VT97M.E7OG+ M5R%TXY5][??^BK!^_:3^\5C6=/EK56X>:[5$&R]O!G/KIK$;P6\>1=48GH.A MSR1*PS"7&8P85H8B11G,8X1A&*5I$C$I0FG55V5&WB?>RUM)P$Z4*] ) QII MFJY%!TT1#@324YVV(H%6)MVP;WN#<2@6V,LU8KSWG%\8,P/YDWX-[ SNS_D- M<$DXFONS\)>W-!OGF\]3*'>YDYW5QTD#H($R0!& M*8XA0C*"E! $91:'/"6"Y8%1T9,!K3EB.[;U =9X]5MOSR@XQ'CQCGTT)GU^HEK\P$=4_]K[A^YT9[%"HV'9VJ;Q"[D%(/Y=%/=?UX)? M?U.^W'U7>O.V6&YT9D SJ_9FLZ[7ZORCG+\][061:2YR$< PIKE3ITU+>B:DXB^]D,09H23$*B#@94 MG1/4Y@QSABE$21;G84QQ'EHUN_?/XL3FX'"L_2'+A\TCMTP#_9T !VPW;0@Z MQG60LCWN6\Z[\?^AFGD0+_M1V=FO"3ZE20=R38>MK^$^_AF<=R+09 "?C!&: MCI)]Q=G-^JO0L7+9C92V*"H[\^K$IK6AJ!5.EM5#DU_4D;:O#3LG=[^5\R"R MG8ERE]:JBJM')J="K7/KS5:+U2/,8;E5WV.NJ:CJ^RSJ==>Y4-^3+P**,Y"(0HK83LJ-VU22-^TPKO"B,M_2_4PHSI^E=%/$TG>[RH_;;UUW%KZOJH%OX_?WU M-UHL+;:QGB6FOHVXOZ^: @_0$#1O+S@D^?!&YDEH.T6[JVB3U:LHJQ]WF<*' M+?5/\?"ZTQD([;3C]:T[V\YG(-SA#FCRN*_6H1]6W]1'75;M++Q(XDSF,,Q9 M!!'' I)03DJ9(>ND9>D#4Z!L]NN)J2_!I;(O00[A,M\NQTOML"GI M>\IFH&=$G*P+Z"&M%V[_>4;LX;Z?YUZRWVP_K.I"/:E,QVVY+)A:[+8JV:=R M?79ZM/'?EH!NMI8N /3=7VG%@GZG?V(9<$YW;4]S5_*%:%3FS2 M"OU>B/K-IJITQ0 *:8 "%,(\3C%$) L@EB2#*668(DSCE,?F>KKH2/B"%Z0A/,P3[]=$[+I;ZV4'RG#30M*] 1]TG M&#;IT1Y!<>O>V^ /][0ZNU M'E_[63R6U7HA,L8P9CF,A0P@RE"NS!O.8"AXE)*$&A,;M2U5L",+ M6KKFP] N@=-ON3R);&>O[*6UFI V((_3H+1+:\XV+VU J,.Q:4./^F@X]^[' M6NVYFZ+^NJV2J!YRKD MMMJVO@>/E7@H-@] ^1G_1I]DL0)K/3AA65++OH_#F)J= _Q -*8O'9!EU?:E M>TX=;']\ -^;OOJTD?WJ>F2?I&O=.7HOV+NN1_S^#G9]+[K9BS?TL5C399,2 MP8NUCI]_6#'M _#7F_6G.>K8G$]%T;!3_N2D>FR^_,A9T.V#PL2U,L;,9QKB:F8XIT+*S M(!T'X) %L.4!Y)MU<^WR))0-47SX,QRVDGNR'\9D9S4CMF <6Q/K]]V,RJ^T M6-4?RUJIUE][GB"7B&6B& 8WJSVUEC\ M8T-K_J*;A6V'V2_/#K-GRHM1!CU<4XC@@$$4DAC0A1/C0^=B@LZG:B[XOJV^*0KM.^ZJ"0( MI2(3RGU(*8(9 ,M-^CZ+;*7Y# M&'34KD!7OK5M<.%_8)^AH)Y4?HC:K-IN*/JQHIN^YACUK& M?K<-9/Q:*1]$]_Q+*$,(,APE$ 5)K*?U)##, DFCG"(<6:EX/[FI(S8=\2;K MQN0+WFK9E8+/>#?=7E3>_+JFOQOKK_ MJ-/P/Q8T+Y;%^FF!69)EJ0BA"+B$B,3J.(#4EI^''$=!FB*1V(WD=>=E8CO1 M<*9/Q)MZ?SZHBB8)I4FW++=L@6532K+L&.LK'O'^>9C9F)E0MC- #5.PE%"Q MU1XQP)8Q'3_?LM;<.>V8 PUW8,>>QR'"XS'R-6)X!"?S#B >#]G)>&(/2XX) MB7P\>Y0Z:!O?%?^>'8:^H%F"99K%4/E$D;:..:01"R"*$\03*9. 6.7]>^!I M8BNI,YO *_%C._9&N:;J?Y40X*%J&L MI0RS/(5QI#/]<);I2FL&62B)R"D3ZO=6]0&V'$QL-'?\M/DT'4=@RY)E18$U MO&:V<%+0["S?EBS8T[T"ST%\4PE>K$%SV_>'9@J\;[GR6<7@BHBO2@=K^O-6 M0[C"6IA;XNJJ:@ASCQBN';TT=DC[M/?)7FV8KSP3LU_UQLMDI M]1FQO-4=79;#L4O*LZ5F;(QR3H3GO5#./N&V4:M#UXU\5Z^+![H6]2(6*6-) M&D*.< I1D(60YH1#AIGZ_T"*.#$J)SJ__,1*HV,*N@9V2\YN3SU"PFS#=)?/ M3G&.1;MJ&QD\@3^Z_T[2Q?.\=)YVMJ/%9]VVS@MVO"==>,I^P[D5Y35;;^AR M^:0SY73IK47'K_-O3WUC\NX&;*DVV9E-I;DZ+K1%>+;]*R\@,+PSC1?>\H9D ME-Q6FU6_:$Z;UH4E9]N\^D4ZW,0&GG2]TA12Z,34+VME"-\6WPHN5ERW(6^N M3_3#/;%V" M2NB/L5@*_8^B'83]:MFD!M)=%SOUJVT_#RW%UW*I/H/:T $=\6&87IY.";'M MA6K'"VB8 3MNFJO5-J?B\!.89%2(,Q[>KEZM&9CY.M85H-,K6N>5W"S:QW)U MKRO0=/JG[B?0S=C(4!83/UL1B/WG:WI7Z"0[_VC97.3N7[*.3R'8/YT,W@:YOZ+SM\Y!':Z MV3O/J+A9;.TQ?5BI8TW3@N3W%6U3"01_6]3-1=V"QEPF,D]@F%G MZIHV'WO:5^" .G@[A(JUT3*6U),=&J8WJVDQ%O_86IB_Z!Q>?:0%[]*&MBWC MF.24YRF"812G$*5Y /,D0!!%+,Q9&O(,6S7V/$MEZMN.EN9V;I!U2<@Y7(R# MF>.DM8Y7-H+N9@=Y:Y-G))"_@.,9&G/'%"^+>29LV/.P>V3PKHMC_$;7G4/P M>=N*J;Z1MU6Q8L4C77Y8Z8R^.YVANY !0H'$"!*F.WFQ%$,J.89YE@9!%&59 MSJT&DKNQ,;$ZJR],9A] =$#3/, X+4;C I =3T]739(P:*C[C4.Z2^\Q3NG MQ.QQ3'>@SL4Y1ZSF&-31UR(?M+/,WRJ*JWMU_BA*WAQ!ZG. M-'A43[F/3'#%W# :,SV2EF&7!KN6(]"R!%J>KMH@2GT%=D"W#V\Y:XI>/=:W MCL3&5Q3%D8MYPR7CH#J)BXQ5U8L4"81#AF%&4L%1)DZ$A$] M296(* R3E.046U7,]Y.;.FWD@+@.5I[TS;$L6.B'SLP6^0/$SN0<8W'2)<=C MN8&1B+YJ"_J)S5M(8"3X2=6 V5NNE[I?OHKE4L=5Z>IID48YERQ,H(Q)K)N9 MZCA''D-.>2B(C (2&34S/;_\/!>[#470D;2]VGV&ANGEKJN,3M>[9N(Y7/"> MDV+$%>^SY6:^Y#TGRNDU[]FG'.:7?"Q6XD:VA5KO*6MJMG593\65QKX7^EPB MWKW^"640MY[ZSQ2>BT^UR/=B$P22335T4!)$E H*!1)E*.>)PG-C?%_>0F MOB9N.A2#_8WHR+/2 '1F9R5_@-A9X_YVHE= $9^E"\6!D-,WF-#$?I;>$0>" M6[2%.'S+=GK@CV;O;/BPS+LSP-+,"OA%R,X2> #'7\?!$WFG[CJX)_AS=!X\ M <"X^^#IFXX]A<7WKJ&#CM=6Y4K]E34M .JVAKG]B1$ MH!MKQ3!@49P'4D2Y72VZ+0,3&P_=U6*U7CYM[S+VO($ORCAS6O%V+/W?Q6XT MO66#8EO$S8S*E#C:F1C%R2%LSWF9IT3>%0Q?;8YMR<_;]]@1G)-&R*[KV)?J M?Q:U.B$W:[\5NDZH6#4'YK?JAZ8%^WUK3&Y4=J3!,]I $S>OU^^%H=],^$3 MSAPX"F]5M&\BF5/I?N_"LQ7PFXAW6,9O]+R;O_"ABX&^%>U_/ZR>I]$M4HI2 MS#&&@8R0\@_T=+DH(S!+!>4$RSQ6QPG[>5!#=(V^OWYF4CIGI YB9[;3>X'" M296WE,&K+>T_Z_[ 1^FK_K9Q4TD];=N#Y&;=IDV%/]Z6C=^;J-[D4]G.H5NM M%W&:8*+G%"4L5+8 $64+:)Y#F282LRA($4YLS@H6M"?>T2_4H%R!U8X#S_4H M![ &C%#&XP3&::".8&D0PSP*N/I;',6B M;Z&=*38J_KD"GX:_COX+@4[EGZLDZ(#RSU4<= J)=9G0F25\N7!-FY1]+_?] M](0%%W&.(Q9!%O)<3Z1DD,@,P812*5@<1GEH-63"@O;4%KSI N0\*<(&1%>W MS@LT7CR\%JR#T0\&L'GP]@8!F,SQNTSYA7W 04B&W<'A)1P"-)NE"(,\"77_ MTS8J^GY)[XUC,^=?GSHLH_L$:+(P?-;[UBJLVR>]04AFO."6T9A^F<$?FKRG MOK\#PKD%9"ZL.5\LIE^H9V&8@4<=,O=T[=#'DJYV^2(K_F_T218K_SRZUP MZ,VKLUIPOGPZ%SF?Y=$Y+>!V='I#ZZ_Z?_H:_AM=BF8,@CJS%7K8R9<0SC,IV)(Q;-;=VS@O66 M]-"8+2NH#$(2?@!PN*F<6G:+P((?#-S"")>P\!0R&!:M-T#0\_I\X8!A&9X= M_@T>M[_-^++^QVW%;JJ[NNH&3:F5?Q/KKR7?IV4;7FV8K#6Q]>GZ[2@/4R@( MP-V7SV#/"FAY,;_L, )G^.;#-RYV1LD$$O"'U]QT6Z&=KD>,",QV5V(C[N'% MB=5[CI&\9I)2\S5H^Q.U]1X+3.(\3IB 2"#=L9[&D 0R@3E/6)0@(;/0:O+4 M!3H3:_R;@SE15UT#LS:+BKNW-+L$&441#<)80I'KYI7*/8.Y^D["+ Q8E!.> MI7'D$-8<#YQSP/(U73;CC,]$)_W#)P1B,9,QE%&>*?@""G&F@,0RR_.,I0CQ MP#H&Z0L\Z^CB%KIGH43_H!D&#,?#8!D*;/7N2ZMWV\9W+56/X;U^L7P%[BY0 MF3+7JJSKVZJ4Q7K! I;%.$$P9#F'2)DXB$F:0)&F82J" M+,Y08-,BX6!MJSW!OA]"0PD\-J3LE/!0?C/%U*H MPY5G5:(S(ATKSKE''-LQZB#1-?O/35$7VFU[4S;U@>JHK/Y6%[Q).RM7V[2S MIVUC]C3-" ]" I,@E!!%NM$4RF+EAR4B#) .]EJUP';D8V+'K(6XV0NU6]&U M_=VEH3Y= :?J 5?0S;1Y!BCM-+]A"!QP= 7V/(%G3%WMDR.7,Z^^60WW^?IW0_V5:=-?J(/8D$)I2EF% J,L6X_&4.* ME&,@0Y3R5' N-01Z[9O\5(Q YJ!N\I86.[[?:"9[>V>H+#3R.-1 M%UM4]A,1)AG);2#K!(,MCBF]V/2*"R+WC:BX](KC' JQ5+^]_U6LU.Z\O%[Q M:_Y0K J]MAZ@MZV"3UB&."<"9C$)(,($0Y(1";,D( F*9"QSJPY#9F0GWVD; M)J[ ?GFFNUGOU55M02E@6!PS2)-;!NDA"FB8Z>23 F&4!BB(YZ5@M MS<7$AD5]P_#$4[4:+.W=B4D0&N=H',W4TL1?<*36H>PO-5&KX>'G'JAU"-/H M>5K/%G.S1<\FV=P\MG?337D3SD@F<"QA*+6]89A S 6&/),"8Q&&,HEL[,U% M2A/;E)O-NM;-#G6(LIV*U?; MZR1OPR4F3'Q(KZ=P3B:4=42'2Z+L[85@Z)Y ML@>7Z:"=P+0@(4!BB%#"?JQ$'U%3Q&ZH\PPBG79;+) MJ+L'ZYGW+J.ACF/B@V/K+0!RNR>P%GOD+<"@Q*/C^\\DFBAZW])XT=C\\[GT M Y'W,4/LFQ3.:\:JC>"?14[7HE[H03*)Q!E,E%)"%#,!*:OS)=T?9[79XG6%QZQT_>Z6B]^HS^*A\U#YPE&$6(HT=?^8:R3!Y7S MG"=QI, 1L: H"[/8:.L]67EB7>]HF>G#J=C]&CY*&#O][LAX='$O,M^W7ZJ7 M#O9*]:_]/GFZWBQZ<5&,K59_HPLTX2O0D#8O MJ;DL=;]">!/83CL.9>W.7'['.!C)Y50?,=>T&-7Y4\K!ZQH#EBL]?>I&WM$?MZ)Z3>N"-1G5BY#C)$$A@Q'68T"Y M#"&.!89!S&08QL ARS4)3TL#+I?IP:EWET)8W M6%8WN'\**&=9JJ?P(*I]A"3(()$I4F=F3.,L(U(*O/@FJKS\J3Z'0X[^?_)) MF(7&9D'7SHJW+(%7FJD_ VVCP#.D]XPUM_'J=X]E39G"<\T<0?U[)<25 MKFP&C1QM'8S7/K'CL/37-=:1C[E[R(Z#ZTQ'V9$+VA^0WC7SKZ\Y5U_HNOO/ MQV(EP@5-"$H3D4*9IQ%$A%!(F20PD$3]'24RDD8!A%XJ$^\U+5W04;S:_@5H MVN!F97&:NHS3\-'*B_1V-LA9<(=I\3V"C1@:?V[5F6?']PAV.D*^[V''*S6U M+B^6&YWLT^4%%Z+6&<%ORP=:K!8H#?3-MR[JR0A$020@"71Q-<(RP2R2E%N5 M5 \1G#K*?T >[.E?-5GEX(^6!]M;MR$,S;P,G\A87A., \7^8LY04E]W=$/D MYKVN,Q3^Y.;.]#T/+9QTKLV=0E]L._^R'*<2AS (I$[%XQ'$"@+,J[5TP4AK?H]':_QFC[[;=S: SA M,W-K_(-B9^QV>.PYF&>,L9W@GGP=0Z*S>CQV0!S[/99O.QZ#ELORNVY]\[ZL MWI:;?"TWRXYBK8>*%]]T_'Y;>)\H#P@'(5-.4(S4P2@-(>&(PQ01PJ)0"(1< MIJ1:,6&D,*,[['Y4Q\R_ KIE#,BR KQC#=".-\O3DA74"M8\ICR +*$::AI" M&H8$!AFED4RR@&%LWY[*/]*CFU;MFE7E;0^F*4'%F>(8!1R*A.F*7*+VO33/ M81X1(6)."678MFG5Q)!:M[)ZUR; SX"FX>E^*GPLC_H=2;"G>06NG^GWFTKP M8@UTB'B*IALN./@*!%C1GCX'.Q$K=SD3MVG6Y M#Y*]!!+.24"2*(1!FBN02"9A+B6&J2 QCL,T#W/A<$(8@]7X@=[30F9F 3U\ M6^QL7ROU <4)?*(!H3P9NTM49C5S Z(>&[BAQ]U,V]]H56A/Z+/2A&8 @10) MBK*$P@0U@4"D3ID\(I"G+* 917&46-FT8P(3&[,M.:#I64UFN(B(F3:.D=-. M#:U$M%; 2W)XTKR3Y6=5N4O"'>O:Q>?&)*E^6:O5'@X[6V'=(C1G$J8QPQ"% M2!T-*,80RXC*E,9Q3JV"[A?H3*QR7?[=CJQ)RRLKF,P4T(/P=GKH(K=CCN!% MJ;QF )Y2>8'\OHNBGL_>N_RXJZI^4XN5U=-G^OTWM;2R \LV"?"SJ$7U3=2+ M",F8)H&$+"$11#+@ZD"/*,P"FD0YR;.86>V0PR0G5F!%%SQL"=NJ["!YH7P$-Q8[\+@UXRX)/M385UYN&#Q*<6=E- 3C5>^,WW7OCAE%^5ZQU M1PW&$JS;=Z>$QQ %20QS'B0P(EP&.!$HDLBV+^YV\:F#=9J&_OJ&T:O\S]MD MMB?[IK@[,/I5>:R(EH$X2^FBS&J$^YNL=F[X!Z+<:X#[LDS]C6/']I^ MU7<5;VZDU1GUMBK9-2\?UX*_7])[T]K'P84F]V@;^DUT5]^<;;EH0KZ:%<$W M>A!1QY%Y?>0P0OTJYAT)8G(990D8UI.[2A-K/-G MFC!ITJ"A/;+WU!XM,V?8"P9VJNTH_NA&5">B3=2,:D_G11M2G8@[U)3J] 77 M$T3+*XOZ^:.V6@&"E7HMS40/,C5G4[CU;(.!TW'"B,!L)PH;<0\/%5;OCW*-ODAHP*1B&+(I> 0I2R'.$$"1E$2JR-%EN/E.)W64KX0EA82AA0 )UGD^I@(0&"%)!.&%9%")AE:[:0VN>>VE%&NQIC[R< M/H^9J1_O!0E;E]T1!,>;ZE[QO-Y6GZ?T C?6O2*?O[7N?\7>CWZO)%#>U&?! MRF^B>GJ[$7=E-Z_F1KY;R5)].9I+\H>UJ3MML>3$>MQQ K:L +X18%UNYRCI M.Z #?JYTP?+&=.ZL+7C#_O5$N-EIO6?(K)QK!P"D$^O?%BJZ8.N3O:V4.:L5I&%&18"B3-(,H MSJD>1)5"%J(P"+'@:6 U'68$+Q.;GBUG!S73.BM$E9)9# M\$9\'&;>QTP@V]FI$?A.TJ_5(UB^QNR-X&3>V7OC(3L9R.=A23?K^(Y6N@"Y MOA55T_#OK6XV)/C.X9=<))(C#!'.4H@HC2!)6 #35*0A)B3-L&77T@&*-BKH MV)NTH0=68@V*KJ'FLFFHJ3N1JG\_E*NV(>E?+6=G#4")4!+*2"<]%8#3;!#R"8V?HMX2;9JH-Z2NPQ6J*PZBA MH+Z&DPU0FW=$F9GH)X/*#%]S;7FJCKP?N')="UFP)M3_:=-4^^8)3J,,1S . M(J+L:2H@UC,C.$&)D)ADD33*IAZD-+'F=QU =:#E.770DK=M?7H)KWY%]XJ" MI8J[ N#0 G5 N!%M4"^M/',KU $!3]NA#KTPLAKBDU@OLCA%21#'D&+.(4*! MVK,3/2BX(^58W:#%%WF8AG$B(<.Z6 OGNE,]9S#D M*8]DGG"4X<6Z7-/EQ.+O2,PJOFF,VTTHVZ#VKF!#T9F@*N. >]_U%WKIEZFT M.!#J8DW%X3-V)D-/D?JL/J2V9I:R-,Y8F,,@C_1LAR2$-.4)C"B)$$81CG*C MRL9GJTX=[-'] >NULI]+\)N@.C3?E?69%Q$_1Z%?9YQELXRQN(EE-2;M1(P1 M(]+V:\TV'NV$__=-U+U7=2U.LNGJN[?NY2J0[;?ZI-/8ZSIJ4P0;%N M28;51D/4MIO1D 9)BB6VW&?-",^@7NJT5W3FW288C+)Q8PON#R9M='LS&KN?(%W M; :]K>L:6VSL,&5Z',1;NJ;[AKE!C%/"E0^585V[+2 A*8(LB#,>QHPGR'C^ M;!^A>2*+![2!)CZ8.:88K]XIR'% M@>?ML]3N=.2JN5SX6B[5*Y_7*XN$M/-O3ZQ[#5%P0!5\%NM-M;).,KL@>[_6 M^1';3M]<);:;B=LKE-M W/-+SC<-MU>D9Z-P^Y]TW03?-)?+7]9J0VT6KV\V MZWI-F][?BRC.&$,)A2S"#**,!5#MA R*#&>28*$KN.VVPCYR\VR(+0>@8>&J M_<;6X( +VXVQ%T#3[=$7+$Z;I#,B#INEB: CMLS>Y6?>.$U$/=T^C=YR*)GD M_W%7WHI25V6]7]E729Y_?6*-550W];H).]^5X/;=S;.BOROPOBS7JW)M,6G^ M$@S#&ZH'!.R4TU3X*0H=^V5UJVV\L.9\Y8S]0CVK8!QXU"T>]X;67]\OR^^? M%*_JK_KRK-;3> YS$J^UW]STZ3U3+Y0&-)""QC"EA*K3:<0A3:((BB"6B,4) M)=BJM\)8AB;6?L46U'P!NN/!,OMM-.)FP;@Y<;2S(9HSH%G3V=$-@'"]@;3#0/WK)P9"DLO4WJ9 MG!V;PM+A5QS&(1_WHWI3MIWF&M_UKJ*K6HJJ$OS]9JTHWM(G[>?>EF*(>V=E3T5[ MOAG;$Z/W;#;WU+3K\NK="%JQ8+[*$I#(F$<1! MDBA?.T20"!' #'$:QDF:BB2WJU <)FJCXDY%B@=Q^P;#; ML;:TP:ZH[M4A,!U]CUT7S87UY(<;$)S5'3<'X-@KMWC3_BJ@R^9N4LT-P_\' MKTSLW7:4# -]Q^(,A_$=);%3M8Z(MUSY"XP[Q>$/UYDM]GZ&^<-X^[E?.\;8 MRX>'HKDTT:7^;YH\LGNQ8N?#NRQ+J4@R"G,4,H@$22'A00QE$F$ADHAQ9)4R M;T5]8D4ZX*6)]#[CQD?\R0YJPTCZ5 !:ALT]8FJ/V[$VEO7E1%25O+_4_"T6C8&H_;QZ[_DXKWO067]"< M9F$L*:1AUESRA9 F:0"%R#C.(II+;)1].HZ-J0/ABA\]95TW\*EV/(!:,P%> M%5VOB_JR,^H3<3/3-#V.=C:J(01:AD#+$6A9VJ;P7($]6VUR#V@8NP(-:Q[; M'HV"QE?'(SA!CI&@.;$OF2E#\9^39X '#N5]H&+ M4S&+@;2C:EKZUI^]M,5 V',5+B:OC9B8MNW7OCL])W&<"IS&D/,D@XBC&&(D M&>0A(EF:T4]VBTP20Q@EZ1?(Y" M.Z$Q_QBT2V*>'8%V\6%';>P:B.Y;A38^]+;XD0E"J20<)I+KCL9!!BD-*-1I M:6%,\Q!CJYDC_>0FUL\M<74@WU*_ O>])T47S QUUAL2ELJ[!>'S 0BYD&4E MP/5R67YOHA8ZY>9-)7BQ!A\55Q.,,3&3WY>F]Q.;5^6-!#_1?;.W7/WQ:\[5 M=Z9NMOJ;ZK8JOQ5*F(4DC,@DD% 0[8AG*88DP#FD,4TRR7B2YI;5<><)S>.! M=[0/?,PM?5N_^P)!"V:/N%^_4E1YXWCY& MI4MVKMEZ0Y?+IUM:\+_59^IFKTH\$FL=8U,8Z*X MX*^??J_UD-.N0\UA<$JS*)(QXE"&0011F#.8\XC (.>2L3 /8V9UE6?/ MPM262!>42>45UT!_MJ#<LN< L]F)8EKP[.R0X@4TV&VY ?D3>*49 L7J MSV#'TV%1WA1A!'=,/)T\'!B8]33B#M#Q"67$2HZA"^5?<=V,O_@FO@BVJ9K% MVSZ#@K]7HFKSN6F3Y6_D<1__C]L!\HLT"S*.6 AY3!%$"0IA+BF'H0BIP"(, MXMC*BOEB;.IPR &;8,\GV#+:6KP#5IOI:"?S*L ?FF'0<&R98.7M$S0,N;S MYV(9G)GS([$/V7C&SU=PQQ=;\X:!/(-Y$C#RO?Z8B;HZAMB2;-H>*D+[OH>* MXFM:%ZPAN\@Y)R(G 0P8"2$B.(,TC77 .0J2, LSA(UR,1SI3WZPW=+?>I** M 0!!KAEHTL)XN5S2JFZF(C4I8I898K9XFUG."5&T,Y#=U-Y7'YO149TUW&%Z MV'%5&\.&H]8D^A[G:XV%UQ&_YM1?8.RO-33G1P';+^/81%ITE6I-$PCQIJQW M=VQZO$>>B(BD5)UI999 E,<"TE"&ZH@;AQF3F EN=0/63VYB^[,E#N2VX\45 M8#;=4@U!BRB+!,H%%(A(/1(F@'DJF((O"?,\11$E?+$2][K$G@?/F(GHJVEU/[%Y6U(;"7[2 M<-KL+3=#J18MULHQ_*:/]6OUA2CRI6AS$@Y[^G<]_S^)'^N[[V+Y3?RF#/C7 M>B'")"08*QL:D$B=LF4,"487120A-H9T'#L3&UKUW4KL+,)(=,TL MQGR8V5F4EB_8, ;VG(&&M:MF%$B3XW_(Y!7XNZ 5N%EY].W\X./)'(UD9E9S MY0>X8W/F:57W0LO+;8.S@.>!,F$"J[,J8D&N+SYB&$81RI (8YP9)4:8$)O^ MLK69O=OVQFW+DD!YD&[O7*TTHF^P;URL;U%/V@5?^>T7;".@Q]+'E^T<;"/T MN<)&SUV#=UZ3S9@.7?[PMM3M2Q8XE(&@(H0LB/3TH#" )$\22#E5!PT:A9), M-SUHS\?49\9GXVZ:.AOP1TO9,MSOBK/A:6AZ]"R/22[ 33OXYU3LEYCW<\#% MSSOFYQ2J4=-]SBSG9JR. _5-'&R7*1 @)#'A"*8DX1!%20!S(71J1I22*(D0 M2JA==Z->>C;*X]38J(W@KH1N]]=&?I=-Y%>'QUGGN&BN+',P^D&D24CC(,DA M"6,!$<\E)$DF(*8XYBP3:9!8M6/U!J&#]7X1 ,T,MC=8[,SRZ77I57=1,$4" MBI&0GHQP/ZU93:V1V,<&U>PEAUZM^@I!K_'OQ?KKFXTZZ3R(JAT#?R.[#G3Z MOK/6^>Z9E)A#B>(,JG,<@P0%,20I3?.8DI!(H_[S5E0GM@ M29THL.V3@6)[N&LY -\5"V#+PQ78X[3M;OEQ*IPLFHY.@9=;%U%?N-EU M!+65O[?%I_%B\_7LM)7O61-.ZY?MJPUN1?F;T"N:%A+L7IC8K-V^NS'/]]]+ MT6^BG 6P,T%ZU,T?+1%/V?8G3#LETN]7F2U'_H3QP_3WTU^.#N7>TNJF:B>N M_XTN-V+K:RQ$% >$T0QF@F"(*$&0QDD, QF%)$FHB"5SC.A>HCEK8/>15N"; MINXES<@$4>L(KP^$24*^0Q+[C_Q>I/A2 > A"'KB MP(.O>JV#V0^,V26R+P(D&-7V(N,(023S!.*$!I"&>8;B.! \1(NU+MDQ,QKF MI*ULQXX!\T.#6 .VKWW9M(4;SS'-)#9F9&!:I?]0*KK M8=1\E;CT #!M:YTB?^^ M C5(N4@H8S#0E\XHH,H["1("DR2CG*F(>&)790M&_KT:#D5Q!I" M,W,R!3!VQN0L)@?-=AH^@-=Z75?A?36V-"4[;RM+2S!.FE?:ON^:OIRO/ZSJ M==6$=)H>\1'CA#&IK -CREC0+(-8(@(#+"G!09)C9G5_<4IBZBOG)L%T1W&H MR[PI+F868)RT=KIN*:A#^NPE6;RES)X0F#E-]I* IZFQ%Y^FD@E;=T M1W]<@>OUNBKRS;KQDM:E#NIX[5MFCLAL%5\_6Y'7)1-L\:;#)>_>W[JIBOMB M19=-)LY&&?L5?UX8H6@VI1%')P2DS(D,,(,BUDF](<\@S9+_C[HW79(;1]8% M7X5F=^Q,E5GB#A=P._TKM?65C:J4)F6?MCOU(PRKQ)[(B&PR0J4\3S\ EUBY MP!$@L\;.4BH5"7?_&.YP ([/?90**FB08N*'1O5\;M19<.G5:>AU*M8]00XW MG8XMM-^:WW1R]$W&P]3R2-NOY6 @0]9Y<^ ..*)>%'^[L^L9?NRP8VQG&(V> M;]\N9;F#;V>(G)V(NQOUIN81]]^^[=Z794W?];2SZ!UQ/L#,4\%I;P4EN*SO MQGI*_'8CMOO*.R>5>])H6G6:N$!E/+0[ P06L5UB8=MUHM_66YM.7(SZ&CTG M^@T;:#DQ\+!EU;240F_:BR8'52N%+S6I?<_"R!=8,)E'**!1IANP"T19*!%G M/*6YQ#C"( 82<]$SN_E!$6]'?GI*IB'MK06&9HO+>9"!^?L1E':YJ;3PM!IU MEQDU2ZR+]K;I@U CN%Q)PLUW52=L+GC9HF$P(%<5Q/ 1+%::#VK,S:XJ-@_E MEHFJ:DO+:;)L?1,L3U'(8J;@X$D 6#[VRYB[IJX1JD_Z6[& M-<< *@8+N-MMA?G\M9G3U7C&]@(63K?;;;<: GQFV"IGW*#1IHCP^..F(P)3P0F*(V$1)@'&!S/?3?:$ULRW'&T33SX1DPLM_ [8=GH8(<(_N=U^.,2WVE MMXPEHBQ$]>:A;'<:ZS+E-C&,8AY& :<(YYH)3S",2)SG2*'/ M4AZDS,>@"P8CLN:.&;5D[XUWD-U4T ,CQ0A6AM'!#0+ B#!@O,,+/0#[7'G\ MB*1EO7S:Y"O/-GCEULS@-[)K"90_RT_;S;='43[5<>/\T"SF+,]IE"(J.==D MEPSE,A&(QIH3BB=Q$EA6Z9HI,+??[Y^>2/G27/4L-JQX)FOO@;P\U:M)W3)N M]UU/A.63]VE+-H=TV#:#,$0=FDJXQ](^ISCJHO]-:X-J_!;,+&!P.$\Q#,6_ M4JX! VO/A6$:H>K;R8%?L:#)$29R *$XX@B%9HR%+.0!2DEDFD. M$_/2PY.Q05$&7F/8]*A:'^7!PLG@\\EF13-?E$9+@8(HIABSP _,BE+=J31S$J!K+2NRUA/6 M#]',^,^U7,#6N1OH#4X6%@<4%A1J];P3_>Z\,_G>B8IWWE')BZ<>7@=_P$G' MXM_![F!DF>\!.U-Q"MWH$8P;2"XR2 M6/=5"&6FLKI0-\O)0BZQ+T0,HAWN$S+S_''E8U:G0KWHF*5[M]I\8XAW?C8T M9H^K#EM](I;MEC5BY%7GJ[%G[9SQ<_F-;%JV<>WJVW7!ZW^YW_ ']?6[F>:S M;&M+R;KFI:AW1G0%ZGI;[D>%O:/&COM#SXVGH[#G7+U%0^9YIC_U?U($194S0? MO=VP'M]PN)ECY6#/]O_2%+;J7VMMS OR34$:#XDSX0.+F^ MJ8S%"OF!1I^6]4-?A;N^W8V;1:_9.+]: [Y/L]0EFD4OSCB\+?-:5V2F[\4X MN0QS=D-N*S]NU(]85+NV?=+E678H&,61CQ(_#-4*)90H2TB*0HEBXO&#M&Z_3KQ+:C9 MW2$V--_HIO#46,O?!S:TKO?6K^F[=IM #Z6F8]F]/*C?@KY._/[?^^)9_WCZ M-A02G(1(QD&"(LD8EYS1) *1U4"$SQQ&.U7JC82#'N.-7V\' MU&R'9BZ88%&UT^+.J_4X!VK^;14;$!QMF8!$+[H=8@/*Y5:'U1@6:YGU^OU/ MP?;Z(N-;E45_V^H*1Q@-_]@8=YNOO\BGMO:UF/-WB=]6/%9-I>0E +2#V)& M$<6$(LPP1D2MFI"D))'Z=)8G@46;^TG!1C_BFSO=']30:>[;8E?\MTJIO"_B MQW;]H^;'.;_T!IO[I\&-1'J/]<'7%ZKA7GN,X+#=.;C!@*8]QI8[_VA57"4 M $W;:)7^C R[6/(S;=IIZF/P]"W,QH=#VC=$?6\FOGX70B]Z[CFORVH::K5F MU5.]>0%UPZWW9599Y$<4A[E*FF(UPQ/U)TJQ+J F42HXSF5H0>@[N]XS1Y/S MMM'5G7?0R3M5ZH0 M]UR!);0+?65S=*/O^"W@X7!&3Z;)3?Q8B Z)3B>7^M7 M8$E>[%/T4RTO)]ZRQIG5U)S5 WG1HVG-&"N5F),K/GU[P9D?YCX/?!2(/$68 M)C&B,5?S2!RG@J6AG_B@ZDE+/>;>1VMTZ Z6@"62MMB:A>L%$ /NOK4*>:U& M]9Y[A^")4O/OOM\(C:N2;4LMEJWJO@VJJ\+O&X>S;\!S'+5K5[[*I'HS,8LWME@,S M.;C15HUYAFURV)RG1\CB#7J&#>UKTC/RM.-S^T^ R%(B.$9CRG<>3DN/XHO]YD_%3]4?O"H_K[024-S6VL2%G&SGT0?R+QKW'^?@V!\;%[SZN6 M]."DW*B53M5U$#[,4,3/@S3%(0K32,WB:90@0A*)N"01YCS+<@RZ<#DD:.9@ MT(D]MK.VGLH'H3)S>1< P/S$8:ZXNX?$+,O4/6'L%2_WU/.6G+G' M7N!U _ 5)\I7R%@9C=MV]%76M[? MO/_#_Y^^'WC/I/1^:.%_\\+8O_/]^O^\2N-8>62_^[XMB_\6_&]>@-.[.,SN MXCSQBJK2*U\]ZV]/6EJ0G?>;@OG[?_R/(/'_%@5WGJX-K1\+<'(7ANE=$N4C M;[\3K*ZM.!L@ E+Z7GXVL]!QR\> A8SV.]2B[KQ:V)WWL<;$(:?O@#FN&'TO MAU^6SW? N"LVWZ'GW,SC[XKU?B?XY]UW49YL=1[FK"S@J;4ZASST<2@) 5&,.]%JYB#EA*G =C'CYK.91;_%/P8L)B[U'98EB9@I@+K1 MZ?\_=!!3P=;MX-:'R?JLYZ'<2E%5]>GV!R&JM_M2-X!>R82F N<1RJA>&OI! MAH@?<,29"*4?X="'7<@:%S=ST/PDOBG'TVY9B=UNW13;,?/FO(:8&9\%.T(" M?.1;G^Z>"O:T9!6^&ME.#W4-;'1W=CLF;.DC6@/#>TYB3=ZRS+6:&I3-MT^" M5.)+\>W[[K/\1R4:WJ^G;;EK(U%;.+&*HXCF,8\0I2E%. X3E$5^@+(DXR(, M>>9'H)L$4 5F#@:Z )>1ZKNWUNIXPJI:;T/VM\USH5>5%^0&II:>ZNHUL"K5=!] 1^+)^'MMMYOOS]\/-D+ M45-KK1;@*J[^6DP_G(70,V-/;L'"GCM!D+> M0VKL2Y^+*%>+B"!C"*>I;OJ2,DWRD.$P#F7(,:2_PMGH(&>W[;# &ED>J25; MT.]"EPFV%@*]M18SQQ*@3W^7!+NOE.#WF=5+J>LH?=>DV7JY_\]B]_WMOMIM MGT3Y1R"2K.M*.JL_]";K&M-ML(X\T422!2I@((P MS75G=A:@-(S3/*>YBB6A!4_#J% C%[F9H^'8A^UXA7[CR4:Q9D, %E3&@32+ M([?C8A4Z6K'=^OZZ19V[4&%DH:/H,"YKT8!@9/9E##![R9:BY8?8[,4'I6E? MJ &>T!F.-M\ON%7 T\A[_3/A+$=L0,.=L6*825V8&P,$Q35#!NQU*W*PCQM> M_"CXGJSAI&!7[\Z]L;1>>RD4M^\[;0.DY)T S/ !R!@7PN*=& MX52PUTCV?FEE_^KP:,?(2%<'.>/"ECVV,3+\ZI#&["V8JW-1K-YO=FI%^:%8 MB[+E GQ9,4*E$%(B/]6^G6D&.9PE=<\EJOX;2.38S MU=V%XPEY2U\W-C._Y[*QX8M6')[^K_[M708!\$UYSAGQ3^Z)!-*97^2Z @+FO&PR@1)>C1MK27/8/NB3)Y:A9 M%Q27X\_:I32'VO.&H5!*RN+ YXA)IA8& _4V*N(DI#R($-9$F"$U5);_8EBW? X8IF(_22-3=?=0T)F M=JU6K-?(];1@3TGVM&CS-?@@0M,+<1=VPSS.RF30HGS*)JN5^>"@BRW/I\PZ M7:-//FO1UJ_>4_M:[.IF<1Q'K.4$92&3"W.!4\0P;%:8B:"!30. M0I\:W7L:E;+$EC:@]]P@&.,NY\Q$FZUJ+=+[K%>#M=#IHR2 V8 >>R[,MVNJ M9PD#K(?>E'FC3?,&7UZN2]Z4_F=M\28?AJ]@=39.GHP.PTX>GWN_3J_+E!CS MI6=GQO1*T\("X+[0E/*@->.%NE9+Q&Z,Q5:$%TJ?+@ O_Y/E>J_M#_E9#K!" MO'EIB&C>KDE5'2^F1-Q72\!8):V,$[T?&Z$\R1(D!,XD)XF?PUH06>HQL_NT MLG7_QL,9Z:=M5?U:TZ-T7$A:2^#2TA)UPS7H_%@"%ZLG36%'"6;H2P=JK=II MIX#'/[?-7WJ_B=WW+9_E2I$C!%VME2VU6'91?1M45ZOO&X>SBX)O](U(M:FUKM>*9$HBZ1:)W"1$BQP%$0!)+B=#S]SS-+"O"_&Z_ !",PB MC;UAL !RL,EATCMN@R,7OAA\4<_L-^S2X0:>LEAG=VW/]$G0;V2W+XO=R[U4 MOV"]CO^@/NV*I0GS$[76SE,2(IP%#&4Y)8@%,LCBG ;*P8P7W)/B9O:S1[6" M$$0+!*Q#IS$R6(<[M1SFB,<.A%KXG=>)O_-J))I=,:V"4TP BW2GV-BMUF_' M"+9P-S9Y= 4_/?'UBXDSX4Q+%#?ALYH]+8<>KF0?IOM9W'^QJ'L5HAJ MF+>D^OY0;K4XM0K]1R7XQ\V!5.>>*;EU&Z45#9(\%#Q%$<]4EILF 2*$A2@1 M498(*B7C&83_PEPT*..%DV-HAZC9M.1Z^V?E/;<*Z5V;7_9*)Z_8_.H=+Q60 M@UZPE2@ :K-5ZCP PJ*\QDXKX3V3ZJ";#IR]/0CWS8[W13J&L2KPLZJ2PB(<6< MH"# %.$@"A'5]_Y]0007,J0Q 6ULN51NYN7ZV1[T@6.DTD= M;6EX\("AS.G'@VW^+_U)[$\$&CW;?E-7@-^-?J,E#@%<(NGX9,"):J]R7. 2 MU*$S!*Y1W^U+-"PV-9MW0XXNH=F7!=FTB6].T?=B64A1:LVJ5 MQ)%*\R5%/LLDPH0SE$="I95"_7N$TS@2TH*:Y0:5EME#."K1M/OI^ODP?=]@ M+?C_)1N-1CK../\6AK%W9F@M*X4UAHU67J-62^9ZZ-]S@GCS=*V=BKQ'_5R6 M%]\,DK-:9'M-%BY$UTB]+TM]3>&+8-L?HGQI"NL-"Z;ZWITY M9U0BMQNQW5?KE\8EE(.%C*,[79W^6#*2*MRK=X! M%ZO=&C/GM)!K]+D;2#VN.WQWG(>)C(CT]>)/Z L(,O(1S>(,)83$'&#B1/ /OHYF-+MD[AH4MS]XQ:7@O M>\?T6Y8\COMR4T_ ]QO^H?A93\5ML8XO4I_3-$8R2A*$(UU7D:8"R3B6N4@H MBWS0+;UA43/[\D%PW;8;\V%>?6YY)W6&HE)M77U57SKD*@=G^FSSFU@E M$<=I'E,D@RQ%.!$Q(AF72& 1^BS(:!" B$/,1<_LXIUHKP27* +@,W/T>4"! M.;[6P3LJH4N>6X"T'G=-"SGN'55Q%PK@YCL*#0#!BX8*.""7H<-B!.OSZ.9" M@KZ.T'%J%IN]6LFW9U#;377_@Q3K>CMSVW83UCMIW[=K):=Z0ZJ"K7PF\UR' M&)'Y <)4I(CZ/%/?3+(TS4B*)8;QZCC2#.)Q5NP[^D2V:.]TK.L['37]##MH MVQUE*W4]TNFKNYNPDU[DK0;J9OL:'\Z"+.?__Q_.+*]XA<\!2SJN[[,=>+5;H(]Z>O>G'^GTSENKZYU7 M:^NT7,4E?.YJ69QHM72ABTLH>ZI@G YOV6KN\>G;_]K^J5M;O=U47/V[59>Y MP5%F#HNU<-TZ3:%VYRD5FO9INEEPH4 P/>8T0&/ZG,$=$+" -(F!]\<\O>,F M;;5O&S<\]+(=XR9-O&H6-_V&W:)%Q8I2][IX)YI_?MR\?WI>;U^$^"+6>GET MLFFZ2B..PR@B*$BERI'B1*#<#R0*>2Z9H'X0!$8L23;"Y_;X=O.>G9RIP?(9 M$))F2%]TNGAZ9I]SI5O%:7TW,/=XF'#02.L@N0Z$53"!M0+O,$ MJS%N)##\+)OV.@59/VRK0OO8H>D-%2+@)&,HEY1IOG.!"%7+L9"'.,"Y\(D M[:Z:")V[OO5 "-B45#9*>)T6)LUQ[/$TBS"N48)%%@< V5,I&ECLFF!Q3.3K MT"X:@#!(QFCR[@TEFNUJY/V_]\7N9:6W8%A*4\18J%*/3&)$$_VO4F*0395[L6,?,664._>[J3\G_6IZE07O8>;&@>AU&2!$@2F2",18:H"J4HDRS- M2!(D?D96SW4QF?IXY6X)A"[%&>/TAJQU4>F=1\6W8K.I=YBDUPQW,U*8$,(I MR36]($8XDA21)(J1()SC6.*$Y%F+U/L-7PZG3A@<);'A#O$QG31NL1@V133C MWWGWNUU9T/VNV_1Z(&[+:H9MBY@^8+57@-[ZU#[G[R5T&RD^+\INTP3 MM:#TA8\RH0OL*>$ZB@4HD'[J)QD5@9_;<9A-B9X[%S2^76/)C&V.L:&3SX(< M,#]T!]H-?&.F]CNG&)L4_$JL8J: #!.)&8]@VVCUK%J^K32341#2.(]1(A*A MB?,9RC!.4,9I1&069D%NU%MK5,K,8>3+UWM87.B'PBP$W&P@S-NOKKRXK[0; MM+ 8A)*3**81"C, MLURS,N2(ACS5]^I\&7.>4N;#"EV,Y,Y>QG*0J+N;?U69N:B\-]X%X0G,CK&QV% C,9"X:&$ P7 8*V,N6%?7#B<%OY%_; MLJ88U1S+[[9/I-BL9"*S5'"!>)9J;M!,K1S\($&4!CZ6%*=Q3$%E]C#Y,\_V M4]?P:Y5:"EZME/='HQ9P[0 %W2S,S @E+."X1Q%>X6^'A:NR?Z#T9>\"V$%S M=4' 9+$"6%Y:A*$ M>D>?>T$A?A25/FM1,^Y#62A':&X= T-)/S#C@>)FC$_>/N8B+CIK3.>#X0]9%*1,%;&^$W):B>4YE':)Z_W-7$B6CV)#R MY:/2I?I=&:?>5(:NZZ;=3=W_2J0AY8P1Q,,H09AF%&72CU%&PD $A +J#-M M#S>8G!;FS(VINSJ>V31=NNQG;LA[JH1F%VE!_:SO=)WR1#4S>9MUB"QA:1+Z M*$]\%>%#&2-"L(^2(!$1@OLHF5H^S'HP,LQW%L8L<9D['1"W99;5MB_)6L1:5O M71257HYT#"<1B2G/XP!%*I%':'6,6)2 +N2T1S%B"< M\!S1+$@0B?($!SF)0@$J?KE1G]F#1"=5+SN/8H$1XD;,#6/("AR Y2K8'6C-LN&,S?0704\1\/>V'WL[Z5:0[[_ MV;:.;.-MVQ)(7X@23+*<,XJR1 K-?Z?2GR /513,(^Q3G/IF!WE0P3,'N<_[ M7;4CF[I=YG-9;%CQ3-:6C;BF(#18QLT$#"QF73;CJA6Y\PZJ= F2=U1F)L0L MFY@Y1,Y-.[-;$+1O;&8(@W&+LZGQ7J?9F:&5@VW/3-^W2SD?2KU/OWMY4+^/ MW?V&O^_X^=Z\/*H1[W\6U2K(!2:9BJHJB^1J92EU7VA!$:-"9)PD0D582%II M('/FJ-II<.?5.M3\? 'U@-8"&&"IEG"Z!@CBP#;E#L\GA4[3($" M3O< 9CI*Z4PD+IJV 2"X3,T@K\+" Q?%ZKW*YW8O[Y]$^4T%'A6&_MQ]UZ3& M9/.RBAGE--2-E),L0BHF4T0)#1"+94*R+,_BS(AM>$+.S&&@D>QUHKU&MM<* M-W/]*:3&W=VA_3 7MS3=V,$-#1MAXE C-/ZL_G!TXZEQ%W%=0^,Z=S5]W): MM%E_-7=IQ=MM53?(TUP;(0^S$"628(1)*%$>I!G*XS2B62:X##FD3F% SLPU M!IU43S97A3??H/RB_>B8S<(.;+8XL-(M'+0XKY97US.[) @=-;Y''_,@BM9)B7,7^+3RO5H! M[UP#R[L7C6= "RZ;)K)NAL%F/#;1P.RBS<_#^HG]YU4XOY;*>IK+RN*(YGC MG"/)0]WOB6!$0QHB%F1I& HL"&;&Y]?&8N08]9@ (<7<\"F-W!M2/@8&?68/M'3ZS- M1UONO!ILX=EI-?QM5U33UTQC7[;K]8=MJ1FO5S[E81"F 4HRQA F&48Y3AD* M$YD)&HL\$<%M;-.C\F?/Z7I9E;^>$40V2GE_:+6\5B_@@A"*NND>TFQ80K>3 MG,/H@*/:"(S9:*K'I;\R4[41---DU6;#P)M7:(H _OZG8'N=17Z6:D6K)'S8 M@/M73 XTM:GIAZ)B9-U-6[E>([B[_U>+-B]Y&<9HW).=60[E4:\4^/K,]!_EL5.;*5< MA2'/LE#OV<9YBG"<1BBG$45)G,LP#ABAJ?F=;0.!,SOIB08*I^);L5$_VD+I M(CS>:@+:%9@&T&CCQ"DLT"V3(R*' IE._)W7*> 8%= NB5-T;/=';D,)NC%B M;/+$ELCT.$MNAAA;=;$-8OX>?%WQ\..Y9C8&KR.N7IPY=#V0%^]'I6=8N2V? M#C_ ];;:E^+.JW4Q7SE:8I01&\X:9Y>MXWX?:S?$]*W3FD4A^V M[FSYYJ5_@/I&!PD9C1),$8GTJB"+*W[(KRY_+R 2G@L] MEOR^+#]N^&.Q6PO31.C\K9DC82W#/,VYL&@ZQ[$W!A9.'DM2U]0J8>JO15<' MPS5M]UZM2 G M.8KS7"*<,-V4)&8HD2(,1):*B)J3'YP,/+.3U)( *_93DPWV*RP-@3E(+62Z MT\BX,8!M!DNC[+83QC\0;+.@1_'138'3YY=;_/=H>;;([_OOEDW-Z@F25)HY MY=@R>I5E(O$3F:)$8+V1Z7-$<^*C6*2QP%3X00JJ4>\7,[-CUT(1U5)O:(@] M@)!9\GZ[W; XT)A<"_0>R$M]V' V:6H24U)]]][_U-HX+!0=M]154[%^(M'KG[>:T22&G. YI(E4BPA.$\S1" M6::",E7! 1,:12$!!8V\M0'RD)8 "XAL3,UV\R%.;69S:Z[]JPSCC M$#A'DHYK+[5^<3%4(N=3_2;<'H^,?"$=3-671+S2=^X^%)\^[[[ M+/]1-=E^T_7GGK']TWZMMR!.>V:L.([]-!02"9ZKU$#(0.7P0H'(@BC@+ MR M'L$:.]NJ OF56O5Z;A7SUO4EI%*KAK82[:N6^P?P5>K M=.=]Z?#[1]7N!MQU[M-Z+CKUFJGQM)M6V\"JZ=_ZVWCP>^) MO"UV+_>E(&^W7*Q\DB91H@*]P#'77&0$95(0M9IA8<)E1"@Q.K>Y''CN/09] MKU'+\K0P\_L?9[:/!X];+ )N)I@9 [K7T:>YU56.LX$6N[W1I_[IA8W>_V[+ M%7S/N?HZU<.VVI'U_U,\US\.G! _]8E 6<9RA"D.$(E)@F(94QH)/\N9$7OX MN)B9W:2ERVTEWWF-;$\)!_K-"%#37N3&?)A/V5INP10\9M@-1,&]PR[,$SQF MVC5-\.C3,.?4W97;C?;/Y5=1_BA80T,?^5F"TS1',@LDPEPS>.-8H#C(,\G" MB/CF/LN:'C>.^PBS4= M'S/JM._XZ'-V:][+$MCCQ17ARS0EN5!^EF&$,S]#-$L)(B3Q,T9)E@8"MJ@= ME#7[JO5Z+U;I<-B"U;K UJW#J)DM3)T@ 9P86Y&UY;50QR0 QK8Y6C<.RUET M83AI[N7*;_H%.T_^(I[;<^O/LBY=%USSQJW"1%)?-[N0 5-GG'4>I&BG'$)G%.@>&PR+=N-VLR;/4W\LW+;X)LJKI&[O$[V>A6 MT_=4K?^V&ZU,5]P6,I*G"=?-G0.$I62(ZO+7*):YD(1'00SJ]>Q$J[G=NZBT M1&@9G!O S2;GQ6$$1HP3]4YJ8G2A3*.AGN'IBU#POHZ 8ER M[(=J84&R, H"&G"C"M^KD6<.9*TL\ZW*<[.G]RBMC8&%DU:,PU@PJ/P->Y'G MXRVV"=EKQNGN8_\#MIL53!0_=%E;!:SY['ESSJ7D0=@L=9@CQCA;0EY+6'CY M.&CB]=)Q^%%X'>.]9L9]_[-D#V7!C%D7SM^:^YCVIRA940FO%F9>RGAAVKCC MW&85S%]J.9ZA6:!JQGX+K*H9+X9:K)JQWX33:L:!)ZRK&8N=J-MB7W8S4UD/ M^=>VK'L8U:>(69RHY5E(4<:"4#=)SA )8H5;@'D>YR%F&>@6-T#VS"[6:-)V M![_JQ5>O';0Z3=$0EUHND MW*C&RDC:[)4=M?B69!U J#*)TGBP<&X[+#RK/QY(/.,',)!X UAF7 MN-A1T=R*#XRLQM3>40:;R4&6H[4QM>>,Z\;X)>?]6NNY7>AV]3+U=?L>CG N MXGI?!W$APS2*XDA@T/W0"7GS[UV/-26UR).F\#/>L':%"G@KVAX0ESU:9\AY MIJ3]5?JSCN4VIJ]9LE^I\%\3(WV6;TGU_<-Z^^=QXXH*(9)(QBC&L$S>SV!]'Z8$4+]VKI)IM?<-S,/-X5&C!WOP$(.".6 M@86N>+'&1"W+CF5@]!5'ELD[EH3;]2KH\--D>1 QR5,D_(0@[ >1O[Q^_ NFKS^TWPQR^UV^"*RKG M\\&795_N->R*,+G_*G;[]MG@M]Z KN^S XP-S.4F]9/Q9/FC;XM]\? M/IZT?P#NR/>:;[@Y?ZOE-OOT_4;/T!MNTD+[??S>49?=TA\S[&IW?_1ANZGK M[]LM_[-8K^\W5[MZQZ]Z3%9C%@F:4A30%"-,0X$R&:4HI3E/XY!2-;]!9C:0 M])E]N=.EOGUTO6=]^ANWS&=A6)O-HK,A"(L)3L$#S\-6(#B:IF&R%YW%K6"Y MG.3M!K$+1I^VFV^/HGS2-=]O7M[NRU*EZTJPIA-N_Z7S#DS"+*%ACG!&A+Z8 MDJ,\"0,4$9G'F&:Y)$;']G#1,XZ\#906!0"B68B9!QI8?-$Z M(*U$?17C3I\@MHK4$>>HRBSQ!8Z H^ "$+QH9($#J45]& 8XS05/7.FV#7=\_X; N*8PYH ML!JOP@IM"]803[3U>-9DMGKW\Z'<_BBXX&]>_E'I>HZ&44K)O=++3SB,']0PY)1U_#K,@N#S(L)"HB19JC#L-=9KWBU;2*S:_>@<] MO:.B=]Y1U05X;QW"YX[ZUH522[/?.@2RAP#7Y>ASA]F5C/P\2B1!L<]"A$D> MHSP.&4IP%*1!PA(6)JO==D?6KD,I*%P>% "Y,SN&S'WCQ[U1E!47,7E+6"ZY4H::ANP1MC(T"9A0DWYL/"PL'REH%* MKQ8;L7?>[R,(P(O&)HUS52\V+&C94K%)@Z^JQ*;?L&_G4^SJY>#]AC=IR3>A MPH0XV6,_(5?+&?6S*$8AE9J[1'DT%3A!21AS]5]$' <@MX:)GWN1=52FWMH] M4P?>$@@ JUD0F \L6& 8Q6F^$_G;8'#8B0@@?/$V17!@^GH868QB%WZ._4*: M)N?7JZ('4;8]0NI-J564)%D61"GRB8@1CH5*+#!C*"99DLN8XRPRNH-CK<'L M0>BPJ; ]J( \WFCPBUK%\.UZ3S2K8Z31!J@N.4-1Z.0A5<_J+1RAJ>RX!E/Y M!\2.%!O!.T+,]II7 MZ.?"#SE#*8L9PC1GB-*0(X(3*EA*,29&3,_C8N:N*CSIWJ%RSH(5P)7. #AF M$>1VDV%AHI/G'4AFW;,MC=ODC"VC5\C"A!ECAEYS9HP^?7L13WNNOQ))E*9I M%*! _0EAH@G<1"I0F/J$JP6+'_F1;;5.*V/NC* M+WG6W52V&WWLO3ZKU+$O MTNE DBP2*0LCQ$5,$8ZX0+F(! IX3L(8LR3(,&0C^%:0X#N^3FN7.EC,HM:- MQL)"UF4U4O?C^(WL]J7CK=D1PV8H,NHDO%HUT86)8V5#EX]:W#O@_WK<_K[= M/(CM[T)W2'S^L('?/1@;9.Y,@?]K7]7+1-T55"F!'MY_]GY7_W=:,N!]V&YW MF^T.YEE?IYC"/&$ ^XCW 69R@3 4&!3"6AA++ IZ Y=4+@ MS!/LHW[%6Q^5J+?^JA,U_N-_9&&0_LT3M3K V7<*3<.IV"%&P'GY ICWXR# MYV)#RUQ-S%/BEIVE#8V_FK)-W[.LM-ANVBVZS;=F$^+]3QWICQ=I4I%'<2P3 M)/2.)5KIO\Y3_&5JK*O"B$EYR]9#F)I_509A_**=^]?.T)[#'JX.K(B?BTSR M /E)K*\(Y:E:2H;*?[+;G/_ MM#-=24\,,[._:>DM/U.39I\HX'T1NWVYT;VT]R,_3C PTPMIAYC /-,!'*"% MLZ&A5DOGJ;$76SP;&GFZ?#9]Q8)J\XSU2DW.Z[V^>=+;]>"+J(0:_+O*X-^) M'V*]?=:;+.U4O@I9F(I !"B4L>[VF#.4!9&^C,MBPG/FM] M"@#?Z&M\$CM>T@4_#8S"U#6$HU2GSH0M1XGJ&I\SZE3G@[MI1OR&5 5;)5GD MQUDH42CT+6XA=4].P5! (Q*F,DU""=H [I4R\ZYO+4/O\WA%N]6QKDNJ=.T9 M:]H0UR5HGHO"M'X8S1:/-X,#FRFNNQ+?>;7(^?H1GUDT4R_B1L:K]B$^,W.J M!_'YPY;;.-T>T2=!*O&E^/9]]UG^HVJ(9E9<1$(2R5%&I40X303*N R0+Q/& M IHF>4!!VSECTN;.&[4T73ZRKT2SNP/PY9M+5=E!UHR MVDJD9#>;0 [W?4QL=+7_,RIKV7T@$[.O]H.,7K*]GD9W'S?5KJSSS4?=H&F5 M8Q;E49:B-. APE&6HZ@!_6S M6&&&&6<)4VABK#F/?412'*$TE9QQ$OLD TW15EK,[/2=W);EJ.-(\I[54U!F M6>@E3::SUW]5E7>*5/X-9+)X=6F"TKK%J]/$:A;Q&HSNOUNG.._R\FV<[ MO;R',5PM^.IOP,49D;V-#@LSW-\ TS7U_2V#67+B,Z8/A[2P[;K0%Q9@'' M#0JPJ&() )QH?](V5Z3[PX*6)>"?-/B*C'_Z#?C!?E.AI^-$TPM'A9"G9_VG M=X64HA3*%HN*>=BH01OOJ(YWU.?.HH8>"-ZXE\^+&W#?%0C9#&7V M=E!8%0\ 12U62V 'P6EI@>4(%F&D+'7=__V&K%^JHH('C('WYPX-9;G=B.V^ M.K\]TJD!B 1#]AOXO /3@=X];O4V%+S8W7\K1;18BFH4!ADLD@B*C/4Z.^ M<].B9O;23K;7"/<.T@%E'^-0C7NI6P!@OCIHNTT/W7$0 4MSL"PJU*!_R!@ MQ29&YHU6D(R/L%Q9B)$E9[4>9F_8TA!Q(Q#XB 4MPYB>2I@3&1 178N8 =U0)K;5./?UU_M"Z>+4RP&T'*]#- M-B3FAA(6*D]0_'0+BA8,1/8P.",ALE!A81XB>Y"NJ8AN& N^N'DL^7U9OMLW M%6ZF2YKSM^;>ISQVC_ ZD>:KEPL#I]*O?.T8 6+IT6;.=(8/N,> MYFJE>S;[:8JE+V"V_7//3%\>J*ZW6:85XV9Z_VA9<_0,_?: ML)L;YIX,^2K=81P)#-$B9KH",;J[^,$IZD1N=VTJ)F]L:[=.Q5^YVGQGI(/N4(U"I;! M7IHS"&#..6*]S6[:. R0ZV&NX+"\\V7QHP!>WC(QB %7S$:8^8G*>(X#W0W$(;R*!4HI23.I,0Q%CZD;"]"[;1P&^+M(RJF>UG6MD*WJ;HV'Z+RM"C75-A7-C@ENCZ. M_@HTUE>F]9-47S]FV[5C4VW7!:\=MRZZ>3F>[ ;4S[(TC!&/PQ#A5.2(Q#Y% MF.$L8:GO\P34('%,V,R>]U J;RN>U^H'N97>F2+0?APC@)GYH2L88$YY)O6N M*75[\?YH_SE3?XUI0YUUTQ@1M7#OC&FCKSME&+SCM(G?QTW;^]BP.6'G!N_:A>EC M2395T?!$:)Y]?>^;$N'G"*M_()Q3H<\,0D2HG]",TRR.C0\.AH3,O:?2BO6. M\-IP9GILYR9M!KU4U' M!N)0A*DDF33B1KA5D9G]]_&[* 71 @%[ZK?@:G#PL!!: M,.__,%:S=N=UFEULT=?*-1OU6KV%, :<:BR$M=V9Q[R8PTY'' U>G9RR_C+ MG:PX0.'LW,7%>+:E@H_U[%T/_([L!*QB\.+EN:/T49JGQ4&+!B]-G;U7NU'9^KS-Y:;>WLU/9M-^Y^PKEHH-0O= M.]'\\^.F93:H'LA+S866Y4$HTH"B*",^PC01B&+"-7V((#A6_XA!]"&3$N?> MRFBE><^-.' ]PP1>9F<=3E& 18].M/=+)_Q7K]AX!UP>)G"QJ80PL]5=;<2$ MO*6K)J+F> M*J_/DAPE I,D"]-44!#!W(BLN8]&6\IF+?JN(S@C!^DUBW/SMT#JYC'XS(* M(U!@[M_B\;7!HY'K'06[K*F8M,Y92<6PI(4K*B9-OBZHF'YE]@N^]S^+:I5F M(HPEB1'S:89PH)+Z/*$<^20B8492++#1\9^E_)G#@,FU7JW&?!=Z:Y!-LX/9 MH(/F"M/7>,=1F_,"[ZGMR]_=K:7_5:_MGD)SPXW=LV'LPM!#J3L2[EXTR>'N M?L,U#5+=A^)0'13&?LS22"*9:C);%B4H#WF"I$HV.,9Y@GU0\>:DQ)E#32?_ MKN;RW!UZXS:M6&P9"Z=Q-(LM3M&!19.;@0$'$V-C'86/:7F+!@QC\R]#A/F+ M+FCJWY*R?-&E3W6#NQ5.DS 0"48A3E4B$B<^RGT_1#F-.0VS+%+9"*2)S)@P M4"B ]Y+YO-]5*KK6F][/36$W6=_"3W\!E9G+NP( YNWG+/5WNHM5-7Q[Y$9B M^GZC9F&HOQ#UBE3U_4:/<]8/O&/).LS_M:]V=>>!Q^T7H8THUN)WL6NN?GQ2 M'_QQVU?M>&B!<:QV/$QC01;EJ0@C%,>4(!Q1C#(5$5!,5'[ 2")$F(/XBF=0 M^UOSPL7EY\](.^GJX[[[JN?ZH_NOK/(X7HQ\8_1_7G MX8F>$5]7#--SJ+@L-_6,(%^Q6L\IR^+H^9ZQ9R:'SV?#3W_D9.6Y>UJ88##VG/[QX/>;58!0U5KT.-M M!@%.GZT-LSM]-C00=@;=:\/H&?3Y&\N=0?=J>G8&W?^$127\>MT6!9W4!%5M M=8)I0?S(&'-[]GKM]10U %\WUEHXEJ0Z9]:T7*-H_-3?4ONEEY>D[*YIG:48"C&@F_U.CCR=(N?&V>PA;MOO/(P.UP"9YA'(>9@CC@*!< MT@ QE4EA$889QX%Y(O6:'\WP[8>S5T>W4\ZY+LC;\0['1S: _Z8+S6N1G^8]*M#.YRA_W:[(3 M_)UX+@4KFNN:F[/;FZN0D)"%,D0X#-3B/XHDJBO)\R@0/(Q3&3&VVHAO>IQ' M%U5=#I0V\J*\\:(KU46>2Z%6!SCW_%^/6]U/$7QL<_'F H]JQW)@,\Z[3.O%.J >! .1@TQ9:>=G( ML(NYVK1II_YF\+3%>?I#5^C_0%[J^?>S_"J8"I9FUHNN[$.Y@ !P]NH/#[ASQ!EA@IX%FAHX> M[4T,L=PYG9DM9X=NAJ]8[QS^*"KUV3]LRW?;/=W)_;HCI5@1]4KDRP!EF/D( M,R$04;%.X2N3/,NXCS-L5O5C(F[V&IXW1._/T9TG?NII&$@4,XJ4\6Z:$^N! MB7[' Z-F1%'\T#PC=UUO=UT 7O,Q;C1]S!>A<*W(>I@WPV9':])D=QM2PZ*6 MWD^:-+IG.VCZ'=M+7;P^K=<1I. ?-V_)<[$CZU40I41RSA&E88RP'\3*O<,$ M)2%/94 2RC'HL'Q SMR;0 >I=7LK5&P\U@B&7FOJ1\G,M1W8#O3JH]E:HB9\ M>CMAML5UH%&CG-WHZ9>R\*6<45.O[]6,/V[GJ#5IS,>JVJNI?:]F_6\/HBRV MO*ZD^2+TR:%F5JV?JC<6Z@NXJXSDG(64HCR,),)9GJ!,!@*Q./)#&L3"3Q*( M&UMI,;.3:W7JXQJ5898''1H.*)B;VV%L%@1F1PX6(FI!7J./URCD-1K=-15] M=]Y1JX8_RJOU>.4OJA'G_09Z>_^9]WGT']2VZP,'@J,C>.N 2 MJS/,@KC_PBK R8^]=78G/9T\1^J/GM]4V_KF?G,P./6%)XJTCS M081]A+,D1)CKL) S@E(:BE3FJ?!36(-T M0\&S1XJC^).JI+ISNIZFM8IU >[OVPVJLZ5CE]YC6>_YA UD 3?] F:)SQRX MPF+4 ;<[;P#=ROMCGB;L0-M=L8>;BEV62AP(QA6O./1]NP TW-FK.BTP;L\, M=5.O1_79Q"KS_32A/$,Y$P1A1M6?>)*A+(JC@(HDCD/0+K2E'C.')_5;2V'A MQ!9/L^BR $JP8&/7^J]N^E=KYB[XW B-HUADJ\6BH>E&J"XCU:W#P]]#H\PLP>I]$64!5G7M\?J*T(]BU[S MFZ C2$PO]=V ',N(_L=;\";V6JUYA\9=K$U_[1IIVM^@Z?M+_G_)G;?MQSL MC0.OS^R*9U?^&]$ CHP!BZ>]SH&Q,)?KL7,&!YLPZR9>@\LQ%VZNX4W3M]<>M_7?O2&5X.V=R-/]TU5$XC"(!OMI!=%E7H M]OQ!-Z]KK]WVU3Y13[/PO"O6^UWQ0WCOI11L5]^ UD^B6NGN9K19*PF+SKJN M('36;/=FA1;NO^L*P.N6O,Y&OB&.JJ'?B>:?'S=UU=VQ:K$^CUOE(<<\(0SQ M--/W,?0!OJ:RH$SF">&24>Q;<#N:23=RX)M)&FO)'JDE6L3":0P!\FIV#^M0HKCG"8$A2Q)5'Q@ 2)!'J)<8!EG OMYS(QKCGM%S)P;'>5Y MSXU 36GSO\B+5#_^G3Y96QNSK8_@-!X#W%@/\W'C5JM(BY_\WE:IE'-3\K:1Y_&?VUOCT0 %_R_]Z!"37/3#78PK6T M$KAO.VB@4[;,/F/L=FM/!UINB[9'_;-]V;[_#C_-?]?F7@UMQ/L-?Z?6WZM< M]Q/$/$4B]R.$P\Q'>2)3%(6"4!I33D/CX_Q>"3/[4">S)4+QE%1/BS4_T>_' M9=R%G%@+3/^AAH).]4>-L3K6[Q]QL7/]48-.#_;''X3/.;6CLMV>K-:>SIN@]^".WM0>W/.&$:B>- S=^OK-V1/-1A1@9ARP M<-HM;S,.YH1]A3=FMH+\;=@D*^_J&6XQ7QHVY=1S1IZ"^\F#$.7?R^W^N>8N M*ZL/&_ \.#+$W+O-2K)7B_9:V7?>A^UVM]E"'&D,@FF/R)A&-$/L93>>1MAN#_C#'ZS#=\E084%E1L(3'5" MK;["B9JOQV8Z!-@K$9M>J?.7YC@= N]6NM/!<:W+;=0ZX>M.Y3XZK7Q#UCH0 M?/TNA.[G=Z2+/F'L>/.B_N5Y6Y%U';TK-<1ZK_-3_4S#)";XD4CL_F=1K3#! ML<1!B$2D8BD.)$&$"(%8$@C,6$:P6:N99=6>>T^OU:?-/_15"^\/+1=X46^A M;V@6E?]Z7P:X_PC_*#:U10MBY*XV:0FEEZYM6O!#]-1&+2G=L@E'V\OCV(3E M?KW>_JDU5;-0TXY%=V-YK$M##\L]FA/)!<-(D$S30\2QRJ!CC*3P_2Q5_U^$ ML!X=5FK,',"_LN^"[]=UWMS2MNG;B$WKY=W6VWT7WD%-3VY+K^N0XG7V 'M] MV'T,L\@]/\3 4]6^_C_G<)YV _JCULN;A1#N-FA<]1NQ4V+9=B0W 775K>2V MT>P"WJ.N4]V7+W7*W=3 MTRG) HEP3)$/HVP2F*S')& "93GJ>22<3_/0&PW M@Y)F#EN=W&;E"8M P^B8!1DG-D-WST_-O>LNQKAK/6ULFZ- ,"QG45^?-/?2 MG:=?L.5N>*O2IU)3RG#Q\_\6+ZO4%W[(I(_B+,P1Y@E#--+]A5@2^Q$)PY 9 M55\.2IC90UMB@U:H5TOUE%@H?\,E+N,^ZL1:F&^"#;7@)G>2 L?KNM=I5:K]0KD'U[CQ5G,4M0FON:4C65*/<# MB628!YF,I"0!J/;95/#5 _JMW[?^^+9[TWLHK2G(4XH"B6OJ:-]R4B-/!1(##7 M+)-^G&&+^YYFTHV;[GO4J5OF,+'[J^_"Z7-SC[6X/+*888FH641Q"9!5/ MM'SO%ZW!KQJ=9O^KZ*)+IXU7J^,=]'$75&#V.PHIAD(7#2@P("[#"?!M>/W- M[]O-E_U:!#Z- TV64SYM=OS#FGPSK;X9'&#FO$)WA-""/2T9!6=57IK_1T7> MW4C/.0 0XP[O# .8?YN9[_VAM7!4A3-II54-SO"HBU7@3!IV6G\S_;!U[[SF M9$.[^_T/4JP;UHB63T(O_K]OUVJ\JB8A$?R>:JXYMEN%.0E2GV4HB4*U< CC M!.5$8,0"+.,@B<,4QLQJK9M%G#0 MJ[UM5=/7]TZCGD+%_JVG/ 14UC MR,R"DDL@8+%G]!)WY;S=N*FA\U_+?H4FXJ;& RY;NV@-WEZD(3_;V]IOQ$;( M8K?B/&0Y$R&B4A/,)"1%F<@QHBST,Y;(G"1AMR%AYN\#DBPV'V".WDZN._+3 M$XUD9RUZA\ S\_M; +&EFM)(*(E>*]+[I14ZS$9H6?TU:);3:DS)FG[TZP]TU+AKKM-&*F+NP4!Z@[M\+OO ,: MM?Q#F7VG@TOG-C;8F:-/2US8Z8TAN X YJ]:'F*>%!!UQ7C794;_+%5*\5G* M:A5&W,]%R-4,'Z8(IR%#-* 1BFB8\)BDND&DQ;D#4(UE#B!J<6BKY &/,(&8 MFH6..2!:H [QSJM54B@Z/->T@\+5\290^K*GG';07!UV6@YCV:GJZ7F]?1&B M+17^5!!:K.M.66_W9:F/YF0@,R$)0U'@J[ 3!01E41@B1DD6,_7?"#&ZAF\L M<>X=3\9*?1F.G=!) +M136)F%E:<(@$+))UH5+8EXB?"[[Q6O,,65*:6NFH^ M-2EOV;93IN9?-9PR?M&63./CAM?]E$ \&NU+)NC9GW %OL@3F:#U\ M&7>ZMK#X4? ]63OJ$C5HT UL&=U("Q-E7!APS9%Q^8#=O*=;P3^46_45!'_S M\H]*[]@=F:";"S3*S?KO,JU$[C/)L(_23,50'"08T2S.48R9KZRF+(11JMZD MS=QNJ-:G3.GG29675-Y>]V0H-MT^G/IIDX-^=2GBB8[6FW6W?1VSV7,LP?U+OS3A7T/D\##IZ\G0#E:&*_39=%)WTGL%TF M!&X&M0N9W9+CLWS7EAOK>MJNG%878ZZ"(&*",YRQ%/?S[-, M^$D0" M,%"(;+D %[V2YJM V[J@_;\I,2M/XJ=KMU MV_].YCZ/LN88R)HY0G22Z\WYM9;M54?A ML- PAIA90'"$ RP,G$%0B_6^&D =GP#XQRY^YBD19WH3]3I%4"-&#U8_C;UCY\KM4N*#TO/M=E-?A_AGL?O^=E_MMD^B?/^SI9'3 MH47]+W\D/U=9%D4I!RP$+'18X9:G(>J3^ MSQF89K%@9HA@(:+;-JB+P3MUO#^5/EZGD.YCUZKD=3KI\FEWP>,&1!S%%!L- M%@TU-T!T&8%N&;%Z[3S M6O5N:3 T@M]X )H3.N!1K!UJB[0?FL;#41NB$4&OV(YHVOSQMD0&[UMN:I;M M$4M]^_.=+O,1&UY=\.M^5+\:CUR()(DCEA$2 M@'8Y <+GWPG9/^V;VD+>*J(Y4YY+\:/8[BOE2.K#J_51W79 E+IZY(UW,,"& M#Q($O>%VZ4R O=/SU'Q#GK<=;?1#ZIXC2X.]U0M$'"UR0H1O>RNJP4H5]NP M-F/8Q:1/V\TWY<)/^M3W40U14^B3/!"^P"'""6;Z-#9#-!$1BD1$I)\S(B6( MX*)/R,PQ1HM$6F9=@G#G:;%670MZ 3*+$+>:#8L$M<6/,(O!+C]FDB/7[A6Q MJ N/&7GIJJ//PGEB[Y5C<^W<-1%2(+A/XRQ%62Y2Y8R"H+I(@F(BE&>2C 5& M?G@U\MP3?"?+T\+,V6#/K1]WLIML AY(F)D#XGSM5=V*Z_5\I,4X7GL-..5V M[7\ YA)/_.>WU<>-^@F*:M>>%F@"E:)F)?H@])5H&H1^H-PCC^)<^4C*$&&Q MKS)FWR?4)R*.C=C.IT7-OPYOA7E2&"ZO#? 9]R*W5D/W]ANQW4E>0WG>0J!% M.\. MTVEZ]7Z0EB7QO8Z.\.;_K6 _K M+JRKV$]Y'JIPD4F:JKQ"!OKL($ )2VG$./-5$(%>/)V4.O>B2-]XU&T8ZENF MXJ@&_,[H-(!FD<(Y++!(<4"D_L.)!G<>V1UY,&LMW-[S-#;:X7W.:9F+W]LT MAJ'O?J;YRY;;^053:QI=^O"M%$WA=MOW+(APRI/(1]0/5'3(]3X)5ZD&S7P: MIAE/Z-_5HN-%48QL5P*]^%M<#]_$ZD=Y0Y0S>X2L/REEV M;W_*W*L-_LD7K'<*ZET(77.@%LHKEL18A@%!)(TYPM)/U)\X15*YK:_0I'X. M\L^+\9>8IY]U]8N^QU.TLL&K_S-$C%?ZMG9:;E=J2:<5A6_)<[$CZ_H.>/?0 M72\A@]/U?I_5[M;V9Z,OO8[O,ZUGS=[[V&W>V.3L[?CQBFY?>6.Q.=27F5;QSR-@A-QU\WG)%7#-9?B!,4YZ]O-L^D6*S"M.0 MDD0R?=V--@,7LU!SX0O7$7MU4M61?\_VAE>PID ME9\KL)E2;[B'R6V@F@6W.: "1K&:,^V@PIW7P/;U %NGAZ<5<(F5 " M+ID "URVW#4?D<7#?MEO.(=PU&CQZ\7CK]J?XOGL;V%\+NRIVO/$$FNZVQ0 MF@2Z46T4(A(F I$\3E(L QSEH(J ?C%S'_@IH5Y]DX?7]UK &Y<#X(@D(6E" M$I0$^D T2GQ$@S! +":QR&7(_9BO=ML=62\&SD'8JX-CN!"\V618[+N\XG1R M!M,NJG\CNWWI^*QEW$J'MYYZA"Q^[VG8T+Z;3R-/6P8R74*E^^)^?'HNMS_. M3NHE3Q/LA[ZF@U,.BP.,,I+GFD\Z#'$J\ERFH&@V+&OND-9)]HH3T4#''4'* MT'O=V ]TX8/IIU+GJ&N8MLZ5ZXY(6M9_ITV^QO:,7OJ9'6>[2E[%%9Q>_S-^R;((ABF_?5.11AVOJA7PMD<-/.3Q1CGOEV+3/@#<_@6#G@KAY\1'>>CG"#,_1#D/ M8Q2&>91HYN$<$\BR;T[0X>M!$] )_]>^TL_H4KWGK?[A%V2M>QX^;;N/L-SW M,,M59T09-K,= &XU\1I5] ENHX5WHH9NP%0KZ+#5B1T0KOJ> *4OVP3%#IJK MCBB6P\ W\-4\]&V[$5\$4YEW^?+^Y[/ZJ;5-%70^KINGL>:\\@6\G6\U^,Q3 M0JN3URFE=W .:FD7NE3,?(??#LOI_?[9882%'S"",QP!W 2)U8& G<3%C@=N M N3TL."V@5S4))ST,ZOK(/:;75<;Q CV_<#W42 90UCR!&4^#U',F,]I%F9^ M#*J$-A4\ MC0:U?);ZCA&QKUC?,0W&>'V'P?L6NZ@U&<4]^_>^J H]"1R(]U^SE#*JK$,D@Q5G]O3'HU*&;FR-OT>2%'P7=> 6MO,8&2P1ZI$]MA M[M^8?7]J-K"KQX39@)U0)^;;[8!:P0#;]YRT;G2_<_CMY?8Y)RTXV]^P:65Y4S%;C);.7=+5OR%JW%/WZ72@E-_R>\UI)LCZR[53'E5F U^&"49Q M1B*$?1FC/,494F&/^1&GE 6@;/,5;)@Y?)ZV%VUIII1*IQ7M^K_LO@MP%_"_ MS(_ +*/[BW]:8')X=H6AFK[#4,W:+_45L764?KZ&!8MFLJ_XB2Z3XM=4Q6YJ M.]S2;V^F5O>TJOO)K A/<2XP13F6'.'$3Q"-J$19DC*J$NPD4 MTP 0T*&GN M_8T##T%[];OZ3UC@'X;(+#P[,1P61(\V=S*]/SJI#H/CI&6.0MBPG$4#S:2Y ME^%@^H59NL0=\P>1XBA(?(:". X0IEF"2*0KC3A6N:0@H81=HS(5/+-+6[6. M-P;-S*OG@ +FY 9]WV8B6X7:ODR'MU=*/Z!@ 'NYW3K1-W_K(\U:386YL:RWPUM*P2997E'H&7/ ^TK YYY>/ M1IZSFWN/V;B^S?1QTY)?M87G620B/\@P8ID^(\3J_V54I<\B8Y0)D?D\ ^W: MC$J;>WOZ(+N^78>*3S0/HJ8V6SK# ?@5O4@!#,4[!O9Z*KE^JBL9=NL MFYA]U5K=Z"6'5:Q#U4_W=2VA7K4?5H4\IT1*'B,J8Z(6SG&"LI0RE*=Q2F06 MY"'LFLZ-^LP<)1[ZZR<=U$P"(#<+(@L""0LS=C65=]Y1QUF6]X[PFK/T$J#- MZY=BPJ$S*LVT&-8R]:D/659!$N+_K[IKZXU;1]+O\RL$+# X Y@872A*P@(# M^"1V8""QC<0'B\5Y:/#J]([=\K;:3C*_?DFI6ZV^J5D4)<\^G)/$;K&J/C6+ M5<6ZQ%'!4*;_AK#"&6)I%J.$)H*0*!(%5I $\F99D)J"YX4_F$<"6I,"FB^- MU)9V"E@6H$'2+P#;>X4][S[[DA.X,VJJ04W63 YYF)N9 M*F7PY?;^IC-^J+Y0K&Y=>#*'VT:\KN-M]7G8-JR6 MJ]E766TNR>HQM&$>)UD19R@/8W-'18E)DJ"(*LI"(6+%A96[?63M\4/8\VJ= MLGZ_G)?+X%[J/P1H1.\Q2/KWYT!!P0%J)QFM-UZ/-'U'F7ZL24 111C'*6)20,"9IR K; M0;L[*X\>*GXSMQSGG9\S\O?OFD%20:/!E@*!ANT>9=YIV.[N2I,-VSTJ0'?8 M[O$/..0[ZZ_KN*7,DQ2;UE(R,LU8 M8I;K'<-2E*J4%I%0(>/*.@/9DNC(F\D0 B3@VB+5O[?&DA^V[=8,!"T'069))3A17B*BNTT4'2.,R4RB.KM,SSI$;>?W458)?X16#(!YH^X'3M!\O"]/ & 6PW M]DCO8F3TPP P+;S!X690N'PI8$:$E8"]ID/_"M,9#%:2[)@)=D^XYL5L;INJ MA_+$]7Q]1<5H)46WB?-7V11LR6]R^3;GL@D2F1X CXMZE68X+>5QP42A/:PB M3Q!6288HT?_DJ90ASY)<2)"U,3;#8SMKAC54\V9NWEOF_OH?$0G__UV]FW7$MN%PNS=SWIMR]G75N^D^9[FM! MAT6?^433X.@M)6ED=B?.:IH&_,/$J(GH.IX2G=/G3K5N:MV"L($J!CWX&@Z@%35JZES:UI^>M1[%B+ZTEE]I*;5-Q9"'^@*FV<X\VDD6=HW):LQ\+"LZ+YJBP\36C:TL*S A_4%IY_ I[FI!>Y ME>6FB[YE7M/.0V,G,I4+='MU9[G5#D7JWUF#I(%MI(T@'H.Q)[EWRCO:76FR M1*.C G0SBXY_8&A?EP^T^G[]5/[X]OKR\E2[:;O5]J;!1*\W- M3TSOG:HN03<_WEX+7O+5_,WAN'1]5W9GZ01O *8?NN"W"%^<>@]3]4!Q L=[ M'Q,8%^_4B\0)JM/]1-R6^9A$8HDC5$8AEIEL-3,E"$8Y2S"8<&(4-S*(3I+:62+H"$],%I_'JY^ MU> 5!)@N6,N_(=MQV_IC]$#Y ?DHOG!P2T=QQ0.6DF(C8V]&2N\"TR6DV,BQ MDX]B]<#0T,[5;V_O23FE-[4W-(I+B5,88,1%K MI:9"@6A"(\32L$BY(%QFH.EDPUF:,.!3LQAT>*S#.#M57)WN QU&UY$(R^0U MCZ\+&NB9XB6XQWS&PW] ^&6^87F8_<'G4\VO&VRH3[*YL^V5^[53_[=)$V9&H8KI;1@ MLRQ319S%3/NB6AMCGG"4XR1%B1 8BXQ%2F00UW1:]D=V<&^U&]>0--$<$X0' M!K*F?9>6H;%_VS<$#+9ISBZ:2'Z'P8M@RWO0?,2H^;T?[CZQUOYM$N%O&[G^ MUNV5OI&M*<-JI/,8SWN7M^(K0C@M\]/&'-_EQ1Q$,=^'"T=/H:F=,REIZZ!] M5*24<(81"=,4X3RD*$^3$&5YS#C+>,1(##+\]RF,;,<_R.5S\+FDIW.)+8&P M-*F'B >TD-?UIG7^H/]KBI.2^#)<#]:?U@X])=Z!67GR@TXI1?>RO)4E.*FH M^]@$:47W5W?![=4=*+-H1[+^W3)0*-@^Z4^+Z]!+-89KJK,'N9 M=B[$ (\Y]# 5__-0&@5:]PFT;5K:?6AD!=6YT%B50;T;-ZZ(9Z4QJWOZ,Y*TS4:/2; 3F?1HQ]P,\O7U=FF4M8DSRSE%\J_SQ=R M^>MR(=J.+K-,42IS7* L9]*T>E.(8FT&Y*1@"<[31*2YPZAZ.^I67\G!@^KO M]<^_TZH9F>K8_\@233NCWB,X3OMU0]_LUC4'0W)$; D M.JEG -BWU4 /NVF.]K9TO]5+O]9I^IR656WL&&XJ1* 0#!OD: /.H02EC7NCVN^VAL M6S2;:ZXGM8M?S%3_*BB_G+W7=05N":W_E=V:E M"6X!/UU>WK<3.#L\@*X%SP%R/BKA%PN8)NN#P?- 89BHKI>,YY:?\M[14M2] MJTC;I]Q<&1-MO*GK#HU6^*P]I1NM(*I92$.9DBQ$@DB"L"(,4:D44EIL$H4D M)Y)"W)<3=$;>U4VOJ99L\*4IW"R\UD\2 _;QTZ"@QV3,V)Y[C'J>3WJF#Z7^_TVK.9QP7N4B+&)$LS_463B/$3$"",%+D M*A>%C/E,K\3*0=-(3]&'?+F[7-C'(S:3,^EZG0C3*E0EE$7/+<:J+.Z+B[1('L49\(;:X/ M)%)D'$G*"H1Y&"*F3RC$A3ZF.!=IF&:SA5R]%]9M@'XU$.GW@]CNE!OM:PH[ M^X 3=6MN1AZ<>PZ$,I7'#XA@.D(5^E!D]=L1',:Q-:[\&1SV6S$ZXYIL_J\HQ<[ MKU[*BCY]6I:O+VVYB.F156JBBU9O M\JKIFC_+2<(94PDJ0H41EMH%IHHF2!6Y)"S/,7XZEM_TND ,=]#6/0K\:PP=9'8H(GF356>)]1UD=RG)VEM611QS'%S1J$R38AM\G?U$76=!E,R#C5[=;UI_W MY=.<_QJG6;HK(KZRN:'DI\WK=@3G(,/;=9VAS01O%D(J[2ZMY&=M:X@;;15B(5*$\EZG)]22($IDA7A2B"-,$IW'BUCC0AOS8(:). MD[HM.ZCF)]@R%#0<#>T&:(6WG:H:#T68HO(,X(!V?A YP7L1Q MRA1'(3,MFV.3GQ 5VF9B3 F"G6PV]W^]HU'Z^9NPA:]CPJM,$0^5)N M[HQ,J^@& W:@](:OZ-+!8[XPDW&64LQ7UY37=OXEY_IY;?)=2U,S+S=]Y#[/ MG^>KF8A$@3G.$8FP]A&%F3T9,^TCIF&$"4F)R@$-/:#D1U9TAA]C5/":HT"M M6;H(RI=F"+ )^]3<0-I;@#&VB%>/BAQ,EVU :Y@)KEO06GZ"-4.=N=TU3Z." M"&D9,B:8CAU$_(,*;"GBBDE_AQ'PJA,V''&5>+?_B/,J;O;K]6GS^/K5$.M& M^-=7DY?,W%7RU2RD2<8(DT@DBB&;S(VND>_HK>*N,VZ>]Z&?C47?&D=H72[;2]:L15\%@ZJ!7)G^!N&/" M.)4VMHM,5L"XSW:W3/'@=VXFP3$3Y(_%:V7ZA+_H?]<](+7E8:S2:RGUR^+& M/GV4LS224<$3A1A)G#3G]WP.V._DE@].3T-7P%&\;J.\0-QIJWX/X\QN #?C ^GDYW M=SXF/=H'P[5_K@]?T#5VOV[#\+DM).9APA,<4Y00$2+MOX0H#Y,0,:%X)BGG M16R5&GF:Q-B7@]LI5)]=JZR/X&(;*A\B+30$#A+4(:9]2A9OL>H# A/'H$\) M>!A;/OE)N#5]K?DM%_*KY.6;7/[Z^"H?2FWC_>\K?6HS".[4 _WYNUQ(-5]5 ME\\K6\O;9>V1]^.:I6##4R!>I>EHN,^6.0PU8\&&L]KK?;5M .D,['FC?VQ, M@?&"L> $^0Y#,''R,YP(3N:3#(&CZ[\,6F=H7I')9JZ]IVV3("X%P[%)8 S3 M#.$B8MJQ"3&BE. MEU+"6]#V FII17B""6A/=!!JAAO5E,=)4;01T7N^SQ%2[Y3=RTBKFR^)E;J),H"#?Z15&WLD-X:"F;!J?/LR?ZQ/PR^W]32=8 M9IF*:.+!RHSX M$/6(CX4$'K1GP+*,#'J# !C^VQMP4:YU1R:44U;5F=D/(1!JJ34QPEA0TS+'$2+!8[_PB$2C/"4[EXOJ&TT[-> MX8&IVEU;E:+>?L=57[6V7;):CI'31C<:1$1 E*)54(2V)J%KA$>9*HC+*B M"&D(&ZKAB;.1U?9-MV:[V4^BVR:F;+FM[;DZMD)_0B=T^'I+G*:QI$2;RU$2 M(AQ+CFC.(Q0IJ2@.54)(!*F6?Y^W!*^Q___UENS.CW?!'G;.[!3Y-[ ?[Z&T MG=&BF;T(NNP:)_Z>+KU.=/(.G;?A+K[XFG@$C&6.$N'^05@ P/4% !4 !M M9'AG+3(P,C0P,S,Q7W!R92YX;6S.AK* M6JTZ4DLJ5_N^Q )),!6NR AU1*2.Y%_?8.0\1&8,W+FIJF7K:-S$\!$$0!#X ME__Q_73VRS=O'=[^\6J2S4YRO?WFY1%AC_N7WZ?K++^LO^,O?%LN_3[_!+Q]FL"Z+ MY2EC_[;Y9R\77W\LIR=?UK](+O7E7[O\T^4_H]?!@"Q,YIR8UCPQD L!N5] M5,88E?^_DW_F:&W"PIF(0C&=G62^_A @HRT(">D7]:.SZ?SO_UQ_B+#"7XB] M^6KSRW_]PY?U^NL__^E/O__^^Q^_Q^7LCXOER9\DY^I/EW_[#Q=__?N]O_^[ MVOQM$4+XT^9/K_[J:OK07Z3/BC_][[^\^Y2^X"FPZ7RUAGFJ"ZRF_[S:_.:[ M18+U1NI/TO7+UK]1?\4N_QJKO\6$9$K\\?LJ_^'?_NF77\[%L5S,\".67^I_ M__KQ[=62I]-3S-__F!:G?ZI_]*>7"X("$;GY1^L?7_%?_[":GGZ=X>7O?5EB M^=<_G.;O)ZQJDZOSI?[?\W_XI^L5ORYQ13#9+;G^C#I "IZD^J)-1&"O>6.Y?( M871?[K3/]'.\=PV)2B:B3*N(HLF^N=IOJFYI\L4R_ M+)89EV0J+I>#9;JEU?L@O?@;?_H*2_H02U^FLWSYK\MR<=I"5^M% \F=JX7( M_<,OQ'7!Y1+SNW.M;&5NP]F:#"AN_F8+C?^O,UC2%V<_/N+7Q7(] 5-D0..8 METXS[41B(<7 HN':.Z-$3K*)\N\LO!,.9/\X.$:>G4#B RZGB_QZGE_1H3N1 MJ'GP&%B!$IB6(K @'#+B!'A6Q(-M8PUN+;L3'%3_<#AEV3"-H+_1/+'EXNS^7KYX^4BXT1K 3(0IJTM%&L;GIEW M)*60+ 9(1G(;&P#C42)VPHGK'2?MY-P%;#[#][>9Q#Y$PJ6%W\Y]UTCF*" MP:"4BH(G:3+3R@$+"A2+J$ XZ,E_?3]\O/B M]_FD@"8?&3E#AT@&T H&43C&E3#$4 J^Z':PN%YXM]05_TE0<:! >\+$YFA\ MO_RP7'R;SA-.'+PIT@[D6BLNF0\$<*DU5T44XP#; >/.ZKNAH^/,9C/1 M]@21#XO5&F;___3KQG5"6W02X)D%Y:KK1*A#;^*#C<7&TW '2< MXCQ8=".KO-Z%SCY\6)<*1U?\)T]F2H"MD_#Q=SW "V7*>(3*9?&2:HR5O!PKS*6H>4Y"B M')?"O+OB;NKO.(=YE A'5O_G)=1ZDT\_3N-B-N$Q:YFS9N2R4%@<4B"SI2/C M$;R*65E7S%&ZO[7<;HKO.&UYN/ ZV?2OOZ3#2D]& M2P*RH 68:$!(>9SW]]"JNV&@XY3DT:+L(AQX>;:LXCJ_@:N0)AV&SUW2#2?2*R@6B[@$B]QEV^ MA#6>+)8_)A",Y2055H)"IB.1'V(@FUA*%$HC"M7BPNO6HKN5376?@SQR2>J^SDA@#2YE,G0;OR.-8I+]_^D)R6[T_6]<7&S6RGI"] MLSZ+?,Z(YB(Q@%CJU1NZ:*TVOL6-Q&,T[ :2CK.3C<7PFP=8G65)9D^@YZA\0&-4C'IXZJR'UQV-VATG+D\7IACWU>=ATIO MIJL$L_]$6%Z6EB=;0*$1+&'UE7S2#)2NN3DM;0G"X)')K&TK[X:)CI.:343: M2;7^-1-OZ'=6$PX\9YT"XYG$H24OS"N96;#&>14=(+1YO'%GX=U T7&6LX5 MN\+$^4.4 M+KQF6O^7/]T3WCOZC0.>8+__[=7KWSZ]?D4_^?3^W=M7+SZ_?O7KBW^[#Y;L1. KY--$5Q5_?OR9CJ'>9J2 M"5B!#-W"!D7.L=H]D&0'"/F#K#R$E9?7LQS_<_K_W,V_08S8F;U8OT2ELL? MT_G)?\#L#"=*<./KJQ4A:D<6$3R)*9+4 P7 HQ]M%#G$.SL1%@/6#H* (NA MM=$!Q%ZD5-_+K3YB0F(ISO W7%]>.MO,)7*G&#>"I.5,8#[G^A@;0_2)!Y\? MN\\_R"H]0L\X?3"& U0SV7> H[?S;T3U8OF#6)A(8MS)D)@2)3/-R?T'3PPX MP=%XV@F2/Y9P.P0W-]5(.7> E-O$(R8.)066 M$ (1+QWS3EG&,1FC##IA>&MO96]\-+_L&= ].5BZAT-CL899HW-G\167ZQ\? M9D#BF.?JL7^M60GZ^7E: M\AK/!C[8CYOOQUA1MV7Q1")_EE9Z=GL]I6\Q42 M VEZKL5Y?G%:ZW;_>_/+B?:MTZ9A^>JQY\ M["8)@,X T(&U?$_R@%IU_A#?9/I1R. %4RIK8D%F%F64S$6IA070)3U6F7G0 M$?L803TX\4V V$[L'6#HU<6RM>W.*7Z&[^>"JH$)6A\MYX5!0-H- ?0^?-BD7^?SF83"EF]YMJ05^EKAJPZ MF8E\"JN= /I!.?]8+Z-#@'*Y=@\N?!-8'"3,#D#PEL0]/YG&&5[A^/7W-#NK ME8=7/!E%9H_H8U*4VBHX2!80,Y,R801I>3&/W;H?ECYZFJX>_/LFX&FNA Z M=2.8_6TQ3Y=)U!0%Q2SU!2[(6I)4"T](:"8(I751)MOF3LU#A(S3:V\(9^9H M,7> E7/Z)[F$DK,N# G.%-%:RX#<=I:\(N!GIZ-IG50Z7WF<=GJ#7;+N)<@. M4@/OIA"GL^EZBBN*Z#95\%\6,Q+ZJL:(ZQ_7HC$R^EJ[))P@WSQ@9#X(2Q;1 M@4ST9S$^]N+Y$(#L2MNX8?K@)1Z#J*@#RW.#K[N9NB2QUMP9IK)+=1\"B[Z^ M[L08E0V*8VA=&[6=FG&O[H?1_G:(':.*@T'U#9=QT0I6B_G)9UR>OL)X=7\, MVDFPHC##54U.D5A\IN@P2H 02U+AT0$K!^'I/AG= .DH'=^%SI'B[L 0798> M?( ?M>[@JLN IF/E-1$I) C*,YXT&6:>R0L0W+)06Z=*Y8U-K:]&GB1J MW(3R0)!JJXH^#-/R[&%&BM2E<,E4[9ZGN7/,)\59[8?AA4DRP&,O3CSU$#T'6#H!@?ORZOIZNMB!;,_+Q=G7]_.+])<]+MI,5]/Y\3PQ07- M8GYUEDLCLZR/GZ6M#U>POH!&I$#&00C!AL@'C/L.(7G0 [T1PMY,Y&,J M&%RLESX$>N3(O ^9T0DOI5=!!YE;0^9!2KJ)_P9,0!VO@@[LSEWS>8,3X8+/ MH6@FY*;[4+8L)BM8%BG& E9+U[H>.ZU/T FP8T44FCK?*N=5G1C>6["?2>)1&^E[ [.,5J'ZOI^G3S#&^>7VXB M@1.A#K:7'(Q C:UO=Q\AIYL ;3@W"*(D\O3>N3[#X5XP9K P'H2&%W$*4]Y2=.3.$R8R+Q%$FP1V-91-H* MRF4%/DJ9H7G6\0F:NDE;/TOF($T7YUA=/S]'F[T9408)^O]RL MF3(5GE.G8A&8\P\ M$NXU44P'/OR]#OTOSM9?%LOI?V.>8)!DWTUALD1+_B))R6N>6"ZUR7()D)N_ MGWR$G+$CP>?#UE&*Z!%3;U>K,V(C03:6-@=+18N:]'<,P&7FG2\&C \FM&[& MM(64L2/ Y\;2 0KH$4F#+ M@"'A?_A]<<7G]_2GS;SW;=\?@B_?1=. M&OGLYZTCKK!XW1O*2,E+34A82WY1P<2\+X6L4 G)Z>"\;=W=75X_;Z7I7^+W^&[Q.,0L04@'%=NV=P%UAP M,;(8 X@B 4"V[II[ )GC>NXMD',_(3JLKKHX(%=D\6LGA4UF!9??I@E7GQ:S M/,DR:0C5SANRQ#K:P "C8DGPE&U(@>O6B??MU(SKN@\!KD:2[P!#?UXN5JL/ MRT69KB?")+3">\9%G?E:ZO,+*(Y\!2-LL"KETOHUU8WEQW7*AT#)H;+M()=^ MU4SLHL7K=1\',#D'P3,KQ<9:6$,"*5A8T25)KZ,.S4_SK<2,ZW4/ 9DV,7[$UXL%:F9)FP1=9T&=!AFY&.71ZD M#)RX:Y["W8FR<1VB1C"X>\777B<=(.TCJ88(J",37I'/-UMLNF]>,@,F)"&Y M91*TK2.F% 6GHI#Q!40HWBC5.NGT*$'C^D+#X*J=!D:$4PW=-QWP5^OIR48A MQ-:5;9_GBY?/$^ @LM+ E,':GS@F!B5I%J+3)6.1ZF[_E/M)@1W7&M4"P)0D"]VO;T,Z=9B263<>6A?17OXQ2-ZS$- M8WX:ZJ #1+T]_0K3Y7DR]RXO][LG:L%!6>+&0!9,^Z!8K%TZ:9=XG4N)4K3N MOK,7@>.^1Q@&;\-IJ /X78GL/+IY1Q'L)":/IEC'-I.8M<^& 0^:#+,1PCK/ MN6W=$>,!,L:%TJ#!WH&R[B!/\-MBOKC-Q<56NQ(0!A-!N\!,UC7Q84A L1B6 M;2PJ%2@RMWZ=^211X[YG&0)*;?70@1TBPXJDE_4M9FHW\FHRM5&1K.@F?18% MBP&1<1NEBY7+TMJEVD;+N#F"QBJ_W[OY>/EW@*/-8^6MHIJ8:)3PTC G%9E; M2)Q%C)$Y#M9*GR2$YD?;HQ2-FQ\8%E,-==$!LJX/[F'XR=<8O]%]!Q[@%8L7V_A7G&.]\/**I9IKHQC!=1] MJ<..UNOE-)ZM:[O,R26[+(2E27EZ.F'>5K?U.E MM &>$%K7130C?K<8A?^\4'TNQ7;@<1)3-S)%WFM0J38WX9&V(RK)HO2;K@,1 M3))%-3]@;Q&P&[)^JIK!PP7<@;V[1?PV(_[B&TQGYYOAHJ:[EG-?O,?\%5;3 M-%&8,(1"8L-"S"80#'BQ#,%+\D.CS= \8=>&]-T0^5,5&HZAU"[>_E_V,;A\ M6+=AXSH+X7),R4O&96UE !)H:R*Q4V(R.2H+LG41VJ,$[8:\GZIXL9T"NL#3 MT[N(&-WP>/Z.TT;EA$R7E>M1)TUK43>>NR_3U)'#?[W! >>TH9<=*TBK*38.&,<.0_<$YV$G\7. < M2GL=P/1!$4ZQLC?E*0#RXH"FP8L&*6"MBR%F#)B-JA2()KWK;C"9)V.TI_ MJH<$+97P\SAP%UR>6UP!VAM'\E*FYBOKXQN*>0KCNFC--28/K=_ [4UD7T[< M42 YQ(T[6%\=G)![N@*W6*T=K[3'P*03CK9W[<1 %I[9XG265@01VQ>Q'$QN M7\[<<" =3H<=P'6+&"=>!\PN:69J/D@KC2T@47P6R:8F4FC=.,Y%$;^ULD?KSD#E%++QMCYV%*QFWA MTAXX#>3= 6JNO,!WQ,OF>=]$E" \.7G,1:@OI65A@*8P*X6FDSCQ/, (S[M4 M=#(VH6$\=9B .X#(VWFJ-A)?X?E_W\[OYRL^+F:S-XOE[[#,$T=A0[: ]4:Q M]N'+EH5:4B1-XM6,@Q,2]+"CE3A*I;^T3'3.48\CW1<.K?<4#'/KHX&%)?<3E=9-H\RW6C MD^_>1#<'(G$()!M5!]9X((L?:T/14!*$""GKUDTW#QRM-^1CH&>#TY$:Z 9) M#X00Y]MC8DUQ)IC BJJ%$M%(%HKBS&0O1(A.V-P:4%N)&;U/^;/AJHT^NH'7 MB_Q?9ZMU=1A6GQ=;,AX;_B+)-=<0!^>KBU:E)-?5=(T7G?X_;"C[B&EQ,M]\ MY7SZ-^>BY%K8GZ.K*34+"< MBN%98FJ?7MN?RM';2#ZO6S"5.0+A*##FWA M&75IG<7;F\C1NU..C=!&^NL7H.=;L#9 7TY3K8JK?^U%%>=F9,S$I"S!.LZD MCIP1Q\"BX)$1C\&4G(0=H'#I$$I'[^PV-E1;:K)?O&XVY'8F06E9NZDS0&^8 M=A@81 @,O06P/)4@VQ>@'4#HZ(W@QD9K0SW^A& EP1:":<<>?66W*)2_3X M_?3&1O% "NX7T5M=_'O\(ATX( IGN63R\Q,O#++AS!IE"T27A'W.'&X[//]# MW*,]JWH[@//MGL$EHJ%(T[.0>+T8A\"\(W0O)@63; :R]*Q7R(GD4A2P:1'>36[:*.J\03_Q 7.FT4TA1= MS]=#Y>6+3__^YMW[OWVZS4>CGBG77Q^Z1\H6/MKW1'D)JR]O9HO?K^<=9QN= M([FPX*6GR%"+\RX[Q18>I1<*U6!OD1Z@IX'37;_Y8;GX-B7)_?KCKRO,;^=7 M W5?I/7TVW0]O3'Q.=B".19+Q[D,Y],\/#K!O/:\A*@"B-8EQ/M3VIC.\%1E_7NPK8@CH> B.>2F1:2XY@^@B"Q:# MB+J0/%J?%4/P,?(DW>>%]NA Z& S7';,OUV=/R$OF-QN(Q@7G!QD6IE%L)Y9 MEXSG&$!!ZU<9#U,RKJT='R%W(^7CU=4!Z.X'@:\N"+DQ^W>2@DTANLR$,W6T M=0XDL4SLB:S(0;*_,?NK,_@S3^:J*%%?OYZ^_5^F= M35=?SMW]5QC7$Q.]CL9'1FSX.@U3UM'NDAEAM(%8C#>MG^\\2=2XCRV[ VA; M)?8#SE=(!*3I^0D0K579 SG=6MMZ 6@856O^L3:F?E](7"]H ZU?G-99P/^]8>QBCOK$ L\ZJL02)"#G M TA0W)(O4L@#5[).46\=^NQ+X[CO%[N#YZ J[@#"&SFNB/XWB^6KQ5E/T3/NP\7NH-E,=5T, M7[BYE]Z7MZ38^0A.S/-F1-[&@1$&?/8&F E9T194Y, (VI$9G DJ)^OE ML ?^=MI&?FK8'UB'T&D'6+V?KKV2X$7#INN[-:-(@H8SGNJP1B$"@PR)2>4T M)^='J>8SAW>G;N0WAMWA=2"]=HG8RX"0Y([3;YLNR3IA#(XGYE(=P58+CZ,M MQ&( P5$*AH;9AR5^A6F^=(C)%^;9 M)&0%!9T,R6KL\$MB,4TS/>WJ^_X/+:-SE/ M<)%\0!9NF92>MI!TBI@+G+95+LIE]-R9X1W !RCKK2$RT*TOJ=YDJC>^J ^LSMWB&JZ#" N M.UU\Q%F%];LIQ.EL$XM-I"-[SCD9=(&UH)2\B)@C9TZI4D!%'\SP T2VT]=; MG]-G0F CA74)QIK]/+O-4TE!EVP%0YMT??.H62C%4[#D:M^*D'1J_6!P%[IZ MZUSZ?.;O& 5U";K;KL1-UK(3Y#@(\B)0%:9=0 ;&D7L1E".?UB!/K>__]B"O MMW:DHWA^AZJK R3N_L3CP:=&,GM3/ 3:;0A,^V*93[65M58.?2D*4FP,SN,H M'C=*?N8'-<^HW,.AO*!=VJ8AR6ZL;FZ*-MQBOL$L8 0)SC'NN6?::)(S.3(L M.$DB#MZX4!HC^2B"QPVYGQG(SZ?:G\HD3U)T62IN65(U\.,B,2C*L\*)8\$C M\=JZRGQWZL8-SKLUM7LIK0.SNH6SFN1?/7V(7 G72!=B%):94DBXW".%A099 MO2!(7NU+>R?#99VIG,*1:.["M'^#'Y72L]'_.IDO<./(DA'Q6^;VL M)#7.6RM<8L:K1,$"!Q83C[1C7=0A>4B\]>WU;I1UV>I@4,S*@Z71)R%N[JKM1UF6W M@E'1>;P"QT=G;4=UQ=F;Q?+%UZ^S:=I(;5-]]X&6(::DM"0B;5F.U:U)GAPG MFR43G@LRCC:4CVMXGSL4&E*M/81"RT5"S)LV8N\6\Q.RY*?OR%=9 MD7B)FNEZHL$Y55 R50HYT=X98HB3)8"0DXT"([8N\R-K]]?Y*H M+D.=L7!XO-HZP^'#=3Q+592PT M%@Z/5UL'.#P7'FY:@7Q83DF.7V%V&?1-2D)A2GWC'HTF=QP*V75!'+FL!:=? MZ^9]A1XEJ,MHYSGQUTY=_83BE^2?M^.ZW:)KDVB8<*6DL/5I9;"BMH$'%A2Q M23XW)I]XL*8U#)\DJLO[QF;4WA2RR:$?5DV85U+#@@ M*7G#0T!K?6S=#74+*>-6 7< NA8JZA-P#P?X 8SSO+ZDA.CKY2;%]B@B R"V MO$IDQUL_B7B2J''K@#L#X?%J&Q^.YW=-=QW:VQM,9IYE?=(K=4HD+Y[)NW6" M!6]#X3R99)\<;;/#.N.V[1D16ZUUT$%T>\G$Q<.ASXO/\/UOT_67.G"*!/=F ML=S24AV4*P4#L"P=1?$R6MH]&)G3SA=$5R^,!G+T]J5UY-8]'1C#9]'R^#9R M?XE/BLNF!%68U\B9-F 8%)L86K!11NEU;%V[LSMU(_?PZ0"X VFR@[OKRE;] M_UJ%] UFY[OS?0:796=W/K[^G+S _P8^TK5[3 M_B4E)"Z4E5(S8VMK6"NKLQ.!.9--++5_\=UJH";/*9Z/PW$3GX/=A7<,DY]] M$TVX)X?,:K(860JF>9W+Q8MD($V.2:(@1/>T)\9-J/8)\;V4>.2H4I+ LM&L M[J-8=C;5B0G$: RA]E4FYB,73('7*F&L=08_'6X'R\)VBMM]E-CGB-W?8$U1 M[Z+\>K:J>975;6IW&Z1[[QM'CLM]G*9&0W'?+T]@?M'ZE#S?U6(VS>=PGN;H3HE^)!0NM8)ZR:$'ST_Y1@B MZHO2V6)%.OY,ROR5OOOWB>2T@^JF!>$UQ:CU!% 4K4*)26/@5O+6#1E:\S!N M%=WSX_G>P)4Q,=$L"]?,LGZ:GLRG99I@OKYH+47>^@<22JI)@0/,[.,?/-+F M[D%M(P-\?YDK%&)]49%)YQ%X[?:6+/,(R+B2N6@3@@NMTY+;J3EZ^.ACDKT& M.W*!.M6"JJ0CN1+D3T!M(AL=!Q4S5T*T;K.Z&V4C#R=M@Y)[(T;;*Z4_"W2_ M0?%ON#[$\CS\H2,MS@[4-;(TURM<@T?*R*/QP)#G6D=K5(TX.5^ !? HZ4""D%O?-3U"SO$]\^Y]^AJH0?JL%(],&$W! M0*[O_9$VA! E>AZ+\[%]/^[M](P]9J -)NZWP6ND@8:S )L9B\MQ77#CH?Z! M/LBV3QUI2':BL)%9N36\[&;O@BL@:>&C]\'49DGD;VJO6.!&,V-L+7-7.H4! M'@<^3E2#)T /+_ 0X*W,QBD-C&\&N=6G]E%N9E:C(W& MV& 5VD[TS>N"6J+ MGP?>_ RCIQY]F-M#+@\T20]]YFB_Y@G*&IFB/R\6^??I;$9ZOKOD ^>;%=DB M*CK58B9MVY#J6)O"#%HO#$;DOG7GIKT(/-X+VK;"->)==,8:0!9BHL @2U<# M ]I?=;BDU+(DVSK3OP-9XQJDX5!TWTMJJZ$>G:6+#MP70U<.2A'?_<3Q*9KM M%+5RBL['+=2@>;,(:=5 MLN9BBH$9*V MI76&U%M_/M+EOL:H\[8ZH"LM&&SH["YW2$!2S3GFIA$^A MM(Z[MI RK@UIH/^[YJ.%R/LS#[>&P'[ YEBOGF <% )T2.?.[:::%=* M&YF0U["<3^=L"5BXCPR[W.MK:@=!(.7C#M(.00M %M7_&VCY5@S M[-U!-9VL FXA):XE)8QEP;YF)WD( R,$-S60GIJ0)#NX:DS:"[S'Z.=^C MG^'[89'/S7]^= YF"R7-;IT2XF+UHV?'J-G[-NE-IAX M8,A2&PWT:#(^G7TERU!3U#"[YF]Q52$.FWOX1+^Z:I-*O_70$[U#JO&:+7YL MY=XP4FAD[&Y2=TG1Z]F=JE-AG+0.:JJN5G+5H=:QU >J2H7@30+/6YN"7>AJ M\4"D?O=A#=TH,^.@LBT1&+^X*VWCFL7FZ'GH M^4=S%?47K=689[K>B(WV_OE#WQ.<'UJ)_-CGCK1F.U/:R#[=6._%G?4>.(J# ME#$A)Q3(R&O70T[NMO ,E043DT"5FL\SVX? HRW6+HM=;PI1? "E,K-";1J: M.Q82]^2>B,)=R1)EZYKE_2@5U];N1N4@M6>3*,>V59UYGR] Z MR2,=5E*V;Y6V$VG']^IZ=)D;[X.0:Q&,95[Z3#".BD7O.$M:6@A!2=#Z>470 MB>$9 D/W6W,-H*7^C,V6.:$'V)[')HX>;HIVH:_5W=B#2]%Y0W_P=;&"V9^7 MB[.OUWZYTU)X:9$5DVNG0.D8H,Y,U&DD28NH>.OMN2>)1]^FW?KJ54N.AZEX ML+[7R2+K%;'BCD(7V@DL1-H@,AJ@N$5;!>3[N0$Q>._B[CFUVY_E M>_2)W&#O6)_E/>M8[UJ=B-X&KUG"0$=A@,1\%)EY"Q&0V\1SZ^T^W+O67V$U M7;TO=Q;XY@,K-3=QNE'7[KG4?E-RU M60,HI8?^ELOI8GG>!^LCIAFL5INMO=%5_B_R.#=EZKA*R^G7\XZ'-@>>16 E M(53^!(M9<\:+D@E1%J7:/R/8C\9Q9]T,!+]!%=4!$&^UM;B[J8Q5J@BN:I6? MJJ_ / LB.Z84!I-$\$:VOL5XC)YQA]@,!+!F"N@ 3']=X?OR>K6>GL(:5Q/N M1-$2$S-R\]9/U%<\)!8)X%74T93SFB 7B.?TA?,9S.\BBY6ORW(I+Y;P"8![8R?OC$'2OU=$SZ:V#X_+^9G\QVU1 )7RS6)Y/ M#*E5X)]O?-,QZC4VG$_C-)Q8\;6P'P&;?5W M?77)"P,,DF7RU5T41>;<^IIH MP(8ZU];V:I&79\NZO>[ N#C-10B1MDH!8ALH6*T_E)A06V>]L*V=@EUI&[L4 MN@U6MI^##373GX'9TM#F<'/S^ >':;\SH"EZNHD*YMKJS0+S NNX'*EJVUG' M,FJ),EJ>;?/IEZ,UX;E1X8K6H(V%!>XET\)[!J5X%JU(7F8)&EK;X:>IZKWA MSCY8V;GASF$ZZ<\4/=#,YABO9]O'VK?<&=#\[-D\_:>.?FF9RQ3.?3-;Z;?L-[2]\]HKDL5M5&>%E3#"#!,@^< MLV)$@%2[\$'K5Z8'DOHS->C9!VV/>5=#:;*##,,EFXO:PWX;BV_.ZOR*%Z>+ MY?JB'?Y%!YT[O-=W*REX9%[5CONUR7U,O,ZQMX78,W2PM.[VUY+^<;,1SP_M M9]=Y?R?ZG8901V7\'_A0VW950P81C[0:4@Y5MC&RG*I%<]XQ<'4ND?%%^V"2 MRJW/I@&;5MW*'M]I>G0'VIZ+$C*7S!6NF:Z#.[R&0'+(EALE+<750R;Y'Z6N MW]94^^#ET=Q^.^WT9WCN]'XZW/ \_*&VG:D&-#Q;^A,58U4"J%?7M3]1LH9Y ME)PY9R2%J'3$->\;/$Q_JFM O_Y>K]+/IJLOYV/?ZGHW>CV"P1*%9,@C;1HM MD 47-4%:UNYJ6@G1^B'FCJ1UV;]J'WQLMS'M5#*B)[\9_W[-T_OE]&0Z/W_T M76^CZE.""X*N;D9?+E;WXA:.:$L=42FD(VZ%*BSHY!@6KWW*.1DAGK)%;4@9 MUPUO"+@1---11'FQG>Y$QX")ET!BK"-)M*_7JS;5WI6JUJHYGINWY7N,GG%+ M2@>U;4<*OQ>#MB@4F"(I9OUP^*F4RUD2)TK[R+0B9],K4R_M91*9%Y1W$XI/ MF*TG%ARWIG0HX]12REV9H+_4R:N;Z.%]N>G4WN'/%L6#DH5!R;5J'VHZ@V?& M=?U]S"7"<)'>;C2.6V4ZJ*D:0$G]!7R/=.T\//A[^J/#]1H=,"CBD#LKU"=OZ=&!A1,;SJXG'X]NYS.O;W'L(#B@)?(/ #Y+TA! MMK><(NV0"YAB8Y&MWW*WYV+<('9@1(^BZOZ\QV8]40_W-5N3T$N7V ']V)VZ M?6K$Y$S@+&1-'H*6EL4Z0"$7(XU))DML;H.>H5?L]19^JB7IG=<0 H(7$!GH M4B?^26 ! S#%B]!1>57<4#4D>Y+Z$W22W0=;VVWP< KLS]!>=($[W$S>_D"; MOHR#/N_]B$J04ARNM8;)47Z!3!,@O<.7=&Q/'-KPH8]S^#D9(DG%R[$ M39E?HSI+[S-*R6)]J:4!#7DSD3.AA,HY $39.O#>B;"QGW:V1\\#7)9 9 MICWM8T^")E03").]K<]>,]-. ,+@2IRP!SZ@51WVW1R'W0]DE!_#F6.F%M?+=>3&[2_^#Y=36R!$E0!9B0($E^2 MU97.#"01+1)1O]L=(WW[!@;I5]?X>V#9D;,ISZSQ11OQ]X.<5XM3F,XGQB-& M:SW+/M31;I)V70R"1:V]HSU8E-NI7=ONV#E?>!ST'*V^AV%P@"Q'!\*WZ6H3 MG>_4,/4O>!IQ.7$K"9+TI/.&$7,D6D];-ABE&+D'TOB@E&P> MU1Y%\+C5"R.=DL^OZ@YP_7[]!9I*$VVK!3O:^^FR#SM,Z:"B!&=\#&T=F8&:,M[7XY_7BY65U86 MM:8 RTL6@HX47VGZF8W LA%9ZCKG.[8>T?DX16/?P!Z'@Z=[F!XL_0ZN20#13XZL^"#8R0SF750@C>O!MV+P Z[Y1Z# MM,%TTX]S]>!!<:^UU'4_)$-Y98_D, MZ,5QGKD,@2R=<'6\K.U03^;3E=X_M25A, D[PWP.SYS# I6(S>,JYB=#)9JT/K3AA[ MDCCR&,@.S>!AVNLH2M[+V#N #,E&9F)M+REH,P:L>2@-)D1IN6W> Z+],3W< MU,D.\7F(YHX\IE_/\Z##CHX(FN]]H]6XHR$#U<=FV&!227 7Z23DB>E8GQM* MJTC+J1AT.>;4>O#/@/..KC[]$7[_"]FYY11F=81"?7BTPN4W7$V4\%Y:RYD1 MHM2R^\S DR<0N!'%9=H\V#IQ]S15_42BCLXXL&@S,^*BB16.U;CWT=@>RQ@T"!D=8(WWT!+': MWG_U!7,=+7"')U3?7']?A'APT^TJXOPNK M+3/Q/IV=GL+RQZ(\].='.-C'+#?,]+_].7VVV8!26QMCV(1[%/V!]BPD1!8@ M"A>3ECFU;K8DD@LU0<=D9,Y M3UH$#$HISI]M*.4U6;T\OFN)AUV'4QZHG)[Q5AFZ?#L$LJ"(AJE0/0?ZD5CB MGD(7;8HEJA(,<)'T%%F=6K=#H;#S'-3#]-(!U*Y8N'PD5D [D3,3COQ9G;VB MG6@2$V!!@ G"\=;AXQT2.H70H2J^^]3I"'EW )+.84R9YO'79NT[PGIZI(7+\$@"L-\='4*NBC,0P'&423@,A5UP471*?@2! O*6J9YR,P; M5^CX!HLI1:'2'1NU94K1UB7&'0\S%$0:BK4#D[-52N^NWHUR;ZTK)C!C9*DS M;H@C0,]$!D&^G@$56M_\/4U5+TT'QL@.'*::GL&V><\WL1H3!+*K1=.&T3)K M%E(BEK+T('2A$*-U&X''*>HTGCM0_[O":W]E= "M\R;ZN'$&/TY/OJS?E[^N MSL?&_UI?T."+E,Y.SS;/:VX.D)_X8JTQP%E")RGJ2)9%Q17#HH#3_PPOK2OL M#Z6UT\BP#1R?18%=E#]OO\BXG 6QFQ1>(?&0IN< F-\6BK*I0/2:*:U*[S ]G@D6#2[LW_VG;*C,"R=9P5!LAC)(]/< MD\_N2TVG:^G(C2>=M:X1'92A3B/R47?' %#HYXW"H3(IY';M*)CH;'$!'',B M&:8U%A:X< S!833!>QF>[6JX&5>=YB7&W2@#@:*_RJ^W]*_G)U.*SC>,KS9M MDLZ?WU_41!WUD&+7CQ_]PN(@+AK5<-5BT=^GLQDAXRXA#Y0<>@0*%G5FDLPH M(VL:",Y1,/+7429'AM>T?K^W%X'M:KMJ,>T:WTV_X;UES_-!7(!R]0K?*$E; MIY9@^F@L$[PX80K7*K=.XN].W;CICN$PM;W6JZF^^LB";./GUQ]_@?]:+#?C M5C?5),&83 8<2&1.U,$7CD69(\-HE9 8,;@!$A^[DM=+]5=;A-S/>0RBKKZ1 M>,W8;W!Z>1.3ZN69=H91($KL(6UJ\"8Q3#$9:V6RO/49L2>)XR)R,*CL#LFC M]=8!+#^0;WM='H#*"<6#9EX95<.^Q, *SQPWG*2F32G-LV0W">@64L>K^FY4 M65UM6 M8L:]'7A.,+711P? (K]VO9S&LZJD33Q^R8=V$BP*SJRO#9I%4@P41)(3((#P M)IO6-Z';:!DWY_Z@$QOB'3N,X.9 G8)COEB@&G-C8ZN>-Z\ M?_]3-'7K?AV(@MUAMK]*^H;8MMH I8.A8]\Q!\Z2O;:<>1\D2U[J5"(!ICPC MZ+HLZQ@3ABW4UL]UW".,UO?R0NN0BI:LE#H-W)7:L-X:)E6*T5J3M6G=R?UQ MBKKU[ ;'W;[JZ* 4XMHU>3O/6)YR3\ $%=&+^D P, V\UB.+6J+NL@K*68#6 MM0W[43BNT1OCKJ&YWCHXDI_@Z5YFDG-C:LDS*\Z8VFU/,I Q,5%,+ FS3+[U MG<.>)/9R[] >+?=ZN0RGNOZ1^6#R0,L@C#:P_'N=Y;;Y1>7E,O$D309N8F1%6E_# M,O)1') ?K"3YPTE@,:W3RX\2U#7TCH?#8BC=C/T(\.+V97K92?"2!4P!);G ML03.M!*&02I(!TE"711ZD^_T2-OR O#A[X_=F_%YT-)*P!T8HSUL^W6()@L/ MJIC"7(ZV%@-:%BT85H0RH0 H$5L_=3^$SEX2RSWY=89F=Y.C^Y M#/,F-E) GVJ_G%@K5J,KS),1H]@_R<1CK;=MWUET/QJ[/EL;H&8_F!ZGPBX@ M^D#&_3Y74(2Q]04.ZDCG0K:*!4,2M0I?+SPR@IPZR MA0\D/._S%(HWJ!7MUR+(@PV<]E:@GV4% 21(+V/[CMY/TS7N,Z;QD'>TCGZ* MIQ:O5^OI:;UW>7.VZ0)UX]KG]?>O.%_5YXSW)-_T0<91)+1_MM%.(J,\[L@@ MLM8:&**H)5>T!4)6R"0JPZ4-QN?62;-G?=SQR#725H5=":<^U *9D-E$>UB[ M%%G$Z!E9#8F&;(8MSUC5_"2]/],#D'UPM\?58%N==N"(/G;]?I_+CU@3(:3G M6@*U2C#[3X3E)!D@[]L#'4"66"X9F7?U46*)4A6; ]Q-% U:1K$CV=V6]S3& MV![U%D,H_*?#^&]T3G[^'6??\"^+^?H+Q;&"8Z$(DJ'1Y,7Y%!B4""PG0Y)' MQX5N76U[',7=5@SUA.RCU/S3@;INV\^_+R84IV)1W#*QV;F 0#L7Z^ 6;R!H M:X5\1H]C.Z'=%A_U!.%#E/IS(I>@B!,D-I12D2!6WZV%P)FG\X9%#L(6E8JQ MX]KA*U+'S5'\3.C=6[$_)7[?+,Z6DP)2U=E^3'%5DT$H60">&*002LPRT"$S M.GPKI>/V/_F)T+NW6L>^Z-_.8N4JW:FSWO1\N>83'::D/3.R\BF\81[!,R%C M,A1CEZ3O)'*V5 ,<0<1.R+3_,,A\5IWU;5@W)=DN%F4,G1"0:[F$+0Q8+^1US-7"EB\=>4.P"WVM)O'! MCUIN4LO;-JO";'6%'[(>W@1NZ*P+J0;+F4*.$I@-UBJ1%)C2? ;?=G*.-3P7 M0OT$]/F7B]/3Z6I%*KF< 2^+L(Z;Q*P(U3UUNC9OURPIH077TIK0VNX\2M#( M;:<;H>*N56FG@[&]K M./F*$-:XFT7BCLZ%P'#P)15*<$Y*UC'[71AV22'>; M0&P;I'#KNR-W>VZ,@F,%UX'W[V>"1=C'LFQ=:>36P0/:FC;"[<#ZO%S,-Q+YVW3] MY>79:KTXQ27YNV?S_&X*<3J;KG]<[8$2!'+,+#HKF4X@&=3ZI.PT1B6$57& M25$[4C=R\]V!K-) VNG$0GU>PC><3;RQ/.04F-A4NUFH19"\!I::-HQ!9=6. M$Z-N?G;K4W,V%)J]"^8][PP M4;R-/(B(J?5\\LORP>.0Y'\V)+61?7^)O'>+^_P?+U%<:,<7UWK@>I)E8QSH9#K8< R'2.%WA0A,1.L*:YP@[%UL/HP)4>W4*2O MOMW,ZKP>NA<"^A!1LLQ]9#HDH ,WDH\OBT,MBO2V=>[R 3+&S>(UT/N]_HA' MBKJ#<^@V"YL&!4X:[1)P)M&1=Z;!L9 B_>"5CH:': 8&R_A=1XY6[*- V5O* MW>'DQ@MQ!3X[+NCDW4QFL4&R:$5A2MD89SM\M8'[%174&ZV]CH^MB9 MN/%&*NTRZ5@AYJ\\HV!E6!3%%@8*9SB M-5Z#?N$2,T)E;6J]AV^=UWV(CI[ <[RSL?;W+99Y M[C)3.CN=( 3::P/CI0=7Y7@-/P&9 \3= VBF:RKSTV MZ&"%(#G+WH$C&YR<;QT+W:>B+[ ML!.LI;U$@LFFZ-JO6;!0>[-DKIWETGJ4K=^'/D'2N&?4 "!JJ8(.$'6^&]Y MVER-GD^M"A9+\)ZI\WM1VAT^J'J(6ZZ\LF"Q]2R M39_3O& (+*5,/!A=:M>5Q'R1BKQ\TC)O;6X>HF/<@^I8W3X*E0,$W0%8/N*W MQ>S;='YRFYE+"RFD1=2).4=^GA:!^$@0B3>/Y.^9[%)KU#Q*4$_P.43?BZ&$ MWP&2WN%Z75LBW'+:A,F9G#3)(&,M44Z%0:REA=E)QY/+Q;8^H!ZB8US7ICEN MCA9U!W#Y=3G-)W@CVU0[9/!0>PN@]DPKJ1DH1'+. *(L/AK9^BGH71K&]62: MP^0H$7< D4^8SFC5ZN%=,$"&T.J(FF) SLEC)[?=ATS&T0I7NPUGD5I?P=\C M8MRZW^8@.4[((Z)DM5Q//L+\Y#PWQ:,/VD3#A.>UM;@@ZU=XO=5 HZVWA3R[ M79!!7[V!"OK5-2)N+3@N"EH%/8?+L ?%7_I)+@8#$JKW3C_X^K8RDVG3F>BU M-FOM=KI?WD7U8[JA1RCKKKH/D-S("O_+=#X]/3N](%Q9$;SS@9D,E=R(S(L0 MF4L@HG?9YK)3UY,G5'YKT9&5?HC*%BWD-[;BX?L-PJ/Q2*&Y(O9-IA/)9A:% M,2QF4Z2306>]4^_GIQ1_<]%Q@H=FBC]8?AUX@/\!RVD]W#["^MSJ.9!$* A6 MAQW2T9:009TE@B8*K[W3TK3NOWR7AG$?X[1.=QXEXS3(<+MRQR\LN8M_WWW YK\/K MWTSG,$_3^4GEY]/[-Q\OA]F;B-PD"JU]P-JR/K(8@F#98D@\$+<[/N+;<<%Q MTY6-\#&8A,=&33V";[81^H#+Z2)OS"R2->5((I*P*<:+G'E=YUYD[6L?/S*Y M?">@;%]CW*>?K=R/EH+L$P\7.Z?D(@P$Q0 KL&V,#$Q!)H7@X"&$(L41B!C3 MV6BJPZ=Q<8! >T-&[4'W?GYY4KH<4N;2,1_J="8I(_..&.,Z@=%09Z3L5MS^ MZ#+=8>,0/3Z&CL.%VB,\/O^^N'2DDM$I.L^*S!2J@ZISW(MGV9@2M"V2W/F# MX7&US#BNQC/#XS"A=@F/VAOXZI[&2G*2R!7#0KR(&!C!6[-4KX.D-]A46.EG&G54"*ZU+>+;9]?)UQ MLJ;/C9##Q-I!ANQV7/?N:EPID 1T"IGEVFE0NZC(G9*<@0YTD"IKP;>>M;F% ME'%;U@S[W/LP>7< FW7SC]NE@N%[_7VD;X2G^R_C%!97) -"QP M#$QG\KVB) 95(1NTZS[T]?0*^$! //*(IJEVQC[2'F+L14JD(]+6 M&X3:Z/OM/"T1:+7IZ70](7:\L&374ZI-N.N8+@B86,G&U@RF*F6WKI![+]W3 MR\_C8/4,HO\9@/7ZU[>?7[WXR]EL/?TZF]:C'J2I;Y%805/GS=9GTH%ORN=R M0AXKR\VP=7?UGA[?/!.\CE) !X?F;:']"JOIZA/1 OG]_.;5BYAHE-O"K,EM=FO9)0J5\Q#J=KSZV$Q1%@:=-%#W4[B4Q$E : M0^U)HGJZ66V#L+9Z.!A8WW 9%P- Z^UJ=0;S1 [#C4<,$U-*2-(Z9A50(.-S MG8KA.$N!)U>,,^1P#@BM!XGJ*7G1'EK'ZZ$+:'W$K_"C2FAUFQ&N!)<&GV$Z7[U;K%9D6N>O MOZ^G\Y.SZ>I+9>Q]V3"4,4MM!&?.F7J"U_)M)2)MCIBE)YZ\T(U!]"11.\$I M_$QP:JN'_8$5SH$UQY/JP'UN^$K_>IL\?) K[1S7G#,/13"-H!E@'6#GE/#) M@')WBTF:&JG#'2K!?R: M55$!Y;KH83+7^=G*\R7F>'-W+%UY?D-XHV81"6# M* (PSV6MVQ2)U3P,JTU+DY'!H&[>*>U08G=#XD^?W&^ON X0NCU,?ET*IMH, M_@9S$"$GGQ.+VO+J==8G#TDPB,D;';,5,.R%Y1,$[H;$G^(^8'@%=8"^F_,' MWL!T^1\P.\.)*RA$]I&)Y,@]A3K?.D7-E!1.4Y1C@FX=8SY(R&YH^BG2_^T$ MW@PU0XW=^)2^8#Z;X:+<=E$7&Q>UW2R.W=9I.Z#C -Z&G=HA@S2$#LN$+V1O M7"8L:E L6T4@-9B$&^) :#^UXV_+Z9I._%(#F7-0;[;?1>[EY6*UGM31?$&2 MQRFY0:9Y#!0U\UP'5_#D.6A36K?0>9JJ\>LJCD3%70O56!&CYKXVEZY_G<-Y M(1OF2RZJR!9G\_6&UT4I$S2<6"+;*US:9/,4"X)[5K-X-@4'3N_69WV'Q<8O MF6B$F$&D.W:-1)7/A^5E'$P_.YV>G4Z02YNXJCUY:VNIY)!YZR4S*:/G0920 M=W_Y=N_SXUQ?:4YZ!U"XT/H[9J.#KC^4R#ZZZ]S,N1%9MQ4\3:'G VYB09RN3F"0.:6S __0.,\XBE\6[*.ZCI27KI;^,NTYD[XFQ^T36/CQM0*WLF*(3 M)-8@GZ%NF4 MYSUB$Y SN30=!]B(QYSYTD@Y;=;'>>=-]9+KT5D??9C< $J.#,PRACG! [B! M9-/[S0CPY;"2U,.)"H253O48/JWLO%.GAJ"G'/,;0-*^U#4"QEBRN;.3S/V M7,J!**(1F'V6I"0UCK(PAH8TO#GKA)ERWO1I_&X -L_>Z&934*>9F0_/)"JF MP AH4A-7,Q84'"]K-:A3:DA23*7BR6:'*6K)D3I1Z ?R0P=*H $\/>?0DU2A M^Q2AQRU>*9^H9<&!AZC!3>0:CI^B-@\ 5S4=)*]^G+@4*@YJKG(B M:@)]Z\^NN[*O4A<7C[OY$)=76#M#,.CX)".PR^74%.E33N?V@L%YQ;)\]NP1 MHNK/*1\-:27%T0"^GO+J[0M&44VU!0L1T9 \'!6>P%X$\S')I*S$5+,PQFOH M'G):>KHH?T\.X7T#,#JJ@3?[NY)$VT@ER7U16 ZB.*0YL"\* ZPR%,@?M_AK M/VWM7(^#P-#W;CQ%,DT@;EL3OWU4PR%H$ZF(R+NUN\XTAWZEIZ9BE_51:43 .8.ZJ?K[C77E.2YV5("FY+#MM%"\QSQDHG M#9'N[%=F.W=E233TO3I[B>9TK+W(V"_L3(*:)MK90%A$!#R4/+C4@$_L$I*: MFV!-PK%XJ[<]I+1S2XZ*J^%B*(:F\]5_G*/NX]SU'A7K/!*+CD9BP4HG^3DZ M:>28LRAZYI7F6*;B3?3.5^<1M'"*4HZ$)09QYB0<+^WS"(\ A\%[9LN;[Z^C MSJ./W+O4>?1A=0/VTL[<="4U(?!W432!(!Z"!9Y(AX*B1.<.8EB,88VW7^?1 M2[A=ZCSZ<+I!M&S>V 5+G L7D 47-_NE%&EK#<*.>D<)9U:45B^OILZCEX2[ MU7GT87<+H-DN/[!!&Z>81MZ%//PV5S. (D8>#'Q*DB.>%N\F]#KJ/'K)]GB= M1Q]&-P"5#[-E7'RR=UG9?EQ^B_/-_U_<#S,4*HD(OB%))B'.X1P9DS>&A>$* M?$>P^ OCY@A)]3VLPB J*8(&$+6CWH$'DA). MB1&.)$>-B!=:XUL,N[@-=F]T0X41*T:! /%S4C":D \]A3VIE,I+; MEP,"]R#DZ*=:NF]*H*0L;QNX@'94R("9A?.;1VZ0E&N^B4".9LO+3650>6\Y=/X MW0!L#B7!.4Y("A8C9IR \V03:J7P*J$:00CM#QSHG]S,,&)!)(^' 9N0XIX]0FW\4GE*OHZ7C/B$, M++L8S5\?#VXC2*8=X.U@VY54!D?P1)#(S?%YXGELD'9(:L:$X41R/69E=1\X MC69YCP6GH?QN(/FX1W*M%A$S[Q6BVA'8F:'(:8R1#-Y)CX,PQ3/>"Q=7G+T. ML91M7E RS9GJ[_[PU[2*X8$A&0HY[DKAH"@8$*VS*$VA 8UVR,Y.IM2MIQ!4:$ M60$AO*):LOO1M>_^^!ZGBSA&*=F>3XQ52=9E1^,6DCGI>&+6(AU]?OQ+!&[# MQ% PAGDJG'+%2]G/5TB6O#013@(2W'+$<]=PPXQ$5DAOHC/)^W$OPG8+R?K( MO4LA61]6-V#![RQ^$409FR+/&A.\D.@%LM1$9*324B2)/2X=)WT=A62]A-NE MD*P/IQM$RR8-P[-@O6(>Q6#@#!ELX0Q%C6C$"6[U8*POW?#OU122]9)PMT*R M/NQN 33;]4U>)Z]!\2)"81L\ %.T51RYY$048.LS4KQ2]744DO62[?%"LCZ, M;@ J.XH5%&&.)*9 Q\8\RL(S8$AN":T)4\98(_2XV4QMEOT,N8D&RG#\-K/X6\'$][ M,0T[ZA$VFE,$Y;W(!>!2Y&),2<%#4 8QY2+UP<+.7NB=/6\A?;[:$F9.%?+L M'!RO#:7#U4[!"*IR@FE*.>P4'9RT0!DBSBNIE.S#<$:7YIL;<(<,-051R(EB(&K3$J$AIP8(9*MM.LZ=Z,+H!L!P>;&.= MB1$;CUS0/C?CT\BDW-&=1.>Y<;9\C=#PJ4)GGDG51]Z]I@KU87X#2-J70$4- MW-K,4_ ,5%;&"FRPD(02.:EUKA@4X@'TN?51(>D4_-H&Q5GI$/(A>EIRQLJ@ MJACWFT/2_4MP3C_Z-(\WD]N;*V^)#EQA9 G):>0)>"9%0+ 3$I5EBB@Z*IQV M$-62KS8&IH;*H780Z(7>?3N[N9DL,[/>Q[BX$HYQYQA&43N9^U@GI&T4*'*B MA4C4)=>M /+@9UHRDX9AI#!+&] Z.^[EJR"#UD*"SZI2;H3D(G(^640B4=(Z MH34M;6#O(*,3:L1K0$TI7C>?_??0)FE=+'!7+NEOW\IE<_TZT3]NBE_@4F'O M&6(X/X8S;9&U%D 1J:?62!UQZ4ENYTOQ,\F% !L#GU0#V'4@ '9B$=8QZ4@D MU>:OFN+71^Y=4OSZL+J!:VA'(-5X*I)($3$FP,K2V*!<^8UDLHG@H(0H/K+^ MQ*>(LZ;W]1+L\:>(/EQN#B>;B*GA*J;<(<8]+^T6O MXBFBEVR[/$7T870#8-GNGD65-#9(!V3G%I\4BSP/RB(A,38N8,5>-L7\2[0H MZR77HRW*^C"Y 93LR$+"+EG)&4'820+\< D9GPP2E HO&09),PN!TI"@C$AR\09[]0AM,C@Y)S'221!#\5\WGZR7CKOE\?1A> M._YV.&'(]U MKA6!HY3+ KG).2,6&0WH=X;0J(!IL;A=^VJ*FWI)N..4K![L;@$TVS4WAB+V[JP^@&H++OV<,ZGR(+ M*\.-PS;RY&26/)AU/+IH$]>B=(CEU>1QX'2B_UP;6?!HO?Y]=":65 M2DX@G1,5.(T8[!"ND'->"*D3^,FE7Y-/H;,E/[,"-$^1UJM$)$ L7F'#(O)^L88;%XGY_3*&W)TJR%RMX2>XVX?#^[G5]9+(RS"38I M-08K/O=H)CEJX -GG&JIQ)B=C#L3VF9:W%E1V5M>M1\!=NSP[B+!X@^[@>.E M&9$*1:,=V,M@EMAD'%(L6,:#MUZ_J*;LT-5XYZ^!OR,P-H&M-=S#KVU M\_G=ND3F=KJ\TD2E)'E"S.?V V 0@";.J6(J,:PQ)XJ5GT"RGYY.6%*O 4O% MN=]>KNZ'"#N#G^(OL\7B4YSGO/79],LWX/5CC\LW=C'Q\#>W_\Z 7-Y"7QZ8 MZSO&_@OE K^S\RG +']Q]:TG@R@B$=I;Q$0$CP![EHL)(HHN"6>C#N7'*^RC M97BAP3WOW\-)?@L^^&1Z"Q_Z^#W.5W)<7"61C/!) 5%$(BZC1]H'CR+!1DHC M'36E=WNRVNO+8)V>\02PP(-X9A9PF%@'S=.[J8!,NCYV.K]2:B2=D4$Z)FDJ'0KN3V7=D-LH.!M95 VHJCT[7)^N+R"^ M57;>SS??\]Z\LH1R1Q!65( :EA+!^7+(4G#1:<+&N](/O7WHJVOMC8V5;M < M+K@&0/E,O>\S>>'K?9M<@YL7*%;PB-DDJ@+\ZY6%7U.?Z7$OR MV"O.M Y6J=(^22'2ZP:*Q[^SSR34!F[[?\?)UV_+&"Y^P!Z_Q@^W.;/L8UKM M:_'Q=KE8VFGNH[/>7/"4!\PLTHJ#ZQ; T+614D04EL2IR!3AA1';B\"Z >A1 M<#F>@!K0I"\YMMK$ ]NH(R8:(W+=,EP+3N2^[3(@:9,E6,G BV?!'"2H;DAZ M%'25$T #:#JNOV&;JQVN]GK%+!>P XEPMFIXU +!;\ *\7""F/;)I''C,4=) M;"M . CBP]WVA4!FO//9(^@?X67"'#% :36R2%E6-&ELZ= M/YG8MD*"8X%S+.F=#%.P ]QLS/OW2@O)50H>:9F;VSG"U^D/5D=AG8,_B:7] MZ)V$M!49+ >PX5Q_I2_ /TVN;\&4K?(&W.7;YW@%[LV#L=^!$SBD4FB&/&?9 M9: 8[E;OD,'*YU0\#U;D*WD'ON?RQW0!&CMD3D]^Q%47B57>U[HK; QKH^/F M^^URTXGQ)4'KXAMNA0Y$8Y2$3X@31Y#-BETDKHA)AK!8VCXLNX.VS,>3$+?5 M$J2>B!LP+"]^M_/P4'V*A:2K)L9>>8ZXI0GN#I;?F:2F4J; M-9'PLJWKR6)I %/W)D@,F4MQNMA(<&ZG7U=!^L6;N\>_\VF=.+O:\>.VI^'3 MM9T^Z;] $N:PTYS4D0<-4#!KG(<3SVPTR6+!4RP=*!QC'W41/@!6+[5F;1DW M@///$:Z?B5]NGJ1^FTZ6B\]??KMO+$4"DR)J% AG:0V 9H36 /C![TFQ^8Z<^KA^1-ML@6@EB MA46,L'R()WJ. M+5$8^<@HXHE*9+FTR!FNO796J>)=Q4O17OG^;L@[KP&&!@Y!J8PF*UGDP1"4 M0 ,@KJ-#&G.,M V,*>JL*=[HX9QI:N.Y[U5P-U):6Q\0M(;][>WEFVVSO2((XBQB9!/A2%%AE8'=$%WZ.>1D8NNJ^/;P/9J@&T TG-L? M<;Z8N]1,'255[TG4M,_;%HUEB?%V^9O45$WC%5'YPV410,%$=WY]F@_O^0@T6#. M1"40L0Y.CPT!&MY*4S!_XD73UJ0[\.!AH ?[^:0I&(M#@&)!*#DYVB M1(9X#1Q/"C8IG&*EX[_EBSY'>[YKPFX93Z #W+SE*"4J&P6P:EKP..OVL6F! M<,E&!@=0!!I@6_>&X.;:>G/,E>N6)*Z\"313%DS\"'E/O].<2)ESI2+'CQ&9;# MJ:X+Z+.";-LJ/J?$&\#XB=R^\D*9A"5!T5C87!($&:,,TL%B;HRQ.I8&]HFD MME6JW:!Z[B7+!J+4>PS^?1N]DL;PH!U'U#N)>$P:67!,$=AJ5 BA0"64SF/K M26+=UCU-6,5C"K4!S.Y1 X]EH":,VT)SJ6'I?< MF\@FO:_3(')*HZ"3Y=4<((\VFWFV5;#MB#!N ZQXVPA6CX)+1'(4@\RAB 1X?G$(4;3("<\X3&[ME MT(:4MIH&E819"=Z_JL9!NPV@<1H%'?[6>(V!>NQQ[$9 <$M*)AE#-H^9YBY' M;9AE*&ILN-"!B>(^XBMI!(1II-AXB@AP G&K,3*2:N29TCS*P$TJWLWBK] ( MJ _B1FX$U$?$#=S# _?\YF[W JM&(X3;1&FVH#W<3)RJ@+3'%@4N9>*YWBXV M5O-X:#M_JB9%O5!:M@RR&&2:/3U/RJ=QBB9P+Y#G8*MQ13W2.!M7.CGFG0]2 METXB.$;3JZYE+ >>3J ^49(-(/-+G /];Y[7;VQJ\ W5 D=)D/!YRE3N[6XB MH4AH9V1R/@E6W K93TZ+>#Q5[B]-BT)": !/A_LFX>@Q@1L%*2YA,X)89'#* M]?46 Y.,ARNE,**&-[TZB$H@.XV=<'2_I(0'LR1#3VB'O,X$IF!@F.F26@1XDJG2TY MI''9F3-["^&G!/,;P-#^+GXN1^ E^!X)4V .E1$YRPA2<##]:PVUBO'1*6AETZ12;(H2W M& (9&W-E@7\" (JAOM@+]OII]]+^,>AM>L9*N]-UV@)S!QF-*T6>D/WSCLUW&74EI5\'% MQ"E1"%MK-FR+,>13GOZYLOM=] G MZPJ=1Q[.TEN[^/;^>O:[G88/LZF'GWZ>_HB+7*8.OWH_F8+SEHL>,I.&9M(4 MIV&@KAN7)X4TY5,B[PE[M_[%8_&+,6!_8I%RD^4 9JASR(&WA;QBT<)AT+1X MM5P7NH;GN<)Y ,9_LI,\^^PJ>AH9BQXYQ7-AF%D-*B9Y?A[A4GH1=?G9J\]( MJ)P84!H+VTFIIS.\ <_BB?&2=W E-=?6!0QB=3S?#+DUG74YMULJB8TM/Z7N M!0F5G=WQ\7(ZPQO RSU/7FKYB]U:?MOTH$QC@F5"B;,\N\-P9%UR.1IE,>$B M &,+ VPHS97G9(R-R+.*M"*$5QT[+Q:+N+SP_[V=+"99@F"W+B9A8[%>SNUT ML:;IO9W,_V6O;^/'].MD.KFYW13%? 6V/_MWKD)T G,C$0DI[]Y9V+TS^9%0 M>9]HE-X<,_/&(:WNS7M>6,V:D7$3 Z<_YPK7C^FW15PQXZ,#:WL:P\_3=W_X M;[F!P/O9?..H3;_^$BU\=F+=Y#HWV7**:AV%1-A0EP.T$5G&.4J!)PMGEI0OW3B*TKH%1%(&O%7G54*:$+@H2&)$L$XF;N=/ULWPJ6>ZCB.3 M-I#VT^;+#RQ\.UOD)E;!,^NX1C09@P P&&DM.*(BY$8"3(F >X!K]U?J9OK4 MQE,!SK?W/).+>R?KP1IV&AX\-S_LP:7#J@.?4/K27>A1Y,EG+UY^=AMPGCLI MI0U($BK P,JMP;1+2!'IO%><.5]^OE$/ @P+IT1C-6?$SJ3D(J!VY&0\I65LM@*33@FK[-XB73;*OI@9K%Q1*(2=X M"VV0U10V9>$F]LS%0$M79NRFI"W,])?P$3B.1X MGD2>*47P[0KS M,E#)X>Y$5.$\"-89I 'KB&EN1*2.;XEYMSZ 59_H OCI40\\^V#EFM!B5\7I M7&Q!]!O$$FO O1<:F21$3B(!?X\SBHRG/$CI"7>=S.\NPJ]Y_@<(ZZ6X3^!< M98%OWASO"3=PF7GB492YR:SW.7(8(E)*4V>43Z3;/(TC(G_VTFA."??K2.LB\F^)/YUX#Y M_QY0NXR_3'[DA]HE<"//+5Y=?XLW=[_:_YW-WU[;Q;ICB]*U)Y&J/UP8N$9'()\90[ MGBLX7=I%X+ -P?C2E6(]2:SKKXP&E>Z0'"RW!F#YTV2Q'G8"8ELEL]Q7NR?A MK=%*H!@">&P,_N$' M"DS%B7=.,Y12#(A38)&3TB'*"5-)8$IMZ5>-O<14[H$R>FCV-*XW )_-H*7% MY6RUFWEF2E"TB"JX&UDIB(TO': M;I2U%C\"VXHS#H-G,X)L0&UV9<.^%'NJ M1"1"$40ESG50N35?8BH/!DM6$Q&B&/MN[DER6_YO&45[3BF^%@V\9Z_K1.4K M+#FSA:[*8R]'49'%Y=&:E?CHH.6G M2Y>?+U5NYLLE\,H195%R3I$0L4S:GJ3F^OG*^G4 I" S&U [._3N+FWZ4&_[ M-M>*39=7.%D3J#/(.Y*K=CA&SL"/V#G*1""6N;$SS#N2V@E[YG5@[YQ2:P"< M]]'2][/Y+_&KO?X2E\M-PY K9S"UC@:DL/.(P\%"VIL\'3$/N59*P*]'"EOO M(*=;K!J_+I258G][)5>?(ZCKV_CE]N;&SN]F:?.SN_L"=_[']"7.?TQ\'%!] MU>\# PNQ!NRF4$W6YHOW(Y=S/;'2PVZ3V<1*^B$ BG(!"W7"$+I@@8HH)QYCTW MM$1=P%X"ZB6,#Y?I-D &,KAV9.*?L\6J*\DS<^4^M3HZ^$^2B"2#$2=<(A,# M1E$&ZYGEGG>,31SX2'4P#)7?; 1FU@;%I_GDA\U;2$#_KLUX%I74N1VW$@YN M].Q\$&"3]IP&[X6E@79"QK$OU:LQ& $>1=E:&R.KY*E=FY"8&1NH0%)IG,$L)?# M"?=87KT__3KBD'V \LQ(&U<4M2WY_5OZF#86;U;H69ES+J,Q2%J6)[]9AK2Q M&D5#&$]*2,V[X:OK%^N:9*/#:A3&-WNK;3^1;?9X"12/\=RW8_FQ'ON.[>3, M-Z*05@=M ()"@/:AB2-G2$)Y3KAGN;@3=^H&T:)X_1JB +:AT\)<\.$U M4/6 M"(H$]Y0&88WK]DC_EWSJZR7\8T]]?231!I)VA"69C-(3P1"&^Q)Q%CG2&+O\ M([6&F,"ZS:[XDSSU]9)IIZ>^/@RN;>?_>W8[#??]CIQ-@5*#?,R-KH2,H*>3 M0$IPIRRATHINIOR31:L+>ZA\9@6855O(7V[G7R?>7F](CRD0$1A!P3D,]S') M*E%K9'G4U&$9F.K6Y_/YNBT^RYTLZ@$L:R#"W342&ZR,V.32;V<]XA9TGP;O M%!Q)8R7%5D1^?@C$J+M,_I.-)XY&).EO!4 M*^JD8*KTV*(_[<-++[@4>'CI([OV0E1Y),%Z]GP,CZ/G'U4#_/GWV<)>_V,^ MN_V>IS:M&;#[7UL/Y_T"]*SR]0>$MLY!UL"0V-DY5RB4MIL L"J>$_PX&]?A MY SE*+$H$'>2(QN# B.!1"JEXTR4?A3N26*9(=X/S']CK^W4QR_?8ES"-R]" M6%6WV.O'\1UP(?82[_JR%$+Y0!Q'PA@-FDGP==TFY4S:R!VUJC0GS[2UNC?# MF(C>/7^\+:PT8/2,SY95& .[9"7IZ= MU3U 38+Z[ >O-\(:.'>]-OBDT:D4D3@3,?("@ZEJL#,JECY( M)Y+Z9S\9_5&WW7=V= C4CNU]CE_C-*X3KWZ-8>+!VWMSN\@I HO?II/E?19Y ME)A+B5$@-#>PU+GG'ZS")B'BF!8LAA#DJ)IRFZ2Z4IOPF_3F[M=HIXM5Q<[E-SO]8J_CA;/3,)MF'7#_?&24BE%X9%+(1@P<6VV( M@7L@1FR84>)ET>1(@:*>A#<+U%/ M W5,TNV 3B/?T4]>6T :R>Y:,%REQ)Q MHB.RH#^0$B9QHX*GIG3WC#-NKVZ/YM=@:K2*M0:.X;-='M[D/U:.Q?6*8S>3 M:9ZDLG(SWOWQ/4X7\2HZ%KAD%+QB$ [X+.!36'"2J8O,4*$LB2.\012B_L\> MP3@1H(>,JO.AI79DH\>V/P-P@-!O^6$C_HC7L^]9H(^;EMX*N*-]-,![1F'3 ME 7$-9>*&!)3Z-:RHA1%?W8W=1CLZPF_@9MA+9Q?9HM%SK38$[&*RX_ITOYQ ML5Q/U7L(0UIG0URY<$&9E$+Y%WPB"L'EJE/$1'A?5"&D!A*UWL4(_[/ M;ER5N1?J8*585_F3$W56:R^B__^_SG[\G^C#>OF+W^T\7$YN-DQ?"^9X@LTS MT#]==(UW'QYAOOL+/7-E3B:^4([+EV]P!M[811YL<9-5Y.98S?/XW%7ZXIN[ MQ[^SZ3BZ(F]-(WP&#L$G.!)/'J+*JI%12!R;U8LTH XC1I[>9&([+Z!)]=SF^FX?VU_5I$4L]7K.('GR2GG9QH1$KY MQ+^=+L*\G)A>+%G%*#]9^VWSHA%!_7/V^R-]937@GJ6KV- G">XP;RH+\.%. MS95 [V?S;!?^RUX//FZ'UJUB O<270>NM'#P%F^O9XMX.7L@=Q4D+'?ZCJQ? M959=_R/8C4O-RG,D,=89)%=(>HT([>=IF/R8A%M[OLZRYU. MT4&F%!?6N1-U=N_J9:>X,8.2]>'^+ [Z\7O>V_C!YF??J=N1I5;(>1>K&X## MBK:+[_!Y/UEGP4R^?ELNOEQ\_C(*+(Y_KVK*QCGAT9GUM0V87;<'W.AYA^6] M@?N%JPSW'>X/O.!+"Z+[;1KFUW=?OT1_.Y\L)W%Q<;,<+K>=J]89EMM?:H=8 MTH+(WOTQ]Y_F$U_@?#TNU4DX#3RM;6V^!8G\ VZ Y4]V&=_;R?Q?]OJV@&AV MK-E)1@T\J.UG1V5A/3_9=[_^9[F"TMMOTZ^?_#"U=V3I3J*K^\;6C3GU.ZCM MSFU\-U\%OD=*RMQ>O4A"YA&B!R9C9J%^CG[V(\[O/J:M;VV!X23<=_K @".[ M6?7^,\.CS#L7K!8@ZR.?IX?U$%LJ*]F<47G?1@_^=W"T>==ZU>1UD.^S3DSX M2[\#C&*==!7*WR\ ?[\ ])+-A]GT0YR5$,KSE>J]F!WB]>S(QANZ5R(L>3.9 MKKLTP"^+73!;"U=3:J=:!EW85%OE??VZW&QJ<+3I^5+5,AE/E=9N5E26SSU! M4WM]MY@LRB3I[%VT6E;C0-M[+WLJ2^_+\C^?YO[C_'(Q?[=83F[L^FFI7+IW MIP]42WD\5:I]V%99PA]OEZ#CIZM&^.54Z?Y5J^5 GBK+HPQJYP+\,%O^3WRX MJ6.I?.0N'ZB6$EG@LCS*MLH2?@^+SJ;Q?JL7FC^F?LYOX=G8[ M7<[O?K&_CR'[@Q^K]W!>$@%=^-D@#&#'_[VUUP]-(5>-3M[$:4R3Y>!DB9,^ M6.^IOB0@67K)1 4<,+:M/5V$%C8CWZY;"-+3 MJ'3B3Y?U!YQK8,[P7)^'1:H]N/:0PM,3^7+WM1^$_HC^-G?X?0MJXNML?CNEWUU4!2S?GRI++I/<59 M3H^KU,PI.<[KV8&-UT_R 9(^%!''R[7J%?7V%,H>)OR=JWC.F^;O_,2_\Q/[ MR2;\[^5LY8\//1[/5ZJ61G7H=.S<;&T!7%\_D%7F:+Q\5Z%\EI\CK(E]I^"I 2'HSZCRE-/*S[?EKFK!U?O9X*/$V6G?E5 M6V?&.%\/(%HL;@M*]-"ZU;)S3]6CQWE46Z-^RTU@P@.AI:1X:-UJ>;FG:M?C M/*I^%F>7>8!0B7?@EVM52[<]^?["04$M2N):LEUIXN MKP.TH9T\1*,Q4E5*-^]:LEB][HN".\*:VV7D?&;[X\;68;MR[:+U4UU.M MS"/L:4AZ*\J>:(B20MRU=KT\U0*R/,"L%E3I ZG%%>K>E>MEF [1J\<853NS MXK^WD^5=[I&U9B6X-S>K7J _31(0$V&WI:3;\U/U$DY/%/=IK*SM-KY0,_]: MK"Z151?1;[-KX/+G92E/LM^GZN6JGAR[.X65S>_3!;+@D_=^U?M),Z6PEE' M&51;@-N:96@D9,^2G;(56@IF'69-]29$NAK([,:F#&R(/A M_LML47K"TO.U.PFQE0#60?94MW9>6-Y#C]_.!3N)JZ4 U"&VU"YUS@95WE$A M@>U:KY.\6@H8'6!*"R'^(NTQGR[424 M17EVL:&Z$3(;G"IYOT8G>;04@WFQ M^3;2O >+HV^^*FTI3-)@FNIL^@\P7#:$_107?CY9/<,4RE,]OGPG(;84 .G. MLNKW4IADNNPUQ_3'X^Y*/3\?6[V39%N*A71F6*L--7Z>+B; ULNY7353?3+J M\#GE [MK'/A,D58;7;=1H._&UJ>V ')B_>K>98?$PAZ6>Y.;,PWON+%SP8K% MG<=D\2SZ=8 9M6.6#Z0-KFI[L50UV1SD]DZI-%3G=G%]O4.7E*D W;]P [(Z M4 QZE"%_-Q.H=8;^;BSP=V.!?K[UD(2^H'%L>0V8%EJ]77]A/;<<8T MH0!7=)68U[=CN6JUM:W>82@WN73WBO5J:$_1AGOXT82L?KJ=KP@K(*2'I>I5Q9XB MG9<<:$(L7Z*_G4^6D[BX^/KUXH>=7 ].X#VP;KVZUU,$=I WK^.5\=/L>N)A M Y_F,S_B*^.SSXSPRKA_&\5?&9]^:@LC!9X;=Z\_*!:_63X\7;J42W=\]49> M) _*[7D OR._JK^Q[*+SPVRY(;5,&+G[5QJ)*@^4\P'^C:_1-W^0_^'L(O[? M_^__ 5!+ 0(4 Q0 ( 'R GEA]_#;^5Q4 *6& > " M 0 !E>#$P,2UF;W)M;V9R "FSP '@ @ &3%0 97@Q,#(M9F]R M;6]F<'-U86=R965M96YT,C N:'1M4$L! A0#% @ ?(">6&(H>")J&0 MS9H !X ( !.S0 &5X,3 S+69O M " >%- !E>#$P-"UM:6UE9'AX8W)E9&ET86=R965M92YH=&U02P$"% ,4 M " !\@)Y8O;5IV_<' P)0 #P @ $^ @, 97@S,3%C M96]S;W@N:'1M4$L! A0#% @ ?(">6&642G3S!P +R4 \ M ( !8@H# &5X,S$R8V9O#,R,6-E;W-O>"YH=&U02P$" M% ,4 " !\@)Y8MK_)ZL $ ")%0 #P @ %S%P, 97@S M,C)C9F]S;W@N:'1M4$L! A0#% @ ?(">6)8,N<:6V0 ET@, !$ M ( !8!P# &UD>& M6&ZRP8EQ#@ 6I@ !$ ( !)?8# &UD>&'-D4$L! A0#% @ ?8">6":1Z?7T* ;Y8! !4 ( ! MQ00$ &UD>&PM! !M9'AG+3(P,C0P,S,Q7V1E9BYX M;6Q02P$"% ,4 " !]@)Y8;**(]WC3 "D-P@ %0 @ '& M:00 ;61X9RTR,#(T,#,S,5]L86(N>&UL4$L! A0#% @ ?8">6.$N'^05 M@ P/4% !4 ( !<3T% &UD>& XML 82 mdxg-20240331_htm.xml IDEA: XBRL DOCUMENT 0001376339 2024-01-01 2024-03-31 0001376339 2024-04-24 0001376339 2024-03-31 0001376339 2023-12-31 0001376339 2023-01-01 2023-03-31 0001376339 us-gaap:CommonStockMember 2023-12-31 0001376339 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001376339 us-gaap:TreasuryStockCommonMember 2023-12-31 0001376339 us-gaap:RetainedEarningsMember 2023-12-31 0001376339 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001376339 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001376339 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001376339 us-gaap:CommonStockMember 2024-03-31 0001376339 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001376339 us-gaap:TreasuryStockCommonMember 2024-03-31 0001376339 us-gaap:RetainedEarningsMember 2024-03-31 0001376339 us-gaap:CommonStockMember 2022-12-31 0001376339 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001376339 us-gaap:TreasuryStockCommonMember 2022-12-31 0001376339 us-gaap:RetainedEarningsMember 2022-12-31 0001376339 2022-12-31 0001376339 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001376339 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001376339 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-03-31 0001376339 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001376339 us-gaap:CommonStockMember 2023-03-31 0001376339 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001376339 us-gaap:TreasuryStockCommonMember 2023-03-31 0001376339 us-gaap:RetainedEarningsMember 2023-03-31 0001376339 2023-03-31 0001376339 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2024-03-31 0001376339 us-gaap:EquipmentMember 2024-03-31 0001376339 us-gaap:EquipmentMember 2023-12-31 0001376339 us-gaap:FurnitureAndFixturesMember 2024-03-31 0001376339 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001376339 us-gaap:LeaseholdImprovementsMember 2024-03-31 0001376339 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001376339 us-gaap:ConstructionInProgressMember 2024-03-31 0001376339 us-gaap:ConstructionInProgressMember 2023-12-31 0001376339 mdxg:AssetRetirementCostMember 2024-03-31 0001376339 mdxg:AssetRetirementCostMember 2023-12-31 0001376339 us-gaap:PatentsMember 2024-03-31 0001376339 us-gaap:PatentsMember 2023-12-31 0001376339 us-gaap:LicensingAgreementsMember 2024-03-31 0001376339 us-gaap:LicensingAgreementsMember 2023-12-31 0001376339 us-gaap:DistributionRightsMember 2024-03-31 0001376339 us-gaap:DistributionRightsMember 2023-12-31 0001376339 us-gaap:TrademarksAndTradeNamesMember 2024-03-31 0001376339 us-gaap:TrademarksAndTradeNamesMember 2023-12-31 0001376339 mdxg:PatentsinProcessMember 2024-03-31 0001376339 mdxg:PatentsinProcessMember 2023-12-31 0001376339 mdxg:CitizensCreditAgreementMember us-gaap:LineOfCreditMember 2024-01-19 0001376339 us-gaap:RevolvingCreditFacilityMember mdxg:CitizensCreditAgreementMember us-gaap:LineOfCreditMember 2024-01-19 0001376339 us-gaap:LetterOfCreditMember mdxg:CitizensCreditAgreementMember us-gaap:LineOfCreditMember 2024-01-19 0001376339 us-gaap:BridgeLoanMember mdxg:CitizensCreditAgreementMember us-gaap:LineOfCreditMember 2024-01-19 0001376339 us-gaap:SecuredDebtMember mdxg:CitizensCreditAgreementMember us-gaap:LineOfCreditMember 2024-01-19 0001376339 srt:MinimumMember mdxg:CitizensCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember 2024-01-19 2024-01-19 0001376339 srt:MaximumMember mdxg:CitizensCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember 2024-01-19 2024-01-19 0001376339 srt:MinimumMember mdxg:CitizensCreditAgreementMember us-gaap:LineOfCreditMember mdxg:SecuredOvernightFinancingRateSOFRMember 2024-01-19 2024-01-19 0001376339 srt:MaximumMember mdxg:CitizensCreditAgreementMember us-gaap:LineOfCreditMember mdxg:SecuredOvernightFinancingRateSOFRMember 2024-01-19 2024-01-19 0001376339 us-gaap:BridgeLoanMember mdxg:CitizensCreditAgreementMember us-gaap:LineOfCreditMember mdxg:SecuredOvernightFinancingRateSOFRMember 2024-01-19 2024-01-19 0001376339 us-gaap:SecuredDebtMember mdxg:CitizensCreditAgreementMember us-gaap:LineOfCreditMember mdxg:DebtAmortizationYearOneMember 2024-01-19 0001376339 us-gaap:SecuredDebtMember mdxg:CitizensCreditAgreementMember us-gaap:LineOfCreditMember mdxg:DebtAmortizationYearTwoMember 2024-01-19 0001376339 us-gaap:SecuredDebtMember mdxg:CitizensCreditAgreementMember us-gaap:LineOfCreditMember mdxg:DebtAmortizationYearThreeMember 2024-01-19 0001376339 us-gaap:SecuredDebtMember mdxg:CitizensCreditAgreementMember us-gaap:LineOfCreditMember mdxg:DebtAmortizationYearFourMember 2024-01-19 0001376339 us-gaap:SecuredDebtMember mdxg:CitizensCreditAgreementMember us-gaap:LineOfCreditMember mdxg:DebtAmortizationYearFiveMember 2024-01-19 0001376339 us-gaap:RevolvingCreditFacilityMember mdxg:CitizensCreditAgreementMember us-gaap:LineOfCreditMember 2024-01-19 2024-01-19 0001376339 us-gaap:SecuredDebtMember mdxg:CitizensCreditAgreementMember us-gaap:LineOfCreditMember 2024-01-19 2024-01-19 0001376339 mdxg:HayfinLoanAgreementTermLoanMember us-gaap:NotesPayableOtherPayablesMember 2024-01-19 2024-01-19 0001376339 2024-01-19 2024-01-19 0001376339 us-gaap:RevolvingCreditFacilityMember mdxg:CitizensCreditAgreementMember us-gaap:LineOfCreditMember 2024-02-27 2024-02-27 0001376339 us-gaap:SecuredDebtMember mdxg:CitizensCreditAgreementMember us-gaap:LineOfCreditMember 2024-03-31 0001376339 mdxg:HayfinLoanAgreementTermLoanMember us-gaap:NotesPayableOtherPayablesMember 2023-12-31 0001376339 srt:MinimumMember us-gaap:SecuredDebtMember mdxg:CitizensCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember 2024-01-19 2024-01-19 0001376339 srt:MaximumMember us-gaap:SecuredDebtMember mdxg:CitizensCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember 2024-01-19 2024-01-19 0001376339 srt:MinimumMember us-gaap:SecuredDebtMember mdxg:CitizensCreditAgreementMember us-gaap:LineOfCreditMember mdxg:SecuredOvernightFinancingRateSOFRMember 2024-01-19 2024-01-19 0001376339 srt:MaximumMember us-gaap:SecuredDebtMember mdxg:CitizensCreditAgreementMember us-gaap:LineOfCreditMember mdxg:SecuredOvernightFinancingRateSOFRMember 2024-01-19 2024-01-19 0001376339 srt:MinimumMember us-gaap:SecuredDebtMember mdxg:CitizensCreditAgreementMember us-gaap:LineOfCreditMember mdxg:SecuredOvernightFinancingRateSOFRMember 2024-03-31 0001376339 mdxg:TermLoanFacilityAndHayfinLoanAgreementMember 2024-01-01 2024-03-31 0001376339 mdxg:TermLoanFacilityAndHayfinLoanAgreementMember 2023-01-01 2023-03-31 0001376339 us-gaap:RevolvingCreditFacilityMember mdxg:CitizensCreditAgreementMember us-gaap:LineOfCreditMember 2024-01-01 2024-03-31 0001376339 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-03-31 0001376339 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0001376339 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-31 0001376339 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0001376339 us-gaap:PerformanceSharesMember 2024-01-01 2024-03-31 0001376339 us-gaap:PerformanceSharesMember 2023-01-01 2023-03-31 0001376339 us-gaap:EmployeeStockMember 2024-01-01 2024-03-31 0001376339 us-gaap:EmployeeStockMember 2023-01-01 2023-03-31 0001376339 us-gaap:SeriesBPreferredStockMember 2024-01-01 2024-03-31 0001376339 us-gaap:SeriesBPreferredStockMember 2023-01-01 2023-03-31 0001376339 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-03-31 0001376339 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0001376339 us-gaap:RestrictedStockMember 2024-01-01 2024-03-31 0001376339 us-gaap:RestrictedStockMember 2023-01-01 2023-03-31 0001376339 us-gaap:EmployeeStockMember 2024-01-01 2024-03-31 0001376339 us-gaap:EmployeeStockMember 2023-01-01 2023-03-31 0001376339 us-gaap:PerformanceSharesMember 2024-01-01 2024-03-31 0001376339 us-gaap:PerformanceSharesMember 2023-01-01 2023-03-31 0001376339 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-31 0001376339 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0001376339 mdxg:TELAAPAMember 2024-03-15 2024-03-15 0001376339 srt:MinimumMember mdxg:TELAAPAMember 2024-03-15 2024-03-15 0001376339 srt:MaximumMember mdxg:TELAAPAMember 2024-03-15 2024-03-15 0001376339 mdxg:TELAAPAMember us-gaap:DistributionRightsMember 2024-03-15 2024-03-15 0001376339 mdxg:TELAAPAMember 2024-03-31 0001376339 mdxg:HospitalSiteOfServiceMember 2024-01-01 2024-03-31 0001376339 mdxg:HospitalSiteOfServiceMember 2023-01-01 2023-03-31 0001376339 mdxg:PrivateOfficeSiteOfServiceMember 2024-01-01 2024-03-31 0001376339 mdxg:PrivateOfficeSiteOfServiceMember 2023-01-01 2023-03-31 0001376339 mdxg:OtherSiteOfServiceMember 2024-01-01 2024-03-31 0001376339 mdxg:OtherSiteOfServiceMember 2023-01-01 2023-03-31 0001376339 mdxg:WoundMember 2024-01-01 2024-03-31 0001376339 mdxg:WoundMember 2023-01-01 2023-03-31 0001376339 mdxg:SurgicalMember 2024-01-01 2024-03-31 0001376339 mdxg:SurgicalMember 2023-01-01 2023-03-31 0001376339 us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember mdxg:RegenerativeMedicineBusinessUnitMember 2024-01-01 2024-03-31 0001376339 us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember mdxg:RegenerativeMedicineBusinessUnitMember 2023-01-01 2023-03-31 shares iso4217:USD iso4217:USD shares pure mdxg:service_site mdxg:product_line 0001376339 --12-31 2024 Q1 false 10-Q true 2024-03-31 false 001-35887 MIMEDX GROUP, INC. FL 26-2792552 1775 West Oak Commons Ct NE Marietta GA 30062 770 651-9100 Common Stock, par value $0.001 per share MDXG NASDAQ Yes Yes Large Accelerated Filer false false false 147603955 48487000 82000000 57016000 53871000 24454000 21021000 6095000 5624000 2801000 1745000 138853000 164261000 7340000 6974000 3499000 2132000 38747000 40777000 19441000 19441000 12550000 5257000 1251000 205000 221681000 239047000 1000000 1000000 9697000 9048000 17913000 22353000 9196000 9361000 344000 1352000 4071000 2894000 42221000 46008000 18453000 48099000 5276000 2223000 65950000 96330000 0.001 0.001 250000000 250000000 147528596 147528596 146227639 146227639 148000 146000 280000000 276249000 -124417000 -133678000 155731000 142717000 221681000 239047000 84709000 71676000 12987000 12419000 71722000 59257000 55129000 52250000 2841000 3484000 311000 3673000 189000 190000 54000 0 13198000 -340000 -1690000 -1553000 -99000 2000 11409000 -1891000 2348000 51000 9061000 -1942000 200000 -3041000 9261000 -4983000 9061000 -3626000 0.06 -0.03 0 -0.03 0.06 -0.06 0.06 -0.03 0 -0.03 0.06 -0.06 146404587 114398813 150028107 114398813 146227639 146000 276249000 0 0 -133678000 142717000 4340000 4340000 109920 766000 766000 121783 797000 797000 1069254 2000 -2152000 -2150000 9261000 9261000 147528596 148000 280000000 0 0 -124417000 155731000 113705447 114000 173804000 0 0 -191906000 -17988000 4345000 4345000 1439676 1000 -179000 -57770 178000 0 -179000 58104 179000 0 235419 680000 680000 -4983000 -4983000 115380542 115000 178829000 334 -1000 -196889000 -17946000 9061000 -1942000 4340000 3904000 -2031000 0 -1401000 0 558000 714000 317000 334000 199000 -60000 189000 190000 -185000 0 22000 22000 69000 121000 3344000 1551000 2941000 1474000 471000 -934000 1001000 -1030000 283000 -686000 -4440000 -2494000 522000 1956000 -195000 -398000 6785000 600000 -807000 -4648000 5978000 -4048000 5000000 0 1144000 633000 -120000 44000 -6024000 -677000 30000000 0 19783000 0 766000 0 13000 4000 500000 0 1101000 0 50000000 0 30000000 0 -250000 0 2152000 0 -33467000 -4000 -33513000 -4729000 82000000 65950000 48487000 61221000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Nature of Business</span><div style="margin-bottom:10pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MiMedx Group, Inc. (together with its subsidiaries, except where the context otherwise requires, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">“MIMEDX,”</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">“Company”</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) is a pioneer and leader in placental biologics focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. All of our products sold in the United States are regulated by the United States Food and Drug Administration (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">“FDA”</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s product portfolio and product development focuses on Wound and Surgical markets.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s business is focused primarily on the United States of America but the Company also has a small commercial presence in several international locations, including Japan.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Significant Accounting Policies</span><div style="margin-bottom:10pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the Company’s Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2023 Form 10-K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”), filed with the Securities and Exchange Commission (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SEC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) on February 28, 2024 for a description of all significant accounting policies.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:10pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GAAP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations for the periods presented have been included. The operating results for the three months ended March 31, 2024 and 2023 are not necessarily indicative of the results that may be expected for the full fiscal year. The balance sheet as of December 31, 2023 was derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements should be read in conjunction with the historical consolidated financial statements of the Company included in the 2023 Form 10-K.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of long term debt of $1.0 million as of December 31, 2023, which was presented in other current liabilities in previously-issued financial statements, has been reclassified to be presented in a separate line item still within current liabilities in the March 31, 2024 balance sheet presentation.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of MiMedx Group, Inc. and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported consolidated statements of operations during the reporting period. Actual results could differ from those estimates. Significant estimates include estimated useful lives and potential impairment of property and equipment, estimates of impairment for goodwill and intangible assets, estimates of useful lives for intangible assets, estimates of loss for contingent liabilities, estimate of allowance for doubtful accounts, estimate of fair value and the probable achievement of share-based payments, estimates of returns and allowances, and valuation of deferred tax assets.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Standards Not Yet Adopted</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Financial Accounting Standards Board (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FASB</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) issued Accounting Standards Update (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) 2023-07, “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting: Improvements to Reportable Segment Disclosures (Topic 280)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”. The standard improves disclosures about a public entity’s reportable segments and addresses requests from investors for additional, more detailed information about a reportable segment’s expenses. Additionally, ASU 2023-07 extends the disclosure requirements under Accounting Standards Codification (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) Topic 280 to entities with a single reportable segment. ASU 2023-07 is effective for annual reporting periods beginning after December 15, 2023, and interim periods in fiscal years beginning after December 15, 2024. As of March 31, 2024, the Company is evaluating the impact of this standard on its consolidated financial statements.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvement to Income Tax Disclosures (Topic 740)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”, which requires additional disclosures for income tax rate reconciliations, income taxes paid, and certain other tax disclosures. ASU 2023-09 is intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to the rate reconciliation and income taxes paid information. Adoption is required for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other ASUs issued and not yet effective as of March 31, 2024, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company’s current and future financial position and results of operations.</span></div> <div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:10pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GAAP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations for the periods presented have been included. The operating results for the three months ended March 31, 2024 and 2023 are not necessarily indicative of the results that may be expected for the full fiscal year. The balance sheet as of December 31, 2023 was derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements should be read in conjunction with the historical consolidated financial statements of the Company included in the 2023 Form 10-K.</span></div> <div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of long term debt of $1.0 million as of December 31, 2023, which was presented in other current liabilities in previously-issued financial statements, has been reclassified to be presented in a separate line item still within current liabilities in the March 31, 2024 balance sheet presentation.</span></div> 1000000 -1000000 <div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of MiMedx Group, Inc. and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation.</span></div> <div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported consolidated statements of operations during the reporting period. Actual results could differ from those estimates. Significant estimates include estimated useful lives and potential impairment of property and equipment, estimates of impairment for goodwill and intangible assets, estimates of useful lives for intangible assets, estimates of loss for contingent liabilities, estimate of allowance for doubtful accounts, estimate of fair value and the probable achievement of share-based payments, estimates of returns and allowances, and valuation of deferred tax assets.</span></div> <div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Standards Not Yet Adopted</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Financial Accounting Standards Board (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FASB</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) issued Accounting Standards Update (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) 2023-07, “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting: Improvements to Reportable Segment Disclosures (Topic 280)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”. The standard improves disclosures about a public entity’s reportable segments and addresses requests from investors for additional, more detailed information about a reportable segment’s expenses. Additionally, ASU 2023-07 extends the disclosure requirements under Accounting Standards Codification (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) Topic 280 to entities with a single reportable segment. ASU 2023-07 is effective for annual reporting periods beginning after December 15, 2023, and interim periods in fiscal years beginning after December 15, 2024. As of March 31, 2024, the Company is evaluating the impact of this standard on its consolidated financial statements.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvement to Income Tax Disclosures (Topic 740)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”, which requires additional disclosures for income tax rate reconciliations, income taxes paid, and certain other tax disclosures. ASU 2023-09 is intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to the rate reconciliation and income taxes paid information. Adoption is required for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other ASUs issued and not yet effective as of March 31, 2024, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company’s current and future financial position and results of operations.</span></div> Accounts Receivable, Net<div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net, consisted of the following (in thousands):</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.228%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, gross</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,282 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,015 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowance for doubtful accounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,266)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,144)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,016 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,871 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity related to the Company’s allowance for doubtful accounts for the three months ended March 31, 2024 was as follows (in thousands):</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.964%"><tr><td style="width:1.0%"></td><td style="width:79.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.798%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for Doubtful Accounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,144 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bad debt expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2024</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,266 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.964%"><tr><td style="width:1.0%"></td><td style="width:79.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.798%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for Doubtful Accounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,783 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bad debt expense reversal</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(122)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2023</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,601 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net, consisted of the following (in thousands):</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.228%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, gross</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,282 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,015 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowance for doubtful accounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,266)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,144)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,016 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,871 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 60282000 57015000 3266000 3144000 57016000 53871000 <div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity related to the Company’s allowance for doubtful accounts for the three months ended March 31, 2024 was as follows (in thousands):</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.964%"><tr><td style="width:1.0%"></td><td style="width:79.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.798%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for Doubtful Accounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,144 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bad debt expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2024</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,266 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.964%"><tr><td style="width:1.0%"></td><td style="width:79.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.798%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for Doubtful Accounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,783 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bad debt expense reversal</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(122)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2023</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,601 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 3144000 199000 77000 3266000 3783000 -60000 122000 3601000 Inventory<div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.228%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,136 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,609 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,521 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,709 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,675 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,454 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,021 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.228%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,136 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,609 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,521 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,709 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,675 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,454 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,021 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1136000 825000 8609000 8521000 14709000 11675000 24454000 21021000 Property and Equipment, Net<div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, consisted of the following (in thousands):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:61.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and clean room equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,504 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,954 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,989 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,141 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,141 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,870 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,791 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset retirement cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease right-of-use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,798 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,002 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,458)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,028)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,340 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,974 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, consisted of the following (in thousands):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:61.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and clean room equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,504 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,954 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,989 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,141 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,141 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,870 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,791 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset retirement cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease right-of-use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,798 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,002 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,458)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,028)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,340 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,974 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 14504000 13954000 2205000 1989000 8141000 8141000 1870000 1791000 889000 938000 189000 189000 27798000 27002000 20458000 20028000 7340000 6974000 Intangible Assets, Net<div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net, are summarized as follows (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:38.338%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.762%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.762%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.762%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortized intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and know-how</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,968 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,949)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,019 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,039 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,818)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,221 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,602 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,602 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortized intangible assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,570 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,016)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,554 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,039 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,872)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,167 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tradenames and trademarks</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents in Process</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">988 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">988 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,082 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,082 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,566 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,550 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,129 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,257 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized $0.1 million of impairment of intangible assets during the three months ended March 31, 2024 related to patents which were abandoned.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected future amortization of intangible assets as of March 31, 2024, is as follows (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:85.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated<br/>Amortization <br/>Expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 (excluding the three months ended March 31, 2024)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,708 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,883 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,729 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,728 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,726 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,780 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortized intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,554 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net, are summarized as follows (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:38.338%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.762%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.762%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.762%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortized intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and know-how</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,968 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,949)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,019 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,039 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,818)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,221 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,602 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,602 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortized intangible assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,570 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,016)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,554 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,039 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,872)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,167 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tradenames and trademarks</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents in Process</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">988 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">988 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,082 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,082 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,566 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,550 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,129 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,257 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 9968000 7949000 2019000 10039000 7818000 2221000 1000000 67000 933000 1000000 54000 946000 7602000 0 7602000 0 0 0 18570000 8016000 10554000 11039000 7872000 3167000 1008000 1008000 1008000 1008000 988000 988000 1082000 1082000 20566000 12550000 13129000 5257000 100000 <div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected future amortization of intangible assets as of March 31, 2024, is as follows (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:85.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated<br/>Amortization <br/>Expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 (excluding the three months ended March 31, 2024)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,708 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,883 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,729 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,728 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,726 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,780 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortized intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,554 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1708000 1883000 1729000 1728000 1726000 1780000 10554000 Accrued Expenses<div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"></td><td style="width:63.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.945%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commissions to sales agents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,954 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,136 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,380 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal and settlement costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,235 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">834 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued Group Purchasing Organization fees</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,338 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated sales returns</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,085 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,096 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued travel</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,165 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,196 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,361 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"></td><td style="width:63.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.945%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commissions to sales agents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,954 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,136 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,380 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal and settlement costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,235 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">834 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued Group Purchasing Organization fees</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,338 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated sales returns</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,085 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,096 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued travel</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,165 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,196 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,361 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2954000 4136000 1380000 745000 1235000 834000 1235000 1338000 1085000 1096000 142000 433000 1165000 779000 9196000 9361000 Long Term Debt, Net<div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Citizens Credit Agreement</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 19, 2024, the Company entered into a Credit Agreement (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Citizens Credit Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) with certain lenders party thereto, and Citizens Bank, N.A., as administrative agent (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Agent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”). The Citizens Credit Agreement provides for senior secured credit facilities in an aggregate principal amount of up to $95.0 million consisting of: (i) a $75.0 million senior secured revolving credit facility (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revolving Credit Facility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) with a $10.0 million letter of credit sublimit and a $10.0 million swingline loan sublimit, and (ii) a $20.0 million senior secured term loan facility (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Term Loan Facility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">” and, together with the Revolving Credit Facility, the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Facilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”). All obligations are required to be paid in full on January 19, 2029 (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Maturity Date</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”). The Company has the option to obtain one or more incremental Term Loan Facilities and/or increase the commitments under the Revolving Credit Facility in an aggregate principal amount equal to the greater of (i) $50.0 million and (ii) 1.00 times the Company’s Consolidated EBITDA (as defined therein), each subject to the existing or any new lenders’ election to extend additional term loans or revolving commitments.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Company’s option, borrowings under the Citizens Credit Agreement (other than any swingline loan) will bear interest at a rate per annum equal to (i) the Alternate Base Rate, as defined therein, or (ii) a Term SOFR as defined therein, in each case plus an applicable margin ranging from 1.25% and 2.50% with respect to Alternate Base Rate borrowings and 2.25% and 3.50% for Term SOFR borrowings, plus a fallback provision of 0.1%. Swingline loans will bear interest at a rate per annum equal to one-month Term SOFR plus the applicable margin. The applicable margin will be determined based on the Company’s consolidated total net leverage ratio.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to pay a quarterly commitment fee on any unused portion of the Revolving Credit Facility, letter of credit fees, and other customary fees to the Agent and the Lenders. The Term Loan Facility will amortize on a quarterly basis at 1.25% (for year one and two), 1.88% (for year three and four), and 2.5% (for year five) based on the aggregate principal amount outstanding under the Term Loan Facility, with the remainder due on the Maturity Date. The Company must make mandatory prepayments in connection with certain asset dispositions and casualty events, subject in each case to customary reinvestment rights. The Company may prepay borrowings under the Credit Facilities at any time, without premium or penalty, and may, at its option, reduce the aggregate unused commitments under the Revolving Credit Facility in whole or in part, in each case subject to the terms of the Credit Agreement. The Company must also comply with certain financial covenants, including a maximum total net leverage ratio and a minimum consolidated fixed charge coverage ratio, as well as other customary restrictive covenants.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 19, 2024, the Company borrowed $30.0 million under the Revolving Credit Facility and $20.0 million under the Term Loan Facility. Proceeds from the initial drawings under the Credit Facilities together with cash on hand were used to repay in full the $50.0 million principal amount and other outstanding obligations under the Company’s prior senior secured term loan with Hayfin (the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> “Hayfin Loan Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) and to pay related fees, premiums, costs and expenses (collectively with the entry into the Citizens Credit Agreement and the initial borrowings thereunder, the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Refinancing Transactions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”). The Company recorded a loss on extinguishment of debt of $1.4 million. This amount is reflected as a part of interest expense, net on the unaudited condensed consolidated statement of operations for the three months ended March 31, 2024. The composition of the loss on extinguishment of debt was as follows (amounts in thousands):</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.204%"><tr><td style="width:1.0%"></td><td style="width:74.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 19, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized deferred financing costs</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized original issue discount</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepayment premium</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,401 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, on February 27, 2024, the Company repaid the initial $30.0 million drawing under the Revolving Credit Facility and had no outstanding borrowings under this facility as of March 31, 2024. Deferred financing costs and original issue discount allocated to the Revolving Credit Facility are amortized straight-line through the expiration of the commitment term. The Revolving Credit Facility is currently subject to a commitment fee of 0.25% per annum of the amount undrawn, which is recognized as interest expense.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Original issue discount and deferred financing costs incurred as part of the Credit Facilities were allocated between the Term Loan Facility and the Revolving Credit Facility on the basis of the maximum potential principal outstanding permitted under the Citizens Credit Agreement. The allocation of the deferred financing costs and original issue discount between the Term Loan Facility and the Revolving Credit Facility were as follows (in thousands):</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"><tr><td style="width:1.0%"></td><td style="width:23.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.188%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 19, 2024</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan Facility</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving Credit Facility</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Long term debt</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other assets</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Original issue discount</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">839 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,063 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred financing</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balances of the Term Loan Facility as of March 31, 2024 and the Hayfin Loan Agreement as of December 31, 2023 were as follows (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.520%"><tr><td style="width:1.0%"></td><td style="width:21.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.791%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.791%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.069%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.831%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long term debt</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long term debt, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long term debt</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long term debt, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding principal</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,750 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(781)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Original issue discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(215)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long term debt, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,453 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,099 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Citizens Term Loan Facility bears interest at a rate per annum equal to (i) the Alternate Base Rate, as defined therein, or (ii) a Term SOFR as defined therein, in each case plus an applicable margin ranging from 1.25% and 2.50% with respect to Alternate Base Rate borrowings and 2.25% and 3.50% for Term SOFR borrowings, plus a fallback provision of 0.1%. The applicable margin is determined based on the Company’s consolidated total net leverage ratio. The Term Loan Facility carried an interest rate of 7.9% as of March 31, 2024. Interest expense related to the Term Loan Facility and the Hayfin Loan Agreement included in interest expense, net in the unaudited condensed consolidated statements of operations, was as follows (amounts in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"><tr><td style="width:1.0%"></td><td style="width:70.045%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.945%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.947%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stated interest</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,436 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of original issue discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">703 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,557 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense related to the Revolving Credit Facility included in interest expense, net in the unaudited condensed consolidated statements of operations, was as follows (amounts in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.204%"><tr><td style="width:1.0%"></td><td style="width:74.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.374%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitment fee</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of original issue discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of principal payments due on the Term Loan Facility, by year, from March 31, 2024 through maturity are as follows (in thousands):</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:85.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 (excluding the three months ended March 31, 2024)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding principal</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,750 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><div style="margin-bottom:10pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024, the fair value of the Term Loan Facility was $19.3 million. This valuation was calculated based on a series of Level 2 and Level 3 inputs, including a discount rate based on the credit risk spread of debt instruments of similar risk character in reference to U.S. Treasury instruments with similar maturities, with an incremental risk premium for risk factors specific to the Company. Fair value was calculated by discounting the remaining cash flows associated with the Term Loan Facility to March 31, 2024 using this discount rate.</span></div> 95000000 75000000 10000000 10000000 20000000 50000000 1.00 0.0125 0.0250 0.0225 0.0350 0.001 0.0125 0.0125 0.0188 0.0188 0.025 30000000 20000000 50000000 -1400000 The composition of the loss on extinguishment of debt was as follows (amounts in thousands):<div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.204%"><tr><td style="width:1.0%"></td><td style="width:74.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 19, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized deferred financing costs</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized original issue discount</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepayment premium</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,401 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 781000 120000 500000 -1401000 30000000 0.0025 <div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Original issue discount and deferred financing costs incurred as part of the Credit Facilities were allocated between the Term Loan Facility and the Revolving Credit Facility on the basis of the maximum potential principal outstanding permitted under the Citizens Credit Agreement. The allocation of the deferred financing costs and original issue discount between the Term Loan Facility and the Revolving Credit Facility were as follows (in thousands):</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"><tr><td style="width:1.0%"></td><td style="width:23.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.188%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 19, 2024</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan Facility</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving Credit Facility</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Long term debt</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other assets</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Original issue discount</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">839 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,063 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred financing</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div> 224000 839000 1063000 54000 202000 256000 <div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balances of the Term Loan Facility as of March 31, 2024 and the Hayfin Loan Agreement as of December 31, 2023 were as follows (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.520%"><tr><td style="width:1.0%"></td><td style="width:21.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.791%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.791%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.069%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.831%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long term debt</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long term debt, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long term debt</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long term debt, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding principal</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,750 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(781)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Original issue discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(215)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long term debt, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,453 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,099 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 1000000 18750000 1000000 49000000 0 82000 0 781000 0 215000 0 120000 1000000 18453000 1000000 48099000 0.0125 0.0250 0.0225 0.0350 0.079 Interest expense related to the Term Loan Facility and the Hayfin Loan Agreement included in interest expense, net in the unaudited condensed consolidated statements of operations, was as follows (amounts in thousands):<div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"><tr><td style="width:1.0%"></td><td style="width:70.045%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.945%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.947%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stated interest</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,436 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of original issue discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">703 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,557 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense related to the Revolving Credit Facility included in interest expense, net in the unaudited condensed consolidated statements of operations, was as follows (amounts in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.204%"><tr><td style="width:1.0%"></td><td style="width:74.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.374%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitment fee</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of original issue discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 661000 1436000 29000 105000 13000 16000 703000 1557000 30000 16000 42000 88000 <div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of principal payments due on the Term Loan Facility, by year, from March 31, 2024 through maturity are as follows (in thousands):</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:85.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 (excluding the three months ended March 31, 2024)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding principal</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,750 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 750000 1000000 1500000 1500000 2000000 13000000 19750000 19300000 Net Income (Loss) Per Common Share<div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss) per common share is calculated using two methods: basic and diluted.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basic Net Income (Loss) Per Common Share</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a reconciliation of net income (loss) to net income (loss) available to common stockholders and calculation of basic net income (loss) per common share for each of the three months ended March 31, 2024 and 2023 (in thousands, except share and per share amounts):</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"></td><td style="width:70.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.797%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.798%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,061 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,942)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from discontinued operations, net of tax</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,041)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,261 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,983)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile to income (loss) available to common stockholders:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated dividend on previously converted Series B Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,684 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) available to common stockholders from continuing operations</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,061 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,626)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,404,587 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,398,813 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net income (loss) per common share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.06 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.03)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.03)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net income (loss) per common share</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.06 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.06)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Diluted Net Income (Loss) Per Common Share</span></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of diluted net income (loss) per common share (in thousands, except share and per share amounts):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:70.982%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.491%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) available to common stockholders from continuing operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,061 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,626)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends on Series B Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,684 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: antidilutive adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,684)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total adjustments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) available to common shareholders from continuing operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,061 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,626)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,041)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,404,587 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,398,813 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential common shares (a)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock unit awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,016,109 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,499,970 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock unit awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,802 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">639 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total adjustments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,623,520 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding adjusted for potential common shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,028,107 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,398,813 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net income (loss) per common share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.06 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.03)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.03)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net income (loss) per common share</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.06 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.06)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Weighted average common shares outstanding for the calculation of diluted net income (loss) per common share does not include the following adjustments for potential common shares below because their effects were determined to be antidilutive for the periods presented.</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:71.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.491%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,559,946 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock unit awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">567,167 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,152 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,740 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock unit awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,133 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential common shares</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,151,138 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> <div style="margin-bottom:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a reconciliation of net income (loss) to net income (loss) available to common stockholders and calculation of basic net income (loss) per common share for each of the three months ended March 31, 2024 and 2023 (in thousands, except share and per share amounts):</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"></td><td style="width:70.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.797%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.798%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,061 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,942)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from discontinued operations, net of tax</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,041)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,261 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,983)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile to income (loss) available to common stockholders:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated dividend on previously converted Series B Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,684 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) available to common stockholders from continuing operations</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,061 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,626)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,404,587 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,398,813 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net income (loss) per common share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.06 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.03)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.03)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net income (loss) per common share</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.06 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.06)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 9061000 -1942000 200000 -3041000 9261000 -4983000 0 1684000 9061000 -3626000 146404587 114398813 0.06 -0.03 0 -0.03 0.06 -0.06 <div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of diluted net income (loss) per common share (in thousands, except share and per share amounts):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:70.982%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.491%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) available to common stockholders from continuing operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,061 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,626)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends on Series B Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,684 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: antidilutive adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,684)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total adjustments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) available to common shareholders from continuing operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,061 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,626)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,041)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,404,587 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,398,813 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential common shares (a)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock unit awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,016,109 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,499,970 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock unit awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,802 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">639 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total adjustments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,623,520 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding adjusted for potential common shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,028,107 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,398,813 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net income (loss) per common share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.06 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.03)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.03)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net income (loss) per common share</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.06 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.06)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Weighted average common shares outstanding for the calculation of diluted net income (loss) per common share does not include the following adjustments for potential common shares below because their effects were determined to be antidilutive for the periods presented.</span></div> 9061000 -3626000 0 1684000 0 1684000 0 0 9061000 -3626000 200000 -3041000 146404587 114398813 2016109 0 1499970 0 106802 0 639 0 3623520 0 150028107 114398813 0.06 -0.03 0 -0.03 0.06 -0.06 <div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:71.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.491%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,559,946 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock unit awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">567,167 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,152 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,740 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock unit awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,133 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential common shares</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,151,138 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 0 29559946 0 567167 0 5152 0 5740 0 13133 0 0 0 30151138 Income Taxes<div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a continuing operations basis, the effective tax rates for the Company were 20.6% and (2.7)% for the three months ended March 31, 2024 and 2023, respectively. Restricted stock vestings impacted the effective tax rate for the three months ended March 31, 2024. Net operating losses generated for the three months ended March 31, 2023 were offset by a valuation allowance.</span></div> 0.206 -0.027 Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities<div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selected cash payments, receipts, and non-cash activities are as follows (in thousands):</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:59.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.302%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,403 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,452 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of minimum earn out</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,731 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use assets arising from operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,820 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of shares pursuant to employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of equipment in accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">626 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration payable to TELA</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unpaid deferred financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> <div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selected cash payments, receipts, and non-cash activities are as follows (in thousands):</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:59.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.302%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,403 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,452 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of minimum earn out</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,731 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use assets arising from operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,820 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of shares pursuant to employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of equipment in accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">626 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration payable to TELA</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unpaid deferred financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 1403000 1452000 8000 0 2731000 0 1820000 0 797000 680000 626000 223000 366000 0 149000 0 Commitments and Contingencies<div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TELA and Regenity Agreements</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 15, 2024, the Company entered into an Asset Purchase Agreement (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TELA APA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) with TELA Bio, Inc. (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">“TELA”</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) to obtain exclusive rights to sell and market a 510(k)-cleared collagen particulate xenograft product in the United States pursuant to a preexisting Manufacturing and Supply Agreement (the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">“TELA-Regenity Supply Agreement”</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) between TELA and Regenity Biosciences, Inc. (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regenity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”), which retains all intellectual property rights and regulatory clearances related to the product. Pursuant to the TELA APA, the Company paid $5.0 million of initial consideration to TELA and will be required to make future payments of $0.4 million to acquire TELA’s remaining product inventory, as well as future profit share payments (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Profit Share Payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) of between a minimum of $3.0 million and a maximum of $7.0 million based on MIMEDX’s net sales of the product over the two-years following its commercialization of the product. </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Simultaneously with entry into the TELA APA, the Company executed a new Manufacturing and Supply Agreement (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Supply Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) with Regenity, replacing the previous TELA-Regenity Supply Agreement. The Supply Agreement maintains MIMEDX’s exclusive right to sell and market the product in the United States and requires MIMEDX to purchase a minimum amount of the xenograft product from Regenity annually through December 31, 2033. Should MIMEDX fail to meet a purchasing minimum in any one period, it has the option (among others) to amend its distribution rights under the Supply Agreement to be non-exclusive.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction was accounted for as an acquisition of assets. The cost to acquire the assets on the transaction date was assessed to be $8.1 million, reflecting the $5.0 million of initial consideration, $0.4 million to acquire inventory, and $2.7 million, reflecting the fair value of the minimum amount of the Profit Share Payments, were allocated amongst the assets acquired. The Company assigned $7.6 million to the distribution rights acquired and $0.5 million to inventory. These amounts are reflected in the consolidated balance sheets as part of intangible assets, net and inventory, respectively, on the unaudited condensed consolidated balance sheet as of March 31, 2024.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $2.7 million fair value for the minimum amount of Profit Share Payments reflects the anticipated timing of such Profit Share Payments, discounted to present value at a discount rate approximating the Company’s borrowing rate plus a risk premium.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the minimum Profit Share Payment, $1.1 million is reflected as part of other current liabilities in the unaudited condensed consolidated balance sheet as of March 31, 2024, reflecting the extent of the obligation that is anticipated to be repaid within twelve months of that date. The remaining balance is reflected in other liabilities.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation and Regulatory Matters</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company and its subsidiaries may be a party to pending and threatened legal, regulatory, and governmental actions and proceedings (including those described below). In view of the inherent difficulty of predicting the outcome of such matters, particularly where the plaintiffs or claimants seek very large or indeterminate damages or where the matters present novel legal theories or involve a large number of parties, the Company generally cannot predict what the eventual outcome of the pending matters will be, what the timing of the ultimate resolution of these matters will be, or what the </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">eventual recovery, loss, fines or penalties related to each pending matter may be. The Company's unaudited condensed consolidated balance sheet as of March 31, 2024 reflects the Company's current best estimate of probable losses associated with these matters, including costs to comply with various settlement agreements, where applicable. For more information regarding the Company’s legal proceedings, refer to Note 16, “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">” in the 2023 Form 10-K.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not accrued for any potential losses related to legal matters as of March 31, 2024. The Company made no payments toward the resolution of legal matters involving the Company during the three months ended March 31, 2024. The Company paid $0.2 million during the three months ended March 31, 2023.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a description of certain litigation and regulatory matters to which the Company is a party:</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Welker v. MiMedx, et. al.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 4, 2022, Troy Welker and Min Turner, former optionholders of the Company, brought a lawsuit in Fulton County State Court against the Company, former directors Terry Dewberry and Charles Evans, and former officers Parker H. “Pete” Petit, William C. Taylor, and Michael Senken alleging violations of the Georgia Racketeer Influenced and Corrupt Organizations (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RICO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) Act against all defendants, and conspiracy to violate the Georgia RICO Act and breach of fiduciary duty against the individual defendants. On motion by the Company, the case has been moved to the Fulton County Business Court. The Company and the individual defendants filed answers and motions to dismiss, which were denied on the RICO claims, but granted with respect to the breach of fiduciary duty claims against the individual defendants. The Company is defending against the allegations and is obligated to indemnify certain of its current and former officers and directors who are party to this proceeding. </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Former Employee Litigation and Related Matters</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 12, 2021, the Company filed suit in the Circuit Court of the Eleventh Judicial District in and for Miami-Dade County, Florida (MiMedx Group, Inc. v. Petit, et. al.) against its former CEO, Parker H. “Pete” Petit, and its former COO, William C. Taylor, seeking a determination of its rights and obligations under indemnification agreements with Petit and Taylor following a federal jury’s guilty verdict against Petit for securities fraud and Taylor for conspiracy to commit securities fraud. On March 26, 2024, the Company filed an amended complaint against only Petit as the Company previously reached as settlement with Taylor. The Company is seeking a declaratory judgment that Petit is not entitled to indemnification in connection with certain cases and the Company is also seeking to recoup amounts previously paid on behalf of Petit in connection with such cases. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, the Company and Mr. Taylor reached an agreement to settle the matter between them. Negotiations with Mr. Petit are ongoing.</span></div> 5000000 400000 3000000 7000000 P2Y 8100000 5000000 400000 2700000 7600000 500000 2700000 1100000 0 200000 Revenue<div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Sales by Site of Service</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MIMEDX has three main sites of service for its products (1) Hospital settings and wound care clinics, which are stable reimbursement settings in which products are used for surgical applications, (2) Private offices, which generally represents doctors and practitioners with independent operations, and (3) Other, which includes federal facilities, international sales, and other sites of service.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of net sales by site of service (in thousands):</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.070%"><tr><td style="width:1.0%"></td><td style="width:39.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.825%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.827%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospital</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,757 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,171 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private Office</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,332 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,487 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,620 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,018 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,709 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,676 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Sales by Product Line</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MIMEDX has two product lines (1) Wound, which reflects products typically used in Advanced Wound Care settings, including the treatment of chronic, non-healing wounds, and (2) Surgical, which reflects products principally used in surgical </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">settings, including the closure of acute wounds or to protect and reinforce tissues and/or regions of interest. The Company manages its product portfolio and pipeline, based upon opportunities in each of these settings.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of net sales by product line (in thousands):</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.070%"><tr><td style="width:1.0%"></td><td style="width:39.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.825%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.827%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wound</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,049 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,206 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Surgical</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,660 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,470 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,709 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,676 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have significant foreign operations or a single external customer from which 10% or more of revenues were derived during the three months ended March 31, 2024 or 2023.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AXIOFILL</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received a determination letter on March 25, 2024 reaffirming the FDA’s position that AXIOFILL does not meet the regulatory classification requirements of a Human Cell, Tissue or Cellular or Tissue-based Product under Section 361 of the Public Health Service Act. The Company strongly disagrees with this determination and has filed suit in the U.S. District Court for the Northern District of Georgia against the FDA on this matter.</span></div> 3 <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of net sales by site of service (in thousands):</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.070%"><tr><td style="width:1.0%"></td><td style="width:39.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.825%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.827%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospital</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,757 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,171 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private Office</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,332 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,487 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,620 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,018 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,709 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,676 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of net sales by product line (in thousands):</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.070%"><tr><td style="width:1.0%"></td><td style="width:39.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.825%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.827%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wound</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,049 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,206 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Surgical</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,660 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,470 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,709 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,676 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 43757000 42171000 30332000 21487000 10620000 8018000 84709000 71676000 2 57049000 45206000 27660000 26470000 84709000 71676000 Discontinued Operations<div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disbanding of Regenerative Medicine Business Unit</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 20, 2023, the Company announced the disbanding of its Regenerative Medicine business unit and the suspension of its Knee Osteoarthritis clinical trial program. During the fourth quarter of 2023, the Company materially completed the regulatory obligations associated with the clinical trial.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statement Impact of Discontinued Operations</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income and expenses of the discontinued operation have been classified as income (loss) from discontinued operations in the consolidated statements of operations for the three months ended March 31, 2024 and 2023 as follows (in thousands):</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.707%"><tr><td style="width:1.0%"></td><td style="width:58.978%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.469%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.471%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(200)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,012 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from discontinued operations</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,041)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> <div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income and expenses of the discontinued operation have been classified as income (loss) from discontinued operations in the consolidated statements of operations for the three months ended March 31, 2024 and 2023 as follows (in thousands):</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.707%"><tr><td style="width:1.0%"></td><td style="width:58.978%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.469%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.471%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(200)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,012 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from discontinued operations</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,041)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 0 29000 -200000 3012000 200000 -3041000 false false false false